<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>🦎 的知識花園 🌱 on</title><link>https://htlin222.github.io/garden/</link><description>Recent content in 🦎 的知識花園 🌱 on</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><atom:link href="https://htlin222.github.io/garden/index.xml" rel="self" type="application/rss+xml"/><item><title>Setup</title><link>https://htlin222.github.io/garden/notes/setup/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/setup/</guid><description>Making your own Quartz Setting up Quartz requires a basic understanding of git. If you are unfamiliar, this resource is a great place to start!</description></item><item><title>Editing Content in Quartz</title><link>https://htlin222.github.io/garden/notes/editing/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/editing/</guid><description>Editing Quartz runs on top of Hugo so all notes are written in Markdown.
Folder Structure Here&amp;rsquo;s a rough overview of what&amp;rsquo;s what.</description></item><item><title>Obsidian Vault Integration</title><link>https://htlin222.github.io/garden/notes/obsidian/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/obsidian/</guid><description>Setup Obsidian is the preferred way to use Quartz. You can either create a new Obsidian Vault or link one that your already have.</description></item><item><title>Preview Changes</title><link>https://htlin222.github.io/garden/notes/preview-changes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/preview-changes/</guid><description>If you&amp;rsquo;d like to preview what your Quartz site looks like before deploying it to the internet, the following instructions guide you through installing the proper dependencies to run it locally.</description></item><item><title>Deploying Quartz to the Web</title><link>https://htlin222.github.io/garden/notes/hosting/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/hosting/</guid><description>Hosting on GitHub Pages Quartz is designed to be effortless to deploy. If you forked and cloned Quartz directly from the repository, everything should already be good to go!</description></item><item><title>Aldosterone</title><link>https://htlin222.github.io/garden/Aldosterone/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Aldosterone/</guid><description>[!info] 🌱 來自: [[overview-sodium and water homeostasis]]
Aldosterone 留鈉排鉀
[[aldosterone synthetic pathway]]
primary hormone that regulates total body sodium (and ∴ volume)</description></item><item><title>aldosterone synthetic pathway</title><link>https://htlin222.github.io/garden/aldosterone-synthetic-pathway/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aldosterone-synthetic-pathway/</guid><description>[!info] 🌱 來自: [[Aldosterone]]
aldosterone synthetic pathway Figure: adrenocorticotropic hormone (ACTH) , angiotensin II (Ang II) , and K + regulate steroidogenic acute regulatory protein (StAR) , which stimulates cholesterol uptake by mitochondria and thus substrate availability for synthesis of all of the steroid hormones.</description></item><item><title>Antidiuretic hormone</title><link>https://htlin222.github.io/garden/Antidiuretic-hormone/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antidiuretic-hormone/</guid><description>[!info] 🌱 來自: [[overview-sodium and water homeostasis]]
Antidiuretic hormone primary hormone that regulates sodium concentration stimuli: hyperosmolality (290–295 mOsm), ↓↓ effective arterial volume, angiotensin II action: insertion of [[aquaporin-2 channels]] in [[principal cells]] → passive water reabsorption urine osmolality is an indirect functional assay of the ADH-renal axis Uosm range 50 mOsm/L (no ADH) to 1200 mOsm/L (maximal ADH) The normal range for urine specific gravity is 1.</description></item><item><title>Calcium homeostasis in normal humans</title><link>https://htlin222.github.io/garden/Calcium-homeostasis-in-normal-humans/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Calcium-homeostasis-in-normal-humans/</guid><description> [!info] 🌱 來自: [[calcium disorders]]
Calcium homeostasis in normal humans Figure:</description></item><item><title>mac的一些好用軟體</title><link>https://htlin222.github.io/garden/mac%E7%9A%84%E4%B8%80%E4%BA%9B%E5%A5%BD%E7%94%A8%E8%BB%9F%E9%AB%94/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mac%E7%9A%84%E4%B8%80%E4%BA%9B%E5%A5%BD%E7%94%A8%E8%BB%9F%E9%AB%94/</guid><description>[!info] 🌱 來自: [[index]]
mac的一些好用軟體 👷 工事中，敬請期待 🚧</description></item><item><title>Obsidian</title><link>https://htlin222.github.io/garden/Obsidian/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Obsidian/</guid><description>[!info] 🌱 來自: [[如何打造一座知識花園]]
Obsidian 👷 工事中，敬請期待 🚧</description></item><item><title>principal cells</title><link>https://htlin222.github.io/garden/principal-cells/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/principal-cells/</guid><description> [!info] 🌱 來自: [[Antidiuretic hormone]]
principal cells Backlink： [[Aldosterone]] [[Antidiuretic hormone]]</description></item><item><title>Vimwiki設定</title><link>https://htlin222.github.io/garden/Vimwiki%E8%A8%AD%E5%AE%9A/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vimwiki%E8%A8%AD%E5%AE%9A/</guid><description>[!info] 🌱 來自: [[如何打造一座知識花園]]
Vimwiki設定 👷 工事中，敬請期待 🚧</description></item><item><title>卡片盒筆記法</title><link>https://htlin222.github.io/garden/%E5%8D%A1%E7%89%87%E7%9B%92%E7%AD%86%E8%A8%98%E6%B3%95/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%E5%8D%A1%E7%89%87%E7%9B%92%E7%AD%86%E8%A8%98%E6%B3%95/</guid><description>[!info] 🌱 來自: [[如何打造一座知識花園]]
卡片盒筆記法 👷 工事中，敬請期待 🚧</description></item><item><title>如何打造一座知識花園</title><link>https://htlin222.github.io/garden/%E5%A6%82%E4%BD%95%E6%89%93%E9%80%A0%E4%B8%80%E5%BA%A7%E7%9F%A5%E8%AD%98%E8%8A%B1%E5%9C%92/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%E5%A6%82%E4%BD%95%E6%89%93%E9%80%A0%E4%B8%80%E5%BA%A7%E7%9F%A5%E8%AD%98%E8%8A%B1%E5%9C%92/</guid><description> [!info] 🌱 來自: [[index]]
如何打造一座知識花園 [[卡片盒筆記法]] [[蜥蜴與VIM]] [[Vimwiki設定]] [[Obsidian]]</description></item><item><title>蜥蜴與VIM</title><link>https://htlin222.github.io/garden/%E8%9C%A5%E8%9C%B4%E8%88%87VIM/</link><pubDate>Fri, 13 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%E8%9C%A5%E8%9C%B4%E8%88%87VIM/</guid><description>[!info] 🌱 來自: [[如何打造一座知識花園]]
蜥蜴與VIM 👷 工事中，敬請期待 🚧</description></item><item><title>24-hour urinary free cortisol</title><link>https://htlin222.github.io/garden/24-hour-urinary-free-cortisol/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/24-hour-urinary-free-cortisol/</guid><description>[!info] 🌱 來自: [[3 options for screening for hypercortisolism]]
24-hour urinary free cortisol Normal range is 4 to 40 mcg/24 hours or 11 to 110 nmol/day.</description></item><item><title>3 options for screening for hypercortisolism</title><link>https://htlin222.github.io/garden/3-options-for-screening-for-hypercortisolism/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/3-options-for-screening-for-hypercortisolism/</guid><description> [!info] 🌱 來自: [[Approach to suspected Cushing’s syndrome]]
3 options for screening for hypercortisolism [[24-hour urinary free cortisol]] (UFC) [[dexamethasone suppression test]]; [[11 pm Salivary Cortisol]]</description></item><item><title>48-hr LD-dexamethasone suppression test</title><link>https://htlin222.github.io/garden/48-hr-LD-dexamethasone-suppression-test/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/48-hr-LD-dexamethasone-suppression-test/</guid><description>[!info] 🌱 來自: [[Approach to suspected Cushing’s syndrome]]
48-hr LD-dexamethasone suppression test 48-h LD DST + CRH = 0.</description></item><item><title>adrenal incidentaloma</title><link>https://htlin222.github.io/garden/adrenal-incidentaloma/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/adrenal-incidentaloma/</guid><description>[!info] 🌱 來自: [[Primary Hyperaldosteronism]]
adrenal incidentaloma All patients with an adrenal mass that is discovered during diagnostic testing for another condition (an “incidentaloma”) should undergo biochemical testing to detect pheochromocytoma and excess cortisol secretion, and those who also have high blood pressure should undergo biochemical testing to detect primary hyperaldosteronism.</description></item><item><title>Approach to suspected Cushing’s syndrome</title><link>https://htlin222.github.io/garden/Approach-to-suspected-Cushings-syndrome/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-suspected-Cushings-syndrome/</guid><description> [!info] 🌱 來自: [[Diagnosis-Cushing’s Syndrome]]
Approach to suspected Cushing’s syndrome</description></item><item><title>BIPSS</title><link>https://htlin222.github.io/garden/BIPSS/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/BIPSS/</guid><description>[!info] 🌱 來自: [[Diagnosis-Cushing’s Syndrome]]
BIPSS bilat. Inferior petrosal 顳骨岩部 sinus vein sampling; ✓ petrosal:peripheral ACTH ratio (⊕ ≥2 basal, ≥3 after CRH)</description></item><item><title>catheter-directed pharmacomech</title><link>https://htlin222.github.io/garden/catheter-directed-pharmacomech/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/catheter-directed-pharmacomech/</guid><description>[!info] 🌱 來自: [[Mechanical intervention-venous thromboembolism]]
catheter-directed pharmacomech low-dose lytic infused (eg, tPA 1 mg/h for 12–24 hr per catheter) + U/S or mech fragmentation of clot.</description></item><item><title>CRH stimulations test</title><link>https://htlin222.github.io/garden/CRH-stimulations-test/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CRH-stimulations-test/</guid><description> [!info] 🌱 來自: [[Approach to suspected Cushing’s syndrome]]
CRH stimulations test CRH stim test = 1 µg/kg IV; ✓ cortisol and ACTH (⊕ if &amp;gt; 35% ↑ in ACTH or &amp;gt;20% ↑ in cortisol above baseline)</description></item><item><title>Cushing’s disease</title><link>https://htlin222.github.io/garden/Cushings-disease/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cushings-disease/</guid><description>[!info] 🌱 來自: [[Approach to suspected Cushing’s syndrome]]
Cushing’s disease Cushing’s syndrome 2° to pituitary ACTH hypersecretion
[[Cushing’s Syndrome]]</description></item><item><title>dexamethasone suppression test</title><link>https://htlin222.github.io/garden/dexamethasone-suppression-test/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dexamethasone-suppression-test/</guid><description>[!info] 🌱 來自: [[Diagnosis-Cushing’s Syndrome]]
dexamethasone suppression test give 1 mg at 11 p.m.; ✓ 8 a.m. serum cortisol (suppression if &amp;lt;1.</description></item><item><title>Diagnosis Cushing’s Syndrome</title><link>https://htlin222.github.io/garden/Diagnosis-Cushings-Syndrome/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-Cushings-Syndrome/</guid><description>[!info] 🌱 來自: [[Cushing’s Syndrome]]
Diagnosis Cushing’s Syndrome Typically performed in outPt setting Very difficult as inPt b/c hypercortisolism from acute illness and hosp.</description></item><item><title>Fondaparinux</title><link>https://htlin222.github.io/garden/Fondaparinux/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fondaparinux/</guid><description>[!info] 🌱 來自: [[Initial anticoagulation options for-venous thromboembolism]]
Fondaparinux Fondaparinux的建議劑量為每日一次2.5毫克。第一劑Fondaparinux應以靜脈注. 射的方式給藥，後續的劑量則應以皮下注射的方式給藥</description></item><item><title>Nonaldosterone mineralocorticoid excess</title><link>https://htlin222.github.io/garden/Nonaldosterone-mineralocorticoid-excess/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonaldosterone-mineralocorticoid-excess/</guid><description>[!info] 🌱 來自: [[Etiologies-hyperaldosteronism]]
Nonaldosterone mineralocorticoid excess 11β-HSD defic. (→ lack of inactivation of cortisol, which binds to mineralocorticoid recept.</description></item><item><title>pheochromocytoma</title><link>https://htlin222.github.io/garden/pheochromocytoma/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pheochromocytoma/</guid><description> [!info] 🌱 來自: [[Etiologies of hypercortisolism]]
pheochromocytoma</description></item><item><title>postthrombotic syndrome</title><link>https://htlin222.github.io/garden/postthrombotic-syndrome/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/postthrombotic-syndrome/</guid><description>[!info] 🌱 來自: [[Complications &amp;amp; prognosis-venous thromboembolism]]
postthrombotic syndrome PTS symptoms include leg pain sensations of leg heaviness, pulling, or fatigue limb swelling Symptoms can be present in various combinations, may be persistent or intermittent, and are usually aggravated by standing or walking and tend to improve with rest and leg elevation.</description></item><item><title>Rationale of BIPSS</title><link>https://htlin222.github.io/garden/Rationale-of-BIPSS/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rationale-of-BIPSS/</guid><description>[!info] 🌱 來自: [[BIPSS]]
Rationale of BIPSS In the setting of hypercortisolemia, the procedure is performed to differentiate a pituitary from an ectopic source of ACTH.</description></item><item><title>somatostatin scan</title><link>https://htlin222.github.io/garden/somatostatin-scan/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/somatostatin-scan/</guid><description>[!info] 🌱 來自: [[Approach to suspected Cushing’s syndrome]]
somatostatin scan An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis.</description></item><item><title>surgical embolectomy</title><link>https://htlin222.github.io/garden/surgical-embolectomy/</link><pubDate>Thu, 12 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/surgical-embolectomy/</guid><description>[!info] 🌱 來自: [[Mechanical intervention-venous thromboembolism]]
surgical embolectomy if large, proximal PE + hemodynamic compromise + contraindic. to lysis; consider in experienced ctr if large prox.</description></item><item><title>54321-PUMA-嘔怕</title><link>https://htlin222.github.io/garden/54321-PUMA-%E5%98%94%E6%80%95/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/54321-PUMA-%E5%98%94%E6%80%95/</guid><description>[!info] 🌱 來自: [[Diagnosis of migraine]]
54321-PUMA-嘔怕 一般對偏頭痛有「54321」這個診斷標準 5是患者在就診之前有5次以上的頭痛情形； 4與3分別是頭痛時間達4小時或到3天之間； 2 in 4 是在
unilateral location 頭部單側發作 pulsating quality 博動性症狀與運動 moderate or severe pain intensity 中、重度頭痛（疼痛指數7至10分） aggravation by or causing avoidance of routine physical activity 活動時症狀會加劇 1 in 2 則是有噁心、嘔吐或畏光、怕吵這2項擇1， 如有這5種情形，即可認定是偏頭痛病症。</description></item><item><title>central role of tissue factor in tumor progression and thrombosis</title><link>https://htlin222.github.io/garden/central-role-of-tissue-factor-in-tumor-progression-and-thrombosis/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/central-role-of-tissue-factor-in-tumor-progression-and-thrombosis/</guid><description> [!info] 🌱 來自: [[Venous Thromboembolism and Cancer]]
central role of tissue factor in tumor progression and thrombosis</description></item><item><title>Cockcroft-Gault formula</title><link>https://htlin222.github.io/garden/Cockcroft-Gault-formula/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cockcroft-Gault-formula/</guid><description> [!info] 🌱 來自: [[Hestia Criteria for Outpatient Pulmonary Embolism Treatment]]
Cockcroft-Gault formula</description></item><item><title>critical actions of Pulmonary Embolism Severity Index PESI</title><link>https://htlin222.github.io/garden/critical-actions-of-Pulmonary-Embolism-Severity-Index-PESI/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/critical-actions-of-Pulmonary-Embolism-Severity-Index-PESI/</guid><description>[!info] 🌱 來自: [[Pulmonary Embolism Severity Index PESI]]
critical actions of Pulmonary Embolism Severity Index PESI The PESI is only meant for risk stratification of pulmonary embolism after the diagnosis has been made.</description></item><item><title>d-dimer</title><link>https://htlin222.github.io/garden/d-dimer/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/d-dimer/</guid><description>[!info] 🌱 來自: [[Diagnostic studies—DVT]]
d-dimer by-product of the blood clotting and break-down process that can be measured via analysis of a blood sample.</description></item><item><title>deep vein thrombosis</title><link>https://htlin222.github.io/garden/deep-vein-thrombosis/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/deep-vein-thrombosis/</guid><description> [!info] 🌱 來自: [[venous thromboembolism]]
deep vein thrombosis [[Clinical manifestations—DVT]] [[Simplified Wells Pretest Probability Scoring of DVT]] [[Diagnostic studies—DVT]]</description></item><item><title>Diagnostic studies—DVT</title><link>https://htlin222.github.io/garden/Diagnostic-studiesDVT/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studiesDVT/</guid><description>[!info] 🌱 來自: [[deep vein thrombosis]]
Diagnostic studies—DVT [[d-dimer]]: (DVT excluded at D-dimer levels &amp;lt;0.5 µg/mL = 500 µg/L).</description></item><item><title>fluoroquinolones</title><link>https://htlin222.github.io/garden/fluoroquinolones/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fluoroquinolones/</guid><description>[!info] 🌱 來自: [[preferred antibiotics for uncomplicated cystitis caused by ESBL-E]]
fluoroquinolones have been associated with an increased risk for prolonged QTc intervals, tendinitis and tendon rupture, aortic dissections, seizures, peripheral neuropathy, and Clostridioides difficile infections, compared to other antibiotics</description></item><item><title>Hestia Criteria for Outpatient Pulmonary Embolism Treatment</title><link>https://htlin222.github.io/garden/Hestia-Criteria-for-Outpatient-Pulmonary-Embolism-Treatment/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hestia-Criteria-for-Outpatient-Pulmonary-Embolism-Treatment/</guid><description>[!info] 🌱 來自: [[Risk factors-venous thromboembolism]]
Hestia Criteria for Outpatient Pulmonary Embolism Treatment Hemodynamically unstable sBP &amp;lt;100 mmHg and HR &amp;gt;100, needing ICU care, or by clinician judgment</description></item><item><title>Homan’s sign</title><link>https://htlin222.github.io/garden/Homans-sign/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Homans-sign/</guid><description>[!info] 🌱 來自: [[Clinical manifestations—DVT]]
Homan’s sign Homan’s sign test also called dorsiflexon sign test is a physical examination procedure that is used to test for Deep Vein Thrombosis (DVT).</description></item><item><title>IDSA Guidance</title><link>https://htlin222.github.io/garden/IDSA-Guidance/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/IDSA-Guidance/</guid><description>[!info] 🌱 來自: [[Treatment of UTIs]]
IDSA Guidance [[treatment of antimicrobial-resistant gram-negative infections]]</description></item><item><title>Interpretation of Pulmonary Embolism Severity Index PESI</title><link>https://htlin222.github.io/garden/Interpretation-of-Pulmonary-Embolism-Severity-Index-PESI/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Interpretation-of-Pulmonary-Embolism-Severity-Index-PESI/</guid><description>[!info] 🌱 來自: [[Pulmonary Embolism Severity Index PESI]]
Interpretation of Pulmonary Embolism Severity Index PESI 0-65 I 0.0-1.6%</description></item><item><title>preferred antibiotics for uncomplicated cystitis caused by ESBL-E</title><link>https://htlin222.github.io/garden/preferred-antibiotics-for-uncomplicated-cystitis-caused-by-ESBL-E/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/preferred-antibiotics-for-uncomplicated-cystitis-caused-by-ESBL-E/</guid><description>[!info] 🌱 來自: [[treatment of antimicrobial-resistant gram-negative infections]]
preferred antibiotics for uncomplicated cystitis caused by ESBL-E Nitrofurantoin and trimethoprim-sulfamethoxazole have been shown to be safe and effective options for uncomplicated cystitis, including uncomplicated ESBL-E cystitis.</description></item><item><title>PRES</title><link>https://htlin222.github.io/garden/PRES/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/PRES/</guid><description>[!info] 🌱 來自: [[warning signs of headache]]
PRES Posterior reversible encephalopathy syndrome (PRES)
characterized by headache, visual disturbances seizures altered mental states.</description></item><item><title>pulmonary embolism</title><link>https://htlin222.github.io/garden/pulmonary-embolism/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pulmonary-embolism/</guid><description> [!info] 🌱 來自: [[venous thromboembolism]]
pulmonary embolism [[Clinical manifestations—PE]] [[Modified Wells Pretest Probability Scoring for PE ]] [[Diagnostic studies of PE]] [[Approach to suspected PE]] [[Workup for idiopathic VTE]] [[Risk stratification for Pts with PE]]</description></item><item><title>Pulmonary Embolism Severity Index PESI</title><link>https://htlin222.github.io/garden/Pulmonary-Embolism-Severity-Index-PESI/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pulmonary-Embolism-Severity-Index-PESI/</guid><description>[!info] 🌱 來自: [[Risk factors-venous thromboembolism]]
Pulmonary Embolism Severity Index PESI Predicts 30-day outcome of patients with pulmonary embolism using 11 clinical criteria.</description></item><item><title>Red Flags-SNOOP for headache</title><link>https://htlin222.github.io/garden/Red-Flags-SNOOP-for-headache/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Red-Flags-SNOOP-for-headache/</guid><description>[!info] 🌱 來自: [[warning signs of headache]]
Red Flags-SNOOP for headache Systemic Sx (fever, weight loss) Secondary risk factors (HIV, cancer) Neurologic Sx (confusion, impaired alertness or consciousness) Onset (sudden, abrupt, or split-second) Older (&amp;gt;50 yr) Pattern change Progressive Precipitated by Valsalva Postural aggravation Papilledema Dodick DW.</description></item><item><title>risk classification of pulmonary embolism</title><link>https://htlin222.github.io/garden/risk-classification-of-pulmonary-embolism/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/risk-classification-of-pulmonary-embolism/</guid><description>[!info] 🌱 來自: [[Risk stratification for Pts with PE]]
risk classification of pulmonary embolism High risk (“massive”): * hemodyn unstable w/ arrest, * obstructive shock * persistent HoTN Intermediate risk (“submassive”): * sPESI ≥1 * “Intermediate-high” if both RV dysfunction &amp;amp; elevated Tn * “Intermediate-low” if either or neither RV dysfunction or elevated Tn Low risk: * clinically stable, * sPESI = 0, * normal RV function, * normal Tn [[simplified PE severity index]]</description></item><item><title>simplified PE severity index</title><link>https://htlin222.github.io/garden/simplified-PE-severity-index/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/simplified-PE-severity-index/</guid><description>[!info] 🌱 來自: [[Risk stratification for Pts with PE]]
simplified PE severity index age &amp;gt;80 y</description></item><item><title>tamoxifen</title><link>https://htlin222.github.io/garden/tamoxifen/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/tamoxifen/</guid><description>[!info] 🌱 來自: [[Virchow’s triad]]
tamoxifen 建議參考劑量 每日20～40mg。
常見副作用 月經週期不規則、潮紅、陰道分泌物。
少見但嚴重之副作用 深層靜脈栓塞、 史蒂芬強生症候群、 白內障、 子宮內膜癌、 間質性肺炎、 肺栓塞。
致吐等級 低。</description></item><item><title>treatment of antimicrobial-resistant gram-negative infections</title><link>https://htlin222.github.io/garden/treatment-of-antimicrobial-resistant-gram-negative-infections/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/treatment-of-antimicrobial-resistant-gram-negative-infections/</guid><description>[!info] 🌱 來自: [[IDSA Guidance]]
treatment of antimicrobial-resistant gram-negative infections [[preferred antibiotics for uncomplicated cystitis caused by ESBL-E]]</description></item><item><title>Venous Thromboembolism and Cancer</title><link>https://htlin222.github.io/garden/Venous-Thromboembolism-and-Cancer/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Venous-Thromboembolism-and-Cancer/</guid><description>[!info] 🌱 來自: [[Risk factors-venous thromboembolism]]
Venous Thromboembolism and Cancer Venous Thromboembolism and Cancer | Circulation
Pathophysiological changes that favor thrombosis in patients with cancer include platelet activation direct factor X activation, decreased hepatic anticoagulant synthesis reduced hepatic clearance of coagulation factors and autoimmune phenomena such as the development of antiphospholipid antibodies Most patients with active cancer have evidence of chronic systemic coagulation activation, such as elevated plasma d-dimer levels</description></item><item><title>Virchow’s triad</title><link>https://htlin222.github.io/garden/Virchows-triad/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Virchows-triad/</guid><description>[!info] 🌱 來自: [[Risk factors-venous thromboembolism]]
Virchow’s triad s.i.t: statis, injury, thrombophilia
Stasis: bed rest, inactivity CHF CVA w/in 3 mo air travel &amp;gt;6 h.</description></item><item><title>warning signs of headache</title><link>https://htlin222.github.io/garden/warning-signs-of-headache/</link><pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/warning-signs-of-headache/</guid><description>[!info] 🌱 來自: [[Clinical evaluation of Secondary causes of headaches]]
warning signs of headache (should prompt neuroimaging)
Explosive onset (vasc) “worst HA of life” (SAH, RCVS) meningismus (SAH, infxn) Positional: lying &amp;gt;standing (↑ ICP) N/V (↑ ICP; migraines) coughing/bearing down (↑ ICP) Visual sx: diplopia, blurring, ↓ acuity (GCA, glaucoma, ↑ ICP) eye pain glaucoma, trigeminal autonomic cephalalgia optic neuritis Abnl exam (struct.</description></item><item><title>epithelial sodium channel - ENaC</title><link>https://htlin222.github.io/garden/epithelial-sodium-channel-ENaC/</link><pubDate>Tue, 10 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/epithelial-sodium-channel-ENaC/</guid><description>[!info] 🌱 來自: [[Liddle’s syndrome]]
epithelial sodium channel - ENaC open in response to signals that sodium levels in the blood are too low, which allows sodium to flow into cells.</description></item><item><title>licorice</title><link>https://htlin222.github.io/garden/licorice/</link><pubDate>Tue, 10 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/licorice/</guid><description>[!info] 🌱 來自: [[Etiologies-of-Metabolic-Alkalosis]]
licorice (glycyrrhizic acid inhibits 11β-HSD)
皮質醇，一種糖皮質激素，與糖皮質激素受體結合。 然而，由於其與醛固酮的分子相似性， 它也在較高濃度下與鹽皮質激素受體結合。 醛固酮和皮質醇對鹽皮質激素受體有相似的親和力； 然而，循環中的皮質醇遠遠多於醛固酮。
為了防止皮質醇對鹽皮質激素受體的過度刺激 11β-HSD將具有生物活性的皮質醇轉化為不再與鹽皮質激素受體結合的非活性皮質醇 11β-HSD與腎上腺皮質激素受體共定位。 甘草含有甘草酸和甘草次酸，能抑制11β-HSD，導致鹽皮質激素過多症候群。 皮質醇水平隨之升高</description></item><item><title>Liddle’s syndrome</title><link>https://htlin222.github.io/garden/Liddles-syndrome/</link><pubDate>Tue, 10 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Liddles-syndrome/</guid><description>[!info] 🌱 來自: [[Etiologies-hyperaldosteronism]]
Liddle’s syndrome Liddle syndrome is an inherited form of high blood pressure (hypertension).
caused by mutations in the SCNN1B or SCNN1G gene.</description></item><item><title>opportunistic infections</title><link>https://htlin222.github.io/garden/opportunistic-infections/</link><pubDate>Tue, 10 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/opportunistic-infections/</guid><description>[!info] 🌱 來自: [[infectious disease]]
opportunistic infections test</description></item><item><title>abdominal pain</title><link>https://htlin222.github.io/garden/abdominal-pain/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/abdominal-pain/</guid><description>abdominal pain</description></item><item><title>acid-base abnormalities</title><link>https://htlin222.github.io/garden/acid-base-abnormalities/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acid-base-abnormalities/</guid><description>acid-base abnormalities</description></item><item><title>adult-onset Still’s disease</title><link>https://htlin222.github.io/garden/adult-onset-Stills-disease-/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/adult-onset-Stills-disease-/</guid><description>from: [[rheumatology]]
adult-onset Still’s disease</description></item><item><title>aids hiv infection</title><link>https://htlin222.github.io/garden/aids-hiv-infection/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aids-hiv-infection/</guid><description>from: [[symptom to diagnosis]]
aids hiv infection</description></item><item><title>approach to rheumatic disease</title><link>https://htlin222.github.io/garden/approach-to-rheumatic-disease/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/approach-to-rheumatic-disease/</guid><description>from: [[rheumatology]]
approach to rheumatic disease</description></item><item><title>brother</title><link>https://htlin222.github.io/garden/brother/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/brother/</guid><description>from: [[orphan]]
brother [[cousin]]</description></item><item><title>BufNewFile</title><link>https://htlin222.github.io/garden/BufNewFile/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/BufNewFile/</guid><description>BufNewFile</description></item><item><title>Clinical features-peripheral artery disease</title><link>https://htlin222.github.io/garden/Clinical-features-peripheral-artery-disease/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-features-peripheral-artery-disease/</guid><description> [!info] 🌱 來自: [[peripheral artery disease]]
Clinical features-peripheral artery disease</description></item><item><title>Conservative therapy of nerve root compression</title><link>https://htlin222.github.io/garden/Conservative-therapy-of-nerve-root-compression/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Conservative-therapy-of-nerve-root-compression/</guid><description>from: [[Evaluation and treatment of nerve root compression]]
Conservative therapy of nerve root compression avoid bending/lifting; soft collar (cervical radiculopathy); NSAIDs; muscle relaxants; lidocaine patch/ointment; Rx neuropathic pain (see “Peripheral Neuropathies”); physical/occup therapy.</description></item><item><title>crystal deposition arthritides</title><link>https://htlin222.github.io/garden/crystal-deposition-arthritides/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/crystal-deposition-arthritides/</guid><description>from: [[rheumatology]]
crystal deposition arthritides</description></item><item><title>Diagnosis-peripheral artery disease</title><link>https://htlin222.github.io/garden/Diagnosis-peripheral-artery-disease/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-peripheral-artery-disease/</guid><description> [!info] 🌱 來自: [[peripheral artery disease]]
Diagnosis-peripheral artery disease</description></item><item><title>differential diagnosis of back pain</title><link>https://htlin222.github.io/garden/differential-diagnosis-of-back-pain/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/differential-diagnosis-of-back-pain/</guid><description>from: [[back and spinal cord disease]]
differential diagnosis of back pain [[Musculoskeletal ddx of back pain]]
Spinal cord (myelopathy) nerve root (radiculopathy):</description></item><item><title>Duty note of hypokalemia</title><link>https://htlin222.github.io/garden/Duty-note-of-hypokalemia/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Duty-note-of-hypokalemia/</guid><description>from: [[/Users/htlin/Documents/Medical/hypokalemia]]
Duty note of hypokalemia</description></item><item><title>Etiologies of spinal cord compression</title><link>https://htlin222.github.io/garden/Etiologies-of-spinal-cord-compression/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-spinal-cord-compression/</guid><description>from: [[spinal cord compression]]
Etiologies of spinal cord compression tumor (vertebral mets intradural meningioma/[[neurofibroma]]) epidural abscess/ hematoma, vascular malformation (dural AV fistula) degen.</description></item><item><title>Evaluation and treatment of nerve root compression</title><link>https://htlin222.github.io/garden/Evaluation-and-treatment-of-nerve-root-compression/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-and-treatment-of-nerve-root-compression/</guid><description>from: [[nerve root compression]]
Evaluation and treatment of nerve root compression (NEJM 2016;374:1763)
MRI if sx not improved after 6 wk of conservative tx; if nondiagnostic, consider EMG/NCS</description></item><item><title>Evaluation and treatment of spinal cord compression</title><link>https://htlin222.github.io/garden/Evaluation-and-treatment-of-spinal-cord-compression/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-and-treatment-of-spinal-cord-compression/</guid><description>from: [[spinal cord compression]]
Evaluation and treatment of spinal cord compression Empiric spine immobilization (collar, board) for all trauma patients</description></item><item><title>History taking of back and spinal cord disease</title><link>https://htlin222.github.io/garden/History-taking-of-back-and-spinal-cord-disease/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/History-taking-of-back-and-spinal-cord-disease/</guid><description>from: [[back and spinal cord disease]]
History taking of back and spinal cord disease location, timing (acute/subacute/chronic) worse w/ Valsalva radiation trauma wt loss cancer fever immunocompromised IVDU neurologic symptom saddle anesthesia Lhermitte phenomenon bowel/bladder/sexual sx (retention, incontinence)</description></item><item><title>inpatient diabetes management</title><link>https://htlin222.github.io/garden/inpatient-diabetes-management/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/inpatient-diabetes-management/</guid><description> [!info] 🌱 來自: [[endocrinology]]
inpatient diabetes management</description></item><item><title>Laboratory of back and spinal cord disease</title><link>https://htlin222.github.io/garden/Laboratory-of-back-and-spinal-cord-disease/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Laboratory-of-back-and-spinal-cord-disease/</guid><description>from: [[back and spinal cord disease]]
Laboratory of back and spinal cord disease (depending on suspicion): CBC w/ diff, ESR/CRP, Ca, PO4, CSF, BCx</description></item><item><title>mother</title><link>https://htlin222.github.io/garden/mother/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mother/</guid><description>mother [[father]]</description></item><item><title>Musculoskeletal ddx of back pain</title><link>https://htlin222.github.io/garden/Musculoskeletal-ddx-of-back-pain/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Musculoskeletal-ddx-of-back-pain/</guid><description>from: [[differential diagnosis of back pain]]
Musculoskeletal ddx of back pain involving spine (vertebra, facet joints), paraspinal muscles &amp;amp; ligaments sacroiliac joint, or hip joint Spondylolisthesis vertebral fx OA inflam.</description></item><item><title>nerve root compression</title><link>https://htlin222.github.io/garden/nerve-root-compression/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nerve-root-compression/</guid><description>nerve root compression (NEJM 2015;372:1240 &amp;amp; Continuum 2021;27:163)
Radicular pain aggravated by activity (esp. bending, straining, coughing), relieved by lying</description></item><item><title>Neuro exam of back and spinal cord disease</title><link>https://htlin222.github.io/garden/Neuro-exam-of-back-and-spinal-cord-disease/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Neuro-exam-of-back-and-spinal-cord-disease/</guid><description>from: [[back and spinal cord disease]]
Neuro exam of back and spinal cord disease full motor (incl. sphincter tone); gait; sensory (temp/pain, position, vibration; ↑ perineal; ?</description></item><item><title>neurofibroma</title><link>https://htlin222.github.io/garden/neurofibroma/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/neurofibroma/</guid><description>from: [[Etiologies of spinal cord compression]]
neurofibroma</description></item><item><title>neurogenic claudication</title><link>https://htlin222.github.io/garden/neurogenic-claudication/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/neurogenic-claudication/</guid><description>from: [[nerve root compression]]
neurogenic claudication Lumbar spinal stenosis (with nerve root compression)
Radicular back/buttock pain
Radiating down legs
Worse with Walking &amp;amp; standing; Hyperextension/lying prone</description></item><item><title>Pathophysiology of nerve root compression</title><link>https://htlin222.github.io/garden/Pathophysiology-of-nerve-root-compression/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-of-nerve-root-compression/</guid><description>from: [[nerve root compression]]
Pathophysiology of nerve root compression &amp;lt;65 y: 90% from disc herniation. ≥65 y also w/ more degenerative contributors: ligamentous hypertrophy, osteophyte formation, facet arthropathy, neural foraminal narrowing</description></item><item><title>Patrick FABER test</title><link>https://htlin222.github.io/garden/Patrick-FABER-test/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Patrick-FABER-test/</guid><description>from: [[back and spinal cord disease]]
Patrick FABER test (SI joint synd): severe pain on hip ext rotation; 70% Se, 100% Sp</description></item><item><title>Red flags of back and spinal cord disease</title><link>https://htlin222.github.io/garden/Red-flags-of-back-and-spinal-cord-disease/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Red-flags-of-back-and-spinal-cord-disease/</guid><description>from: [[back and spinal cord disease]]
Red flags of back and spinal cord disease acute change (pain, weakness), upper motor neuron signs (hyperreflexia, upgoing toes) cauda equina conus medullaris syndromes (saddle anesthesia bowel/bladder or sexual dysfunction reduced rectal tone loss of sacral reflexes) dyspnea when flat (C3–C5) pain at rest or at night</description></item><item><title>referred pain from visceral disease of back pain</title><link>https://htlin222.github.io/garden/referred-pain-from-visceral-disease-of-back-pain/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/referred-pain-from-visceral-disease-of-back-pain/</guid><description>from: [[differential diagnosis of back pain]]
referred pain from visceral disease of back pain GI: PUD cholelithiasis pancreatitis pancreatic cancer GU: pyelonephritis nephrolithiasis uterine or ovarian cancer salpingitis Vascular: aortic dissection leaking aortic aneurysm</description></item><item><title>rheumatoid arthritis</title><link>https://htlin222.github.io/garden/rheumatoid-arthritis/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/rheumatoid-arthritis/</guid><description>from: [[rheumatology]]
rheumatoid arthritis</description></item><item><title>sciatica</title><link>https://htlin222.github.io/garden/sciatica/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/sciatica/</guid><description>from: [[nerve root compression]]
sciatica = radicular pain radiating from buttocks down lateral aspect of leg, often to knee or lateral calf ± numbness and paresthesias radiating to lateral foot.</description></item><item><title>screening and health maintenance</title><link>https://htlin222.github.io/garden/screening-and-health-maintenance/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/screening-and-health-maintenance/</guid><description>from: [[symptom to diagnosis]]
screening and health maintenance</description></item><item><title>spinal cord compression</title><link>https://htlin222.github.io/garden/spinal-cord-compression/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/spinal-cord-compression/</guid><description>from: [[neurology]]
spinal cord compression (Continuum 2021;27:163)
[[Etiologies of spinal cord compression]]
Acute: flaccid paraparesis and absent reflexes (“spinal shock”)</description></item><item><title>spondyloarthritis</title><link>https://htlin222.github.io/garden/spondyloarthritis/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/spondyloarthritis/</guid><description>from: [[rheumatology]]
spondyloarthritis</description></item><item><title>spurling sign</title><link>https://htlin222.github.io/garden/spurling-sign/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/spurling-sign/</guid><description>from: [[back and spinal cord disease]]
spurling sign (cervical radiculopathy):
radicular pain with: downward force to extended &amp;amp; ipsilaterally rotated head 30% Se, 93% Sp</description></item><item><title>straight leg raise</title><link>https://htlin222.github.io/garden/straight-leg-raise/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/straight-leg-raise/</guid><description>from: [[back and spinal cord disease]]
straight leg raise (sciatica or lumbosacral radiculopathy): radicular pain at 30–70°
ipsilateral: 92% Se, 28% Sp</description></item><item><title>Vascular Claudication</title><link>https://htlin222.github.io/garden/Vascular-Claudication/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vascular-Claudication/</guid><description>from: [[nerve root compression]]
Vascular Claudication Peripheral artery disease
(with limb ischemia)
Cramping leg pain
Mostly in calves; radiating up legs</description></item><item><title>vim append</title><link>https://htlin222.github.io/garden/vim-append/</link><pubDate>Mon, 09 Jan 2023 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/vim-append/</guid><description>from: [[Vimwiki]]
vim append</description></item><item><title/><link>https://htlin222.github.io/garden/change/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/change/</guid><description/></item><item><title/><link>https://htlin222.github.io/garden/chest/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chest/</guid><description/></item><item><title/><link>https://htlin222.github.io/garden/coronary/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/coronary/</guid><description/></item><item><title/><link>https://htlin222.github.io/garden/orphan/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/orphan/</guid><description>[[mother]] [[sister]] [[brother]]</description></item><item><title/><link>https://htlin222.github.io/garden/stable/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/stable/</guid><description/></item><item><title>1</title><link>https://htlin222.github.io/garden/PART-1-The-Profession-of-Medicine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/PART-1-The-Profession-of-Medicine/</guid><description>The Profession of Medicine PA RT 1 The Practice of Medicine The Editors
1 ENDURING VALUES OF THE MEDICAL PROFESSION No greater opportunity, responsibility, or obligation can fall to the lot of a human being than to become a physician.</description></item><item><title>2018 ACC AHA Cholesterol Guidelines</title><link>https://htlin222.github.io/garden/2018-ACC-AHA-Cholesterol-Guidelines/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/2018-ACC-AHA-Cholesterol-Guidelines/</guid><description>2018 ACC AHA Cholesterol Guidelines Population Recommendation
Very high-risk ASCVD* High-intensity statin; add EZE then PCSK9i if LDL-C ≥70
Clinical ASCVD High-intensity statin (?</description></item><item><title>5-y survival of lung cancer</title><link>https://htlin222.github.io/garden/5-y-survival-of-lung-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/5-y-survival-of-lung-cancer/</guid><description>5-y survival of lung cancer ~70–90% for stage I, 50–60% stage II, 15–35% stage III, 0–10% stage IV (J Thorac Oncol 2016;11:39); survival improving with newer therapies (NEJM 2020;383:640).</description></item><item><title>5H5T</title><link>https://htlin222.github.io/garden/5H5T/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/5H5T/</guid><description>5H5T 5H Hypovolemia: volume Hypoxia: oxygenate H+ ions (acidosis): NaHCO3 Hypo/hyper K: KCI/Ca et al. Hypothermia: warm
5T [[POCUS]] Tension PTX: needle decomp.</description></item><item><title>ABG-vs-VBG</title><link>https://htlin222.github.io/garden/ABG-vs-VBG/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ABG-vs-VBG/</guid><description>ABG-vs-VBG concordant for pH (~0.04), HCO3 (~2 mEq) but not PCO2 (~8±17 mmHg) VBG can be used to screen for hypercarbia w/ PCO2 cutoff ≥45 mmHg (100% Se), but may not accurately assess degree of hypercarbia (Am J Emerg Med 2012;30:896)</description></item><item><title>Ablation-atrial fibrillation</title><link>https://htlin222.github.io/garden/Ablation-atrial-fibrillation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ablation-atrial-fibrillation/</guid><description>Ablation-atrial fibrillation (Heart Rhythm 2017;14:e445; JACC 2020;75:1689)
Controlling triggers in pulm veins effective when little atrial fibrosis; as AF persists, substrate more complex Pulm vein isolation (radiofreq or cryo; NEJM 2016;374:2235): ~70% success; superior to AAD (JAMA 2014;311:692; NEJM 2021;384:305 &amp;amp; 316) &amp;amp; ↑ QoL (JAMA 2019;321:1059) If NYHA II–IV + EF &amp;lt;35%, ablation ↓ D/HF hosp vs.</description></item><item><title>abnormal liver tests</title><link>https://htlin222.github.io/garden/abnormal-liver-tests/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/abnormal-liver-tests/</guid><description>abnormal liver tests [[Tests of hepatocellular injury or cholestasis]] [[Tests of hepatic function]] [[Patterns of LFTs]] [[Acute mild-to-moderate elevation in ALT AST ]] [[Chronic mild-to-moderate elevation in ALT AST ]] [[Acute severe elevation in ALT AST]] [[Approach to abnormal liver tests with cholestatic pattern]] [[Approach to abnormal liver tests with infiltrative pattern]] [[Medication causes of abnormal LFTs]]</description></item><item><title>about line</title><link>https://htlin222.github.io/garden/about-line/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/about-line/</guid><description>about line</description></item><item><title>ACC AHA Classification for Office-Based BP</title><link>https://htlin222.github.io/garden/ACC-AHA-Classification-for-Office-Based-BP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ACC-AHA-Classification-for-Office-Based-BP/</guid><description>ACC AHA Classification for Office-Based BP (HTN 2018;71:e13) Category Systolic (mmHg) Diastolic (mmHg) Normal &amp;lt;120 &amp;lt;80 Elevated 120–129 &amp;lt;80 Stage 1 hypertension 130–139 80–89 Stage 2 hypertension ≥140 ≥90</description></item><item><title>accessory pathways wolff-parkinson-white</title><link>https://htlin222.github.io/garden/accessory-pathways-wolff-parkinson-white/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/accessory-pathways-wolff-parkinson-white/</guid><description>accessory pathways (wolff-parkinson-white) [[Definitions-accessory pathways (wolff-parkinson-white)]] [[Classic tachycardias of WPW accessory pathways]] [[Treatment-accessory pathways (wolff-parkinson-white)]]</description></item><item><title>Acetaminophen hepatotoxicity</title><link>https://htlin222.github.io/garden/Acetaminophen-hepatotoxicity/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acetaminophen-hepatotoxicity/</guid><description>Acetaminophen hepatotoxicity (Clin J Transl Hepatol 2016;4:131; BMJ 2016;353:i2579)
[[Pathophysiology-Acetaminophen hepatotoxicity]]
CYP2E1 induced by fasting, alcohol, certain anticonvulsants and anti-TB drugs, resulting in injury with even low doses (2–6 g) of acetaminophen</description></item><item><title>Acetaminophen-toxicology</title><link>https://htlin222.github.io/garden/Acetaminophen-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acetaminophen-toxicology/</guid><description>Acetaminophen-toxicology Vomiting, ↑ AG &amp;amp; nl OG metabolic acidosis, hepatitis &amp;amp; hepatic failure, renal failure
N-acetylcysteine (NAC) infusion
Hemodialysis if massive O/D</description></item><item><title>acid-base disturbances</title><link>https://htlin222.github.io/garden/acid-base-disturbances/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acid-base-disturbances/</guid><description>acid-base disturbances [[Definitions-acid-base disturbances]] [[Consequences-of-Severe-Acid-Base-Disturbances]] [[Workup-acid-base disturbances]] [[metabolic-acidosis]] [[metabolic-alkalosis]] [[respiratory-acidosis]] [[respiratory-alkalosis]]</description></item><item><title>Acinetobacter sp</title><link>https://htlin222.github.io/garden/Acinetobacter-sp/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acinetobacter-sp/</guid><description>Acinetobacter sp aerobic non-fermentative coccobacilary gram negative bacilli
cause soft tissue, wounds and bone, urinary tract infections, meningitis ;eye infection resistance is a problem 50% multidrug resistant extended spectrum beta-lactamase Tigecycine is not recommended sub-theraputic serum concentrations in bacteremia increased risk of all cause mortality</description></item><item><title>ACLS</title><link>https://htlin222.github.io/garden/ACLS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ACLS/</guid><description>ACLS [[CPR人力配置]] [[ICU]]
[[electrocardiography]] [[arrhythmias]] [[Pulseless Arrest]] [[ACLS Tachycardia Algorithm]] [[ACLS Bradycardia Algorithm]]</description></item><item><title>ACLS Bradycardia Algorithm</title><link>https://htlin222.github.io/garden/ACLS-Bradycardia-Algorithm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ACLS-Bradycardia-Algorithm/</guid><description>ACLS Bradycardia Algorithm 小藍上不到4個叫慢(&amp;lt;60pbm)，八個叫快(100bpm+) bradycardia w/ Pulse (HR &amp;lt;50 &amp;amp; inadequate for clinical condition) Airway, IV Access, O2, monitor BP &amp;amp; rhythm, 12-lead ECG if Type ll 2° AVB or 3° AVB proceed to pacing ASAP 二度2以上不用Adenosine atropine 1 mg IV q3-5min, max 3 mg 打三次 心律判讀 規則:一或三</description></item><item><title>ACLS Tachycardia Algorithm</title><link>https://htlin222.github.io/garden/ACLS-Tachycardia-Algorithm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ACLS-Tachycardia-Algorithm/</guid><description>ACLS Tachycardia Algorithm [[electrocardiography]]
unstable = hypotension, change of MS, s/s shock, chest pain, heart failure</description></item><item><title>Acromegaly</title><link>https://htlin222.github.io/garden/Acromegaly/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acromegaly/</guid><description>Acromegaly (↑ GH; 10% of adenomas; Nat Rev Dis Primer 2019;5:1)
Physiology: stimulates secretion of insulin-like growth factor 1 (IGF-1) Clinical manifestations: ↑ soft tissue, arthralgias, jaw enlargement, headache, carpal tunnel syndrome, macroglossia, hoarseness, sleep apnea, amenorrhea, impotence, diabetes mellitus, acanthosis/skin tags, ↑ sweating, HTN/CMP, colonic polyps Diagnostic studies: low utility in checking random GH levels because of pulsatile secretion ↑ IGF-1 (somatomedin C); ± ↑ PRL; OGTT → GH not suppressed to &amp;lt;1 (&amp;lt;0.</description></item><item><title>Acute Anti Ischemic and Analgesic Treatment</title><link>https://htlin222.github.io/garden/Acute-Anti-Ischemic-and-Analgesic-Treatment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-Anti-Ischemic-and-Analgesic-Treatment/</guid><description>Acute Anti Ischemic and Analgesic Treatment Nitrates (SL or IV) 0.3–0.4 mg SL q5min × 3, then consider IV if still sx Use for relief of sx, Rx for HTN or HF.</description></item><item><title>acute aortic syndromes</title><link>https://htlin222.github.io/garden/acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-aortic-syndromes/</guid><description>acute aortic syndromes [[Definitions-acute aortic syndromes]] [[Classification-acute aortic syndromes]] [[Risk factors-acute aortic syndromes]] [[Clinical Manifestations and Physical Exam-acute aortic syndromes]] [[Initial evaluation diagnostic studies-acute aortic syndromes]] [[Treatment-acute aortic syndromes]] [[Complications-acute aortic syndromes]]</description></item><item><title>acute bacterial meningitis</title><link>https://htlin222.github.io/garden/acute-bacterial-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-bacterial-meningitis/</guid><description>acute bacterial meningitis Definition Inflammation of tissue around the brain/spinal cord Usually arising from nasopharynx (hematogenous spread), bacteremia, or direct inoculation (surgery, contiguous infection, trauma, foreign body [eg, CSF shunt]) [[Microbiology in Bacterial Meningitis]] Clinical manifestations (Lancet 2016;339:16) Headache (84%), fever (74%), stiff neck (74%), photosensitivity, GCS &amp;lt;14 (71%), nausea (62%), seizure (23%); 95% have 2 of 4: HA, fever, stiff neck, ΔMS Presentation may be atypical (eg, lethargy w/o fever) in elderly and immunosupp.</description></item><item><title>Acute bacterial skin and skin structure infections</title><link>https://htlin222.github.io/garden/Acute-bacterial-skin-and-skin-structure-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-bacterial-skin-and-skin-structure-infections/</guid><description>Acute bacterial skin and skin structure infections Primary Regimens Elevate the involved leg Inpatient parenteral therapy: Penicillin G 1 to 2 million units IV q6h If history of pencillin skin rash and nothing to suggest IgE-mediated allergic reaction: Cefazolin 1 gm IV q8h or Ceftriaxone 2 gm IV once daily If history/evidence of past IgE-mediated allergic reaction (anaphylaxis), then may be forced to use: Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 μg/mL x hr (see vancomycin AUC dosing calculator); alternative is trough of 15-20 μg/mL Linezolid 600 mg IV/po bid Treat IV until afebrile; then outpatient Penicillin V-K 500 mg po qid ac and hs for a total of 10 days of therapy.</description></item><item><title>acute coronary syndromes</title><link>https://htlin222.github.io/garden/acute-coronary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-coronary-syndromes/</guid><description>acute coronary syndromes [[NSTE-ACS]] (Circ 2014;130:e344; EHJ 2021;42:1289) [[STEMI]] (Circ 2013;127:529; EHJ 2018;39:119) [[CHECKLIST AND LONG TERM POST ACS MANAGEMENT]]</description></item><item><title>Acute hemolytic</title><link>https://htlin222.github.io/garden/Acute-hemolytic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-hemolytic/</guid><description>Acute hemolytic : fever, HoTN, flank pain, AKI w/in 24 h. Due to ABO incompatibility → preformed Abs vs. donor RBCs.</description></item><item><title>Acute Infectious Etiologies</title><link>https://htlin222.github.io/garden/Acute-Infectious-Etiologies-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-Infectious-Etiologies-/</guid><description>Acute Infectious Etiologies [[NONINFLAMMATORY-Acute Infectious Etiologies]] [[INFLAMMATORY-Acute Infectious Etiologies]]</description></item><item><title>Acute interstitial nephritis</title><link>https://htlin222.github.io/garden/Acute-interstitial-nephritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-interstitial-nephritis/</guid><description>Acute interstitial nephritis etiology Allergic: β-lactams, sulfa drugs, NSAIDs, PPIs Infection: pyelo, viral, legionella, TB, leptospirosis Infiltrative: sarcoid, lymphoma, leukemia Autoimmune: Sjögren’s, TINU, IgG4, SLE, ICIs treatment (CJASN 2017;12:2046 &amp;amp; JASN 2020;31:435)</description></item><item><title>acute kidney injury AKI</title><link>https://htlin222.github.io/garden/acute-kidney-injury-AKI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-kidney-injury-AKI/</guid><description>acute kidney injury (AKI) [[Definition-acute kidney injury (AKI)]] [[Workup-acute kidney injury (AKI)]] [[Etiologies and Diagnosis of Acute Kidney Injury ]] [[General treatment-acute kidney injury (AKI)]] [[Managing complications-acute kidney injury (AKI)]]</description></item><item><title>Acute Kidney Injury in Patients with Liver Disease | American Society of Nephrology</title><link>https://htlin222.github.io/garden/Acute-Kidney-Injury-in-Patients-with-Liver-Disease-American-Society-of-Nephrology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-Kidney-Injury-in-Patients-with-Liver-Disease-American-Society-of-Nephrology/</guid><description/></item><item><title>acute liver failure</title><link>https://htlin222.github.io/garden/acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-liver-failure/</guid><description>acute liver failure [[Definition-acute liver failure]] [[Etiology-acute liver failure]] [[Clinical manifestations-acute liver failure]] [[Workup-acute liver failure]] [[Management-acute liver failure]] [[Prognosis-acute liver failure]]</description></item><item><title>acute mesenteric ischemia</title><link>https://htlin222.github.io/garden/acute-mesenteric-ischemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-mesenteric-ischemia/</guid><description>acute mesenteric ischemia [[Definition and causes-acute mesenteric ischemia]]
[[Clinical manifestations-acute mesenteric ischemia]]
[[Diagnostic studies-acute mesenteric ischemia]]</description></item><item><title>Acute mild-to-moderate elevation in ALT AST</title><link>https://htlin222.github.io/garden/Acute-mild-to-moderate-elevation-in-ALT-AST-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-mild-to-moderate-elevation-in-ALT-AST-/</guid><description>Acute mild-to-moderate elevation in ALT AST (&amp;lt;15× ULN)
Assess risk of EtOH/drug/toxin: H&amp;amp;P; in EtOH AST:ALT ratio &amp;gt;2:1</description></item><item><title>acute pancreatitis</title><link>https://htlin222.github.io/garden/acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-pancreatitis/</guid><description>acute pancreatitis [[Pathogenesis-acute pancreatitis]] [[Etiologies-acute pancreatitis]] [[Clinical manifestations-acute pancreatitis]] [[Diagnostic studies-acute pancreatitis]] [[Severity-acute pancreatitis]] [[Prognosis-acute pancreatitis]] [[Treatment-acute pancreatitis]] [[Complications-acute pancreatitis]]</description></item><item><title>acute respiratory distress syndrome</title><link>https://htlin222.github.io/garden/acute-respiratory-distress-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/acute-respiratory-distress-syndrome/</guid><description>acute respiratory distress syndrome [[Berlin definition]] [[Pathophysiology-acute respiratory distress syndrome]] [[Pathology-acute respiratory distress syndrome]] [[Etiologies-acute respiratory distress syndrome]] [[Treatment-acute respiratory distress syndrome]] [[Mechanisms of VILI Ventilator Strategies (see ARDSnet.</description></item><item><title>Acute severe elevation in ALT AST</title><link>https://htlin222.github.io/garden/Acute-severe-elevation-in-ALT-AST/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-severe-elevation-in-ALT-AST/</guid><description>Acute severe elevation in ALT AST (&amp;gt;1000)
Massive elevations (&amp;gt;5000) usually due to ischemic injury or drug-induced hepatitis</description></item><item><title>Acute Treatment of Hypercalcemia</title><link>https://htlin222.github.io/garden/Acute-Treatment-of-Hypercalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-Treatment-of-Hypercalcemia/</guid><description>Acute Treatment of Hypercalcemia Normal saline (4–6 L/d) h during Rx Natriuresis → ↑ renal Ca excretion 排鈉 → ↑ 腎鈣排泄</description></item><item><title>Acute treatment of Migraine</title><link>https://htlin222.github.io/garden/Acute-treatment-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-treatment-of-Migraine/</guid><description>Acute treatment of Migraine First-line medication NSAIDs (acetylsalicylic acid, ibuprofen or diclofenac potassium) Second-line medication Triptans When triptans provide insufficient pain relief, combine with fast-acting NSAIDs Third-line medication Ditans Gepants Adjunct medications for nausea and/or vomiting Prokinetic antiemetics (domperidone or metoclopramide)</description></item><item><title>Acute treatment-nephrolithiasis</title><link>https://htlin222.github.io/garden/Acute-treatment-nephrolithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-treatment-nephrolithiasis/</guid><description>Acute treatment-nephrolithiasis (JAMA 2020;323:1961)
Analgesia (narcotics ± NSAIDs; combination superior, Ann Emerg Med 2006;48:173), ensure adequate fluid repletion, antibiotics if UTI</description></item><item><title>Acute tubular necrosis ATN</title><link>https://htlin222.github.io/garden/Acute-tubular-necrosis-ATN/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Acute-tubular-necrosis-ATN/</guid><description>Acute tubular necrosis (ATN) Allergic: β-lactams, sulfa drugs, NSAIDs, PPIs
Infection: pyelo, viral, legionella, TB, leptospirosis</description></item><item><title>Additional Diabetes Treatment Options</title><link>https://htlin222.github.io/garden/Additional-Diabetes-Treatment-Options/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Additional-Diabetes-Treatment-Options/</guid><description>Additional Diabetes Treatment Options DPP-4 inhibitors (~0.5–1%) Block degrad. GLP-1 &amp;amp; GIP → ↑ insulin. ↑ risk of HF w/ saxagliptin (NEJM 2013;369:1317), not w/ others.</description></item><item><title>Additional pleural fluid studies</title><link>https://htlin222.github.io/garden/Additional-pleural-fluid-studies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Additional-pleural-fluid-studies/</guid><description>Additional pleural fluid studies (NEJM 2002;346:1971)
NT-proBNP ≥1500 pg/mL has 91% Se &amp;amp; 93% Sp for CHF (Am J Med 2004;116:417)</description></item><item><title>Adeno or Other in Stage IV NSCLC Treatment</title><link>https://htlin222.github.io/garden/Adeno-or-Other-in-Stage-IV-NSCLC-Treatment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Adeno-or-Other-in-Stage-IV-NSCLC-Treatment/</guid><description>Adeno or Other in Stage IV NSCLC Treatment Genetics % Treatment [[EGFR]] ~15 1st line: osimertinib if L858R, ex19del (NEJM 2018;378:113) [[EGFR ex20 insertion]] 2–3 Subsequent Rx w/ amivantamab (JCO 2021;39:3391) or mobocertinib (JAMA Onc 2021;7:e214761) after platinum chemo ALK ~4 1st line: alectinib pref.</description></item><item><title>Adrenal crisis in adrenal insufficiency</title><link>https://htlin222.github.io/garden/Adrenal-crisis-in-adrenal-insufficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Adrenal-crisis-in-adrenal-insufficiency/</guid><description>Adrenal crisis in adrenal insufficiency (NEJM 2019;381;852)
Precipitants: preexisting adrenal insufficiency + serious infection or GI illness, bilateral adrenal hemorrhage or infarction, pituitary infarction Presentation: shock + anorexia, N/V, abd pain, weakness, fatigue, confusion, coma, fever Lab findings: hyponatremia, hyperkalemia (1°) Rx: hydrocortisone 100 mg IV followed by 50 mg IV q6 + IVF; do not delay for dx tests</description></item><item><title>adrenal disorders</title><link>https://htlin222.github.io/garden/adrenal-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/adrenal-disorders/</guid><description>adrenal disorders [[Cushing’s Syndrome]] (Hypercortisolism) [[hyperaldosteronism]] [[adrenal insufficiency]]</description></item><item><title>adrenal incidentalomas</title><link>https://htlin222.github.io/garden/adrenal-incidentalomas/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/adrenal-incidentalomas/</guid><description>adrenal incidentalomas Epidemiology
4% of Pts undergoing abdominal CT scan have incidentally discovered adrenal mass; prevalence ↑ with age Differential diagnosis Nonfunctioning mass: adenoma, cysts, abscesses, granuloma, hemorrhage, lipoma, myelolipoma, primary or metastatic malignancy Functioning mass: pheochromocytoma, adenoma (cortisol, aldosterone, sex hormones), other endocrine tumor, carcinoma Hormonal workup (EJE 2016;175:G1; NEJM 2021;384:1542) Rule out subclinical Cushing’s syndrome in all Pts using 1 mg overnight DST (Sp 91%).</description></item><item><title>adrenal insufficiency</title><link>https://htlin222.github.io/garden/adrenal-insufficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/adrenal-insufficiency/</guid><description>adrenal insufficiency [[Etiologies-adrenal insufficiency]] [[Clinical manifestations-adrenal insufficiency]] [[Diagnostic studies-adrenal insufficiency]] [[Treatment-adrenal insufficiency]] [[Adrenal insufficiency and critical illness]] [[Adrenal crisis in adrenal insufficiency]] [[pheochromocytoma and paraganglioma]] [[adrenal incidentalomas]]</description></item><item><title>Adrenal insufficiency and critical illness</title><link>https://htlin222.github.io/garden/Adrenal-insufficiency-and-critical-illness/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Adrenal-insufficiency-and-critical-illness/</guid><description>Adrenal insufficiency and critical illness (NEJM 2003;348:727; JAMA 2009;301:2362)
Low cortisol binding proteins; ∴ dx of adrenal insufficiency problematic (NEJM 2013;368:1477) Adrenal insufficiency rare in most cases of shock unless adrenal infarction or bleed, Waterhouse-Friderichson, CNS or pituitary bleed Reasonable to collect cortisol level in HoTN Pt w/ suspicion for adrenal insufficiency Can consider above dx criteria, but decision for Rx should also be based on clinical assessment due to risk of false ⊖ and ⊕ results in context of altered physiology If concerned, initiate corticosteroids early: use hydrocortisone 100 mg IV followed by 50 mg IV q6h Controversial data for empiric steroids in all critically ill Pts [[sepsis and shock]]</description></item><item><title>aflatoxin</title><link>https://htlin222.github.io/garden/aflatoxin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aflatoxin/</guid><description>黃麴毒素（Aflatoxin）是由許多麴菌屬（Aspergillus）黴菌所產生的黴菌毒素（mycotoxin）統稱，其中最有名的是黃麴菌（[[Aspergillus flavus]]）</description></item><item><title>AIP acute IP Hamman-Rich syndrome</title><link>https://htlin222.github.io/garden/AIP-acute-IP-Hamman-Rich-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/AIP-acute-IP-Hamman-Rich-syndrome/</guid><description>AIP acute IP (Hamman-Rich syndrome) Diffuse ground-glass opacities, consolidations w/ lobular sparing. Path/imaging similar to DAD (diffuse, bilateral, central&amp;gt;periph ground glass or consolidative opacities).</description></item><item><title>Airway-Management</title><link>https://htlin222.github.io/garden/Airway-Management/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Airway-Management/</guid><description>Airway-Management ✨Functional anatomy of the upper airway重點: 在舌根下方，會厭將口咽與喉咽或下嚥分開。 會厭通過在吞嚥過程中覆蓋喉部（聲門）的開口來防止誤吸。 喉是由九個軟骨以及韌帶和肌肉組成的軟骨骨架。 甲狀軟骨的部分功能是保護聲帶。 [[predictors of difficult mask ventilation]] [[equipment of airway-management]] [[positioning-airway-management]] [[preoxygenation]] [[bag and mask ventilation]] [[premedication of airway-management]] [[laryngoscopy and confirmation of placement]]</description></item><item><title>Albuterol of COPDAE</title><link>https://htlin222.github.io/garden/Albuterol-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Albuterol-of-COPDAE/</guid><description>Albuterol of COPDAE MDI 4–8 puffs q1–2h or Nebulizer 2.5–5 mg q1–2h Benefit if component of reversible bronchoconstriction</description></item><item><title>alcohol withdrawal</title><link>https://htlin222.github.io/garden/alcohol-withdrawal/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/alcohol-withdrawal/</guid><description/></item><item><title>Alcohol-associated hepatitis</title><link>https://htlin222.github.io/garden/Alcohol-associated-hepatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Alcohol-associated-hepatitis/</guid><description>Alcohol-associated hepatitis Sx: progressive jaundice, tender hepatomegaly, fever, ascites, GIB, encephalopathy
Labs: ALT usually &amp;lt;300–500 w/ AST:ALT &amp;gt; 2:1, ↓ plt, ↑ Tbili &amp;amp; INR indicate severe hepatitis</description></item><item><title>Aldosterone-antagonists</title><link>https://htlin222.github.io/garden/Aldosterone-antagonists/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Aldosterone-antagonists/</guid><description>Aldosterone-antagonists Add after RASi and bB if adeq. renal fxn and w/o hyperkalemia
25–30% ↓ mort. in NYHA II–IV &amp;amp; EF ≤35% (NEJM 2011;364:11)</description></item><item><title>Allergic Transfusion reactions</title><link>https://htlin222.github.io/garden/Allergic-Transfusion-reactions/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Allergic-Transfusion-reactions/</guid><description>Allergic Transfusion reactions urticaria; rarely, anaphylaxis due to rxn to txfused proteins, especially in IgA-deficient Pts w/ anti-IgA Abs (use washed products).</description></item><item><title>allergy immunology</title><link>https://htlin222.github.io/garden/allergy-immunology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/allergy-immunology/</guid><description>allergy immunology Allergic Rhinitis/Conjunctivitis/Sinusitis Anaphylaxis Drug Allergy Food Allergy Urticaria and Angioedema Eosinophilia and Mast-Cell Disorders Immunodeficiency</description></item><item><title>Alterations in Body Temperature</title><link>https://htlin222.github.io/garden/Alterations-in-Body-Temperature/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Alterations-in-Body-Temperature/</guid><description>Alterations in Body Temperature Chapter 18: Fever [[fever of unknown origin]] Chapter 19: Fever and Rash Chapter 20: Fever of Unknown Origin</description></item><item><title>Alterations in Circulatory and Respiratory Functions</title><link>https://htlin222.github.io/garden/Alterations-in-Circulatory-and-Respiratory-Functions/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Alterations-in-Circulatory-and-Respiratory-Functions/</guid><description>Alterations in Circulatory and Respiratory Functions Chapter 37: Dyspnea Chapter 38: Cough Chapter 39: Hemoptysis Chapter 40: [[Hypoxia and Cyanosis]] Chapter 41: Edema Chapter 42: Approach to the Patient with a Heart Murmur Chapter 43: Palpitations</description></item><item><title>Alterations in Gastrointestinal Function</title><link>https://htlin222.github.io/garden/Alterations-in-Gastrointestinal-Function/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Alterations-in-Gastrointestinal-Function/</guid><description>Alterations in Gastrointestinal Function Chapter 44: Dysphagia Chapter 45: Nausea, Vomiting, and Indigestion Chapter 46: Diarrhea and Constipation Chapter 47: Unintentional Weight Loss Chapter 48: Gastrointestinal Bleeding Chapter 49: Jaundice Chapter 50: Abdominal Swelling and Ascites</description></item><item><title>Alterations in Renal and Urinary Tract Function</title><link>https://htlin222.github.io/garden/Alterations-in-Renal-and-Urinary-Tract-Function/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Alterations-in-Renal-and-Urinary-Tract-Function/</guid><description>Alterations in Renal and Urinary Tract Function Chapter 51: Interstitial Cystitis/Bladder Pain Syndrome Chapter 52: Azotemia and Urinary Abnormalities Chapter 53: Fluid and Electrolyte Disturbances Chapter 54: Hypercalcemia and Hypocalcemia Chapter 55: Acidosis and Alkalosis</description></item><item><title>Alterations in the Skin</title><link>https://htlin222.github.io/garden/Alterations-in-the-Skin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Alterations-in-the-Skin/</guid><description>Alterations in the Skin Chapter 56: Approach to the Patient with a Skin Disorder Chapter 57: Eczema, Psoriasis, Cutaneous Infections, Acne, and Other Common Skin Disorders Chapter 58: Skin Manifestations of Internal Disease Chapter 59: Immunologically Mediated Skin Diseases Chapter 60: Cutaneous Drug Reactions Chapter 61: Photosensitivity and Other Reactions to Sunlight</description></item><item><title>ambulatory</title><link>https://htlin222.github.io/garden/ambulatory/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ambulatory/</guid><description>ambulatory Acute Respiratory Tract Infection Dizziness [[Low Back Pain]] Hypertension Hypercholesterolemia Cancer Screening Vaccination Smoking Cessation Chronic Pain and Opioids</description></item><item><title>Amiodarone</title><link>https://htlin222.github.io/garden/Amiodarone/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Amiodarone/</guid><description>Amiodarone 150 mg/3 mL loading infusion：150 mg in 100 mL over 10 min； followed by 900 mg in 500 mL over 6 hr MAX initial infusion rate 30 mg/min。 5-7 mg/kg /V over 30-60 mg/min, 10-g load</description></item><item><title>amiodarone and thyroid disease</title><link>https://htlin222.github.io/garden/amiodarone-and-thyroid-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/amiodarone-and-thyroid-disease/</guid><description>amiodarone and thyroid disease Overview (JCEM 2021;106:226) 6 mg iodine per 200-mg tablet; risk of thyroid dysfunction lower with lower doses ✓ TSH prior to therapy, at 4-mo intervals on amio, and for 1 y after if amio d/c’d Hypothyroidism (occurs in ~10%; more common in iodine-replete areas) Pathophysiology (1) Wolff-Chaikoff effect: iodine load ↓ I– uptake, organification and release of T4 &amp;amp; T3 (2) inhibits T4 → T3 conversion (3) ?</description></item><item><title>amyloidosis</title><link>https://htlin222.github.io/garden/amyloidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/amyloidosis/</guid><description>amyloidosis [[Systemic diseases with secondary glomerular involvement]]</description></item><item><title>anaphylaxis</title><link>https://htlin222.github.io/garden/anaphylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/anaphylaxis/</guid><description>anaphylaxis [[Definition and pathophysiology-anaphylaxis]] [[Diagnosis-anaphylaxis]] [[Treatment-anaphylaxis]] [[Disposition-anaphylaxis]] [[Angioedema]]</description></item><item><title>Anaplastic thyroid cancer</title><link>https://htlin222.github.io/garden/Anaplastic-thyroid-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anaplastic-thyroid-cancer/</guid><description>Anaplastic thyroid cancer ♀:♂ 1.5–2:1; poorly differentiated, extremely aggressive, mortality 90% at 5 y P/w rapidly growing fixed &amp;amp; hard neck mass, regional or distant spread in 90% at dx Rx options include surgery, radiation, trach, chemo, investigational clinical trials</description></item><item><title>ANCA positive Vasculitis</title><link>https://htlin222.github.io/garden/ANCA-positive-Vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ANCA-positive-Vasculitis/</guid><description>ANCA positive Vasculitis Differential diagnosis of ANCA (Nat Rev Dis Primers 2020;6:71) #⭐
anti-PR3: GPA, EGPA, microscopic polyangiitis (rarely), levamisole (contam.</description></item><item><title>anemia</title><link>https://htlin222.github.io/garden/anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/anemia/</guid><description>anemia ↓ in RBC mass: Hct &amp;lt;41% or Hb &amp;lt;13.5 g/dL (men); Hct &amp;lt;36% or Hb &amp;lt;12 g/dL (women)</description></item><item><title>Anemia in chronic kidney disease</title><link>https://htlin222.github.io/garden/Anemia-in-chronic-kidney-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anemia-in-chronic-kidney-disease/</guid><description>Anemia in chronic kidney disease goal Hb 10–11.5 g/dL, worse outcomes if target higher (NEJM 2009;361:2019)
epoetin (start 80–120 U/kg SC, divided 3×/wk) or darbepoetin (0.</description></item><item><title>Anemia of chronic inflammation</title><link>https://htlin222.github.io/garden/Anemia-of-chronic-inflammation-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anemia-of-chronic-inflammation-/</guid><description>Anemia of chronic inflammation (ACI; NEJM 2012;366:4)
↓ RBC production due to impaired iron utilization and functional iron deficiency from ↑ hepcidin; cytokines (IL-6, TNF-α) cause ↓ Epo responsiveness/production</description></item><item><title>Anemias of other chronic disorders</title><link>https://htlin222.github.io/garden/Anemias-of-other-chronic-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anemias-of-other-chronic-disorders/</guid><description>Anemias of other chronic disorders Anemia of CKD: ↓ Epo; treat w/ Epo &amp;amp; iron (see “Chronic Kidney Disease”)</description></item><item><title>Angioedema</title><link>https://htlin222.github.io/garden/Angioedema/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Angioedema/</guid><description>Angioedema (J Allergy Clin Immunol 2013;131:1491)
Localized swelling of skin/mucosa; involves face, lips, tongue, uvula, larynx, and bowels</description></item><item><title>anion gap</title><link>https://htlin222.github.io/garden/anion-gap/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/anion-gap/</guid><description>anion gap (AG) = Na+ – (Cl– + HCO3–) = unmeasured anions – unmeasured cations If ↑ glc, use measured not corrected Na Expected AG is [albumin] × 2.</description></item><item><title>Annotations</title><link>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-Annotations-8122022-123726-AM/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-Annotations-8122022-123726-AM/</guid><description>Annotations Mdnotes File Name: [[Nonspecific Low Back Pain]] Annotations (8/12/2022, 12:37:26 AM)
“Nonspecific Low Back Pain * Nonspecific low back pain is diagnosed on the basis of the exclusion of specific causes, usually by means of history taking and physical examination.</description></item><item><title>Anorectal disorders</title><link>https://htlin222.github.io/garden/Anorectal-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anorectal-disorders/</guid><description>Anorectal disorders Internal, external hemorrhoids; anal fissures, rectal ulcers, rectal varices (Rx by ↓ portal venous pressure in cirrhosis), XRT</description></item><item><title>Anti Depressant KFSYSCC</title><link>https://htlin222.github.io/garden/Anti-Depressant-KFSYSCC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anti-Depressant-KFSYSCC/</guid><description>1.2.3
Category Medication Selective Serotonin Reuptake Inhibitors Escitalopram, Sertraline Serotonin Norepinephrine Reuptake Inhibitors Duloxetine, Venlafaxine Tricyclic Amitriptyline, Amitriptyline 5-HT Triazolopyridine Trazodone Other 5-HT Receptor Modulators Vortioxetine Tetracyclic Mirtazapine, Aminoketone Bupropion [ How does this thing work?</description></item><item><title>Anti-GBM Disease</title><link>https://htlin222.github.io/garden/Anti-GBM-Disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anti-GBM-Disease/</guid><description>Anti-GBM Disease (linear staining) &amp;lt;15% of total (CJASN 2017;12:1162)
Goodpasture’s Glomerulonephritis: 有 Pulm Hemorrhage: 有 Anti-GBM disease: 有 Anti-GBM Glomerulonephritis: 有 Pulm Hemorrhage: - Anti-GBM disease: 有</description></item><item><title>Anti-IL5</title><link>https://htlin222.github.io/garden/Anti-IL5/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anti-IL5/</guid><description>Anti-IL5 (eg, mepolizumab, benralizumab): mixed data on ↓ exacerb in Pts with eos (NEJM 2017;377:1613 我們發現血液中含有大量嗜酸性白血球的重度氣喘患者，可以從服用 mepolizumab、 reslizumab 或 benralizumab 來減少氣喘發作。在生活品質和呼吸測試方面均有小幅的改善，但改善幅度可能太小以至於無法被患者察覺。我們同意國際指引稱這些藥物可以新增到重度氣喘患者的標準治療中之說法。需要進一步的研究來闡明一些方面，例如如何評價治療反應以及給予治療多長時間。&amp;amp; 2019;381:1023)</description></item><item><title>Antiarrhythmic Drugs AAD for AF</title><link>https://htlin222.github.io/garden/Antiarrhythmic-Drugs-AAD-for-AF/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antiarrhythmic-Drugs-AAD-for-AF/</guid><description>Antiarrhythmic Drugs (AAD) for AF III IC IA Underlying disease &amp;amp; maintenance AAD of choice: None or minimal (incl HTN wlo LVH): class IC (“pill in pocket&amp;quot;).</description></item><item><title>antibiotics</title><link>https://htlin222.github.io/garden/antibiotics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/antibiotics/</guid><description>antibiotics</description></item><item><title>Antibiotics of COPDAE</title><link>https://htlin222.github.io/garden/Antibiotics-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antibiotics-of-COPDAE/</guid><description>Antibiotics of COPDAE Amox, TMP-SMX, doxy, azithro, antipneumococcal FQ all reasonable (no single abx proven superior). Consider local flora and avoid repeat courses of same abx.</description></item><item><title>Antibiotics-sepsis and shock</title><link>https://htlin222.github.io/garden/Antibiotics-sepsis-and-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antibiotics-sepsis-and-shock/</guid><description>Antibiotics-sepsis and shock Start empiric IV abx as soon as possible after recognition of severe sepsis or septic shock; every hr delay in abx admin a/w 7.</description></item><item><title>Anticoagulant in chronic kidney disease</title><link>https://htlin222.github.io/garden/Anticoagulant-in-chronic-kidney-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anticoagulant-in-chronic-kidney-disease/</guid><description>Anticoagulant in chronic kidney disease : ESRD at ↑ bleed risk; if using DOAC, consider apixiban &amp;gt;rivaroxaban &amp;gt;dabigatran due to protein binding/renal clearance (JASN 2017;28:2241)</description></item><item><title>Anticoagulant Therapy</title><link>https://htlin222.github.io/garden/Anticoagulant-Therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anticoagulant-Therapy/</guid><description>Anticoagulant Therapy For NSTEMI UFH: 60 U/kg IVB (max 4000 U) then 12 U/kg/h (max 1000 U/h initially) × 48 h or until end of PCI 24% ↓ D/MI (JAMA 1996;276:811)</description></item><item><title>Anticoagulation antiplatelet therapy-prosthetic-heart-valves</title><link>https://htlin222.github.io/garden/Anticoagulation-antiplatelet-therapy-prosthetic-heart-valves/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anticoagulation-antiplatelet-therapy-prosthetic-heart-valves/</guid><description>Anticoagulation antiplatelet therapy-prosthetic-heart-valves (Circ 2021;143:e72)
Mechanical: warfarin (not DOAC), INR 3 or 2.5 if low-risk mech AVR (none of following: prior thromboembolism, AF, EF &amp;lt;30–35%, hypercoagulable).</description></item><item><title>Anticoagulation-Treatment of Chronic HF with Reduced EF</title><link>https://htlin222.github.io/garden/Anticoagulation-Treatment-of-Chronic-HF-with-Reduced-EF/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Anticoagulation-Treatment-of-Chronic-HF-with-Reduced-EF/</guid><description>Anticoagulation-Treatment of Chronic HF with Reduced EF [[antiplatelet Therapy of STEMI]] If AF, VTE, LV thrombus, ± if large akinetic LV segments.</description></item><item><title>antimetabolites</title><link>https://htlin222.github.io/garden/antimetabolites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/antimetabolites/</guid><description>antimetabolites [[Methotrexate]]</description></item><item><title>Antiphospholipid antibodies</title><link>https://htlin222.github.io/garden/Antiphospholipid-antibodies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antiphospholipid-antibodies/</guid><description>Antiphospholipid antibodies [[Antiphospholipid syndrome (APS)]]
✓ if: SLE, age &amp;lt;40 y &amp;amp; arterial thromb, recurrent venous thromb, spontaneous abortion</description></item><item><title>Antiphospholipid syndrome APS</title><link>https://htlin222.github.io/garden/Antiphospholipid-syndrome-APS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antiphospholipid-syndrome-APS/</guid><description>Antiphospholipid syndrome (APS) [[Definition-Antiphospholipid syndrome]] (APS) Features: DVT/PE/CVA, recurrent fetal loss, ↓ plts, hemolytic anemia, livedo reticularis
“Catastrophic APS”: ≥3 organ systems in &amp;lt;1 wk w/ ⊕ APLA &amp;amp; tissue microthrombi; 44% mortality (Arth Rheum 2006;54:2568); Rx w/ plasmapheresis, rituximab</description></item><item><title>Antiplatelet Therapy</title><link>https://htlin222.github.io/garden/Antiplatelet-Therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antiplatelet-Therapy/</guid><description>Antiplatelet Therapy [[Aspirin]] P2Y12 (ADP receptor) inhibitor (choose one of the following in addition to ASA). Timing (on presentation or at angiography) remains controversial.</description></item><item><title>Antiplatelet Therapy of STEMI</title><link>https://htlin222.github.io/garden/Antiplatelet-Therapy-of-STEMI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antiplatelet-Therapy-of-STEMI/</guid><description>Antiplatelet Therapy of STEMI Aspirin 162–325 mg × 1 (crushed/chewed) then 81 mg qd 23% ↓ in death (Lancet 1988;ii:349) Should not be stopped if CABG required</description></item><item><title>Antiretrovirals ARVs</title><link>https://htlin222.github.io/garden/Antiretrovirals-ARVs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antiretrovirals-ARVs/</guid><description>Antiretrovirals (ARVs) [[nucleoside reverse transcriptase inhibitor NRTI-Antiretrovirals (ARVs)]] [[non- nucleoside reverse transcriptase inhibitor-NNRTI-Antiretrovirals (ARVs)]] [[protease inhibitors - PI-Antiretrovirals (ARVs)]] [[entry inhibitors-EI-Antiretrovirals (ARVs)]] [[integrase strand transfer inhibitor-INSTI-Antiretrovirals (ARVs)]]</description></item><item><title>Antituberculous Medications</title><link>https://htlin222.github.io/garden/Antituberculous-Medications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antituberculous-Medications/</guid><description>Antituberculous Medications [[Antituberculous Treatment Regimens]]
*Risk of hepatitis ↑ w/ pre-existing liver disease. Consult ID, consider holding/replacing PZA or INH.</description></item><item><title>Antituberculous Treatment Regimens</title><link>https://htlin222.github.io/garden/Antituberculous-Treatment-Regimens/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Antituberculous-Treatment-Regimens/</guid><description>Antituberculous Treatment Regimens [[Antituberculous Medications]]
Pulmonary TB ≥4% INH-resist. in community (incl. most of U.S.) INH + RIF + PZA + EMB until suscept.</description></item><item><title>aortic aneurysms</title><link>https://htlin222.github.io/garden/aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aortic-aneurysms/</guid><description>aortic aneurysms [[Definitions-aortic aneurysms]] [[Epidemiology-aortic aneurysms]] [[Pathophysiology risk factors -aortic aneurysms]] [[Screening-aortic aneurysms]] [[Diagnostic studies-aortic aneurysms]] [[Treatment-aortic aneurysms]]
Surgery-aortic aneurysms (EHJ 2014;25:2873)</description></item><item><title>aortic-regurgitation</title><link>https://htlin222.github.io/garden/aortic-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aortic-regurgitation/</guid><description>aortic-regurgitation [[Etiology-aortic-regurgitation]] (Circ 2006;114:422) [[Clinical-manifestations-aortic-regurgitation]] [[Physical-exam-aortic-regurgitation]] [[Classic-Eponymous-Signs-in-Chronic-AR]] (South Med J 1981;74:459) [[Diagnostic-studies-aortic-regurgitation]] [[Treatment-aortic-regurgitation]] (Lancet 2016;387:1312; Circ 2021;143:e72)</description></item><item><title>aortic-stenosis</title><link>https://htlin222.github.io/garden/aortic-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aortic-stenosis/</guid><description>aortic-stenosis [[Etiology-aortic-stenosis]] [[Clinical-manifestations-aortic-stenosis]] [[Physical-exam-aortic-stenosis]] [[Diagnostic-studies-aortic-stenosis]] [[valve-replacement]] (Circ 2021;143:e72) [[TAVI]] (transcatheter AoV implantation) (JAMA 2021;325:2480; Circ 2021;143:e72)</description></item><item><title>Aplastic anemia</title><link>https://htlin222.github.io/garden/Aplastic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Aplastic-anemia/</guid><description>Aplastic anemia (stem cell failure) (NEJM 2015;373:35)
Epidemiology: 2–5 cases/106/y; biphasic (major peak in adolescents, 2nd peak in elderly)</description></item><item><title>Appearance of cerebrospinal fluid</title><link>https://htlin222.github.io/garden/Appearance-of-cerebrospinal-fluid/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Appearance-of-cerebrospinal-fluid/</guid><description>Appearance of cerebrospinal fluid Clear and colorless：正常CSF Turbid：可能代表 WBC &amp;gt; 200 或 RBC &amp;gt; 400 Bloody：RBC &amp;gt; 6000 Xanthochromia：CSF 中的 RBC 分解 → 形成 oxyhemoglobin 使 CSF 變粉紅色 → 被轉成 bilirubin 使 CSF 變成黃色。（除了 SAH 之外，在 CSF total protein &amp;gt; 150mg/dL 或 serum bilirubin &amp;gt; 10–15 mg/dL 時也可能發生）</description></item><item><title>approach to abnormal hemostasis</title><link>https://htlin222.github.io/garden/approach-to-abnormal-hemostasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/approach-to-abnormal-hemostasis/</guid><description>approach to abnormal hemostasis (NEJM 2014;370:847)</description></item><item><title>Approach to abnormal liver tests with cholestatic pattern</title><link>https://htlin222.github.io/garden/Approach-to-abnormal-liver-tests-with-cholestatic-pattern/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-abnormal-liver-tests-with-cholestatic-pattern/</guid><description>Approach to abnormal liver tests with cholestatic pattern</description></item><item><title>Approach to abnormal liver tests with infiltrative pattern</title><link>https://htlin222.github.io/garden/Approach-to-abnormal-liver-tests-with-infiltrative-pattern/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-abnormal-liver-tests-with-infiltrative-pattern/</guid><description>Approach to abnormal liver tests with infiltrative pattern</description></item><item><title>Approach to acute AF</title><link>https://htlin222.github.io/garden/Approach-to-acute-AF/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-acute-AF/</guid><description>Approach to acute AF (Adapted from Circ 2014;130:e199)</description></item><item><title>Approach to anemia and common causes</title><link>https://htlin222.github.io/garden/Approach-to-anemia-and-common-causes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-anemia-and-common-causes/</guid><description>Approach to anemia and common causes</description></item><item><title>Approach to Diuresis</title><link>https://htlin222.github.io/garden/Approach-to-Diuresis-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-Diuresis-/</guid><description>Approach to Diuresis Loop diuretic PO: ✓ response at 1–3 h, redose at 2× prior dose if needed</description></item><item><title>Approach to glomerulonephritis based on immunofluorescence pattern</title><link>https://htlin222.github.io/garden/Approach-to-glomerulonephritis-based-on-immunofluorescence-pattern/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-glomerulonephritis-based-on-immunofluorescence-pattern/</guid><description>Approach to glomerulonephritis based on immunofluorescence pattern 看圖說故事</description></item><item><title>Approach to hypernatremia</title><link>https://htlin222.github.io/garden/Approach-to-hypernatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-hypernatremia/</guid><description>Approach to hypernatremia</description></item><item><title>Approach to hypokalemia</title><link>https://htlin222.github.io/garden/Approach-to-hypokalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-hypokalemia/</guid><description>Approach to hypokalemia</description></item><item><title>Approach to metabolic acidosis</title><link>https://htlin222.github.io/garden/Approach-to-metabolic-acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-metabolic-acidosis/</guid><description>Approach to metabolic acidosis</description></item><item><title>Approach to microcytic anemias</title><link>https://htlin222.github.io/garden/Approach-to-microcytic-anemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-microcytic-anemias/</guid><description>Approach to microcytic anemias</description></item><item><title>Approach to newly diagnosed HIV positive Pt</title><link>https://htlin222.github.io/garden/Approach-to-newly-diagnosed-HIV-positive-Pt/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-newly-diagnosed-HIV-positive-Pt/</guid><description>Approach to newly diagnosed HIV positive Pt (CID 2020;73:e3572)
Counsel re: excellent prognosis w/adherence to treatment, treatment options, &amp;amp; disclosure Lab evaluation: CD4 count, HIV VL &amp;amp; genotype, CBC w/ diff.</description></item><item><title>Approach to oxygenation, hypoxemia, and hypoxemic respiratory failure</title><link>https://htlin222.github.io/garden/Approach-to-oxygenation-hypoxemia-and-hypoxemic-respiratory-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-oxygenation-hypoxemia-and-hypoxemic-respiratory-failure/</guid><description>Approach to oxygenation, hypoxemia, and hypoxemic respiratory failure Common misconceptions and mistakes Hypoxemia is a significant cause of dyspnea A cutaneous O 2 sat ≥ 92% predicts adequate oxygenation and is the appropriate target for O 2 orders 100% O 2 suppresses respiratory drive in CO 2 retainers O 2 supplementation for patients with COPD is given to improve exercise tolerance Confusing failure of oxygen delivery to tissues, hypoxia (the job of the circulatory system) with hypoxemia, and failure to maintain an adequate Pa o 2 (the job of the respiratory system) 常見的誤解和錯誤 低氧血症是導致呼吸困難的重要原因 皮膚 O 2 sat ≥ 92% 預示氧合充足，是 O 2 級的合適目標 100% O 2 抑制 CO 2 保持器中的呼吸驅動 為 COPD 患者補充 O 2 以提高運動耐量 將無法向組織輸送氧氣、缺氧（循環系統的工作）與低氧血症以及無法維持足夠的 Pa o 2（呼吸系統的工作）相混淆 [[oxygenation]]</description></item><item><title>Approach to polyuria</title><link>https://htlin222.github.io/garden/Approach-to-polyuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-polyuria/</guid><description>Approach to polyuria</description></item><item><title>Approach to previously established HIV positive Pt</title><link>https://htlin222.github.io/garden/Approach-to-previously-established-HIV-positive-Pt/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-previously-established-HIV-positive-Pt/</guid><description>Approach to previously established HIV positive Pt H&amp;amp;P (mucocutaneous, neurocognitive, OIs, malignancies, STDs); meds and adherence Review ARVs (past and current); if hospitalized typically continue ARVs, if any must be held, stop all to ↓ risk of resistance Regimen failure: cannot achieve undetectable VL after months on ARVs, viral rebound (VL &amp;gt;200 copies/mL ×2 after prior suppression), ↓ CD4 count or clinical worsening</description></item><item><title>Approach to suspected DVT</title><link>https://htlin222.github.io/garden/Approach-to-suspected-DVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-suspected-DVT/</guid><description>Approach to suspected DVT</description></item><item><title>Approach to suspected PE</title><link>https://htlin222.github.io/garden/Approach-to-suspected-PE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-suspected-PE/</guid><description>Approach to suspected PE</description></item><item><title>Approach to syncope-syncope</title><link>https://htlin222.github.io/garden/Approach-to-syncope-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-syncope-syncope/</guid><description>Approach to syncope-syncope (Adapted from JACC 2017;70:e39)</description></item><item><title>Approach to thrombocytopenia</title><link>https://htlin222.github.io/garden/Approach-to-thrombocytopenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-thrombocytopenia/</guid><description>Approach to thrombocytopenia</description></item><item><title>Approach to treatment-of-hyponatremia</title><link>https://htlin222.github.io/garden/Approach-to-treatment-of-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-treatment-of-hyponatremia/</guid><description>Approach to treatment-of-hyponatremia depends on volume status, acuity of hyponatremia, and if symptomatic
Acute sx: initial rapid correction of [Na]serum (2 mEq/L/h for the first 2–3 h) until sx resolve</description></item><item><title>Approach to TSH levels</title><link>https://htlin222.github.io/garden/Approach-to-TSH-levels/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-to-TSH-levels/</guid><description>Approach to TSH levels</description></item><item><title>Approach-electrocardiography</title><link>https://htlin222.github.io/garden/Approach-electrocardiography/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Approach-electrocardiography/</guid><description>Approach-electrocardiography Rate tachy or brady rhythm ? P waves regularity P &amp;amp; QRS relationship Intervals PR, QRS, QT Axis LAD or RAD chamber abnormal LAA, RAA, LVH, RVH QRST changes ?</description></item><item><title>arrhythmias</title><link>https://htlin222.github.io/garden/arrhythmias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/arrhythmias/</guid><description>arrhythmias [[bradycardias av block and av dissociation]] [[supraventricular tachycardias (SVTS)]] [[accessory pathways (wolff-parkinson-white)]] [[wide-complex tachycardias (WCTS)]]</description></item><item><title>Arrhythmias post MI</title><link>https://htlin222.github.io/garden/Arrhythmias-post-MI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Arrhythmias-post-MI/</guid><description>Arrhythmias post MI Arrhythmias post-MI (treat all per ACLS protocols if unstable or symptomatic)
AF (10–16% incidence): βB or amio, ± digoxin (particularly if HF), heparin</description></item><item><title>ascites</title><link>https://htlin222.github.io/garden/ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ascites/</guid><description>ascites Due to portal HTN (defined as hepatic venous pressure gradient [HVPG] &amp;gt;5 mmHg)
Develops in 60% w/in 10 y; often first decompensating event</description></item><item><title>Ascites fluid total protein AFTP</title><link>https://htlin222.github.io/garden/Ascites-fluid-total-protein-AFTP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ascites-fluid-total-protein-AFTP/</guid><description>Ascites fluid total protein (AFTP) useful when SAAG ≥1.1 to distinguish cirrhosis (AFTP &amp;lt;2.5 g/dL) from cardiac ascites (AFTP ≥2.5 g/dL).</description></item><item><title>aseptic meningitis</title><link>https://htlin222.github.io/garden/aseptic-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aseptic-meningitis/</guid><description>aseptic meningitis Definition Clinical/lab evidence of meningeal inflammation with negative bacterial cx (CSF &amp;amp; blood)
[[Etiologies-aseptic meningitis]]</description></item><item><title>Aspergillosis</title><link>https://htlin222.github.io/garden/Aspergillosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Aspergillosis/</guid><description>Aspergillosis (Lancet 2021;397:499)
ABPA: airway hypersensitivity secondary to aspergillus colonization Chronic pulmonary aspergillosis: includes aspergilloma (fungus ball), pulm. nodules, chronic cavitary and chronic fibrotic pulmonary aspergillosis that can present with subacute cough, dyspnea, hemoptysis; aspergilloma/nodules can be asymptomatic Invasive aspergillosis: seen in immunosupp.</description></item><item><title>Aspergillus flavus</title><link>https://htlin222.github.io/garden/Aspergillus-flavus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Aspergillus-flavus/</guid><description>Monday 22年7月18日 02:59:03
Write about Aspergillus flavus here!</description></item><item><title>Aspirin</title><link>https://htlin222.github.io/garden/Aspirin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Aspirin/</guid><description>Aspirin 162–325 mg × 1, then 81 mg qd (non–enteric-coated, chewable) 50–70% ↓ D/MI (NEJM 1988;319:1105) Low dose (~81 mg) pref long term (NEJM 2010;363:930) If allergy, use clopi and/or desensitize to ASA</description></item><item><title>Assess severity-initial management-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Assess-severity-initial-management-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Assess-severity-initial-management-gastrointestinal-bleeding/</guid><description>Assess severity-initial management-gastrointestinal bleeding VS including orthostatic Δs, JVP. Tachycardia (can be masked by βB use) suggests 10% volume loss, orthostatic hypotension 20% loss, shock &amp;gt;30% loss.</description></item><item><title>asthma</title><link>https://htlin222.github.io/garden/asthma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/asthma/</guid><description>asthma [[Definition and epidemiology]] [[Clinical manifestations]] [[Physical examination]] [[Diagnostic studies]] [[differential diagnosis]] [[Asthma plus syndromes]] CHRONIC MANAGEMENT [[Reliever medications-asthma]] [[Controller medications]] [[Immunotherapies-asthma]] [[Principles of treatment-asthma]] [[Asthma Stepwise Therapy]] EXACERBATION [[Evaluation-asthma-EXACERBATION]] [[Severity of Asthma Exacerbation]] [[Initial treatment details of asthma]] [[Disposition of patients after initial treatment of asthma exacerbation]] [[ICU-level care-asthma-EXACERBATION]]</description></item><item><title>Asthma plus syndromes</title><link>https://htlin222.github.io/garden/Asthma-plus-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Asthma-plus-syndromes/</guid><description>Asthma plus syndromes Atopy = asthma + allergic rhinitis + atopic dermatitis
Aspirin-exacerbated respiratory disease (Samter’s syndrome) = asthma + ASA sensitivity + nasal polyps (J Allergy Clin Immunol 2015;135:676)</description></item><item><title>Asthma Stepwise Therapy</title><link>https://htlin222.github.io/garden/Asthma-Stepwise-Therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Asthma-Stepwise-Therapy/</guid><description>Asthma Stepwise Therapy</description></item><item><title>asymptomatic glomerular hematuria</title><link>https://htlin222.github.io/garden/asymptomatic-glomerular-hematuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/asymptomatic-glomerular-hematuria/</guid><description>asymptomatic glomerular hematuria Definition and etiologies Hematuria ± proteinuria of glomerular origin w/o renal insufficiency or systemic disease (nonglomerular more common; see “Hematuria”) Ddx: any cause of GN (esp.</description></item><item><title>At client</title><link>https://htlin222.github.io/garden/setup/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/setup/</guid><description>[教學][NAS] Synology NAS SSH 免密碼登入 | Gary&amp;rsquo;s &amp;hellip;Lasamia (garynil.tw)
At client ssh-keygen at home Copy id rsa.pub file to NAS home dir via</description></item><item><title>atezolizumab</title><link>https://htlin222.github.io/garden/atezolizumab/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/atezolizumab/</guid><description>作用機轉 Atezolizumab是屬於[[PD-L1]]的免疫檢查點抑制劑。T淋巴細胞 (T細胞)與癌細胞上有許多免疫檢查點，有些是促進它們活化就像踩油門，有些反而是抑制它們就像踩煞車。
其中PD-L1是屬於抑制性免疫檢查點，而PD-L1免疫檢查點抑制劑則是抑制PD-L1，也就是拿掉煞車，重新喚醒T細胞發揮其抗癌作用。
適應症 肝細胞癌、非小細胞肺癌、小細胞肺癌、泌尿道上皮癌、三陰性乳癌、黑色素細胞瘤。
用法用量 每二至三週一次，每次給予840-1200mg。
副作用
常見 高血壓(17-30%)、脫髮(32-56%)、便秘(12-36%)、食慾降低(15-30%)、腹瀉(11-33%)、噁心(12-50%)、關節痛(12-26%)、虛弱(12-51%)、神經病變(33-56%)、咳嗽(27%)、呼吸困難(32%)、疲倦(47-61%)
嚴重 心肌炎(1%)、腎上腺功能不全(0.4-0.8%)、糖尿病(0.1％)、腦下垂體發炎(0.4%)、甲狀腺功能亢進(1.6％-19％)、甲狀腺功能低下(4.6-22％)、腹部疼痛(10-17%)、大腸炎(2%)、肝炎(14-53%)、急性腎損傷(2.2％)、血尿(14％)、泌尿道感染(22％)、肺部發炎(5.5％)、發燒(14-49％)、輸注反應(1.6-11％)</description></item><item><title>atrial fibrillation</title><link>https://htlin222.github.io/garden/atrial-fibrillation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/atrial-fibrillation/</guid><description>atrial fibrillation [[Classification-atrial fibrillation]] [[Epidemiology and etiologies-atrial fibrillation]] Evaluation-atrial fibrillation H&amp;amp;P, ECG, CXR, TTE (LA size, thrombus, valves, LV fxn, pericardium), K, Mg, Cr, TFTs In acute AF &amp;lt;48º, ~70% spont.</description></item><item><title>Atrial flutter</title><link>https://htlin222.github.io/garden/Atrial-flutter/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Atrial-flutter/</guid><description>Atrial flutter peice of note</description></item><item><title>Atrial-Abnormality</title><link>https://htlin222.github.io/garden/Atrial-Abnormality/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Atrial-Abnormality/</guid><description>Atrial-Abnormality ECG P-wave criteria
Left Atrial Abnormality (LAA) Right Atrial Abnormality (RAA)</description></item><item><title>ATTRACTION-3</title><link>https://htlin222.github.io/garden/ATTRACTION-3/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ATTRACTION-3/</guid><description>ATTRACTION-3 Summary Background Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in patients with previously treated advanced oesophageal squamous cell carcinoma.</description></item><item><title>Atypical ANCA patterns</title><link>https://htlin222.github.io/garden/Atypical-ANCA-patterns/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Atypical-ANCA-patterns/</guid><description>Atypical ANCA patterns drug-induced vasculitis, nonvasculitic rheumatic diseases, ulcerative colitis, primary sclerosing cholangitis, endocarditis, cystic fibrosis</description></item><item><title>aura</title><link>https://htlin222.github.io/garden/aura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/aura/</guid><description>aura Aura is defined as transient focal neurological symptoms that usually precede, but sometimes accompany, the headache phase of a migraine attack.</description></item><item><title>Autoimmune hemolytic anemia</title><link>https://htlin222.github.io/garden/Autoimmune-hemolytic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Autoimmune-hemolytic-anemia/</guid><description>Autoimmune hemolytic anemia Acquired, antibody-mediated RBC destruction
Warm AIHA: IgG Abs opsonize RBCs at body temp → removal by spleen</description></item><item><title>autoimmune hepatitis AIH</title><link>https://htlin222.github.io/garden/autoimmune-hepatitis-AIH/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/autoimmune-hepatitis-AIH/</guid><description>autoimmune hepatitis (AIH) [[Classification-autoimmune hepatitis (AIH)]] [[Diagnosis and treatment-autoimmune hepatitis (AIH) ]]</description></item><item><title>autoimmune pancreatitis</title><link>https://htlin222.github.io/garden/autoimmune-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/autoimmune-pancreatitis/</guid><description>autoimmune pancreatitis Pathogenesis (Am J Gastro 2018;113:1301) Type 1: lymphoplasmacytic sclerosing panc. w/ dense fibrosis; ↑ IgG4; high relapse Type 2: idiopathic duct-centric pancreatitis; minimal ↑ IgG4; a/w IBD; fewer relapses Clinical manifestations Abdominal pain, can p/w obstructive jaundice and panc mass mimicking panc Ca Can be primary, or in a/w IgG4 cholangiopathy, salivary gland disease (eg, Sjögren’s), mediastinal or RP fibrosis, interstitial nephritis, autoimmune thyroiditis, UC/PSC, RA Diagnosis Labs: cholestatic LFTs (↑ Aϕ &amp;gt;AST/ALT), ↑ γ-globulins and IgG4, ⊕ ANA, RF HISORt criteria: Histology, Imaging (“sausage pancreas,” bile duct stricture), Serology, other Organ involvement, Response to therapy Treatment Glucocorticoids 1st-line; immunomod.</description></item><item><title>Autoimmune Polyglandular Syndromes</title><link>https://htlin222.github.io/garden/Autoimmune-Polyglandular-Syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Autoimmune-Polyglandular-Syndromes/</guid><description>Autoimmune Polyglandular Syndromes (NEJM 2018;378:1132) Type Features
I (APECED) Child onset, mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, AIRE mutation
II Adult onset, adrenal insufficiency, autoimmune thyroid disease, diabetes mellitus type 1; polygenic</description></item><item><title>autoinflammatory syndromes</title><link>https://htlin222.github.io/garden/autoinflammatory-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/autoinflammatory-syndromes/</guid><description/></item><item><title>AV Block</title><link>https://htlin222.github.io/garden/AV-Block/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/AV-Block/</guid><description>AV Block (Circ 2019;140:e382) Type Features
1° Prolonged PR (&amp;gt;200 ms), all atrial impulses conducted (1:1).
2° Mobitz I (Wenckebach) Progressive ↑ PR until impulse not conducted (→ ”grouped beating”).</description></item><item><title>AV dissociation</title><link>https://htlin222.github.io/garden/AV-dissociation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/AV-dissociation/</guid><description>AV dissociation Default: slowing of SA node allows subsidiary pacemaker (eg, AV junction) to take over Usurpation: acceleration of subsidiary pacemaker (eg, AV junctional tach, VT) 3° AV block: atrial pacemaker unable to capture ventricles, subsidiary pacemaker emerges; distinguish from isorhythmic dissociation (A ≈ V rate, some P waves nonconducting)</description></item><item><title>Axis-deviation</title><link>https://htlin222.github.io/garden/Axis-deviation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Axis-deviation/</guid><description>Axis-deviation Left axis deviation (LAD) Definition: axis beyond –30° (S &amp;gt;R in lead II)
Etiologies: LVH, LBBB, inferior MI, WPW</description></item><item><title>back and spinal cord disease</title><link>https://htlin222.github.io/garden/back-and-spinal-cord-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/back-and-spinal-cord-disease/</guid><description>[[differential diagnosis of back pain]] Initial evaluation of back and spinal cord disease Lancet 2017;389:736 &amp;amp; Continuum 2021;27:12
[[History taking of back and spinal cord disease]]</description></item><item><title>Background of vasculitis</title><link>https://htlin222.github.io/garden/Background-of-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Background-of-vasculitis/</guid><description>Background of vasculitis [Vasculitis Pathophysiology Overview - YouTube]( https://www.youtube.com/watch?v=D9h6-LPySPI&amp;ab channel=ArmandoHasudungan) [Vasculitis | Clinical Presentation - YouTube]( https://www.youtube.com/watch?v=VfdeBT7e-dc&amp;ab channel=Medscape) Classified by size of predominant vessel affected (Arthritis Rheum 2013;65:1); overlap of vessel size affected is common 看一下這張圖： 有很多部分會重疊：注意是所有種的都會影響到大中小，所以不能排除 Clinical manifestations based on size of vessels involved; specific symptom constitutional sx (low-grade fever, fatigue, weight loss, myalgias, anorexia) common to all from inflammatory response Vasculitis is typically divided into 2 main categories: primary (idiopathic) secondary, caused by an underlying condition, such as an autoimmune process, infection, a neoplastic process, or certain medications Vasculitis can occur in any vessel type in any organ system of the body.</description></item><item><title>bacteremia</title><link>https://htlin222.github.io/garden/bacteremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/bacteremia/</guid><description>bacteremia Definitions 1° bacteremia: bloodstream infection due to direct inoculation of the blood Central line associated bloodstream infection (CLABSI): bacteremia in which the same organism is growing from peripheral and catheter cultures (CID 2009;49:1) 2° bacteremia: infection of another site (eg, UTI, PNA, colitis, etc.</description></item><item><title>bacteremia and endocarditis</title><link>https://htlin222.github.io/garden/bacteremia-and-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/bacteremia-and-endocarditis/</guid><description>bacteremia and endocarditis [[bacteremia]] [[bacterial endocarditis]]</description></item><item><title>bacterial endocarditis</title><link>https://htlin222.github.io/garden/bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/bacterial-endocarditis/</guid><description>bacterial endocarditis Definition
Infection of endothelium of heart (including but not limited to the valves) including both prosthetic valve endocarditis (PVE) and native valve endocarditis (NVE) [[Risk Factors-bacterial endocarditis]] Fungal: ↑ risk w/ DM, indwelling lines, immunosupp.</description></item><item><title>Bacterial peritonitis</title><link>https://htlin222.github.io/garden/Bacterial-peritonitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Bacterial-peritonitis/</guid><description>Bacterial peritonitis (Gut 2012;61:297; Hepatology 2021;74:1014)
⊕ Ascites Culture Ascites PMN≥250/µL [[Spontaneous bacterial peritonitis (SBP)]] [[secondary bacterial peritonitis]] Ascites PMN&amp;lt;250/µL [[Nonneutrocytic bacterascites (NNBA)]] ⊖ Ascites Culture Ascites PMN≥250/µL [[Culture-negative neutrocytic ascites (CNNA)]] [[Peritoneal dialysis-associated-Bacterial peritonitis]]</description></item><item><title>bag and mask ventilation</title><link>https://htlin222.github.io/garden/bag-and-mask-ventilation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/bag-and-mask-ventilation/</guid><description>bag and mask ventilation ✨重點: 到目前為止，使用袋子和罩為患者通氣的能力是任何氣道提供者掌握的最重要的技能。 如果可以進行面罩通氣，則無法進行氣管插管並不致命，這使其成為 ASA 困難氣道算法的重要組成部分。 面罩通氣的相對禁忌症是飽腹/反流風險、嚴重的面部創傷和不穩定的頸椎骨折。 進行面罩通氣時，提供者左手拿著面罩，將面罩放在患者的鼻子和嘴巴上，第三、第四和第五根手指握住下頜骨，將面部抬入面罩， 同時拇指和食指在靠近電路連接的面罩的領口周圍形成一個“C”形。 當袋子被擠壓時，應該注意到胸罩上升和冷凝，並且應該聽到沒有空氣逸出，這表明由於密封不足而導致洩漏。 應注意不要壓迫下頜下組織，因為這會使氣道塌陷並使通氣更加困難。 如果面罩通氣困難，可以採用雙手技術，其中一名提供者雙手握住面罩，拇指放在面罩頂部，其餘手指放在下頜骨上，將面部抬入面罩，同時助手擠壓袋子. 口腔和鼻腔氣道也很有用，因為它們將舌頭和會厭拉離咽後壁，從而允許更多的氣流。</description></item><item><title>Barrett’s esophagitis</title><link>https://htlin222.github.io/garden/Barretts-esophagitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Barretts-esophagitis/</guid><description>Barrett’s esophagitis (BE): metaplastic columnar mucosa above GE jxn replaces squam epithel. Screen if chronic (&amp;gt;5 y) and/or frequent GERD (≥1/wk) in ♂ w/ ≥2 risk factor for Barrett’s/esophageal adeno: &amp;gt;50 y, white, hiatal hernia, central adiposity, smoking, FHx of Barrett’s/esophageal adeno.</description></item><item><title>basic techniques and procedures</title><link>https://htlin222.github.io/garden/basic-techniques-and-procedures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/basic-techniques-and-procedures/</guid><description>basic techniques and procedures [[Airway-Management]] [[Sedation-and-Analgesia]] [[Vascular-Access]] [[POCUS]] Bedside Percutaneous Dilational Tracheostomy [[Nutritional Support and Total Parenteral Nutrition]] Glycemic Control [[Hyperglycemic Emergencies]] [[Prevention of Complications in intensive care unit]] [[pain and palliative care]] Bronchoscopy</description></item><item><title>basophilia</title><link>https://htlin222.github.io/garden/basophilia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/basophilia/</guid><description>basophilia Neoplasm MPN, CML, AML, Hodgkin lymph.
Infection TB, smallpox, parasites
Alteration in BM or reticuloendothelial compartment Hemolytic anemia, splenectomy</description></item><item><title>begins</title><link>https://htlin222.github.io/garden/begins/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/begins/</guid><description>begins [[zettle]]
Backlink： [[Clinical manifestations-cholelithiasis]] [[Clinical-manifestations-aortic-regurgitation]] [[Clinical-manifestations-mitral-regurgitation]]</description></item><item><title>Behçet’s syndrome</title><link>https://htlin222.github.io/garden/Beh%C3%A7ets-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Beh%C3%A7ets-syndrome/</guid><description>Behçet’s syndrome (Nat Rev Dis Primers 2021;7:67)
Systemic vasculitis affecting all vessel sizes, venous and arterial, a/w painful oral and/or genital ulcers Epi: usually young adults (25–35 y); ♂ = ♀, ↑ severity in ♂; a/w HLA-B51; ↑ prev on old Silk Road (Turkey, Middle East, Asia) w/ 5 vs.</description></item><item><title>Bell’s palsy</title><link>https://htlin222.github.io/garden/Bells-palsy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Bells-palsy/</guid><description>Bell’s palsy Definition &amp;amp; clinical manifestations
Acute idiopathic unilat. facial nerve palsy (CN VII), often presumed HSV reactivation P/w unilateral facial muscle weakness, hyperacusis, ↓ taste, lacrimation, &amp;amp; salivation Risk factors: pregnancy (preeclampsia), obesity, HTN, diabetes, preceding URI Diagnosis (Otol Head Neck Surg 2013;149:656)</description></item><item><title>Benzodiazepines-toxicology</title><link>https://htlin222.github.io/garden/Benzodiazepines-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Benzodiazepines-toxicology/</guid><description>Benzodiazepines-toxicology ↓ mentation, ataxia, ↓ RR
Flumazenil not rec (can precipitate withdrawal/seizures)</description></item><item><title>Beta blockers-toxicology</title><link>https://htlin222.github.io/garden/Beta-blockers-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Beta-blockers-toxicology/</guid><description>Beta blockers-toxicology Bradycardia, AV block, hypotension, HF, hypoglycemia
Glucagon, vasopressors, pacing</description></item><item><title>bevacizumab</title><link>https://htlin222.github.io/garden/bevacizumab/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/bevacizumab/</guid><description>bevacizumab Avastin®；癌思停®注射劑。
轉移性大腸直腸癌(mCRC) Avastin®(bevacizumab) 與含有5-fluorouracil為基礎的化學療法合併使用，可以作為轉移性大腸或直腸癌病人的第一線治療。
Avastin®與含有5-fluorouracil/leucovorin/oxaliplatin的化學療法合併使用，可以作為先前接受過以fluoropyrimidine為基礎的化學療法無效且未曾接受過Avastin®治療的轉移性大腸或直腸癌病人的治療。
Avastin (bevacizumab)與含有fluoropyrimidine-irinotecan-或fluoropyrimidine-oxaliplatin-為基礎的化學療法合併使用，可以做為第一線已接受過以Avastin 併用化療後惡化之轉移性大腸或直腸癌病人的第二線治療。
說明: Avastin (bevacizumab) 不適用於高風險的二期以及三期大腸癌輔助性療法 (high risk stage II and III adjuvant colon cancer; aCC)</description></item><item><title>biliary tract disease</title><link>https://htlin222.github.io/garden/biliary-tract-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/biliary-tract-disease/</guid><description>biliary tract disease [[cholelithiasis]] [[cholecystitis]] [[choledocholithiasis]] [[cholangitis]]</description></item><item><title>Biologics</title><link>https://htlin222.github.io/garden/Biologics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Biologics/</guid><description>Biologics (eg, TNF inhibitors, anti-B- cell Rx; ✓ for TB before starting) Bacteria: sepsis, septic arthritis, TB, NTM, Listeria, Legionella Fungi: Pneumocystis, Histo, Coccidio, Aspergillus, endemic fungi Viruses: JC virus (PML), EBV, HSV, VZV, HBV Parasites: Strongyloides reactivation</description></item><item><title>Bioprosthetic</title><link>https://htlin222.github.io/garden/Bioprosthetic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Bioprosthetic/</guid><description>Bioprosthetic Bovine pericardial or porcine heterograft (eg, Carpentier-Edwards), homograft Less durable, but min. thrombogenic; consider if &amp;gt;~65 y, lifespan &amp;lt;20 y, or Ø anticoag If 50–69 y, 2× reop but ½ bleeding or stroke vs.</description></item><item><title>Blastomycosis</title><link>https://htlin222.github.io/garden/Blastomycosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Blastomycosis/</guid><description>Blastomycosis (CID 2008;46:1801)
Epidemiology endemic to the eastern ½ of U.S. Clinical manifestations Acute: PNA w/o hilar LAN that can progress to ARDS Chronic: cough + “B” sx, fibronodular infiltrates, masses ± cavitary lesions (Ddx TB, histo) Disseminated (seen in immunosupp.</description></item><item><title>Bleeding Treatment for idiopathic thrombocytopenic purpura</title><link>https://htlin222.github.io/garden/Bleeding-Treatment-for-idiopathic-thrombocytopenic-purpura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Bleeding-Treatment-for-idiopathic-thrombocytopenic-purpura/</guid><description>Bleeding Treatment for idiopathic thrombocytopenic purpura Aminocaproic acid Inhibits plasmin activation
Methylprednisolone 1 g/d IV × 3 d See above</description></item><item><title>Blood Products and Indications</title><link>https://htlin222.github.io/garden/Blood-Products-and-Indications-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Blood-Products-and-Indications-/</guid><description>Blood Products and Indications (Lancet 2013;381:1845)
[[Packed red blood cells]] (PRBCs) [[Platelets-transfusion]] (plts) (Annals Int Med 2015;162:205) [[Fresh frozen plasma]] (FFP) [[Cryoprecipitate]] [[Irradiated blood products]] [[CMV-negative]] [[Leuko-reduced blood products]] [[IV immune globulin]] (IVIg) [[Therapeutic apheresis]] [[Massive transfusion]]</description></item><item><title>BP control in chronic kidney disease</title><link>https://htlin222.github.io/garden/BP-control-in-chronic-kidney-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/BP-control-in-chronic-kidney-disease/</guid><description>BP control in chronic kidney disease goal ideally &amp;lt;120/80, a/w ↓ mortality. ACEI or ARB, not both. For outPts, ✓ Cr &amp;amp; K in 1–2 wk, d/c if Cr ↑ 30% or K &amp;gt;5.</description></item><item><title>bradycardias av block and av dissociation</title><link>https://htlin222.github.io/garden/bradycardias-av-block-and-av-dissociation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/bradycardias-av-block-and-av-dissociation/</guid><description>bradycardias av block and av dissociation [[Sinus bradycardia]] [[Tachycardia-bradycardia (“tachy-brady”) syndrome]] [[AV Block]] [[AV dissociation]] [[Temporary pacing wires]]</description></item><item><title>breast cancer</title><link>https://htlin222.github.io/garden/breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/breast-cancer/</guid><description>breast cancer [[index]]
[[Epidemiology of breast cancer]] [[Clinical manifestations of breast cancer]] [[Screening of breast cancer]] [[Diagnostic evaluation of breast cancer]] [[Staging of breast cancer]] [[general approach to treatment of breast cancer]] (JAMA 2019;321:288 &amp;amp; 1716) [[surgery and radiation for local control of breast cancer]] [[systemic therapy of breast cancer]]</description></item><item><title>Broad categories-interstitial lung disease</title><link>https://htlin222.github.io/garden/Broad-categories-interstitial-lung-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Broad-categories-interstitial-lung-disease/</guid><description>Broad categories-interstitial lung disease (1) Sarcoid; (2) Exposures (eg, drugs, XRT, organic &amp;amp; inorganic dusts, vaping);
(3) Collagen vasc dis (eg, scleroderma, ANCA, myositis, RA); (4) Idiopathic PNAs (qv)</description></item><item><title>bronchiectasis</title><link>https://htlin222.github.io/garden/bronchiectasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/bronchiectasis/</guid><description>bronchiectasis [[Definition and epidemiology-bronchiectasis]] [[Initial workup-bronchiectasis]] [[Treatment-bronchiectasis]] [[Non-tuberculous mycobacterium-bronchiectasis]]</description></item><item><title>Bronchodilators</title><link>https://htlin222.github.io/garden/Bronchodilators/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Bronchodilators/</guid><description>Bronchodilators (1st-line): long-acting muscarinic antag (LAMA), β2-agonists (LABA) LAMA (eg, tiotropium): ↓ exacerb, slows ↓ FEV1, ↓ admit, ↓ resp failure; better than [[ipratropium]] or LABA (NEJM 2008;359:1543; 2011;364:1093; 2017;377:923)</description></item><item><title>Budd-Chiari syndrome</title><link>https://htlin222.github.io/garden/Budd-Chiari-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Budd-Chiari-syndrome/</guid><description>Budd-Chiari syndrome (World J Hepatol 2016;8:691)
Hepatic outflow obstruction 2/2 occlusion of hepatic vein(s) or IVC → sinusoidal congestion and portal HTN.</description></item><item><title>Bundle-Branch-Blocks</title><link>https://htlin222.github.io/garden/Bundle-Branch-Blocks/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Bundle-Branch-Blocks/</guid><description>Bundle-Branch-Blocks Normal Initial depol. left to right across septum (r in V1 &amp;amp; q in V6; nb, absent in LBBB) followed by LV &amp;amp; RV free wall, with LV dominating (nb, RV depol.</description></item><item><title>buy mac</title><link>https://htlin222.github.io/garden/buy-mac/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/buy-mac/</guid><description>M1 256GB 16GB with AirPods 2 NT$33,200
M2 512GB 8G with AirPods 2 NT$43,900
M2 512GB 16GB with AirPod 2 NT$49,300</description></item><item><title>C5-9 deficiency</title><link>https://htlin222.github.io/garden/C5-9-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/C5-9-deficiency/</guid><description>C5-9 deficiency Terminal complement pathway deficiency is a genetic condition affecting the complement membrane attack complex (MAC)
Suspect terminal complement pathway deficiency with patients who have more than one episode of Neisseria infection.</description></item><item><title>Calciphylaxis</title><link>https://htlin222.github.io/garden/Calciphylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Calciphylaxis/</guid><description>Calciphylaxis calcific uremic arteriopathy, NEJM 2018;378:1704)
Pathophys: calcification of media in dermal small- to med-sized blood vessels &amp;amp; SC fat → ischemia and skin necrosis w/ painful lesions (NEJM 2007;356:1049)</description></item><item><title>Calcitriol</title><link>https://htlin222.github.io/garden/Calcitriol/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Calcitriol/</guid><description>Calcitriol [Calcitriol (1, 25-OH Vitamin D3) | KFSYSCC Formulary]( https://www.unboundmedicine.com/ucentral/view/KFSYSCC%20Formulary/2236448/all/Calcitriol 1 25 OH Vitamin D3 ?q=D3)
Hypocalcemia: Dialysis patients: Adults: initially, 0.</description></item><item><title>Calcium channel blockers-toxicology</title><link>https://htlin222.github.io/garden/Calcium-channel-blockers-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Calcium-channel-blockers-toxicology/</guid><description>Calcium channel blockers-toxicology Bradycardia, AV block, hypotension, HF, hyperglycemia
IVF, vasopressors, Ca infusion, hyperinsulinemic euglycemia,
? intralipid emulsion, pacing</description></item><item><title>calcium disorders</title><link>https://htlin222.github.io/garden/calcium-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/calcium-disorders/</guid><description>calcium disorders [[Calcium homeostasis in normal humans]]
[[Laboratory Findings in Calcium Disorders]] [[Control of Mineral Homeostasis by Parathyroid Hormone and the Calcium-Sensing Receptor]].</description></item><item><title>Callouts</title><link>https://htlin222.github.io/garden/notes/callouts/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/callouts/</guid><description>Callout support Quartz supports the same Admonition-callout syntax as Obsidian.
This includes
12 Distinct callout types (each with several aliases) Collapsable callouts See documentation on supported types and syntax here.</description></item><item><title>Cameron’s lesions</title><link>https://htlin222.github.io/garden/Camerons-lesions/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Camerons-lesions/</guid><description>Cameron’s lesions Linear erosions in hiatal hernia due to mech trauma of diaphragm</description></item><item><title>cancer biology</title><link>https://htlin222.github.io/garden/cancer-biology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cancer-biology/</guid><description>cancer biology Cancer Hallmarks and Stem Cells Mechanisms of Oncogenesis Growth Factor Signaling Cell Cycle Control Apoptosis and TP53 DNA Repair and Angiogenesis</description></item><item><title>cancer complications</title><link>https://htlin222.github.io/garden/cancer-complications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cancer-complications/</guid><description>cancer complications Tumor Lysis Syndrome (TLS) Neutropenic Fever Superior Vena Cava (SVC) Syndrome Symptom Management Metastatic Spinal Cord Compression &amp;amp; Brain Metastases [[leptomeningeal disease]] Venous Thromboembolism (VTE) in Malignancy Malignant Bowel Obstruction (MBO) Treatment Toxicities</description></item><item><title>cancer pharmacology</title><link>https://htlin222.github.io/garden/cancer-pharmacology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cancer-pharmacology/</guid><description>cancer pharmacology [[antimetabolites]]</description></item><item><title>Cancer screening of inflammatory bowel disease</title><link>https://htlin222.github.io/garden/Cancer-screening-of-inflammatory-bowel-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cancer-screening-of-inflammatory-bowel-disease/</guid><description>Cancer screening of inflammatory bowel disease (NEJM 2015;372:1441)
Colon cancer: risk in UC ~2% at 10 y, ~8% at 20 y, ~18% at 30 y.</description></item><item><title>cancer survivorship</title><link>https://htlin222.github.io/garden/cancer-survivorship/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cancer-survivorship/</guid><description>cancer survivorship</description></item><item><title>Candida species</title><link>https://htlin222.github.io/garden/Candida-species/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Candida-species/</guid><description>Candida species Microbiology: normal GI flora; C. albicans &amp;amp; nonalbicans spp. Epidemiology: neutropenia, immunosupp., broad-spectrum abx, intravascular catheters (esp. if TPN), IVDU, abd surgery, DM, renal failure, age &amp;gt;65 [[Clinical manifestations-Candida species]] [[Treatment-Candida species]] (CID 2016;62:409) ***(())</description></item><item><title>Cangrelor</title><link>https://htlin222.github.io/garden/Cangrelor/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cangrelor/</guid><description>Cangrelor Only IV P2Y12 inhibitor Rapid onset/offset; t½ 3–5 min 22% ↓ CV events (mostly peri-PCI MI and stent thrombosis) vs.</description></item><item><title>CAPT-resistant GNB</title><link>https://htlin222.github.io/garden/CAPT-resistant-GNB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CAPT-resistant-GNB/</guid><description>CAPT-resistant GNB Gram-negative bacteria (GNB) co-resistant to carbapanems, aminoglycosides, polymyxins and tigecycline (CAPT-resistant) Treatment options for K. pneumoniae, P.</description></item><item><title>CAR-T-Toxicity</title><link>https://htlin222.github.io/garden/CAR-T-Toxicity/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CAR-T-Toxicity/</guid><description>CAR-T-Toxicity Toxicities Cytokine release syndrome (CRS): fever, HoTN, shock secondary to overwhelming cytokine release from proliferating T cells Immune effector cell-associated neurotoxicitiy synd.</description></item><item><title>Carbon monoxide-toxicology</title><link>https://htlin222.github.io/garden/Carbon-monoxide-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Carbon-monoxide-toxicology/</guid><description>Carbon monoxide-toxicology HA, dizziness, nausea, ΔMS
carboxyHb level, CO-oximetry
100% normobaric oxygen, hyperbaric O2 in severe cases</description></item><item><title>Cardiac conditions-Endocarditis Prophylaxis</title><link>https://htlin222.github.io/garden/Cardiac-conditions-Endocarditis-Prophylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardiac-conditions-Endocarditis-Prophylaxis/</guid><description>Cardiac conditions-Endocarditis Prophylaxis Prosthetic valve; previous endocarditis; congenital heart disease (CHD) including unrepaired or incompletely repaired cyanotic CHD (palliative shunts or conduits), 1st 6 mo after completely repaired CHD using prosthetic material; cardiac transplant recipients w/ valvulopathy.</description></item><item><title>Cardiac output PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/Cardiac-output-PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardiac-output-PA-catheter-and-tailored-therapy/</guid><description>Cardiac output PA catheter and tailored therapy Thermodilution: saline injected in RA or intermittent heating of prox thermal filament in some PA lines (“continuous CO”).</description></item><item><title>Cardiac resynch therapy (CRT) Biventricular BiV pacing</title><link>https://htlin222.github.io/garden/Cardiac-resynch-therapy-CRT-Biventricular-BiV-pacing/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardiac-resynch-therapy-CRT-Biventricular-BiV-pacing/</guid><description>Cardiac resynch therapy (CRT) Biventricular (BiV) pacing (JACC 2013;61:e6)
3-lead pacemaker (RA, RV, coronary sinus to LV); R &amp;gt;S in V1 suggests approp LV capture Synch LV fxn (↑ CO/EF, ↓ adv remodeling); ↓ HF sx &amp;amp; hosp, ↑ survival (NEJM 2010;363:2385) Indications: LVEF ≤35% + NYHA II–IV despite med Rx + SR + LBBB ≥150 ms (also reasonable if LBBB ≥120 ms, any non-LBBB ≥150 ms, or &amp;gt;40% V-pacing); mort.</description></item><item><title>cardiac rhythm management devices</title><link>https://htlin222.github.io/garden/cardiac-rhythm-management-devices/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cardiac-rhythm-management-devices/</guid><description>cardiac rhythm management devices [[Pacemaker Code]] [[Common Pacing Modes]] [[Indications for Permanent Pacing]] [[Pacemaker Complications]] [[Cardiac resynch therapy (CRT) Biventricular (BiV) pacing]] [[Implantable cardiac defibrillator (ICD)]] [[Device infection]]</description></item><item><title>cardiac risk assessment for noncardiac surgery</title><link>https://htlin222.github.io/garden/cardiac-risk-assessment-for-noncardiac-surgery/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cardiac-risk-assessment-for-noncardiac-surgery/</guid><description>cardiac risk assessment for noncardiac surgery [[Preoperative evaluation]] [[Approach to preop CV eval for non-CV surgery]] [[Noninvasive Testing Result-cardiac risk assessment for noncardiac surgery]]</description></item><item><title>Cardiac-resynch-therapy</title><link>https://htlin222.github.io/garden/Cardiac-resynch-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardiac-resynch-therapy/</guid><description>Cardiac-resynch-therapy Consider if EF ≤35%, LBBB (QRS ≥130 ms) and symptomatic HF
36% ↓ mort. &amp;amp; ↑ EF in NYHA III–IV (CARE-HF, NEJM 2005;352:1539)</description></item><item><title>Cardiogenic shock</title><link>https://htlin222.github.io/garden/Cardiogenic-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardiogenic-shock/</guid><description>Cardiogenic shock Myocardial infarction
Myocarditis
Arrhythmia
Valvular
Severe aortic valve insufficiency
Severe mitral valve insufficiency</description></item><item><title>cardiology</title><link>https://htlin222.github.io/garden/cardiology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cardiology/</guid><description>cardiology [[electrocardiography]] [[chest pain]] [[noninvasive evaluation of CAD]] [[coronary angiography PCI]] [[stable ischemic heart disease]] [[acute coronary syndromes]] [[PA catheter and tailored therapy]] [[heart failure]] [[cardiomyopathies]] [[valvular heart disease]] [[pericardial disease]] [[hypertension]] [[aortic aneurysms]] [[acute aortic syndromes]] [[arrhythmias]] [[atrial fibrillation]] [[syncope]] [[cardiac rhythm management devices]] [[cardiac risk assessment for noncardiac surgery]] [[peripheral artery disease]] Coronary Artery Disease (CAD) and Acute Coronary Syndrome (ACS) Congestive Heart Failure (CHF) Arrhythmias Valvular Disease Pericardial Disease and Myocarditis</description></item><item><title>cardiomyopathies</title><link>https://htlin222.github.io/garden/cardiomyopathies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cardiomyopathies/</guid><description>cardiomyopathies Diseases with mechanical and/or electrical dysfunction of the myocardium
[[dilated cardiomyopathy]] (DCM) [[MYOCARDITIS]] [[HYPERTROPHIC-CARDIOMYOPATHY]] (HCM) [[hypertrophic cardiomyopathy]] [[RESTRICTIVE&amp;mdash;INFILTRATIVE]] CMP [[restrictive infiltrative]]</description></item><item><title>Cardiorenal syndrome</title><link>https://htlin222.github.io/garden/Cardiorenal-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardiorenal-syndrome/</guid><description>Cardiorenal syndrome (CJASN 2017;12:1624)
Multifactorial pathophys including: ↓ CO, ↑ renal venous congestion, ↑ RAAS Bidirectionality: acute CHF → AKI, and oliguric AKI can worsen CHF (JACC 2008;52:1527) Rx IV loop diuretics (bypass gut edema; dosing below) no diff.</description></item><item><title>cardiovascular critical care</title><link>https://htlin222.github.io/garden/cardiovascular-critical-care/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cardiovascular-critical-care/</guid><description>cardiovascular critical care [[Hemodynamic-Monitoring]] Vasoactive-Drugs Mechanical Circulatory Support Cardiac Arrhythmias [[Shock-Syndromes]] [[Cardiac-Arrest]]</description></item><item><title>Cardiovascular-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Cardiovascular-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardiovascular-complications-of-HIV-AIDS/</guid><description>Cardiovascular-complications of HIV AIDS Higher rates of CAD, stroke, VTE, dilated CMP; pulm. HTN; pericarditis/effusion</description></item><item><title>Cardioversion</title><link>https://htlin222.github.io/garden/Cardioversion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cardioversion/</guid><description>Cardioversion Consider if: 1st AF, sx, tachycardia-mediated CMP, or difficult to rate control If AF &amp;gt;48 h 2–5% risk stroke w/ cardioversion (pharmacologic or electric) ∴ either TEE to r/o thrombus or ensure therapeutic anticoagulation ≥3 wk prior If needs to cardiovert urgently, often anticoagulate acutely (eg, IV UFH) For AF &amp;lt;36 hrs, no Δ in % in SR at 4 wks w/ early cardioversion vs.</description></item><item><title>cardioversion of ACLS Tachycardia Algorithm</title><link>https://htlin222.github.io/garden/cardioversion-of-ACLS-Tachycardia-Algorithm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cardioversion-of-ACLS-Tachycardia-Algorithm/</guid><description>cardioversion of ACLS Tachycardia Algorithm Ancillary equipment O2 sat monitor suction, IV line intubation equipment Premedicate call anesthesia service midazolam 1-5 mg fentanyl 100-300 mcg Synch cardioversion 100J 雙向 越加越大 小麻 50-200 J biphasic 100-200 J monophasic</description></item><item><title>Cat bite</title><link>https://htlin222.github.io/garden/Cat-bite/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cat-bite/</guid><description>Cat bite *Cat scratch disease caused by Bartonella acquired via cat scratch or bite. Results in lymphadenitis.
Pasturella spp Rapid onset erythema, swelling, lymphangitis, fever Amox/clav</description></item><item><title>Categories-diabetes mellitus</title><link>https://htlin222.github.io/garden/Categories-diabetes-mellitus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Categories-diabetes-mellitus/</guid><description>Categories-diabetes mellitus Type 1 (Lancet 2018;391:2449): islet cell destruction; absolute insulin deficiency; ketosis in absence of insulin; prevalence 0.4%; usual onset in childhood but can occur throughout adulthood; ↑ risk if ⊕ FHx; HLA associations; anti-GAD, anti-islet cell &amp;amp; anti-insulin autoAb Type 2 (Lancet 2017;389:2239): insulin resistance + relative insulin ↓; prevalence 6%; onset generally later in life; no HLA assoc.</description></item><item><title>Causes of Hemolytic Anemia by Mechanism</title><link>https://htlin222.github.io/garden/Causes-of-Hemolytic-Anemia-by-Mechanism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Causes-of-Hemolytic-Anemia-by-Mechanism/</guid><description>Causes of Hemolytic Anemia by Mechanism (Lancet 2000;355:1169 &amp;amp; 1260)
Intrinsic Enzyme deficiency G6PD deficiency Hemoglobinopathies Sickle cell anemia, thalassemia Membrane abnormalities Hereditary spherocytosis PNH, spur cell anemia in liver Extrinsic-Acquired Immune-mediated Autoimmune; drug-induced, tx rxn Traumatic MAHA; prostheses (valves, TIPS) Direct infections, toxins Malaria, babesiosis; snake &amp;amp; spider venoms; Wilson’s; hypotonic infusions Entrapment Hypersplenism</description></item><item><title>Causes of low Mg</title><link>https://htlin222.github.io/garden/Causes-of-low-Mg/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Causes-of-low-Mg/</guid><description>Causes of low Mg hypomagnesemia
GI loss (diarrhea, bypass, pancreatitis, malnutrition, PPI)
renal loss (diuretics, nephrotoxic drugs, EtOH, ↑ Ca, 1° wasting syndromes, volume expansion)</description></item><item><title>Causes of Shock Classified by Mechanism and Hemodynamics</title><link>https://htlin222.github.io/garden/Causes-of-Shock-Classified-by-Mechanism-and-Hemodynamics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Causes-of-Shock-Classified-by-Mechanism-and-Hemodynamics/</guid><description>Causes of Shock Classified by Mechanism and Hemodynamics 分類 [[Distributive shock]] [[Hypovolemic shock]] [[Obstructive shock]] [[Cardiogenic shock]]
Shown is an algorithm for the initial assessment of a patient in shock (Panel A), relative frequencies of the main types of shock (Panel B), and schematic representations of the four main types of shock (Panel C).</description></item><item><title>Celiac disease</title><link>https://htlin222.github.io/garden/Celiac-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Celiac-disease/</guid><description>Celiac disease (JAMA 2017;318:647; Lancet 2018;391:70; Gastro 2019;156:4)
Immune rxn in genetically predisposed Pts (~1% pop) to gliadin, a component of gluten (wheat protein) → small bowel inflammatory infiltrate → impaired absorption</description></item><item><title>Cell count of ascites</title><link>https://htlin222.github.io/garden/Cell-count-of-ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cell-count-of-ascites/</guid><description>Cell count of ascites normal limit of PMNs in ascitic fluid up to 250 PMNs/mm3. Bloody tap (typically from traumatic para) can skew cell count; subtract 1 PMN for every 250 RBCs to correct PMN count.</description></item><item><title>Cell count of cerebrospinal fluid</title><link>https://htlin222.github.io/garden/Cell-count-of-cerebrospinal-fluid/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cell-count-of-cerebrospinal-fluid/</guid><description>Cell count of cerebrospinal fluid RBC 正常 CSF RBC &amp;lt; 5 若上升可能原因有 traumatic tapping、SAH 等</description></item><item><title>Cellulitis Treatment</title><link>https://htlin222.github.io/garden/Cellulitis-Treatment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cellulitis-Treatment/</guid><description>Cellulitis Treatment (NEJM 2014;370:2238; CID 2014;59:e10; JAMA 2016;316:325 &amp;amp; 2017;317:2088) | Purulent | Usual Micro | Severity | Treatment |</description></item><item><title>Central adrenal insufficiency</title><link>https://htlin222.github.io/garden/Central-adrenal-insufficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Central-adrenal-insufficiency/</guid><description>Central adrenal insufficiency Sx similar to 1° adrenal insufficiency (see “Adrenal Disorders”) except: no salt cravings or hyperkalemia (b/c aldo preserved) no hyperpigmentation (b/c ACTH/MSH is not ↑)</description></item><item><title>Central diabetes insipidus</title><link>https://htlin222.github.io/garden/Central-diabetes-insipidus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Central-diabetes-insipidus/</guid><description>Central diabetes insipidus ↓ ADH
Typically from mass lesion extrinsic to sella; pituitary tumor does not typically present w/ DI Clinical manifestations: severe polyuria, thirst, nl to mild hyperNa (severe if ↓ access to H2O) Diagnostic studies: see “Sodium and Water Homeostasis” [[overview-sodium and water homeostasis]] [[polyuria]]</description></item><item><title>Central hypogonadism</title><link>https://htlin222.github.io/garden/Central-hypogonadism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Central-hypogonadism/</guid><description>Central hypogonadism Clinical manifestations: ↓ libido, impotence, oligomenorrhea or amenorrhea, infertility, ↓ muscle mass, osteoporosis Physical exam: ↓ testicular size; loss of axillary, pubic and body hair Dx with: ↓ a.</description></item><item><title>Central hypothyroidism</title><link>https://htlin222.github.io/garden/Central-hypothyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Central-hypothyroidism/</guid><description>Central hypothyroidism ↓ TSH
Sx of central hypothyroidism similar to 1° (see “Thyroid Disorders”) except absence of goiter Dx with free T4 in addition to TSH, as TSH may be low or inappropriately normal</description></item><item><title>Central vein stenosis</title><link>https://htlin222.github.io/garden/Central-vein-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Central-vein-stenosis/</guid><description>Central vein stenosis assoc. with longer HD duration, tunneled catheters. HeRO grafts bypass subclavian stenosis with flow into central vein (J Vasc Access 2016;17:138).</description></item><item><title>Cerebral edema-Management-acute liver failure</title><link>https://htlin222.github.io/garden/Cerebral-edema-Management-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cerebral-edema-Management-acute-liver-failure/</guid><description>Cerebral edema-Management-acute liver failure consider ICP monitoring if grade 3/4 enceph; if ↑ ICP → mannitol 0.5–1.0 mg/kg; if arterial NH3 &amp;gt;150, grade 3/4 enceph, AKI or on vasopressors → prophylactic 3% saline with goal Na 145–155 mEq/L; barbiturates &amp;amp; hypothermia if refractory ↑ ICP</description></item><item><title>cerebrospinal fluid lab results</title><link>https://htlin222.github.io/garden/cerebrospinal-fluid-lab-results/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cerebrospinal-fluid-lab-results/</guid><description>cerebrospinal fluid lab results 正常：清、低壓&amp;lt;18、少球&amp;lt;5、含糖50+、低蛋白&amp;lt;40
[[Appearance of cerebrospinal fluid]] [[open pressure]] 正常 9–18 cmH2O [[Cell count of cerebrospinal fluid]] 正常 CSF RBC &amp;lt; 5 [[WBC of cerebrospinal fluid]] 正常 CSF WBC &amp;lt; 5 [[Protein of cerebrospinal fluid]] 正常 15–40 mg/dL [[Glucose of cerebrospinal fluid]] 正常約 50–75 mg/dL，約是 serum 的 0.</description></item><item><title>CHA2DS2-VASc</title><link>https://htlin222.github.io/garden/CHA2DS2-VASc/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CHA2DS2-VASc/</guid><description>CHA2DS2-VASc CHF (1 point); HTN (1); Age ≥75 y (2); DM (1), Stroke/TIA (2); Vascular disease (eg, MI, PAD, Ao plaque) (1); Age 65–74 (1); ♀ Sex category (1) Annual risk of stroke (Lancet 2012;379:648): at low end, ~1% per point: 0 → ~0%, 1 → 1.</description></item><item><title>change in mental status</title><link>https://htlin222.github.io/garden/change-in-mental-status/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/change-in-mental-status/</guid><description>change in mental status [[Consciousness Arousal]] [[Etiologies of Decreased Responsiveness]] [[Initial evaluation of change in mental status]] see [[Stepwise Evaluation of a Patient with Delirium]] [[The Confusion Assessment Method]]</description></item><item><title>Characteristics of Pleural Fluid</title><link>https://htlin222.github.io/garden/Characteristics-of-Pleural-Fluid/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Characteristics-of-Pleural-Fluid/</guid><description>Characteristics of Pleural Fluid</description></item><item><title>CHECKLIST AND LONG TERM POST ACS MANAGEMENT</title><link>https://htlin222.github.io/garden/CHECKLIST-AND-LONG-TERM-POST-ACS-MANAGEMENT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CHECKLIST-AND-LONG-TERM-POST-ACS-MANAGEMENT/</guid><description>CHECKLIST AND LONG TERM POST ACS MANAGEMENT Risk stratification Stress test if anatomy undefined; consider stress if signif residual CAD post-PCI of culprit Assess LVEF prior to d/c; EF ↑ ~6% in STEMI over 6 mo (JACC 2007;50:149) Antiplatelet therapy Aspirin: 81 mg daily (no clear benefit to higher doses) P2Y12 inhibitor: ticagrelor or prasugrel preferred over clopi.</description></item><item><title>Chemical Causes of Cellular Hypoxia</title><link>https://htlin222.github.io/garden/Chemical-Causes-of-Cellular-Hypoxia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chemical-Causes-of-Cellular-Hypoxia/</guid><description>Chemical Causes of Cellular Hypoxia CO binds to Hb more avidly than does O2. Pulse oximeter (Ox) misreads COHb as HbO2 → falsely nl sat.</description></item><item><title>chemo side effects</title><link>https://htlin222.github.io/garden/chemo-side-effects/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chemo-side-effects/</guid><description>chemo side effects</description></item><item><title>Chest Discomfort</title><link>https://htlin222.github.io/garden/Chest-Discomfort/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chest-Discomfort/</guid><description>Chest Discomfort [[chest pain]]</description></item><item><title>chest pain</title><link>https://htlin222.github.io/garden/chest-pain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chest-pain/</guid><description>[[Typical Characteristics and Diagnostic Studies of Chest Pain]]
Initial diagnostic studies [[Focused history of chest pain]]
Targeted exam: VS (incl.</description></item><item><title>chest radiograph</title><link>https://htlin222.github.io/garden/chest-radiograph/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chest-radiograph/</guid><description>chest radiograph Tips: Are There Many Lung Lesion Can I ?
Consolidation: 水、血、膿 SILHOUETTE SIGN heart, aorta, or diaphragm bronchopneumonia: Multifocal consolidation DIFFUSE CONSOLIDATION: crazy paving pulmonary edema ARDS pulmonary hemorrhage Pneumocystis Cryptogenic organizing pneumonia predominant peribronchial and peripheral distribution FOCAL AND MULTIFOCAL CONSOLIDATION EXTENSIVE CONFLUENT AND DIFFUSE CONSOLIDATION ACUTE CAUSES OF PARENCHYMAL CONSOLIDATION CHRONIC CAUSES OF PARENCHYMAL CONSOLIDATION Atelectasis Obstructive atelectasis Distal to obstruction of a bronchus</description></item><item><title>cholangitis</title><link>https://htlin222.github.io/garden/cholangitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cholangitis/</guid><description>cholangitis Definition &amp;amp; etiologies (World J Gasrointest Pathophysiol 2018:9:1)
Bile duct obstruction causes stasis → infection proximal to the obstruction Etiologies: BD stone (~85%); malignant (biliary, pancreatic) or benign stricture; infection w/ fluke (Clonorchis sinensis, Opisthorchis viverrini); recurrent pyrogenic cholangitis Clinical manifestations Charcot’s triad: RUQ pain, jaundice, fever/chills; present in ~70% of Pts Reynolds’ pentad: Charcot’s triad + shock and Δ MS; present in ~15% of Pts Diagnostic studies RUQ U/S: often demonstrates dilation of bile ducts Labs: ↑ WBC (with left shift), bilirubin, Aφ, amylase; may see ⊕ BCx ERCP; percutaneous transhepatic cholangiogram if ERCP unsuccessful [[Treatment-cholangitis]]</description></item><item><title>cholecystitis</title><link>https://htlin222.github.io/garden/cholecystitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cholecystitis/</guid><description>cholecystitis [[Pathogenesis-cholecystitis]] [[Clinical manifestations-cholecystitis]] [[Diagnostic studies-cholecystitis]] [[Treatment-cholecystitis]] [[Complications-cholecystitis]]</description></item><item><title>choledocholithiasis</title><link>https://htlin222.github.io/garden/choledocholithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/choledocholithiasis/</guid><description>choledocholithiasis Definition Gallstone lodged in common bile duct (CBD) Epidemiology Occurs in 15% of Pts w/ gallbladder stones; can form de novo in CBD due to biliary stasis Clinical manifestations RUQ/epigastric pain 2° obstrxn of bile flow → ↑ CBD pressure, jaundice, pruritus, nausea Rarely asymptomatic [[Diagnostic studies-choledocholithiasis]] Treatment ERCP &amp;amp; papillotomy w/ stone extraction (± lithotripsy) CCY w/in 6 wk unless contraindication (&amp;gt;15% Pts develop indication for CCY if unRx’d) Complications Cholangitis, cholecystitis, pancreatitis, stricture</description></item><item><title>cholelithiasis</title><link>https://htlin222.github.io/garden/cholelithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cholelithiasis/</guid><description>cholelithiasis [[Epidemiology pathogenesis-cholelithiasis]] [[Types of gallstones-cholelithiasis]] [[Clinical manifestations-cholelithiasis]] [[Diagnostic studies-cholelithiasis]] [[Treatment-cholelithiasis]] [[Complications-cholelithiasis]]</description></item><item><title>chronic kidney disease CKD</title><link>https://htlin222.github.io/garden/chronic-kidney-disease-CKD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chronic-kidney-disease-CKD/</guid><description>chronic kidney disease (CKD) [[Definition and etiologies-chronic kidney disease (CKD)]] [[Stages of CKD]] [[Signs and Symptoms of Uremia -chronic kidney disease (CKD)]] [[Complications-treatment-chronic kidney disease (CKD)]]</description></item><item><title>chronic mesenteric ischemia</title><link>https://htlin222.github.io/garden/chronic-mesenteric-ischemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chronic-mesenteric-ischemia/</guid><description>chronic mesenteric ischemia Pathophysiology: ↓ blood flow to gut typically because of mesenteric atherosclerosis Sx: “intestinal angina” = postprandial abd pain, early satiety, &amp;amp; ↓ wt due to fear of eating.</description></item><item><title>Chronic migraine</title><link>https://htlin222.github.io/garden/Chronic-migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chronic-migraine/</guid><description>Chronic migraine Chronic migraine is defined as ≥15 headache days per month for &amp;gt;3 months and fulfilment of ICHD-3 criteria for migraine on ≥8 days per month.</description></item><item><title>Chronic mild-to-moderate elevation in ALT AST</title><link>https://htlin222.github.io/garden/Chronic-mild-to-moderate-elevation-in-ALT-AST-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chronic-mild-to-moderate-elevation-in-ALT-AST-/</guid><description>Chronic mild-to-moderate elevation in ALT AST (&amp;lt;15× ULN)
Viral hepatitis: ✓ HBsAg, anti-HBs, anti-HBc, anti-HCV, IgM anti-HAV
NAFLD: consider BMI, ✓ lipid panel, HbA1c, liver U/S or elastography</description></item><item><title>chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chronic-obstructive-pulmonary-disease/</guid><description>CHRONIC OBSTRUCTIVE PULMONARY DISEASE [[Definition and epidemiology-chronic obstructive pulmonary disease]] [[Emphysema vs. Chronic Bronchitis]] [[Pathogenesis-chronic obstructive pulmonary disease]] [[Clinical manifestations-chronic obstructive pulmonary disease]] [[Diagnostic studies-chronic obstructive pulmonary disease]] [[Chronic treatment-chronic obstructive pulmonary disease]] [[Staging and prognosis-chronic obstructive pulmonary disease]] EXACERBATION [[COPD Exacerbation Treatment]]</description></item><item><title>Chronic or refractory for idiopathic thrombocytopenic purpura</title><link>https://htlin222.github.io/garden/Chronic-or-refractory-for-idiopathic-thrombocytopenic-purpura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chronic-or-refractory-for-idiopathic-thrombocytopenic-purpura/</guid><description>Chronic or refractory for idiopathic thrombocytopenic purpura Romiplostim or eltrombopag Allows splenectomy to be deferred
Fostamatinib: 75–150 mg BID Spleen tyrosine kinase (SYK) inhibitor</description></item><item><title>chronic pancreatitis</title><link>https://htlin222.github.io/garden/chronic-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/chronic-pancreatitis/</guid><description>chronic pancreatitis [[Pathogenesis etiology-chronic pancreatitis]] [[Clinical manifestations-chronic pancreatitis]] [[Diagnostic studies-chronic pancreatitis ]] [[Treatment-chronic pancreatitis]]</description></item><item><title>Chronic treatment-chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Chronic-treatment-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chronic-treatment-chronic-obstructive-pulmonary-disease/</guid><description>Chronic treatment-chronic obstructive pulmonary disease COPD Staging and Recommended Therapies by GOLD Criteria
一年兩次以下算A,B A Short-acting inh dilator prn B LAMA 一年兩次以上算C,D C LAMA D LAMA + LABA ± ICS 考慮在支氣管擴張劑中添加PDE-4抑制 Treatment [[Bronchodilators]] [[Corticosteroids for chronic obstructive pulmonary disease]] Triple Therapy (LAMA+LABA+ICS) ↓ exac, ↓ hosp, ↑ PNA (NEJM 2020;383:35) [[Roflumilast]] [[Anti-IL5]] daily azithro ↓ exacerbations, but not routine (JAMA 2014;311:2225) [[Oxygen for chronic obstructive pulmonary disease]] Night NPPV if recent exacerb &amp;amp; PaCO2 &amp;gt;&amp;ldquo;53&amp;rdquo; ↓ risk of readmit or death (JAMA 2017;317:2177) [[Prevention of chronic obstructive pulmonary disease]] Rehabilitation: ↓ dyspnea and fatigue, ↑ exercise tolerance, ↑ QoL (NEJM 2009;360:1329) Surgery &amp;amp; bronchoscopic interventions Lung volume reduction surgery: ↑ exercise capacity, ↓ mortality if FEV1 &amp;gt;20%, upper lobe, low exercise capacity (NEJM 2003;348:2059) Bronchoscopic lung reduction with endobronchial valves or coils: ↑ lung fxn but significant complications (PTX, PNA) (NEJM 2015;373:2325; Lancet 2015;386:1066; JAMA 2016;315:175) Lung transplant: ↑ QoL and ↓ sx (Lancet 1998;351:24), ?</description></item><item><title>Chronic treatment-nephrolithiasis</title><link>https://htlin222.github.io/garden/Chronic-treatment-nephrolithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chronic-treatment-nephrolithiasis/</guid><description>Chronic treatment-nephrolithiasis (CJASN 2016;11:1305 &amp;amp; 2017;12:1699)
Increase fluid intake (&amp;gt;2 L/d) for goal UOP 2 L/d (J Nephrol 2016;29:211)</description></item><item><title>Chvostek sign</title><link>https://htlin222.github.io/garden/Chvostek-sign/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Chvostek-sign/</guid><description>Chvostek sign 與低鈣血症相關的臨床發現
指的是面部肌肉的抽搐 當輕輕敲擊一個人的 臉頰，在耳前。
引起面部神經的非典型反應， (CN VII) 支配面部的許多肌肉。
通過輕輕拍打個人的臉頰 耳前 2 厘米（約 0.75 英寸）， 在第 7 顱腦 (CN VII) 的面神經路線上。</description></item><item><title>cirrhosis</title><link>https://htlin222.github.io/garden/cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cirrhosis/</guid><description>cirrhosis [[Definition-cirrhosis]] [[Etiologies-cirrhosis]] [[Clinical manifestations-cirrhosis]] [[Physical exam-cirrhosis]] [[Laboratory studies-cirrhosis]] [[Workup-cirrhosis]] [[Prognosis-cirrhosis]] [[ascites]] [[Spontaneous bacterial peritonitis]] [[Gastroesophageal varices and UGIB-cirrhosis]] [[Hepatic encephalopathy (HE)]] [[Hepatorenal syndrome (HRS)]] [[hepatocellular carcinoma]] [[Hepatopulmonary syndrome (HPS)]] [[Other Complication-cirrhosis]] [[Liver transplantation]] Other Etiologies [[Hemochromatosis &amp;amp; iron overload syndromes]] [[Wilson disease]] [[α1-antitrypsin deficiency (α1-AT)]] [[Primary biliary cholangitis (PBC)]] [[Primary sclerosing cholangitis (PSC)]]</description></item><item><title>CJK + Latex Support (测试)</title><link>https://htlin222.github.io/garden/notes/CJK-+-Latex-Support-%E6%B5%8B%E8%AF%95/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/CJK-+-Latex-Support-%E6%B5%8B%E8%AF%95/</guid><description>Chinese, Japanese, Korean Support 几乎在我们意识到之前，我们已经离开了地面。
우리가 그것을 알기도 전에 우리는 땅을 떠났습니다.
私たちがそれを知るほぼ前に、私たちは地面を離れていました。
Latex Block math works with two dollar signs $$.</description></item><item><title>classes of hemorrhagic shock</title><link>https://htlin222.github.io/garden/classes-of-hemorrhagic-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/classes-of-hemorrhagic-shock/</guid><description>classes of hemorrhagic shock 15 30 40</description></item><item><title>Classic tachycardias of WPW accessory pathways</title><link>https://htlin222.github.io/garden/Classic-tachycardias-of-WPW-accessory-pathways/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Classic-tachycardias-of-WPW-accessory-pathways/</guid><description>Classic tachycardias of WPW accessory pathways Orthodromic AVRT: narrow-complex SVT (typically), conducting ↓ AVN &amp;amp; ↑ accessory pathway; requires retrograde conduction and ∴ can occur w/ concealed bypass tracts Antidromic AVRT (rare): wide-complex SVT, conducting ↓ accessory pathway &amp;amp; ↑ AVN; requires antegrade conduction and ∴ should see pre-excitation pattern during SR AF w/ rapid conduction down accessory pathway; ∴ wide-complex irregular SVT; requires antegrade conduction; ∴ should see pre-excitation in SR.</description></item><item><title>Classic-Eponymous-Signs-in-Chronic-AR</title><link>https://htlin222.github.io/garden/Classic-Eponymous-Signs-in-Chronic-AR/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Classic-Eponymous-Signs-in-Chronic-AR/</guid><description>Classic-Eponymous-Signs-in-Chronic-AR Sign Description Corrigan’s pulse “water hammer” pulse (ie, rapid rise/fall or distention/collapse) Hill’s sign (popliteal SBP – brachial SBP) &amp;gt;60 mmHg Duroziez’s sign to-and-fro murmur heard over femoral artery w/ light compression Pistol shot sounds pistol shot sound heard over femoral artery Traube’s sound double sound heard over femoral artery when compressed distally de Musset’s sign head-bobbing with each heartbeat (low Se) Müller’s sign systolic pulsations of the uvula Quincke’s pulses subungual capillary pulsations (low Sp)</description></item><item><title>Classification criteria of Behçet’s syndrome</title><link>https://htlin222.github.io/garden/Classification-criteria-of-Beh%C3%A7ets-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Classification-criteria-of-Beh%C3%A7ets-syndrome/</guid><description>Classification criteria of Behçet’s syndrome (#1 + ≥2 others is 91% Se &amp;amp; 96% Sp; Lancet 1990;335:1078)
Recurrent oral aphthous ulceration (≥3× in 1 y, usually 1st manifestation) Recurrent genital ulceration (labia in females, scrotum in males) Eye lesions: uveitis, scleritis, retinal vasculitis, optic neuritis; may threaten vision Skin lesions: pustules, papules, folliculitis, erythema nodosum (scarring) ⊕ pathergy test (prick forearm w/ sterile needle → pustule) (not sensitive in Caucasians)</description></item><item><title>Classification of Pain</title><link>https://htlin222.github.io/garden/Classification-of-Pain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Classification-of-Pain/</guid><description>Classification of Pain ✨重點: 推斷的病理生理學（傷害性與非傷害性） 時間進程（急性與亞急性與慢性） 位置（局部疼痛區域與廣義） 病因（例如，癌症、關節炎、神經損傷或這些的組合） neurophysiologic classification of pain 神經生理學分類基於推斷的疼痛機制。 基本上有兩種類型：（1）傷害性，這是由於疼痛敏感結構的損傷，和（2）非傷害性，它是神經性和心理性的。 傷害性疼痛可細分為軀體性疼痛和內臟性疼痛（取決於激活了哪組傷害感受器）。 神經性疼痛可細分為外周性疼痛和中樞性疼痛（取決於被認為負責維持疼痛的神經系統中的損傷部位）。 儘管這個術語已經使用了很多年，但心因性疼痛是一個非常模糊的術語，應該只用於那些最終排除了所有非心因性原因的情況——也就是說，一個人很少經歷心因性疼痛獨自的。 我們經常看到被低估的慢性疼痛患者被診斷為心因性疼痛，而事實上，他們的疼痛有一個明確的病因，但由於診斷評估不理想而被忽視。</description></item><item><title>Classification-acute aortic syndromes</title><link>https://htlin222.github.io/garden/Classification-acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Classification-acute-aortic-syndromes/</guid><description>Classification-acute aortic syndromes (proximal more common than distal; JACC 2019;74:1494 &amp;amp; 2020;76:1703)
Proximal: involves ascending Ao, regardless of origin (= Stanford A, DeBakey I &amp;amp; II) Distal: involves descending Ao only, distal to L subclavian art.</description></item><item><title>Classification-atrial fibrillation</title><link>https://htlin222.github.io/garden/Classification-atrial-fibrillation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Classification-atrial-fibrillation/</guid><description>Classification-atrial fibrillation (Circ 2014;130:e199)
Paroxysmal (terminates spontaneously or within 7 d) vs. persistent (&amp;gt;7 d) vs. long-standing persistent (&amp;gt;1 y) vs.</description></item><item><title>Classification-autoimmune hepatitis AIH</title><link>https://htlin222.github.io/garden/Classification-autoimmune-hepatitis-AIH/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Classification-autoimmune-hepatitis-AIH/</guid><description>Classification-autoimmune hepatitis (AIH) (J Hep 2015;62:S100, World J Gastro 2015;21:60)
Type 1: anti-smooth muscle Ab (ASMA), ANA; anti-soluble liver antigen (anti-SLA), a/w more severe disease and relapsing disease (found in 10–30% Pts), IgG often ↑</description></item><item><title>clinical case of epidural abscess</title><link>https://htlin222.github.io/garden/clinical-case-of-epidural-abscess/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/clinical-case-of-epidural-abscess/</guid><description>clinical case of epidural abscess A 50-year-old woman with end-stage kidney disease from hypertensive nephrosclerosis presents for her regularly scheduled hemodialysis session.</description></item><item><title>clinical characteristics of bleeding disorders</title><link>https://htlin222.github.io/garden/clinical-characteristics-of-bleeding-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/clinical-characteristics-of-bleeding-disorders/</guid><description>clinical characteristics of bleeding disorders Platelet/Vascular Defect Skin, mucous membranes Petechiae, ecchymoses Bleeding After minor cuts: yes Bleeding After surgery: immediate, mild Coagulation Defect Deep in soft tissues (muscles, joints) Hemarthroses, hematomas Bleeding After minor cuts: unusual Bleedgin After surgery: delayed, severe</description></item><item><title>Clinical evaluation of Secondary causes of headaches</title><link>https://htlin222.github.io/garden/Clinical-evaluation-of-Secondary-causes-of-headaches/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-evaluation-of-Secondary-causes-of-headaches/</guid><description>Clinical evaluation of Secondary causes of headaches (Neurology 2019;92:134 &amp;amp; JAMA 2021;325:1874)
Hx: onset (sudden vs. gradual), quality, evolution (progressive), severity, location, duration, triggers, alleviating factors, positional, hormonal (menstruation), preceding trauma, assoc.</description></item><item><title>Clinical features-cystic fibrosis</title><link>https://htlin222.github.io/garden/Clinical-features-cystic-fibrosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-features-cystic-fibrosis/</guid><description>Clinical features-cystic fibrosis Recurrent PNA, sinus infections
Distal intestinal obstruction syndrome (DIOS), pancreatic insufficiency (steatorrhea, malabsorption, failure to thrive, weight loss), CF-related diabetes, infertility</description></item><item><title>Clinical manifestation-bacterial endocarditis</title><link>https://htlin222.github.io/garden/Clinical-manifestation-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestation-bacterial-endocarditis/</guid><description>Clinical manifestation-bacterial endocarditis (Lancet 2016;387:882)
Persistent bacteremia → fever (80–90%), rigors, night sweats, anorexia, myalgias Valvular or perivalvular infection → HF, conduction abnormalities (eg, AVB) Septic emboli: stroke, embolic MI, renal/splenic/pulmonary infarcts, septic arthritis, osteo Immune complex phenomena: arthritis, glomerulonephritis Subacute endocarditis can present with subacute progressive “B” sx (fatigue, wt loss)</description></item><item><title>Clinical manifestations</title><link>https://htlin222.github.io/garden/Clinical-manifestations/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations/</guid><description>Clinical manifestations Classic triad = wheezing, cough, dyspnea; others include chest tightness, sputum; symptoms typically chronic with episodic exacerbation</description></item><item><title>Clinical manifestations dx studies-hyperosmolar hyperglycemic state</title><link>https://htlin222.github.io/garden/Clinical-manifestations-dx-studies-hyperosmolar-hyperglycemic-state/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-dx-studies-hyperosmolar-hyperglycemic-state/</guid><description>Clinical manifestations dx studies-hyperosmolar hyperglycemic state (Diabetes Care 2014;37:3124)
Volume depletion and Δ MS ↑ serum glc (usually &amp;gt;600 mg/dL) and ↑ meas.</description></item><item><title>Clinical Manifestations and Physical Exam-acute aortic syndromes</title><link>https://htlin222.github.io/garden/Clinical-Manifestations-and-Physical-Exam-acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-Manifestations-and-Physical-Exam-acute-aortic-syndromes/</guid><description>Clinical Manifestations and Physical Exam-acute aortic syndromes (JAMA 2000;283:897) Feature
Proximal Distal “Aortic” pain (abrupt, severe, tearing or ripping quality, maximal at onset [vs.</description></item><item><title>Clinical manifestations complications-herpes zoster</title><link>https://htlin222.github.io/garden/Clinical-manifestations-complications-herpes-zoster/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-complications-herpes-zoster/</guid><description>Clinical manifestations complications-herpes zoster Uncomplicated: pain in a dermatomal distribution → dermatomal eruption of erythematous papules → vesicles → crusted plaques in varying stages of evolution Disseminated: vesicles across multiple dermatomes, visceral organ involvement (pneumonia, hepatitis, CNS) seen in immunosupp.</description></item><item><title>Clinical manifestations gastroesophageal reflux disease</title><link>https://htlin222.github.io/garden/Clinical-manifestations-gastroesophageal-reflux-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-gastroesophageal-reflux-disease/</guid><description>Clinical manifestations gastroesophageal reflux disease Esophageal: heartburn, atypical chest pain, regurgitation, sour taste, dysphagia Extraesophageal: dry cough, asthma (often poorly controlled), laryngitis, dental erosions Patients with GERD often present with heartburn, regurgitation, mild dysphagia, and noncardiac chest pain.</description></item><item><title>Clinical manifestations of acute coronary syndromes</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-acute-coronary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-acute-coronary-syndromes/</guid><description>Clinical manifestations of acute coronary syndromes Cardiac chest pain (“angina”): retrosternal pressure/pain/tightness ± radiation to neck, jaw, arms. Precipitated by exertion (physical or emotional), ↓ w/ rest or NTG.</description></item><item><title>Clinical manifestations of breast cancer</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-breast-cancer/</guid><description>Clinical manifestations of breast cancer Breast mass (hard, irregular, fixed, nontender), nipple discharge (higher risk if unilateral, limited to 1 duct, bloody, associated with mass) Special types: Paget disease → unilateral nipple eczema + nipple discharge; inflammatory breast cancer → skin erythema and edema (peau d’orange) Metastases: lymph nodes, bone, liver, lung, brain 相關連結： [[breast cancer]]</description></item><item><title>Clinical manifestations of Cryoglobulinemic vasculitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-Cryoglobulinemic-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-Cryoglobulinemic-vasculitis/</guid><description>Clinical manifestations of Cryoglobulinemic vasculitis Type I hyperviscosity (cold worsens sx) → HA, visual Δ, livedo, digital ischemia
Type II/III vasculitis (not affected by cold) → fever, derm (54–80%; purpura, livedo reticularis, ulcers), arthralgia (44–70%; symmetric migratory, small/med joints), glomerulonephritis (50%; MPGN), neurologic (17–60%; peripheral neuropathy (polyneuropathy &amp;gt;mononeuritis multiplex), ↓ Hgb, ↓ plt, ↑ B-cell lymphoma risk, GI (5%; pain, HSM, ↑ LFTs).</description></item><item><title>Clinical manifestations of Eosinophilic gran with polyangiitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-Eosinophilic-gran-with-polyangiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-Eosinophilic-gran-with-polyangiitis/</guid><description>Clinical manifestations of Eosinophilic gran with polyangiitis (Rheumatol 2020;59:iii84)
Initial sx: asthma sinusitis allergic rhinitis (new asthma in adult raises suspicion) Eosinophilic infiltrative disease: transient pulm infiltrates, gastroenteritis esophagitis Systemic small-vessel vasculitis: neuropathy (mononeuritis multiplex), renal (glomerulonephritis), skin (palpable purpura, petechial, nodules) Cardiac: coronary arteritis, myocarditis, CHF valvular insufficiency (Medicine 2009;88:236)</description></item><item><title>Clinical manifestations of Giant cell arteritis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-Giant-cell-arteritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-Giant-cell-arteritis/</guid><description>Clinical manifestations of Giant cell arteritis (NEJM 2014;371:50): constitutional sx: fevers, fatigue, wt loss
Temporal artery (TA) → headache, tender TAs and scalp, absent TA pulse</description></item><item><title>Clinical manifestations of Granulomatosis with polyangiitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-Granulomatosis-with-polyangiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-Granulomatosis-with-polyangiitis/</guid><description>Clinical manifestations of Granulomatosis with polyangiitis Upper respiratory tract: perforation of nasal septum, chronic sinusitis, otitis media, mastoiditis. Lower respiratory tract: hemoptysis, cough, dyspnea.</description></item><item><title>Clinical manifestations of IgA vasculitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-IgA-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-IgA-vasculitis/</guid><description>Clinical manifestations of IgA vasculitis 關節、肚子、腎、皮
Palpable purpura on extensor surfaces (lower extremity first) &amp;amp; buttocks Polyarthralgias (nondeforming) esp. involving hips, knees, &amp;amp; ankles Colicky abdominal pain ± GIB or intussusception Nephritis ranging from microscopic hematuria &amp;amp; proteinuria to ESRD</description></item><item><title>Clinical manifestations of lung cancer</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-lung-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-lung-cancer/</guid><description>Clinical manifestations of lung cancer ~10% asymptomatic at dx, detected incidentally (only 16% w/ localized dis. at presentation) Endobronchial growth of 1° tumor: cough, hemoptysis, dyspnea, pain, wheezing, post-obstructive pneumonia; more common with squamous or small cell (central location) Regional spread: can cause dysphagia (esophageal compression), stridor (tracheal obstruction), hoarseness (recurrent laryngeal nerve palsy).</description></item><item><title>clinical manifestations of peptic ulcer disease</title><link>https://htlin222.github.io/garden/clinical-manifestations-of-peptic-ulcer-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/clinical-manifestations-of-peptic-ulcer-disease/</guid><description>clinical manifestations of peptic ulcer disease Epigastric gnawing abdominal pain: relieved with food (DU) or worsened by food (GU) Complic.</description></item><item><title>Clinical manifestations of Polyarteritis nodosa</title><link>https://htlin222.github.io/garden/Clinical-manifestations-of-Polyarteritis-nodosa/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-of-Polyarteritis-nodosa/</guid><description>Clinical manifestations of Polyarteritis nodosa (Arth Rheum 2010;62:616):
const. sx (80%): wt loss, fever, fatigue Neuro (79%): mononeuritis multiplex, peripheral neuropathies, stroke Musculoskeletal (64%): extremity pain, myalgias, arthralgias, arthritis Renal (51%): HTN, hematuria, proteinuria, renal failure; glomerulonephritis unusual GI (38%): abd pain, GIB/infarction, cholecystitis; GU (25%): ovarian or testicular pain Skin (50%): livedo reticularis, purpura, nodules, ulcers, Raynaud’s Ophthalmic (9%): retinal vasculitis, retinal exudates, conjunctivitis, uveitis Cardiac (22%): coronary arteritis, cardiomyopathy, pericarditis Pulmonary: rare; if lung involvement, suspect other vasculitis</description></item><item><title>Clinical Manifestations of Sarcoidosis</title><link>https://htlin222.github.io/garden/Clinical-Manifestations-of-Sarcoidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-Manifestations-of-Sarcoidosis/</guid><description>Clinical Manifestations of Sarcoidosis Pulmonary
Hilar LAN; fibrosis; pulm hypertension. Stages: I = bilat hilar
LAN; II = LAN + ILD; III = ILD only; IV = diffuse fibrosis.</description></item><item><title>Clinical manifestations peptic ulcer disease</title><link>https://htlin222.github.io/garden/Clinical-manifestations-peptic-ulcer-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-peptic-ulcer-disease-/</guid><description>Clinical manifestations peptic ulcer disease Epigastric gnawing abdominal pain: relieved with food (DU) or worsened by food (GU)</description></item><item><title>Clinical manifestations-acute liver failure</title><link>https://htlin222.github.io/garden/Clinical-manifestations-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-acute-liver-failure/</guid><description>Clinical manifestations-acute liver failure Initial presentation: N/V, malaise, RUQ pain, jaundice, encephalopathy, multiorgan failure
Neurologic: encephalopathy: grade 1 = attn deficit, disordered sleep; grade 2 = asterixis, confusion; grade 3 = somnolence, rigidity; grade 4 = coma; ↑ ICP w/ bradycardia &amp;amp; HTN</description></item><item><title>Clinical manifestations-acute mesenteric ischemia</title><link>https://htlin222.github.io/garden/Clinical-manifestations-acute-mesenteric-ischemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-acute-mesenteric-ischemia/</guid><description>Clinical manifestations-acute mesenteric ischemia Arterial occlusion: sudden intense abd pain out of proportion to tenderness on exam
Venous occlusion: often more insidious in onset, intermittent pain with peaks and valleys</description></item><item><title>Clinical manifestations-acute pancreatitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-acute-pancreatitis/</guid><description>Clinical manifestations-acute pancreatitis Epigastric abdominal or LUQ pain (90%), only ½ w/ bandlike pain radiating to back
10% pain-free (due to analgesic/steroid use, immunosuppressed, ΔMS, ICU); ∴ ✓ lipase in unexplained shock, periumbilical or flank (Cullen or Grey Turner signs) bruising</description></item><item><title>Clinical manifestations-adrenal insufficiency</title><link>https://htlin222.github.io/garden/Clinical-manifestations-adrenal-insufficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-adrenal-insufficiency/</guid><description>Clinical manifestations-adrenal insufficiency (Lancet 2021;397:613)
Primary or secondary: weakness and fatigability (95%), weight loss (70%), orthostatic hypotension (60%), nausea (50%), vomiting (50%), hyponatremia (75%) Primary only (extra s/s due to lack of aldosterone and ↑ ACTH): marked orthostatic hypotension (because volume depleted), salt craving, hyperpigmentation (seen in creases, mucous membranes, pressure areas, nipples), hyperkalemia Secondary only: ± other manifestations of [[hypopituitary syndromes]]</description></item><item><title>clinical manifestations-anemia</title><link>https://htlin222.github.io/garden/clinical-manifestations-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/clinical-manifestations-anemia/</guid><description>clinical manifestations-anemia Symptoms: ↓ O2 delivery → fatigue, exertional dyspnea, angina (if CAD)
Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension</description></item><item><title>Clinical manifestations-Candida species</title><link>https://htlin222.github.io/garden/Clinical-manifestations-Candida-species/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-Candida-species/</guid><description>Clinical manifestations-Candida species Mucocutaneous cutaneous (eg, red, macerated lesions in intertriginous zones); oral thrush (exudative, erythematous or atrophic; if unexplained, r/o HIV); esophageal (odynophagia; ± oral thrush); vulvovaginal, balanitis</description></item><item><title>Clinical manifestations-cholecystitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-cholecystitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-cholecystitis/</guid><description>Clinical manifestations-cholecystitis History: RUQ/epigastric pain ± radiation to R shoulder/back, nausea, vomiting, fever
Physical exam: RUQ tenderness, Murphy’s sign = ↑ RUQ pain and inspiratory arrest with deep breath during palpation of R subcostal region, ± palpable gallbladder</description></item><item><title>Clinical manifestations-cholelithiasis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-cholelithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-cholelithiasis/</guid><description>Clinical manifestations-cholelithiasis Asx in ~80%. Biliary pain develops in 1–4%/y. Once sx, rate of complications ~1–3%/y.
Biliary pain = episodic RUQ or epigastric pain; begins abruptly, continuous, resolves slowly and lasts 30 min–3 h; ± radiation to scapula; precip by fatty foods; nausea</description></item><item><title>Clinical manifestations-chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Clinical-manifestations-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-chronic-obstructive-pulmonary-disease/</guid><description>Clinical manifestations-chronic obstructive pulmonary disease Chronic cough, sputum production, dyspnea; later stages → freq exacerb, AM headache, wt loss</description></item><item><title>Clinical manifestations-chronic pancreatitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-chronic-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-chronic-pancreatitis/</guid><description>Clinical manifestations-chronic pancreatitis Epigastric pain, N/V; over time can be painless; signs of exocrine insuff (steatorrhea, wt loss) or endocrine insuff (DM: polydipsia, polyuria); 13× ↑ risk of pancreatic cancer</description></item><item><title>Clinical manifestations-cirrhosis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-cirrhosis/</guid><description>Clinical manifestations-cirrhosis Nonspecific sx (anorexia, fatigue) or jaundice, encephalopathy, ascites, variceal bleeding</description></item><item><title>Clinical manifestations-clostridioides difficile infection</title><link>https://htlin222.github.io/garden/Clinical-manifestations-clostridioides-difficile-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-clostridioides-difficile-infection/</guid><description>Clinical manifestations-clostridioides difficile infection Asx colonization: &amp;lt;3% healthy adults; ~20% in hospitalized patients on antibiotics
Acute watery diarrhea (&amp;gt;3 stool/d), occ bloody ± mucus, lower abd pain, fever, ↑↑↑ WBC</description></item><item><title>Clinical manifestations-crohn’s disease</title><link>https://htlin222.github.io/garden/Clinical-manifestations-crohns-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-crohns-disease/</guid><description>Clinical manifestations-crohn’s disease Abdominal pain,
loose/frequent stools (up to 50% ⊕ FOBT),
malaise,
wt loss</description></item><item><title>Clinical manifestations-Cushing’s Syndrome</title><link>https://htlin222.github.io/garden/Clinical-manifestations-Cushings-Syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-Cushings-Syndrome/</guid><description>Clinical manifestations-Cushing’s Syndrome Nonspecific: glucose intolerance or DM, HTN, obesity, oligo- or amenorrhea, osteoporosis More specific: central obesity w/ extremity wasting, dorsocervical fat pads, spont.</description></item><item><title>Clinical manifestations-diabetic ketoacidosis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-diabetic-ketoacidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-diabetic-ketoacidosis/</guid><description>Clinical manifestations-diabetic ketoacidosis (Diabetes Care 2009;32:1335 &amp;amp; 2016;39:S99)
Polyuria, polydipsia, &amp;amp; dehydration → ↑ HR, HoTN, dry mucous membranes, ↓ skin turgor N/V, abdominal pain (either due to intra-abdominal process or DKA), ileus Kussmaul’s respirations (deep) to compensate for metabolic acidosis with odor of acetone Δ MS → somnolence, stupor, coma; mortality ~1% even at tertiary care centers</description></item><item><title>Clinical manifestations-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Clinical-manifestations-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-gastrointestinal-bleeding/</guid><description>Clinical manifestations-gastrointestinal bleeding Hematemesis = blood in vomitus (UGIB)
Coffee-ground emesis = emesis of blood exposed to gastric acid (UGIB)</description></item><item><title>Clinical manifestations-hyperaldosteronism</title><link>https://htlin222.github.io/garden/Clinical-manifestations-hyperaldosteronism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-hyperaldosteronism/</guid><description>Clinical manifestations-hyperaldosteronism Mild-to-moderate HTN: 16-22% of all HTN, 11% of refractory cases (Annals 2020;173:10) Headache, muscle weakness, polyuria, polydipsia; no peripheral edema because of “escape” from Na retention; malignant HTN is rare Classically hypokalemia (but often normal), metabolic alkalosis, mild hypernatremia</description></item><item><title>Clinical manifestations-hypercalcemia</title><link>https://htlin222.github.io/garden/Clinical-manifestations-hypercalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-hypercalcemia/</guid><description>Clinical manifestations-hypercalcemia (“bones, stones, abdominal groans, and psychic moans”)
[[Primary hyperparathyroidism]]
Hypercalcemic crisis (usually when Ca &amp;gt;13–15): polyuria, dehydration, ΔMS</description></item><item><title>Clinical manifestations-hyperkalemia</title><link>https://htlin222.github.io/garden/Clinical-manifestations-hyperkalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-hyperkalemia/</guid><description>Clinical manifestations-hyperkalemia Weakness, nausea, paresthesias, palpitations; Renal: ↓ NH4+ secretion → acidosis
ECG: ST depression, peaked T waves, ↓ QT, ↑ PR interval, ↑ QRS width, loss of P wave, sine wave pattern, PEA/VF (ECG: low sens.</description></item><item><title>Clinical manifestations-hypocalcemia</title><link>https://htlin222.github.io/garden/Clinical-manifestations-hypocalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-hypocalcemia/</guid><description>Clinical manifestations-hypocalcemia Neuromuscular irritability: perioral paresthesias, cramps, ⊕ Trousseau’s (inflation of BP cuff ≥3 min → carpal spasm), ⊕ Chvostek’s (tapping facial nerve → contraction of facial muscles), laryngospasm; irritability, depression, psychosis, seizures, ↑ QT</description></item><item><title>Clinical manifestations-hypokalemia</title><link>https://htlin222.github.io/garden/Clinical-manifestations-hypokalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-hypokalemia/</guid><description>Clinical manifestations-hypokalemia Nausea, vomiting, ileus, weakness, muscle cramps, rhabdomyolysis, ↓ insulin secretion
Renal: ammoniagenesis, phosphaturia, hypocitraturia, NaCl &amp;amp; HCO3 retention, polyuria</description></item><item><title>Clinical manifestations-mitral-stenosis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-mitral-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-mitral-stenosis/</guid><description>Clinical manifestations-mitral-stenosis Dyspnea and pulmonary edema (if due to RHD, sx usually begin in 30s) precipitants: exercise, fever, anemia, volume overload (incl.</description></item><item><title>Clinical manifestations-necrotizing soft-tissue infections</title><link>https://htlin222.github.io/garden/Clinical-manifestations-necrotizing-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-necrotizing-soft-tissue-infections/</guid><description>Clinical manifestations-necrotizing soft-tissue infections Erythema, edema, warmth + systemic illness ± crepitus, bullae, necrosis Rapid progression of clinical signs Pain out of proportion to apparent cellulitis; skin hyperesthetic and later anesthetic</description></item><item><title>Clinical manifestations-nephrolithiasis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-nephrolithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-nephrolithiasis/</guid><description>Clinical manifestations-nephrolithiasis Hematuria (absence does not exclude diagnosis), flank pain, N/V, dysuria, frequency
Ureteral obstruction (stones &amp;gt;5 mm unlikely to pass spont.</description></item><item><title>Clinical manifestations-osteomyelitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-osteomyelitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-osteomyelitis/</guid><description>Clinical manifestations-osteomyelitis Surrounding soft-tissue compromise ± fistula to superficial skin ± Fever, malaise, and night sweats (more common in hematogenous than contiguous) Vertebral osteomyelitis (esp.</description></item><item><title>Clinical manifestations-pericardial tamponade</title><link>https://htlin222.github.io/garden/Clinical-manifestations-pericardial-tamponade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-pericardial-tamponade/</guid><description>Clinical manifestations-pericardial tamponade Cardiogenic shock (hypotension, fatigue) without pulmonary edema Dyspnea (seen in ~85%) may be due to ↑ respiratory drive to augment venous return 症狀：胸痛、暈厥前兆或暈厥、呼吸困難或呼吸急促、端坐呼吸 體格檢查：低血壓、心動過速、JVP 升高、無肺爆裂音、心音減弱、心包摩擦音（罕見）、外周水腫 矛盾脈（吸氣時收縮壓降低&amp;gt;10 mmHg） ECG：不敏感或特異：心動過速、低電壓（肢體導聯最大 QRS 振幅 &amp;lt;0.</description></item><item><title>Clinical manifestations-pericarditis and pericardial effusion</title><link>https://htlin222.github.io/garden/Clinical-manifestations-pericarditis-and-pericardial-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-pericarditis-and-pericardial-effusion/</guid><description>Clinical manifestations-pericarditis and pericardial effusion NEJM 2014;371:2410; JACC 2020;75:76)
Pericarditis: retrosternal CP, pleuritic, positional (often ↓ by sitting forward), → trapezius; may be absent in TB, neoplastic, XRT, or uremic; ± fever; ± s/s of systemic etiologies</description></item><item><title>Clinical manifestations-pheochromocytoma and paraganglioma</title><link>https://htlin222.github.io/garden/Clinical-manifestations-pheochromocytoma-and-paraganglioma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-pheochromocytoma-and-paraganglioma/</guid><description>Clinical manifestations-pheochromocytoma and paraganglioma (NEJM 2019;381:552)
Neuroendocrine neoplasm leads to inappropriate and paroxysmal release of adrenergic agents including epinephrine, norepinephrine, and rarely dopamine Classic triad: episodic headaches, palpitations and profuse sweating; only 50% have paroxysmal hypertension and most Pts do not have three classic sx Paroxysms can be triggered by meds (eg, β-blockers), abdominal manipulation Up to 40% of pheos/paragangliomas thought to have underlying genetic etiology; genetic testing frequently recommended Associated with MEN2A/2B, von Hippel Lindau, NF1, familial paraganglioma (mutations in succinate dehydrogenase gene B, C and D), MAX or TMEM127 mutations</description></item><item><title>Clinical manifestations-Portal vein thrombosis PVT</title><link>https://htlin222.github.io/garden/Clinical-manifestations-Portal-vein-thrombosis-PVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-Portal-vein-thrombosis-PVT/</guid><description>Clinical manifestations-Portal vein thrombosis (PVT) acute: abd pain, fever, variceal bleed or asx w/ incidental finding on U/S or CT. If mesenteric vein involved may p/w intestinal infarct.</description></item><item><title>Clinical manifestations-Screening for latent TB</title><link>https://htlin222.github.io/garden/Clinical-manifestations-Screening-for-latent-TB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-Screening-for-latent-TB/</guid><description>Clinical manifestations-Screening for latent TB (Lancet 2016;387:1211)
Constitutional symptoms are common in all manifestations, but may be absent Primary TB pneumonia: middle or lower lobe consolidation, ± effusion, ± cavitation TB pleurisy: pulmonary effusion ± pericardial and peritoneal effusions secondary to granuloma breakdown and local inflammation; can occur in primary or reactivation Reactivation TB pulmonary disease: upper lobe infiltrate ± volume loss ± cavitation Milliary TB: diffuse millet seed-sized lesions, more common in immunosupp.</description></item><item><title>Clinical manifestations-ulcerative colitis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-ulcerative-colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-ulcerative-colitis/</guid><description>Clinical manifestations-ulcerative colitis Grossly bloody diarrhea, lower abdominal cramps, tenesmus, small, frequent BM
Extracolonic (&amp;gt;25%): erythema nodosum, pyoderma gangrenosum, aphthous ulcers, uveitis, episcleritis, thromboembolic events (esp.</description></item><item><title>Clinical manifestations-urinary tract infections</title><link>https://htlin222.github.io/garden/Clinical-manifestations-urinary-tract-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-urinary-tract-infections/</guid><description>Clinical manifestations-urinary tract infections Cystitis: dysuria, urgency, frequency, hematuria, suprapubic pain; fever absent. R/o vaginitis if symptoms of cystitis &amp;amp; urethritis.</description></item><item><title>Clinical manifestations—DVT</title><link>https://htlin222.github.io/garden/Clinical-manifestationsDVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestationsDVT/</guid><description>Clinical manifestations—DVT Calf pain
swelling (&amp;gt;3 cm c/w unaffected side)
venous distention
erythema, warmth, tenderness, palpable cord,</description></item><item><title>Clinical manifestations—PE</title><link>https://htlin222.github.io/garden/Clinical-manifestationsPE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestationsPE/</guid><description>Clinical manifestations—PE Dyspnea (~50%),
pleuritic chest pain (~40%),
cough (~23%),
hemoptysis (~8%)</description></item><item><title>clinical reasoning</title><link>https://htlin222.github.io/garden/clinical-reasoning/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/clinical-reasoning/</guid><description>clinical reasoning [[positive and negative predictive values of tests]] [[symptom to diagnosis]] [[Physical Exam Secret]] cardinal manifestations [[Pain]] [[Alterations in Body Temperature]] [[Nervous System Dysfunction]] [[Disorders of Eyes, Ears, Nose, and Throat]] [[Alterations in Circulatory and Respiratory Functions]] [[Alterations in Gastrointestinal Function]] [[Alterations in Renal and Urinary Tract Function]] [[Alterations in the Skin]] [[Hematologic Alterations]]</description></item><item><title>clinical research methods</title><link>https://htlin222.github.io/garden/clinical-research-methods/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/clinical-research-methods/</guid><description>clinical research methods Phase I Clinical Trials Phase I，人體藥理研究 Phase II and III Clinical Trials Phase II，治療探索 Phase III，治療確認 長庚紀念醫院臨床試驗中心 Biomarker Development Biostatistics Regulatory Aspects of Clinical Trials</description></item><item><title>Clinical-manifestations-aortic-regurgitation</title><link>https://htlin222.github.io/garden/Clinical-manifestations-aortic-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-aortic-regurgitation/</guid><description>Clinical-manifestations-aortic-regurgitation Acute: sudden ↓ forward SV and ↑ LVEDP (noncompliant ventricle) → pulmonary edema ± hypotension and cardiogenic shock Chronic: clinically silent while LV dilates (to ↑ compliance to keep LVEDP low) more than it hypertrophies → chronic volume overload → LV decompensation → CHF Natural hx: variable progression (unlike AS, can be fast or slow); once decompensation begins, prognosis poor w/o AVR (mortality ~10%/y)</description></item><item><title>Clinical-manifestations-aortic-stenosis</title><link>https://htlin222.github.io/garden/Clinical-manifestations-aortic-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-aortic-stenosis/</guid><description>Clinical-manifestations-aortic-stenosis (usually indicates AVA &amp;lt;1 cm2 or concomitant CAD
Angina: ↑ O2 demand (hypertrophy) + ↓ O2 supply (↓ cor perfusion pressure) ± CAD Syncope (exertional): peripheral vasodil.</description></item><item><title>Clinical-manifestations-mitral-regurgitation</title><link>https://htlin222.github.io/garden/Clinical-manifestations-mitral-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clinical-manifestations-mitral-regurgitation/</guid><description>Clinical-manifestations-mitral-regurgitation Acute: sudden ↓ forward SV and ↑ LVEDP (noncompliant ventricle) → pulmonary edema ± hypotension and cardiogenic shock Chronic: clinically silent while LV dilates (to ↑ compliance to keep LVEDP low) more than it hypertrophies → chronic volume overload → LV decompensation → CHF Natural hx: variable progression (unlike AS, can be fast or slow); once decompensation begins, prognosis poor w/o AVR (mortality ~10%/y)</description></item><item><title>Clopidogrel</title><link>https://htlin222.github.io/garden/Clopidogrel/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Clopidogrel/</guid><description>Clopidogrel 300–600 mg × 1 → 75 mg qd ~6 h to steady state Wait 5 d prior to surgery ASA+clopi → 20% ↓ CVD/MI/stroke vs.</description></item><item><title>clostridioides difficile infection</title><link>https://htlin222.github.io/garden/clostridioides-difficile-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/clostridioides-difficile-infection/</guid><description>clostridioides difficile infection [[Pathogenesis epidemiology-clostridioides difficile infection]] [[Clinical manifestations-clostridioides difficile infection]] [[Diagnosis-clostridioides difficile infection]] [[Initial treatment-clostridioides difficile infection ]] [[Recurrent infection-clostridioides difficile infection]]</description></item><item><title>Cluster headache</title><link>https://htlin222.github.io/garden/Cluster-headache/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cluster-headache/</guid><description>Cluster headache and other trigeminal autonomic cephalalgias (TACs) (Continuum 2018;24:1137) Characterized by unilateral headache a/w ipsilateral autonomic sx (rhinorrhea, red/tearing eye, miosis, ptosis, lid edema, sweating), subtypes differentiated by timing.</description></item><item><title>CMV-negative</title><link>https://htlin222.github.io/garden/CMV-negative/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CMV-negative/</guid><description>CMV-negative From CMV-negative donors. For CMV-seronegative pregnant women, transplant candidates/recipients, SCID, AIDS Pts.</description></item><item><title>coagulation cascade and sites of action for anticoagulants</title><link>https://htlin222.github.io/garden/coagulation-cascade-and-sites-of-action-for-anticoagulants/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/coagulation-cascade-and-sites-of-action-for-anticoagulants/</guid><description>coagulation cascade and sites of action for anticoagulants See “Coagulopathies” for reversal agents for anticoagulants. APC, activated protein C; AT, antithrombin; PrC, protein C; PrS, protein S; TF, tissue factor; TFPI, tissue factor pathway inhib.</description></item><item><title>Coagulation factor inhibitors</title><link>https://htlin222.github.io/garden/Coagulation-factor-inhibitors/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Coagulation-factor-inhibitors/</guid><description>Coagulation factor inhibitors (anti-factor antibodies; anti-factor VIII most common)
Etiologies: hemophilia; postpartum; lymphoproliferative &amp;amp; autoimmune disorders; cancers
Diagnosis: ↑ PTT (does not normalize w/ mixing study); Bethesda assay quantitates titer</description></item><item><title>coagulopathies</title><link>https://htlin222.github.io/garden/coagulopathies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/coagulopathies/</guid><description>coagulopathies [[Screening Test Abnormalities in Inherited and Acquired Coagulopathies]] [[Further coagulation tests]] [[Hemophilias]] [[Coagulation factor inhibitors]] [[Disseminated intravascular coagulation (DIC)]] [[Vitamin K deficiency]] [[Properties and Antidotes for Anticoagulants Fibrinolytics]]</description></item><item><title>Coccidioidomycosis</title><link>https://htlin222.github.io/garden/Coccidioidomycosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Coccidioidomycosis/</guid><description>Coccidioidomycosis Epidemiology: endemic to SW U.S., Central and South America Clinical manifestations Acute: subclinical PNA, arthralgias, rash (erythema nodosum) Chronic lung disease (seen in immunosupp): dyspnea, chest pain, hemoptysis, “B” sx Disseminated (immunosupp, pregnant): meningitis, osteo, monoarthritis, cutaneous Treatment: no Rx for mild PNA in immunosupp.</description></item><item><title>Colitis</title><link>https://htlin222.github.io/garden/Colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Colitis/</guid><description>Colitis Infectious (see “Acute Diarrhea”), IBD, ischemic colitis, XRT
[[diarrhea]] [[inflammatory bowel disease]]</description></item><item><title>Collagen vascular diseases</title><link>https://htlin222.github.io/garden/Collagen-vascular-diseases/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Collagen-vascular-diseases/</guid><description>Collagen vascular diseases (Chest 2013;143:814)
Rheumatologic disease Scleroderma: ILD in ~50%; PHT seen in ~10% of Pts with limited disease</description></item><item><title>colonoscopy for LGIB</title><link>https://htlin222.github.io/garden/colonoscopy-for-LGIB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/colonoscopy-for-LGIB/</guid><description>colonoscopy for LGIB colonoscopy (identifies cause in &amp;gt;70%); early colo (w/in 24 h) unlikely to improve outcome vs. late (24-96 h) (Gastro 2020;158:168).</description></item><item><title>colorectal cancer</title><link>https://htlin222.github.io/garden/colorectal-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/colorectal-cancer/</guid><description>colorectal cancer colon cancer [[index]]
[[Role of Circulating Tumor DNA in Guiding Adjuvant Therapy in Colon Cancer]]</description></item><item><title>Common biases in clinical reasoning</title><link>https://htlin222.github.io/garden/Common-biases-in-clinical-reasoning/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Common-biases-in-clinical-reasoning/</guid><description>Common biases in clinical reasoning Availability 下了自己熟的的診斷 Considering easily remembered diagnoses more likely irrespective of prevalence
Base rate neglect 找了斑馬 Pursuing &amp;ldquo;zebras”</description></item><item><title>Common Diagnostic Tests in Thyroid Disorders</title><link>https://htlin222.github.io/garden/Common-Diagnostic-Tests-in-Thyroid-Disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Common-Diagnostic-Tests-in-Thyroid-Disorders/</guid><description>Common Diagnostic Tests in Thyroid Disorders Thyroid-stimulating hormone (TSH) Most sensitive test to detect 1° hypo- and hyperthyroidism. Used as primary screening test for thyroid disease.</description></item><item><title>Common Etiologies of SVT</title><link>https://htlin222.github.io/garden/Common-Etiologies-of-SVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Common-Etiologies-of-SVT/</guid><description>Common Etiologies of SVT Atrial Sinus tachycardia (ST) Caused by pain, fever, hypovolemia, hypoxia, PE, anemia, anxiety, withdrawal, β-agonists, etc.</description></item><item><title>Common Pacing Modes</title><link>https://htlin222.github.io/garden/Common-Pacing-Modes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Common-Pacing-Modes/</guid><description>Common Pacing Modes VVI Ventricular pacing on demand w/ single lead in RV. Sensed ventricular beat inhibits V pacing. Used in chronic AF with symptomatic bradycardia.</description></item><item><title>Commonly drug-induced Acute interstitial nephritis</title><link>https://htlin222.github.io/garden/Commonly-drug-induced-Acute-interstitial-nephritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Commonly-drug-induced-Acute-interstitial-nephritis/</guid><description>Commonly drug-induced Acute interstitial nephritis β-lactams, sulfa drugs, NSAIDs, PPIs, quinolones, allopurinol</description></item><item><title>Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Comparison-of-bronchodilator-responsiveness-in-asthma-and-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Comparison-of-bronchodilator-responsiveness-in-asthma-and-chronic-obstructive-pulmonary-disease/</guid><description>Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease 將支氣管擴張劑反應視為陽性的其他標準是支氣管擴張劑後 FEV1 百分比增加大於基線的 15%，支氣管擴張劑後 FEV1 增加大於預測值的 10% (10) 或 FEV1 絕對增加 400 ml (6)。</description></item><item><title>Compensation-for-Acid-Base-Disorders</title><link>https://htlin222.github.io/garden/Compensation-for-Acid-Base-Disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Compensation-for-Acid-Base-Disorders/</guid><description>Compensation-for-Acid-Base-Disorders (NEJM 2014;371:1434) Respiratory: hyper/hypoventilation alters PaCO2 to counteract 1° metabolic process Renal: excretion/retention of H+/HCO3– to counteract 1° respiratory process Respiratory compensation occurs in mins-hrs; renal compensation takes days</description></item><item><title>Complicated vs uncomplicated parapneumonic</title><link>https://htlin222.github.io/garden/Complicated-vs-uncomplicated-parapneumonic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complicated-vs-uncomplicated-parapneumonic/</guid><description>Complicated vs uncomplicated parapneumonic complicated ⊕ Gram stain or culture or pH &amp;lt;7.2 or glucose &amp;lt;60
complicated parapneumonic effusions usually require tube thoracostomy for resolution</description></item><item><title>Complications Gastro 2020;158:760</title><link>https://htlin222.github.io/garden/Complications-gastroesophageal-reflux-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-gastroesophageal-reflux-disease/</guid><description>Complications (Gastro 2020;158:760) Reflux esophagitis (erosions/ulcers above GE jxn), strictures (caused by chronic inflamm) [[Barrett’s esophagitis]].</description></item><item><title>Complications &amp; prognosis-venous thromboembolism</title><link>https://htlin222.github.io/garden/Complications-prognosis-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-prognosis-venous-thromboembolism/</guid><description>Complications &amp;amp; prognosis-venous thromboembolism [[postthrombotic syndrome]] (23–60%) pain, edema, venous ulcers
Recurrent VTE:
1%/y (after 1st VTE) to 5%/y (after recurrent VTE) Chronic thromboembolic PHT after acute PE ~2–3%, consider thromboendarterectomy</description></item><item><title>Complications gastroesophageal reflux disease</title><link>https://htlin222.github.io/garden/Complications-gastroesophageal-reflux-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-gastroesophageal-reflux-disease-/</guid><description>Complications gastroesophageal reflux disease (Gastro 2020;158:760)
Reflux esophagitis (erosions/ulcers above GE jxn), strictures (caused by chronic inflamm)
Barrett’s esoph.</description></item><item><title>complications of bacterial meningitis</title><link>https://htlin222.github.io/garden/complications-of-bacterial-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/complications-of-bacterial-meningitis/</guid><description>complications of bacterial meningitis The neurologic complications of bacterial meningitis include: Impaired mental status
Increased intracranial pressure and cerebral edema</description></item><item><title>complications of HIV AIDS</title><link>https://htlin222.github.io/garden/complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/complications-of-HIV-AIDS/</guid><description>complications of HIV AIDS Any S. pneumo, TB, VZV, HPV complications, Kaposi’s sarcoma, lymphoma, ↑ CVD risk, ↓ bone density.</description></item><item><title>Complications of HTN</title><link>https://htlin222.github.io/garden/Complications-of-HTN/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-of-HTN/</guid><description>Complications of HTN Neurologic: TIA/CVA, ruptured aneurysms, vascular dementia Retinopathy: stage I = arteriolar narrowing; II = copper-wiring, AV nicking; III = hemorrhages and exudates; IV = papilledema Cardiac: CAD, LVH, HF, AF Vascular: aortic dissection, aortic aneurysm (HTN = key risk factor for aneurysms) Renal: proteinuria, renal failure</description></item><item><title>Complications PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/Complications-PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-PA-catheter-and-tailored-therapy/</guid><description>Complications PA catheter and tailored therapy Central venous access: pneumo/hemothorax (~1%), arterial puncture (if inadvertent cannulation w/ dilation → surgical/endovasc eval), air embolism, thoracic duct injury</description></item><item><title>Complications-acute aortic syndromes</title><link>https://htlin222.github.io/garden/Complications-acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-acute-aortic-syndromes/</guid><description>Complications-acute aortic syndromes (occur in ~20%; Circ 2010;121:e266; Lancet 2015;385:800)
Freq assess (sx, BP, UOP), pulses, labs (Cr, Hb, lactic acid), imaging (~7 d or sooner if ∆s) Uncontrolled BP or persistent pain may indicate complication/extension Progression: propagation of dissection, ↑ aneurysm size, ↑ false lumen size Rupture: pericardial sac → tamponade (avoid pericardiocentesis unless PEA); blood in pleural space, mediast.</description></item><item><title>Complications-acute pancreatitis</title><link>https://htlin222.github.io/garden/Complications-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-acute-pancreatitis/</guid><description>Complications-acute pancreatitis Systemic: ARDS, abdominal compartment syndrome, AKI, GIB (pseudoaneurysm), DIC
Metabolic: hypocalcemia, hyperglycemia, hypertriglyceridemia
Fluid collections:</description></item><item><title>Complications-aortic aneurysms</title><link>https://htlin222.github.io/garden/Complications-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-aortic-aneurysms/</guid><description>Complications-aortic aneurysms (Circ 2010;121:e266; Nat Rev Cardiol 2011;8:92)
Pain: gnawing chest, back, or abdominal pain; new or worse pain may signal rupture Rupture: risk ↑ w/ diameter, ♀, current smoking, HTN TAA: ~2.</description></item><item><title>Complications-cholecystitis</title><link>https://htlin222.github.io/garden/Complications-cholecystitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-cholecystitis/</guid><description>Complications-cholecystitis Gangrenous cholecystitis: necrosis w/ risk of empyema and perforation
Emphysematous cholecystitis: infection by gas-forming organisms (air in GB wall)</description></item><item><title>Complications-cholelithiasis</title><link>https://htlin222.github.io/garden/Complications-cholelithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-cholelithiasis/</guid><description>Complications-cholelithiasis Cholecystitis: 20% of Pts with symptomatic biliary pain progress to cholecystitis w/in 2 y
Choledocholithiasis → cholangitis or gallstone pancreatitis</description></item><item><title>Complications-crohn’s disease</title><link>https://htlin222.github.io/garden/Complications-crohns-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-crohns-disease/</guid><description>Complications-crohn’s disease Perianal disease: fissures, fistulas, skin tags, perirectal abscesses (in 24% of Pts; perianal disease precedes intestinal symptoms)</description></item><item><title>Complications-diabetes mellitus</title><link>https://htlin222.github.io/garden/Complications-diabetes-mellitus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-diabetes-mellitus/</guid><description>Complications-diabetes mellitus (NEJM 2004;350:48; 2016;374:1455; CJASN 2017;12:1366)
Retinopathy nonproliferative: “dot &amp;amp; blot” and retinal hemorrhages, cotton-wool/protein exudates proliferative: neovascularization, vitreous hemorrhage, retinal detachment, blindness treatment: photocoagulation, surgery, intravitreal bevacizumab injections</description></item><item><title>Complications-prosthetic-heart-valves</title><link>https://htlin222.github.io/garden/Complications-prosthetic-heart-valves/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-prosthetic-heart-valves/</guid><description>Complications-prosthetic-heart-valves Structural failure (r/o endocarditis); mechanical valves: rare except for Bjork-Shiley; bioprosth: up to 30% rate w/in 10–15 y, mitral &amp;gt;aortic; consider TAVR (JACC 2017; 69:2253) Paravalvular leak (r/o endocarditis); small central jet of regurg is normal in mech.</description></item><item><title>Complications-treatment-chronic kidney disease CKD</title><link>https://htlin222.github.io/garden/Complications-treatment-chronic-kidney-disease-CKD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-treatment-chronic-kidney-disease-CKD/</guid><description>Complications-treatment-chronic kidney disease (CKD) (JAMA 2019;322:1294; KI 2021;99:S1)
General: renal referral when GFR &amp;lt;30 or proteinuria, access planning (avoid subclavian lines, preserve an arm by avoiding phlebotomy, BP measurements, IVs)</description></item><item><title>Complications-ulcerative colitis</title><link>https://htlin222.github.io/garden/Complications-ulcerative-colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Complications-ulcerative-colitis/</guid><description>Complications-ulcerative colitis Toxic megacolon (5%): colon dilatation (≥6 cm on KUB), colonic atony, systemic toxicity, &amp;amp; ↑ risk of perf.</description></item><item><title>computed tomogram in central nervous system infection</title><link>https://htlin222.github.io/garden/computed-tomogram-in-central-nervous-system-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/computed-tomogram-in-central-nervous-system-infection/</guid><description>computed tomogram in central nervous system infection 什麼情況下要先做CT再做Lumbar Puncture： #📚 The most appropriate sequence in managing a patient with suspected bacterial meningitis and a new-onset, 10-second seizure is to obtain blood cultures, then initiate dexamethasone and empiric antimicrobial therapy, and then obtain a CT scan of the head (before performing a lumbar puncture)</description></item><item><title>config</title><link>https://htlin222.github.io/garden/config/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/config/</guid><description>echo -e &amp;ldquo;site name:MyDocs\ntheme:\n\tname:material&amp;rdquo; &amp;raquo; /volume1/docker/mkdocs/mkdocs.yml
docker run &amp;ndash;rm -i -v /volume1/docker/mkdocs:/docs squidfunk/mkdocs-material new . docker run -d &amp;ndash;name=mkdocs -p 9898:8000 -v /volume1/docker/mkdocs:/docs &amp;ndash;restart always squidfunk/mkdocs-material</description></item><item><title>Configuration</title><link>https://htlin222.github.io/garden/notes/config/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/config/</guid><description>Configuration Quartz is designed to be extremely configurable. You can find the bulk of the configuration scattered throughout the repository depending on how in-depth you&amp;rsquo;d like to get.</description></item><item><title>Confusion and Delirium</title><link>https://htlin222.github.io/garden/Confusion-and-Delirium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Confusion-and-Delirium/</guid><description>Confusion and Delirium [[terms used to describe patients with delirium]]
altered attention &amp;amp; awareness,
develops over hrs to days,</description></item><item><title>Connective tissue disease as Etiologies of Classic FUO</title><link>https://htlin222.github.io/garden/Connective-tissue-disease-as-Etiologies-of-Classic-FUO/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Connective-tissue-disease-as-Etiologies-of-Classic-FUO/</guid><description>Connective tissue disease as Etiologies of Classic FUO [[Giant cell arteritis]] [[Polymyalgia rheumatica]] headache, scalp pain, jaw claudication, visual disturbances, myalgias, arthralgias, ↑ ESR</description></item><item><title>Consciousness Arousal</title><link>https://htlin222.github.io/garden/Consciousness-Arousal/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Consciousness-Arousal/</guid><description>Consciousness Arousal Arousal: spectrum from awake/alert → drowsy → stupor → coma Terms vague &amp;amp; subjective, so most useful to describe response to increasing stimulation (eg, voice → noxious).</description></item><item><title>Consequences-of-Severe-Acid-Base-Disturbances</title><link>https://htlin222.github.io/garden/Consequences-of-Severe-Acid-Base-Disturbances/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Consequences-of-Severe-Acid-Base-Disturbances/</guid><description>Consequences-of-Severe-Acid-Base-Disturbances (NEJM 1998;338:26 &amp;amp; 107)
Cardiovascular Acidemia (pH &amp;lt;7.20) ↓ contractility, arteriolar vasodilation ↓ MAP &amp;amp; CO; ↓ response to catecholamines ↑ risk of arrhythmias Alkalemia (pH &amp;gt;7.</description></item><item><title>Consider Advanced Airway</title><link>https://htlin222.github.io/garden/Consider-Advanced-Airway/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Consider-Advanced-Airway/</guid><description>Consider Advanced Airway Endotracheal intubation or supraglottic advanced aiway Clinical assessment: bilat. chest expansion &amp;amp; breath sounds Device to ✔ tube placement Continuous waveform capnography (~100% Se ＆ Sp) Colorimetric exhaled CO, detection (~clinical assess.</description></item><item><title>consider the potential harms</title><link>https://htlin222.github.io/garden/consider-the-potential-harms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/consider-the-potential-harms/</guid><description>consider the potential harms Consider the potential harms of both a missed diagnosis and the treatment. A. It is very harmful to miss certain diagnoses, such as MI or pulmonary embolism, while it is not so harmful to miss others, such as mild carpal tunnel syndrome.</description></item><item><title>Constipation</title><link>https://htlin222.github.io/garden/Constipation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Constipation/</guid><description>Constipation (Annals 2015;162:ITC1, Nat Rev Dis Primers 2017;3:17095; JAMA 2019;322:2239)
[[Definition of Constipation]] [[Etiologies of Constipation]] Dx: H&amp;amp;P w/ DRE.</description></item><item><title>constrictive pericarditis</title><link>https://htlin222.github.io/garden/constrictive-pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/constrictive-pericarditis/</guid><description>constrictive pericarditis [[Etiology-constrictive pericarditis]] [[Pathophysiology-constrictive pericarditis]]
Clinical manifestations (NEJM 2011;364:1350)
Right-sided &amp;gt;left-sided heart failure (systemic congestion &amp;gt;pulmonary congestion) [[Physical exam-constrictive pericarditis]] [[Diagnostic studies-constrictive pericarditis]] [[Constrictive Pericarditis vs.</description></item><item><title>Contact</title><link>https://htlin222.github.io/garden/Contact/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Contact/</guid><description>Site officiel: http://www.notational.net/fr/
Dévelopment: http://github.com/scrod/nv/tree/
Contact: Zachary Schneirov scrod@notational.net
Traduction: David Bosman david.bosman@gmail.com</description></item><item><title>Context sensitive half time</title><link>https://htlin222.github.io/garden/Context-sensitive-half-time/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Context-sensitive-half-time/</guid><description>Context sensitive half time Context sensitive half time | Deranged Physiology</description></item><item><title>Continuous veno-venous hemofiltration CVVH</title><link>https://htlin222.github.io/garden/Continuous-veno-venous-hemofiltration-CVVH/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Continuous-veno-venous-hemofiltration-CVVH/</guid><description>Continuous veno-venous hemofiltration (CVVH) Hemofiltration rather than dialysis. Blood under pressure passes down one side highly permeable membrane filtering H2O and solutes via TMP gradient (convective clearance); filtrate discarded.</description></item><item><title>Contraindications to Fibrinolysis</title><link>https://htlin222.github.io/garden/Contraindications-to-Fibrinolysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Contraindications-to-Fibrinolysis/</guid><description>Contraindications to Fibrinolysis Absolute Contraindications *Any prior ICH *Intracranial neoplasm, aneurysm, AVM *Ischemic stroke or closed head trauma w/in 3 mo; head/spinal surg.</description></item><item><title>Contrast-induced acute kidney injury</title><link>https://htlin222.github.io/garden/Contrast-induced-acute-kidney-injury/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Contrast-induced-acute-kidney-injury/</guid><description>Contrast-induced acute kidney injury Definition increase in the creatinine of 0.5mg/dL or a 25% increase from basline w/i 3 days after the contrast media and abscense of alternative cause (CIAKI) (NEJM 2019;380:2146) natural history 24-48h increase after exposure and peak at 3-5 days resolves in 7 to 10 days if prolonged duration: look for other cause, e.</description></item><item><title>Control of Mineral Homeostasis by Parathyroid Hormone and the Calcium-Sensing Receptor</title><link>https://htlin222.github.io/garden/Control-of-Mineral-Homeostasis-by-Parathyroid-Hormone-and-the-Calcium-Sensing-Receptor/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Control-of-Mineral-Homeostasis-by-Parathyroid-Hormone-and-the-Calcium-Sensing-Receptor/</guid><description>Control of Mineral Homeostasis by Parathyroid Hormone and the Calcium-Sensing Receptor 重要名詞： 鈣敏感受體：calcium-sensing receptor (CaSR), 重點 血鈣降低會引發: 主要通過甲狀旁腺激素 (PTH) 和離子鈣 (Ca2+) 對 PTH 受體和鈣敏感受體 (CaSR) 的作用介導，這兩者都是 7-跨膜G蛋白偶聯受體( 7-transmembrane, G-protein–coupled receptors.</description></item><item><title>Controller medications</title><link>https://htlin222.github.io/garden/Controller-medications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Controller-medications/</guid><description>Controller medications (JAMA 2020;324:2301)
ICS Rx of choice. Superior to LAMA if sputum w/ ≥2% eos (NEJM 2019;380:2009). PO steroids may be needed for severely uncontrolled asthma; avoid if possible b/c of systemic side effects.</description></item><item><title>COP cryptogenic organizing PNA</title><link>https://htlin222.github.io/garden/COP-cryptogenic-organizing-PNA/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/COP-cryptogenic-organizing-PNA/</guid><description>COP cryptogenic organizing PNA Patchy, migratory consolidations; subpleural &amp;amp; peribronchial. Excessive proliferation of granulation tissue in small airways and alveolar ducts.</description></item><item><title>COPD Exacerbation Treatment</title><link>https://htlin222.github.io/garden/COPD-Exacerbation-Treatment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/COPD-Exacerbation-Treatment/</guid><description>COPD Exacerbation Treatment [[Ipratropium of COPDAE]] [[Albuterol of COPDAE]] [[Corticosteroids of COPDAE]] [[Antibiotics of COPDAE]] [[Oxygenation of COPDAE]] [[Noninvasive positive-pressure ventilation of COPDAE]] [[Endotracheal intubation of COPDAE]] [[Other measures of COPDAE]] [[Post-exacerb care of COPDAE]]</description></item><item><title>Coronary angiography</title><link>https://htlin222.github.io/garden/Coronary-angiography/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Coronary-angiography/</guid><description>Coronary angiography Immediate/urgent coronary angiography (w/in 2 h) if refractory/recurrent angina or hemodynamic or electrical instability
Routine angiography (aka “invasive strategy”) = coronary angiography for all</description></item><item><title>coronary angiography PCI</title><link>https://htlin222.github.io/garden/coronary-angiography-PCI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/coronary-angiography-PCI/</guid><description>coronary angiography PCI Precath checklist Peripheral arterial exam (radial, femoral, DP, PT pulses; bruits); palmar arch eval (eg, w/ pulse oximetry &amp;amp; plethysmography) not routinely done.</description></item><item><title>Coronary artery bypass grafting CABG -related MI</title><link>https://htlin222.github.io/garden/Coronary-artery-bypass-grafting-CABG-related-MI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Coronary-artery-bypass-grafting-CABG-related-MI/</guid><description>Coronary artery bypass grafting (CABG)-related MI is arbitrarily defined as elevation of cTn values &amp;gt;10 times the 99th percentile URL in patients with normal baseline cTn values.</description></item><item><title>Coronary-angiography-for-SIHD</title><link>https://htlin222.github.io/garden/Coronary-angiography-for-SIHD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Coronary-angiography-for-SIHD/</guid><description>Coronary-angiography-for-SIHD High-risk noninvasive testing results suggestive of left main or multivessel CAD Angina that is refractory to optimal medical therapy Uncertain dx after noninvasive testing, occupational need (eg, pilot) Unexplained heart failure or ↓ EF</description></item><item><title>coronavirus covid-19</title><link>https://htlin222.github.io/garden/coronavirus-covid-19/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/coronavirus-covid-19/</guid><description>coronavirus (covid-19) Microbiology &amp;amp; epidemiology
Person-to-person transmission via respiratory particles; asx &amp;amp; pre-sx transmission can occur Incubation period: up to 14 days, median time of 4–5 days from exposure to sx onset Presentation Ranges from asx to severe illness.</description></item><item><title>Correction of overanticoagulation</title><link>https://htlin222.github.io/garden/Correction-of-overanticoagulation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Correction-of-overanticoagulation/</guid><description>Correction of overanticoagulation (Circ 2021;143:e72)
Risk from major bleeding must be weighed against risk of valve thrombosis Not bleeding: if INR 5–10, withhold warfarin Bleeding: PCC (or FFP); reversal agent for DOACs; ± low-dose (1 mg) vit K IV if on VKA</description></item><item><title>Corticosteroids for chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Corticosteroids-for-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Corticosteroids-for-chronic-obstructive-pulmonary-disease/</guid><description>Corticosteroids for chronic obstructive pulmonary disease (inhaled, ICS): ~11% ↓ in exacerbations &amp;amp; slows ↓ FEV1; no Δ in mortality (Lancet 2016;387:1817).</description></item><item><title>Corticosteroids of COPDAE</title><link>https://htlin222.github.io/garden/Corticosteroids-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Corticosteroids-of-COPDAE/</guid><description>Corticosteroids of COPDAE Prednisone 40 mg/d × 5d (JAMA 2013;309:2223); some Pts will benefit from higher dose/longer course if severe Methylprednisolone 125 mg IV q6h × 72 h for more severe exacerbations ↓ treatment failure, ↓ hosp.</description></item><item><title>COVID-19 associated AKI</title><link>https://htlin222.github.io/garden/COVID-19-associated-AKI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/COVID-19-associated-AKI/</guid><description>COVID-19 associated AKI</description></item><item><title>CPR人力配置</title><link>https://htlin222.github.io/garden/CPR%E4%BA%BA%E5%8A%9B%E9%85%8D%E7%BD%AE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CPR%E4%BA%BA%E5%8A%9B%E9%85%8D%E7%BD%AE/</guid><description>CPR人力配置 三人組：
換下來的人要負責check pulse 給藥的人要負責電(如果可以的話) Endo前要完成壓胸電擊給藥兩分鐘</description></item><item><title>CPS-22C3</title><link>https://htlin222.github.io/garden/CPS-22C3/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CPS-22C3/</guid><description>CPS-22C3 PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs</description></item><item><title>CRC screening</title><link>https://htlin222.github.io/garden/CRC-screening/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CRC-screening/</guid><description>CRC screening (JAMA 2021;325:1978)
Colonoscopy gold standard. Other options: FOBT/FIT yearly, flex sig q5y or flex sig q10y + FIT every year, fecal DNA testing (eg, Cologuard) q3y or CT colonography q5y Start screening in average risk Pts at age 45 (typically q10y unless abnl found) If ⊕ FHx, start age 40, or 10 y before age of dx in youngest family member, repeat q5y</description></item><item><title>Criteria-Hepatorenal syndrome HRS</title><link>https://htlin222.github.io/garden/Criteria-Hepatorenal-syndrome-HRS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Criteria-Hepatorenal-syndrome-HRS/</guid><description>Criteria-Hepatorenal syndrome (HRS) (1) cirrhosis w/ ascites; (2) acute kidney injury (serum Cr ↑ ≥0.3 mg/dL w/in 48 h or ≥50% ↑ in serum Cr from baseline; Gut 2015;64:531) (3) Ø improvement in Cr after d/c diuretic &amp;amp; volume expansion (1 g/kg/d of albumin × 2 d); (4) Ø shock (prerenal azotemia/ATN); (5) Ø nephrotoxic meds; (6) Ø intrinsic kidney disease</description></item><item><title>crohn’s disease</title><link>https://htlin222.github.io/garden/crohns-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/crohns-disease/</guid><description>crohn’s disease (Lancet 2017;389:1741)
[[Clinical manifestations-crohn’s disease]] [[Diagnosis-crohn’s disease]] [[Complications-crohn’s disease]] Prognosis Variable at 1 y: ~50% in remission, ~20% flare, ~20% low activity, ~10% chronic active At 20 y, majority will have required some surgery; overall life expectancy is slightly ↓</description></item><item><title>Cryoglobulinemic vasculitis</title><link>https://htlin222.github.io/garden/Cryoglobulinemic-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cryoglobulinemic-vasculitis/</guid><description>Cryoglobulinemic vasculitis (Lancet 2012;379:348; Nat Rev Dis Primers 2018;4:11)
Cryoglobulins: proteins that precipitate from serum or plasma on exposure to cold and redissolve on rewarming, characterized by their composition; a/w chronic immune stimulation and/or lymphoproliferation Distinguish from cryofibrinogenemia = proteins (eg, fibrin, fibrinogen) that precipitate only from plasma; found in autoimmune dis, malignancies, infxns; unclear clinical significance [[Types of Cryoglobulinemia]] (J Autoimmun 2019;105:102313) Epidemiology: ~1/100,000, but prevalence varies with HCV rates; ♀ &amp;gt;♂ Etiologies (idiopathic in ~10%) Hematologic diseases: multiple myeloma, MGUS, Waldenström’s, chronic lymphocytic leukemia in type I; B-cell lymphomas or solid-organ malignancies in type II Infxns (types II &amp;amp; III): viral (HCV [&amp;gt;80% RNA ⊕], HBV, HIV, HAV, EBV, CMV), bacterial (endocarditis, strep, etc.</description></item><item><title>Cryoprecipitate</title><link>https://htlin222.github.io/garden/Cryoprecipitate/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cryoprecipitate/</guid><description>Cryoprecipitate Enriched for fibrinogen, vWF, VIII, and XIII. 1st line for fibrinogen &amp;lt;100 mg/dL. For bleeding in vWD factor XIII deficiency, use if other products not available.</description></item><item><title>Cryptococcus</title><link>https://htlin222.github.io/garden/Cryptococcus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cryptococcus/</guid><description>Cryptococcus Epidemiology: immunosupp. most susceptible (espec. AIDS, transplant recipients, and cirrhosis); can occur in healthy hosts (esp C. gattii) Clinical manifestations CNS (meningoencephalitis): subacute HA, fever, meningismus, CN abnl, ± stupor Other sites: pulm.</description></item><item><title>Cryptococcus neoformans</title><link>https://htlin222.github.io/garden/Cryptococcus-neoformans/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cryptococcus-neoformans/</guid><description>Cryptococcus neoformans A common infectious cause of subacute and chronic meningoencephalitis associated with raised intracranial pressure in immunocompromised patients is Cryptococcus neoformans.</description></item><item><title>CSF leak</title><link>https://htlin222.github.io/garden/CSF-leak/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CSF-leak/</guid><description>CSF leak headache clear fluid leaking from the nose or ear. Some CSF leaks may heal with conservative treatments such as bed rest.</description></item><item><title>culture negative-bacterial endocarditis</title><link>https://htlin222.github.io/garden/culture-negative-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/culture-negative-bacterial-endocarditis/</guid><description>culture negative-bacterial endocarditis = abiotrophic strep, HACEK (Haemophilus para-influenzae &amp;amp; aphrophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella), T. whipplei, Bartonella, Coxiella, Chlamydia, Legionella, Brucella (JAMA 2007;297:1354; Annals 2007;147:829; J Clin Microbiol 2012;50:216)</description></item><item><title>Culture-negative neutrocytic ascites CNNA</title><link>https://htlin222.github.io/garden/Culture-negative-neutrocytic-ascites-CNNA/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Culture-negative-neutrocytic-ascites-CNNA/</guid><description>Culture-negative neutrocytic ascites (CNNA) : cell counts suggest infxn but cx ⊖. No recent abx, w/o other explan. for counts. Often do have SBP and should be treated with empiric regimen.</description></item><item><title>Cushing’s Syndrome</title><link>https://htlin222.github.io/garden/Cushings-Syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cushings-Syndrome/</guid><description>Cushing’s Syndrome Cushing’s syndrome = cortisol excess Cushing’s disease = Cushing’s syndrome 2° to pituitary ACTH hypersecretion [[Etiologies of hypercortisolism]] [[Clinical manifestations-Cushing’s Syndrome]] [[Diagnosis Cushing’s Syndrome]] [[Treatment of Cushing’s syndrome]]</description></item><item><title>Custom Domain</title><link>https://htlin222.github.io/garden/notes/custom-Domain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/custom-Domain/</guid><description>Registrar This step is only applicable if you are using a custom domain! If you are using a &amp;lt;YOUR-USERNAME&amp;gt;.github.io domain, you can skip this step.</description></item><item><title>Cutaneous arteritis</title><link>https://htlin222.github.io/garden/Cutaneous-arteritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cutaneous-arteritis/</guid><description>Cutaneous arteritis Sometimes called &amp;ldquo;benign cutaneous [[Polyarteritis nodosa]]&amp;rdquo; cPAN can nevertheless result in significant morbidity due to painful skin nodules, digital infarcts, ulcerations, and other complications</description></item><item><title>cutaneous leukocytoclastic angiitis</title><link>https://htlin222.github.io/garden/cutaneous-leukocytoclastic-angiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cutaneous-leukocytoclastic-angiitis/</guid><description>cutaneous leukocytoclastic angiitis Occurs 7–10 days after certain medications (penicillins, cephalosporins, sulfonamides, phenytoin, allopurinol) or infections (eg, HCV, HIV). Palpable purpura, no visceral involvement.</description></item><item><title>Cutaneous-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Cutaneous-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cutaneous-complications-of-HIV-AIDS/</guid><description>Cutaneous-complications of HIV AIDS Eosinophilic folliculitis; warts (HPV); HSV &amp;amp; VZV; MRSA SSTI; scabies; candidiasis; eczema; prurigo nodularis; psoriasis; drug eruption; subungual onychomycosis Molluscum contagiosum (poxvirus): 2–5 mm pearly papules w/ central umbilication Kaposi’s sarcoma (KSHV or HHV8): red-purple nonblanching nodular lesions Bacillary angiomatosis (disseminated Bartonella): friable violaceous vascular papules</description></item><item><title>CXR of Diagnostic studies-chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/CXR-of-Diagnostic-studies-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/CXR-of-Diagnostic-studies-chronic-obstructive-pulmonary-disease/</guid><description>CXR of Diagnostic studies-chronic obstructive pulmonary disease (see Radiology inserts):
hyperinflation, flat diaphragms, ± interstitial markings &amp;amp; bullae</description></item><item><title>Cyanide-toxicology</title><link>https://htlin222.github.io/garden/Cyanide-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cyanide-toxicology/</guid><description>Cyanide-toxicology Coma, seizure, metabolic acidosis, hypotension
IV Na nitrite and Na thiosulfate
IV hydroxocobalamin
Call local Poison Control for assistance with management.</description></item><item><title>Cyclic vomiting syndrome</title><link>https://htlin222.github.io/garden/Cyclic-vomiting-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cyclic-vomiting-syndrome/</guid><description>Cyclic vomiting syndrome acute recurrent vomiting; a/w marijuana use, personal or FHx of migraine. Acute Rx: antiemetics, IVF, sumatriptan (1st line, followed by aprepitant x 3 d), BDZs; prevention: TCAs/AEDs; avoid marijuana.</description></item><item><title>cynosis</title><link>https://htlin222.github.io/garden/cynosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cynosis/</guid><description>cynosis central cyanosis can be detected reliably when the SaO2 has fallen to 85%; in others, particularly in dark-skinned persons, it may not be detected until it has declined to 75%</description></item><item><title>cystic fibrosis</title><link>https://htlin222.github.io/garden/cystic-fibrosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/cystic-fibrosis/</guid><description>cystic fibrosis [[Definition and pathophysiology-cystic fibrosis]] [[Clinical features-cystic fibrosis]] [[Treatment-cystic fibrosis]]</description></item><item><title>Cytomegalovirus</title><link>https://htlin222.github.io/garden/Cytomegalovirus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Cytomegalovirus/</guid><description>Cytomegalovirus Retinitis, esophagitis, colitis, hepatitis, neuropathies, encephalitis. CMV VL may be ⊖. Consider tissue biopsy. Rx: ganciclovir, valganciclovir, foscarnet, or cidofovir.</description></item><item><title>Dako 28-8</title><link>https://htlin222.github.io/garden/Dako-28-8/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dako-28-8/</guid><description>Dako 28-8 S</description></item><item><title>ddMVAC</title><link>https://htlin222.github.io/garden/ddMVAC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ddMVAC/</guid><description>Dose-dense MVAC chemotherapy for urothelial carcinoma Keyword: ddMVAC [Dose-dense MVAC chemotherapy for urothelial carcinoma - UpToDate]( https://www.uptodate.com/contents/image?imageKey=ONC%2F111814&amp;topicKey=ONC%2F3000&amp;source=see link)
durg: methotrexate vinblastine doxorubicin cisplatin Pretreatment considerations: 吐: 高 vesicant/irritant properties Infection prophylaxis: 高 G-CSF: 240mcg/m2 SC daily on d4-d10 Monitor Parameters: CBC/Electrolytes/Neurologic/3rd space fluid collection/LVEF</description></item><item><title>Ddx causes of myocardial ischemia infarction other than atherosclerotic plaque rupture</title><link>https://htlin222.github.io/garden/Ddx-causes-of-myocardial-ischemia-infarction-other-than-atherosclerotic-plaque-rupture-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ddx-causes-of-myocardial-ischemia-infarction-other-than-atherosclerotic-plaque-rupture-/</guid><description>Ddx causes of myocardial ischemia infarction other than atherosclerotic plaque rupture Ischemia w/o plaque rupture (“type 2” MI): ↑ demand (eg, ↑ HR), ↓ supply (eg, HoTN).</description></item><item><title>Ddx-of-dominant-R-wave-in-V1-or-V2</title><link>https://htlin222.github.io/garden/Ddx-of-dominant-R-wave-in-V1-or-V2/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ddx-of-dominant-R-wave-in-V1-or-V2/</guid><description>Ddx-of-dominant-R-wave-in-V1-or-V2 Ventricular abnl: RVH (RAD, RAA, deep S waves in I, V5, V6); HCM; Duchenne’s
Posterior MI: anterior R wave = posterior Q wave; often with IMI</description></item><item><title>deafferentation pain</title><link>https://htlin222.github.io/garden/deafferentation-pain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/deafferentation-pain/</guid><description>deafferentation pain 傳入神經痛是神經性疼痛的一個分支，它可能使幾乎任何類型的軀體感覺系統損傷在其過程中的任何時候都複雜化。 例子包括由外周（幻肢）或中樞（丘腦疼痛）病變引起的明確的綜合徵。 在所有這些情況下，疼痛通常發生在臨床感覺喪失的區域。 對於幻肢痛，疼痛實際上是在不再存在的區域感覺到的。 丘腦疼痛患者，也稱為 Dejerine-Roussy 綜合徵，報告臨床感覺喪失區域的全部或部分疼痛。</description></item><item><title>Decreased GFR-hyperkalemia</title><link>https://htlin222.github.io/garden/Decreased-GFR-hyperkalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Decreased-GFR-hyperkalemia/</guid><description>Decreased GFR-hyperkalemia Any cause of oliguric or anuric AKI or any cause of end-stage renal disease</description></item><item><title>Definition and causes-acute mesenteric ischemia</title><link>https://htlin222.github.io/garden/Definition-and-causes-acute-mesenteric-ischemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-causes-acute-mesenteric-ischemia/</guid><description>Definition and causes-acute mesenteric ischemia Reduced or absent blood flow to small intestine, typically caused by arterial (ie, SMA or its branches) occlusion or transient hypoperfusion or less often by venous occlusion</description></item><item><title>Definition and clinical manifestations of Migraine</title><link>https://htlin222.github.io/garden/Definition-and-clinical-manifestations-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-clinical-manifestations-of-Migraine/</guid><description>Definition and clinical manifestations of Migraine (Lancet 2018;391:1315 &amp;amp; Continuum 2021;27:586) [[POUNDing Mnemonic]]
Epidemiology: affects 15% of women and 6% of men; onset usually by 30 y</description></item><item><title>Definition and epidemiology</title><link>https://htlin222.github.io/garden/Definition-and-epidemiology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-epidemiology/</guid><description>Definition and epidemiology (Lancet 2018;391:783)
Chronic inflam disorder w/ airway hyperresponsiveness + variable airflow obstruction
Affects 5–10% population; ~85% of cases by age 40 y</description></item><item><title>Definition and epidemiology-bronchiectasis</title><link>https://htlin222.github.io/garden/Definition-and-epidemiology-bronchiectasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-epidemiology-bronchiectasis/</guid><description>Definition and epidemiology-bronchiectasis (NEJM 2002;346:1383)
Obstructive airways disease of bronchi and bronchioles, chronic transmural inflammation w/ airway dilatation and thickening, collapsibility, mucus plugging w/ impaired clearance</description></item><item><title>Definition and epidemiology-chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Definition-and-epidemiology-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-epidemiology-chronic-obstructive-pulmonary-disease/</guid><description>Definition and epidemiology-chronic obstructive pulmonary disease Progressive airflow limitation caused by airway and parenchymal inflammation</description></item><item><title>definition and etiologies of peptic ulcer disease</title><link>https://htlin222.github.io/garden/definition-and-etiologies-of-peptic-ulcer-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/definition-and-etiologies-of-peptic-ulcer-disease/</guid><description>definition and etiologies of peptic ulcer disease (BMJ 2019;367:5495)
Ulcers (break in mucosal lining &amp;gt;5 mm) &amp;amp; erosions (&amp;lt;5 mm) in stomach and duodenum Principal risk factors: H.</description></item><item><title>Definition and etiologies-chronic kidney disease CKD</title><link>https://htlin222.github.io/garden/Definition-and-etiologies-chronic-kidney-disease-CKD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-etiologies-chronic-kidney-disease-CKD/</guid><description>Definition and etiologies-chronic kidney disease (CKD) (Lancet 2021;10302:786)
GFR &amp;lt;60 for ≥3 mo and/or kidney damage (albuminuria, structural abnormality)</description></item><item><title>Definition and pathophysiology-anaphylaxis</title><link>https://htlin222.github.io/garden/Definition-and-pathophysiology-anaphylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-pathophysiology-anaphylaxis/</guid><description>Definition and pathophysiology-anaphylaxis (Ann Emerg Med 2006;47:373)
Severe, rapid onset (mins to hrs), potentially life-threatening systemic allergic response</description></item><item><title>Definition and pathophysiology-cystic fibrosis</title><link>https://htlin222.github.io/garden/Definition-and-pathophysiology-cystic-fibrosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-pathophysiology-cystic-fibrosis/</guid><description>Definition and pathophysiology-cystic fibrosis (NEJM 2015;372:351)
Autosomal recessive genetic disorder due to mutations in chloride channel (CFTR gene)</description></item><item><title>Definition and pathophysiology-hemoptysis</title><link>https://htlin222.github.io/garden/Definition-and-pathophysiology-hemoptysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-and-pathophysiology-hemoptysis/</guid><description>Definition and pathophysiology-hemoptysis Expectoration of blood or blood-streaked sputum Massive hemoptysis: &amp;gt;100 mL/h or &amp;gt;500 mL in 24 h; massive hemoptysis usually from tortuous or invaded bronchial arteries [[Etiologies-hemoptysis]]</description></item><item><title>Definition Clinical Manifestations-HIV AIDS</title><link>https://htlin222.github.io/garden/Definition-Clinical-Manifestations-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-Clinical-Manifestations-HIV-AIDS/</guid><description>Definition Clinical Manifestations-HIV AIDS Acute HIV: rash, lymphadenopathy, fever, oral ulcers, pharyngitis, myalgias, diarrhea Presents ~2–6 wk after exposure; not all HIV infections result in symptoms of acute HIV AIDS: HIV + CD4 &amp;lt;200/mm3 or AIDS-defining opportunistic infection (OI) or malignancy</description></item><item><title>Definition etiologies peptic ulcer disease</title><link>https://htlin222.github.io/garden/Definition-etiologies-peptic-ulcer-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-etiologies-peptic-ulcer-disease-/</guid><description>Definition etiologies peptic ulcer disease Ulcers (break in mucosal lining &amp;gt;5 mm) &amp;amp; erosions (&amp;lt;5 mm) in stomach and duodenum</description></item><item><title>Definition of Constipation</title><link>https://htlin222.github.io/garden/Definition-of-Constipation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-of-Constipation/</guid><description>Definition of Constipation Defined as dissatisfaction w/ defecation or (per Rome IV): ≥2 of following during last 3–6 mos ≥25% of the time: straining, lumpy/hard stools, incomplete evacuation, sensation of anorectal obstruction, manual maneuvers to facilitate defecation, stool frequency &amp;lt;3/wk</description></item><item><title>Definition of fever and neutropenia</title><link>https://htlin222.github.io/garden/Definition-of-fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-of-fever-and-neutropenia/</guid><description>Definition of fever and neutropenia Fever: single oral temp ≥38.3°C (101°F) or ≥38°C (100.4°F) for ≥1 h Neutropenia: ANC &amp;lt;500 cells/µL or &amp;lt;1000 cells/µL with predicted nadir &amp;lt;500 cells/µL</description></item><item><title>Definition, precipitants, pathophysiology-hyperosmolar hyperglycemic state</title><link>https://htlin222.github.io/garden/Definition-precipitants-pathophysiology-hyperosmolar-hyperglycemic-state/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-precipitants-pathophysiology-hyperosmolar-hyperglycemic-state/</guid><description>Definition, precipitants, pathophysiology-hyperosmolar hyperglycemic state (Med Clin North Am 2017;101:587)
Extreme hyperglycemia (w/o ketoacidosis) + hyperosm. + Δ MS in T2D (typically elderly) Precip same as for DKA, but also include dehydration and renal failure Hyperglycemia → osmotic diuresis → vol depletion → prerenal azotemia → ↑ glc, etc.</description></item><item><title>Definition-acute kidney injury AKI</title><link>https://htlin222.github.io/garden/Definition-acute-kidney-injury-AKI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-acute-kidney-injury-AKI/</guid><description>Definition-acute kidney injury (AKI) #🌲 #📚
(KDIGO 2012;2:1)
Stages in ICU correspond to ↑ hospital mortality and LOS (Crit Care Med 2009;37:2552) Diagnostic criteria Increase in serum creatinine of ≥0.</description></item><item><title>Definition-acute liver failure</title><link>https://htlin222.github.io/garden/Definition-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-acute-liver-failure/</guid><description>Definition-acute liver failure Acute liver injury + coagulopathy + encephalopathy w/o preexisting liver dis. (&amp;lt;26 wks)
Fulminant if encephalopathy &amp;lt;8 wks from jaundice onset, subfulminant if 8–26 wks</description></item><item><title>Definition-Antiphospholipid syndrome</title><link>https://htlin222.github.io/garden/Definition-Antiphospholipid-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-Antiphospholipid-syndrome/</guid><description>Definition-Antiphospholipid syndrome dx requires ≥1 clinical &amp;amp; ≥1 laboratory criteria
Clinical: thrombosis (any) or complication of pregnancy (≥3 spont. abortions before 10 wk or ≥1 fetal loss after 10 wk or premature birth before 34 wk)</description></item><item><title>Definition-cirrhosis</title><link>https://htlin222.github.io/garden/Definition-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-cirrhosis/</guid><description>Definition-cirrhosis (Dig Dis 2016;34:374; NEJM 2016;375:767; J Hep 2016;64:717)
Definition fibrosis &amp;amp; regenerative nodules causing distortion of hepatic architecture</description></item><item><title>Definition-diabetes mellitus</title><link>https://htlin222.github.io/garden/Definition-diabetes-mellitus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-diabetes-mellitus/</guid><description>Definition-diabetes mellitus (Diabetes Care 2022;45:S256)
Either HbA1c ≥6.5, fasting glc ≥126 mg/dL, or glc 2 h after OGTT ≥200 mg/dL × 2 (for any test) or single random glc ≥200 mg/dL w/ classic sx of hyperglycemia; all tests equally reasonable (nb, may be ⊕ on one test but not another); OGTT preferred during preg Blood glc higher than normal, but not frank DM (“prediabetics,” ~40% U.</description></item><item><title>Definition-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Definition-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-gastrointestinal-bleeding/</guid><description>Definition-gastrointestinal bleeding 上消化道 (GI) 出血是指來自 Treitz 韌帶上方
Intraluminal blood loss anywhere from the oropharynx to the anus
Classification: upper = above the ligament of Treitz; lower = below the ligament of Treitz</description></item><item><title>Definition-glomerulonephritis</title><link>https://htlin222.github.io/garden/Definition-glomerulonephritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-glomerulonephritis/</guid><description>Definition-glomerulonephritis Lancet 2016;387:2036; JASN 2016;27:1278)
↑ glomerular inflammation → endothelial &amp;amp; podocyte injury
Histology: proliferative (↑ cells), sclerosing (scar), necrotizing (areas cell death).</description></item><item><title>Definition-necrotizing soft-tissue infections</title><link>https://htlin222.github.io/garden/Definition-necrotizing-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-necrotizing-soft-tissue-infections/</guid><description>Definition-necrotizing soft-tissue infections Fulminant tissue destruction, systemic toxicity &amp;amp; high mortality. Surgical emergency. May include cellulitis, fasciitis, myositis, myonecrosis (gas gangrene).</description></item><item><title>Definition-nephrotic syndrome</title><link>https://htlin222.github.io/garden/Definition-nephrotic-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-nephrotic-syndrome/</guid><description>Definition-nephrotic syndrome (JASN 2014;25:2393)
Podocyte injury (effacement) → loss of proteins (albumin, ATIII, Ig)
Clinically: proteinuria &amp;gt;3.</description></item><item><title>Definition-syncope</title><link>https://htlin222.github.io/garden/Definition-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definition-syncope/</guid><description>Definition-syncope Symptom of sudden transient loss of consciousness due to global cerebral hypoperfusion If CPR or cardioversion required, then SCD and not syncope (different prognosis) Presyncope = prodrome of light-headedness without LOC</description></item><item><title>Definitions heart failure</title><link>https://htlin222.github.io/garden/Definitions-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-heart-failure/</guid><description>Definitions heart failure 各種定義
Failure of heart to pump blood forward at rate sufficient to meet metabolic demands of peripheral tissues, or ability to do so only at abnormally high cardiac filling pressures Low output (↓ cardiac output) vs.</description></item><item><title>Definitions-accessory pathways wolff-parkinson-white</title><link>https://htlin222.github.io/garden/Definitions-accessory-pathways-wolff-parkinson-white/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-accessory-pathways-wolff-parkinson-white/</guid><description>Definitions-accessory pathways (wolff-parkinson-white) Accessory pathway (bypass tract) of conducting myocardium connecting atria &amp;amp; ventricles, allowing impulses to bypass normal AVN delay Pre-excitation (WPW) pattern: ↓ PR interval, ↑ QRS width w/ δ wave (slurred onset, can be subtle).</description></item><item><title>Definitions-acid-base disturbances</title><link>https://htlin222.github.io/garden/Definitions-acid-base-disturbances/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-acid-base-disturbances/</guid><description>Definitions-acid-base disturbances Acidemia → pH &amp;lt;7.36, alkalemia → pH &amp;gt;7.44; pH = 6.10 + log([HCO3]/[0.03xPCO2]) Acidosis → process that ↑ [H+] or ↓ pH by ↓ HCO3 or ↑ PaCO2 Alkalosis → process that ↓ [H+] or ↑ pH by ↑ HCO3 or ↓ PaCO2 Primary disorders: metabolic acidosis or alkalosis, respiratory acidosis or alkalosis [[Compensation-for-Acid-Base-Disorders]] The physiological approach uses the carbonic acid–bicarbonate buffer system.</description></item><item><title>Definitions-acute aortic syndromes</title><link>https://htlin222.github.io/garden/Definitions-acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-acute-aortic-syndromes/</guid><description>Definitions-acute aortic syndromes (Circ 2010;121:e266; Eur Heart J 2012;33:26)
Aortic dissection: intimal tear → blood extravasates into Ao media (creates false lumen) Intramural hematoma (IMH): vasa vasorum rupture → medial hemorrhage that does not communicate with aortic lumen; 6% of aortic syndromes; clinically managed as AoD Penetrating ulcer: atherosclerotic plaque penetrates elastic lamina → medial hemorrhage</description></item><item><title>Definitions-and-clinical-manifestations</title><link>https://htlin222.github.io/garden/Definitions-and-clinical-manifestations/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-and-clinical-manifestations/</guid><description>Definitions-and-clinical-manifestations Pneumonia: s/s (fever, cough, purulent sputum, dyspnea) + new infiltrate on chest imaging Community-acquired pneumonia (CAP): pneumonia acquired outside of hospital setting Hospital-acquired pneumonia (HAP): pneumonia acquired ≥48 hrs after hospitalization Ventilator-associated pneumonia (VAP): pneumonia acquired ≥48 hrs after intubation Lung empyema: accumulation of pus in pleural space Lung abscess: parenchymal necrosis with confined cavitation Aspiration pneumonitis: acute lung injury after inhalation of gastric contents without infection, though bacterial infection can occur within 24–72 hrs of injury</description></item><item><title>Definitions-aortic aneurysms</title><link>https://htlin222.github.io/garden/Definitions-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-aortic-aneurysms/</guid><description>Definitions-aortic aneurysms True (≥50% dilation of all 3 layers; &amp;lt;50% = ectasia) vs. false (rupture w/in adventitia) Location: root (annuloaortic ectasia), thoracic aortic aneurysm (TAA), thoracoabdominal aortic aneurysm (TAAA), abdominal aortic aneurysm (AAA) Type: fusiform (circumferential dilation) vs.</description></item><item><title>Definitions-sepsis and shock</title><link>https://htlin222.github.io/garden/Definitions-sepsis-and-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-sepsis-and-shock/</guid><description>Definitions-sepsis and shock Sepsis Life-threatening organ dysfxn (SOFA ≥2) due to infection Quick SOFA (qSOFA): ≥2 of the following: RR ≥22, 有夠喘 ΔMS, 有夠昏 SBP ≤100 mmHg 有夠低 [[Shock]] Septic shock Sepsis-induced circulatory and cellular/metabolic abnormalities severe enough to ↑ mortality; hypotension requiring pressors for MAP ≥65 and lactate &amp;gt;2 despite adequate fluid resuscitation 有sepsis而且需要用到升壓劑 Sequential Organ Failure Assessment (SOFA): ↑ points for worsening organ dysfxn:</description></item><item><title>Definitions-skin and soft tissue infections</title><link>https://htlin222.github.io/garden/Definitions-skin-and-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-skin-and-soft-tissue-infections/</guid><description>Definitions-skin and soft tissue infections Cellulitis: infection of dermis and subcutaneous tissue characterized by erythema, warmth, tenderness, and swelling; often occurs as a result of skin breaches (JAMA 2016;315:3) 蜂窩織炎：以紅斑、發熱、壓痛和腫脹為特徵的真皮和皮下組織感染；經常因皮膚破裂而發生 (JAMA 2016;315:3) Skin abscess: subcutaneous collection of pus Staph toxic shock syndrome: rapid onset fever, rash, hypotension, and multiorgan injury.</description></item><item><title>Definitions-tuberculosis</title><link>https://htlin222.github.io/garden/Definitions-tuberculosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-tuberculosis/</guid><description>Definitions-tuberculosis Primary: new Mycobacterium tuberculosis (TB) in a naïve host; symptomatic or asymptomatic; 90% of infected normal hosts will never develop clinically evident disease Latent: well-controlled infection without clinical or radiographic evidence of active disease; can persist for years to decades Reactivated: activation of latent; more likely in the setting of immunosuppression.</description></item><item><title>Definitions-urinary tract infections</title><link>https://htlin222.github.io/garden/Definitions-urinary-tract-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-urinary-tract-infections/</guid><description>Definitions-urinary tract infections Asymptomatic bacteriuria: presence of bacteria in urine without signs or sx of infection Uncomplicated: confined to bladder.</description></item><item><title>Definitions-venous thromboembolism</title><link>https://htlin222.github.io/garden/Definitions-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Definitions-venous-thromboembolism/</guid><description>Definitions-venous thromboembolism Superficial thrombophlebitis: * pain, tenderness, erythema along superficial vein [[deep vein thrombosis]] Proximal = thrombosis of iliac, femoral, or popliteal veins (nb, “superficial” femoral vein part of deep venous system).</description></item><item><title>Delayed hemolytic</title><link>https://htlin222.github.io/garden/Delayed-hemolytic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Delayed-hemolytic/</guid><description>Delayed hemolytic : generally less severe than acute hemolytic; 5–7 d after transfusion, but can be severe → hyperhemolysis. Due to undetected allo-Abs vs.</description></item><item><title>delta-delta</title><link>https://htlin222.github.io/garden/delta-delta/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/delta-delta/</guid><description>delta-delta (Δ/Δ = ΔAG/ΔHCO3) to assess if there is an additional metabolic acid-base disturbance; ΔAG = (calculated AG – expected AG), ΔHCO3 = (24 – HCO3) Δ/Δ = 1–2 → pure AG metabolic acidosis Δ/Δ &amp;lt;1 → AG metabolic acidosis and simultaneous non-AG acidosis Δ/Δ &amp;gt;2 → AG metabolic acidosis and simultaneous metabolic alkalosis For pure lactic acidosis Δ/Δ 1.</description></item><item><title>dermatology</title><link>https://htlin222.github.io/garden/dermatology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dermatology/</guid><description>[[index]]
Keratinocyte Carcinomas (Squamous- and Basal-Cell Carcinomas) Melanoma Acne and Rosacea Psoriasis Atopic Dermatitis &amp;amp; Contact Dermatitis Stasis Dermatitis Cutaneous Herpes Infections Molluscum Contagiosum Warts Other relevant topics in Dermatology are covered in the following rotation guides:</description></item><item><title>determine the pretest probability</title><link>https://htlin222.github.io/garden/determine-the-pretest-probability/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/determine-the-pretest-probability/</guid><description>determine the pretest probability A. Use a validated CDR
Investigators construct a list of potential predictors of a disease, and then examine a group of patients to determine whether the predictors and the disease are present.</description></item><item><title>Device infection</title><link>https://htlin222.github.io/garden/Device-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Device-infection/</guid><description>Device infection (Heart Rhythm 2017;14:e503, NEJM 2019;380:1895)
Presents as pocket infection (warmth, erythema, tenderness) and/or sepsis w/ bacteremia ~2% over 5 y; if S.</description></item><item><title>diabetes mellitus</title><link>https://htlin222.github.io/garden/diabetes-mellitus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diabetes-mellitus/</guid><description>diabetes mellitus [[Definition-diabetes mellitus]] (Diabetes Care 2022;45:S256) [[Categories-diabetes mellitus]]
Clinical manifestations Polyuria, polydipsia, polyphagia with unexplained weight loss; may be asymptomatic [[Diabetes Treatment Approach for ASCVD, HF, or CKD]] [[Additional Diabetes Treatment Options]] [[Insulin Preparations]] (Diabetes Care 2019;42:S90) [[Complications-diabetes mellitus]] [[Outpatient screening and treatment goals-diabetes mellitus]] [[Management of hyperglycemia in inPts]] [[diabetic ketoacidosis]] (DKA) [[hyperosmolar hyperglycemic state]] [[hypoglycemia]] [[SGLT2i]]</description></item><item><title>Diabetes Treatment Approach for ASCVD, HF, or CKD</title><link>https://htlin222.github.io/garden/Diabetes-Treatment-Approach-for-ASCVD-HF-or-CKD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diabetes-Treatment-Approach-for-ASCVD-HF-or-CKD/</guid><description>Diabetes Treatment Approach for ASCVD, HF, or CKD Med (↓ HbA1C) Comments
GLP-1 receptor agonists (~1–2%) ↑ glc-depend. insulin secretion. Delay gastric emptying.</description></item><item><title>Diabetic Foot Infection</title><link>https://htlin222.github.io/garden/Diabetic-Foot-Infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diabetic-Foot-Infection/</guid><description>Diabetic Foot Infection 來自: [[infectious disease]]</description></item><item><title>diabetic foot infections</title><link>https://htlin222.github.io/garden/diabetic-foot-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diabetic-foot-infections/</guid><description>diabetic foot infections [[Microbiology and severity-diabetic foot infections]] Initial evaluation-diabetic foot infections Cleanse, debride, probe, and obtain deep anaerobic + aerobic cultures Assess for PVD: sensation, pulses, ABIs Diagnosis Deep tissue wound cx at time of debridement (ideally prior to antibiotics).</description></item><item><title>diabetic ketoacidosis</title><link>https://htlin222.github.io/garden/diabetic-ketoacidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diabetic-ketoacidosis/</guid><description>diabetic ketoacidosis [[Precipitants-diabetic ketoacidosis]] (the I’s) [[Pathophysiology-diabetic ketoacidosis]] [[Clinical manifestations-diabetic ketoacidosis]] [[Diagnostic studies-diabetic ketoacidosis]] [[Treatment of DKA]]</description></item><item><title>Diagnosis and treatment-autoimmune hepatitis AIH</title><link>https://htlin222.github.io/garden/Diagnosis-and-treatment-autoimmune-hepatitis-AIH-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-and-treatment-autoimmune-hepatitis-AIH-/</guid><description>Diagnosis and treatment-autoimmune hepatitis (AIH) (J Hepatol 2015;63:1543, Clin Liver Dis 2015;19:57)
70% female; bimodal presentation in the second and fifth decades of life</description></item><item><title>Diagnosis gastroesophageal reflux</title><link>https://htlin222.github.io/garden/Diagnosis-gastroesophageal-reflux-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-gastroesophageal-reflux-disease/</guid><description>Diagnosis gastroesophageal reflux (Annals 2015;163:ITC1; Nat Rev Gastro Hepatol 2016;13:501)
Clinical diagnosis based on sx and response to empiric trial of PPI (“PPI test”) EGD if: Ø response to PPI or alarm features: dysphagia, vomiting, ↓ wt, anemia, age &amp;gt;60 If dx uncertain &amp;amp; EGD nl → esoph manometry w/ 24-h pH monitoring ± impedance to dx: “Nonerosive reflux disease”: no erosion, ulceration or Barrett’s; ½ abnl pH.</description></item><item><title>Diagnosis gastroesophageal reflux disease</title><link>https://htlin222.github.io/garden/Diagnosis-gastroesophageal-reflux-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-gastroesophageal-reflux-disease-/</guid><description>Diagnosis gastroesophageal reflux disease (Annals 2015;163:ITC1; Nat Rev Gastro Hepatol 2016;13:501)
Clinical diagnosis based on sx and response to empiric trial of PPI (“PPI test”)</description></item><item><title>diagnosis of Giant cell arteritis</title><link>https://htlin222.github.io/garden/diagnosis-of-Giant-cell-arteritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diagnosis-of-Giant-cell-arteritis/</guid><description>diagnosis of Giant cell arteritis ↑ ESR (Se 84%, Sp 30%), ↑ CRP (Se 86%, Sp 30%), anemia.</description></item><item><title>Diagnosis of heparin-induced thrombocytopenia</title><link>https://htlin222.github.io/garden/Diagnosis-of-heparin-induced-thrombocytopenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-of-heparin-induced-thrombocytopenia/</guid><description>Diagnosis of heparin-induced thrombocytopenia [[Evaluation of Suspected HIT]] (“4T’s”) Clinical: plt &amp;lt;100k or ↓ 50% from baseline; or venous (DVT/PE) or arterial (limb ischemia, CVA, MI) thrombosis (4:1 ratio); skin necrosis; ?</description></item><item><title>Diagnosis of migraine</title><link>https://htlin222.github.io/garden/Diagnosis-of-migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-of-migraine/</guid><description>Diagnosis of migraine Record medical history Apply diagnostic criteria Consider differential diagnoses Examine patient to exclude other causes Use neuroimaging only when a secondary headache disorder is suspected [[54321-PUMA-嘔怕]]</description></item><item><title>Diagnosis of SVT Type</title><link>https://htlin222.github.io/garden/Diagnosis-of-SVT-Type/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-of-SVT-Type/</guid><description>Diagnosis of SVT Type (NEJM 2012;367:1438)
Onset Abrupt on/off argues against sinus tachycardia
Rate Not dx b/c most can range from 140–250 bpm, but: ST usually &amp;lt;150; AFL often conducts 2:1 → vent.</description></item><item><title>Diagnosis of Thrombotic microangiopathies</title><link>https://htlin222.github.io/garden/Diagnosis-of-Thrombotic-microangiopathies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-of-Thrombotic-microangiopathies/</guid><description>Diagnosis of Thrombotic microangiopathies unexplained thrombocytopenia (typically &amp;lt;20k) + MAHA → sufficient for dx ⊕ schistocytes (&amp;gt;2–3/hpf), ⊖ Coombs, normal PT/PTT &amp;amp; fibrinogen ↑↑ LDH (tissue ischemia + hemolysis), ↑ indirect bili.</description></item><item><title>Diagnosis-anaphylaxis</title><link>https://htlin222.github.io/garden/Diagnosis-anaphylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-anaphylaxis/</guid><description>Diagnosis-anaphylaxis any of the three following criteria
Acute illness with skin ± mucosal involvement (rash, flushing, hives), AND at least one of: Respiratory compromise (wheeze, stridor, dyspnea, hypoxemia)</description></item><item><title>Diagnosis-aseptic meningitis</title><link>https://htlin222.github.io/garden/Diagnosis-aseptic-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-aseptic-meningitis/</guid><description>Diagnosis-aseptic meningitis Obtain LP for CSF analysis: lymphocytic pleocytosis common in viral etiologies (see Typical CSF Findings in Meningitis table above) Consider CSF cytology and MRI brain/spine to evaluate for malignancy Consider serum autoimmune and serum viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric treatment</description></item><item><title>Diagnosis-bacterial endocarditis</title><link>https://htlin222.github.io/garden/Diagnosis-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-bacterial-endocarditis/</guid><description>Diagnosis-bacterial endocarditis (CID 2010;51:131; EHJ 2015;36:3075; Circ 2015;132:1435)
Blood cultures (before abx): 3 sets (aerobic &amp;amp; anaerobic bottles) from different sites, ideally spaced ≥1 h apart.</description></item><item><title>Diagnosis-clostridioides difficile infection</title><link>https://htlin222.github.io/garden/Diagnosis-clostridioides-difficile-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-clostridioides-difficile-infection/</guid><description>Diagnosis-clostridioides difficile infection (Ann Intern Med 2018;169:49)
Only test if symptomatic (diarrhea, s/s of colitis); test liquid stool (unless concern for ileus)</description></item><item><title>Diagnosis-crohn’s disease</title><link>https://htlin222.github.io/garden/Diagnosis-crohns-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-crohns-disease/</guid><description>Diagnosis-crohn’s disease Ileocolonoscopy + bx along w/ small bowel assessment (eg, MR-enterography)
Small bowel/ileitis (~25%), ileocolonic (~50%), colonic (~25%); isolated upper tract rare</description></item><item><title>Diagnosis-Glucose-6-phosphate dehydrogenase</title><link>https://htlin222.github.io/garden/Diagnosis-Glucose-6-phosphate-dehydrogenase/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-Glucose-6-phosphate-dehydrogenase/</guid><description>Diagnosis-Glucose-6-phosphate dehydrogenase smear may show RBC Heinz bodies (oxidized Hb) that result in bite cells once removed by spleen; ↓ G6PD levels (may be normal after acute hemolysis because older RBCs have already lysed and young RBCs may still have near-normal levels)</description></item><item><title>Diagnosis-hyperaldosteronism</title><link>https://htlin222.github.io/garden/Diagnosis-hyperaldosteronism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-hyperaldosteronism/</guid><description>Diagnosis-hyperaldosteronism (JCEM 2016;101:1889; Endo Metab Clin 2019;48:681; J Clin Endo Met 2021;106:2423)
5–10% of Pts w/ HTN; ∴ screen if HTN + hypoK, adrenal mass, refractory/early onset HTN Screening: ↓↓ renin, aldo &amp;gt;15–20 ng/dL, plasma aldo:renin ratio (&amp;gt;20 if 1°); obtain 8 a.</description></item><item><title>Diagnosis-necrotizing soft-tissue infections</title><link>https://htlin222.github.io/garden/Diagnosis-necrotizing-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-necrotizing-soft-tissue-infections/</guid><description>Diagnosis-necrotizing soft-tissue infections Clinical dx is sufficient to initiate urgent surgical exploration Aspiration of necrotic center; BCx; Gram stain; lactate, AST, &amp;amp; CK for deep tissue necrosis Imaging: noncontrast CT, but do not delay Rx/surgery (Arch Surg 2010;145:452) Microbiologic dx from Gram stain and culture of surgical specimens LRINEC score: 主要是Lab的參考 If high suspicion for necrotizing fasciitis through clinical history and physical exam, do not calculate a LRINEC score and go straight to operative debridement.</description></item><item><title>Diagnosis-osteomyelitis</title><link>https://htlin222.github.io/garden/Diagnosis-osteomyelitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-osteomyelitis/</guid><description>Diagnosis-osteomyelitis (JAMA 2008;299:806)
Crucial to obtain cx data of causative organism to avoid long-term empiric abx Bone biopsy or tissue cx obtained surgically or via percutaneous biopsy (send aerobic, anaerobic, mycobacterial, and fungal cultures + pathology) unless ⊕ blood cx.</description></item><item><title>Diagnosis-sexually transmitted infections</title><link>https://htlin222.github.io/garden/Diagnosis-sexually-transmitted-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-sexually-transmitted-infections/</guid><description>Diagnosis-sexually transmitted infections (MMWR 2021;70:1; JAMA 2022;327:161)
Syphilis: 1st step is treponemal test: IgG to T. pallidum. ⊕ for life.</description></item><item><title>Diagnosis-skin and soft tissue infections</title><link>https://htlin222.github.io/garden/Diagnosis-skin-and-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-skin-and-soft-tissue-infections/</guid><description>Diagnosis-skin and soft tissue infections [[Differential Diagnosis of Cellulitis]] Clinical diagnosis based on physical examination Cultures from intact skin are not helpful and should not be performed (CID 2014;59:e10) BCx are typically low yield (~5–10%) Ultrasound can be used to identify deep abscesses and facilitate drainage.</description></item><item><title>Diagnosis-ulcerative colitis</title><link>https://htlin222.github.io/garden/Diagnosis-ulcerative-colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnosis-ulcerative-colitis/</guid><description>Diagnosis-ulcerative colitis Colonoscopy: involves rectum (95%) &amp;amp; extends prox., circumfer., &amp;amp; contig. w/in colon
Location: proctitis (30–60%), L-sided (15–45%) and extensive (pancolitis; 15–35%)</description></item><item><title>Diagnostic and staging evaluation of lung cancer</title><link>https://htlin222.github.io/garden/Diagnostic-and-staging-evaluation-of-lung-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-and-staging-evaluation-of-lung-cancer/</guid><description>Diagnostic and staging evaluation of lung cancer [[Staging of lung cancer]]
[[5-y survival of lung cancer]]
Imaging: CT w/ contrast of chest &amp;amp; abd/pelvis to assess for mets (adrenal, liver, bones).</description></item><item><title>Diagnostic approach-fever syndromes</title><link>https://htlin222.github.io/garden/Diagnostic-approach-fever-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-approach-fever-syndromes/</guid><description>Diagnostic approach-fever syndromes Thorough history including ROS, PMH/PSH, immunizations, including from childhood Fever curve (holding antipyretics); look at trend/pattern. Less likely to mount fever if: ESRD/ESLD, extremes of age, protein calorie malnutrition, immunosupp.</description></item><item><title>Diagnostic clues that favor VT</title><link>https://htlin222.github.io/garden/Diagnostic-clues-that-favor-VT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-clues-that-favor-VT/</guid><description>Diagnostic clues that favor VT (assume until proven o/w)
Prior MI, CHF, or LV dysfunction best predictors that WCT is VT (Am J Med 1998;84:53) Hemodynamics and rate do not reliably distinguish VT from SVT MMVT is regular, but initially it may be slightly irregular, mimicking AF w/ aberrancy; grossly irregularly irregular rhythm suggests AF w/ aberrancy or pre-excitation ECG features that favor VT (Circ 2016;133:e506) AV dissociation (independent P waves, capture or fusion beats) proves VT Very wide QRS (&amp;gt;140 ms in RBBB-type or &amp;gt;160 in LBBB-type); extreme axis deviation QRS morphology atypical for BBB (longest precordial RS &amp;gt;100 ms and R wider than S) RBBB-type: absence of tall R′ (or presence of monophasic R) in V1, r/S ratio &amp;lt;1 in V6 LBBB-type: onset to nadir &amp;gt;60 ms in V1, q wave in V6 Initial R wave in aVR; concordance (QRS in all precordial leads w/ same pattern/direction)</description></item><item><title>Diagnostic evaluation of breast cancer</title><link>https://htlin222.github.io/garden/Diagnostic-evaluation-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-evaluation-of-breast-cancer/</guid><description>Diagnostic evaluation of breast cancer Palpable breast mass: age &amp;lt;30 y → observe for resolution over 1–2 menstrual cycles; age &amp;lt;30 y, unchanging mass → U/S → aspiration if mass not simple cyst; age &amp;gt;30 y or solid mass on U/S or bloody aspirate or recurrence after aspiration → mammo (detect other lesions) and either fine-needle asp.</description></item><item><title>Diagnostic evaluation of fever and neutropenia</title><link>https://htlin222.github.io/garden/Diagnostic-evaluation-of-fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-evaluation-of-fever-and-neutropenia/</guid><description>Diagnostic evaluation of fever and neutropenia Exam: skin, oropharynx, lung, perirectal area, surgical &amp;amp; catheter sites; avoid rectal exam Studies: U/A, blood (periph &amp;amp; through each indwelling catheter port), urine, &amp;amp; sputum cx; for localizing s/s → ✓ stool (C.</description></item><item><title>Diagnostic evaluation of hypercoagulable states</title><link>https://htlin222.github.io/garden/Diagnostic-evaluation-of-hypercoagulable-states/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-evaluation-of-hypercoagulable-states/</guid><description>Diagnostic evaluation of hypercoagulable states (not routinely required for initial VTE; NEJM 2017;377:1177)
APC resistance screen; prothrombin PCR test; functional assays for proteins C and S, ATIII; homocysteine level; factor VIII levels; anticardiolipin and lupus anticoagulant Ab.</description></item><item><title>Diagnostic evaluation of thrombocytopenia</title><link>https://htlin222.github.io/garden/Diagnostic-evaluation-of-thrombocytopenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-evaluation-of-thrombocytopenia/</guid><description>Diagnostic evaluation of thrombocytopenia H&amp;amp;P: meds, infxns, underlying conditions, splenomegaly, lymph nodes, bleeding hx
CBC with differential: isolated thrombocytopenia vs.</description></item><item><title>Diagnostic evaluation-anemia</title><link>https://htlin222.github.io/garden/Diagnostic-evaluation-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-evaluation-anemia/</guid><description>Diagnostic evaluation-anemia History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including pica), FHx
CBC w/ diff.; RBC params incl.</description></item><item><title>Diagnostic evaluation-hemolytic anemias</title><link>https://htlin222.github.io/garden/Diagnostic-evaluation-hemolytic-anemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-evaluation-hemolytic-anemias/</guid><description>Diagnostic evaluation-hemolytic anemias ↑ retic count (RI &amp;gt;2%), ↑ LDH, ↓ hapto (83% Se, 96% Sp), ↑ indirect bili, ✓ vit C &amp;amp; Cu</description></item><item><title>Diagnostic evaluation-hypopituitary syndromes</title><link>https://htlin222.github.io/garden/Diagnostic-evaluation-hypopituitary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-evaluation-hypopituitary-syndromes/</guid><description>Diagnostic evaluation-hypopituitary syndromes Hormonal studies Chronic: ↓ target gland hormone + ↓ or (inappropriately) normal trophic pituitary hormone Acute: will develop defic.</description></item><item><title>diagnostic process</title><link>https://htlin222.github.io/garden/diagnostic-process/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diagnostic-process/</guid><description>diagnostic process [[Common biases in clinical reasoning]]. [[model for clinical reasoning]] [[determine the pretest probability]] [[consider the potential harms]] [[the threshold model]]: likelihood ratio nomogram</description></item><item><title>Diagnostic studies</title><link>https://htlin222.github.io/garden/Diagnostic-studies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies/</guid><description>Diagnostic studies (JAMA 2017;318:279)
Spirometry: ↓ FEV1, ↓ FEV1/FVC, coved flow-volume loop; lung volumes: ± ↑ RV &amp;amp; TLC ⊕ bronchodilator response (↑ FEV1 ≥12% &amp;amp; ≥200 mL) strongly suggestive of asthma</description></item><item><title>Diagnostic studies acute coronary syndromes</title><link>https://htlin222.github.io/garden/Diagnostic-studies-acute-coronary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-acute-coronary-syndromes/</guid><description>Diagnostic studies acute coronary syndromes ECG: ST ↓/↑, TWI, new LBBB, hyperacute Tw; Qw/PRWP may suggest prior MI &amp;amp; ∴ CAD ✓ ECG w/in 10 min of presentation, with any ∆ in sx &amp;amp; at 6–12 h; compare w/ baseline</description></item><item><title>Diagnostic studies of hypertrophic cardiomyopathy</title><link>https://htlin222.github.io/garden/Diagnostic-studies-of-hypertrophic-cardiomyopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-of-hypertrophic-cardiomyopathy/</guid><description>Diagnostic studies of hypertrophic cardiomyopathy (EHJ 2014;35:2733)
ECG: LVH, anterolateral TWI and inferior pseudo-Qw, ± apical giant TWI (apical variant)</description></item><item><title>Diagnostic studies of PE</title><link>https://htlin222.github.io/garden/Diagnostic-studies-of-PE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-of-PE/</guid><description>Diagnostic studies of PE (EHJ 2014;35:3033)
CXR (limited Se &amp;amp; Sp): 12% nl, atelectasis, effusion, ↑ hemidiaphragm, Hampton hump (wedge-shaped density abutting pleura); Westermark sign (avascularity distal to PE)</description></item><item><title>diagnostic studies of peptic ulcer disease</title><link>https://htlin222.github.io/garden/diagnostic-studies-of-peptic-ulcer-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diagnostic-studies-of-peptic-ulcer-disease/</guid><description>diagnostic studies of peptic ulcer disease Testing for H. pylori: stool Ag, urea breath testing (UBT) or EGD + rapid urease test (RUT) False ⊖ Ag, UBT, RUT if on abx, bismuth, PPI; ∴ stop prior to testing if possible Serology: ↓ utility, useful only to exclude infection in lower prevalence areas EGD (definitive dx): if fail empiric Rx or alarm features (see “GERD”); bx GU to r/o malig &amp;amp; H.</description></item><item><title>Diagnostic studies of solitary pulmonary nodule</title><link>https://htlin222.github.io/garden/Diagnostic-studies-of-solitary-pulmonary-nodule/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-of-solitary-pulmonary-nodule/</guid><description>Diagnostic studies of solitary pulmonary nodule PET: detects metab. activity of tumors, 97% Se &amp;amp; 78% Sp for malig (esp if &amp;gt;8 mm).</description></item><item><title>Diagnostic studies of thoracentesis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-of-thoracentesis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-of-thoracentesis/</guid><description>Diagnostic studies of thoracentesis ✓ total protein, LDH, glucose, cell count with differential, Gram stain &amp;amp; culture, pH; (arterial blood gas)</description></item><item><title>Diagnostic studies peptic ulcer disease</title><link>https://htlin222.github.io/garden/Diagnostic-studies-peptic-ulcer-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-peptic-ulcer-disease-/</guid><description>Diagnostic studies peptic ulcer disease Testing for H. pylori: stool Ag, urea breath testing (UBT) or EGD + rapid urease test (RUT) False ⊖ Ag, UBT, RUT if on abx, bismuth, PPI; ∴ stop prior to testing if possible Serology: ↓ utility, useful only to exclude infection in lower prevalence areas</description></item><item><title>Diagnostic studies-acute mesenteric ischemia</title><link>https://htlin222.github.io/garden/Diagnostic-studies-acute-mesenteric-ischemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-acute-mesenteric-ischemia/</guid><description>Diagnostic studies-acute mesenteric ischemia Dx relies on high level of suspicion; rapid dx essential to avoid infarction (occurs w/in hrs)</description></item><item><title>Diagnostic studies-acute pancreatitis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-acute-pancreatitis/</guid><description>Diagnostic studies-acute pancreatitis (Am J Gastro 2013;108:1400)
Dx requires 2 of 3: characteristic abd pain; lipase or amylase &amp;gt;3× ULN; ⊕ imaging</description></item><item><title>Diagnostic studies-adrenal insufficiency</title><link>https://htlin222.github.io/garden/Diagnostic-studies-adrenal-insufficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-adrenal-insufficiency/</guid><description>Diagnostic studies-adrenal insufficiency (JCEM 2016;101:364)
Early a.m. serum cortisol: &amp;lt;3 µg/dL virtually diagnostic ≥18 µg/dL generally consistent with intact adrenal function, lower cutoff w/ modern specific assays (see Appendix) Standard (250 µg) cosyntropin stimulation test (testing ability of ACTH → ↑ cortisol) normal = 60-min (or 30-min) post-ACTH cortisol ≥18 µg/dL abnormal in primary b/c adrenal gland diseased and unable to give adequate output abnormal in chronic secondary b/c adrenals atrophied and unable to respond (very rarely, may be normal in acute pituitary injury b/c adrenals still able to respond → use early a.</description></item><item><title>Diagnostic studies-aortic aneurysms</title><link>https://htlin222.github.io/garden/Diagnostic-studies-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-aortic-aneurysms/</guid><description>Diagnostic studies-aortic aneurysms (JACC 2020;76:201)
Contrast CT: quick, noninvasive, high Se &amp;amp; Sp for all aortic aneurysms TTE/TEE: TTE most useful for root and proximal Ao; TEE can visualize other sites of TAA MRI: favored over CT for AoRoot imaging; useful in AAA but time consuming; noncontrast “black blood” MR to assess aortic wall Abdominal U/S: screening/surveillance test of choice for infrarenal AAA</description></item><item><title>Diagnostic studies-cholecystitis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-cholecystitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-cholecystitis/</guid><description>Diagnostic studies-cholecystitis RUQ U/S: high Se &amp;amp; Sp for stones, but need specific signs of cholecystitis: GB wall thickening &amp;gt;4 mm, pericholecystic fluid and a sonographic Murphy’s sign</description></item><item><title>Diagnostic studies-choledocholithiasis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-choledocholithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-choledocholithiasis/</guid><description>Diagnostic studies-choledocholithiasis (J Hepatol 2016;65:146; Gastrointest Endosc 2019;89:1075)
Labs: ↑ bilirubin, Aϕ; transient spike in ALT or amylase suggests passage of stone RUQ U/S: BD stones seen ~50–80% of cases; usually inferred from dilated CBD (&amp;gt;6 mm) ERCP preferred modality when likelihood high (eg, visualized stone, cholangitis, bili &amp;gt;4, or dilated CBD on U/S + bili 1.</description></item><item><title>Diagnostic studies-cholelithiasis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-cholelithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-cholelithiasis/</guid><description>Diagnostic studies-cholelithiasis Labs normal in most
RUQ U/S: Se &amp;amp; Sp &amp;gt;95% for stones &amp;gt;5 mm; should be performed after ≥8 h fast for distended, bile-filled gallbladder.</description></item><item><title>Diagnostic studies-chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Diagnostic-studies-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-chronic-obstructive-pulmonary-disease/</guid><description>Diagnostic studies-chronic obstructive pulmonary disease [[CXR of Diagnostic studies-chronic obstructive pulmonary disease]]
PFTs: obstruction: ↓↓ FEV1, ↓ FVC, FEV1/FVC &amp;lt;0.</description></item><item><title>Diagnostic studies-chronic pancreatitis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-chronic-pancreatitis-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-chronic-pancreatitis-/</guid><description>Diagnostic studies-chronic pancreatitis (Pancreas 2014;43:1143; Am J Gastro 2020;115:322)
Labs: amylase/lipase ↑ early, may be nl later. ⊕ fecal fat, ↓ stool elastase &amp;amp; A1AT.</description></item><item><title>Diagnostic studies-constrictive pericarditis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-constrictive-pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-constrictive-pericarditis/</guid><description>Diagnostic studies-constrictive pericarditis ECG: nonspecific, AF common (up to 33%) in advanced cases CXR: calcification (MTb most common), espec in lateral view (although not specific) Echocardiogram: ± thickened pericardium, “septal bounce” = abrupt displacement of septum during rapid filling in early diastole Cardiac catheterization: atria w/ Ms or Ws (prominent x and y descents) ventricles: dip-and-plateau or square-root sign (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau) discordance between LV &amp;amp; RV pressure peaks during respiratory cycle (Circ 1996;93:2007) CT or MRI: thickened pericardium (&amp;gt;4 mm; Se ~80%) w/ tethering (Circ 2011;123:e418)</description></item><item><title>Diagnostic studies-diabetic ketoacidosis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-diabetic-ketoacidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-diabetic-ketoacidosis/</guid><description>Diagnostic studies-diabetic ketoacidosis ↑ Anion gap metabolic acidosis (pH &amp;lt;7.3 &amp;amp; HCO3 &amp;lt;18): can later develop nonanion gap acidosis due to urinary loss of ketones (HCO3 equiv.</description></item><item><title>Diagnostic studies-encephalitis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-encephalitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-encephalitis/</guid><description>Diagnostic studies-encephalitis (CID 2013;57:1114)
CSF analysis: lymphocytic pleocytosis; PCR for HSV (95% Se &amp;amp; Sp), VZV; consider other PCR based on risk factors (CMV/EBV, HIV, JC, adeno/enterovirus, WNV) Consider testing for autoimmune etiologies and serologic viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric HSV/VZV Rx MRI (CT if unavailable); HSV temporal lobe; W.</description></item><item><title>Diagnostic studies-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Diagnostic-studies-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-gastrointestinal-bleeding/</guid><description>Diagnostic studies-gastrointestinal bleeding (JACR 2021;18:S139)
UGIB: EGD w/in 24 h (NEJM 2020;382:1299). If severe bleed, ↑ dx/Rx yield if erythro 250 mg IV given 30 min prior to endoscopy to clear stomach contents.</description></item><item><title>Diagnostic studies-hypercalcemia</title><link>https://htlin222.github.io/garden/Diagnostic-studies-hypercalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-hypercalcemia/</guid><description>Diagnostic studies-hypercalcemia [[hyperparathyroidism]] Hyperparathyroidism (HPT) and malignancy account for 90% of cases of ↑ Ca; HPT more likely if asx or chronic; malignancy (usually overt) more likely if acute or sx 甲狀旁腺功能亢進（HPT）和惡性腫瘤佔↑Ca病例的90%； 如果 asx 或慢性，HPT 更有可能；如果急性或 sx，則更有可能發生惡性腫瘤（通常是明顯的） [[Parathyroid MIBI Scan]] Ca, alb, ICa, PTH (may be inapprop.</description></item><item><title>Diagnostic studies-interstitial lung disease</title><link>https://htlin222.github.io/garden/Diagnostic-studies-interstitial-lung-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-interstitial-lung-disease/</guid><description>Diagnostic studies-interstitial lung disease see Appendix &amp;amp; Radiology inserts)
CXR and high-resolution chest CT Upper lobe predom: hypersensitivty, coal, silica, smoking-related, sarcoidosis, Langerhan’s</description></item><item><title>Diagnostic studies-mitral-stenosis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-mitral-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-mitral-stenosis/</guid><description>Diagnostic studies-mitral-stenosis ECG: LAE (“P mitrale”), ± AF, ± RVH CXR: dilated LA (flat L heart border, R double density, displaced L mainstem bronchus) Echo: estimate pressure gradient (∇), RVSP, valve area, valve echo score (0–16, based on leaflet mobility &amp;amp; thick, subvalvular thick.</description></item><item><title>Diagnostic studies-pericardial tamponade</title><link>https://htlin222.github.io/garden/Diagnostic-studies-pericardial-tamponade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-pericardial-tamponade/</guid><description>Diagnostic studies-pericardial tamponade ECG: ↑ HR, ↓ voltage (seen in 42%), electrical alternans (20%), ± signs of pericarditis</description></item><item><title>Diagnostic studies-pericarditis and pericardial effusion</title><link>https://htlin222.github.io/garden/Diagnostic-studies-pericarditis-and-pericardial-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-pericarditis-and-pericardial-effusion/</guid><description>Diagnostic studies-pericarditis and pericardial effusion Need ≥2 of the following: chest pain (as noted above), friction rub, ECG findings, effusion [[typical electrocardiogram in a patient with acute pericarditis]] CXR: if lg effusion (&amp;gt;250 mL) → ↑ cardiac silhouette w/ “water-bottle” heart &amp;amp; epicardial halo Echocardiogram: presence, size, &amp;amp; location of effusion; presence of tamponade physiology; pericarditis itself w/o spec.</description></item><item><title>Diagnostic studies-pheochromocytoma and paraganglioma</title><link>https://htlin222.github.io/garden/Diagnostic-studies-pheochromocytoma-and-paraganglioma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-pheochromocytoma-and-paraganglioma/</guid><description>Diagnostic studies-pheochromocytoma and paraganglioma (JCEM 2014;99:1915)
24° urinary fractionated metanephrines: 98% Se, 98% Sp. Screening test of choice if low-risk (b/c false ⊕ with severe illness, renal failure, OSA, labetalol due to assay interference, acetaminophen, TCAs, medications containing sympathomimetics).</description></item><item><title>Diagnostic studies-pleural effusion</title><link>https://htlin222.github.io/garden/Diagnostic-studies-pleural-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-pleural-effusion/</guid><description>Diagnostic studies-pleural effusion [[Thoracentesis]] [[Transudate vs exudate]] [[Complicated vs uncomplicated parapneumonic]] (Chest 1995;108:299) [[Additional pleural fluid studies]]</description></item><item><title>Diagnostic studies-pneumonia</title><link>https://htlin222.github.io/garden/Diagnostic-studies-pneumonia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-pneumonia/</guid><description>Diagnostic studies-pneumonia (AJRCC 2019;200:e45)
Sputum Gram stain/Cx: reliable if high quality (ie, sputum not saliva; &amp;lt;10 squam cells/lpf). If bacterial PNA should be purulent (&amp;gt;25 PMN/lpf).</description></item><item><title>Diagnostic studies-urinary tract infections</title><link>https://htlin222.github.io/garden/Diagnostic-studies-urinary-tract-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-urinary-tract-infections/</guid><description>Diagnostic studies-urinary tract infections (NEJM 2016;374:562)
Urinalysis: pyuria + bacteriuria ± hematuria ± nitrites Urine Cx (clean-catch midstream or straight-cath) Obtain cx only if symptoms (although in ill Pts, can include ∆MS, autonomic instability) ⊕ if: ≥105 CFU/mL, though &amp;lt;105 but ≥102/mL may still indicate UTI in some scenarios Pyuria &amp;amp; ⊖ UCx=sterile pyuria.</description></item><item><title>Diagnostic workup-hemoptysis</title><link>https://htlin222.github.io/garden/Diagnostic-workup-hemoptysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-workup-hemoptysis/</guid><description>Diagnostic workup-hemoptysis Localize bleeding site
(r/o GI or ENT source by H&amp;amp;P ± endo);
determine whether</description></item><item><title>Diagnostic-studies-aortic-regurgitation</title><link>https://htlin222.github.io/garden/Diagnostic-studies-aortic-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-aortic-regurgitation/</guid><description>Diagnostic-studies-aortic-regurgitation ECG: can see LVH, LAD, abnl repol; CXR: cardiomegaly ± ascending Ao dilatation Echo: severity of AR (severe = regurg jet width ≥65% LVOT, regurg fraction ≥50%, effective regurg orifice ≥0.</description></item><item><title>Diagnostic-studies-aortic-stenosis</title><link>https://htlin222.github.io/garden/Diagnostic-studies-aortic-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-aortic-stenosis/</guid><description>Diagnostic-studies-aortic-stenosis ECG: may see LVH, LAE, LBBB, AF (in late disease) CXR: cardiomegaly, AoV calcification, poststenotic dilation of ascending Ao, pulmonary congestion Echo: valve morph.</description></item><item><title>Diagnostic-studies-mitral-regurgitation</title><link>https://htlin222.github.io/garden/Diagnostic-studies-mitral-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-mitral-regurgitation/</guid><description>Diagnostic-studies-mitral-regurgitation Diagnostic studies
ECG: can see LVH, LAD, abnl repol; CXR: cardiomegaly ± ascending Ao dilatation Echo: severity of AR (severe = regurg jet width ≥65% LVOT, regurg fraction ≥50%, effective regurg orifice ≥0.</description></item><item><title>Diagnostic-studies-workup-pulmonary hypertension</title><link>https://htlin222.github.io/garden/Diagnostic-studies-workup-pulmonary-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostic-studies-workup-pulmonary-hypertension/</guid><description>Diagnostic-studies-workup-pulmonary hypertension High-res chest CT: dilat. &amp;amp; pruning of pulm arteries, ↑ RA &amp;amp; RV; r/o parenchymal lung dis. ECG: RAD, RBBB, RAE (“P pulmonale”), RVH (Se 55%, Sp 70%) PFTs: disproportionate ↓ DLCO, mild restrictive pattern; r/o obstructive &amp;amp; restrictive lung dis.</description></item><item><title>Diagnostics for active TB</title><link>https://htlin222.github.io/garden/Diagnostics-for-active-TB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diagnostics-for-active-TB/</guid><description>Diagnostics for active TB (CID 2017;64:11)
Pulmonary TB: common CXR findings discussed above; induced sputum AFB smear &amp;amp; culture (3 samples at least 8 h apart) ± NAAT/ PCR (GeneXpert); consider bronchoscopy + BAL ± transbronchial biopsy.</description></item><item><title>diarrhea</title><link>https://htlin222.github.io/garden/diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diarrhea/</guid><description>diarrhea acute diarrhea [[Acute Infectious Etiologies ]] [[Evaluation acute diarrhea]] [[Treatment acute diarrhea]] [[clostridioides difficile infection]] chronic diarrhea (&amp;gt;4 wk) [[General evaluation or chronic diarrhea]] [[Osmotic diarrhea]] [[Secretory diarrhea]] [[Functional IBS]] [[Malabsorption]] [[Maldigestion]] [[Inflammatory diarrhea]] [[Workup of chronic diarrhea]]</description></item><item><title>differential diagnosis</title><link>https://htlin222.github.io/garden/differential-diagnosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/differential-diagnosis/</guid><description>differential diagnosis (“all that wheezes is not asthma…”)
Hyperventilation &amp;amp; panic attacks
Upper airway obstruction or inh foreign body; laryngeal/vocal cord dysfxn (eg, 2° to GERD)</description></item><item><title>Differential Diagnosis of Cellulitis</title><link>https://htlin222.github.io/garden/Differential-Diagnosis-of-Cellulitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Differential-Diagnosis-of-Cellulitis/</guid><description>Differential Diagnosis of Cellulitis Stasis dermatitis Bilateral leg involvement; circumferential erythema and swelling; usually no fevers 雙腿；周圍紅斑和腫脹;通常不發燒 Contact dermatitis Unusual patterns of distribution; pruritus; no fevers Inflammatory arthritis Erythema overlies a joint; pain with range of motion</description></item><item><title>Differential Diagnosis of Delirium</title><link>https://htlin222.github.io/garden/Differential-Diagnosis-of-Delirium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Differential-Diagnosis-of-Delirium/</guid><description>Differential Diagnosis of Delirium Toxins Prescription medications: especially those with anticholinergic properties, narcotics, and benzodiazepines Drugs of abuse: alcohol intoxication and alcohol withdrawal, opiates, ecstasy, LSD, GHB, PCP, ketamine, cocaine, “bath salts,” marijuana and its synthetic forms Poisons: inhalants, carbon monoxide, ethylene glycol, pesticides Metabolic Conditions Electrolyte disturbances: hypoglycemia, hyperglycemia, hyponatremia, hypernatremia, hypercalcemia, hypocalcemia, hypomagnesemia Hypothermia and hyperthermia Pulmonary failure: hypoxemia and hypercarbia Liver failure/hepatic encephalopathy Renal failure/uremia Cardiac failure Vitamin deficiencies: B12, thiamine, folate, niacin Dehydration and malnutrition Anemia Infections Systemic infections: urinary tract infections, pneumonia, skin and soft tissue infections, sepsis CNS infections: meningitis, encephalitis, brain abscess Endocrine Conditions Hyperthyroidism, hypothyroidism Hyperparathyroidism Adrenal insufficiency Cerebrovascular Disorders Global hypoperfusion states Hypertensive encephalopathy Focal ischemic strokes and hemorrhages (rare): especially nondominant parietal and thalamic lesions Autoimmune Disorders CNS vasculitis Cerebral lupus Neurologic paraneoplastic and autoimmune encephalitis Seizure-Related Disorders Nonconvulsive status epilepticus Intermittent seizures with prolonged postictal states Neoplastic Disorders Diffuse metastases to the brain Gliomatosis cerebri Carcinomatous meningitis CNS lymphoma Hospitalization Terminal end-of-life delirium</description></item><item><title>Differential Diagnosis of Dyspnea</title><link>https://htlin222.github.io/garden/Differential-Diagnosis-of-Dyspnea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Differential-Diagnosis-of-Dyspnea/</guid><description>Differential Diagnosis of Dyspnea Lung Airways Alveoli (can fill with water, pus, or blood) Interstitium Pleural Heart Endocardium Conduction system Myocardium: HF Coronary arteries Pericardium Chest wall neuromuscular disease Blood Metabolic disorders</description></item><item><title>Digoxin</title><link>https://htlin222.github.io/garden/Digoxin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Digoxin/</guid><description>Digoxin 23% ↓ HF hosp., no ∆ mort (NEJM 1997;336:525); ? ↑ mort w/ ↑ levels (NEJM 2002;347:1403); optimal 0.5–0.8 ng/mL (JAMA 2003;289:871)</description></item><item><title>Digoxin-toxicology</title><link>https://htlin222.github.io/garden/Digoxin-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Digoxin-toxicology/</guid><description>Digoxin-toxicology N/V, bradycardia, AV block, delirium, xanthopsia
✓ serum dig level (but may be inaccurate if &amp;lt;6 h since last dose), renal function</description></item><item><title>dilated cardiomyopathy</title><link>https://htlin222.github.io/garden/dilated-cardiomyopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dilated-cardiomyopathy/</guid><description>dilated cardiomyopathy Definition and epidemiology (JACC 2016;67:2996; Lancet 2017;390:400) LV or biventricular dilatation and global ↓ contractility ± ↓ wall thickness in the absence of ischemia/infarct, valvular disease or HTN.</description></item><item><title>DILATED-CARDIOMYOPATHY</title><link>https://htlin222.github.io/garden/DILATED-CARDIOMYOPATHY/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/DILATED-CARDIOMYOPATHY/</guid><description>DILATED-CARDIOMYOPATHY</description></item><item><title>diltiazem</title><link>https://htlin222.github.io/garden/diltiazem/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diltiazem/</guid><description>diltiazem Wt/4
15-20 mg IV over 2 min, 20-25 mg 15 later prn, 5-15 mg/h 1 ibutilide 1 mg over 10 min, repeat * 1 if needed</description></item><item><title>DIP desquamative IP</title><link>https://htlin222.github.io/garden/DIP-desquamative-IP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/DIP-desquamative-IP/</guid><description>DIP desquamative IP Diffuse ground-glass opacities, reticular lines; lower zones. Peripheral macrophage in alveoli.
30–50 yo smokers
Sx wks–mos
Death rare</description></item><item><title>Direct Oral Anticoagulants DOACs for NVAF</title><link>https://htlin222.github.io/garden/Direct-Oral-Anticoagulants-DOACs-for-NVAF/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Direct-Oral-Anticoagulants-DOACs-for-NVAF/</guid><description>Direct Oral Anticoagulants (DOACs) for NVAF Apixaban (FXa inhib) 5 mg bid (2.5 mg bid if ≥ 2 of: ≥80 y, ≤60 kg, Cr ≥1.</description></item><item><title>Disease state specific regimens-diuresis</title><link>https://htlin222.github.io/garden/Disease-state-specific-regimens-diuresis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disease-state-specific-regimens-diuresis/</guid><description>Disease state specific regimens-diuresis Renal insufficiency: loop diuretic (↑ dose to achieve effective delivery to ThAL) ± thiazide</description></item><item><title>disease-specific management of kidney disease</title><link>https://htlin222.github.io/garden/disease-specific-management-of-kidney-disease-2/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/disease-specific-management-of-kidney-disease-2/</guid><description>disease-specific management of kidney disease [[Acute interstitial nephritis]] [[Cardiorenal syndrome]] [[Contrast-induced acute kidney injury]] [[Hepatorenal syndrome (HRS)]] [[Pulmonary-Renal Syndromes]] [[Obstructive diseases-disease-specific management of kidney disease ]] [[Polycystic kidney disease]] [[Rhabdomyolysis]] [[Scleroderma renal crisis]] [[COVID-19 associated AKI]] [[Thrombotic microangiopathies]]</description></item><item><title>disease-specific management of kidney disease</title><link>https://htlin222.github.io/garden/disease-specific-management-of-kidney-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/disease-specific-management-of-kidney-disease/</guid><description>disease-specific management of kidney disease</description></item><item><title>disorder of test</title><link>https://htlin222.github.io/garden/disorder-of-test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/disorder-of-test/</guid><description>disorder of test 來自: [[disorders of hemostasis]]</description></item><item><title>Disorders of EGJ Outflow</title><link>https://htlin222.github.io/garden/Disorders-of-EGJ-Outflow/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disorders-of-EGJ-Outflow/</guid><description>Disorders of EGJ Outflow Isolated EGJ outflow obstruction or achalasia. Achalasia: simult. ↓ amp contractions &amp;amp; ↓ LES relaxation; barium swallow w/ dilated esophagus &amp;amp; distal “bird’s beak” narrowing; mostly idiopathic, although can be a/w Chagas; Rx: pneumatic dilation as effective as Heller myotomy (local expertise dependent) (Gut 2016;65:732); peroral endoscopic myotomy; CCB/nitrates/PDEi; botox if Ø surg cand.</description></item><item><title>Disorders of Eyes, Ears, Nose, and Throat</title><link>https://htlin222.github.io/garden/Disorders-of-Eyes-Ears-Nose-and-Throat/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disorders-of-Eyes-Ears-Nose-and-Throat/</guid><description>Disorders of Eyes, Ears, Nose, and Throat Chapter 32: Disorders of the Eye Chapter 33: Disorders of Smell and Taste Chapter 34: Disorders of Hearing Chapter 35: Upper Respiratory Symptoms, Including Earache, Sinus Symptoms, and Sore Throat Chapter 36: Oral Manifestations of Disease</description></item><item><title>disorders of hemostasis</title><link>https://htlin222.github.io/garden/disorders-of-hemostasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/disorders-of-hemostasis/</guid><description>disorders of hemostasis [[clinical characteristics of bleeding disorders]] [[approach to abnormal hemostasis]] [[coagulation cascade and sites of action for anticoagulants]] [[purpura]]</description></item><item><title>disorders of leukocytes</title><link>https://htlin222.github.io/garden/disorders-of-leukocytes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/disorders-of-leukocytes/</guid><description>disorders of leukocytes [[neutrophilia]] [[neutropenia]] [[monocytosis]] [[eosinophilia]] [[basophilia]] [[lymphocytosis]] [[lymphadenopathy]]</description></item><item><title>Disorders of Peristalsis</title><link>https://htlin222.github.io/garden/Disorders-of-Peristalsis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disorders-of-Peristalsis/</guid><description>Disorders of Peristalsis Absent contractility (failed peristalsis); distal esophageal spasm (uncord. peristalsis w/ simult. contractions); hypercontractile esoph (high amp contract.</description></item><item><title>disorders of the colon</title><link>https://htlin222.github.io/garden/disorders-of-the-colon/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/disorders-of-the-colon/</guid><description>disorders of the colon [[diverticulosis]] [[diverticulitis]] [[polyps]]</description></item><item><title>Disposition of patients after initial treatment of asthma exacerbation</title><link>https://htlin222.github.io/garden/Disposition-of-patients-after-initial-treatment-of-asthma-exacerbation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disposition-of-patients-after-initial-treatment-of-asthma-exacerbation/</guid><description>Disposition of patients after initial treatment of asthma exacerbation</description></item><item><title>Disposition-anaphylaxis</title><link>https://htlin222.github.io/garden/Disposition-anaphylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disposition-anaphylaxis/</guid><description>Disposition-anaphylaxis Mild rxn limited to urticaria or mild bronchospasm can be observed for ≥6 h; admit all others</description></item><item><title>Disseminated intravascular coagulation DIC</title><link>https://htlin222.github.io/garden/Disseminated-intravascular-coagulation-DIC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disseminated-intravascular-coagulation-DIC/</guid><description>Disseminated intravascular coagulation (DIC) (NEJM 2014;370:847)
Etiologies: trauma, shock, infection, malignancy (esp. APL), obstetric complications
[[pathogenesis of disseminated intravascular coagulation (DIC)]]:</description></item><item><title>Disseminated Mycobacterium avium complex DMAC</title><link>https://htlin222.github.io/garden/Disseminated-Mycobacterium-avium-complex-DMAC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Disseminated-Mycobacterium-avium-complex-DMAC/</guid><description>Disseminated Mycobacterium avium complex (DMAC) Fever, night sweats, wt loss, abd pain, diarrhea, pancytopenia. Can cause localized lymphadenitis. Rx: clarithro/azithro + ethambutol ± rifampin/rifabutin.</description></item><item><title>Distinguihing Characteristics of Vascuiti Subtypes</title><link>https://htlin222.github.io/garden/Distinguihing-Characteristics-of-Vascuiti-Subtypes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Distinguihing-Characteristics-of-Vascuiti-Subtypes/</guid><description>Distinguihing Characteristics of Vascuiti Subtypes</description></item><item><title>Distributive shock</title><link>https://htlin222.github.io/garden/Distributive-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Distributive-shock/</guid><description>Distributive shock Septic shock
Pancreatitis
Severe burns
Anaphylactic shock
Neurogenic shock
Endocrine shock
Adrenal crisis</description></item><item><title>diuresis</title><link>https://htlin222.github.io/garden/diuresis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diuresis/</guid><description>diuresis [[General considerations-diuresis]] [[Loop diuretics]] [[Thiazide diuretics ]] [[K-sparing diuretics]] [[Approach to Diuresis ]](if inadequate diuresis, go to next step) [[Disease state specific regimens-diuresis]]</description></item><item><title>Diverticular bleed</title><link>https://htlin222.github.io/garden/Diverticular-bleed/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Diverticular-bleed/</guid><description>Diverticular bleed Pathophysiology: Intimal thickening and medial thinning of vasa recta as they course over dome of diverticulum → weakening of vascular wall → arterial rupture.</description></item><item><title>diverticulitis</title><link>https://htlin222.github.io/garden/diverticulitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diverticulitis/</guid><description>diverticulitis [[Pathophysiology of diverticulitis]] Diagnostic studies Abdominal CT (I+O+): diverticula, bowel wall thickening, pericolic fat ± abscess, fistula Colonoscopy contraindic.</description></item><item><title>diverticulosis</title><link>https://htlin222.github.io/garden/diverticulosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/diverticulosis/</guid><description>diverticulosis Definition &amp;amp; pathophysiology (Aliment Pharm Ther 2015;42:664)
Acquired herniations of colonic mucosa &amp;amp; submucosa in areas where vasa recta penetrate Abnormal motility and ↑ intraluminal pressure cause protrusion of colonic wall Epidemiology Risk factors: ↓ fiber, chronic constipation, obesity, smoking, physical inactivity, EtOH, NSAIDs, ↑ age (10% if &amp;lt;40 y; 50–66% if &amp;gt;80 y); ↑ red meat consumption Left side (90%, mostly sigmoid) &amp;gt;R side of colon (except in Asia where 75–85% R-sided) Clinical manifestations Usually asx; 5–15% develop diverticular hemorrhage (see “GIB”) and 10–25% diverticulitis Limited data for ↑ fiber diet or avoiding nuts/seeds (Thera Adv Gastro 2016;9:213)</description></item><item><title>dizziness</title><link>https://htlin222.github.io/garden/dizziness/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dizziness/</guid><description>[[index]]</description></item><item><title>Dofetilide</title><link>https://htlin222.github.io/garden/Dofetilide/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dofetilide/</guid><description>Dofetilide 500 mcg PO bid 500 mcg bid increase QT, increase risk of TdP; renal adj %
Backlink: [[Antiarrhythmic Drugs (AAD) for AF]]</description></item><item><title>Dog bite</title><link>https://htlin222.github.io/garden/Dog-bite/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dog-bite/</guid><description>Dog bite Pasturella &amp;amp; Capnocytophaga spp Can cause severe sepsis w/ DIC &amp;amp; gangrene in asplenic/cirrhotics and other immunosupp. Amox/clav If Capno.</description></item><item><title>dotfile</title><link>https://htlin222.github.io/garden/dotfile/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dotfile/</guid><description>Dotfiles (MacOS custom configuration specifications) – Index
@epperla2021doublerefractory</description></item><item><title>Dronedarone</title><link>https://htlin222.github.io/garden/Dronedarone/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dronedarone/</guid><description>Dronedarone n/a 400 mg bid decrease side effects &amp;amp; effic. vs. [[Amiodarone]]
%
Backlink: [[Antiarrhythmic Drugs (AAD) for AF]]</description></item><item><title>Drug fever</title><link>https://htlin222.github.io/garden/Drug-fever/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Drug-fever/</guid><description>Drug fever Anticonvulsants Minocycline [[Other antimicrobial agents of Drug fever]] Allopurinol Heparin Immune checkpoint inhibitors</description></item><item><title>Drug Therapy of Pulseless Arrest</title><link>https://htlin222.github.io/garden/Drug-Therapy-of-Pulseless-Arrest/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Drug-Therapy-of-Pulseless-Arrest/</guid><description>Drug Therapy of Pulseless Arrest Establish IV/O access (do not interrupt CPR) Epinephrine 1 mg IV q3-5min (or 2 mg via ETT) Amiodarone 300 mg IVB; 2&amp;quot; dose 150 mg 如果是VF再考慮，一般的PEA就不需要 Lidocaine 1-1.</description></item><item><title>Drug Treatment-lipid disorders</title><link>https://htlin222.github.io/garden/Drug-Treatment-lipid-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Drug-Treatment-lipid-disorders/</guid><description>Drug Treatment-lipid disorders Drug ↓ LDL ↓ TG Side Effects/Comments
Statins 30–60% 10–25% ↑ ALT in 0.5–3%; ✓ before starting and then prn Myalgias &amp;lt;10%, rhabdo &amp;lt;0.</description></item><item><title>Drug-induced hemolytic anemia</title><link>https://htlin222.github.io/garden/Drug-induced-hemolytic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Drug-induced-hemolytic-anemia/</guid><description>Drug-induced hemolytic anemia Acquired, Ab-drug mediated destruction vs. direct drug effect. Abx: ceph., sulfa drugs, rifampin, ribavirin. CV: methyldopa, procainamide, quinidine, thiazides.</description></item><item><title>Drug-induced TMA</title><link>https://htlin222.github.io/garden/Drug-induced-TMA/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Drug-induced-TMA/</guid><description>Drug-induced TMA (clinically similar to TTP; Blood 2017;129:2857)
Immune-mediated (Ab reacts w/ plts &amp;amp; endothelial cells): eg, quinine, gemcitabine?
Direct toxicity mediated: eg, gemcitabine, mitomycin, tacrolimus, CsA, bevacizumab</description></item><item><title>Drugs and toxins that cause acute liver failure</title><link>https://htlin222.github.io/garden/Drugs-and-toxins-that-cause-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Drugs-and-toxins-that-cause-acute-liver-failure/</guid><description>Drugs and toxins that cause acute liver failure (nearly 80% of cases in U.S.; Gastro 2015;148:1353, Clin Liver Dis 2017;21:151)</description></item><item><title>drugs routinely used for intrathecal application</title><link>https://htlin222.github.io/garden/drugs-routinely-used-for-intrathecal-application/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/drugs-routinely-used-for-intrathecal-application/</guid><description>drugs routinely used for intrathecal application [[Methotrexate]] MTX, AraC a.k.a Cytarabin (including the depot form of liposome-encapsulated AraC) and thiotepa.</description></item><item><title>Duration of full-intensity anticoagulation-venous thromboembolism</title><link>https://htlin222.github.io/garden/Duration-of-full-intensity-anticoagulation-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Duration-of-full-intensity-anticoagulation-venous-thromboembolism/</guid><description>Duration of full-intensity anticoagulation-venous thromboembolism Superficial venous thrombosis: 4 wk
1st prox DVT or PE 2° reversible/time-limited risk factor or distal DVT:</description></item><item><title>Duration of therapy of fever and neutropenia</title><link>https://htlin222.github.io/garden/Duration-of-therapy-of-fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Duration-of-therapy-of-fever-and-neutropenia/</guid><description>Duration of therapy of fever and neutropenia Known source: complete standard course (eg, 14 d for bacteremia) Unknown source: continue antibiotics until afebrile and ANC &amp;gt;500 cells/µL Less clear when to d/c abx when Pt is afebrile but prolonged neutropenia</description></item><item><title>Dx of Hemochromatosis</title><link>https://htlin222.github.io/garden/Dx-of-Hemochromatosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dx-of-Hemochromatosis/</guid><description>Dx of Hemochromatosis iron sat &amp;gt;45% (iron/TIBC × 100%); ↑ ferritin (acute phase reactant, so poor Sp; often nl in young Pts).</description></item><item><title>Dx studies of Cryoglobulinemic vasculitis</title><link>https://htlin222.github.io/garden/Dx-studies-of-Cryoglobulinemic-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dx-studies-of-Cryoglobulinemic-vasculitis/</guid><description>Dx studies of Cryoglobulinemic vasculitis ✓ Cryoglobulins (keep blood warmed to 37°C en route to lab to avoid false ⊖, loss of RF and ↓↓ C3, C4).</description></item><item><title>Dx studies of Granulomatosis with polyangiitis</title><link>https://htlin222.github.io/garden/Dx-studies-of-Granulomatosis-with-polyangiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dx-studies-of-Granulomatosis-with-polyangiitis/</guid><description>Dx studies of Granulomatosis with polyangiitis 90% ⊕ ANCA (80% PR3, 20% MPO), less Se in limited upper-airway disease
CXR or CT → nodules, infiltrates, cavities; sinus CT → sinusitis ± bone erosions ↑ BUN &amp;amp; Cr, proteinuria, hematuria; sediment w/ RBC casts, dysmorphic RBCs Biopsy → necrotizing granulomatous inflammation of arterioles, capillaries, veins.</description></item><item><title>Dx-Portal vein thrombosis PVT</title><link>https://htlin222.github.io/garden/Dx-Portal-vein-thrombosis-PVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dx-Portal-vein-thrombosis-PVT/</guid><description>Dx-Portal vein thrombosis (PVT) LFTs usually nl; begin w/ U/S w/ Doppler, confirm w/ MRA or CT (I+), angio; consider hypercoag w/u.</description></item><item><title>Dx-Wilson disease</title><link>https://htlin222.github.io/garden/Dx-Wilson-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dx-Wilson-disease/</guid><description>Dx-Wilson disease ↑ 24-h urine Cu, ↓ serum ceruloplasmin (Se 90%), liver bx w/ hepatic Cu content, genetic testing for ATP7B gene helpful if unclear dx.</description></item><item><title>Dyslipidemias</title><link>https://htlin222.github.io/garden/Dyslipidemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dyslipidemias/</guid><description>Dyslipidemias 1° (inherited causes): familial hyperchol. (1:250): defective LDL receptor; ↑↑ chol; ↑ CAD; familial hyperTG: ↑ TG &amp;amp; pancreatitis; familial combined hyperlipid.</description></item><item><title>dysmotility and nutrition</title><link>https://htlin222.github.io/garden/dysmotility-and-nutrition/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dysmotility-and-nutrition/</guid><description>dysmotility and nutrition [[Functional GI disease]] [[Gastroparesis]] [[Paralytic ileus of the colon &amp;amp; small bowel]] [[Constipation]] [[Nutritional Support and Total Parenteral Nutrition]]</description></item><item><title>dysnatremias</title><link>https://htlin222.github.io/garden/dysnatremias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dysnatremias/</guid><description>dysnatremias [[overview-sodium and water homeostasis]]</description></item><item><title>Dysphagia</title><link>https://htlin222.github.io/garden/Dysphagia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Dysphagia/</guid><description>Dysphagia Oropharyngeal: inability to propel food from mouth through UES into esophagus Esophageal: difficulty swallowing &amp;amp; passing food from esophagus into stomach [[Structural dysphagia]] [[Neuromuscular dysphagia]]</description></item><item><title>dyspnea</title><link>https://htlin222.github.io/garden/dyspnea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/dyspnea/</guid><description>dyspnea [[Evaluation-dyspnea]] [[alterations in circulatory and respiratory functions]] (Harrison&amp;rsquo;s) [[symptom to diagnosis of dyspnea]] Airway obstruction (↑ resistance to airflow) Asthma, COPD, bronchiectasis, cystic fibrosis, tumor, foreign body, vocal cord dysfunction, anaphylaxis</description></item><item><title>Early Goal-Directed Therapy EGDT</title><link>https://htlin222.github.io/garden/Early-Goal-Directed-Therapy-EGDT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Early-Goal-Directed-Therapy-EGDT/</guid><description>Early Goal-Directed Therapy (EGDT) Historically: IVF &amp;amp; pressors for MAP ≥65 mmHg, CVP 8–12 mmHg, UOP ≥0.5 mL/kg/h; inotropes &amp;amp; PRBCs for ScvO2 ≥70% in 6 h (NEJM 2001;345:1368)</description></item><item><title>Early intravenous administration of glucocorticoids in central nervous system infection</title><link>https://htlin222.github.io/garden/Early-intravenous-administration-of-glucocorticoids-in-central-nervous-system-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Early-intravenous-administration-of-glucocorticoids-in-central-nervous-system-infection/</guid><description>Early intravenous administration of glucocorticoids in central nervous system infection Developed regions 對所有疑似細菌性腦膜炎且微生物未知的成年人使用Dexamethasone 只有當 CSF 革蘭染色和/或 CSF 或血培養顯示肺炎鏈球菌時，才應繼續使用 Dexamethasone 為 0.</description></item><item><title>Eaton-Lambert</title><link>https://htlin222.github.io/garden/Eaton-Lambert/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Eaton-Lambert/</guid><description>Eaton-Lambert Lambert-Eaton myasthenic syndrome
anti-P/Q-type voltage-gated Ca2+ channel Abs 神經部 - 藍伯 - 伊頓肌無力症 (Lambert-Eaton myasthenic syndrome, LEMS)</description></item><item><title>ECG-in-young-athletes</title><link>https://htlin222.github.io/garden/ECG-in-young-athletes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ECG-in-young-athletes/</guid><description>ECG-in-young-athletes Normal patterns may include LVH, RVH, early repolarization Evaluate if: arrhythmia, HR &amp;lt;30, ↑ QT, ε/δ waves, LBBB, Brugada pattern, QRS &amp;gt;140 ms, PR &amp;gt;400 ms, Mobitz II, 3˚ AVB, ST depression, TWI</description></item><item><title>Echocardiogram for Constrictive vs Restrictive Pericarditis</title><link>https://htlin222.github.io/garden/Echocardiogram-for-Constrictive-vs-Restrictive-Pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Echocardiogram-for-Constrictive-vs-Restrictive-Pericarditis/</guid><description>Echocardiogram for Constrictive vs Restrictive Pericarditis Constrictive Respirophasic variation (25–40%): inspir. → ↑ flow across TV and ↓ flow across MV e′ (tissue velocity) nl/↑ (&amp;gt;12 cm/sec) Expir.</description></item><item><title>Education and patient centricity</title><link>https://htlin222.github.io/garden/Education-and-patient-centricity/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Education-and-patient-centricity/</guid><description>Education and patient centricity Provide appropriate reassurance Agree on realistic objectives Identify predisposing and/or trigger factors Follow strategy to individualize therapy according to symptoms and needs</description></item><item><title>Effect of 1 L infusion in 70-kg male</title><link>https://htlin222.github.io/garden/Effect-of-1-L-infusion-in-70-kg-male/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Effect-of-1-L-infusion-in-70-kg-male/</guid><description>Effect of 1 L infusion in 70-kg male w/ [Na]serum 110 mEq/L &amp;amp; Uosm 616 mOsm/kg
0.9% NaCl 154 mEq/L No UOP +1.</description></item><item><title>Effect of IV fluids-treatment-of-hyponatremia</title><link>https://htlin222.github.io/garden/Effect-of-IV-fluids-treatment-of-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Effect-of-IV-fluids-treatment-of-hyponatremia/</guid><description>Effect of IV fluids-treatment-of-hyponatremia complex as depends not only on [Na]infusate but also UOP and Uosm
If minimal UOP and none of infused Na excreted 分子: (current [Na] serum ×TBW) + [Na]infusate 分母：TBW + 1 If euvolemic (eg, in SIADH) &amp;amp; all infused Na excreted 分子: (current [Na] serum x TBW) + [Na]infusate - [Na]infusate 分母: TBW+1 - (Infusate osm/U osm) In SIADH “fixed” high Uosm.</description></item><item><title>Efficacy concerns PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/Efficacy-concerns-PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Efficacy-concerns-PA-catheter-and-tailored-therapy/</guid><description>Efficacy concerns PA catheter and tailored therapy Efficacy concerns (NEJM 2006;354:2213; JAMA 2005;294:1664)
No benefit to routine PAC use in high-risk surgery (JACC 2014;62:e77), sepsis, ARDS</description></item><item><title>EGFR ex20 insertion</title><link>https://htlin222.github.io/garden/EGFR-ex20-insertion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/EGFR-ex20-insertion/</guid><description>EGFR ex20 insertion EGFR 第20號外顯子(exon 20）插入突變是非小細胞肺癌(NSCLC) 中的特亞群 約佔所有 EGFR 突變 9%，這類型患者對於現有的三代 EGFR 受體酪胺酸激酶抑製劑（TKI）治療並不敏感 與常見的 EGFR exon 19 缺失或 L858R 突變的患者相比，預後更差 存活期中位數不到 17 個月，5 年生存率僅為 6% 因此，目前臨床上的標準治療方案是是常規化療，尚無 FDA 核准的標靶療法。 Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer</description></item><item><title>electrocardiography</title><link>https://htlin222.github.io/garden/electrocardiography/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/electrocardiography/</guid><description>approach to EKG [[貼片]]
[[Approach-electrocardiography]] (a systematic approach is vital) [[Axis-deviation]] [[Bundle-Branch-Blocks]] (Circ 2009;119:e235) [[Prolonged-QT-interval]] (NEJM 2008;358:169; www.torsades.org) [[Atrial-Abnormality]] [[Left-ventricular-hypertrophy]] (LVH) (Circ 2009;119:e251) [[Right-ventricular-hypertrophy]] (RVH) (Circ 2009;119:e251; JACC 2014;63:672) [[Ddx-of-dominant-R-wave-in-V1-or-V2]] [[Poor-R-wave-progression]] (PRWP) (Am Heart J 2004;148:80) [[Pathologic-Q-waves]] [[ST-elevation]] (STE) (NEJM 2003;349:2128; Circ 2009;119:e241 &amp;amp; e262) [[ST-depression]] (STD) [[T-wave-inversion]] (TWI; generally ≥1 mm; deep if ≥5 mm) (Circ 2009;119:e241) [[Low-voltage]] [[Electrolyte-abnormalities]] [[ECG-in-young-athletes]] (JACC 2017;69:805)</description></item><item><title>Electrolyte-abnormalities</title><link>https://htlin222.github.io/garden/Electrolyte-abnormalities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Electrolyte-abnormalities/</guid><description>Electrolyte-abnormalities ↑ K: tented Tw, ↓ QT, ↑ PR, AVB, wide QRS, STE; ↓ K: flattened Tw, U waves, ↑ QT</description></item><item><title>emergency medicine</title><link>https://htlin222.github.io/garden/emergency-medicine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/emergency-medicine/</guid><description>emergency medicine [[thereis]] a note t[[est zettel]]</description></item><item><title>empiric replacement fluids can be used for fluid losses</title><link>https://htlin222.github.io/garden/empiric-replacement-fluids-can-be-used-for-fluid-losses/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/empiric-replacement-fluids-can-be-used-for-fluid-losses/</guid><description>empiric replacement fluids can be used for fluid losses Sample Osmolarity calculations - GlobalRPH
Sweat: 5% dextrose (D5) {1/4} normal saline solution with 5 KCl/L Gastric, colon: D 5 {1/2} normal saline solution with 30 KCl/L Bile, pancreas, small bowel: lactated Ringer’s solution Third space (interstitial loss): lactated Ringer’s solution 關於 [[TaitaNo5]]</description></item><item><title>Empiric Treatment of Bacterial Meningitis</title><link>https://htlin222.github.io/garden/Empiric-Treatment-of-Bacterial-Meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Empiric-Treatment-of-Bacterial-Meningitis/</guid><description>Empiric Treatment of Bacterial Meningitis (Lancet 2012;380:1693)
Adults &amp;lt;50 y: Ceftriaxone + vancomycin (trough 15–20), consider acyclovir IV Adults &amp;gt;50 y: Ceftriaxone + vancomycin + ampicillin, consider acyclovir IV Immunosuppressed: [Cefepime or meropenem] + vanc ± amp (not nec.</description></item><item><title>Empiric treatment-aseptic meningitis</title><link>https://htlin222.github.io/garden/Empiric-treatment-aseptic-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Empiric-treatment-aseptic-meningitis/</guid><description>Empiric treatment-aseptic meningitis Suspected bacterial meningitis: see empiric treatment of bacterial meningitis above Suspected viral meningitis: if concern for HSV meningoencephalitis → IV acyclovir Unclear etiology: consider initiation of empiric bacterial meningitis treatment while observing and awaiting CSF studies</description></item><item><title>encephalitis</title><link>https://htlin222.github.io/garden/encephalitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/encephalitis/</guid><description>encephalitis Definition Inflammation of brain parenchyma characterized by impaired cerebral function (AMS, neurologic deficits) often due to primary viral infection or post-viral inflammation [[Etiologies-encephalitis]] Clinical manifestations Fever + ΔMS (subtle to severe), seizure, focal neuro deficit, HA in meningoencephalitis [[Diagnostic studies-encephalitis]] Treatment HSV/VZV: IV acyclovir 10 mg/kg IV q8h; consider empiric treatment given frequency</description></item><item><title>Endocarditis Prophylaxis</title><link>https://htlin222.github.io/garden/Endocarditis-Prophylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Endocarditis-Prophylaxis/</guid><description>Endocarditis Prophylaxis [[Cardiac conditions-Endocarditis Prophylaxis]] [[Procedures-Endocarditis Prophylaxis]] [[Regimens-Endocarditis Prophylaxis]]</description></item><item><title>Endocrine metabolic</title><link>https://htlin222.github.io/garden/Endocrine-metabolic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Endocrine-metabolic/</guid><description>Endocrine metabolic Hypogonadism; adrenal insufficiency (CMV, MAC, TB, HIV, or med-related); sarcopenia; osteopenia/porosis/fragility fractures (at all CD4 counts) Lipodystrophy: central obesity, peripheral lipoatrophy, dyslipidemia, hyperglycemia</description></item><item><title>endocrine-Secondary Causes of Hypertension</title><link>https://htlin222.github.io/garden/endocrine-Secondary-Causes-of-Hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/endocrine-Secondary-Causes-of-Hypertension/</guid><description>endocrine-Secondary Causes of Hypertension Hyperaldo or Cushing’s (1–5%) Hypokalemia Metabolic alkalosis See “Adrenal Disorders” [[adrenal disorders]]
Pheochromocytoma (&amp;lt;1%) Paroxysmal HTN, H/A, palp.</description></item><item><title>endocrinology</title><link>https://htlin222.github.io/garden/endocrinology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/endocrinology/</guid><description>endocrinology [[pituitary disorders]] [[thyroid disorders]] [[adrenal disorders]] [[calcium disorders]] [[diabetes mellitus]] [[lipid disorders]] [[phosphate disorders]] Resident 360 topics Diabetes [[inpatient diabetes management]] Thyroid Disorders Adrenal Disorders Osteoporosis Calcium-Based Disorders Obesity Pituitary Disorders Male Hypogonadism Transgender Health Other topics related to endocrinology are covered in the following rotation guides: Falls and Fracture Prevention (Geriatrics) Polycystic Ovary Syndrome (PCOS), Menopause (Women&amp;rsquo;s Health)</description></item><item><title>Endotracheal intubation of COPDAE</title><link>https://htlin222.github.io/garden/Endotracheal-intubation-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Endotracheal-intubation-of-COPDAE/</guid><description>Endotracheal intubation of COPDAE Consider if PaO2 &amp;lt;55–60, ↑’ing PaCO2, ↓’ing pH, ↑ RR, respiratory fatigue, Δ MS or hemodynamic instability</description></item><item><title>Endovascular repair EVAR-aortic aneurysms</title><link>https://htlin222.github.io/garden/Endovascular-repair-EVAR-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Endovascular-repair-EVAR-aortic-aneurysms/</guid><description>Endovascular repair EVAR-aortic aneurysms (Circ 2015;131:1291; NEJM 2019;380:2126)
Requires favorable aortic anatomy TEVAR (thoracic EVAR) for descending TAA ≥5.5 cm may ↓ periop morbidity and possibly mortality (Circ 2010;121:2780; JACC 2010;55:986; J Thorac CV Surg 2010;140:1001 &amp;amp; 2012;144:604) AAA: guidelines support open repair or EVAR for infrarenal AAA in good surg candidates ↓ short-term mort.</description></item><item><title>Entecavir or tenofovir</title><link>https://htlin222.github.io/garden/Entecavir-or-tenofovir/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Entecavir-or-tenofovir/</guid><description>Entecavir or tenofovir nucleo(s/t)ide analogs, well tolerated, low resistance; at 5 y, HBeAg seroconversion is 30–40% &amp;amp; loss of HBsAg is 5–10% (Lancet Gastro Hep 2016;1:185).</description></item><item><title>entry inhibitors-EI-Antiretrovirals ARVs</title><link>https://htlin222.github.io/garden/entry-inhibitors-EI-Antiretrovirals-ARVs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/entry-inhibitors-EI-Antiretrovirals-ARVs/</guid><description>entry inhibitors-EI-Antiretrovirals (ARVs) maraviroc (MVC; Selzentry) Dizziness, hepatotoxicity; ✓ CCR5 tropism assay</description></item><item><title>eosinophilia</title><link>https://htlin222.github.io/garden/eosinophilia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/eosinophilia/</guid><description>eosinophilia (&amp;gt;500/µL)
Infection Usually parasitic (helminths)
Allergic Drugs; asthma, hay fever, eczema; ABPA
Collagen vasc dis. RA, EGPA (Churg-Strauss), eosinophilic fasciitis, PAN</description></item><item><title>Eosinophilic esophagitis</title><link>https://htlin222.github.io/garden/Eosinophilic-esophagitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Eosinophilic-esophagitis/</guid><description>Eosinophilic esophagitis (JAMA 2021;326:1310):
often young/middle-aged ♂. Dx: &amp;gt;15 eos/hpf on bx, esoph dysfxn (ie, dysphagia, food impaction). Rx: 1st line is PPI (½ respond); alternative (or if fail PPI) is 3Ds: 1st elimination Diet (Ø milk, soy, eggs, wheat, nuts, fish); if no Δ, Drugs (swallow inh steroids); if ongoing sx &amp;amp; stricturing, Dilation (Gastro 2020;158:1776).</description></item><item><title>Eosinophilic gran with polyangiitis</title><link>https://htlin222.github.io/garden/Eosinophilic-gran-with-polyangiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Eosinophilic-gran-with-polyangiitis/</guid><description>Eosinophilic gran with polyangiitis Eosinophilic granulomatosis with polyangiitis
EGPA,
formerly Churg-Strauss
Similar to GPA w/ more frequent cardiac involvement,</description></item><item><title>Epidemiology pathogenesis-cholelithiasis</title><link>https://htlin222.github.io/garden/Epidemiology-pathogenesis-cholelithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Epidemiology-pathogenesis-cholelithiasis/</guid><description>Epidemiology pathogenesis-cholelithiasis (J Hepatol 2016;65:146; Gastro 2016;151:351)
Affects ~10% of Western populations, 15–25% of people develop sx over 10–15 y</description></item><item><title>Epidemiology and etiologies-atrial fibrillation</title><link>https://htlin222.github.io/garden/Epidemiology-and-etiologies-atrial-fibrillation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Epidemiology-and-etiologies-atrial-fibrillation/</guid><description>Epidemiology and etiologies-atrial fibrillation (Circ A&amp;amp;E 2018;11:e006350)
1–2% of pop. has AF (10% of those age ≥80); M &amp;gt;F; lifetime risk ~25%; mean age 75 y Acute (up to 50% w/o identifiable cause) Cardiac: HF, new CMP, myo/pericarditis, ischemia/MI, HTN crisis, valve dis.</description></item><item><title>Epidemiology and risk factors-lung cancer</title><link>https://htlin222.github.io/garden/Epidemiology-and-risk-factors-lung-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Epidemiology-and-risk-factors-lung-cancer/</guid><description>Epidemiology and risk factors-lung cancer Most common cause of cancer-related death for both men and women in the U.S. Two main types: non-small cell (NSCLC, ~85% of cases); small cell (SCLC, ~15%) 兩種主要類型：非小細胞（NSCLC，約85％的病例）；小單元（SCLC，〜15％） NSCLC comprised of adeno (40%), squamous cell (SCC, 20%), &amp;amp; large cell (5%) carcinomas, as well as other / not classified (20%) NSCLC由Adeno（40％），鱗狀細胞（SCC，20％）和大細胞（5％）癌組成，以及其他 /未分類（20％） Cigarette smoking: 85% of lung cancers occur in smokers; risk ∝ total pack-yrs, ↓ risk after quitting/reducing but not to baseline (Int J Cancer 2012;131:1210).</description></item><item><title>Epidemiology of breast cancer</title><link>https://htlin222.github.io/garden/Epidemiology-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Epidemiology-of-breast-cancer/</guid><description>Epidemiology of breast cancer Epidemiology In U.S., most common cancer in women; 2nd leading cause of cancer death in women</description></item><item><title>Epidemiology-aortic aneurysms</title><link>https://htlin222.github.io/garden/Epidemiology-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Epidemiology-aortic-aneurysms/</guid><description>Epidemiology-aortic aneurysms (Circ 2010;121:e266, 2011;124:2020; Nat Rev Cardiol 2011;8:92)
TAA: ~10/100,000 Pt-yrs; ♂:♀ 2:1; ~60% root/ascending; 40% descending AAA: ~4–8% prev in those &amp;gt;60 y; 5× more common in ♂; mostly infrarenal</description></item><item><title>Epidemiology-HIV AIDS</title><link>https://htlin222.github.io/garden/Epidemiology-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Epidemiology-HIV-AIDS/</guid><description>Epidemiology-HIV AIDS ~1.2 million Americans living w/ HIV (13% unaware); ~37 million worldwide High risk groups: MSM, transgender women, IVDU, sex worker, partners of high-risk Pts Transmission: sexual (risk 0.</description></item><item><title>Epidemiology-tuberculosis</title><link>https://htlin222.github.io/garden/Epidemiology-tuberculosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Epidemiology-tuberculosis/</guid><description>Epidemiology-tuberculosis (NEJM 2016;375:1081)
Transmission via aerosols; untreated active dx requires airborne isolation in healthcare facilities and community isolation measures; must involve local public health authorities Acquisition: residents/travel in TB-endemic area, IVDU, resident/worker in correctional facility or homeless shelter, close contact w/ active TB Reactivation: risk is 5% in first 2 yr, 5–10% overall; ↑ if HIV ⊕, immunosupp.</description></item><item><title>epidural abscess</title><link>https://htlin222.github.io/garden/epidural-abscess/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/epidural-abscess/</guid><description>epidural abscess [[clinical case of epidural abscess]] [[Etiology-epidural abscess]] Clinical manifestations-epidural abscess 背痛（約四分之三的患者）
發燒（幾乎一半的患者）
神經功能缺損（約三分之一的患者）</description></item><item><title>equipment of airway-management</title><link>https://htlin222.github.io/garden/equipment-of-airway-management/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/equipment-of-airway-management/</guid><description>equipment of airway-management ✨重點: 適當的準備對於所有氣道管理情況都是必不可少的。 基本設備包括氧氣源（牆壁或罐）、抽吸裝置、氣囊面罩通氣迴路、直接和/或視頻喉鏡、多種尺寸的氣管插管、聲門上氣道裝置、血壓/心電圖/脈搏血氧儀和 CO 2 檢測裝置。 聲門上氣道裝置包括插入患者口腔並位於聲門上方的喉罩氣道 (LMA)。 由於這些裝置不能防止胃內容物吸入，因此在 ICU 中，它們通常僅限於面罩通氣和氣管插管困難情況下的救援裝置。 雖然有多種類型的直接喉鏡可供選擇，但最常見的兩種是 Macintosh 刀片 (MAC) 兩者都有多種尺寸，但通常 MAC 3 近年來，視頻喉鏡是間接喉鏡檢查的一種形式，已在大多數機構中很容易獲得。 視頻喉鏡在刀片的形狀、插入口腔時的正確位置、視頻源的位置以及可重複使用/一次性部件方面各不相同。 Glidescope® 有自己的（非一次性）管心針，伴隨著獨特的刀片形狀。 視頻喉鏡的一個潛在問題是，雖然它可以提供聲門開口的清晰視圖，但仍可能難以將氣管插管操縱到正確位置。 ✨重點: 氣管導管 (ETT) 也有各種材料和尺寸可供選擇。 ICU 中最常用的是由聚氯乙烯製成的 ETT，帶有斜面尖端以更好地觀察插入，側孔（墨菲眼）以防止在粘液栓的情況下完全閉塞，以及充氣袖帶。 ETT 的尺寸根據以毫米為單位的 內徑 確定，通常適合成人的尺寸。 7.</description></item><item><title>ER PR</title><link>https://htlin222.github.io/garden/ER-PR/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ER-PR/</guid><description>ER PR Endo (NEJM 2019;380: 1226) Tamoxifen: adjuvant Rx for low-risk pre-meno; ↓ recurrence &amp;amp; ↓ mortality; 10 y superior to 5 y (Lancet 2011;378:771 &amp;amp; 2013;381:805) Aromatase inhib (AI; anastrozole, letrozole, exemestane): adjuvant Rx for post-meno; ↑ OS vs.</description></item><item><title>Erosive gastropathy</title><link>https://htlin222.github.io/garden/Erosive-gastropathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Erosive-gastropathy/</guid><description>Erosive gastropathy (4–30%)
Precipitants: ASA/NSAID, EtOH, cocaine, gut ischemia, XRT
Stress-related mucosal injury in ICU Pts. Risk factors include severe coagulopathy, mech vent &amp;gt;48 h, high-dose glucocorticoids</description></item><item><title>Erythema multiforme</title><link>https://htlin222.github.io/garden/Erythema-multiforme/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Erythema-multiforme/</guid><description>Erythema multiforme symmetric “target” lesions often of palms, soles, &amp;amp; mucous memb Infxn etiol: HSV, Mycoplasma, syphilis, VZV, EBV, CMV, adenovirus, etc.</description></item><item><title>Erythema nodosum</title><link>https://htlin222.github.io/garden/Erythema-nodosum/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Erythema-nodosum/</guid><description>Erythema nodosum tender erythematous or violaceous nodules usually symmetric on LE Infxn etiol: Strep, TB, EBV, Bartonella, HBV, psittacosis, fungal, L.</description></item><item><title>esophageal and gastric disorders</title><link>https://htlin222.github.io/garden/esophageal-and-gastric-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/esophageal-and-gastric-disorders/</guid><description>esophageal and gastric disorders dysphagia [[structural dysphagia]] [[neuromuscular dysphagia]] gastroesophageal reflux disease [[pathophysiology gastroesophageal reflux disease]] [[clinical manifestations gastroesophageal reflux disease]] [[diagnosis gastroesophageal reflux disease]] [[treatment gastroesophageal reflux disease]] [[complications gastroesophageal reflux disease]] peptic ulcer disease [[definition and etiologies of peptic ulcer disease]] [[clinical manifestations of peptic ulcer disease]] [[diagnostic studies of peptic ulcer disease]] [[treatment of peptic ulcer disease]] [[GI prophylaxis if taking ASA and nonsteroidal anti-inflam drug]]</description></item><item><title>esophageal and gastric disorders</title><link>https://htlin222.github.io/garden/GI-prophylaxis-if-taking-ASA-NSAID-peptic-ulcer-disease.md/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/GI-prophylaxis-if-taking-ASA-NSAID-peptic-ulcer-disease.md/</guid><description>esophageal and gastric disorders [[Dysphagia]] [[Etiologies of and approach to dysphagia]] [[Structural dysphagia]] [[Neuromuscular dysphagia]]
GASTROESOPHAGEAL REFLUX DISEASE (GERD) [[Pathophysiology-gastroesophageal reflux disease]] [[Clinical manifestations gastroesophageal reflux disease]] [[Diagnosis gastroesophageal reflux disease]] [[Treatment gastroesophageal reflux disease]] [[Complications gastroesophageal reflux disease ]]</description></item><item><title>esophageal cancer</title><link>https://htlin222.github.io/garden/esophageal-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/esophageal-cancer/</guid><description>esophageal cancer OVERALL BOTTOM LINE The incidence of esophageal cancer has increased in certain populations (e.g. adenocarcinoma in patients with undertreated reflux esophagitis) without much improvement in survival over the past three decades.</description></item><item><title>Esophageal or gastric varices</title><link>https://htlin222.github.io/garden/Esophageal-or-gastric-varices/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Esophageal-or-gastric-varices/</guid><description>Esophageal or gastric varices (4–20%)
(Clin Gastro Hepatol 2015;13:2109; J Gastro Hepatol 2016;31:1519; Hep 2017;65:310)
See “Cirrhosis”
2° to portal HTN.</description></item><item><title>Esophagitis</title><link>https://htlin222.github.io/garden/Esophagitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Esophagitis/</guid><description>Esophagitis (15%)
Rx offending cause + high-dose PPI; repeat EGD to r/o Barrett’s.</description></item><item><title>est zettel</title><link>https://htlin222.github.io/garden/est-zettel/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/est-zettel/</guid><description>est zettel 來自: [[emergency medicine]]</description></item><item><title>Ethylene glycol-toxicology</title><link>https://htlin222.github.io/garden/Ethylene-glycol-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ethylene-glycol-toxicology/</guid><description>Ethylene glycol-toxicology CNS depression, ↑ AG &amp;amp; OG metabolic acidosis
Ethanol or fomepizole, NaHCO3
Consider hemodialysis</description></item><item><title>Etiologies and Diagnosis of Acute Kidney Injury</title><link>https://htlin222.github.io/garden/Etiologies-and-Diagnosis-of-Acute-Kidney-Injury-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-and-Diagnosis-of-Acute-Kidney-Injury-/</guid><description>Etiologies and Diagnosis of Acute Kidney Injury [[Prerenal acute kidney injury etiology]] [[Intrinsic acute kidney injury etiology]] [[Post-renal acute kidney injury etiology]] [[Urine Dipstick]]</description></item><item><title>Etiologies of Acute Pericarditis</title><link>https://htlin222.github.io/garden/Etiologies-of-Acute-Pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Acute-Pericarditis/</guid><description>Etiologies of Acute Pericarditis ✨ 學習重點 🦎 急性心包炎（病毒性、細菌性、結核性或特發性起源）。 自身免疫性疾病。 心肌梗塞或心臟手術後。 尖銳或鈍性胸部創傷，包括心臟診斷或介入手術。 惡性腫瘤，特別是非心臟原發性腫瘤的轉移擴散。 縱隔輻射。 腎功能衰竭伴尿毒症。 粘液性水腫。 主動脈夾層延伸到心包。 藥物 Idiopathic (~90%) Most presumed to be undiagnosed viral etiologies 大多數被認為是未確診的病毒病因</description></item><item><title>Etiologies of and approach to dysphagia</title><link>https://htlin222.github.io/garden/Etiologies-of-and-approach-to-dysphagia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-and-approach-to-dysphagia/</guid><description>Etiologies of and approach to dysphagia</description></item><item><title>Etiologies of Classic FUO</title><link>https://htlin222.github.io/garden/Etiologies-of-Classic-FUO/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Classic-FUO/</guid><description>Etiologies of Classic FUO [[Infection as Etiologies of Classic FUO]] ~30%
[[Connective tissue disease as Etiologies of Classic FUO]] ~30%</description></item><item><title>Etiologies of Constipation</title><link>https://htlin222.github.io/garden/Etiologies-of-Constipation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Constipation/</guid><description>Etiologies of Constipation Primary etiologies: slow transit vs. pelvic floor dyssynergia Secondary etiologies (4 Ms; JAMA 2016:315:185) Mech obstruction: malignancy, compression, rectocele, strictures</description></item><item><title>Etiologies of Decreased Responsiveness</title><link>https://htlin222.github.io/garden/Etiologies-of-Decreased-Responsiveness/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Decreased-Responsiveness/</guid><description>Etiologies of Decreased Responsiveness see: [[Differential Diagnosis of Delirium]]
1° Neurologic (usually with focal signs) Vasc: ischemic stroke/TIA, ICH, VST, PRES, vasculitis, pituitary apoplexy Seizure: postictal, status, nonconvulsive Infxn: meningitis, encephalitis, abscess Trauma: TBI, concussion, diffuse axonal injury ↑ intracranial pressure: mass, edema, hydrocephalus, herniation Autoimmune/paraneoplastic enceph.</description></item><item><title>Etiologies of Hematuria</title><link>https://htlin222.github.io/garden/Etiologies-of-Hematuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Hematuria/</guid><description>Etiologies of Hematuria Extrarenal (far more common) Nephrolithiasis Neoplasm: transitional cell, prostate Infxn: cystitis, urethritis, prostatitis Foley trauma BPH [[Schistosoma haematobium]] Intrarenal Nephrolithiasis or crystalluria Neoplasm Trauma/exercise Vascular: renal infarcts, renal v.</description></item><item><title>Etiologies of High elevated PaCO2</title><link>https://htlin222.github.io/garden/Etiologies-of-High-elevated-PaCO2/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-High-elevated-PaCO2/</guid><description>Etiologies of High elevated PaCO2 Hypercapnia - P.CO2 = k x VCO2 / (respiratory rate * tidal volume * (1-Vd/tidal volume))</description></item><item><title>Etiologies of Hypercalcemia</title><link>https://htlin222.github.io/garden/Etiologies-of-Hypercalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Hypercalcemia/</guid><description>Etiologies of Hypercalcemia [[hyperparathyroidism]] (HPT) (NEJM 2018;379:1050; Lancet 2018;391:168) 1°: adenoma (85%), hyperplasia (15–20%; spont. vs. MEN1/2A), carcinoma (&amp;lt;1%), meds (Lithium → ↑ PTH) 3°: after long-standing 2° hyperparathyroidism (as in renal failure) → autonomous nodule develops, requires surgery [[Secondary hyperPTH]] Familial hypocalciuric hypercalcemia (FHH) Inact.</description></item><item><title>Etiologies of hypercortisolism</title><link>https://htlin222.github.io/garden/Etiologies-of-hypercortisolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-hypercortisolism/</guid><description>Etiologies of hypercortisolism Most commonly iatrogenic caused by exogenous glucocorticoids (though underreported) [[Cushing’s disease]] (60–70% of non-iatrogenic CS): ACTH-secreting pituitary adenoma (usually microadenoma) or hyperplasia Adrenal tumor (10–15%): adenoma or (rarely) carcinoma Ectopic ACTH (10–15%): SCLC, carcinoid, islet cell tumors, medullary thyroid carcinoma, [[pheochromocytoma]]</description></item><item><title>Etiologies of Hypocalcemia</title><link>https://htlin222.github.io/garden/Etiologies-of-Hypocalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Hypocalcemia/</guid><description>Etiologies of Hypocalcemia [[Laboratory Findings in Calcium Disorders]]
[[Hypoparathyroidism]] [[Pseudo-hypoparathyroidism]] Vit D defic. or resist (NEJM 2011;364:248; JCEM 2012;97:1153)
⭐ 學習重點 ⭐ 大多數血清 25-羥基維生素 D (25[OH]D) 為 12 至 20 ng/mL（30 至 50 nmol/L）的健康成人不需要任何額外評估。 血清 25(OH)D 水平 &amp;lt;12 ng/mL 的患者有發生骨軟化症的風險。 在此類患者中，我們測量血清鈣、磷、鹼性磷酸酶、甲狀旁腺激素 (PTH)、電解質、血尿素氮 (BUN)、肌酐和組織轉谷氨酰胺酶抗體（以評估乳糜瀉）。 在某些情況下需要 X 光片，例如存在骨痛。 [[Synthesis and Metabolism of Vitamin D]].</description></item><item><title>Etiologies of Non-AG Metabolic Acidosis</title><link>https://htlin222.github.io/garden/Etiologies-of-Non-AG-Metabolic-Acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Non-AG-Metabolic-Acidosis/</guid><description>Etiologies of Non-AG Metabolic Acidosis GI losses of HCO3 Diarrhea, intestinal or pancreatic fistulas or drainage
RTAs [[Renal tubular acidoses]]</description></item><item><title>Etiologies of Prolonged-QT-interval</title><link>https://htlin222.github.io/garden/Etiologies-of-Prolonged-QT-interval/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Prolonged-QT-interval/</guid><description>Etiologies of Prolonged-QT-interval Antiarrhythmics class Ia (procainamide, disopyramide), class III (amio, sotalol, dofet)
Psych drugs antipsychotics (phenothiazines, haloperidol, atypicals), Li, ?</description></item><item><title>Etiologies of Proteinuria</title><link>https://htlin222.github.io/garden/Etiologies-of-Proteinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Proteinuria/</guid><description>Etiologies of Proteinuria [[Glomerular proteinuria]] [[Tubulointerstitial proteinuria]] [[Overflow proteinuria]] [[Isolated proteinuria]]</description></item><item><title>Etiologies-acute pancreatitis</title><link>https://htlin222.github.io/garden/Etiologies-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-acute-pancreatitis/</guid><description>Etiologies-acute pancreatitis (JAMA 2021;325:382)
Gallstones (40%): ♀ &amp;gt;♂; usually due to small stones (&amp;lt;5 mm) or microlithiasis/sludge
Alcohol (30%): ♂ &amp;gt;♀; 4–5 drinks/day over ≥5 yrs; usually chronic w/ acute flares</description></item><item><title>Etiologies-adrenal insufficiency</title><link>https://htlin222.github.io/garden/Etiologies-adrenal-insufficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-adrenal-insufficiency/</guid><description>Etiologies-adrenal insufficiency Primary = adrenocortical disease = Addison’s disease autoimmune: isolated or in assoc w/ APS (see table on page 7-2) infection: TB, CMV, histoplasmosis, paracoccidioidomycosis vascular: hemorrhage (usually in setting of sepsis), adrenal vein thrombosis, HIT, trauma metastatic disease: (90% of adrenals must be destroyed to cause insufficiency) deposition diseases: hemochromatosis, amyloidosis, sarcoidosis drugs: azole antifungals, etomidate (even after single dose), rifampin, anticonvulsants Secondary = pituitary failure of ACTH secretion (but adrenal aldosterone intact b/c RAA axis) any cause of primary or secondary hypopituitarism (see “Pituitary Disorders”) glucocorticoid therapy (can occur after ≤2 wk of “suppressive doses”; dose effect variable; even &amp;lt;10 mg of prednisone daily chronically can be suppressive) megestrol (a progestin with some glucocorticoid activity)</description></item><item><title>Etiologies-Aplastic anemia</title><link>https://htlin222.github.io/garden/Etiologies-Aplastic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-Aplastic-anemia/</guid><description>Etiologies-Aplastic anemia idiopathic (½ – ⅔ of cases)
Stem cell destruction: radiation, chemotherapy, chemicals (eg, benzene)</description></item><item><title>Etiologies-ascites</title><link>https://htlin222.github.io/garden/Etiologies-ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-ascites/</guid><description>Etiologies-ascites Portal HTN Related (SAAG ≥1.1) Presinusoidal obstruction portal or splenic vein thrombosis, schisto- somiasis, sarcoidosis
Sinusoidal obstruction: cirrhosis, acute hepatitis (including EtOH), malignancy (HCC or mets)</description></item><item><title>Etiologies-aseptic meningitis</title><link>https://htlin222.github.io/garden/Etiologies-aseptic-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-aseptic-meningitis/</guid><description>Etiologies-aseptic meningitis (Neurology 2006;66:75)
Viral: enteroviruses are most common cause (summer/fall; rash, GI, URI sx), HIV, HSV, VZV, mumps (parotitis), lymphocytic choriomeningitis virus (rodent exposure), encephalitis viruses, adenovirus, polio, CMV, EBV, WNV Focal bacterial infection: brain/epidural/subdural abscess, CNS septic thrombophlebitis Partially treated bacterial meningitis Other infectious: TB, fungal (cryptococcus, coccidiodes), Lyme, syphilis, leptospirosis Neoplasm: intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis Drug-induced meningitis: NSAIDs, IVIG, antibiotics (TMP-SMX, PCN), anti-epileptics Systemic autoimmune illness: SLE, sarcoidosis, Behçet’s, Sjögren’s syndrome, RA Mollaret’s: recurrent lymphocytic meningitis, spontaneously resolving (often HSV-2)</description></item><item><title>Etiologies-cirrhosis</title><link>https://htlin222.github.io/garden/Etiologies-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-cirrhosis/</guid><description>Etiologies-cirrhosis Alcohol, toxins (eg, arsenic)
Nonalcoholic fatty liver disease (NAFLD) is the cause of most “cryptogenic cirrhosis”</description></item><item><title>Etiologies-encephalitis</title><link>https://htlin222.github.io/garden/Etiologies-encephalitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-encephalitis/</guid><description>Etiologies-encephalitis (specific etiology found in &amp;lt;20% of cases; Neurology 2006;66:75; CID 2008;47:303)
HSV-1 all ages/seasons. If sxs recur after Rx, consider viral relapse vs.</description></item><item><title>Etiologies-hemoptysis</title><link>https://htlin222.github.io/garden/Etiologies-hemoptysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-hemoptysis/</guid><description>Etiologies-hemoptysis (Crit Care Med 2000;28:1642)
Infection/Inflammation Bronchitis (most common cause of trivial hemoptysis) Bronchiectasis incl CF (common cause of massive hemoptysis) TB or aspergilloma (can be massive); pneumonia or lung abscess Neoplasm Usually primary lung cancer, sometimes metastasis (can be massive) Cardiovasc PE (can be massive), pulmonary artery rupture (2° to instrumentation), CHF, mitral stenosis, trauma/foreign body, bronchovascular fistula Other Vasculitis (GPA, anti-GBM, Behçet’s, SLE), AVM, anticoag (withunderlying lung disease), coagulopathy, cocaine, pulm hemosiderosis</description></item><item><title>Etiologies-hyperaldosteronism</title><link>https://htlin222.github.io/garden/Etiologies-hyperaldosteronism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-hyperaldosteronism/</guid><description>Etiologies-hyperaldosteronism [[Primary Hyperaldosteronism]] [[Secondary Hyperaldosteronism]] [[Nonaldosterone mineralocorticoid excess]] mimics hyperaldosteronism</description></item><item><title>Etiologies-hypertension</title><link>https://htlin222.github.io/garden/Etiologies-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-hypertension/</guid><description>Etiologies-hypertension Essential (95%): onset 25–55 y; ⊕ FHx. Unclear mechanism but ? additive microvasc renal injury over time w/ contribution of hyperactive sympathetics (NEJM 2002;346:913).</description></item><item><title>Etiologies-hyperthyroidism</title><link>https://htlin222.github.io/garden/Etiologies-hyperthyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-hyperthyroidism/</guid><description>Etiologies-hyperthyroidism Graves’ disease (60–80% of thyrotoxicosis) Thyroiditis: thyrotoxic phase of subacute (granulomatous) or painless (lymphocytic) Toxic adenomas (single or multinodular goiter) Extremely rare: TSH-secreting pituitary tumor or pituitary resistant to thyroid hormone (↑ TSH, ↑ free T4) Misc: amiodarone, iodine-induced, thyrotoxicosis factitia, struma ovarii (3% of ovarian dermoid tumors and teratomas), tumors (eg, choriocarcinoma) secreting hCG (weak bioactivity against TSH-R), large deposits of metastatic follicular thyroid cancer</description></item><item><title>Etiologies-hypoglycemia</title><link>https://htlin222.github.io/garden/Etiologies-hypoglycemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-hypoglycemia/</guid><description>Etiologies-hypoglycemia Pts w/ diabetes: excess insulin, oral hypoglycemics, missed meals, renal failure (↓ insulin &amp;amp; SU clearance); β-blockers can mask adrenergic symptoms of hypoglycemia Pt without diabetes: low fasting glucose w/o sx can be normal ↑ insulin: exogenous insulin, sulfonylureas, insulinoma, anti-insulin antibodies ↓ glucose production: hypopituitarism, adrenal insufficiency, glucagon deficiency, hepatic failure, renal failure, CHF, alcoholism, sepsis, severe malnutrition Postprandial, esp.</description></item><item><title>Etiologies-hypopituitary syndromes</title><link>https://htlin222.github.io/garden/Etiologies-hypopituitary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-hypopituitary-syndromes/</guid><description>Etiologies-hypopituitary syndromes Primary: surgery radiation (develops after avg 4–5 y), tumors (primary or metastatic), infection infiltration (sarcoid, hemochromatosis) autoimmune ischemia (including Sheehan’s syndrome caused by pituitary infarction intrapartum), carotid aneurysms cavernous sinus thrombosis trauma medications (eg, ipilimumab) apoplexy empty sella genetic Secondary: (hypothalamic dysfunction or stalk interruption): tumors (including craniopharyngioma) infection infiltration radiation surgery trauma</description></item><item><title>Etiologies-of thrombocytopenia</title><link>https://htlin222.github.io/garden/Etiologies-of-thrombocytopenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-thrombocytopenia/</guid><description>Etiologies-of thrombocytopenia ↓ production Hypocellular bone marrow: aplastic anemia (qv), rarely MDS, drugs (eg, thiazides, antibiotics, chemotherapy), alcohol, cirrhosis, viral infection</description></item><item><title>Etiologies-of-AG-Metabolic-Acidosis</title><link>https://htlin222.github.io/garden/Etiologies-of-AG-Metabolic-Acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-AG-Metabolic-Acidosis/</guid><description>Etiologies-of-AG-Metabolic-Acidosis “GOLD MARK” = Glycols, Oxoproline, Lactic, D-Lactic, Methanol, ASA, Renal, Ketoacidosis
[[diabetic ketoacidosis]] Diabetes mellitus, alcoholism, starvation (NEJM 2015;372:546)</description></item><item><title>Etiologies-of-Metabolic-Alkalosis</title><link>https://htlin222.github.io/garden/Etiologies-of-Metabolic-Alkalosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-of-Metabolic-Alkalosis/</guid><description>Etiologies-of-Metabolic-Alkalosis Saline responsive UCl &amp;lt;25
GI loss of H+: emesis, NGT suction, villous adenoma, chloridorrhea Renal loss: loop/thiazide, ↓ Cl intake, milk-alkali, Pendred syndrome Posthypercapnia(bilevel positive airway pressure for chronic obstructive pulmonary disease AE), sweat losses in cystic fibrosis Saline resistant UCl &amp;gt;40</description></item><item><title>Etiologies-pancytopenia</title><link>https://htlin222.github.io/garden/Etiologies-pancytopenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-pancytopenia/</guid><description>Etiologies-pancytopenia Hypocellular bone marrow (nl cellularity ~100 – age): aplastic anemia, hypoplastic MDS
Cellular bone marrow: MDS, aleukemic leukemia, PNH, severe megaloblastic anemia</description></item><item><title>Etiologies-pulmonary hypertension</title><link>https://htlin222.github.io/garden/Etiologies-pulmonary-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-pulmonary-hypertension/</guid><description>Etiologies-pulmonary hypertension Primary pulmonary arterial HTN (PAH) (group 1) Precapillary PHT PCWP ≤15 mmHg ↑ transpulm grad ↑ PVR
Idiopathic (IPAH): yearly incidence 1–2 per million; mean age of onset 36 y (♂ older than ♀); ♂: ♀ = ~2:1, usually mild ↑ in PAP Familial (FPAH) Associated conditions (APAH) Connective tissue dis.</description></item><item><title>Etiologies-solitary pulmonary nodule</title><link>https://htlin222.github.io/garden/Etiologies-solitary-pulmonary-nodule/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-solitary-pulmonary-nodule/</guid><description>Etiologies-solitary pulmonary nodule Benign (70%) Granuloma (80%): TB, histo, coccidio Hamartoma (10%) Bronchogenic cyst, AVM, pulm infarct Echinococcosis, ascariasis, aspergilloma GPA, rheumatoid nodule, sarcoidosis Lipoma, fibroma, amyloidoma</description></item><item><title>Etiologies-syncope</title><link>https://htlin222.github.io/garden/Etiologies-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-syncope/</guid><description>Etiologies-syncope Vasovagal (a.k.a. neurocardiogenic, ~25%): ↑ sympathetic tone → vigorous contraction of LV → LV mechanoreceptors trigger ↑ vagal tone (hyperactive Bezold-Jarisch reflex) → ↓ HR (cardioinhib.</description></item><item><title>Etiologies-wide-complex tachycardias WCTS</title><link>https://htlin222.github.io/garden/Etiologies-wide-complex-tachycardias-WCTS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiologies-wide-complex-tachycardias-WCTS/</guid><description>Etiologies-wide-complex tachycardias (WCTS) (Lancet 2012;380:1520)
Ventricular tachycardia (VT): accounts for 80% of WCT in unselected population SVT conducted with aberrancy: either fixed BBB, rate-dependent BBB (usually RBBB), conduction via an accessory pathway or atrially triggered ventricular pacing</description></item><item><title>Etiology-acute liver failure</title><link>https://htlin222.github.io/garden/Etiology-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-acute-liver-failure/</guid><description>Etiology-acute liver failure (J Hepatol 2015;62:S112)
[[Drugs and toxins that cause acute liver failure]]
Viral: HAV, HBV, HCV (rare), HDV + HBV, HEV (esp.</description></item><item><title>Etiology-aortic-regurgitation</title><link>https://htlin222.github.io/garden/Etiology-aortic-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-aortic-regurgitation/</guid><description>Etiology-aortic-regurgitation Valve disease (43%): rheumatic (usually mixed AS/AR + MV disease); bicuspid AoV (natural hx: ⅓→ normal, ⅓→ AS, ⅙→ AR, ⅙→ endocarditis → AR); infective endocarditis; valvulitis (RA, SLE, certain anorectics &amp;amp; serotonergics, XRT) Root disease (57%): HTN, aortic aneurysm/dissection, annuloaortic ectasia (ie, Marfan), aortic inflammation (GCA, Takayasu’s, ankylosing spond.</description></item><item><title>Etiology-aortic-stenosis</title><link>https://htlin222.github.io/garden/Etiology-aortic-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-aortic-stenosis/</guid><description>Etiology-aortic-stenosis Calcific: predominant cause in Pts &amp;gt;70 y; risk factors: HTN, ↑ LDL-C, ↑ Lp(a), ESRD Congenital (ie, bicuspid AoV w/ premature calcification): cause in 50% of Pts &amp;lt;70 y Rheumatic heart disease (AS usually accompanied by AR and MV disease) AS mimickers: subvalvular (HCMP, subaortic membrane) or supravalvular stenosis</description></item><item><title>Etiology-constrictive pericarditis</title><link>https://htlin222.github.io/garden/Etiology-constrictive-pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-constrictive-pericarditis/</guid><description>Etiology-constrictive pericarditis (Circ 2011;124:1270)
Any cause of pericarditis (~1–2% incidence overall after acute pericarditis) Highest risk w/ TB, bacterial, neoplastic, XRT, connective tissue, postcardiac surgery Viral/idiopathic, b/c most common cause of pericarditis, also account for signif proportion</description></item><item><title>Etiology-epidural abscess</title><link>https://htlin222.github.io/garden/Etiology-epidural-abscess/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-epidural-abscess/</guid><description>Etiology-epidural abscess Hematogenous spread (⅔): skin infection, soft tissue (dental abscess), or endocarditis Direct extension (⅓): vertebral osteo, sacral ulcer, spinal anesthesia or surgery, LP Risk factors: IVDU diabetes, renal failure, alcoholism, immunosuppression S.</description></item><item><title>Etiology-mitral-regurgitation</title><link>https://htlin222.github.io/garden/Etiology-mitral-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-mitral-regurgitation/</guid><description>Etiology-mitral-regurgitation Valve disease (43%): rheumatic (usually mixed AS/AR + MV disease); bicuspid AoV (natural hx: ⅓→ normal, ⅓→ AS, ⅙→ AR, ⅙→ endocarditis → AR); infective endocarditis; valvulitis (RA, SLE, certain anorectics &amp;amp; serotonergics, XRT) Root disease (57%): HTN, aortic aneurysm/dissection, annuloaortic ectasia (ie, Marfan), aortic inflammation (GCA, Takayasu’s, ankylosing spond.</description></item><item><title>Etiology-mitral-stenosis</title><link>https://htlin222.github.io/garden/Etiology-mitral-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-mitral-stenosis/</guid><description>Etiology-mitral-stenosis Rheumatic heart disease (RHD): fusion of commissures → “fish-mouth” valve from autoimmune rxn to β strep infxn; seen largely in developing world (Circ 2020;142:e337) Mitral annular calcification: encroachment upon leaflets → fxnal MS; espec in ESRD Postsurgical repair or post-TEER w/ reduced mitral valve area (MVA) Congenital, infectious endocarditis w/ large lesion, myxoma near MV, thrombus Valvulitis (eg, SLE, amyloid, carcinoid) or infiltration (eg, mucopolysaccharidoses)</description></item><item><title>Etiology-osteomyelitis</title><link>https://htlin222.github.io/garden/Etiology-osteomyelitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-osteomyelitis/</guid><description>Etiology-osteomyelitis (Lancet 2004;364:369)
Hematogenous: S. aureus; mycobacterial infection of vertebral body = Pott’s disease Contiguous focus (may be acute or chronic) Open fracture, orthopedic surgery, etc.</description></item><item><title>Etiology-pericardial tamponade</title><link>https://htlin222.github.io/garden/Etiology-pericardial-tamponade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Etiology-pericardial-tamponade/</guid><description>Etiology-pericardial tamponade Any cause of pericarditis but espec malignancy, infectious, uremia, ascending AoD, myocardial rupture, periprocedural complication, trauma, post-cardiotomy Rapidly accumulating effusions most likely to cause tamponade b/c no time for pericardium to stretch (eg, to ↑ compliance) and accommodate ↑ intrapericardial fluid volume</description></item><item><title>Euvolemic-hypotonic-hyponatremia</title><link>https://htlin222.github.io/garden/Euvolemic-hypotonic-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Euvolemic-hypotonic-hyponatremia/</guid><description>Euvolemic-hypotonic-hyponatremia (ie, ↑ TBW relative to total body Na)
[[SIADH]]
Endocrinopathies: ↑ ADH activity seen in glucocorticoid deficiency (co-secretion of ADH &amp;amp; CRH) and severe hypothyroidism/myxedema coma (↓ CO/SVR → ADH release &amp;amp; ↓ GFR)</description></item><item><title>Evaluation acute diarrhea</title><link>https://htlin222.github.io/garden/Evaluation-acute-diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-acute-diarrhea/</guid><description>Evaluation acute diarrhea (NEJM 2014;370:1532; Digestion 2017;95:293; PLOS One 2017;12:11)
Ddx: hyperthyroid, adrenal insufficiency, meds (abx, antacids, immune checkpt inhibitors), appendicitis, diverticulitis, radiation, 1st presentation of bowel disorder (eg, IBD, celiac)</description></item><item><title>Evaluation for the potential causes of heart failure</title><link>https://htlin222.github.io/garden/Evaluation-for-the-potential-causes-of-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-for-the-potential-causes-of-heart-failure/</guid><description>Evaluation for the potential causes of heart failure ECG: evidence for CAD, LVH, LAE, heart block or low voltage (?</description></item><item><title>Evaluation for the presence of heart failure</title><link>https://htlin222.github.io/garden/Evaluation-for-the-presence-of-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-for-the-presence-of-heart-failure/</guid><description>Evaluation for the presence of heart failure CXR (see Radiology insert): pulm edema, pleural effusions ± cardiomegaly, cephalization, Kerley B-lines; lung U/S better than CXR (PPV &amp;amp; NPV 92% vs.</description></item><item><title>Evaluation in patients without diabetes- but have hypoglycemia</title><link>https://htlin222.github.io/garden/Evaluation-in-patients-without-diabetes-but-have-hypoglycemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-in-patients-without-diabetes-but-have-hypoglycemia/</guid><description>Evaluation in patients without diabetes- but have hypoglycemia (JCEM 2009;94:709)
If clinically ill: take measures to avoid recurrent hypoglycemia; ✓ BUN, Cr, LFTs, TFTs, prealbumin; IGF-I/IGF-II ratio when appropriate If otherwise healthy: 72-h fast w/ monitored blood glc; stop for neuroglycopenic sx At time of hypoglycemia: insulin, C peptide (↑ w/ insulinoma and sulfonylureas, ↓ w/ exogenous insulin), β-OH-butyrate, sulfonylurea levels At end of fast, give 1 mg glucagon IV and measure response of plasma glc before feeding</description></item><item><title>Evaluation of Suspected HIT</title><link>https://htlin222.github.io/garden/Evaluation-of-Suspected-HIT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-of-Suspected-HIT/</guid><description>Evaluation of Suspected HIT [[Diagnosis of heparin-induced thrombocytopenia]]
(4T’s)
Thrombocytopenia ↓ &amp;gt;50% and nadir ≥20k</description></item><item><title>Evaluation of vasculitis</title><link>https://htlin222.github.io/garden/Evaluation-of-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-of-vasculitis/</guid><description>Evaluation of vasculitis complete blood count (CBC) (with differential) inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) blood urea nitrogen (BUN)/creatinine levels chest x-ray liver function panel urinalysis antineutrophil cytoplasmic antibody (ANCA) electrolytes [[Principles of Imaging in Vasculitides]]</description></item><item><title>Evaluation-ascites</title><link>https://htlin222.github.io/garden/Evaluation-ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-ascites/</guid><description>Evaluation-ascites (World J Hepatol 2013;5:251; JAMA 2016;316:340)
Physical exam: flank dullness (&amp;gt;1500 mL needed), shifting dullness (Se ~83%) Radiologic: U/S detects &amp;gt;100 mL fluid; MRI/CT (also help with Ddx) Paracentesis: perform in all Pts w/ new ascites, suggested in all hosp.</description></item><item><title>Evaluation-asthma-EXACERBATION</title><link>https://htlin222.github.io/garden/Evaluation-asthma-EXACERBATION/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-asthma-EXACERBATION/</guid><description>Evaluation-asthma-EXACERBATION History: baseline PEF, steroid requirement, ED visits, hospital admissions, prior intubation Current exacerbation: duration, severity, potential precipitants, meds used</description></item><item><title>Evaluation-dyspnea</title><link>https://htlin222.github.io/garden/Evaluation-dyspnea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evaluation-dyspnea/</guid><description>Evaluation-dyspnea History: quality of sensation, tempo, positional dependence, exac./allev. factors, exertion
除了劇烈運動外，不會因呼吸困難而煩惱。 在平坦的地面上行走或在小山坡上行走時呼吸短促。 由於呼吸困難，在平地上走得比同齡人慢，或在平地上以自己的步調行走時不得不停下來休息。 步行 100 m 或平地步行幾分鐘後停止休息。 氣喘吁吁離開家，或日常生活活動氣喘吁籲 （例如，穿衣/脫衣） Cardiopulmonary exam, SaO2, CXR, ECG, ABG, U/S Predictors of CHF: h/o CHF, PND, S3, CXR w/ venous congestion, AF (JAMA 2005;294:1944) Dyspnea w/ nl CXR: CAD, asthma, PE, PHT, early ILD, anemia, acidosis, NM disease Based on results of initial evaluation: PFT, chest CT, TTE, cardiopulmonary testing BNP &amp;amp; NT-proBNP ↑ in CHF (also ↑ in AF, RV strain from PE, COPD flare, PHT, ARDS) &amp;lt;100 pg/mL to r/o CHF (90% Se), 400 to r/i (NEJM 2002;347:161) NT-proBNP</description></item><item><title>Evolution of Necrotizing Fasciitis or Myonecrosis</title><link>https://htlin222.github.io/garden/Evolution-of-Necrotizing-Fasciitis-or-Myonecrosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Evolution-of-Necrotizing-Fasciitis-or-Myonecrosis/</guid><description>Evolution of Necrotizing Fasciitis or Myonecrosis</description></item><item><title>Excruciatingly Useful Shortcuts</title><link>https://htlin222.github.io/garden/Excruciatingly-Useful-Shortcuts/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Excruciatingly-Useful-Shortcuts/</guid><description>In the order of most to least useful:
⌘ L Place insertion point in search/title area Escape Clear current search Return Begin editing note, creating it if necessary Tab Move insertion point between text areas ⌘ K Select previous note in list ⌘ J Select next note in list ⌘ D De-select current note, restoring the search text ⌘ ⇧ V Paste clipboard as a new note ⌘ R Rename the selected note ⌘ ⌫ Delete the selected note(s) ⌘ ⇧ T Tag the selected note ⌘ G Find next occurrence of search text ⌘ ⇧ G Find previous occurrence of search text ⌘ ↩ Open any URL under the insertion point ⌘ ← Move to title-editing when at start of the note-body ⌘ → Move to the note-body when at the end of a title ⌘ ⇧ D Bookmark the selected note ⌘ P Print the selected note(s) ⌘ E Export the selected note(s) to other formats</description></item><item><title>excursion</title><link>https://htlin222.github.io/garden/excursion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/excursion/</guid><description>excursion Wandering from the usual course. The extent of movement of a part such as the extremities or eyes. In diabetes, an increase in blood glucose levels above normal or typical values, esp.</description></item><item><title>Exercise-tolerance-test</title><link>https://htlin222.github.io/garden/Exercise-tolerance-test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Exercise-tolerance-test/</guid><description>Exercise-tolerance-test Generally preferred if Pt can meaningfully exercise; ECG ∆s w/ Se ~65%, Sp ~80%
Typically via treadmill w/ Bruce protocol (modified Bruce or submax if decond.</description></item><item><title>Exposure-interstitial lung disease</title><link>https://htlin222.github.io/garden/Exposure-interstitial-lung-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Exposure-interstitial-lung-disease/</guid><description>Exposure-interstitial lung disease Drugs/Iatrogenic Amiodarone: interstitial pneumonitis ↔ org. PNA ↔ ARDS; Rx: d/c amio; steroids
Other drugs: nitrofurantoin, sulfonamides, inh, hydralazine</description></item><item><title>Extended DOAC strategies-venous thromboembolism</title><link>https://htlin222.github.io/garden/Extended-DOAC-strategies-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Extended-DOAC-strategies-venous-thromboembolism/</guid><description>Extended DOAC strategies-venous thromboembolism After ≥6 mo of anticoag, following regimens compared w/ no extended Rx (or ASA): Full-dose DOAC: * 80–90% ↓ recurrent VTE, 2–5× bleeding, * but no signif excess in major bleeding * (NEJM 2010;363:2499; 2013;368:699 &amp;amp; 709) ½ dose apixa or riva: * ≥75% ↓ recur.</description></item><item><title>Extrapulmonary TB</title><link>https://htlin222.github.io/garden/Extrapulmonary-TB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Extrapulmonary-TB/</guid><description>Extrapulmonary TB Pleural/pericardial effusions or ascites: fluid sampling for AFB cx/smear, NAAT/ PCR, cell counts. Adenosine deaminase (ADA) can be ↑, best validated in ascites.</description></item><item><title>Extrarenal H2O loss Uosm >700–800</title><link>https://htlin222.github.io/garden/Extrarenal-H2O-loss-Uosm-700800/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Extrarenal-H2O-loss-Uosm-700800/</guid><description>Extrarenal H2O loss (Uosm &amp;gt;700–800) GI H2O loss: vomiting, NGT drainage, osmotic diarrhea, fistula, lactulose, malabsorption
Insensible loss: fever, exercise, ventilation, burns</description></item><item><title>Exudates</title><link>https://htlin222.github.io/garden/Exudates/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Exudates/</guid><description>Exudates Lung parenchymal infection (25%) Bacterial (parapneumonic): can evolve along spectrum of exudative (but sterile) → fibropurulent (infected fluid) → organization (fibrosis &amp;amp; formation of rigid pleural peel).</description></item><item><title>Factitious disorder</title><link>https://htlin222.github.io/garden/Factitious-disorder/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Factitious-disorder/</guid><description>Factitious disorder 所以裝病症候群診斷的三個條件：
1.故意表現出一些身體或心理的症狀
2.很單純的只是要伴演病人的角色
3.不能有其他的附帶價值或收獲
還有一種裝病是宣稱他所照顧的人生病，而這個病人必須要仰賴這個宣稱者的照顧（如：母親與小孩的關係）；引起裝病的原因目前的解釋是說，在生長過程中一直受到忽略或放棄，所以希望變成一個病人，從新獲得重視、價值及取得相互依賴的感覺。另一種是藉由裝病騙過醫生，可以得到一種快感；如果是宣稱被照顧的人生病，那這被照顧者是被利用成為工具來獲取上列所說的一些結果。有時媽媽從婚姻中無法得到想要得到的滿足，藉著小朋友的生病有機會照顧他，來滿足自己的不滿足。
裝病的人症狀特質有：經常不停的去看醫生、對一些醫學病名及治療方式都瞭若指掌，甚至可以使用一些醫學名詞、症狀表現又非常戲劇化，如果醫生要叫他做某些檢查，即使有一些危險性，都會毫不考慮答應，甚至樂於接受，有時連開刀也一樣。如果可以偷偷觀察，就會發現不管是自己的症狀或是照顧他人的裝病，都會必須在有人的時候才會發生，因為為了裝病，有時會附帶其他的事需要隱瞞，但往往都是由這些開始被人注意的（例如：謊稱自己是某公司的主管，為了生病而丟了工作，但從沒看過他的同事來看他。)
【治療】
1.主要是以心理治療為主，也瞭解病人的背景以及生活上的需要，與病人立良好的關係 2.某些抗憂鬱的藥物也可以幫上一些忙
3.對於他裝病的事實要用和緩的態度去慢慢破解，才不會有反效果
4.通常病人都還堅持自己不是裝病，雖然週遭的人都不太相信即使事實已經很明顯</description></item><item><title>factitious fever</title><link>https://htlin222.github.io/garden/factitious-fever/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/factitious-fever/</guid><description>factitious fever ✨重點: 一種自我誘發的人工發熱（來自拉丁語factitius，由藝術製造）。 這可能以多種方式發生，最常見的是在溫度檢查之前攝入（和嘴巴含住）熱液體。 人為的發燒通常（但不總是）可以通過測量直腸溫度（甚至可以作為懲罰性威懾）或排尿時的尿溫來抵消。 如果這樣做，請記住尿溫略低於口腔溫度。</description></item><item><title>Familial Mediterranean fever</title><link>https://htlin222.github.io/garden/Familial-Mediterranean-fever/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Familial-Mediterranean-fever/</guid><description>Familial Mediterranean fever (peritonitis, episodic fever, pleuritis; ↑ WBC &amp;amp; ESR during attacks);</description></item><item><title>Family history of migraine</title><link>https://htlin222.github.io/garden/Family-history-of-migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Family-history-of-migraine/</guid><description>Family history of migraine Migraine has a strong genetic component and its prevalence is higher among people with directly affected first-degree relatives than among the general population18,19.</description></item><item><title>Fanconi’s syndrome</title><link>https://htlin222.github.io/garden/Fanconis-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fanconis-syndrome/</guid><description>Fanconi’s syndrome Proximal convoluted tubule 多尿、多飲及脫水。</description></item><item><title>Febrile nonhemolytic</title><link>https://htlin222.github.io/garden/Febrile-nonhemolytic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Febrile-nonhemolytic/</guid><description>Febrile nonhemolytic : fever, rigors 0–6 h post transfusion. Due to Abs vs. donor WBCs and cytokines in blood product. Rx: acetaminophen ± meperidine; r/o infection, hemolysis.</description></item><item><title>fever and neutropenia</title><link>https://htlin222.github.io/garden/fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fever-and-neutropenia/</guid><description>fever and neutropenia [[fever in oncology - duty note]]
[[Definition of fever and neutropenia]] [[Pathophysiology and microbiology of fever and neutropenia]] [[Prevention of fever and neutropenia]] (only if intermediate or high-risk) [[Role of hematopoietic growth factors]] [[Diagnostic evaluation of fever and neutropenia]] [[Risk stratification of fever and neutropenia]] (factors that predict lower risk) [[Initial antibiotic therapy of fever and neutropenia]] [[Modification to initial antibiotic regimen based on site-specific evaluation of fever and neutropenia]] [[Duration of therapy of fever and neutropenia]]</description></item><item><title>fever and rash</title><link>https://htlin222.github.io/garden/fever-and-rash/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fever-and-rash/</guid><description>fever and rash Approach to diagnostic workup
Meningococcemia, endocarditis, RMSF, sepsis, &amp;amp; toxic shock need urgent dx &amp;amp; Rx Workup: CBC w/diff, BMP, LFTs, LDH, CK, U/A, HIV Ag/Ab ± PCR, BCx off abx) To narrow Ddx: characterize time course of rash, progression, &amp;amp; morphology [[Erythema multiforme]] [[Erythema nodosum]] [[Variable and Possible Etiology-fever and rash]] Treatment</description></item><item><title>fever in a returned traveler</title><link>https://htlin222.github.io/garden/fever-in-a-returned-traveler/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fever-in-a-returned-traveler/</guid><description>fever in a returned traveler See CDC.gov/travel for up to date information on regional risks and recommendations [[Region or Exposure Common Etiologies -fever in a returned traveler]]</description></item><item><title>fever in oncology - duty note</title><link>https://htlin222.github.io/garden/fever-in-oncology-duty-note/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fever-in-oncology-duty-note/</guid><description>fever in oncology - duty note ECOG 0–1, age &amp;lt;60 y, solid tumor, no sx, no major comorbidities, no h/o fungal infection, [[MASCC Risk Index]] ≥21 (Support Care Cancer 2013;21:1487)</description></item><item><title>fever of unknown origin</title><link>https://htlin222.github.io/garden/fever-of-unknown-origin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fever-of-unknown-origin/</guid><description>fever of unknown origin Definition &amp;amp; etiologies (NEJM 2022;386:463) Fever (as per above def) on &amp;gt;1 occasion during ≥3 wk &amp;amp; no dx despite 1 wk of evaluation More likely to be unusual manifestation of common disease than an uncommon disease In Pts with HIV: &amp;gt;75% causes are infectious, but rarely due to HIV itself Frequent reassessment needed to identify focal signs and progression of disease [[Etiologies of Classic FUO]] [[Workup-fever of unknown origin]] (Archives 2009;169:2018; AJM 2015;128:1138) [[Treatment-fever of unknown origin]]</description></item><item><title>fever syndromes</title><link>https://htlin222.github.io/garden/fever-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fever-syndromes/</guid><description>fever syndromes Temperature ≥100.4°F or ≥38°C [[What are the most commonly encountered fever patterns]] [[physical findings may help identify the cause of a fever]]</description></item><item><title>Fever workup in patient with HIV AIDS</title><link>https://htlin222.github.io/garden/Fever-workup-in-patient-with-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fever-workup-in-patient-with-HIV-AIDS/</guid><description>Fever workup in patient with HIV AIDS Etiologies (Infect Dis Clin North Am 2007;21:1013) infxn (82–90%): MAC, TB, CMV, early PCP, Histo, Crypto, Coccidio, Toxo, endocarditis noninfectious: lymphoma, drug reaction.</description></item><item><title>Fibrinolysis vs Hospital Transfer for Primary PCI</title><link>https://htlin222.github.io/garden/Fibrinolysis-vs-Hospital-Transfer-for-Primary-PCI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fibrinolysis-vs-Hospital-Transfer-for-Primary-PCI/</guid><description>1.Time required for transport to skilled PCI lab: door-to-balloon &amp;lt;120 min &amp;amp; [door-to-balloon]–[door-to-needle] &amp;lt;1 h favors transfer for PCI
2.Risk from STEMI: high-risk Pts (eg, shock) fare better with mechanical reperfusion</description></item><item><title>Fibromuscular dysplasia</title><link>https://htlin222.github.io/garden/Fibromuscular-dysplasia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fibromuscular-dysplasia/</guid><description>Fibromuscular dysplasia 纖維肌發育不良（FMD）是腎動脈狹窄的重要原因，尤其是在年輕女性中。 據報導，FMD和Alpha 1-抗抗蛋白酶（Alpha 1-AT）缺乏症之間存在罕見的關聯。</description></item><item><title>file1at1031</title><link>https://htlin222.github.io/garden/file1at1031/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/file1at1031/</guid><description/></item><item><title>First-line or upfront therapy for idiopathic thrombocytopenic purpura</title><link>https://htlin222.github.io/garden/First-line-or-upfront-therapy-for-idiopathic-thrombocytopenic-purpura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/First-line-or-upfront-therapy-for-idiopathic-thrombocytopenic-purpura/</guid><description>First-line or upfront therapy for idiopathic thrombocytopenic purpura Steroids: prednisone 0.5–2 mg/kg/d PO tapered ~4 wk, or dexamethasone 40 mg PO × 4 d</description></item><item><title>Flecainide</title><link>https://htlin222.github.io/garden/Flecainide/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Flecainide/</guid><description>Flecainide 300 mg PO x1 100-150 mg bid PreRx w/ AVN blocker. avoid if: structural/ischemic heart dis.
%
Backlink: [[Antiarrhythmic Drugs (AAD) for AF]]</description></item><item><title>Fluid Resuscitation</title><link>https://htlin222.github.io/garden/Fluid-Resuscitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fluid-Resuscitation/</guid><description>Fluid Resuscitation [[sensible and insensible fluid losses]] [[classes of hemorrhagic shock]] [[empiric replacement fluids can be used for fluid losses]]</description></item><item><title>Fluids-sepsis and shock</title><link>https://htlin222.github.io/garden/Fluids-sepsis-and-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fluids-sepsis-and-shock/</guid><description>Fluids-sepsis and shock Aggressive IV fluid resuscitation (30 mL/kg) admin in boluses w/in 3 h of presentation Crystalloid as good as colloid for resuscitation (JAMA 2013;310:1809; NEJM 2014;370:1412) No consistently seen benefit of balanced crystalloid (LR, Plasma-Lyte) vs.</description></item><item><title>Focal segmental glomerulosclerosis</title><link>https://htlin222.github.io/garden/Focal-segmental-glomerulosclerosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Focal-segmental-glomerulosclerosis/</guid><description>Focal segmental glomerulosclerosis (40%; CJASN 2017;12:502).
Primary: permeability factor.
Secondary adaptive (hyperfiltration, sickle cell, obesity, anabolic steroids, OSA, ↑ protein, vesico-ureteral reflux); meds/toxins (IFN, bisphosphonates, NSAIDs, heroin), viral (COVID-19, HIV) or genetic (ApoL1 mutation in AA; JASN 2015;26:1443).</description></item><item><title>Focused history of chest pain</title><link>https://htlin222.github.io/garden/Focused-history-of-chest-pain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Focused-history-of-chest-pain/</guid><description>Focused history of chest pain quality, severity, location, radiation; provoking/palliating factors; intensity at onset; duration, freq, &amp;amp; pattern; setting; assoc sx; cardiac hx &amp;amp; risk factors</description></item><item><title>Folate deficiency</title><link>https://htlin222.github.io/garden/Folate-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Folate-deficiency/</guid><description>Folate deficiency Folate present in leafy green vegetables and fruit; total body stores sufficient for 2–3 mo
Etiologies: malnutrition (alcoholics, anorectics, elderly), ↓ absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim; NEJM 2015;373:1649), ↑ requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis)</description></item><item><title>Follicular thyroid cancer</title><link>https://htlin222.github.io/garden/Follicular-thyroid-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Follicular-thyroid-cancer/</guid><description>Follicular thyroid cancer Peak incidence 40 to 60 y, ♀:♂ 3:1; RFs: childhood radiation; FHx; familial syndrome Mortality 10–20% at 20 y; mets frequently distal due to hematogenous spread Hurthle cell carcinoma: pathologic dx; variant a/w poorer prognosis and ↑ recurrence rate</description></item><item><title>Follow-up, treatment response and failure of Migraine</title><link>https://htlin222.github.io/garden/Follow-up-treatment-response-and-failure-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Follow-up-treatment-response-and-failure-of-Migraine/</guid><description>Follow-up, treatment response and failure of Migraine Use headache calendars Assess effectiveness and adverse events When outcomes are suboptimal, review diagnosis, treatment strategy, dosing and adherence When treatment fails, re-evaluate before changing Referral to specialist care should be reserved for patients whose condition is diagnostically challenging, difficult to treat or complicated by comorbidities</description></item><item><title>Follow-up-aortic aneurysms</title><link>https://htlin222.github.io/garden/Follow-up-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Follow-up-aortic-aneurysms/</guid><description>Follow-up-aortic aneurysms (Circ 2010;121:e266; Nat Rev Cardiol 2011;8:92; JAMA 2013;309:806)
Expansion rate ~0.1 cm/y for TAA, ~0.3–0.4 cm/y for AAA TAA: 6 mo after dx to ensure stable, and if stable, then annually (Circ 2005;111:816) AAA: &amp;lt;4 cm q2–3y; 4–5.</description></item><item><title>Fourth Universal Definition of Myocardial Infarction 2018</title><link>https://htlin222.github.io/garden/Fourth-Universal-Definition-of-Myocardial-Infarction-2018/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fourth-Universal-Definition-of-Myocardial-Infarction-2018/</guid><description>Fourth Universal Definition of Myocardial Infarction (2018) myocardial cell death due to prolonged ischemia Increases in cTnI values have not been reported to occur following injury to noncardiac tissues.</description></item><item><title>Fresh frozen plasma</title><link>https://htlin222.github.io/garden/Fresh-frozen-plasma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fresh-frozen-plasma/</guid><description>Fresh frozen plasma Contains all coagulation factors. For bleeding due to defic. of multiple coag factors (eg, DIC, TTP/HUS, liver disease, dilution).</description></item><item><title>Fresh H2O soft tissue infections</title><link>https://htlin222.github.io/garden/Fresh-H2O-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fresh-H2O-soft-tissue-infections/</guid><description>Fresh H2O soft tissue infections Aeromonas Myonecrosis/rhabdo can occur. FQ, TMP-SMX, or CTX</description></item><item><title>fromNonspecific Low Back Pain-metadata</title><link>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-Annotations-8122022-123726-AM-1/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-Annotations-8122022-123726-AM-1/</guid><description>fromNonspecific Low Back Pain-metadata</description></item><item><title>Functional GI disease</title><link>https://htlin222.github.io/garden/Functional-GI-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Functional-GI-disease/</guid><description>Functional GI disease (~30 types per Rome IV criteria; Gastro 2016;150:1257)
Recurrent GI sx caused by disorders of gut-brain interaction rather than structural cause</description></item><item><title>Functional IBS</title><link>https://htlin222.github.io/garden/Functional-IBS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Functional-IBS/</guid><description>Functional IBS (normal osmotic gap, ↓ diarrhea with fasting): see [[dysmotility and nutrition]]</description></item><item><title>Fungal diagnostics</title><link>https://htlin222.github.io/garden/Fungal-diagnostics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Fungal-diagnostics/</guid><description>Fungal diagnostics Antigen detection 1,3-β-D glucan (Se 75%, Sp 85%): 可以在哪些fungus看得到？ Candida, Aspergillus, Histo, Coccidio, PCP, for invasive infxn in immunocomp host.</description></item><item><title>fungal infections</title><link>https://htlin222.github.io/garden/fungal-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/fungal-infections/</guid><description>fungal infections [[Fungal diagnostics]] [[Candida species]] [[Aspergillosis]] (Lancet 2021;397:499) [[Zygomycetes]] (eg, Mucor, Rhizopus) ENDEMIC FUNGI [[Cryptococcus]] (CID 2010;50:291) [[Histoplasmosis]] [[Coccidioidomycosis]] (CID 2016;63:112) [[Blastomycosis]]</description></item><item><title>Further coagulation tests</title><link>https://htlin222.github.io/garden/Further-coagulation-tests/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Further-coagulation-tests/</guid><description>Further coagulation tests (JAMA 2016;316:2146)
Mixing study: useful if ↑ PT or PTT; mix Pt’s plasma 1:1 w/ normal plasma and retest PT/PTT normalizes → factor deficiency; PT/PTT remains elevated → factor inhibitor</description></item><item><title>Gardening</title><link>https://htlin222.github.io/garden/Gardening/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Gardening/</guid><description>Gardening Sporothrix Ulcerating nodules, lymphatic spread Itraconazole</description></item><item><title>gastroenterology</title><link>https://htlin222.github.io/garden/gastroenterology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/gastroenterology/</guid><description>gastroenterology [[esophageal and gastric disorders]] [[gastrointestinal bleeding]] [[diarrhea]] [[dysmotility and nutrition]] [[disorders of the colon]] [[inflammatory bowel disease]] [[intestinal ischemia]] [[pancreatitis]] [[abnormal liver tests]] [[hepatitis]] [[acute liver failure]] [[cirrhosis]] [[hepatic vascular disease]] [[ascites]] [[biliary tract disease]]</description></item><item><title>Gastroesophageal varices and UGIB-cirrhosis</title><link>https://htlin222.github.io/garden/Gastroesophageal-varices-and-UGIB-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Gastroesophageal-varices-and-UGIB-cirrhosis/</guid><description>Gastroesophageal varices and UGIB-cirrhosis See: [[gastrointestinal bleeding]]
Presence of varices correlates w/ severity of liver dis (40% of Child A Pts → 85% Child C)</description></item><item><title>gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/gastrointestinal-bleeding/</guid><description>gastrointestinal bleeding [[Definition-gastrointestinal bleeding]] [[Clinical manifestations-gastrointestinal bleeding]] [[Initial management-gastrointestinal bleeding]] [[Diagnostic studies-gastrointestinal bleeding]] Etiology UGIB Comment &amp;amp; Treatment (GI Endosc Clin N Am 2015;25:415)</description></item><item><title>Gastrointestinal hepatobiliary-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Gastrointestinal-hepatobiliary-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Gastrointestinal-hepatobiliary-complications-of-HIV-AIDS/</guid><description>Gastrointestinal hepatobiliary-complications of HIV AIDS Esophagitis: Candida, CMV (solitary, lg serpiginous), HSV (multiple, small shallow), giant aphthous ulcers, pills; EGD if no thrush or no response to empiric antifungals Enterocolitis: bacterial (esp.</description></item><item><title>gastrointestinal malignancies</title><link>https://htlin222.github.io/garden/gastrointestinal-malignancies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/gastrointestinal-malignancies/</guid><description>gastrointestinal malignancies [[colorectal cancer]] [[pancreatic tumors]] [[hepatocellular carcinoma]] (HCC) [[esophageal cancer]]</description></item><item><title>Gastroparesis</title><link>https://htlin222.github.io/garden/Gastroparesis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Gastroparesis/</guid><description>Gastroparesis (Nat Rev Dis Primers 2018;4:41)
Delayed gastric emptying w/o mechanical obstruction, typically p/w nausea (&amp;gt;90%), vomiting (&amp;gt;80%), early satiety (60%), postprandial fullness/pain</description></item><item><title>general approach to treatment of breast cancer</title><link>https://htlin222.github.io/garden/general-approach-to-treatment-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/general-approach-to-treatment-of-breast-cancer/</guid><description>general approach to treatment of breast cancer (JAMA 2019;321:288 &amp;amp; 1716)
DCIS Mastectomy or lumpectomy ± RT ± chemoprevention (Lancet 2016;387:849 &amp;amp; 866)</description></item><item><title>General considerations-diuresis</title><link>https://htlin222.github.io/garden/General-considerations-diuresis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/General-considerations-diuresis/</guid><description>General considerations-diuresis ↑ Na &amp;amp; H2O excretion for treatment of HTN or edema in CHF, renal failure, and cirrhosis</description></item><item><title>General evaluation or chronic diarrhea</title><link>https://htlin222.github.io/garden/General-evaluation-or-chronic-diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/General-evaluation-or-chronic-diarrhea/</guid><description>General evaluation or chronic diarrhea (JAMA 2016;315:2712; Gastro 2019;157:3)
Clinically can be classified as watery, fatty, inflammatory
Additional hx: timing (freq, relation to meals; nocturnal diarrhea a/w organic causes like IBD rather than IBS), abd pain, wt loss, prior surg, chemo/XRT, diet (incl caffeine or poorly absorbed carbs/sugars), infectious sxs, immunocompromise, travel, laxative use, stress</description></item><item><title>general oncology</title><link>https://htlin222.github.io/garden/general-oncology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/general-oncology/</guid><description>general oncology Cancer Epidemiology Cancer Prevention &amp;amp; Screening</description></item><item><title>General treatment-acute kidney injury AKI</title><link>https://htlin222.github.io/garden/General-treatment-acute-kidney-injury-AKI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/General-treatment-acute-kidney-injury-AKI/</guid><description>General treatment-acute kidney injury (AKI) (CJASN 2008;3:962)
Prerenal: isotonic IVF ≈ alb (NEJM 2004;350:22). No clear benefit of balanced crystalloids (eg, LR) over normal saline (NEJM 2018;378:829 &amp;amp; 2022;386:815).</description></item><item><title>General-renal replacement and dialysis</title><link>https://htlin222.github.io/garden/General-renal-replacement-and-dialysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/General-renal-replacement-and-dialysis/</guid><description>General-renal replacement and dialysis Acute indications: see “AKI”; choices CVVH vs. HD
Chronic indications: timing of RRT initiation should factor in Pt QoL, uremic sx, risk of development of urgent/acute indications; modalities PD vs.</description></item><item><title>Genetics of Diagnostic and staging evaluation of lung cancer</title><link>https://htlin222.github.io/garden/Genetics-of-Diagnostic-and-staging-evaluation-of-lung-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Genetics-of-Diagnostic-and-staging-evaluation-of-lung-cancer/</guid><description>Genetics of Diagnostic and staging evaluation of lung cancer (usually just in adv/metastatic disease):
EGFR (include in stage IIA-IIIB), ALK, ROS1, MET, KRAS, RET, BRAF, NTRK fusion for all non-squamous disease (incidence lower in SCC but still consider testing); PD-L1 expression</description></item><item><title>Genital Discharge</title><link>https://htlin222.github.io/garden/Genital-Discharge/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Genital-Discharge/</guid><description>Genital Discharge Gonorrhea (N. gonorrhoeae) &amp;amp; Chlamydia (C. trachomatis) ♀: Mucopurulent cervicitis, dysuria, PID; can be asx ♂: Urethritis, infxn of epididymis/prostate All: pharyngitis</description></item><item><title>Genital Lesions</title><link>https://htlin222.github.io/garden/Genital-Lesions/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Genital-Lesions/</guid><description>Genital Lesions Painless Syphilis (T. pallidum) 1°: chancre = firm, indurated, clean base 2°: fever, LAN, rash palms/soles, uveitis, condylomata lata 3°: aortitis/aneurysm, gumma, CN palsies (7/8), tabes dorsalis, aseptic meningitis Latent = asx; early latent &amp;lt;1yr; late &amp;gt;1yr/unknown</description></item><item><title>genitourinary malignancies</title><link>https://htlin222.github.io/garden/genitourinary-malignancies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/genitourinary-malignancies/</guid><description>genitourinary malignancies [[prostate cancer]] [[renal-cell-carcinoma]] [[urothelial carcinoma]]</description></item><item><title>geriatrics</title><link>https://htlin222.github.io/garden/geriatrics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/geriatrics/</guid><description>geriatrics The topics covered are organized as follows:
Falls Frailty Dementia Delirium Medication Management Geriatric Assessment
Other important topics related to geriatrics are covered in the following rotation guides:</description></item><item><title>GI potassium losses</title><link>https://htlin222.github.io/garden/GI-potassium-losses/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/GI-potassium-losses/</guid><description>GI potassium losses GI losses plus metabolic acidosis: diarrhea, laxative abuse, villous adenoma
Vomiting &amp;amp; NGT drainage usually manifest as renal losses due to 2° hyperaldo &amp;amp; met.</description></item><item><title>GI prophylaxis if taking ASA and nonsteroidal anti-inflam drug</title><link>https://htlin222.github.io/garden/GI-prophylaxis-if-taking-ASA-and-nonsteroidal-anti-inflam-drug/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/GI-prophylaxis-if-taking-ASA-and-nonsteroidal-anti-inflam-drug/</guid><description>GI prophylaxis if taking ASA and nonsteroidal anti-inflam drug (Am J Gastro 2009;104:728)
PPI if h/o PUD/UGIB and either (a) on P2Y12 inhib or anticoag, or (b) ≥2 of the following: &amp;gt;60 y, steroids or dyspepsia.</description></item><item><title>GI prophylaxis if taking ASA NSAID peptic ulcer disease</title><link>https://htlin222.github.io/garden/GI-prophylaxis-if-taking-ASA-NSAID-peptic-ulcer-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/GI-prophylaxis-if-taking-ASA-NSAID-peptic-ulcer-disease-/</guid><description>GI prophylaxis if taking ASA NSAID peptic ulcer disease (Am J Gastro 2009;104:728)
PPI if h/o PUD/UGIB and either (a) on P2Y12 inhib or anticoag, or (b) ≥2 of the following: &amp;gt;60 y, steroids or dyspepsia.</description></item><item><title>Giant cell arteritis</title><link>https://htlin222.github.io/garden/Giant-cell-arteritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Giant-cell-arteritis/</guid><description>Giant cell arteritis Females &amp;gt; 50 years old. 阿嫲
Unilateral headache, possible temporal artery tenderness, jaw claudication.</description></item><item><title>Glasgow-Blatchford</title><link>https://htlin222.github.io/garden/Glasgow-Blatchford/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Glasgow-Blatchford/</guid><description>Glasgow-Blatchford Glasgow-Blatchford scores range from 0 to 23, with higher scores indicating higher risk. Positive predictive values were calculated in a study by Laursen et al.</description></item><item><title>glomerular disease</title><link>https://htlin222.github.io/garden/glomerular-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/glomerular-disease/</guid><description>glomerular disease [[glomerulonephritis]] (GN) [[asymptomatic glomerular hematuria]] [[nephrotic syndrome]]</description></item><item><title>Glomerular Diseases</title><link>https://htlin222.github.io/garden/Glomerular-Diseases/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Glomerular-Diseases/</guid><description>Glomerular Diseases Backlink： [[nephrology]] [[nephrotic syndrome]] [[Primary glomerular diseases (grouped by pathology)]]</description></item><item><title>Glomerular proteinuria</title><link>https://htlin222.github.io/garden/Glomerular-proteinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Glomerular-proteinuria/</guid><description>Glomerular proteinuria (can be &amp;gt;3.5 g/d) Disruption of filtration barrier → lose albumin
Etiologies
Glomerulonephritis Nephrotic syndrome</description></item><item><title>glomerulonephritis</title><link>https://htlin222.github.io/garden/glomerulonephritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/glomerulonephritis/</guid><description>glomerulonephritis [[Definition-glomerulonephritis]] [[ANCA positive Vasculitis]] [[Anti-GBM Disease]] [[Immune Complex (IC) Disease (granular staining) ]] [[Oncology-related glomerulopathy]] [[Workup-glomerulonephritis]] [[Approach to glomerulonephritis based on immunofluorescence pattern]] [[Treatment-glomerulonephritis]]</description></item><item><title>Glucose of cerebrospinal fluid</title><link>https://htlin222.github.io/garden/Glucose-of-cerebrospinal-fluid/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Glucose-of-cerebrospinal-fluid/</guid><description>Glucose of cerebrospinal fluid 正常約 50–75 mg/dL，約是 serum 的 0.5–0.8 上升：通常是因為高血糖 下降：通常是 bacteria、TB、fungus、某些腫瘤 ↓↓ (&amp;lt;20)：通常是 bacteria ↓：TB、fungus、某些腫瘤 Viral meningitis、encephalitis 的 glucose 常常是正常的</description></item><item><title>glucose water osmolarity</title><link>https://htlin222.github.io/garden/glucose-water-osmolarity/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/glucose-water-osmolarity/</guid><description>glucose water osmolarity g/180 * 1000
速算：% * 50 = osm/L
e.g. D5W = 5*50 = 250 osm/L</description></item><item><title>Glucose-6-phosphate dehydrogenase</title><link>https://htlin222.github.io/garden/Glucose-6-phosphate-dehydrogenase/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Glucose-6-phosphate-dehydrogenase/</guid><description>Glucose-6-phosphate dehydrogenase (G6PD) deficiency (Lancet 2008;371:64)
X-linked defect of metabolism (G6PD mutations) w/ ↑ susceptibility to oxidative damage</description></item><item><title>Grading-of-Mitral-Stenosis</title><link>https://htlin222.github.io/garden/Grading-of-Mitral-Stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Grading-of-Mitral-Stenosis/</guid><description>Grading-of-Mitral-Stenosis Grading of Mitral Stenosis Stage Mean V (mmHg) Pressure ½ Time MVA (cm-) PA sys (mmHg) Normal 0 n/a 4-6 ＜25 Mild-mod &amp;lt;5 100-149 1.</description></item><item><title>Granulocytopenia or neutropenia</title><link>https://htlin222.github.io/garden/Granulocytopenia-or-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Granulocytopenia-or-neutropenia/</guid><description>Granulocytopenia or neutropenia (includes DM, ESRD → functional impairment) Bacteria: Gram positive: coag ⊖ staph, S. aureus, viridans strep, S. pneumo, other strep; Corynebacterium spp.</description></item><item><title>Granulomatosis with polyangiitis</title><link>https://htlin222.github.io/garden/Granulomatosis-with-polyangiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Granulomatosis-with-polyangiitis/</guid><description>Granulomatosis with polyangiitis GPA, formerly Wegener’s granulomatosis
Predominant type; can see either type (NEJM 2012;367:214);
Necrotizing granulomatous systemic vasculitis frequently affecting upper respiratory tract (nose, sinuses) in addition to kidneys, lower resp tract (lungs), and other organs</description></item><item><title>Graves’ disease</title><link>https://htlin222.github.io/garden/Graves-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Graves-disease/</guid><description>Graves’ disease ♀:♂ ratio is 5–10:1, most Pts between 40 and 60 y at dx ⊕ thyroid antibodies: TSI or TBII (⊕ in 80%), anti-TPO, antithyroglobulin; ANA Clinical manifestations in addition to those of hyperthyroidism (see above): Goiter: diffuse, nontender, w/ thyroid bruit Ophthalmopathy (NEJM 2010;362:726): seen in 50%; up to 90% if formally tested.</description></item><item><title>Growth hormone deficiency</title><link>https://htlin222.github.io/garden/Growth-hormone-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Growth-hormone-deficiency/</guid><description>Growth hormone deficiency ↓ GH
↑ chronic risk for osteoporosis, fatigue, decreased lean body mass Dx with failure to ↑ GH w/ appropriate stimulus (eg, insulin tolerance test, glucagon stimulation, and macimorelin stimulation) GH replacement in adults controversial (Annals 2003;35:419; NEJM 2019;380:2551)</description></item><item><title>HACEK</title><link>https://htlin222.github.io/garden/HACEK/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/HACEK/</guid><description>HACEK fastidious gram-negative bacilli
Haemophilus species, Aggregatibacter Cardiobacterium Eikenella Kingella 10% of [[culture negative-bacterial endocarditis]]</description></item><item><title>head injury</title><link>https://htlin222.github.io/garden/head-injury/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/head-injury/</guid><description>head injury 高風險標準（根據需要神經外科干預的終點得出）： 以下任何一項為陽性，行 CT 掃描：
意識、淤青(眼****)、骨折、老、吐
2小時內GCS &amp;lt;15
疑似開放性或凹陷性顱骨骨折
顱底骨折的任何跡象（鼓室血、浣熊眼、戰鬥徵——乳突瘀斑、腦脊液 [CSF] 耳漏或鼻漏、顱神經異常）(hemotympanum, raccoon eyes, Battle sign—mastoid ecchymosis, cerebrospinal fluid [CSF] otorrhea or rhinorrhea, cranial nerve abnormality)</description></item><item><title>headache</title><link>https://htlin222.github.io/garden/headache/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/headache/</guid><description>headache [[Primary headache syndromes]] [[Secondary causes of headaches]] [[Migraine]] [[Clinical evaluation of Secondary causes of headaches]] [[headaches from symptom to diagnosis]] Backlink： [[Acromegaly]] [[acute bacterial meningitis]] [[ambulatory]] [[Clinical manifestations of Giant cell arteritis]] [[Clinical manifestations-chronic obstructive pulmonary disease]] [[Clinical manifestations-hyperaldosteronism]] [[Clinical manifestations-pheochromocytoma and paraganglioma]] [[CSF leak]] [[Etiologies of Classic FUO]] [[Fever workup in patient with HIV AIDS]] [[hypoglycemia]] [[hypopituitary syndromes]] [[hypothyroidism]] [[neurology]] [[Pain]] [[Pituitary apoplexy]] [[Pituitary tumors]] [[Select clinical manifestations-fever in a returned traveler]] Approaching patients with headache and refractory headache</description></item><item><title>headaches from symptom to diagnosis</title><link>https://htlin222.github.io/garden/headaches-from-symptom-to-diagnosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/headaches-from-symptom-to-diagnosis/</guid><description>headaches from symptom to diagnosis is the headache new or old ? [[old headache]] [[new headache]]</description></item><item><title>heart failure</title><link>https://htlin222.github.io/garden/heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/heart-failure/</guid><description>heart failure [[Definitions heart failure]] (Braunwald’s Heart Disease, 12th ed., 2022) [[History heart failure]] [[New York Heart Association class]] [[Physical exam heart failure]] [[Evaluation for the presence of heart failure]] [[Evaluation for the potential causes of heart failure]] [[precipitants of acute heart failure]] [[Treatment of acute advanced heart failure]] [[Recommended Chronic Therapy by HF Stage]] [[Treatment of Chronic HF with Reduced EF]] [[Heart failure with preserved EF]]</description></item><item><title>Heart failure with preserved EF</title><link>https://htlin222.github.io/garden/Heart-failure-with-preserved-EF/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Heart-failure-with-preserved-EF/</guid><description>Heart failure with preserved EF (JACC 2022;epub)
Epidemiology: ~½ of Pts w/ HF have normal (EF ≥50%); risk factors for HFpEF incl ↑ age, ♀, DM, AF.</description></item><item><title>hectic fever</title><link>https://htlin222.github.io/garden/hectic-fever/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hectic-fever/</guid><description>hectic fever ✨重點: 來自希臘語 hektikos（習慣性），這是一種間歇性發燒，其特點是波動幅度很大，通常高於 2.5°F (1.4°C)。 它有一個典型的每日下午高峰，通常伴有面部潮紅，傳統上與活動性肺結核有關。</description></item><item><title>Hematologic Alterations</title><link>https://htlin222.github.io/garden/Hematologic-Alterations/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hematologic-Alterations/</guid><description>Hematologic Alterations Chapter 62: Interpreting Peripheral Blood Smears Chapter 63: Anemia and Polycythemia Chapter 64: Disorders of Granulocytes and Monocytes Chapter 65: Bleeding and Thrombosis Chapter 66: Enlargement of Lymph Nodes and Spleen</description></item><item><title>Hematologic oncologic-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Hematologic-oncologic-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hematologic-oncologic-complications-of-HIV-AIDS/</guid><description>Hematologic oncologic-complications of HIV AIDS (NEJM 2018;378:1029)
Cytopenia: ACD, BM infiltration by tumor/infxn (eg, MAC/TB), drug toxicity, hemolysis, ITP Non-Hodgkin lymphoma: ↑ frequency with any CD4 count, but incidence ↑ with ↓ CD4 Hodgkin lymphoma (any CD4; impact of ART unclear) CNS lymphoma: CD4 count &amp;lt;50, EBV-associated Kaposi’s sarcoma (HHV-8): at any CD4 count, incidence ↑ b/c CD4 ↓, usu.</description></item><item><title>hematology</title><link>https://htlin222.github.io/garden/hematology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hematology/</guid><description>hematology [[oncology]]
[[anemia]] [[disorders of hemostasis]] [[platelet disorders]] [[coagulopathies]] [[hypercoagulable states]] [[disorders of leukocytes]] [[transfusion therapy]] [[myelodysplastic syndromes]] [[myeloproliferative neoplasms]] [[leukemia]] [[lymphoma and CLL]] [[plasma cell dyscrasias]] [[hematopoietic stem cell transplantation]] [[lymphomas]] [[plasma cell disorders]] [[myeloproliferative disorders]] [[leukemias and myelodysplastic syndromes]] [[stem cell transplantation]] [[benign hematology]]</description></item><item><title>hematopoietic stem cell transplantation</title><link>https://htlin222.github.io/garden/hematopoietic-stem-cell-transplantation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hematopoietic-stem-cell-transplantation/</guid><description>hematopoietic stem cell transplantation graft-versus-host disease
急性 GVHD 可表現為斑丘疹、肝功能障礙和/或腹瀉，因為攻擊的主要目標是皮膚、肝臟和胃腸道 (GI)。
急性 GVHD 仍然是發病率和死亡率的主要原因，尤其是在無關的同種異體移植中。
早期識別和及時治療至關重要。
methotrexate, sirolimus, cyclosporine, and tacrolimus are used for prevention, glucocorticoids, ruxolitinib, and other immunosuppressive agents are used for treatment.</description></item><item><title>hematuria</title><link>https://htlin222.github.io/garden/hematuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hematuria/</guid><description>hematuria [[Etiologies of Hematuria]] [[Workup-of-hematuria]]
Backlink： [[asymptomatic glomerular hematuria]] [[Clinical manifestations of Granulomatosis with polyangiitis]] [[Clinical manifestations of IgA vasculitis]] [[Clinical manifestations of Polyarteritis nodosa]] [[Clinical manifestations-nephrolithiasis]] [[Clinical manifestations-urinary tract infections]] [[Definition-glomerulonephritis]] [[Diagnostic studies-urinary tract infections]] [[Dx studies of Granulomatosis with polyangiitis]] [[Etiologies of Hematuria]] [[glomerular disease]] [[hypertensive crises]] [[IgA nephropathy]] [[Neoplasm Etiologies of Classic FUO]] [[urinalysis]] [[Urine Dipstick]] [[Workup-acute kidney injury (AKI)]] [[Workup-of-hematuria]]</description></item><item><title>Hemochromatosis &amp; iron overload syndromes</title><link>https://htlin222.github.io/garden/Hemochromatosis-iron-overload-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hemochromatosis-iron-overload-syndromes/</guid><description>Hemochromatosis &amp;amp; iron overload syndromes (Am J Gastro 2019;114:1202)
Recessive disorder of iron sensing or transport leading to tissue iron deposition</description></item><item><title>Hemodialysis HD</title><link>https://htlin222.github.io/garden/Hemodialysis-HD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hemodialysis-HD/</guid><description>Hemodialysis (HD) Solute removal across semipermeable membrane, countercurrent blood &amp;amp; dialysate flow
Volume removal: Na/H2O ultrafiltered via transmembrane pressure (TMP) gradient Solutes: Cr, urea, K diffuse from blood → dialysate, HCO3 from dialysate → blood Solute removal inversely proportional to size ∴ effective removal of K, urea, Cr, not PO4 6× vs.</description></item><item><title>Hemodynamic-Monitoring</title><link>https://htlin222.github.io/garden/Hemodynamic-Monitoring/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hemodynamic-Monitoring/</guid><description>Hemodynamic-Monitoring</description></item><item><title>hemolytic anemias</title><link>https://htlin222.github.io/garden/hemolytic-anemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hemolytic-anemias/</guid><description>hemolytic anemias [[Causes of Hemolytic Anemia by Mechanism]] [[Diagnostic evaluation-hemolytic anemias]] [[Glucose-6-phosphate dehydrogenase]] [[Sickle cell anemia ]] [[Hereditary spherocytosis (HS) ]] [[Paroxysmal nocturnal hemoglobinuria]] [[Autoimmune hemolytic anemia]] [[Drug-induced hemolytic anemia]] [[Microangiopathic hemolytic anemia]] [[Hypersplenism]]</description></item><item><title>Hemolytic-uremic syndrome</title><link>https://htlin222.github.io/garden/Hemolytic-uremic-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hemolytic-uremic-syndrome/</guid><description>Hemolytic-uremic syndrome Pathophys: (1) Shiga toxin damages renal endothelial cells → intrarenal thrombi; or (2) complement dysregulation (hereditary or acquired), so-called “atypical HUS”</description></item><item><title>Hemophilias</title><link>https://htlin222.github.io/garden/Hemophilias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hemophilias/</guid><description>Hemophilias (Lancet 2016;388:187)
X-linked recessive factor VIII (hemophilia A) or factor IX (hemophilia B) deficiency
Classification: mild (5–25% normal factor activity), moderate (1–5%), or severe (&amp;lt;1%)</description></item><item><title>hemoptysis</title><link>https://htlin222.github.io/garden/hemoptysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hemoptysis/</guid><description>hemoptysis [[Definition and pathophysiology-hemoptysis]] [[Diagnostic workup-hemoptysis]] [[Treatment-hemoptysis]]</description></item><item><title>Hemothroax</title><link>https://htlin222.github.io/garden/Hemothroax/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hemothroax/</guid><description>Hemothroax Hemothorax is an accumulation of blood within the pleural space. Hematocrit of the pleural fluid is greater than 50% of the hematocrit of the patient’s peripheral blood in hemothorax.</description></item><item><title>Heparin-Induced Thrombocytopenias</title><link>https://htlin222.github.io/garden/Heparin-Induced-Thrombocytopenias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Heparin-Induced-Thrombocytopenias/</guid><description>Heparin-Induced Thrombocytopenias (Chest 2012;141:e495S; NEJM 2015;373:252)
Type I Heparin-Induced Thrombocytopenias(not clin. signif) Direct effect of heparin (non-immune) Incidence 10–20% After 1–4 d of heparin therapy Platelet nadir: &amp;gt;100,000/µL Sequelae: None Can continue heparin and observe Type II Heparin-Induced Thrombocytopenias (clinically significant HIT) Immune (Ab)-mediated IgG against plt factor 4—heparin complex 1–3% with UFH, 0–0.</description></item><item><title>Hepatic encephalopathy HE</title><link>https://htlin222.github.io/garden/Hepatic-encephalopathy-HE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatic-encephalopathy-HE/</guid><description>Hepatic encephalopathy (HE) (NEJM 2016;375:1660; Hepatology 2014; 60:715)
Pathogenesis: failure of liver to detoxify NH3 + other substances (eg, ADMA; J Hepatol 2013;58:38) that cause cerebral edema, ↓ O2 consumption, ↑ ROS → brain dysfxn</description></item><item><title>Hepatic hydrothorax</title><link>https://htlin222.github.io/garden/Hepatic-hydrothorax/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatic-hydrothorax/</guid><description>Hepatic hydrothorax 2° diaphragmatic defect; often unilateral, R &amp;gt;L, ± ascites
Treatment: avoid chest tube (↑ complications); Rx same as ascites (TIPS if refractory).</description></item><item><title>hepatic vascular disease</title><link>https://htlin222.github.io/garden/hepatic-vascular-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatic-vascular-disease/</guid><description>hepatic vascular disease [[Normal hepatic vasculature]] [[Portal vein thrombosis (PVT) ]] [[Splenic vein thrombosis]] [[Budd-Chiari syndrome]] [[Sinusoidal obstruction syndrome (SOS)]]</description></item><item><title>hepatitis</title><link>https://htlin222.github.io/garden/hepatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis/</guid><description>hepatitis VIRAL [[Hepatitis A]] [[Hepatitis B]] [[Hepatitis C]] [[Hepatitis D]] [[Hepatitis E]] Other viruses (human pegivirus, CMV, EBV, HSV, VZV) [[autoimmune hepatitis (AIH)]] [[Alcohol-associated hepatitis]] [[Acetaminophen hepatotoxicity]] [[Ischemic hepatitis]] [[Nonalcoholic fatty liver disease (NAFLD)]]</description></item><item><title>Hepatitis A</title><link>https://htlin222.github.io/garden/Hepatitis-A/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatitis-A/</guid><description>Hepatitis A (ssRNA; 30–45% of acute viral hepatitis in U.S; MMWR 2018;67:1208)
Transmission &amp;amp; RFs: fecal–oral route; contam. food, water, shellfish; daycare ctr; intl travel Incubation: 2–6 wk; no chronic carrier state; once antibody forms → lifelong immunity Sx: ↓ appetite, malaise, fever, N/V, RUQ pain, jaundice; rarely ALF (↑ w/ chronic HCV) Diagnosis: acute hepatitis = ⊕ IgM anti-HAV; past exposure = ⊕ IgG anti-HAV (⊖IgM) Rx for acute HAV: supportive care; refer to liver txplnt center if acute liver failure Vaccinate if: MSM, IVDU, chronic liver disease, international travel; Havrix (2 doses)</description></item><item><title>Hepatitis B</title><link>https://htlin222.github.io/garden/Hepatitis-B/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatitis-B/</guid><description>Hepatitis B Transmission: blood (IVDU, transfusion), sexual, perinatal (vertical) Incubation: 6 wk–6 mo (mean 12–14 wk) Acute infxn: 70% subclinical, 30% jaundice, &amp;lt;1% acute liver failure (up to 60% mortality) Chronic infxn: HBsAg ⊕ &amp;gt;6 mo in &amp;lt;5% of adult-acquired (↑ if immunosupp), &amp;gt;90% of perinatal; ~40% chronic HBV → cirrhosis (↑ risk w/ HCV, HDV, or HIV coinfxn, EtOH) HCC: ↑ risk if cirrhosis, ⊕ FHx HCC, African &amp;gt;20 y old, Asian ♂ &amp;gt;40 y old or ♀ &amp;gt;50 y old, or &amp;gt;40 y old w/ ↑ ALT ± HBV DNA &amp;gt;2000.</description></item><item><title>hepatitis B virus Rx duration</title><link>https://htlin222.github.io/garden/hepatitis-B-virus-Rx-duration/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis-B-virus-Rx-duration/</guid><description>hepatitis B virus Rx duration (1) HBeAg ⊕ immune active w/o cirrhosis: if seroconversion (HBeAg ⊖, anti- HBe ⊕), can stop after 1 y if ALT nl &amp;amp; HBV DNA suppressed or until HBsAg clears; (2) HBeAg ⊖ immune reactivation: indefinite; (3) cirrhosis: indefinite</description></item><item><title>Hepatitis C</title><link>https://htlin222.github.io/garden/Hepatitis-C/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatitis-C/</guid><description>Hepatitis C (ssRNA; ~10% of acute viral hepatitis in U.S.; Lancet 2015;385:1124)
[[Recommended First-Line Oral Direct-Acting Antiviral (DAA) Regimens]]</description></item><item><title>hepatitis C virus acute infxn</title><link>https://htlin222.github.io/garden/hepatitis-C-virus-acute-infxn/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis-C-virus-acute-infxn/</guid><description>hepatitis C virus acute infxn 80% subclinical; 10–20% sx hepatitis w/ jaundice; acute liver failure rare; prob of spont clearance a/w IL28B &amp;amp; HLA class II genotypes (Annals 2013;158:235)</description></item><item><title>hepatitis C virus extrahepatic syndromes</title><link>https://htlin222.github.io/garden/hepatitis-C-virus-extrahepatic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis-C-virus-extrahepatic-syndromes/</guid><description>hepatitis C virus extrahepatic syndromes mixed cryoglobulinemia, porphyria cutanea tarda, lichen planus, leukocytoclastic vasculitis, thyroiditis, MPGN, IPF, NHL and monoclonal gammopathies</description></item><item><title>hepatitis C virus Monitoring on Rx</title><link>https://htlin222.github.io/garden/hepatitis-C-virus-Monitoring-on-Rx/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis-C-virus-Monitoring-on-Rx/</guid><description>hepatitis C virus Monitoring on Rx CBC, INR, LFTs, GFR, HCV VL prior to starting Rx. PIs contraindicated if decomp. liver dx (ascites, encephalopathy) or CPS ≥7.</description></item><item><title>hepatitis C virus recommended First-Line Oral Direct-Acting Antiviral DAA Regimens</title><link>https://htlin222.github.io/garden/hepatitis-C-virus-recommended-First-Line-Oral-Direct-Acting-Antiviral-DAA-Regimens/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis-C-virus-recommended-First-Line-Oral-Direct-Acting-Antiviral-DAA-Regimens/</guid><description>hepatitis C virus recommended First-Line Oral Direct-Acting Antiviral (DAA) Regimens Sofosbuvir &amp;amp; velpatasvir Genotypes 1–6, 12 weeks Rx
Glecaprevir &amp;amp; pibrentasvir Gentotypes 1–6; 8 weeks Rx</description></item><item><title>hepatitis C virus Serologic, virologic, &amp; genetic tests</title><link>https://htlin222.github.io/garden/hepatitis-C-virus-Serologic-virologic-genetic-tests/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis-C-virus-Serologic-virologic-genetic-tests/</guid><description>hepatitis C virus Serologic, virologic, &amp;amp; genetic tests (screen all adults [✓ anti-HCV] JAMA 2020;323:970) anti-HCV (ELISA): ⊕ in 6 wk, does not = recovery or immunity; can be ⊖ after recovery</description></item><item><title>hepatitis C virus Treatment indications</title><link>https://htlin222.github.io/garden/hepatitis-C-virus-Treatment-indications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatitis-C-virus-Treatment-indications/</guid><description>hepatitis C virus Treatment indications ( www.hcvguidelines.org) (Lancet 2019;393:1453; Hepatology 2020;71:686)
Acute: if no spont. clearance at 12–16 wk, can Rx w/ same regimens for chronic HCV Chronic: ↓ HCC &amp;amp; mortality.</description></item><item><title>Hepatitis D</title><link>https://htlin222.github.io/garden/Hepatitis-D/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatitis-D/</guid><description>Hepatitis D (RNA; Gastro 2019:156;461)
Transmission: blood or sexual; endemic in Africa &amp;amp; E. Europe. Generally requires host to already have HBV infxn in order to cause co-infection or superinfection; in rare cases (immunosupp s/p liver transplant) can replicate autonomously.</description></item><item><title>Hepatitis E</title><link>https://htlin222.github.io/garden/Hepatitis-E/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatitis-E/</guid><description>Hepatitis E (ssRNA; World J Gastro 2016;22:7030; Gastro Clin N Am 2017;46:393)
Most common cause of acute viral hepatitis in endemic areas</description></item><item><title>hepatocellular carcinoma</title><link>https://htlin222.github.io/garden/hepatocellular-carcinoma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hepatocellular-carcinoma/</guid><description>hepatocellular carcinoma Risk factors (globally, 3rd leading cause of cancer death, espec. in Africa &amp;amp; Asia) Cirrhosis: present in 70–90% HCC cases Infectious: HCV &amp;amp; HBV (~75%), HBV/HDV coinfection; HBV can cause HCC w/o cirrhosis Toxic: EtOH (⅓ cases in U.</description></item><item><title>Hepatopulmonary syndrome HPS</title><link>https://htlin222.github.io/garden/Hepatopulmonary-syndrome-HPS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatopulmonary-syndrome-HPS/</guid><description>Hepatopulmonary syndrome (HPS) (Dig Dis Sci 2015;60:1914, Hepatology 2021;74:1014) Abnl gas exchange (A-a gradient ≥15 or PaO2 &amp;lt;80) caused by intrapulmonary vascular dilatations leading to intrapulmonary shunting (improves with O2) S/S: platypnea-orthodeoxia (dyspnea &amp;amp; hypoxia w/ sitting up), clubbing, spider angiomas Dx w/ contrast echo showing “late” A-V shunting (contrast in LA 3–6 cycles after RA) Rx: O2; potential embolization if large vessel on CT, TIPS, liver tx only definitive Rx</description></item><item><title>Hepatorenal syndrome HRS</title><link>https://htlin222.github.io/garden/Hepatorenal-syndrome-HRS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hepatorenal-syndrome-HRS/</guid><description>Hepatorenal syndrome (HRS) Reference Hepatology 2021;74:1014 Gastro 2016;150:1525 AJKD 2013;62:1198 Pathophysiology: splanchnic vasodilation and renal vasoconstriction w/ ↓ renal blood flow</description></item><item><title>HER2</title><link>https://htlin222.github.io/garden/HER2/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/HER2/</guid><description>HER2 (Lancet 2017;389: 2415)
HER2- targeted
Trastuzumab (anti-HER2): 1st-line Rx combined w/ chemo Trastuzumab emtansine (mAb linked to chemo): ↓ risk of recurrence/death if residual disease post neoadj.</description></item><item><title>Hereditary spherocytosis HS</title><link>https://htlin222.github.io/garden/Hereditary-spherocytosis-HS-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hereditary-spherocytosis-HS-/</guid><description>Hereditary spherocytosis (HS) (Lancet 2008;372:1411)
Defect in cytoskeleton of RBC membrane (ankyrin, α- and β-spectrin, band 3, &amp;amp; pallidin)</description></item><item><title>herpes simplex virus infection</title><link>https://htlin222.github.io/garden/herpes-simplex-virus-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/herpes-simplex-virus-infection/</guid><description>herpes simplex virus infection 通常引起急性腦炎，伴有快速發熱、頭痛、癲癇發作、 局灶性神經系統體徵和意識改變。 神經影像學通常顯示顳葉變化。 腦脊液分析顯示以淋巴細胞為主，常伴有紅細胞，葡萄糖水平正常 伴有性格改變和MRI顳葉增強的腦炎：單純皰疹病毒腦炎的特徵。 雙側顳葉亮起來高度提示 HSV 腦炎。</description></item><item><title>herpes zoster</title><link>https://htlin222.github.io/garden/herpes-zoster/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/herpes-zoster/</guid><description>herpes zoster Definition &amp;amp; etiology Painful vesicular rash in a peripheral nerve distribution due to reactivation of VZV Spread by contact with active lesion (prior to crusting) in uncomplicated zoster or via airborne transmission in disseminated zoster [[Clinical manifestations complications-herpes zoster]] Diagnosis Clinical diagnosis if uncomplicated.</description></item><item><title>High-risk features-syncope</title><link>https://htlin222.github.io/garden/High-risk-features-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/High-risk-features-syncope/</guid><description>High-risk features-syncope (admit w/ tele; JACC 2017;70:620; EHJ 2018;39:1883)
Age &amp;gt;60 y, h/o CAD, HF/CMP, valvular or congenital heart dis.</description></item><item><title>Histoplasmosis</title><link>https://htlin222.github.io/garden/Histoplasmosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Histoplasmosis/</guid><description>Histoplasmosis (CID 2007;45:807)
Epidemiology: endemic to central &amp;amp; SE U.S., but sporadic cases throughout U.S. Clinical manifestations Acute: PNA ± hilar LAN, often subacute, but high inoculum can cause acute severe PNA Chronic lung disease: cough + B sx ± cavitary lesions (Ddx TB, blasto) Disseminated (seen in immunosupp.</description></item><item><title>History and physical exam-interstitial lung disease</title><link>https://htlin222.github.io/garden/History-and-physical-exam-interstitial-lung-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/History-and-physical-exam-interstitial-lung-disease/</guid><description>History and physical exam-interstitial lung disease Occupational, exposures (eg, birds), tobacco, meds, XRT, FHx, precipitating event
Tempo (acute → infxn, CHF, hypersens pneumonitis, eos PNA, AIP, COP, drug-induced)</description></item><item><title>History heart failure</title><link>https://htlin222.github.io/garden/History-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/History-heart-failure/</guid><description>History heart failure Low output: fatigue, weakness, exercise intolerance, ∆ MS, anorexia Congestive: left-sided → dyspnea, orthopnea, paroxysmal nocturnal dyspnea right-sided → peripheral edema, RUQ discomfort, bloating, satiety</description></item><item><title>History-Initial management-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/History-Initial-management-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/History-Initial-management-gastrointestinal-bleeding/</guid><description>History-Initial management-gastrointestinal bleeding prior upper gastrointestinal bleed tempo of current bleed, specific bleeding manifestations (see above), other GI s/s (eg, abd pain, Δ in bowel habits, weight loss, N/V), ASA/NSAID or EtOH use, anticoag/antiplt drugs, h/o or risk factors for cirrhosis, radiation, prior GI or aortic surgery</description></item><item><title>HIV AIDS</title><link>https://htlin222.github.io/garden/HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/HIV-AIDS/</guid><description>HIV AIDS [[Definition Clinical Manifestations-HIV AIDS]] [[Epidemiology-HIV AIDS]] [[Prophylaxis-HIV AIDS]] [[Screening and Diagnosis-HIV AIDS]] [[Approach to newly diagnosed HIV positive Pt]] [[Antiretrovirals (ARVs)]] [[Approach to previously established HIV positive Pt]] [[OI Prophylaxis-HIV AIDS]] [[complications of HIV AIDS]]</description></item><item><title>Home</title><link>https://htlin222.github.io/garden/Home/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Home/</guid><description/></item><item><title>Horner’s syndrome</title><link>https://htlin222.github.io/garden/Horners-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Horners-syndrome/</guid><description>Horner’s syndrome 是一種影響身體一側的面部和眼睛的疾病。 這是由於從大腦到頭部和頸部的神經通路的破壞引起的。
通常，霍納綜合徵的體徵和症狀包括
TL;DR 瞳孔大小的降低， 眼瞼下垂 臉部受影響側的出汗減少。 Common Sings A persistently small pupil (miosis) A notable difference in pupil size between the two eyes (anisocoria) Little or delayed opening (dilation) of the affected pupil in dim light Drooping of the upper eyelid (ptosis) Slight elevation of the lower lid, sometimes called upside-down ptosis Sunken appearance of the affected eye Little or no sweating (anhidrosis) on the affected side of the face anhidrosis::no sweating</description></item><item><title>Hosting with Docker</title><link>https://htlin222.github.io/garden/notes/docker/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/docker/</guid><description>If you want to host Quartz on a machine without using a webpage hosting service, it may be easier to install Docker Compose and follow the instructions below than to install Quartz&amp;rsquo;s dependencies manually.</description></item><item><title>How does this thing work?</title><link>https://htlin222.github.io/garden/How-does-this-thing-work/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/How-does-this-thing-work/</guid><description>Always begin typing in the
When you select one of the found notes (e.g., using the up/down keys) NV displays its body in the lower text area (what you&amp;rsquo;re reading now).</description></item><item><title>how the human body breathes</title><link>https://htlin222.github.io/garden/how-the-human-body-breathes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/how-the-human-body-breathes/</guid><description>how the human body breathes ✨重點: 要了解機械通氣，您首先必須對人體的呼吸方式有一個基本的了解。 氧氣是人體的食物。 每個細胞都需要它來產生能量並執行其各種功能。 另一方面，二氧化碳 (CO2) 是每個細胞作為其功能的副產品產生的人體垃圾。 眾所周知，肺是從空氣中吸收氧氣並將其帶入體內的器官，同時也排出（呼出）二氧化碳。 但是觸發這種情況發生的機制是什麼，這種交換究竟是如何發生的？ 在本章結束時，您將能夠： 解釋吸氣和呼氣的身體機制。 識別參與呼吸的身體關鍵部位。 定義 FRC 和內在 PEEP 以及對肺泡的重要性。 了解呼吸過程中肺部發生的基本壓力變化。 ✨重點: 數以百萬計的“小氣球”仍然能夠吸入與相同大小的單個氣球相同的總空氣量，但是通過將空氣量分成肺泡而不是一個大氣球，肺的總表面積增加成倍增長。 為什麼這很重要？嗯，每個單獨的肺泡都被稱為“毛細血管”的血管包圍。肺泡和毛細血管相遇的地方是實際發生氣體交換的地方。 可以發生這種交換的表面積的大幅增加允許氣體交換更活躍的區域，並且這種交換可以以更有效和更快的速度發生。 氧氣從肺泡擴散到血液中，二氧化碳從血液中擴散到肺泡，然後從肺中呼出。</description></item><item><title>Humoral immune dysfunction</title><link>https://htlin222.github.io/garden/Humoral-immune-dysfunction/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Humoral-immune-dysfunction/</guid><description>Humoral immune dysfunction (eg, CVID, myeloma) and asplenia Encapsulated bacteria: S. pneumo, H. flu, N. meningitidis (vaccinate against these 3, ideally prior to splenectomy) Other bacteria: E.</description></item><item><title>hyaline casts</title><link>https://htlin222.github.io/garden/hyaline-casts/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyaline-casts/</guid><description>hyaline casts Casts are clusters of urinary sediment elements (red blood cells, white blood cells, fat bodies, etc.) wrapped in a protein matrix.</description></item><item><title>Hydralazine---nitrates</title><link>https://htlin222.github.io/garden/Hydralazine---nitrates/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hydralazine---nitrates/</guid><description>Hydralazine&amp;mdash;nitrates Consider if cannot tolerate ACEI/ARB or in black Pts w/ class III/IV
25% ↓ mort. (NEJM 1986;314:1547); infer. to ACEI (NEJM 1991;325:303)</description></item><item><title>hyperactive delirium</title><link>https://htlin222.github.io/garden/hyperactive-delirium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyperactive-delirium/</guid><description>hyperactive delirium The cognitive syndrome associated with severe alcohol withdrawal (i.e., “delirium tremens”) remains the classic example of the hyperactive subtype, prominent hallucinations, agitation, and hyperarousal, accompanied by life-threatening autonomic instability.</description></item><item><title>hyperaldosteronism</title><link>https://htlin222.github.io/garden/hyperaldosteronism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyperaldosteronism/</guid><description>hyperaldosteronism [[Etiologies-hyperaldosteronism]] [[Clinical manifestations-hyperaldosteronism]] [[Diagnosis-hyperaldosteronism]] [[Treatment-hyperaldosteronism]] Backlink： [[adrenal disorders]] [[adrenal incidentalomas]] [[Clinical manifestations-hyperaldosteronism]] [[Diagnosis-hyperaldosteronism]] [[Disease state specific regimens-diuresis]] [[Etiologies-hyperaldosteronism]] [[Etiologies-of-Metabolic-Alkalosis]] [[Liddle’s syndrome]] [[metabolic-alkalosis]] [[Pathophysiology-metabolic-alkalosis]] [[Primary Hyperaldosteronism]] [[Renal potassium losses]] [[Secondary Hyperaldosteronism]] [[Treatment-hyperaldosteronism]]</description></item><item><title>hypercalcemia</title><link>https://htlin222.github.io/garden/hypercalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypercalcemia/</guid><description>hypercalcemia [[Etiologies of Hypercalcemia]] [[Clinical manifestations-hypercalcemia]] (“bones, stones, abdominal groans, and psychic moans”) [[Diagnostic studies-hypercalcemia]] [[Acute Treatment of Hypercalcemia]] (BMJ 2015;350:h2723) [[Treatment of asymptomatic 1° HPT]] (JCEM 2014;99:3561; JAMA 2020;323:1186)</description></item><item><title>hypercoagulable states</title><link>https://htlin222.github.io/garden/hypercoagulable-states/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypercoagulable-states/</guid><description>hypercoagulable states Suspect in Pts with venous or arterial thrombosis at young age or unusual locations, recurrent thromboses or pregnancy loss, or ⊕ FHx</description></item><item><title>hyperkalemia</title><link>https://htlin222.github.io/garden/hyperkalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyperkalemia/</guid><description>hyperkalemia [[Transcellular shifts-hyperkalemia]] [[Decreased GFR-hyperkalemia]] [[Normal GFR but with ↓ renal K excretion-hyperkalemia]] [[Clinical manifestations-hyperkalemia]] [[Workup-hyperkalemia]] [[Treatment of Hyperkalemia-hyperkalemia]]</description></item><item><title>hypernatremia</title><link>https://htlin222.github.io/garden/hypernatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypernatremia/</guid><description>hypernatremia [[Pathophysiology-hypernatremia]] [[Workup-hypernatremia]] [[Approach to hypernatremia]] [[Extrarenal H2O loss (Uosm &amp;gt;700–800)]] [[Renal H2O loss (Uosm &amp;lt;700–800)]] [[Other (Uosm &amp;gt;700–800)]] [[Treatment-hypernatremia]]</description></item><item><title>hyperosmolar hyperglycemic state</title><link>https://htlin222.github.io/garden/hyperosmolar-hyperglycemic-state/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyperosmolar-hyperglycemic-state/</guid><description>hyperosmolar hyperglycemic state [[Definition, precipitants, pathophysiology-hyperosmolar hyperglycemic state]] [[Clinical manifestations dx studies-hyperosmolar hyperglycemic state]] [[Treatment-hyperosmolar hyperglycemic state]]</description></item><item><title>hyperparathyroidism</title><link>https://htlin222.github.io/garden/hyperparathyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyperparathyroidism/</guid><description>hyperparathyroidism 甲狀旁腺功能亢進症是甲狀旁腺（在頸部，靠近甲狀腺）產生過多的甲狀旁腺激素。 有 4 個小腺體產生這種激素，可幫助您的身體控制所需的鈣水平。</description></item><item><title>hyperpituitary syndromes</title><link>https://htlin222.github.io/garden/hyperpituitary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyperpituitary-syndromes/</guid><description>hyperpituitary syndromes [[Pituitary tumors]] (NEJM 2020;382:937) [[Hyperprolactinemia]] [[Acromegaly]] [[Cushing’s Syndrome]] (↑ ACTH): 5% of adenomas; see “Adrenal Disorders” (Hypercortisolism) Central hyperthyroidism (↑ TSH, ↑ α-subunit): extremely rare; see [[hyperthyroidism]] ↑ FSH &amp;amp; LH: often non-fxn, may present as hypopituitarism b/c compression effects [[Multiple Endocrine Neoplasia]] (MEN) Syndromes [[Autoimmune Polyglandular Syndromes]] (APS)</description></item><item><title>Hyperprolactinemia</title><link>https://htlin222.github.io/garden/Hyperprolactinemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hyperprolactinemia/</guid><description>Hyperprolactinemia * Etiology Prolactinoma (50% of pituitary adenomas) Stalk compression due to nonprolactinoma → ↓ inhibitory dopamine → ↑ PRL (mild)</description></item><item><title>Hypersplenism</title><link>https://htlin222.github.io/garden/Hypersplenism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hypersplenism/</guid><description>Hypersplenism Stasis/trapping in spleen → Mϕ attack/remodel RBCs → spherocytosis → hemolysis
Causes of Splenomegaly RES hyperplasia Hemolytic anemia, sickle cell disease, thalassemia major Immune hyperplasia Infxn [HIV, EBV, CMV, TB, malaria, kala azar (“black water fever” from visceral leishmaniasis), Mycobacterium avium complex], autoimmune disorders (SLE, RA w/ Felty’s syndrome), sarcoidosis, serum sickness Congestion Cirrhosis, CHF, portal/splenic vein thrombosis, schistosomiasis Infiltration (nonmalignant) Lysosomal storage disorders (Gaucher’s, Niemann-Pick), glycogen storage diseases histiocytosis X, splenic cysts Neoplasm causes of massive splenomegaly.</description></item><item><title>hypertension</title><link>https://htlin222.github.io/garden/hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypertension/</guid><description>[[index]]
[[ACC AHA Classification for Office-Based BP]] Epidemiology (Circ 2021;143:e254; Lancet 2021;398:957)
Prevalence 47% in U.S. adults, higher in African-Americans; M = F Of those with HTN, ~40% unaware of dx; of those dx w/ HTN, only ½ achieve target BP [[Etiologies-hypertension]] [[Standard workup-hypertension]] [[Complications of HTN]] [[Treatment-hypertension]] [[Resistant HTN]]</description></item><item><title>hypertensive crises</title><link>https://htlin222.github.io/garden/hypertensive-crises/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypertensive-crises/</guid><description>hypertensive crises Hypertensive emergency: ↑ BP (usually SBP &amp;gt;180 or DBP &amp;gt;120) → target-organ damage Neurologic damage: encephalopathy, hemorrhagic or ischemic stroke, papilledema Cardiac damage: ACS, HF/pulmonary edema, aortic dissection Renal damage: proteinuria, hematuria, acute renal failure; scleroderma renal crisis Microangiopathic hemolytic anemia; preeclampsia-eclampsia Hypertensive urgency: SBP &amp;gt;180 or DBP &amp;gt;120 (?</description></item><item><title>hyperthyroidism</title><link>https://htlin222.github.io/garden/hyperthyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyperthyroidism/</guid><description>hyperthyroidism [[Etiologies-hyperthyroidism]] Clinical manifestations Restlessness, sweating, tremor, moist warm skin, fine hair, tachycardia, AF, weight loss, ↑ frequency of stools, menstrual irregularities, hyperreflexia, osteoporosis, stare and lid lag (due to sympathetic overactivity) Apathetic thyrotoxicosis: seen in elderly who can present with lethargy as only sx Laboratory testing ↑ free T4 and total T3; ↓ TSH (except in TSH-secreting tumors) RAIU scan is very useful study to differentiate causes (see table on page 7-3); cannot do if recent IV contrast or amio load b/c iodine blocks uptake, so ✓ autoantibodies instead Rarely need to ✓ for autoantibodies except in pregnancy (to assess risk of fetal Graves’) May see hypercalciuria ± hypercalcemia, ↑ Aϕ, anemia [[Graves’ disease]] [[Thyroiditis]] [[Treatment-hyperthyroidism]] (Thyroid 2016;26:1343; JCEM 2020;105:3704) Subclinical hyperthyroidism (NEJM 2018;378:2411) Mild ↓ TSH and normal free T4 with only subtle or no sx ~15% → overt hyperthyroidism in 2 y; ↑ risk of AF, CHD, fracture (JAMA 2015;313:2055) Rx controversial: consider if TSH &amp;lt;0.</description></item><item><title>hypertrophic cardiomyopathy</title><link>https://htlin222.github.io/garden/hypertrophic-cardiomyopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypertrophic-cardiomyopathy/</guid><description>hypertrophic cardiomyopathy Definition, epidemiology, pathology (Circ Res 2017;121:749) LV (usually ≥15 mm) and/or RV hypertrophy disproportionate to hemodynamic load</description></item><item><title>hypertrophic pulm osteoarthropathy</title><link>https://htlin222.github.io/garden/hypertrophic-pulm-osteoarthropathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypertrophic-pulm-osteoarthropathy/</guid><description>hypertrophic pulm osteoarthropathy HPOA是一組可能影響器官，肺，骨骼和關節的症狀。這是一種罕見的綜合症，因此沒有太多信息。它也被稱為Bamberger-Marie
患有肺部狀況的人可以獲得HPOA。在癌症中，在非小細胞肺癌患者中最常見。它還影響胸膜間皮瘤患者。
HPOA的症狀 HPOA通常會引起手腕和腳踝的骨骼和關節的炎症。有時，這會顯示在骨掃描或X射線上。腳踝和手腕會腫脹和發炎，從而引起很多痛苦和運動的困難。
HPOA最常見的症狀之一是一種稱為Clubbing finger。這意味著手指和腳趾在末端寬闊 。指甲曲線，變稠並顯得勺狀。
手指的棍棒是肺和心髒病的常見症狀。沒有人確切知道為什麼會clubbing 但這可能是因為血液中沒有足夠的氧氣。
REF: Hypertrophic osteoarthropathy (HPOA) | Lung cancer | Cancer Research UK</description></item><item><title>Hypervolemic hypotonic hyponatremia</title><link>https://htlin222.github.io/garden/Hypervolemic-hypotonic-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hypervolemic-hypotonic-hyponatremia/</guid><description>Hypervolemic hypotonic hyponatremia (ie, ↑ total body Na, ↑ ↑ TBW)
↓ EAV → ↑ RAAS → ↑ aldosterone &amp;amp; ↑ adrenergic tone → ↑↑ ADH (Am J Med 2013;126:S1)</description></item><item><title>hypoactive delirium</title><link>https://htlin222.github.io/garden/hypoactive-delirium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypoactive-delirium/</guid><description>hypoactive delirium In striking contrast is the hypoactive subtype, exemplified by benzodiazepine intoxication, in which patients are withdrawn and quiet, with prominent apathy and psychomotor slowing.</description></item><item><title>hypocalcemia</title><link>https://htlin222.github.io/garden/hypocalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypocalcemia/</guid><description>hypocalcemia [[Etiologies of Hypocalcemia]] [[Control of Mineral Homeostasis by Parathyroid Hormone and the Calcium-Sensing Receptor]]. [[Clinical manifestations-hypocalcemia]] Diagnostic studies Ca, alb, ICa, PTH, 25-(OH)D, 1,25-(OH) 2D (if renal failure or rickets), Cr, Mg, PO4, Aϕ, UCa e.</description></item><item><title>hypoglycemia</title><link>https://htlin222.github.io/garden/hypoglycemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypoglycemia/</guid><description>hypoglycemia Clinical manifestations (glucose &amp;lt;~55 mg/dL)
CNS: headache, visual Δs, Δ MS, weakness, seizure, LOC (neuroglycopenic sx) Autonomic: diaphoresis, palpitations, tremor (adrenergic sx) [[Etiologies-hypoglycemia]] [[Evaluation in patients without diabetes- but have hypoglycemia]] Treatment Glucose tablets, paste, &amp;amp; fruit juice are first-line Rx for Pts who can take POs 25–50 g of D 50 IV; if no access, glucagon 0.</description></item><item><title>hypokalemia</title><link>https://htlin222.github.io/garden/hypokalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypokalemia/</guid><description>hypokalemia [[Transcellular shifts]] (UK:Cr &amp;lt;13 mEq/g) [[GI potassium losses]] (UK:Cr &amp;lt;13 mEq/g) [[Renal potassium losses]] (UK:Cr &amp;gt;13 mEq/g) [[Clinical manifestations-hypokalemia]] [[Workup-hypokalemia]] (JAMA 2021;12:1216) [[Approach to hypokalemia]] [[Treatment-hypokalemia]] [[Duty note of hypokalemia]]</description></item><item><title>hyponatremia</title><link>https://htlin222.github.io/garden/hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hyponatremia/</guid><description>hyponatremia [[Pathophysiology-hyponatremia]] [[workup-hyponatremia]] [[Hypovolemic-hypotonic-hyponatremia]] [[Euvolemic-hypotonic-hyponatremia]] [[Hypervolemic hypotonic hyponatremia]] [[Treatment-of-hyponatremia]] [[JAMA review of hyponatremia]]</description></item><item><title>Hypoparathyroidism</title><link>https://htlin222.github.io/garden/Hypoparathyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hypoparathyroidism/</guid><description>Hypoparathyroidism (NEJM 2019;380:1738; JCEM 2020;105:1722)
[[Control of Mineral Homeostasis by Parathyroid Hormone and the Calcium-Sensing Receptor]]. Iatrogenic (s/p thyroidectomy, rarely after parathyroidectomy); sporadic; familial (APS1, activating Ca-sensing receptor mutations; see page 7-2); Wilson’s, hemochromatosis; hypoMg (↓ secretion and effect); activating Ca-sensing receptor autoAb</description></item><item><title>Hypophosphatemia - Approach to the Patient</title><link>https://htlin222.github.io/garden/Hypophosphatemia-Approach-to-the-Patient/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hypophosphatemia-Approach-to-the-Patient/</guid><description>Hypophosphatemia - Approach to the Patient Hypophosphatemia is commonly defined as a serum phosphate concentration that is &amp;lt; 2.5 mg/dL (0.</description></item><item><title>hypopituitary syndromes</title><link>https://htlin222.github.io/garden/hypopituitary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypopituitary-syndromes/</guid><description>hypopituitary syndromes (Lancet 2016;388:2403; JCEM 2016;11:3888)
[[Etiologies-hypopituitary syndromes]] Clinical manifestations * Hormonal deficiencies: * ACTH, TSH, FSH and LH, GH, prolactin, and ADH * Panhypopituitarism: * deficiencies in multiple hormonal axes * Mass effect: * headache, visual field Δs, cranial nerve palsies [[Central adrenal insufficiency]]: ↓ ACTH [[Central hypothyroidism]] Hypoprolactinemia: ↓ prolactin Inability to lactate [[Growth hormone deficiency]] [[Central hypogonadism]]: ↓ FSH &amp;amp; LH [[Central diabetes insipidus]] [[Pituitary apoplexy]] [[Diagnostic evaluation-hypopituitary syndromes]] [[Treatment-hypopituitary syndromes]]</description></item><item><title>hypotension</title><link>https://htlin222.github.io/garden/hypotension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypotension/</guid><description>hypotension 評估一個低血壓的病人
Distributive Septic：細菌、菇菇、病毒、寄生蟲 Non-septic: 發炎、神經、過敏、內分泌 Inflammatory , Neurogenic , Anaphylactic Other: Andrenal, Arteriovenous shunts Cardiogenic 牆Cardiomyopathic MI, dilated cardiomyopathy, Myocarditis, Drug-induced (eg, beta blockers) 電路Arrhythmogenic Tachyarrhythmia – Atrial, ventricular Brady - atrioventricular block, Mobiz type 2 水路Mechanical valvular, [[myxoma]] Hypovolemic Hemorrhagic trauma, GI, 手術, 女性生殖 Non-hemorrhagic 上吐下瀉、中暑、renal loss(salt wasting)、3rd space loss Obstructive Pulmonary vascular pulmonary embolism, pulmonary hypertension Mechanical Mixed/unknown</description></item><item><title>hypothyroidism</title><link>https://htlin222.github.io/garden/hypothyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/hypothyroidism/</guid><description>hypothyroidism Etiologies Primary (&amp;gt;90% of cases of hypothyroidism; ↓ free T4, ↑ TSH) Goitrous: Hashimoto’s thyroiditis (after hyperthyroid phase of thyroiditis), iodine deficiency, lithium, amiodarone Nongoitrous: surgical destruction, s/p radioactive iodine or XRT, amiodarone Secondary (central): ↓ free T4; TSH low, inappropriately nl, or slightly high (although functionally inactive due to abnormal glycosylation); due to hypothalamic or pituitary failure Hashimoto’s thyroiditis Autoimmune destruction with diffuse lymphocytic infiltration Associated with other autoimmune disease and may be part of APS Type II ⊕ antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg) Abs in &amp;gt;90% Clinical manifestations (Annals 2020;173:ITC1) Early: weakness, fatigue, arthralgias, myalgias, headache, depression, cold intolerance, weight gain, constipation, menorrhagia, dry skin, coarse brittle hair, brittle nails, carpal tunnel syndrome, delayed DTRs (“hung up” reflexes), diastolic HTN, hyperlipidemia Late: slow speech; hoarseness; loss of outer third of eyebrows; myxedema (nonpitting skin thickening due to ↑ glycosaminoglycans); periorbital puffiness; bradycardia; pleural, pericardial, &amp;amp; peritoneal effusions; atherosclerosis Myxedema crisis: vide infra Diagnostic studies (Lancet 2017;390:1550) ↓ free T4; ↑ TSH in 1º hypothyroidism; ⊕ antithyroid Ab (TPO) in Hashimoto’s thyroiditis May see hyponatremia, hypoglycemia, anemia, ↑ LDL, ↓ HDL and ↑ CK Screening recommended for pregnant women [[Treatment of overt hypothyroidism]] (Endocrine 2019;66:18) [[Subclinical hypothyroidism]] (NEJM 2017;376:2556; JAMA 2019;322:153) [[Myxedema coma]] (ie, profound hypothyroidism; Thyroid 2014;24:1670) Backlink： [[amiodarone and thyroid disease]] [[Central hypothyroidism]] [[Common Diagnostic Tests in Thyroid Disorders]] [[Differential Diagnosis of Delirium]] [[Dyslipidemias]] [[Etiologies of Acute Pericarditis]] [[Etiologies of Classic FUO]] [[Etiologies of Prolonged-QT-interval]] [[Euvolemic-hypotonic-hyponatremia]] [[Heart failure with preserved EF]] [[Hyperprolactinemia]] [[hypopituitary syndromes]] [[Myxedema coma]] [[nonthyroidal illness (sick euthyroid syndrome) ]] [[# The Profession of Medicine PA RT 1 ]] [[Physical Exam Secret]] [[respiratory-acidosis]] [[Subclinical hypothyroidism]] [[Thyroiditis]] [[thyroid disorders]] [[Treatment of overt hypothyroidism]] [[Treatment-hypopituitary syndromes]] [[Washington Manual Thyroid Disorders]] [[workup-hyponatremia]]</description></item><item><title>Hypovolemic shock</title><link>https://htlin222.github.io/garden/Hypovolemic-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hypovolemic-shock/</guid><description>Hypovolemic shock Hemorrhagic Trauma
GI bleeding
Ruptured ectopic pregnancy
GI losses Burns Polyuria
Diabetic ketoacidosis
Diabetes insipidus</description></item><item><title>Hypovolemic-hypotonic-hyponatremia</title><link>https://htlin222.github.io/garden/Hypovolemic-hypotonic-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hypovolemic-hypotonic-hyponatremia/</guid><description>Hypovolemic-hypotonic-hyponatremia (ie, ↓↓ total body Na, ↓ TBW)
[[Renal losses of Hypovolemic-hypotonic-hyponatremia]] Extrarenal losses (UNa &amp;lt;10 mEq/L, UCl &amp;lt;10 mEq/L if alkalemia, FENa &amp;lt;1%): hemorrhage, GI loss (diarrhea or vomiting), third-spacing (pancreatitis), ↓ PO intake, insensible losses</description></item><item><title>Hypoxia and Cyanosis</title><link>https://htlin222.github.io/garden/Hypoxia-and-Cyanosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Hypoxia-and-Cyanosis/</guid><description>Hypoxia and Cyanosis Respiratory Anemic Carbon Monoxide Circulatory Specific Organ hypoxia Increeased o2 requirments [[cynosis]]</description></item><item><title>Ibutilide</title><link>https://htlin222.github.io/garden/Ibutilide/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ibutilide/</guid><description>Ibutilide 1 mg IV over 10’ may repeat x 1 n/a Contraindic. if J K or 1 QT (3-8% risk of TdP) give wl IV Mg %</description></item><item><title>ICD</title><link>https://htlin222.github.io/garden/ICD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ICD/</guid><description>ICD For 1° prevention if EF ≤30–35% or 2° prevention; not if NYHA IV
↓ mort. in ischemic CMP but perhaps only SCD in modern era in niCMP (NEJM 2005;352:225 &amp;amp; 2016;375:1221)</description></item><item><title>ICU</title><link>https://htlin222.github.io/garden/ICU/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ICU/</guid><description>ICU part 1: [[basic techniques and procedures]] part 2: [[cardiovascular critical care]] part 3: [[pulmonary critical care]] part 4: [[neurologic critical care]] part 5: [[surgical critical care]] [[sepsis and shock]] [[respiratory failure]] [[mechanical ventilation]] [[acute respiratory distress syndrome]] [[Resuscitation Fluids and Transfusion]] [[acid-base disturbances]] [[Sedation and Delirium]] [[Nutrition in the ICU]] [[Hyperglycemic Emergencies]] (Endocrinology) Acute GI Bleeding, Hepatitis/Liver Failure (Gastroenterology) Palliative Care Disseminated Intravascular Coagulation (Hematology) Neurologic Outcomes after Cardiac Arrest (Neurology) Cardiac Arrest, Syncope, Overdose and Toxidromes (Emergency Medicine) 42 The Febrile Patient, 43 Sepsis 44 Infections Acquired in the Intensive Care Unit 45 Antimicrobial Therapy 48 Acquired Immune Deficiency Syndrome 55 Anticoagulation‐Related Bleeding</description></item><item><title>ICU-level care-asthma-EXACERBATION</title><link>https://htlin222.github.io/garden/ICU-level-care-asthma-EXACERBATION/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ICU-level-care-asthma-EXACERBATION/</guid><description>ICU-level care-asthma-EXACERBATION Invasive ventilation: Large ET tube, Pplat &amp;lt;30 cm H2O (predicts barotrauma better than PIP), max exp time</description></item><item><title>Idiopathic interstitial pneumonias IIPs</title><link>https://htlin222.github.io/garden/Idiopathic-interstitial-pneumonias-IIPs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Idiopathic-interstitial-pneumonias-IIPs/</guid><description>Idiopathic interstitial pneumonias (IIPs) (AJRCCM 2013;188:733)
[[Definition]]: ILD of unknown cause; dx by radiographic, histologic, and clinical features [[Type of Idiopathic interstitial pneumonias (IIPs)]]</description></item><item><title>IgA nephropathy</title><link>https://htlin222.github.io/garden/IgA-nephropathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/IgA-nephropathy/</guid><description>IgA nephropathy (CJASN 2017;12:677; AJKD 2021;78:429)
Most common cause of GN; ♂ pred; peak incidence 20–30s; can also be post-infectious Wide range of clinical presentations: asx hematuria (30–40%), gross hematuria ~1–3 d after URI (10–15%), chronic GN (10%), nephrotic syndrome (5%), RPGN (&amp;lt;5%) Though clinical presentation can be highly suggestive, definitive dx only w/ bx Prognosis: ↑Cr, HTN, proteinuria a/w poor prog.</description></item><item><title>IgA vasculitis</title><link>https://htlin222.github.io/garden/IgA-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/IgA-vasculitis/</guid><description>IgA vasculitis (formerly Henoch-Schönlein purpura [HSP]) (Rheumatol 2019;58:1607)
IgA-mediated small-vessel vasculitis w/ predilection偏好 for skin, GI tract, and kidneys Epidemiology: * incidence 140/million/y; * 冬天的女孩 * ♂ &amp;gt;♀, * children &amp;gt;adults, * winter &amp;gt;summer * May develop ~10 d after onset of upper resp infx or after drug exposure [[Clinical manifestations of IgA vasculitis]] Dx studies: skin bx w/ immunofluorescence → leukocytoclastic vasculitis w/ IgA and C3 deposition in vessel wall; renal bx → mesangial IgA deposition Treatment: * often self-limiting over 4 wk; * steroids ± DMARDs for renal or severe disease [Henoch-Schonlein purpura | Circulatory System and Disease | NCLEX-RN | Khan Academy - YouTube]( https://www.</description></item><item><title>Ignoring Notes</title><link>https://htlin222.github.io/garden/notes/ignore-notes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/ignore-notes/</guid><description>Quartz Ignore Edit ignoreFiles in config.toml to include paths you&amp;rsquo;d like to exclude from being rendered.
1 2 3 4 5 6 .</description></item><item><title>Imaging of Diagnostic studies-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Imaging-of-Diagnostic-studies-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Imaging-of-Diagnostic-studies-gastrointestinal-bleeding/</guid><description>Imaging of Diagnostic studies-gastrointestinal bleeding if too unstable for endo or recurrent bleeding, consider IR embolization or surgery
tagged RBC scan: can identify general luminal location if bleeding rate ≥0.</description></item><item><title>Imaging studies of acute pancreatitis</title><link>https://htlin222.github.io/garden/Imaging-studies-of-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Imaging-studies-of-acute-pancreatitis/</guid><description>Imaging studies of acute pancreatitis (Am J Gastro 2013;108:1400)
Abd U/S: bowel gas often obscures pancreas visualization; however should be ordered to r/o biliary etiology (ie, gallstones, BD dilatation)</description></item><item><title>Imaging-Diagnosis-osteomyelitis</title><link>https://htlin222.github.io/garden/Imaging-Diagnosis-osteomyelitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Imaging-Diagnosis-osteomyelitis/</guid><description>Imaging-Diagnosis-osteomyelitis Plain radiographs: normal early in disease; lytic lesions seen after 2–6 wk MRI: preferred imaging study (overall Se 90%, Sp 82%; Archives 2007;167:125) CT: can demonstrate periosteal reaction and cortical and medullary destruction CT &amp;amp; MRI very Se but ↓ Sp; false ⊕ if contig focus w/ periosteal reaction, Charcot Δs Radionuclide imaging: very Se but non-Sp (false ⊕ if soft-tissue inflammation)</description></item><item><title>Imaging-for-stress-test</title><link>https://htlin222.github.io/garden/Imaging-for-stress-test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Imaging-for-stress-test/</guid><description>Imaging-for-stress-test Use if uninterpretable ECG (V-paced, LBBB, resting ST ↓ &amp;gt;1 mm, digoxin, LVH, WPW), after indeterminate ECG test, or if pharmacologic test</description></item><item><title>IMI complications</title><link>https://htlin222.github.io/garden/IMI-complications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/IMI-complications/</guid><description>IMI complications Heart block: ~20%, occurs in part because RCA typically supplies AV node 40% on present., 20% w/in 24 h, rest by 72 h; high-grade AVB can develop abruptly</description></item><item><title>immune complex IC –associated small-vessel vasculitis</title><link>https://htlin222.github.io/garden/immune-complex-ICassociated-small-vessel-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/immune-complex-ICassociated-small-vessel-vasculitis/</guid><description>immune complex (IC)–associated small-vessel vasculitis see [[Immune Complex (IC) Disease (granular staining) ]]
[[IgA vasculitis]] [[Cryoglobulinemic vasculitis]] [[connective tissue disease–associated vasculitis]] [[cutaneous leukocytoclastic angiitis]]</description></item><item><title>Immune Complex (IC) Disease granular staining</title><link>https://htlin222.github.io/garden/Immune-Complex-IC-Disease-granular-staining-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Immune-Complex-IC-Disease-granular-staining-/</guid><description>Immune Complex (IC) Disease (granular staining) Renal-Limited Diseases Infection-Related GN (Staph &amp;amp; Strep; ↓ C3, ± ASLO) Membranoproliferative GN (MPGN) (↓ C3) Fibrillary and immunotactoid GN (normal C3/C4) [[IgA nephropathy]] (normal C3, ±↑ IgA) (NEJM 2013;368:2402; CJASN 2017;12:677) Systemic Diseases SLE (CJASN 2017;12:825) (⊕ ANA, ⊕ anti-dsDNA, ⊕ anti-Sm, ↓ C3, ↓ C4) Cryoglobulinemia (⊕ cryocrit, ⊕ RF, ⊕ HCV, SPEP, ↓ C3, ↓ C4) Endocarditis (fever, ⊕ BCx, valvular disease, ↓ C3) Henoch-Schönlein purpura ([[IgA nephropathy]] + syst.</description></item><item><title>Immunosuppression-Kidney transplantation</title><link>https://htlin222.github.io/garden/Immunosuppression-Kidney-transplantation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Immunosuppression-Kidney-transplantation/</guid><description>Immunosuppression-Kidney transplantation : calcineurin inhib (tacrolimus&amp;gt;CsA) or CTLA4 inhib (belatacept) (NEJM 2016;374:333), antimetabolite (MMF&amp;gt;AZA), prednisone, mTOR inhib (sirolimus) if others contraindicated</description></item><item><title>Immunotherapies-asthma</title><link>https://htlin222.github.io/garden/Immunotherapies-asthma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Immunotherapies-asthma/</guid><description>Immunotherapies-asthma (NEJM 2017;377:965)
Allergen ImmunoRx (“allergy shots”) may help if sig. allerg. component (JAMA 2016;315:1715)
Anti-IgE (omalizumab) for uncontrolled mod-to-severe allergic asthma (w/ IgE &amp;gt;30) on ICS ± LABA (JAMA 2017; 318:279); ↓ exacerbations in severe asthma (Cochrane 2014;CD003559)</description></item><item><title>immunotherapy and cellular therapy</title><link>https://htlin222.github.io/garden/immunotherapy-and-cellular-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/immunotherapy-and-cellular-therapy/</guid><description>immunotherapy and cellular therapy [[template]]
[Toxicities associated with checkpoint inhibitor immunotherapy - UpToDate]( https://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy?search=irae&amp;source=search result&amp;amp;selectedTitle=1~53&amp;amp;usage type=default&amp;amp;display rank=1) Science: Cancer immunotherapy using checkpoint blockade - PubMed [[irAE]]</description></item><item><title>Impaired cell-mediated immunity</title><link>https://htlin222.github.io/garden/Impaired-cell-mediated-immunity/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Impaired-cell-mediated-immunity/</guid><description>Impaired cell-mediated immunity (CMI) (eg, HIV/AIDS, chronic steroids, posttransplant, DM, ESRD, autoimmune dis.) Bacteria: Salmonella spp., Campylobacter, Listeria, Yersinia, Legionella (Lancet 2016;387:376), Rhodococcus, Nocardia, TB, non-TB mycobacteria Fungi: Candida, Crypto, Histo, Coccidio, Aspergillus, Pneumocystis, Zygomycetes spp.</description></item><item><title>Implantable cardiac defibrillator ICD</title><link>https://htlin222.github.io/garden/Implantable-cardiac-defibrillator-ICD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Implantable-cardiac-defibrillator-ICD/</guid><description>Implantable cardiac defibrillator (ICD) (Circ 2019;140:e382)
RV lead: defib &amp;amp; pacing (± antitachycardia pacing [ATP] = burst pacing &amp;gt; VT rate to stop VT); ± RA lead for dual-chamber PPM.</description></item><item><title>incidence of vasculitides</title><link>https://htlin222.github.io/garden/incidence-of-vasculitides/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/incidence-of-vasculitides/</guid><description>incidence of vasculitides reported to be 40-60 cases per 1 million persons, with giant cell arteritis (GCA) being the most common type of primary systemic vasculitis among adults, particularly those aged &amp;gt; 50 years.</description></item><item><title>Indications for Permanent Pacing</title><link>https://htlin222.github.io/garden/Indications-for-Permanent-Pacing/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Indications-for-Permanent-Pacing/</guid><description>Indications for Permanent Pacing (JACC 2013;61:e6 &amp;amp; 2017;70:e39, Circ 2019;140:e382)
AV block 2° type II, high-grade or 3° AVB; symptomatic 1°, 2° type I AVB or asx with Lamin A/C or neuromuscular disease; bifasc or alter.</description></item><item><title>Indications for surgery-bacterial endocarditis</title><link>https://htlin222.github.io/garden/Indications-for-surgery-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Indications-for-surgery-bacterial-endocarditis/</guid><description>Indications for surgery-bacterial endocarditis (consult early; JTCS 2017;153:1241; Circ 2021;143:e72)
Emergent if refractory cardiogenic shock Urgent (during initial hospitalization): Sx HF Penetrating infection: periannular abscess, heart block, fistula, worsening conduction Persistent infection: ⊕ BCx after &amp;gt;5 d of appropriate abx, ↑ or ?</description></item><item><title>Indications for urgent dialysis</title><link>https://htlin222.github.io/garden/Indications-for-urgent-dialysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Indications-for-urgent-dialysis/</guid><description>Indications for urgent dialysis Acid-base disturbance: refractory acidemia
Electrolyte disorder: hyperK; hyperCa, hyperPO4, tumor lysis syndrome</description></item><item><title>indications of thoracentesis</title><link>https://htlin222.github.io/garden/indications-of-thoracentesis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/indications-of-thoracentesis/</guid><description>indications of thoracentesis all effusions &amp;gt;1 cm in decubitus view if suspect due to CHF, can diurese and see if effusions resolve (75% do so in 48 h); asymmetry, fever, chest pain or failure to resolve → thoracentesis [[parapneumonic effusions]] should be tapped ASAP (cannot exclude infxn clinically)</description></item><item><title>Indications PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/Indications-PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Indications-PA-catheter-and-tailored-therapy/</guid><description>Indications PA catheter and tailored therapy * Diagnosis and evaluation Ddx of shock (cardiogenic vs. distributive; espec if trial of IVF failed or is high risk) and of pulmonary edema (cardiogenic vs.</description></item><item><title>Infection as Etiologies of Classic FUO</title><link>https://htlin222.github.io/garden/Infection-as-Etiologies-of-Classic-FUO/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Infection-as-Etiologies-of-Classic-FUO/</guid><description>Infection as Etiologies of Classic FUO Tuberculosis: disseminated or extrapulm. disease can have normal CXR, PPD/IGRA, sputum AFB; bx (lung, liver, bone marrow) for granulomas has 80–90% yield in milliary disease</description></item><item><title>infections of the nervous system</title><link>https://htlin222.github.io/garden/infections-of-the-nervous-system/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/infections-of-the-nervous-system/</guid><description>infections of the nervous system [[cerebrospinal fluid lab results]]
[[acute bacterial meningitis]] [[aseptic meningitis]] [[encephalitis]] [[Bell’s palsy]] [[herpes zoster]] (SHINGLES) [[Cryptococcus neoformans]] [[herpes simplex virus infection]] 單純皰疹病毒 [[computed tomogram in central nervous system infection]]</description></item><item><title>infectious arthritis and bursitis</title><link>https://htlin222.github.io/garden/infectious-arthritis-and-bursitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/infectious-arthritis-and-bursitis/</guid><description>infectious arthritis and bursitis</description></item><item><title>infectious disease</title><link>https://htlin222.github.io/garden/infectious-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/infectious-disease/</guid><description>infectious disease [[pneumonia]] [[fungal infections]] [[infxns in immunosuppressed hosts]] [[urinary tract infections]] [[sexually transmitted infections]] [[skin and soft tissue infections]] [[infections of the nervous system]] [[bacteremia and endocarditis]] [[tuberculosis]] [[HIV AIDS]] [[tick-borne diseases]] [[fever syndromes]] [[antibiotics]] [[pathogen]] Resident 360 topics [[Diabetic Foot Infection]] [[opportunistic infections]] Tuberculosis Clostridium difficile Infection Tick-Borne Diseases Epidural Abscess and Vertebral Osteomyelitis, Meningitis/Encephalitis (Neurology) Endocarditis (Cardiology) Sexually Transmitted Infections (Women&amp;rsquo;s Health)</description></item><item><title>inflammatory bowel disease</title><link>https://htlin222.github.io/garden/inflammatory-bowel-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/inflammatory-bowel-disease/</guid><description>inflammatory bowel disease Definition (NEJM 2020;383:2652) Ulcerative colitis (UC): inflammation of the colonic mucosa; contiguous, starting at rectum Crohn’s disease (CD): transmural inflammation anywhere along GI tract, skip lesions Epidemiology &amp;amp; pathophysiology (Lancet 2016;387:156 &amp;amp; 2017;390:2769) Age of onset 15–30 y; bimodal w/ 2nd peak at 50–70 y; 1:1 M:F in N America</description></item><item><title>Inflammatory diarrhea</title><link>https://htlin222.github.io/garden/Inflammatory-diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Inflammatory-diarrhea/</guid><description>Inflammatory diarrhea (⊕ fecal WBC, calprotectin, lactoferrin; ⊕ FOB; fever, abd pain)
Infections: chronic C. diff, Entamoeba histolytica, Yersinia, CMV, TB especially in immunocompromised hosts.</description></item><item><title>INFLAMMATORY-Acute Infectious Etiologies</title><link>https://htlin222.github.io/garden/INFLAMMATORY-Acute-Infectious-Etiologies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/INFLAMMATORY-Acute-Infectious-Etiologies/</guid><description>INFLAMMATORY-Acute Infectious Etiologies Predom. colonic invasion. Small-vol diarrhea. LLQ cramps, tenesmus, fever, typically ⊕ fecal WBC or FOB.
Bacterial (SYSCC) Campylobacter Undercooked poultry, unpasteurized milk; carried by -puppies &amp;amp; kittens.</description></item><item><title>infxns in immunosuppressed hosts</title><link>https://htlin222.github.io/garden/infxns-in-immunosuppressed-hosts/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/infxns-in-immunosuppressed-hosts/</guid><description>infxns in immunosuppressed hosts Overview
Many Pts have ≥1 risk (eg, DM, ESRD, transplant, extremes of age) Accurate dx of opportunistic infections and targeted Rx key in this population The following is not an exhaustive list, but a delineation of common or classic etiologies (NEJM 2007;357:2601; Am J Med 2007;120:764; CID 2011;53:798) [[Humoral immune dysfunction]] [[Granulocytopenia or neutropenia]] [[Impaired cell-mediated immunity]] [[Organ dysfunction]] [[Biologics]]</description></item><item><title>Ingestions-caused-metabolic-acidosis</title><link>https://htlin222.github.io/garden/Ingestions-caused-metabolic-acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ingestions-caused-metabolic-acidosis/</guid><description>Ingestions-caused-metabolic-acidosis (NEJM 2018;378:270) Call poison control for guidance (02-28757525-821 北榮毒物科)
Acetaminophen Hepatitis Salicylates Fever, tachycardia, tinnitus; met. acid. + resp. alkalosis</description></item><item><title>Inherited Disorders of Connective Tissue</title><link>https://htlin222.github.io/garden/Inherited-Disorders-of-Connective-Tissue/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Inherited-Disorders-of-Connective-Tissue/</guid><description>Ehlers-Danlos syndrome (EDS) Epidermolysis bullosa (EB) Marfan syndrome Osteogenesis imperfecta</description></item><item><title>Inherited Hypercoagulable States</title><link>https://htlin222.github.io/garden/Inherited-Hypercoagulable-States/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Inherited-Hypercoagulable-States/</guid><description>Inherited Hypercoagulable States Factor V Leiden 3–7% 2.65 Activated protein C (APC) resistance Prothrombin mutation 2% 1.45 G20210A → ↑ prothrombin level Hyperhomocysteinemia 5–10% Inherited or acquired (vitamin defic.</description></item><item><title>Initial antibiotic therapy of fever and neutropenia</title><link>https://htlin222.github.io/garden/Initial-antibiotic-therapy-of-fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-antibiotic-therapy-of-fever-and-neutropenia/</guid><description>Initial antibiotic therapy of fever and neutropenia Empiric regimens should include antipseudomonal activity; consider VRE coverage if ⊕ Low risk: PO abx or home IV abx may be considered in select Pts (JCO 2013;31:1149) PO options: cipro+amoxicillin-clavulanate; levofloxacin; moxifloxacin (avoid if FQ Ppx) High risk: hospital admission &amp;amp; IV abx; monotherapy preferred options: cefepime, imipenem, meropenem, piperacillin/tazobactam, ceftazidime Antifungal Rx added for neutropenic fever ≥4 d despite abx: micafungin, liposomal amphotericin B, caspofungin, anidulafungin, voriconazole, &amp;amp; posaconazole are options</description></item><item><title>Initial anticoagulation options for-venous thromboembolism</title><link>https://htlin222.github.io/garden/Initial-anticoagulation-options-for-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-anticoagulation-options-for-venous-thromboembolism/</guid><description>Initial anticoagulation options for-venous thromboembolism (EHJ 2020;41:543; Chest 2021;160:e545)
Initiate immediately if high or intermed suspicion but dx test results will take ≥4 h</description></item><item><title>Initial evaluation diagnostic studies-acute aortic syndromes</title><link>https://htlin222.github.io/garden/Initial-evaluation-diagnostic-studies-acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-evaluation-diagnostic-studies-acute-aortic-syndromes/</guid><description>Initial evaluation diagnostic studies-acute aortic syndromes (Circ 2010;121:e266; EHJ 2018;39:739)
H&amp;amp;P, incl. bilat BP &amp;amp; radial pulses for symmetry; ECG w/ STE if propagates to cor CXR: abnl in 60–90% [↑ mediast.</description></item><item><title>Initial evaluation of change in mental status</title><link>https://htlin222.github.io/garden/Initial-evaluation-of-change-in-mental-status/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-evaluation-of-change-in-mental-status/</guid><description>Initial evaluation of change in mental status see [[Stepwise Evaluation of a Patient with Delirium]]
History (witness &amp;amp; background crucial): tempo, premorbid sx (eg, focal neuro deficits, HA, infxn, pain, falls), medical conditions (eg, dementia, epilepsy, onc, cardiac, psych, infection/immune status), accompanied by head trauma, current meds (eg, sedatives, opioids, anticoag, anticonvulsants, immunosuppressants), drug/alcohol use General exam: VS, breathing pattern (eg, Cheyne-Stokes), tongue bite (seizure), nuchal rigidity (meningitis, SAH; do not test if c/f trauma/cervical spine fx), ecchymoses, rash, signs of head trauma (eg, Battle sign, raccoon eyes, hemotympanum, CSF rhinorrhea), asterixis, liver disease stigmata, embolic phenomena/endocarditis, s/s drug use Neuro exam</description></item><item><title>Initial evaluation-management-inflammatory bowel disease</title><link>https://htlin222.github.io/garden/Initial-evaluation-management-inflammatory-bowel-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-evaluation-management-inflammatory-bowel-disease/</guid><description>Initial evaluation-management-inflammatory bowel disease H&amp;amp;P (✓ for intestinal &amp;amp; extraintestinal manifestations) and dx studies as above
Lab: consider CBC/diff, LFTs, iron studies, B12, folate, vit D, ESR, CRP, fecal calprotectin</description></item><item><title>Initial evaluation-solitary pulmonary nodule</title><link>https://htlin222.github.io/garden/Initial-evaluation-solitary-pulmonary-nodule/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-evaluation-solitary-pulmonary-nodule/</guid><description>Initial evaluation-solitary pulmonary nodule History: h/o cancer, smoking, age (&amp;lt;30 y = 2% malignant, +15% each decade &amp;gt;30)</description></item><item><title>Initial management-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Initial-management-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-management-gastrointestinal-bleeding/</guid><description>Initial management-gastrointestinal bleeding 嚴重度： [[Assess severity-initial management-gastrointestinal bleeding]] 病史 [[History-Initial management-gastrointestinal bleeding]]: 理學檢查 [[physical exam-initial management-gastrointestinal bleeding]]: 急救 [[resuscitation-initial management-gastrointestinal bleeding]]</description></item><item><title>initial test of hypophosphatemia</title><link>https://htlin222.github.io/garden/initial-test-of-hypophosphatemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/initial-test-of-hypophosphatemia/</guid><description>initial test of hypophosphatemia serum calcium, vitamin D, and parathyroid hormone levels; arterial blood gas; urine phosphorus and creatinine levels; fractional excretion of phosphorus; fractional excretion of phosphorus &amp;lt; 5% suggests a nonrenal mechanism (intracellular uptake or gastrointestinal); x-ray, if osteomalacia is suspected.</description></item><item><title>Initial treatment details of asthma</title><link>https://htlin222.github.io/garden/Initial-treatment-details-of-asthma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-treatment-details-of-asthma/</guid><description>Initial treatment details of asthma Oxygen to keep SaO2 ≥93–95%
Inhaled SABA (eg, albuterol) by MDI (4–8 puffs) or nebulizer (2.</description></item><item><title>Initial treatment-clostridioides difficile infection</title><link>https://htlin222.github.io/garden/Initial-treatment-clostridioides-difficile-infection-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-treatment-clostridioides-difficile-infection-/</guid><description>Initial treatment-clostridioides difficile infection (CID 2021;73:5; Am J Gastro 2021;116:1124)
If possible, d/c abx ASAP; stop antimotility agents &amp;amp; cholestyramine if using (binds vanco)</description></item><item><title>Initial workup-bronchiectasis</title><link>https://htlin222.github.io/garden/Initial-workup-bronchiectasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Initial-workup-bronchiectasis/</guid><description>Initial workup-bronchiectasis H&amp;amp;P: cough, dyspnea, copious sputum production, ±hemoptysis, inspiratory “squeaks”
CXR: scattered or focal; rings of bronchial cuffing; “tram track” of dilated, thick airways</description></item><item><title>inpatient oncology</title><link>https://htlin222.github.io/garden/inpatient-oncology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/inpatient-oncology/</guid><description>inpatient oncology Assessment of Hospitalized Cancer Patients</description></item><item><title>Insulin Preparations</title><link>https://htlin222.github.io/garden/Insulin-Preparations/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Insulin-Preparations/</guid><description>Insulin Preparations</description></item><item><title>integrase strand transfer inhibitor-INSTI-Antiretrovirals ARVs</title><link>https://htlin222.github.io/garden/integrase-strand-transfer-inhibitor-INSTI-Antiretrovirals-ARVs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/integrase-strand-transfer-inhibitor-INSTI-Antiretrovirals-ARVs/</guid><description>integrase strand transfer inhibitor-INSTI-Antiretrovirals (ARVs) bictegravir (BIC; Biktarvy) dolutegravir (DTG; Tivicay) elvitegravir (EVG; Vitekta) raltegravir (RAL; Isentress) cabotegravir (CAB; Vocabria) Class: diarrhea; weight gain; ↑ CPK DTG/BIC ↑ metformin levels; monitor glc DTG a/w 0.</description></item><item><title>interpretation of serum calcium</title><link>https://htlin222.github.io/garden/interpretation-of-serum-calcium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/interpretation-of-serum-calcium/</guid><description>interpretation of serum calcium 離子鈣仍然是評估鈣狀態的金標準，特別是如果由於低白蛋白血症、非典型或無症狀或血清鈣濃度最低限度降低而對低鈣血症的診斷存在疑問。如果沒有已知的可靠測量離子鈣的實驗室，則應使用鈣校正公式對血清白蛋白中的任何異常進行總鈣校正。
對於輕度低鈣血症或慢性低鈣血症（由於甲狀旁腺功能減退症）的患者，無法服用或吸收口服補充劑（如在需要長時間休養的複雜外科手術後可能發生），可能需要靜脈補鈣以預防急性低鈣血症。
最初，IV 鈣（1 或 2 g 葡萄糖酸鈣，相當於 90 或 180 mg 元素鈣，在 50 mL D5W 或 NS 中）可以在 10 到 20 分鐘內輸注。如果需要解決症狀，可在 10 至 60 分鐘後重複。等效劑量，SI 單位：2.</description></item><item><title>interstitial lung disease</title><link>https://htlin222.github.io/garden/interstitial-lung-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/interstitial-lung-disease/</guid><description>interstitial lung disease WORKUP OF ILD [[Broad categories-interstitial lung disease]] [[Rule out mimickers of ILD]] [[History and physical exam-interstitial lung disease]] [[Diagnostic studies-interstitial lung disease]]</description></item><item><title>intestinal ischemia</title><link>https://htlin222.github.io/garden/intestinal-ischemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/intestinal-ischemia/</guid><description>intestinal ischemia [[acute mesenteric ischemia]] [[chronic mesenteric ischemia]] [[ischemic colitis]]</description></item><item><title>Intracardiac pressures PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/Intracardiac-pressures-PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Intracardiac-pressures-PA-catheter-and-tailored-therapy/</guid><description>Intracardiac pressures PA catheter and tailored therapy Transmural pressure (≈ preload) = measured intracardiac pressure – intrathoracic pressure</description></item><item><title>intrathecal chemotherapy</title><link>https://htlin222.github.io/garden/intrathecal-chemotherapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/intrathecal-chemotherapy/</guid><description>intrathecal chemotherapy The distinction between the two different leptomeningeal tumor spreading patterns described above has an impact on the indication for an intrathecal chemotherapy:</description></item><item><title>Intrinsic acute kidney injury etiology</title><link>https://htlin222.github.io/garden/Intrinsic-acute-kidney-injury-etiology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Intrinsic-acute-kidney-injury-etiology/</guid><description>Intrinsic acute kidney injury etiology [[Acute tubular necrosis (ATN)]] Pigmented granular [[muddy brown casts]] ± RBCs &amp;amp; protein from tubular damage FENa &amp;gt;2%, BUN/Cr &amp;lt;20 (except pigment, CIN) FEUN &amp;gt;50% [[Acute interstitial nephritis]] WBCs, WBC casts, ± RBCs w/ neg UCx ⊕ urine eos in abx ⊕ lymphs in NSAIDs [[Small-med vessel acute kidney injury]] ± RBCs ⊕ urine eos in chol emboli Glomerulonephritis Dysmorphic RBCs, RBC casts</description></item><item><title>IPF idiopathic pulm fibrosis</title><link>https://htlin222.github.io/garden/IPF-idiopathic-pulm-fibrosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/IPF-idiopathic-pulm-fibrosis/</guid><description>IPF idiopathic pulm fibrosis UIP imaging pattern: reticular opacities, honeycombing, traction bronchiectasis; peripheral, subpleural, &amp;amp; basal
Sx &amp;gt;12 mo
5-y mort ~80%</description></item><item><title>ipratropium</title><link>https://htlin222.github.io/garden/ipratropium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ipratropium/</guid><description>ipratropium Atrovent，屬於一種支氣管擴張藥。
本品通常用於治療慢性阻塞性肺病以及哮喘，通常以吸入劑或霧化劑的形式銷售。 通常藥效會於15-30分鐘後開始作用， 作用時間維持3至5小時。 口乾、咳嗽，以及支氣管炎。 潛在副作用包含尿瀦留、呼吸道痙攣，</description></item><item><title>Ipratropium of COPDAE</title><link>https://htlin222.github.io/garden/Ipratropium-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ipratropium-of-COPDAE/</guid><description>Ipratropium of COPDAE MDI 4–8 puffs q1–2h or Nebulizer 0.5 mg q1–2h First-line therapy (NEJM 2011;364:1093)</description></item><item><title>irAE</title><link>https://htlin222.github.io/garden/irAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/irAE/</guid><description>irAE [[my report about irAE]] [[oncology]] [[immunotherapy and cellular therapy]]
reference Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series - PubMed PD-1/PD-L and autoimmunity: A growing relationship - ScienceDirect Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab - PubMed Oral mucositis—case series of a rare adverse effect associated with immunotherapy | SpringerLink</description></item><item><title>Iron deficiency</title><link>https://htlin222.github.io/garden/Iron-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Iron-deficiency/</guid><description>Iron deficiency (Lancet 2021;397:233)
↓ marrow iron &amp;amp; depleted body iron stores → ↓ heme synthesis → microcytosis → anemia</description></item><item><title>Iron-supplementation</title><link>https://htlin222.github.io/garden/Iron-supplementation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Iron-supplementation/</guid><description>Iron-supplementation ? IV (not PO) if NYHA II/III, EF ≤40%, Fe-defic (ferritin &amp;lt;100 or 100– 300 &amp;amp; TSAT &amp;lt;20%). ~20% ↓ HF hosp.</description></item><item><title>Irradiated blood products</title><link>https://htlin222.github.io/garden/Irradiated-blood-products/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Irradiated-blood-products/</guid><description>Irradiated blood products Prevents donor T-cell engraftment and risk of transfusion-assoc. GVHD (HSCT, heme malignancy, congenital immunodeficiency).</description></item><item><title>irregular of narrow complex</title><link>https://htlin222.github.io/garden/irregular-of-narrow-complex/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/irregular-of-narrow-complex/</guid><description>irregular of narrow complex AF, AFL, or MAT
Control rate w/ diltiazem or metoprolol or amiodarone</description></item><item><title>Irritable bowel syndrome</title><link>https://htlin222.github.io/garden/Irritable-bowel-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Irritable-bowel-syndrome/</guid><description>Irritable bowel syndrome (JAMA 2015;313:949; Gastro 2015;149:1399 &amp;amp; 2018;154:1140)
Abd discomfort for 6+ mos a/w ≥2: improves w/ defecation, Δ stool frequency, Δ stool form</description></item><item><title>ischemic colitis</title><link>https://htlin222.github.io/garden/ischemic-colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ischemic-colitis/</guid><description>ischemic colitis Definition &amp;amp; pathophysiology Nonocclusive disease 2° to Δs in systemic circulation or anatomic/fxnal Δs in local mesenteric vasculature; often underlying etiology unknown, frequently seen in elderly “Watershed” areas (splenic flexure &amp;amp; rectosigmoid) most susceptible; 25% involve R side; confers worse prognosis (Clin Gastroenterol Hepatol 2015;13:1969) Clinical manifestations, diagnosis, &amp;amp; treatment Usually p/w cramping LLQ pain w/ overtly bloody stool; fever and peritoneal signs should raise clinical suspicion for infarction Disease spectrum: reversible colopathy (35%), transient colitis (15%), chronic ulcerating colitis (20%), resulting stricture (10%), gangrene (15%), fulminant colitis (&amp;lt;5%) Dx: flex sig/colonoscopy or CT abd/pelvis to make diagnosis; r/o IBD, infectious colitis Treatment: bowel rest, IV fluids, broad-spectrum abx, serial abd exams; surgery for infarction, fulminant colitis, hemorrhage, failure of med Rx, recurrent sepsis, stricture Resolution w/in 48 h w/ conservative measures occurs in &amp;gt;50% of cases</description></item><item><title>Ischemic hepatitis</title><link>https://htlin222.github.io/garden/Ischemic-hepatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ischemic-hepatitis/</guid><description>Ischemic hepatitis “Shock liver” w/ AST &amp;amp; ALT &amp;gt;1000 + ↑↑ LDH (ALT:LDH ratio often &amp;lt;1:5); delayed ↑↑ Tbili</description></item><item><title>Isolated proteinuria</title><link>https://htlin222.github.io/garden/Isolated-proteinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Isolated-proteinuria/</guid><description>Isolated proteinuria By def’n: asx, normal renal fxn, sed, &amp;amp; imaging, no h/o renal disease Etiologies Functional (fever, exercise, CHF) Orthostatic (only when upright) Idiopathic (transient or persistent)</description></item><item><title>Isopropanol-toxicology</title><link>https://htlin222.github.io/garden/Isopropanol-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Isopropanol-toxicology/</guid><description>Isopropanol-toxicology CNS depression, gastritis
Supportive care</description></item><item><title>IV Drugs for Hypertensive Crises</title><link>https://htlin222.github.io/garden/IV-Drugs-for-Hypertensive-Crises/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/IV-Drugs-for-Hypertensive-Crises/</guid><description>IV Drugs for Hypertensive Crises (Circ 2018;138:e426; Stroke 2018;49:46) Labetalol 20–80 mg IVB q10min or 0.4–2 mg/min AoD, ACS, Stroke, Eclampsia Esmolol 0.</description></item><item><title>IV immune globulin</title><link>https://htlin222.github.io/garden/IV-immune-globulin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/IV-immune-globulin/</guid><description>IV immune globulin Polyvalent IgG from &amp;gt;1000 donors. For postexposure prophylaxis (eg, HAV), certain autoimmune disorders (eg, ITP, Guillain-Barré, MG, CIDP), congenital or acquired hypogammaglobulinemia (CVID, CLL).</description></item><item><title>Ivabradine</title><link>https://htlin222.github.io/garden/Ivabradine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ivabradine/</guid><description>Ivabradine Reasonable if EF ≤35%, NYHA II or III, HR ≥70, NSR on max bB.
18% ↓ CV mort or HF hosp (Lancet 2010;376:875)</description></item><item><title>JAMA 2021;325:962</title><link>https://htlin222.github.io/garden/JAMA-2021325962/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/JAMA-2021325962/</guid><description>JAMA 2021;325:962 重要性 肺癌是美國第二常見的癌症，也是美國癌症死亡的主要原因。 2020年，估計有228820人被診斷出患有肺癌，135720人死於該疾病。肺癌最重要的危險因素是吸煙。年齡增長也是肺癌的危險因素。肺癌的預後通常不佳，總5年生存率為20.5％。 但是，早期肺癌的預後較好，並且更適合治療。
目的 是更新其2013年建議，美國預防服務工作組（USPSTF）委託對使用低劑量計算機斷層掃描（LDCT）（LDCT）進行篩查的準確性以及肺癌篩查的益處和危害，並委託一項協作建模研究，旨在提供有關開始和結束篩查，最佳篩選間隔以及與多元風險預測模型的修改版本相比，不同篩選策略的相對益處和危害的信息。
人口 此建議聲明適用於50至80歲的成年人，他們有20年的吸煙史，目前吸煙或在過去15年內戒菸。
證據 評估USPSTF以適度的確定性得出結論：使用LDCT進行肺癌的年度篩查在肺癌高風險的人中具有適度的淨益處，因為年齡，累積累積暴露於菸草煙霧以及自從戒菸以來的年份。
建議 USPSTF建議在50至80歲的成年人中對LDCT進行 年度篩查，他們擁有20年的吸煙史，目前吸煙或在過去15年內戒菸。 一旦一個人在15年沒有吸煙或製定健康問題，該篩查應停止篩查，該問題實質上限制了預期壽命或進行治愈性肺手術的能力或意願。 （b建議）該建議取代了2013年USPSTF聲明，該聲明建議在55至80歲的成年人中對LDCT進行年度篩查，他們擁有30年的吸煙史，目前在過去15年內吸煙或退出。
來自: [[lung cancer]]</description></item><item><title>JAMA review of hyponatremia</title><link>https://htlin222.github.io/garden/JAMA-review-of-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/JAMA-review-of-hyponatremia/</guid><description>Diagnosis and Management of Hyponatremia JAMA. 2022;328(3):280-291. 經過這麼多年後，熱騰騰的Hyponatremia review.
&amp;ldquo;Hyponatremia, which is defined as a serum sodium level of less than 135 mEq/L, affects approximately 5% of adults.</description></item><item><title>jupyter</title><link>https://htlin222.github.io/garden/jupyter/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/jupyter/</guid><description>docker run -i &amp;ndash;rm &amp;ndash;user root -p 8888:8888 -e NB UID=1026 -e NB GID=100 -e NB USER=lizard -e CHOWN HOME=yes -e CHOWN HOME OPTS=&amp;quot;-R&amp;quot; -w &amp;ldquo;/home/${NB USER}&amp;rdquo; -v /volume1/docker/jupyter:/home/${NB USER}/ jupyter/minimal-notebook:latest</description></item><item><title>K-sparing diuretics</title><link>https://htlin222.github.io/garden/K-sparing-diuretics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/K-sparing-diuretics/</guid><description>K-sparing diuretics (NEJM 2017;377:1964)
Drugs: spironolactone (Aldactone), amiloride, triamterene, eplerenone
Mech: ↓ Na reabsorption (~1%) in collecting duct (amiloride/triamterene inhibit principal cell Na channel [ENaC]; spironolactone/eplerenone inhibit mineralocorticoid receptor).</description></item><item><title>Kawasaki disease</title><link>https://htlin222.github.io/garden/Kawasaki-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Kawasaki-disease/</guid><description>Kawasaki disease Usually Asian children &amp;lt; 4 years old.
CRASH Conjunctivitis, Bilateral nonexudative bulbar Rash (polymorphous desquamating), Adenopathy (cervical) Strawberry tongue (oral mucositis), Hand-foot changes (edema, erythema), Burn: fever.</description></item><item><title>ketamine</title><link>https://htlin222.github.io/garden/ketamine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ketamine/</guid><description>ketamine contraindicated in patients with underlying conditions in which increased blood pressure would pose a risk of complications such as aortic dissection, uncontrolled hypertension, myocardial infarction, or aneurysms.</description></item><item><title>KEYNOTE-181</title><link>https://htlin222.github.io/garden/KEYNOTE-181/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/KEYNOTE-181/</guid><description>KEYNOTE-181 Purpose: Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy.
Patients and methods: In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, that progressed after one prior therapy, to pembrolizumab 200 mg every 3 weeks for up to 2 years or chemotherapy (investigator&amp;rsquo;s choice of paclitaxel, docetaxel, or irinotecan).</description></item><item><title>kidney disease</title><link>https://htlin222.github.io/garden/kidney-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/kidney-disease/</guid><description>kidney disease [[acute kidney injury (AKI)]] [[disease-specific management of kidney disease]] [[chronic kidney disease (CKD)]] [[diuresis]] [[renal replacement and dialysis]]</description></item><item><title>Kidney transplantation</title><link>https://htlin222.github.io/garden/Kidney-transplantation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Kidney-transplantation/</guid><description>Kidney transplantation (Med Clin N Am 2016;100:435)
Refer when GFR &amp;lt;20. Contraindic: active malig, infxn, ischemia, noncompl, subst use 5-yr survival: living donor 91%; deceased donor 70–84% (AJKD 2016;23:281).</description></item><item><title>King’s College Criteria for Liver Transplantation consideration</title><link>https://htlin222.github.io/garden/Kings-College-Criteria-for-Liver-Transplantation-consideration/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Kings-College-Criteria-for-Liver-Transplantation-consideration/</guid><description>King’s College Criteria for Liver Transplantation consideration Acetaminophen ALF: arterial pH &amp;lt;7.30 or Grade III/IV enceph + INR &amp;gt;6.5 + Cr &amp;gt;3.</description></item><item><title>Laboratory Findings in Calcium Disorders</title><link>https://htlin222.github.io/garden/Laboratory-Findings-in-Calcium-Disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Laboratory-Findings-in-Calcium-Disorders/</guid><description>Laboratory Findings in Calcium Disorders [[interpretation of serum calcium]] [[Serum parathyroid hormone (PTH) concentrations in hypercalcemia and hypocalcemia]] Ca: bones parathyroid hormone: thief of bones 25-(OH)D: intestine to blood Ca PTH Disease PO4 25-(OH)D 1,25-(OH),D up upup Hyperparathyroidism (1° and 3°) down down to normal normal to up up up or normal Familial hypocalciuric hypercalcemia down var.</description></item><item><title>Laboratory studies-cirrhosis</title><link>https://htlin222.github.io/garden/Laboratory-studies-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Laboratory-studies-cirrhosis/</guid><description>Laboratory studies-cirrhosis LFTs: ↑ bili, ↑ PT/INR (poor correlation w/ bleeding; factor VIII nl b/c not synthesized by liver), ↓ alb, ± ↑ aminotransferases (AST &amp;gt;ALT if late) and ↑ Aϕ (variable)</description></item><item><title>Lactic acidosis</title><link>https://htlin222.github.io/garden/Lactic-acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Lactic-acidosis/</guid><description>Lactic acidosis Type A: hypoxic (eg, shock, mesenteric ischemia, CO poisoning, cyanide) Type B: nonhypoxic. ↓ clearance (eg, hepatic dysfxn) or ↑ generation [eg, malig, EtOH, thiamine def.</description></item><item><title>laryngoscopy and confirmation of placement</title><link>https://htlin222.github.io/garden/laryngoscopy-and-confirmation-of-placement/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/laryngoscopy-and-confirmation-of-placement/</guid><description>laryngoscopy and confirmation of placement ✨重點: 在確保適當的準備、設備設置、功能監測器、定位和預氧合後，通常會為患者施用引起呼吸暫停的藥物和麻痺劑，這兩種藥物都是根據患者的情況和臨床情況選擇的。 還應注意，在某些情況下，例如心臟驟停，可能不需要誘導劑。 當患者被認為已適當麻醉時，喉鏡由提供者的左手拿著，而右手用他或她的拇指和食指以剪狀動作打開患者的嘴。 然後將喉鏡插入口中，注意不要損壞患者的嘴唇或牙齒。 在彎曲的 MAC 刀片的情況下，舌頭向左掃過，刀片的尖端放置在會厭前面的會厭谷中，而直的米勒刀片插入會厭下方的中線位置。 喉鏡手柄向上向前提起，露出聲帶。 切勿將手柄向後傾斜，因為這會導致牙齒損傷。 然後在直接可視化下通過聲帶插入 ETT。 插入 ETT 後，管心針（如果使用）和喉鏡一樣被移除。 然後使用 10 mL 注射器將引導氣球充氣至不超過 30 mmHg 的壓力。 為了確認氣管放置，ETT 連接到氣囊通氣迴路並進行通氣，觀察雙側胸部上升、ETT 中的冷凝氣，最重要的是，通過二氧化碳圖觀察連續的呼氣末 CO 2 - 被認為是黃金標準。 如果未檢測到持續的呼氣末 CO 2 ，應懷疑食管插管並重新嘗試喉鏡檢查。 ETT 的遠端應位於聲帶之外但在carina隆突之上，避免主幹插管。 在成人中，這通常與患者唇部的 21-23 厘米相關。 放置後應立即 CXR 以確認正確位置。</description></item><item><title>Late renal dysfxn</title><link>https://htlin222.github.io/garden/Late-renal-dysfxn/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Late-renal-dysfxn/</guid><description>Late renal dysfxn usual AKI causes + calcineurin tox, rejection (NEJM 2010;363:1451), BK virus, recurrence of 1° disease; usual w/u + immunosupp levels, donor-specific antigen (DSA), BK virus load, U/S, then bx if no other cause (CJASN 2008;3:S56; CJASN 2011;6:1774)</description></item><item><title>Left-ventricular-hypertrophy</title><link>https://htlin222.github.io/garden/Left-ventricular-hypertrophy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Left-ventricular-hypertrophy/</guid><description>Left-ventricular-hypertrophy Etiologies: HTN, AS/AI, HCM, coarctation of aorta
Criteria (all w/ Se &amp;lt;50%, Sp &amp;gt;85%; accuracy affected by age, sex, race, BMI)</description></item><item><title>Lennox Gastaut Syndrome</title><link>https://htlin222.github.io/garden/Lennox-Gastaut-Syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Lennox-Gastaut-Syndrome/</guid><description>Lennox Gastaut Syndrome 這個症候群是一個多元性癲癇發作類型的頑固性癲癇患者會出現多種不同類型的發作表現；例如：在睡眠的非快速動眼期時出現僵直發作、非典型失神性發作、失張力型發作或是較少見的肌抽躍發作、廣泛性大發作及局部性抽搐。在發病之後，它會造成智能障礙和退化。在腦電圖中看見彌漫性慢棘複合波（diffuse slow spike-and-wave）和陣發性快速活動期的變化。
好發年齡由1歲至7歲（高峰年齡為3歲至5歲）。患者的男女比約為5:1左右。既往病史、出生史和新生兒史可能是正常的，或可能會有腦部結構異常的病史。神經學檢查和頭圍可能是正常，或者會出現與其腦部結構異常相關的神經發異常。生長發展、智能和認知常有發展障礙，但偶然還是會看到正常發展的小孩。但當發作後，小孩子的其後生長發展就會停滯或甚至退步。
大約有10-30%的患者在早期曾有過其他種類的癲癇症候群，例如West syndromes和Ohtahara syndromes等病史；不過就發病年齡來說，有過去癲癇病史和沒有的族群，其發病年紀並沒有太大差異。偶然有些個案過去會有熱痙攣、局部發作或全身性發作等病史。目前認為的成因包含了腦部結構異常（這是大部分主要的原因，約佔了70%的個案）、遺傳性病因，但仍有些病人是找不到致病原因的。雖然目前的病生理還不清楚，也沒有動物模式被建立，不過有一些假說認為跟免疫誘發的機轉些關聯。
長期來說，其預後並不樂觀，不過還是有很大變異性的。有很少數的患者還是可以擁有正常工作，但約有五到八成的患者具有智能障礙，且需要許多額外的協助。僵直發作通常是此症候群的多元發作類型中最不易控制的一種，也因此約有3-7%的患者會因為這類發作所造成的意外身故。</description></item><item><title>lenvatinib</title><link>https://htlin222.github.io/garden/lenvatinib/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lenvatinib/</guid><description> 藥物介紹：Lenvatinib (Lenvima®,樂衛瑪)-財團法人台灣癌症臨床研究發展基金會
[[hepatocellular carcinoma]]] Lenvatinib在2017年發表的第二期臨床試驗數據顯示，無法開刀或局部治療的肝癌患者(46人)，使用lenvatinib，有37% (17人)的腫瘤可以縮小，有41%(19人)腫瘤可以維持不變。 接著，lenvatinib又進行了一個與肝癌另一標靶藥物sorafenib療效比較的第三期臨床試驗，根據2017美國癌症醫學會年會 (ASCO)於2017-06-04發表的最新數據，總共約950人參加此臨床試驗，一組使用lenvatinib這個藥物，另一組使用sorafenib這個藥物，結果發現，使用lenvatinib的存活期(13.6個月)並不輸給sorafenib(12.3個月)，且有較多(24%)的病人腫瘤顯著縮小，對照組則只有9.2%。惡化時間為7.4個月，對照組為3.7個月，比對照組延長3.7個月。雖然lenvatnib其高血壓的副作用發生率較對照組高，但最令患者困擾的皮膚副作用則較少，lenvatinib為27%，對照組則有52%。 雖然lenvatinib目前尚未取得在肝癌的臨床適應症，此藥在肝癌的效果已有第三期臨床試驗資料可參考。</description></item><item><title>leptomeningeal disease</title><link>https://htlin222.github.io/garden/leptomeningeal-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/leptomeningeal-disease/</guid><description>leptomeningeal disease [[urgent symptomatic interventions of leptomeningeal disease]]</description></item><item><title>Leuko-reduced blood products</title><link>https://htlin222.github.io/garden/Leuko-reduced-blood-products/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Leuko-reduced-blood-products/</guid><description>Leuko-reduced blood products WBCs cause HLA alloimmunization &amp;amp; fever (cytokines) and carry CMV. For chronically transfused Pts, potential Tx recip., h/o febrile nonhemolytic transfusion rxn, cases in which CMV-neg products desired but unavailable.</description></item><item><title>levamisole</title><link>https://htlin222.github.io/garden/levamisole/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/levamisole/</guid><description>levamisole 適應症 治療蛔蟲、鉤蟲、糞圓蟲
Levamisole是tetramisole的左旋異構物，為一廣效的抗寄生蟲藥物， 可使蟲體的神經與奮，並導致肌肉強直、癱瘓，還有阻斷合成能量所 需的酵素，使蟲體無法獲得能量而死亡。</description></item><item><title>Lidocaine</title><link>https://htlin222.github.io/garden/Lidocaine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Lidocaine/</guid><description>Lidocaine 1.0~1.5mg/kg 2% 50kg 75mg 胖一點的100mg</description></item><item><title>Likelihood of ACS Circ 2007 116 e148 Circ 1994 90 1 613 22</title><link>https://htlin222.github.io/garden/Likelihood-of-ACS-Circ-2007-116-e148-Circ-1994-90-1-613-22-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Likelihood-of-ACS-Circ-2007-116-e148-Circ-1994-90-1-613-22-/</guid><description>Likelihood of ACS Circ 2007 116 e148 Circ 1994 90 1 613 22 | Feature | High (any of below) | Intermediate (no high features, any of below) | Low (no high/inter.</description></item><item><title>lipid disorders</title><link>https://htlin222.github.io/garden/lipid-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lipid-disorders/</guid><description>lipid disorders [[Measurements-lipid disorders]] [[Drug Treatment-lipid disorders]] [[Treatment of LDL-C]] (Lancet 2014;384:607) [[Treatment of other lipid fractions]] (Lancet 2014;384:618 &amp;amp; 626) [[2018 ACC AHA Cholesterol Guidelines]] (Circ 2019;139:e1082)</description></item><item><title>Lithium-toxicology</title><link>https://htlin222.github.io/garden/Lithium-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Lithium-toxicology/</guid><description>Lithium-toxicology N/V/D, tremor, hyperreflexia, clonus, drowsiness, seizure, ↑ QT, AV block, bradycardia
IVF (NS), maintain UOP
Consider hemodialysis</description></item><item><title>Localization of MI</title><link>https://htlin222.github.io/garden/Localization-of-MI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Localization-of-MI/</guid><description>Localization of MI Anatomic Area ECG Leads w/ STE Coronary Artery Septal V1–V2 ± aVR Proximal LAD Anterior V3–V4 LAD Apical V5–V6 Distal LAD, LCx, or RCA Lateral I, aVL LCx Inferior II, III, aVF ± aVR RCA (~85%), LCx (~15%) RV V1–V2 &amp;amp; V4R (most Se) Proximal RCA Posterior ST depression V1–V3 (= STE V7–V9 posterior leads, ✓ if clinical suspicion) RCA or LCx</description></item><item><title>Long-term anticoagulation options-venous thromboembolism</title><link>https://htlin222.github.io/garden/Long-term-anticoagulation-options-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Long-term-anticoagulation-options-venous-thromboembolism/</guid><description>Long-term anticoagulation options-venous thromboembolism For nonpregnant Pt without severe renal dysfunction or active cancer → DOAC
For severe renal insufficiency or APLAS → warfarin.</description></item><item><title>Long-term follow-up of Migraine</title><link>https://htlin222.github.io/garden/Long-term-follow-up-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Long-term-follow-up-of-Migraine/</guid><description>Long-term follow-up of Migraine Manage migraine long-term in primary care Repatriate patients from specialist care in a timely manner and with a comprehensive treatment plan Maintain stability of effective treatment in primary care and react to change</description></item><item><title>Long-term management-wide-complex tachycardias WCTS</title><link>https://htlin222.github.io/garden/Long-term-management-wide-complex-tachycardias-WCTS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Long-term-management-wide-complex-tachycardias-WCTS/</guid><description>Long-term management-wide-complex tachycardias (WCTS) (EHJ 2015;36:2793; Circ 2018;138:e272; NEJM 2019;380:1555)
Workup: echo to ✓ LV fxn, cath or stress test to r/o ischemia, ?</description></item><item><title>Loop diuretics</title><link>https://htlin222.github.io/garden/Loop-diuretics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Loop-diuretics/</guid><description>Loop diuretics (NEJM 2017;377:1964)
Drugs: furosemide (Lasix), torsemide, bumetanide (Bumex), ethacrynic acid [[Mechanisms-Loop diuretics]] Dosing: bioavailability PO furosemide ~50%, PO torsemide &amp;amp; bumetanide ~90% 40 mg IV = 80 mg PO Lasix = 20 mg PO/IV torsemide = 1 mg IV/PO bumetanide Dose furosemide bid-qid; qd dosing can yield initial diuresis, but then anti-natriuresis.</description></item><item><title>Low-voltage</title><link>https://htlin222.github.io/garden/Low-voltage/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Low-voltage/</guid><description>Low-voltage QRS amplitude (R + S) &amp;lt;5 mm in all limb leads &amp;amp; &amp;lt;10 mm in all precordial leads</description></item><item><title>lumbar puncture after brain imaging</title><link>https://htlin222.github.io/garden/lumbar-puncture-after-brain-imaging/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lumbar-puncture-after-brain-imaging/</guid><description>lumbar puncture after brain imaging A computed tomography (CT) scan of the head is frequently ordered by clinicians prior to performing a lumbar puncture (LP) to rule out an intracranial abnormality with elevated intracranial pressure</description></item><item><title>lung cancer</title><link>https://htlin222.github.io/garden/lung-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lung-cancer/</guid><description>lung cancer [[Epidemiology and risk factors-lung cancer]] Screening ([[JAMA 2021;325:962]]) Annual low-dose chest CT in ≥20 pack-year current or former (quit w/in 15 y) smokers, age 50–80 y → 20% ↓ lung cancer-related mortality (NEJM 2020;382:503) High rates of screen-detected nodules.</description></item><item><title>lung transplant</title><link>https://htlin222.github.io/garden/lung-transplant/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lung-transplant/</guid><description>lung transplant Overview Indications: end stage, progressive decline despite max medical Rx, &amp;lt;2-y life expectancy; COPD, ILD (IPF), pulmonary HTN, cystic fibrosis, alpha 1-antitrypsin Contraindic: age &amp;gt;70, uncontrolled/unRx’d infxn, malig in prior 5 yrs, severe non-pulm dis.</description></item><item><title>LV failure</title><link>https://htlin222.github.io/garden/LV-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/LV-failure/</guid><description>LV failure Diurese to achieve PCWP ~14 → ↓ pulmonary edema, ↓ myocardial O2 demand ↓ Afterload → ↑ stroke volume &amp;amp; CO, ↓ myocardial O2 demand.</description></item><item><title>lymphadenopathy</title><link>https://htlin222.github.io/garden/lymphadenopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lymphadenopathy/</guid><description>lymphadenopathy Viral HIV, EBV, CMV, HSV, VZV, hepatitis, measles, rubella
Bacterial Generalized (brucellosis, leptospirosis, TB, atypical mycobacteria, syphilis)
Localized (streptococci, staphylococci, cat-scratch disease, tularemia)</description></item><item><title>Lymphocytic pleocytosis</title><link>https://htlin222.github.io/garden/Lymphocytic-pleocytosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Lymphocytic-pleocytosis/</guid><description>Lymphocytic pleocytosis Lymphocytic [[pleocytosis]] is an abnormal increase in the amount of lymphocytes in the cerebrospinal fluid (CSF)</description></item><item><title>lymphocytosis</title><link>https://htlin222.github.io/garden/lymphocytosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lymphocytosis/</guid><description>lymphocytosis (&amp;gt;4000–5000/µL)
Infection Usually viral; “atypical lymphocytes” with mononucleosis syndromes Other: pertussis, toxoplasmosis
Hypersensitivity Drug-induced, serum sickness
Autoimmune Rheumatoid arthritis (large granular lymphocytes), malignant thymoma</description></item><item><title>lymphoma and CLL</title><link>https://htlin222.github.io/garden/lymphoma-and-CLL/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/lymphoma-and-CLL/</guid><description>lymphoma and CLL Pathology Outlines - Lymphoma [[Molecular description of lymphoma]]</description></item><item><title>macos config</title><link>https://htlin222.github.io/garden/macos-config/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/macos-config/</guid><description>macos config MACOS CATALINA 10.15 第三方软件文件提示已损坏解决办法 macOS 10.15 后，苹果加强了对第三方渠道下载软件的证书校验，对于无证书的应用，不允许打开。可以试试使用下面命令：
1 sudo xattr -r -d com.apple.quarantine xxx.app</description></item><item><title>macrocytic anemias</title><link>https://htlin222.github.io/garden/macrocytic-anemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/macrocytic-anemias/</guid><description>macrocytic anemias includes megaloblastic and nonmegaloblastic causes
[[Megaloblastic anemia]] [[Folate deficiency]] [[Vitamin B12 deficiency]] [[Nonmegaloblastic macrocytic anemias]]</description></item><item><title>Major-risk-factor-modification-stable ischemic heart disease</title><link>https://htlin222.github.io/garden/Major-risk-factor-modification-stable-ischemic-heart-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Major-risk-factor-modification-stable-ischemic-heart-disease/</guid><description>Major-risk-factor-modification-stable ischemic heart disease Lipids: statin (typically high-intensity) ± ezetimibe &amp;amp; PCSK9i (see “Dyslipidemia”) BP &amp;lt;130/80 (see “Hypertension”); in SIHD may opt for ACEI and βB (if angina) Diabetes management (qv): HbA1c ≤7% and consider GLP1RA or SGLT2i Smoking cessation; influenza vaccine Diet (↑ vegetables, fruits, whole grains; ↓ saturated fat, trans fatty acids, sweets, red meat, Na); target BMI 18.</description></item><item><title>Malabsorption</title><link>https://htlin222.github.io/garden/Malabsorption/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Malabsorption/</guid><description>Malabsorption (fatty; ↑ fecal fat, ↑ osmotic gap, ↓ diarrhea w/ fasting)
Defective mucosal absorption of nutrients b/c Δs in: mucosal surface (surgical resection) or gen.</description></item><item><title>Maldigestion</title><link>https://htlin222.github.io/garden/Maldigestion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Maldigestion/</guid><description>Maldigestion (fatty; ↑ fecal fat, ↑ osmotic gap, ↓ diarrhea w/ fasting)
Defective intraluminal hydrolysis of nutrients, typ. 2/2 pancreatic/hepatobiliary pathology</description></item><item><title>Malignancy workup-adrenal incidentalomas</title><link>https://htlin222.github.io/garden/Malignancy-workup-adrenal-incidentalomas/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Malignancy-workup-adrenal-incidentalomas/</guid><description>Malignancy workup-adrenal incidentalomas CT and MRI characteristics may suggest adenoma vs. carcinoma Benign features: unenhanced CT &amp;lt;10 Hounsfield units or CT contrast-medium washout &amp;gt;50% at 10 min; size &amp;lt;4 cm; smooth margins, homogenous and hypodense appearance; can follow such incidentalomas w/ periodic scans Suspicious features: size ≥4 cm or ↑ size on repeat scan; &amp;gt;10 Hounsfield units on CT, irregular margins, heterogeneous, dense or vascular appearance; h/o malignancy or young age.</description></item><item><title>Malignancy-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Malignancy-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Malignancy-gastrointestinal-bleeding/</guid><description>Malignancy-gastrointestinal bleeding Endoscopic hemostasis of mass temporizing measure till cancer Rx</description></item><item><title>Mallory-Weiss tear</title><link>https://htlin222.github.io/garden/Mallory-Weiss-tear/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mallory-Weiss-tear/</guid><description>Mallory-Weiss tear GE jxn lacerations due to vomiting → ↑ intraabd pressure &amp;amp; shearing Often self-resolve; Rx→ antiemetics, PPI, endoscopic therapy</description></item><item><title>management of Barrett’s esophagitis</title><link>https://htlin222.github.io/garden/management-of-Barretts-esophagitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/management-of-Barretts-esophagitis/</guid><description>management of Barrett’s esophagitis PPI.
W/o dysplasia: surveillance EGD q3–5y.
Low-grade dysplasia: EGD q12mo; possible endoscopic eradication.
High-grade dysplasia: endoscopic eradication; consider chemoprophylaxis w/ high-dose PPI &amp;amp; ASA (Lancet 2018;392:400).</description></item><item><title>Management of hyperglycemia in inPts</title><link>https://htlin222.github.io/garden/Management-of-hyperglycemia-in-inPts/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Management-of-hyperglycemia-in-inPts/</guid><description>Management of hyperglycemia in inPts (for ICU: see “Sepsis”) (Clin Ther 2013;35:724)
[[Hyperglycemic Emergencies]] (Endocrinology)
Identify reversibl causes/precipitants (dextrose IVF, glucocorticoids, postop, ↑ carb diet)</description></item><item><title>Management of ICU patient-pulmonary hypertension</title><link>https://htlin222.github.io/garden/Management-of-ICU-patient-pulmonary-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Management-of-ICU-patient-pulmonary-hypertension/</guid><description>Management of ICU patient-pulmonary hypertension Avoid tachyarrhythmias &amp;amp; overly aggressive volume resuscitation
Caution w/ vasodilators if any L-sided dysfunction</description></item><item><title>Management-acute liver failure</title><link>https://htlin222.github.io/garden/Management-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Management-acute-liver-failure/</guid><description>Management-acute liver failure (J Clin Exp Hepatol 2015;5:S104; Gastro 2017;152:644)
ICU care at liver transplant center for hemodynamic &amp;amp; ventilatory support; CVVH for AKI</description></item><item><title>management-inflammatory bowel disease</title><link>https://htlin222.github.io/garden/management-inflammatory-bowel-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/management-inflammatory-bowel-disease/</guid><description>management-inflammatory bowel disease (Lancet 2017;398:1756; Mayo 2017;92:1088)
[[Initial evaluation-management-inflammatory bowel disease]] Goals of treatment (Ther Adv Gastro 2015;8:143)
Induce remission of acute flare → maintain remission; mucosal healing 1° goal Step-up Rx (least → most toxic) vs.</description></item><item><title>Management-solitary pulmonary nodule</title><link>https://htlin222.github.io/garden/Management-solitary-pulmonary-nodule/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Management-solitary-pulmonary-nodule/</guid><description>Management-solitary pulmonary nodule Low risk (&amp;lt;5%): serial CT (freq depending on risk); shared decision w/ Pt re: bx</description></item><item><title>Managing complications of Migraine</title><link>https://htlin222.github.io/garden/Managing-complications-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Managing-complications-of-Migraine/</guid><description>Managing complications of Migraine Identify comorbid conditions Select drugs and adiust their use according to comorbidities present Alleviate comborbidities if possible to improve outcome</description></item><item><title>Managing complications-acute kidney injury AKI</title><link>https://htlin222.github.io/garden/Managing-complications-acute-kidney-injury-AKI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Managing-complications-acute-kidney-injury-AKI/</guid><description>Managing complications-acute kidney injury (AKI) May take 1–3 wk to recover from ATN; anticipate volume overload, ↑ K, ↑ PO4, acidosis</description></item><item><title>Managing migraine in special populations</title><link>https://htlin222.github.io/garden/Managing-migraine-in-special-populations/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Managing-migraine-in-special-populations/</guid><description>Managing migraine in special populations Older people Secondary headache, comorbidities and adverse events are all more likely Poor evidence base for all drugs in this age group Children and adolescents Be aware that presentation can differ from migraine in adults Parents and schools have important roles in the management of young children Bed rest alone can be sufficient Use ibuprofen for acute treatment and propranolol, amitriptyline or topiramate for prevention Women who are pregnant or breastfeeding Use paracetamol for acute treatment Avoid preventive treatment if possible Women with menstrual migraine Perimenstrual preventive therapy with long-acting NSAID or triptan</description></item><item><title>Markdownify</title><link>https://htlin222.github.io/garden/Markdownify/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Markdownify/</guid><description>To import a URL as Markdown, turn on the option under &amp;ldquo;Editing&amp;rdquo; in nvALT&amp;rsquo;s Preferences. Now, when you drag a URL to the notes list, it will convert it to Markdown as much as possible.</description></item><item><title>MASCC Risk Index</title><link>https://htlin222.github.io/garden/MASCC-Risk-Index/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/MASCC-Risk-Index/</guid><description>MASCC Risk Index Use in neutropenic patients (see ANC calculator) with fever at least 100.4°F (38ºC). Do not use in patients with acute leukemia undergoing induction chemotherapy or allogeneic hematopoietic stem cell transplant conditioning, per IDSA guidelines.</description></item><item><title>Massive transfusion</title><link>https://htlin222.github.io/garden/Massive-transfusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Massive-transfusion/</guid><description>Massive transfusion Large-vol. PRBC → ↓ Ca, ↑ K, ↓ plt, ↑ coags; initial ratio of 1 PRBC: 1 plt:1 FFP accepted but controversial, follow labs (JAMA Surg 2017;152:574).</description></item><item><title>Measure plasma osmolality</title><link>https://htlin222.github.io/garden/Measure-plasma-osmolality/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Measure-plasma-osmolality/</guid><description>Measure plasma osmolality Hypotonic (Posm &amp;lt;280) most common scenario; true excess of free H2O relative to Na
Isotonic (Posm 280–295): rare lab artifact from</description></item><item><title>Measure Uosm</title><link>https://htlin222.github.io/garden/Measure-Uosm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Measure-Uosm/</guid><description>Measure Uosm although useful for dx in limited circumstances, b/c almost always &amp;gt;300 Uosm &amp;lt;100 in ↑ H2O intake (1o polydipsia) or ↓ solute intake (beer potomania, “tea &amp;amp; toast”)</description></item><item><title>Measurements-lipid disorders</title><link>https://htlin222.github.io/garden/Measurements-lipid-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Measurements-lipid-disorders/</guid><description>Measurements-lipid disorders 腰圍: 體重*1/2 from ileic creast
Lipoproteins = lipid core (cholesteryl esters &amp;amp; triglycerides) + phospholipid surface + proteins.</description></item><item><title>Mechanical complications</title><link>https://htlin222.github.io/garden/Mechanical-complications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mechanical-complications/</guid><description>Mechanical complications Mechanical complications (incid. &amp;lt;1% for each; typically occur a few days post-MI)
Free wall rupture: ↑ risk w/ lysis, large MI, ↑ age, ♀, HTN; p/w PEA or hypoTN, pericardial sx, tamponade; Rx: volume resusc.</description></item><item><title>Mechanical intervention-venous thromboembolism</title><link>https://htlin222.github.io/garden/Mechanical-intervention-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mechanical-intervention-venous-thromboembolism/</guid><description>Mechanical intervention-venous thromboembolism (JACC 2020;76:2117)
[[catheter-directed pharmacomech]]
Catheter-based clot extraction (eg, AngioVac or FlowTriever): ↓ PA pressure</description></item><item><title>mechanical ventilation</title><link>https://htlin222.github.io/garden/mechanical-ventilation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mechanical-ventilation/</guid><description>mechanical ventilation [[Indications-mechanical ventilation ]]
SUPPORTIVE STRATEGIES PRIOR TO INTUB. OR AFTER EXTUB. [[Oxygen Delivery Systems]] [[Noninvasive Positive Pressure Ventilation (NPPV)]]</description></item><item><title>Mechanical-prosthetic-heart-valves</title><link>https://htlin222.github.io/garden/Mechanical-prosthetic-heart-valves/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mechanical-prosthetic-heart-valves/</guid><description>Mechanical-prosthetic-heart-valves Bileaflet (eg, St. Jude Medical); tilting disk; caged-ball Very durable (20–30 y), but thrombogenic and ∴ require anticoagulation consider if age &amp;lt;50 y or if anticoagulation already indicated (JACC 2010;55:2413)</description></item><item><title>Mechanisms and Etiologies of Platelet Function Abnormalities</title><link>https://htlin222.github.io/garden/Mechanisms-and-Etiologies-of-Platelet-Function-Abnormalities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mechanisms-and-Etiologies-of-Platelet-Function-Abnormalities/</guid><description>Mechanisms and Etiologies of Platelet Function Abnormalities</description></item><item><title>mechanisms of hypophosphatemia</title><link>https://htlin222.github.io/garden/mechanisms-of-hypophosphatemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mechanisms-of-hypophosphatemia/</guid><description>mechanisms of hypophosphatemia Intracellular uptake of phosphate from the extracellular fluid #anki acute respiratory alkalosis: increased intracellular pH stimulates phosphofructokinase activity and glycolysis which leads to intracellular uptake of phosphate; hyperventilation (caused for example by sepsis, anxiety, diabetic ketoacidosis, or other underlying conditions) can precipitate intracellular shift of phosphate into cells; refeeding of malnourished patients; administration of insulin or glucose (which stimulates insulin secretion); hungry bone syndrome.</description></item><item><title>Mechanisms-Loop diuretics</title><link>https://htlin222.github.io/garden/Mechanisms-Loop-diuretics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mechanisms-Loop-diuretics/</guid><description>Mechanisms-Loop diuretics inhib NaK2Cl cotransporter in thick ascending limb (ThAL, site of 25% Na reabsorp) → ↓ medullary osmotic gradient &amp;amp; ↓ free H2O reabsorption via ADH</description></item><item><title>Meckel’s diverticulum</title><link>https://htlin222.github.io/garden/Meckels-diverticulum/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Meckels-diverticulum/</guid><description>Meckel’s diverticulum Congenital intestinal pouch due to incomplete obliteration of vitelline duct. 2% of pop, w/in 2′ of IC valve, 2″ long, ♂:♀ 2:1, can present as obscure GIB in adults.</description></item><item><title>medical</title><link>https://htlin222.github.io/garden/medical/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/medical/</guid><description>歡迎來到🦎的Medical Wiki [[cardiology]] [[pulmonary]] [[gastroenterology]] [[nephrology]] [[hematology]] [[oncology]] [[infectious disease]] [[endocrinology]] [[rheumatology]] 內科的其他知識 [[clinical reasoning]] ⚡[[ICU]] [[neurology]] [[ambulatory]] [[ACLS]] [[emergency medicine]] [[POCUS]] [[geriatrics]] [[pain and palliative care]] 其他科 [[dermatology]] [[ophthalmic issues]] [[woman health]] [[obs gyn issues]] [[radiology]] [[mental health]] [[surgical issues]] Draft paper note: [[journals/index.</description></item><item><title>Medical Therapy for IBD</title><link>https://htlin222.github.io/garden/Medical-Therapy-for-IBD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Medical-Therapy-for-IBD/</guid><description>Medical Therapy for IBD (NEJM 2021;385:1302)
[[Medical Therapy of Ulcerative Colitis]] [[Medical Therapy of Crohn’s Disease]]</description></item><item><title>Medical Therapy of Crohn’s Disease</title><link>https://htlin222.github.io/garden/Medical-Therapy-of-Crohns-Disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Medical-Therapy-of-Crohns-Disease/</guid><description>Medical Therapy of Crohn’s Disease Mild Oral 5-ASA: for colonic Crohn’s disease
Symptom control: loperamide/cholestyramine for diarrhea management.</description></item><item><title>Medical Therapy of Ulcerative Colitis</title><link>https://htlin222.github.io/garden/Medical-Therapy-of-Ulcerative-Colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Medical-Therapy-of-Ulcerative-Colitis/</guid><description>Medical Therapy of Ulcerative Colitis Mild Rectal mesalamine or glucocorticoids as suppository or enema Mild- moderate Oral 5-ASA: many formulations (sulfasalazine, mesalamine, olsalazine, balsalazide) depending on disease location.</description></item><item><title>Medication causes of abnormal LFTs</title><link>https://htlin222.github.io/garden/Medication-causes-of-abnormal-LFTs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Medication-causes-of-abnormal-LFTs/</guid><description>Medication causes of abnormal LFTs</description></item><item><title>Medullary thyroid cancer</title><link>https://htlin222.github.io/garden/Medullary-thyroid-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Medullary-thyroid-cancer/</guid><description>Medullary thyroid cancer Neuroendocrine tumor of C cells, peak incidence 40 to 60 y, a/w MEN2A and MEN2B Most commonly solitary nodule; calcitonin production (presents with diarrhea, flushing) and level used to trend dz progression, dx w/ FNA (Se 50–80%); mortality 25–50% at 5 y Surgery first-line treatment</description></item><item><title>Megaloblastic anemia</title><link>https://htlin222.github.io/garden/Megaloblastic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Megaloblastic-anemia/</guid><description>Megaloblastic anemia Impaired DNA synthesis → cytoplasm matures faster than nucleus → ineffective erythropoiesis and macrocytosis; due to folate or B12 deficiency; also in MDS</description></item><item><title>Membranoproliferative GN</title><link>https://htlin222.github.io/garden/Membranoproliferative-GN/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Membranoproliferative-GN/</guid><description>Membranoproliferative GN (5%, mixed nephrotic/nephritic features; CJASN 2014;9:600)
Immune complex mediated: infection (esp. HCV ± cryos, IE, HBV, “shunt” nephritis, other chronic infxns), SLE, cryos, Sjögren’s, lymphomas, dysproteinemia, idiopathic</description></item><item><title>Membranous nephropathy</title><link>https://htlin222.github.io/garden/Membranous-nephropathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Membranous-nephropathy/</guid><description>Membranous nephropathy (30%; CJASN 2017;12:938, JASN 2021;32:268):
Primary: Ab to PLA2R [70%], THSD7A [5%], other (EXT1-2, NELL1, Sema3B)
Secondary: infxn (HBV, HCV, HIV, syphilis) autoimmune (eg, SLE) carcinomas drugs (NSAIDs, penicillamine).</description></item><item><title>mental health</title><link>https://htlin222.github.io/garden/mental-health/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mental-health/</guid><description>mental health</description></item><item><title>Mesangial proliferative GN</title><link>https://htlin222.github.io/garden/Mesangial-proliferative-GN/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mesangial-proliferative-GN/</guid><description>Mesangial proliferative GN (? atypical forms of MCD/FSGS, 5%) IgM, C1q nephropathy</description></item><item><title>metabolic-acidosis</title><link>https://htlin222.github.io/garden/metabolic-acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/metabolic-acidosis/</guid><description>metabolic-acidosis Initial workup (NEJM 2014;371:1434) ✓ [[anion gap]] [[Etiologies-of-AG-Metabolic-Acidosis]] [[Workup-for-AG-metabolic-acidosis]] (AJKD 2021;78:A16) [[Ingestions-caused-metabolic-acidosis]] [[Etiologies of Non-AG Metabolic Acidosis]] [[Workup for non-AG metabolic acidosis]] [[Renal tubular acidoses]] Figure 4-2 [[Approach to metabolic acidosis]]</description></item><item><title>metabolic-alkalosis</title><link>https://htlin222.github.io/garden/metabolic-alkalosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/metabolic-alkalosis/</guid><description>metabolic-alkalosis [[Pathophysiology-metabolic-alkalosis]] [[Etiologies-of-Metabolic-Alkalosis]]
Workup metabolic alkalosis Check volume status and UCl UCl &amp;lt;25 mEq/L → saline responsive UCl &amp;gt;40 mEq/L → saline resistant (unless currently receiving diuretics) (UNa unreliable determinant of volume status in alkalemia → ↑ HCO3- excretion → ↑ Na excretion; negatively charged HCO3- w/ Na+ maintaining electrical neutrality) If UCl &amp;gt;40 and volume replete, ✓ UK; UK &amp;lt;20 laxative abuse; UK &amp;gt;30, ✓ blood pressure Treatment of severe metabolic alkalosis (pH &amp;gt;7.</description></item><item><title>metastatic esophageal cancer</title><link>https://htlin222.github.io/garden/metastatic-esophageal-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/metastatic-esophageal-cancer/</guid><description>metastatic esophageal cancer trial after fluropyrimidine and platinum-based chemotherapy
[[KEYNOTE-181]] [[ATTRACTION-3]] [[CPS-22C3]] [[Dako 28-8]] [[Diagnostic and staging evaluation]]</description></item><item><title>Methanol-toxicology</title><link>https://htlin222.github.io/garden/Methanol-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Methanol-toxicology/</guid><description>Methanol-toxicology CNS depression, blindness
↑ AG &amp;amp; OG met. acidosis
Ethanol or fomepizole, NaHCO3
Consider hemodialysis</description></item><item><title>Methotrexate</title><link>https://htlin222.github.io/garden/Methotrexate/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Methotrexate/</guid><description>Methotrexate MTX is a folic acid antagonist. DNA synthesis is inhibited by inhibition of dihydrofolate reductase, which provides reduced folates for purine synthesis.</description></item><item><title>methylprednisolone</title><link>https://htlin222.github.io/garden/methylprednisolone/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/methylprednisolone/</guid><description>methylprednisolone [[acute respiratory distress syndrome]] IV (succinate): Loading dose of 1 mg/kg over 30 minutes, 1 to 14: 1 mg/kg/day in divided doses or as a continuous infusion.</description></item><item><title>MI in absence of obstructive CAD</title><link>https://htlin222.github.io/garden/MI-in-absence-of-obstructive-CAD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/MI-in-absence-of-obstructive-CAD/</guid><description>MI in absence of obstructive CAD Definition: MI but w/o coronary stenosis ≥50% in any major epicardial vessel More common in younger Pts, women, Black/Pacific race or Hispanic Advanced coronary imaging (eg, OCT) &amp;amp; cardiac MRI to exclude missed coronary obstruction, other causes of myocyte injury (eg, myocarditis), other causes of ↑ Tn (eg, PE) ~75% ischemic (ie, plaque disruption identified) and 25% alternative dx (eg, myocarditis)</description></item><item><title>Microangiopathic hemolytic anemia</title><link>https://htlin222.github.io/garden/Microangiopathic-hemolytic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microangiopathic-hemolytic-anemia/</guid><description>Microangiopathic hemolytic anemia (MAHA; NEJM 2014;371:654)
Intra-arteriolar fibrin damages RBCs → acquired intravascular hemolysis
Etiologies: hemolytic-uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), malignancy, malignant HTN, eclampsia/HELLP, mech.</description></item><item><title>Microbiology and severity-diabetic foot infections</title><link>https://htlin222.github.io/garden/Microbiology-and-severity-diabetic-foot-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microbiology-and-severity-diabetic-foot-infections/</guid><description>Microbiology and severity-diabetic foot infections (CID 2004;39:885)
Mild (superficial ulcer, no involvement of deeper structures, surrounding erythema &amp;lt;2 cm, and no systemic illness): usually S.</description></item><item><title>Microbiology in Bacterial Meningitis</title><link>https://htlin222.github.io/garden/Microbiology-in-Bacterial-Meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microbiology-in-Bacterial-Meningitis/</guid><description>Microbiology in Bacterial Meningitis 六隻：S.N.H.L.E.S
(NEJM 2011;364:2016)
S. pneumoniae (30–60%) Look for preceding infection (bacteremia, pneumonia, endocarditis) Drug-resistant S. pneumoniae: ~40% PCN-resistant (even intermediate resistance problematic) ~&amp;lt;10% 3rd-gen.</description></item><item><title>Microbiology-necrotizing soft-tissue infections</title><link>https://htlin222.github.io/garden/Microbiology-necrotizing-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microbiology-necrotizing-soft-tissue-infections/</guid><description>Microbiology-necrotizing soft-tissue infections Necrotizing soft tissue infections = NSTI
Type I: polymicrobial (mixed aerobes &amp;amp; anaerobes), typically in older Pts w/ above RFs.</description></item><item><title>Microbiology-of-Pneumonia</title><link>https://htlin222.github.io/garden/Microbiology-of-Pneumonia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microbiology-of-Pneumonia/</guid><description>Microbiology-of-Pneumonia Clinical Setting: CAP Etiologies No pathogen identified in 50–60%, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in &amp;lt;5% Viruses: influenza, RSV, hMPV, parainfluenza, rhinovirus, coronavirus S.</description></item><item><title>Microbiology-skin and soft tissue infections</title><link>https://htlin222.github.io/garden/Microbiology-skin-and-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microbiology-skin-and-soft-tissue-infections/</guid><description>Microbiology-skin and soft tissue infections 皮膚和軟組織感染 (SSTI) 很常見，範圍從輕度蜂窩組織炎到危及生命的壞死性軟組織感染 (NSTI)。關鍵的管理考慮因素包括做出準確的診斷、評估感染的化膿性和嚴重程度，以及選擇抗生素以針對最可能的微生物。在本節中，我們將介紹以下疾病的診斷和治療
(CID 2014;59:e10)
Purulent: MRSA (NEJM 2006;355:666) causes up to 75% of purulent skin/soft tissue infections, followed by MSSA and strep Non-purulent: Strep, MSSA, aerobic GNRs.</description></item><item><title>Microbiology-urinary tract infections</title><link>https://htlin222.github.io/garden/Microbiology-urinary-tract-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microbiology-urinary-tract-infections/</guid><description>Microbiology-urinary tract infections Uncomplicated: E. coli (80%), Proteus, Klebsiella, S. saprophyticus (CID 2004;39:75). In healthy, nonpregnant women, lactobacilli, enterococci, Group B strep, and coag-neg staph (except S.</description></item><item><title>microcytic anemias</title><link>https://htlin222.github.io/garden/microcytic-anemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/microcytic-anemias/</guid><description>microcytic anemias [[Approach to microcytic anemias]] [[Iron deficiency]] [[Thalassemias]] [[Sideroblastic anemia]]</description></item><item><title>Microscopic polyangiitis</title><link>https://htlin222.github.io/garden/Microscopic-polyangiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Microscopic-polyangiitis/</guid><description>Microscopic polyangiitis Necrotizing vasculitis commonly involving lung, kidneys, and skin with pauci-immune glomerulonephritis and palpable purpura. Presentation similar to granulomatosis with polyangiitis Similar to GPA, but w/o ENT/upper airway involvement &amp;amp; nongranulomatous Epidemiology: incidence 4/million/y.</description></item><item><title>Migraine</title><link>https://htlin222.github.io/garden/Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Migraine/</guid><description>Migraine 小麻內容 [[Definition and clinical manifestations of Migraine]] [[Treatment of Migraine]] (Lancet 2021;397:1505 &amp;amp; Continuum 2021;27:613) Step 1: [[When to suspect migraine]] Step 2: [[Diagnosis of migraine]] Step 3: [[Education and patient centricity]] Step 4: [[Acute treatment of Migraine]] Step 5: [[Preventive treatment of Migraine]] Step 6: [[Managing migraine in special populations]] Step 7: [[Follow-up, treatment response and failure of Migraine]] Step 8: [[Managing complications of Migraine]] Step 9: [[Recognizing and managing comorbidities of Migraine]] Step 10: [[Long-term follow-up of Migraine]]</description></item><item><title>Migraine with aura</title><link>https://htlin222.github.io/garden/Migraine-with-aura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Migraine-with-aura/</guid><description>Migraine with aura [[aura]]
Approximately one third of individuals with migraine experience aura, either with every attack or with some attacks.</description></item><item><title>Migraine without aura</title><link>https://htlin222.github.io/garden/Migraine-without-aura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Migraine-without-aura/</guid><description>Migraine without aura Migraine without aura is characterized by recurrent headache attacks that last 4–72 h. Typical features of an attack include a unilateral location, pulsating quality, moderate or severe pain intensity, and aggravation by routine physical activity,</description></item><item><title>Milk-alkali syndrome</title><link>https://htlin222.github.io/garden/Milk-alkali-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Milk-alkali-syndrome/</guid><description>Milk-alkali syndrome 乳鹼綜合徵由高鈣血症、代謝性鹼中毒和與攝入大量鈣和可吸收鹼相關的急性腎損傷三聯徵組成。 該綜合徵最初與使用牛奶和碳酸氫鈉治療消化性潰瘍疾病有關[1]。 牛奶-鹼綜合徵曾經是高鈣血症的典型病因，但隨著消化性潰瘍病新療法的出現幾乎消失了，並且被認為是導致高鈣血症病例不到 1% 的原因 三個因素是造成這種發病率增加的原因： - 重視鈣療法對骨質疏鬆症的防治。 - 現成的非處方碳酸鈣製劑。 - 使用碳酸鈣以減少慢性腎病患者繼發性甲狀旁腺功能亢進（參見“成人慢性腎病高磷血症的管理”）</description></item><item><title>Minimal change disease</title><link>https://htlin222.github.io/garden/Minimal-change-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Minimal-change-disease/</guid><description>Minimal change disease (20%, more common in children; CJASN 2017;12:332) allergies, NSAIDs, ampicillin, Hodgkin’s disease, SLE, DM, MG, celiac disease</description></item><item><title>mitral-regurgitation</title><link>https://htlin222.github.io/garden/mitral-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mitral-regurgitation/</guid><description>mitral-regurgitation [[Etiology-mitral-regurgitation]] (NEJM 2010;363:156 &amp;amp; 2020;383:1458) [[Clinical-manifestations-mitral-regurgitation]] [[Physical-exam-mitral-regurgitation]] [[Diagnostic-studies-mitral-regurgitation]] (Circ 2021;143:e72) [[Treatment-mitral-regurgitation]] (Circ 2021;143:e72)</description></item><item><title>mitral-stenosis</title><link>https://htlin222.github.io/garden/mitral-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mitral-stenosis/</guid><description>mitral-stenosis [[Etiology-mitral-stenosis]] (Lancet 2012;379:953) [[Clinical manifestations-mitral-stenosis]] (Lancet 2009;374:1271) [[Physical exam-mitral-stenosis]] [[Diagnostic studies-mitral-stenosis]] [[Treatment-mitral-stenosis]] (Lancet 2016;387:1324; Circ 2021;143:e72)</description></item><item><title>mitral-valve-prolapse</title><link>https://htlin222.github.io/garden/mitral-valve-prolapse/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/mitral-valve-prolapse/</guid><description>mitral-valve-prolapse Definition and Etiology
Billowing of MV leaflet ≥2 mm above mitral annulus in parasternal long axis echo view Primary: sporadic or familial myxomatous proliferation of spongiosa of MV apparatus Secondary: trauma, endocarditis, congenital, CTD (eg, Marfan’s, OI, Ehlers-Danlos) Clinical manifestations (usually asymptomatic) MR, endocarditis, emboli, arrhythmias (rarely SCD from VT from papillary muscle) High-pitched, midsystolic click (earlier w/ ↓ preload) ± mid-to-late systolic murmur No Rx per se [endocarditis Ppx not rec.</description></item><item><title>Mixed-disorders</title><link>https://htlin222.github.io/garden/Mixed-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mixed-disorders/</guid><description>Mixed-disorders If compensation less or greater than predicted, may be two disorders: PaCO2 too low → concomitant 1° resp. alk.</description></item><item><title>Modalities-renal replacement and dialysis</title><link>https://htlin222.github.io/garden/Modalities-renal-replacement-and-dialysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Modalities-renal-replacement-and-dialysis/</guid><description>Modalities-renal replacement and dialysis [[Hemodialysis (HD)]] Physiology: Diffusion Access: AV fistula/graft or CVC Prescription: Duration, volume goal; K, Na, Ca, HCO3 in bath, anticoag Complic.</description></item><item><title>model for clinical reasoning</title><link>https://htlin222.github.io/garden/model-for-clinical-reasoning/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/model-for-clinical-reasoning/</guid><description>model for clinical reasoning Step 1: Identify the Problem Step 2: Frame the Differential Diagnosis Step 3: Organize the Differential Diagnosis Step 4: Limit the Differential Diagnosis Step 5: Explore Possible Diagnoses Using History and Physical Exam Findings Step 6: [[Rank the Differential Diagnosis]] Step 7: Test Your Hypotheses Step 8: Re-rank the Differential Based on New Data Step 9: Test the New Hypotheses</description></item><item><title>Modification to initial antibiotic regimen based on site-specific evaluation of fever and neutropenia</title><link>https://htlin222.github.io/garden/Modification-to-initial-antibiotic-regimen-based-on-site-specific-evaluation-of-fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Modification-to-initial-antibiotic-regimen-based-on-site-specific-evaluation-of-fever-and-neutropenia/</guid><description>Modification to initial antibiotic regimen based on site-specific evaluation of fever and neutropenia Vancomycin only if HoTN, PNA, clinically apparent catheter-related or soft-tissue infxn, gram ⊕ BCx, mucositis + on quinolone Ppx; d/c when BCx ⊖ × 48 h for GPCs Mouth/esoph (ulcer, thrush): anaerobic (if necrotizing), anti-HSV and/or antifungal Rx Sinus/nasal: add vanc if periorbital cellulitis, ampho if concern for Aspergillus/Mucor Abd pain/diarrhea: PO vanc if concern for C.</description></item><item><title>Modified Duke Criteria</title><link>https://htlin222.github.io/garden/Modified-Duke-Criteria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Modified-Duke-Criteria/</guid><description>Modified Duke Criteria Definitive: 2 major or 1 major+3 minor or 5 minor; Possible: 1 major+1 minor or 3 minor</description></item><item><title>Modified Wells Pretest Probability Scoring for PE</title><link>https://htlin222.github.io/garden/Modified-Wells-Pretest-Probability-Scoring-for-PE-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Modified-Wells-Pretest-Probability-Scoring-for-PE-/</guid><description>Modified Wells Pretest Probability Scoring for PE (Annals 2011;154:709)
*Prior PE or DVT=1.5 points
*Active cancer =1.0
*Immobilization (bed rest ≥3 d) or surgery w/in 4 wk=1.</description></item><item><title>Molecular description of lymphoma</title><link>https://htlin222.github.io/garden/Molecular-description-of-lymphoma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Molecular-description-of-lymphoma/</guid><description>Molecular description of lymphoma Marginal zone B cell lymphoma, MALT type IGH clonally rearranged t(11;18)
DLBCL IGH clonally rearranged t(8;14) c-myc-IGH t(14;18) IGH-BCL2</description></item><item><title>molecular diagnostics</title><link>https://htlin222.github.io/garden/molecular-diagnostics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/molecular-diagnostics/</guid><description>molecular diagnostics Sequencing Cytogenetics</description></item><item><title>monocytosis</title><link>https://htlin222.github.io/garden/monocytosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/monocytosis/</guid><description>monocytosis (&amp;gt;500/µL)
Infection Usually TB, SBE, Listeria, Brucella, Rickettsia, fungi, parasites, syphilis
Inflammation IBD, sarcoidosis, collagen vascular diseases
Stress MI, splenectomy, exercise (Cytokine 2013;61:364)</description></item><item><title>Monomorphic ventricular tachycardia MMVT</title><link>https://htlin222.github.io/garden/Monomorphic-ventricular-tachycardia-MMVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Monomorphic-ventricular-tachycardia-MMVT/</guid><description>Monomorphic ventricular tachycardia (MMVT) All beats look similar; predominantly upward in V1 = RBBB-type vs. downward = LBBB-type In obviously structurally abnormal heart: prior MI (scar); CMP In apparently nl heart that is actually diseased: subtle HCM, infiltrative CMP, myocarditis, arrhythmogenic CMP (ACM): incomplete RBBB, ε wave (terminal notch in QRS) &amp;amp; TWI in V1–V3 on resting ECG LBBB-type VT, dx w/ MRI (Lancet 2009;373:1289) In structurally normal heart w/ normal resting ECG &amp;amp; cardiac MRI: RVOT VT: LBBB-type VT or PVCs w/ inferior axis; typically ablate LVOT VT: RBBB-type VT or PVCs w/ superior axis; responds to verapamil</description></item><item><title>Mount-Sinai-Expert-Guides</title><link>https://htlin222.github.io/garden/Mount-Sinai-Expert-Guides/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mount-Sinai-Expert-Guides/</guid><description>Mount-Sinai-Expert-Guides PART 1: BASIC TECHNIQUES AND PROCEDURES, 1 1 [[Airway-Management]], 3 2 Sedation and Analgesia, 10 3 Vascular Access, 17 4 Bedside Ultrasound, 26 5 Bronchoscopy, 37 6 Bedside Percutaneous Dilational Tracheostomy, 42 7 Nutritional Support and Total Parenteral Nutrition, 49 8 Glycemic Control, 55 9 Prevention of Complications, 62 10 Palliative Care, 68</description></item><item><title>muddy brown casts</title><link>https://htlin222.github.io/garden/muddy-brown-casts/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/muddy-brown-casts/</guid><description>muddy brown casts Urine Sediment of the Month: Granular &amp;amp; &amp;ldquo;Muddy Brown&amp;rdquo; Casts - Renal Fellow Network
尿液沉積物顯示多種泥濘的棕色顆粒鑄件。 這些發現強烈暗示著急性腎損傷患者（急性腎衰竭）的急性管狀壞死。</description></item><item><title>Multiple Endocrine Neoplasia</title><link>https://htlin222.github.io/garden/Multiple-Endocrine-Neoplasia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Multiple-Endocrine-Neoplasia/</guid><description>Multiple Endocrine Neoplasia Type Main Features
1 (MENIN inactiv.) Parathyroid hyperplasia/adenomas → hypercalcemia (~100% penetrance) Pancreatic islet cell neoplasia (gastrin, VIP, insulin, glucagon) Pituitary adenomas (fxn or non-fxn)</description></item><item><title>Mx of ACLS Tachycardia Algorithm</title><link>https://htlin222.github.io/garden/Mx-of-ACLS-Tachycardia-Algorithm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Mx-of-ACLS-Tachycardia-Algorithm/</guid><description>Mx of ACLS Tachycardia Algorithm adenosine 6 mg rapid IVP then 20-cc NS bolus, 12 mg IVP q2min 2 if needed</description></item><item><title>my report about irAE</title><link>https://htlin222.github.io/garden/my-report-about-irAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/my-report-about-irAE/</guid><description>https://docs.google.com/presentation/d/1JZhMp-Iv gJbsajKC7M-fHTpygJ3Or npNY85xAuhTg/edit?usp=sharing</description></item><item><title>myelodysplastic syndromes</title><link>https://htlin222.github.io/garden/myelodysplastic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/myelodysplastic-syndromes/</guid><description>myelodysplastic syndromes see: [[pancytopenia]]</description></item><item><title>Myelophthisic anemia</title><link>https://htlin222.github.io/garden/Myelophthisic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Myelophthisic-anemia/</guid><description>Myelophthisic anemia (see also “Primary Myelofibrosis”)
Infiltration of bone marrow by cancer (commonly metastatic solid tumors), leukemia, infection, fibrosis (primary myelofibrosis), granulomas, lysosomal storage disorders</description></item><item><title>myeloproliferative neoplasms</title><link>https://htlin222.github.io/garden/myeloproliferative-neoplasms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/myeloproliferative-neoplasms/</guid><description>[[index]]</description></item><item><title>MYOCARDITIS</title><link>https://htlin222.github.io/garden/MYOCARDITIS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/MYOCARDITIS/</guid><description>MYOCARDITIS Etiologies Infectious (Lancet 2012;379:738; JACC 2012;59:779) Viruses (parvoB19, Coxsackie, adeno, HIV, SARS-CoV-2/vaccine, etc.) Bacterial, fungal, rickettsial, TB, Lyme (mild myocarditis, often with AVB) Chagas: apical aneurysm ± thrombus, RBBB, megaesophagus/colon (Lancet 2018;391:82) Autoimmune Idiopathic giant cell myocarditis (GCM): avg age 42, fulminant, AVB/VT (Circ HF 2013;6:15) Eosinophilic (variable peripheral eos): hypersensitivity (mild HF but at risk for SCD) or acute necrotizing eosinophilic myocarditis (ANEM; STE, effusion, severe HF) Collagen vasc.</description></item><item><title>myofascial pain syndrome</title><link>https://htlin222.github.io/garden/myofascial-pain-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/myofascial-pain-syndrome/</guid><description>myofascial pain syndrome ✨重點: myofascial pain syndrome肌筋膜疼痛綜合徵被定義為一種區域性疼痛綜合徵，其特徵是在繃緊的肌肉帶中存在觸發點和局部深部肌肉壓痛區域。 觸發點上的壓力會重現疼痛。 相比之下，纖維肌痛是一種全身性疼痛疾病，與身體所有四個像限的壓痛點相關， 持續至少 3 個月，通常伴有睡眠障礙、腸易激綜合徵和抑鬱症。 在肌筋膜疼痛綜合徵中，這些相關特徵明顯不那麼頻繁。</description></item><item><title>Myxedema coma</title><link>https://htlin222.github.io/garden/Myxedema-coma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Myxedema-coma/</guid><description>Myxedema coma Presentation: hypothermia, hypotension, hypoventilation, Δ MS (coma rare), hyponatremia, hypoglycemia; often precipitated by infxn or major cardiopulmonary or neurologic illness Treatment: supportive care most important.</description></item><item><title>myxoma</title><link>https://htlin222.github.io/garden/myxoma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/myxoma/</guid><description>myxoma 黏液瘤」（myxoma），脂肪瘤裡是脂肪， 而黏液瘤則是以黏液素或稱黏蛋白（mucin）為主要成份， 最常見的是長在心臟裡，但也會長在骨骼、泌尿生殖道，在皮下或是皮膚中比較少見。</description></item><item><title>Names for vasculitides</title><link>https://htlin222.github.io/garden/Names-for-vasculitides/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Names-for-vasculitides/</guid><description>Names for vasculitides [[other names for vasculitides]]
Immune complex SVV Anti-glomerular basement membrane (anti-GBM) disease Cryoglobulinemic vasculitis (CV) IgA vasculitis (Henoch-Schönlein) (IgAV) Hypocomplementemic urticarial vasculitis (HUV) (anti-C1g vasculitis)</description></item><item><title>narrow complex</title><link>https://htlin222.github.io/garden/narrow-complex/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/narrow-complex/</guid><description>narrow complex regular [[vagal maneuvers]] adenosine 6 12 12 ☠️ 可能會惡化成Vt converts: Likely AVNRT Or AVRT Rx recurrence w/ adenosine or long-acting AV nodal agent such as diltiazem or metoprolol does not convert: Possibly AFL, ATAC, NPUT Control rate w/ [[diltiazem]] or metoprolol or [[amiodarone]] 150 bolus drip 30min [[irregular of narrow complex]]</description></item><item><title>NCCN guideline</title><link>https://htlin222.github.io/garden/NCCN-guideline/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/NCCN-guideline/</guid><description>NCCN guideline [[Acute Lymphoblastic Leukemia]] Acute Myeloid Leukemia Ampullary Adenocarcinoma [[Anal Carcinoma]] Basal Cell Skin Cancer B-Cell Lymphomas Bladder Cancer Bone Cancer Breast Cancer Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma Chronic Myeloid Leukemia Colon Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal Stromal Tumors (GIST) Gestational Trophoblastic Neoplasia Hairy Cell Leukemia Head and Neck Cancers Hepatobiliary Cancers Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Malignant Peritoneal Mesothelioma Malignant Pleural Mesothelioma Melanoma Cutaneous Melanoma Uveal Merkel Cell Carcinoma Multiple Myeloma Myelodysplastic Syndromes MyeloidLymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes Myeloproliferative Neoplasms Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive Mature B-Cell Lymphomas Pediatric Central Nervous System Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Systemic Light Chain Amyloidosis Systemic Mastocytosis T-Cell Lymphomas Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vulvar Cancer Waldenström Macroglobulinemia Lymphoplasmacytic Lymphoma Wilms Tumor (Nephroblastoma)</description></item><item><title>necrotizing soft-tissue infections</title><link>https://htlin222.github.io/garden/necrotizing-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/necrotizing-soft-tissue-infections/</guid><description>necrotizing soft-tissue infections (NEJM 2017;377:2253)
[[Definition-necrotizing soft-tissue infections]] [[Evolution of Necrotizing Fasciitis or Myonecrosis]] [[Microbiology-necrotizing soft-tissue infections]] [[Clinical manifestations-necrotizing soft-tissue infections]] [[Diagnosis-necrotizing soft-tissue infections]]</description></item><item><title>Neoplasm Etiologies of Classic FUO</title><link>https://htlin222.github.io/garden/Neoplasm-Etiologies-of-Classic-FUO/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Neoplasm-Etiologies-of-Classic-FUO/</guid><description>Neoplasm Etiologies of Classic FUO Lymphoma: LAN, HSM, ↓ Hct or plt, ↑ LDH; leukemia; myelodysplasia
Renal cell carcinoma: microscopic hematuria, ↑ Hct</description></item><item><title>nephrolithiasis</title><link>https://htlin222.github.io/garden/nephrolithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nephrolithiasis/</guid><description>nephrolithiasis [[Types of stones and risk factors]] [[Clinical manifestations-nephrolithiasis]] [[Workup-nephrolithiasis]] [[Acute treatment-nephrolithiasis]] [[Chronic treatment-nephrolithiasis]]</description></item><item><title>nephrology</title><link>https://htlin222.github.io/garden/nephrology-copy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nephrology-copy/</guid><description>nephrology [[acid-base disturbances]] [[sodium and water homeostasis]] [[potassium homeostasis]] [[kidney disease]] [[glomerular disease]] [[urinalysis]] [[nephrolithiasis]] Acute Kidney Injury (AKI) Chronic Kidney Disease (CKD) and End-Stage Kidney Disease (ESKD) Glomerular Diseases Disorders of Sodium Homeostasis Kidney Transplant Immunosuppression Kidney Stones Additional topics are covered in the following rotation guides:</description></item><item><title>nephrology</title><link>https://htlin222.github.io/garden/nephrology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nephrology/</guid><description>nephrology [[acid-base disturbances]]
[[sodium and water homeostasis]]
[[potassium homeostasis]]
[[kidney disease]]
[[glomerular disease]]</description></item><item><title>nephrotic syndrome</title><link>https://htlin222.github.io/garden/nephrotic-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nephrotic-syndrome/</guid><description>nephrotic syndrome [[proteinuria]] [[Definition-nephrotic syndrome]] [[Primary glomerular diseases (grouped by pathology)]] [[Systemic diseases with secondary glomerular involvement]] [[Workup-nephrotic syndrome]] [[Treatment-nephrotic syndrome]] [[glomerular disease.</description></item><item><title>Nervous System Dysfunction</title><link>https://htlin222.github.io/garden/Nervous-System-Dysfunction/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nervous-System-Dysfunction/</guid><description>Nervous System Dysfunction Chapter 21: Syncope Chapter 22: Dizziness and Vertigo Chapter 23: Fatigue Chapter 24: Neurologic Causes of Weakness and Paralysis Chapter 25: Numbness, Tingling, and Sensory Loss Chapter 26: Gait Disorders, Imbalance, and Falls Chapter 27: [[Confusion and Delirium]] Chapter 28: Coma Chapter 29: Dementia Chapter 30: Aphasia, Memory Loss, and Other Cognitive Disorders Chapter 31: Sleep Disorders</description></item><item><title>neurologic critical care</title><link>https://htlin222.github.io/garden/neurologic-critical-care/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/neurologic-critical-care/</guid><description>neurologic critical care 26 Delirium 30 Intracranial Pressure and Neuromonitoring 31 Coma and Brain Death 32 Toxicology and Drug Reactions</description></item><item><title>Neurologic Psychologic-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Neurologic-Psychologic-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Neurologic-Psychologic-complications-of-HIV-AIDS/</guid><description>Neurologic Psychologic-complications of HIV AIDS Meningitis: Crypto (dx w/ CSF; serum CrAg 90% Se), bacterial (inc. Listeria), viral (HSV, CMV, 1° HIV), TB, histo, Coccidio, lymphoma; neurosyphilis (cranial nerve palsies) Space-occupying lesions: may present as HA, focal deficits or Δ MS.</description></item><item><title>neurology</title><link>https://htlin222.github.io/garden/neurology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/neurology/</guid><description>neurology [[change in mental status]] [[seizures]] [[alcohol withdrawal]] [[dizziness]] [[stroke]] [[weakness and neuromuscular dysfunction]] [[headache]] [[back and spinal cord disease]] [[spinal cord compression]] [[nerve root compression]] [[head injury]] part 4: [[neurologic critical care]]</description></item><item><title>Neuromuscular dysphagia</title><link>https://htlin222.github.io/garden/Neuromuscular-dysphagia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Neuromuscular-dysphagia/</guid><description>Neuromuscular dysphagia (solids &amp;amp; liquids; Neurogastero Motil 2021;33:e14058)
Caused by aberrant motility or innervation of oropharynx/esophagus Oropharyngeal: consider CNS disorders (eg, stroke, ALS, myopathies, CNS tumors) Esophageal: motility disorder w/ dysphagia, chest pain, GERD; dx: conventional or high-res manometry w/ esophageal pressure topography.</description></item><item><title>neutropenia</title><link>https://htlin222.github.io/garden/neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/neutropenia/</guid><description>neutropenia (&amp;lt;1000/µL)
Congenital Myelokathexis, Shwachman-Diamond-Oski, Chédiak-Higashi, retic dysgen., WHIM syndrome, cyclic neutropenia, monoMAC syndrome (↓ monos, NKs)
Infection Viral (CMV, EBV, HIV); bacterial (Brucella, Rickettsia, TB); malaria</description></item><item><title>neutrophilia</title><link>https://htlin222.github.io/garden/neutrophilia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/neutrophilia/</guid><description>neutrophilia (&amp;gt;7500–10,000/µL)
Infection Usually bacterial; ± toxic granulations, Döhle bodies
Inflammation Burn, tissue necrosis, MI, PE, collagen vascular disease
Drugs and toxins Corticosteroids, β-agonists, lithium, G-CSF; cigarette smoking</description></item><item><title>new note</title><link>https://htlin222.github.io/garden/new-note/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/new-note/</guid><description>AM/AMP Ampicillin Aminopenicillin 10 AMC/&amp;lsquo;A/C&amp;rsquo;/AUG/XL/AML* Amoxicillin + clavulanic acid Aminopenicillin 25/10 AMX/AMOX/AC/AML* Amoxicillin</description></item><item><title>new report</title><link>https://htlin222.github.io/garden/new-report/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/new-report/</guid><description>https://docs.google.com/presentation/d/1JZhMp-Iv gJbsajKC7M-fHTpygJ3Or npNY85xAuhTg/edit?usp=sharing</description></item><item><title>New York Heart Association class</title><link>https://htlin222.github.io/garden/New-York-Heart-Association-class/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/New-York-Heart-Association-class/</guid><description>New York Heart Association class Class I: no sx w/ ordinary activity class II: sx w/ ordinary activity class III: sx w/ minimal activity class IV: sx at rest</description></item><item><title>nitrofurantoin</title><link>https://htlin222.github.io/garden/nitrofurantoin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nitrofurantoin/</guid><description>nitrofurantoin Tradename Macrodantin, Furadantin, Macrobid
Usage and Dosing Nitrofurantoin is used to treat uncomplicated lower urinary tract infections (UTI), e.</description></item><item><title>nnnnnnnnew note</title><link>https://htlin222.github.io/garden/nnnnnnnnew-note/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nnnnnnnnew-note/</guid><description>A new note</description></item><item><title>non- nucleoside reverse transcriptase inhibitor-NNRTI-Antiretrovirals ARVs</title><link>https://htlin222.github.io/garden/non-nucleoside-reverse-transcriptase-inhibitor-NNRTI-Antiretrovirals-ARVs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/non-nucleoside-reverse-transcriptase-inhibitor-NNRTI-Antiretrovirals-ARVs/</guid><description>non- nucleoside reverse transcriptase inhibitor-NNRTI-Antiretrovirals (ARVs) efavirenz (EFV; Sustiva) etravirine (ETR; Intelence) nevirapine (NVP; Viramune) rilpivirine (RPV; Edurant) Class: rash, hepatitis, mixed CYP450 inducer/inhib EFV: CNS effects (incl depression) NVP: rash and hypersensitivity [risk factors are female, CD4 &amp;gt;250, pregnancy (∴ avoid)]</description></item><item><title>Non-tuberculous mycobacterium-bronchiectasis</title><link>https://htlin222.github.io/garden/Non-tuberculous-mycobacterium-bronchiectasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Non-tuberculous-mycobacterium-bronchiectasis/</guid><description>Non-tuberculous mycobacterium-bronchiectasis (NTM; eg, MAC, Mycobacterium kansaii)
Chronic cough, ↓ wt; Lady Windermere syndrome: R middle lobe and lingula bronchiectasis in elderly ♀ who suppress expectoration</description></item><item><title>Nonalcoholic fatty liver disease NAFLD</title><link>https://htlin222.github.io/garden/Nonalcoholic-fatty-liver-disease-NAFLD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonalcoholic-fatty-liver-disease-NAFLD/</guid><description>Nonalcoholic fatty liver disease (NAFLD) (JAMA 2020;323:1175; Lancet 2021;397:2212)
Definition: fatty infiltration of liver + absence of EtOH or other cause of steatosis (HCV, etc.</description></item><item><title>NONINFLAMMATORY-Acute Infectious Etiologies</title><link>https://htlin222.github.io/garden/NONINFLAMMATORY-Acute-Infectious-Etiologies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/NONINFLAMMATORY-Acute-Infectious-Etiologies/</guid><description>NONINFLAMMATORY-Acute Infectious Etiologies Predom. disruption small intestine absorp. &amp;amp; secretion. Voluminous diarrhea, N/V. ⊖ Fecal WBC &amp;amp; FOB.
Preformed toxin “Food poisoning,” &amp;lt;24 h dur.</description></item><item><title>Noninvasive positive-pressure ventilation of COPDAE</title><link>https://htlin222.github.io/garden/Noninvasive-positive-pressure-ventilation-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Noninvasive-positive-pressure-ventilation-of-COPDAE/</guid><description>Noninvasive positive-pressure ventilation of COPDAE Initiate early if moderate/severe dyspnea, ↓ pH / ↑ PaCO2, RR &amp;gt;25 Results in 58% ↓ intubation, ↓ LOS by 3.</description></item><item><title>Nonmegaloblastic macrocytic anemias</title><link>https://htlin222.github.io/garden/Nonmegaloblastic-macrocytic-anemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonmegaloblastic-macrocytic-anemias/</guid><description>Nonmegaloblastic macrocytic anemias Liver disease: often macrocytic, may see target cells, or spur cell anemia w/ hemolysis
Alcoholism: BM suppression &amp;amp; macrocytosis independent of folate/B12 defic.</description></item><item><title>Nonneutrocytic bacterascites NNBA</title><link>https://htlin222.github.io/garden/Nonneutrocytic-bacterascites-NNBA/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonneutrocytic-bacterascites-NNBA/</guid><description>Nonneutrocytic bacterascites (NNBA) ⊕ cx w/o ↑ PMNs. Natural course may resolve w/o Rx. Start abx if symptomatic; if asymptomatic repeat para in 48 hrs.</description></item><item><title>Nonpharmacologic stroke prevent</title><link>https://htlin222.github.io/garden/Nonpharmacologic-stroke-prevent-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonpharmacologic-stroke-prevent-/</guid><description>Nonpharmacologic stroke prevent</description></item><item><title>Nonspecific Low Back Pain</title><link>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-metadata/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-metadata/</guid><description>Nonspecific Low Back Pain Metadata Item Type: [[Article]] Authors: [[Alessandro Chiarotto]], [[Bart W. Koes]] Date: [[2022-05-05]] Date Added: [[2022-08-07]] URL: https://doi.</description></item><item><title>Nonspecific Low Back Pain</title><link>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain/</guid><description>Nonspecific Low Back Pain ![[Nonspecific Low Back Pain-metadata#Metadata]]
Other files:
Mdnotes File Name: [[Nonspecific Low Back Pain]] Metadata File Name: [[Nonspecific Low Back Pain-metadata]] Zotero links [Local library](zotero://select/items/1 YKXMT6WM) Cloud library Notes</description></item><item><title>Nonspecific Low Back Pain - New Note</title><link>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-New-Note/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nonspecific-Low-Back-Pain-New-Note/</guid><description>Related to: [[Nonspecific Low Back Pain-zotero]]
Notes [[Annotations]]</description></item><item><title>nonthyroidal illness sick euthyroid syndrome</title><link>https://htlin222.github.io/garden/nonthyroidal-illness-sick-euthyroid-syndrome-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nonthyroidal-illness-sick-euthyroid-syndrome-/</guid><description>nonthyroidal illness (sick euthyroid syndrome) (J Endocrinol 2010;205:1)
TFT abnormalities in Pts w/ severe nonthyroidal illness (∴ in acute illness, ✓ TFTs only if ↑ concern for thyroid disease); may have acquired transient central hypothyroidism If thyroid dysfxn suspected in critically ill Pt, TSH alone not reliable; must measure total T4, free T4, &amp;amp; T3 Mild illness: ↓ T4 → T3 conversion, ↑ rT3 → ↓ T3; in severe illness: ↓ TBG &amp;amp; albumin, ↑↑ rT3 → ↓↓ T3, ↑ degradation of T4, central ↓ TSH → ↓↓ T3, ↓↓ T4, ↓ free T4, ↓ TSH Recovery phase: ↑ TSH followed by recovery of T4 and then T3 Replacement thyroxine not helpful or recommended for critically ill Pts w/ ↓ T3 and T4 unless other s/s of hypothyroidism</description></item><item><title>Normal GFR but with ↓ renal K excretion-hyperkalemia</title><link>https://htlin222.github.io/garden/Normal-GFR-but-with-renal-K-excretion-hyperkalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Normal-GFR-but-with-renal-K-excretion-hyperkalemia/</guid><description>Normal GFR but with ↓ renal K excretion-hyperkalemia Normal aldosterone function ↓ EAV (K excretion limited by ↓ distal Na delivery &amp;amp; urine flow): CHF, cirrhosis</description></item><item><title>Normal hepatic vasculature</title><link>https://htlin222.github.io/garden/Normal-hepatic-vasculature/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Normal-hepatic-vasculature/</guid><description>Normal hepatic vasculature (Modified from The Nature of Disease Pathology for the Health Professions, 2007. Hepatology 2009;49:1729.)</description></item><item><title>normocytic anemias</title><link>https://htlin222.github.io/garden/normocytic-anemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/normocytic-anemias/</guid><description>normocytic anemias [[Anemia of chronic inflammation ]] [[Anemias of other chronic disorders]] [[Pure red cell aplasia]]</description></item><item><title>NSCLC Treatment</title><link>https://htlin222.github.io/garden/NSCLC-Treatment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/NSCLC-Treatment/</guid><description>NSCLC Treatment Localized disease: surgery if possible; RT (eg, stereotactic ablative radiotherapy [SABR]) vs. chemo/RT if not (see Figure 5-7)</description></item><item><title>NSIP nonspecific IP</title><link>https://htlin222.github.io/garden/NSIP-nonspecific-IP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/NSIP-nonspecific-IP/</guid><description>NSIP nonspecific IP Homogenous ground-glass opacities or consolid., reticular irreg lines; subpleural sparing; symmetric, peripheral, basal. Cellular &amp;amp; fibrotic subtypes.</description></item><item><title>NSTE-ACS</title><link>https://htlin222.github.io/garden/NSTE-ACS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/NSTE-ACS/</guid><description>NSTE-ACS Key issues are antithrombotic regimen and decision regarding angiography
[[Antiplatelet Therapy]] [[Anticoagulant Therapy]] (choose one) [[Coronary angiography]] (Circ 2014;130:e344) [[TIMI Risk Score]] (TRS) for UA/NSTEMI (JAMA 2000;284:835)</description></item><item><title>nucleoside reverse transcriptase inhibitor NRTI-Antiretrovirals ARVs</title><link>https://htlin222.github.io/garden/nucleoside-reverse-transcriptase-inhibitor-NRTI-Antiretrovirals-ARVs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/nucleoside-reverse-transcriptase-inhibitor-NRTI-Antiretrovirals-ARVs/</guid><description>nucleoside reverse transcriptase inhibitor NRTI-Antiretrovirals (ARVs) Class: GI intol, lipoatrophy, lactic acidosis
abacavir (ABC; Ziagen) ABC: hypersensitivity (3%), ✓ HLA-B*5701</description></item><item><title>Nutritional Support and Total Parenteral Nutrition</title><link>https://htlin222.github.io/garden/Nutritional-Support-and-Total-Parenteral-Nutrition/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Nutritional-Support-and-Total-Parenteral-Nutrition/</guid><description>Nutritional Support and Total Parenteral Nutrition Enteral &amp;amp; parenteral with similar clinical outcomes (Lancet 2018;391:133) Enteral (EN): starting w/in 48 h of ICU admit may ↓ infection &amp;amp; mortality.</description></item><item><title>NV would have selected</title><link>https://htlin222.github.io/garden/NV-would-have-selected/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/NV-would-have-selected/</guid><description>Wow</description></item><item><title>Obscure GIB</title><link>https://htlin222.github.io/garden/Obscure-GIB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Obscure-GIB/</guid><description>Obscure GIB (Am J Gastro 2015;110:1265; Gastro 2017;152:497)
Definition: continued bleeding (melena, hematochezia) despite ⊖ EGD &amp;amp; colo; 5% of GIB Etiologies: Dieulafoy’s lesion, GAVE, small bowel angiodysplasia, ulcer or cancer, Crohn’s disease, aortoenteric fistula, Meckel’s diverticulum, hemobilia Diagnosis: repeat EGD w/ push enteroscopy/colonoscopy when bleeding is active If ⊖, video capsule to evaluate small intestine (contraindic.</description></item><item><title>Obstructive diseases-disease-specific management of kidney disease</title><link>https://htlin222.github.io/garden/Obstructive-diseases-disease-specific-management-of-kidney-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Obstructive-diseases-disease-specific-management-of-kidney-disease-/</guid><description>Obstructive diseases-disease-specific management of kidney disease Dx: renal U/S if undifferentiated or CT abd/pelvic (I–) if suspect nephrolithiasis
Rx: Foley if urethra vs.</description></item><item><title>Obstructive shock</title><link>https://htlin222.github.io/garden/Obstructive-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Obstructive-shock/</guid><description>Obstructive shock Tension pneumothorax
Cardiac tamponade
Constrictive pericarditis
Pulmonary embolism
Aortic dissection</description></item><item><title>OI Prophylaxis-HIV AIDS</title><link>https://htlin222.github.io/garden/OI-Prophylaxis-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/OI-Prophylaxis-HIV-AIDS/</guid><description>OI Prophylaxis-HIV AIDS ( https://aidsinfo.nih.gov/guidelines &amp;amp; JAMA 2018;320:379, HIV.gov:2020) OI Indication 1° Prophylaxis
Tuberculosis ⊕ PPD (≥5 mm), IGRA, or high-risk exposure See treatment for latent TB</description></item><item><title>old headache</title><link>https://htlin222.github.io/garden/old-headache/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/old-headache/</guid><description>old headache Are there indication for brain imaging? YES: Obtain appropriate imaging
Does the headache fufill the highly specific [[POUNDing Mnemonic]] for migraines</description></item><item><title>Ommaya</title><link>https://htlin222.github.io/garden/Ommaya/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ommaya/</guid><description>Ommaya （1）操作更加安全、便捷，患者疼痛少。 （2）可依據顱內壓行腦脊液引流，及時改善顱高壓症狀；便於重複送檢腦脊液，瞭解藥物濃度及腫瘤指標的動態變化，有助於調整用藥、療效評價及評估預後。 （3）藥物隨腦脊液的循環，可均勻分佈於中樞神經系統（central nervous system, CNS）的各個部位，藥物濃度可達到同等劑量經腰椎穿刺給藥的10倍[6]，因而有更好的生存獲益[14]。
基於此，優先推薦選擇經Ommaya囊腦室內給藥來進行鞘內化療 [7, 15-17] 經Ommaya囊鞘內化療已成功用於治療多種惡性腫瘤相關的LM（表 1）。
Ommaya囊置入術後併發症發生率較低[18]，常見的併發症包括：顱內出血、導管易位和堵塞、繼發感染以及化療藥物毒副反應等。該患者Ommaya囊置入術後，短期內出現噁心、嘔吐以及睡眠障礙，考慮和藥物刺激、腦脊液波動相關。</description></item><item><title>oncologic emergencies</title><link>https://htlin222.github.io/garden/oncologic-emergencies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/oncologic-emergencies/</guid><description>oncologic emergencies [[fever and neutropenia]] (FN) (NCCN Guidelines v.1.2021)</description></item><item><title>oncology</title><link>https://htlin222.github.io/garden/oncology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/oncology/</guid><description>oncology [[hematology]] [[NCCN guideline]]
Pocket Oncology [[general oncology]] [[inpatient oncology]] [[clinical research methods]] [[radiation oncology]] [[cancer biology]] [[molecular diagnostics]] [[cancer immunology]] [[cancer genetics]] [[cancer pharmacology]] [[chemo side effects]] [[cancer complications]] [[pain and palliative care]] [[cancer survivorship]] [[infectious disease]] [[immunotherapy and cellular therapy]] [[oncologic emergencies.</description></item><item><title>Oncology-related glomerulopathy</title><link>https://htlin222.github.io/garden/Oncology-related-glomerulopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Oncology-related-glomerulopathy/</guid><description>Oncology-related glomerulopathy (CJASN 2016;11:1681)
Associations between malig (solid tumors &amp;amp; heme) and/or their Rx (HSCT &amp;amp; chemo- therapeutics) and GN, nephrotic syndrome, and thrombotic microangiopathies (TMA)</description></item><item><title>open pressure</title><link>https://htlin222.github.io/garden/open-pressure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/open-pressure/</guid><description>open pressure 正常 9–18 cmH2O Open pressure 上升可能原因包括：infection、bleeding、tumor 、某些 encephalitis 等。</description></item><item><title>OpenAIDemo</title><link>https://htlin222.github.io/garden/OpenAIDemo/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/OpenAIDemo/</guid><description>What are the treatment of lung cancer
Lung cancer is the leading cause of cancer death in both men and women in the United States.</description></item><item><title>ophthalmic issues</title><link>https://htlin222.github.io/garden/ophthalmic-issues/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ophthalmic-issues/</guid><description>ophthalmic issues</description></item><item><title>Ophthalmologic-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Ophthalmologic-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ophthalmologic-complications-of-HIV-AIDS/</guid><description>Ophthalmologic-complications of HIV AIDS CMV retinitis (CD4 usu &amp;lt;50); Rx: ganciclovir or valganciclovir, foscarnet, or cidofovir HZV, VZV, syphilis (any CD4 count, treat as neurosyphilis) or Toxo (CD4 usually &amp;lt;100)</description></item><item><title>Opioids-toxicology</title><link>https://htlin222.github.io/garden/Opioids-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Opioids-toxicology/</guid><description>Opioids-toxicology ↓ mentation, ↓ RR, miosis
IV naloxone</description></item><item><title>Optimal-medical-therapy-stable ischemic heart disease</title><link>https://htlin222.github.io/garden/Optimal-medical-therapy-stable-ischemic-heart-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Optimal-medical-therapy-stable-ischemic-heart-disease/</guid><description>Optimal-medical-therapy-stable ischemic heart disease ASA 75–162 mg/d; can substitute clopi if ASA-intolerant. ~12 mos after PCI, clopi monoRx ↓ risk of ischemic and bleeding events by ~30% c/w ASA monoRx (Lancet 2021;397:2487).</description></item><item><title>Oral anticoagulation-atrial fibrillation</title><link>https://htlin222.github.io/garden/Oral-anticoagulation-atrial-fibrillation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Oral-anticoagulation-atrial-fibrillation/</guid><description>Oral anticoagulation-atrial fibrillation (Circ 2014;130:e199 &amp;amp; 2019;140:125; EHJ 2021;42:373)
All valvular AF because stroke risk very high Nonvalvular AF (NVAF): stroke risk ~4.</description></item><item><title>Oral-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Oral-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Oral-complications-of-HIV-AIDS/</guid><description>Oral-complications of HIV AIDS Aphthous ulcers; KS; thrush/oral candidiasis (curd-like patches, often painless)
Oral hairy leukoplakia: painless proliferation of papillae w/ adherent white coating usually on lateral tongue, caused by EBV but not precancerous</description></item><item><title>Organ dysfunction</title><link>https://htlin222.github.io/garden/Organ-dysfunction/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Organ-dysfunction/</guid><description>Organ dysfunction Liver (esp. cirrhosis): Vibrio spp., encapsulated bacteria ESRD: impaired granulocyte fxn and CMI as above Iron overload (or deferoxamine Rx): Yersinia, Zygomycetes</description></item><item><title>Organopho- sphate-toxicology</title><link>https://htlin222.github.io/garden/Organopho-sphate-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Organopho-sphate-toxicology/</guid><description>Organopho- sphate-toxicology Salivation, lacrimation, diaphoresis, miosis, emesis, bronchospasm, ΔMS
Endotracheal intubation for respiratory failure, atropine, pralidoxime, benzodiazepines</description></item><item><title>orthopaedic</title><link>https://htlin222.github.io/garden/orthopaedic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/orthopaedic/</guid><description>orthopaedic [[Joint Hypermobility Syndrome]]</description></item><item><title>Orthostatic proteinuria</title><link>https://htlin222.github.io/garden/Orthostatic-proteinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Orthostatic-proteinuria/</guid><description>Orthostatic proteinuria typically in adolescents; ~90% of young ♂ with isolated proteinuria have orthostatic proteinuria; typically resolves spontaneously</description></item><item><title>Osmotic diarrhea</title><link>https://htlin222.github.io/garden/Osmotic-diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Osmotic-diarrhea/</guid><description>Osmotic diarrhea (watery; ⊖ fecal fat, ↑ osmotic gap, ↓ diarrhea w/ fasting)
Caused by ingestion of poorly absorbed cations/anions (Mg, sulfate, phos; found in laxatives) or poorly absorbed carbs (eg, mannitol, sorbitol [found in chewing gum]) or lactose if lactose intolerant.</description></item><item><title>osteomyelitis</title><link>https://htlin222.github.io/garden/osteomyelitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/osteomyelitis/</guid><description>osteomyelitis Infection of bone due to hematogenous seeding or direct spread from contiguous focus [[Etiology-osteomyelitis]] [[Clinical manifestations-osteomyelitis]] [[Diagnosis-osteomyelitis]] [[Treatment-osteomyelitis]]</description></item><item><title>Other Uosm >700–800</title><link>https://htlin222.github.io/garden/Other-Uosm-700800/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Other-Uosm-700800/</guid><description>Other (Uosm &amp;gt;700–800) Na overload: hypertonic saline (eg, resuscitation w/ NaHCO3), mineralocorticoid excess
Seizures, ↑ exercise: ↑ intracellular osmoles → H2O shifts → transient ↑ [Na]serum</description></item><item><title>Other antimicrobial agents of Drug fever</title><link>https://htlin222.github.io/garden/Other-antimicrobial-agents-of-Drug-fever/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Other-antimicrobial-agents-of-Drug-fever/</guid><description>Other antimicrobial agents of Drug fever antimicrobial agents are also the most common cause of drug fever, accounting for approximately one-third of episodes</description></item><item><title>Other Complication-cirrhosis</title><link>https://htlin222.github.io/garden/Other-Complication-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Other-Complication-cirrhosis/</guid><description>Other Complication-cirrhosis [[Portopulmonary hypertension (POPH)]] Cirrhotic cardiomyopathy: ↓ inotropic &amp;amp; chronotropic response, ↓ systolic &amp;amp; diastolic fxn, ↑ QT, hyperkinetic circulation, high output; ↑ troponin &amp;amp; BNP Infxns: unless immune, vaccinate for HAV, HBV, PCV13, PPSV23, COVID-19; flu yearly.</description></item><item><title>Other diagnostic studies-syncope</title><link>https://htlin222.github.io/garden/Other-diagnostic-studies-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Other-diagnostic-studies-syncope/</guid><description>Other diagnostic studies-syncope (consider based on results of H&amp;amp;P and ECG)
Ambulatory ECG monitoring: if suspect arrhythmogenic syncope Holter monitoring (continuous ECG 24–72 h): useful if frequent events Event recorder (activated by Pt to record rhythm): limited role if LOC w/o prodrome External loop recorder (continuously saves rhythm, ∴ can be activated after an event): useful for episodes (including w/o prodrome) likely to occur w/in 2–6 wks; can be coupled w/ mobile cardiac telemetry than can be auto-triggered for specific rhythms External patch recorder (1-lead recording; saves for 1–4 wks): Pt-activated or auto-triggered; more comfortable for Pts Implantable loop recorders (SC; can record 2–3 y; can be triggered): useful if episodes &amp;lt;1/mo; dx in 55% of cases; recommended for recurrent syncope w/o prodrome Echo: consider to r/o structural heart disease (eg, CMP [incl HCMP &amp;amp; ARVC], valvular disease [incl AS, MS, MVP], myxoma, amyloid, PHT, ± anomalous coronaries) ETT/CCTA/Cath: esp.</description></item><item><title>Other measures of COPDAE</title><link>https://htlin222.github.io/garden/Other-measures-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Other-measures-of-COPDAE/</guid><description>Other measures of COPDAE Mucolytics overall not supported by data (Chest 2001;119:1190) Monitor for cardiac arrhythmias</description></item><item><title>other names for vasculitides</title><link>https://htlin222.github.io/garden/other-names-for-vasculitides/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/other-names-for-vasculitides/</guid><description>other names for vasculitides Variable vessel vasculitis (VVV) Behcet&amp;rsquo;s disease (BD) Cogan&amp;rsquo;s syndrome (CS)
Single-organ vasculitis (SOV) Cutaneous leukocytoclastic angiitis Cutaneous arteritis Primary central nervous system vasculitis Isolated aortitis Others</description></item><item><title>Other Post MI Complications</title><link>https://htlin222.github.io/garden/Other-Post-MI-Complications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Other-Post-MI-Complications/</guid><description>Other Post MI Complications Complication Clinical Features Treatment LV thrombus ~30% incid. (espec lg antero-apical MI) AC×3-6 mo (?</description></item><item><title>other solid tumors</title><link>https://htlin222.github.io/garden/other-solid-tumors/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/other-solid-tumors/</guid><description>[[index]]
[[hepatocellular carcinoma]] (HCC) [[urothelial carcinoma]] [[ddMVAC]]] [[esophageal cancer]] [[renal-cell-carcinoma]]</description></item><item><title>other-Secondary Causes of Hypertension</title><link>https://htlin222.github.io/garden/other-Secondary-Causes-of-Hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/other-Secondary-Causes-of-Hypertension/</guid><description>other-Secondary Causes of Hypertension Obstructive sleep apnea (qv); alcohol Medications: OCP, steroids, [[licorice]]; NSAIDs (espec COX-2); Epo; CsA; TKI Aortic coarctation: ↓ LE pulses, systolic murmur, radial-femoral delay; abnl TTE, CXR Polycythemia vera: ↑ Hct</description></item><item><title>Outpatient screening and treatment goals-diabetes mellitus</title><link>https://htlin222.github.io/garden/Outpatient-screening-and-treatment-goals-diabetes-mellitus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Outpatient-screening-and-treatment-goals-diabetes-mellitus/</guid><description>Outpatient screening and treatment goals-diabetes mellitus (Diabetes Care 2022;45;S83 &amp;amp; S144)
✓ HbA1C q3–6mo, goal &amp;lt;7% for most Pts. Goal &amp;lt;6.</description></item><item><title>Overflow proteinuria</title><link>https://htlin222.github.io/garden/Overflow-proteinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Overflow-proteinuria/</guid><description>Overflow proteinuria ↑ production of freely filtered proteins Etiologies Multiple myeloma Myoglobinuria</description></item><item><title>Overview-immunotherapy and cellular therapy</title><link>https://htlin222.github.io/garden/Overview-immunotherapy-and-cellular-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Overview-immunotherapy-and-cellular-therapy/</guid><description>Overview-immunotherapy and cellular therapy immunotherapy and cellular therapy
Immune checkpoints: co-inhibitory signaling molecules that limit immune responses Cytotoxic T-lymphocyte-assoc. protein 4 (CTLA-4): ↓ T cell activation via negative signals and ligand competition w/ CD28 (activating co-stim.</description></item><item><title>Overview-potassium homeostasis</title><link>https://htlin222.github.io/garden/Overview-potassium-homeostasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Overview-potassium-homeostasis/</guid><description>Overview-potassium homeostasis Renal: K excretion regulated at distal nephron (CCD) by principal &amp;amp; α-intercalated cells Distal Na delivery &amp;amp; urine flow: Na absorption → lumen electronegative → K secretion Metabolic alkalemia and aldosterone: increase Na absorption and K secretion nb, diurnal urinary K excretion (day &amp;gt;night), ∴ 24-h sample preferred over spot Transcellular shifts: most common cause of acute ∆ in serum K (98% intracellular)</description></item><item><title>overview-sodium and water homeostasis</title><link>https://htlin222.github.io/garden/overview-sodium-and-water-homeostasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/overview-sodium-and-water-homeostasis/</guid><description>overview-sodium and water homeostasis General (NEJM 2015;372:55 &amp;amp; 373:1350)
Disorders of serum sodium are generally due to Δs in total body water, not sodium Hyper- or hypo-osmolality → rapid water shifts → Δs in brain cell volume → Δ MS, seizures Key hormones [[Antidiuretic hormone]] (ADH) [[Aldosterone]]</description></item><item><title>Oxygen for chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Oxygen-for-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Oxygen-for-chronic-obstructive-pulmonary-disease/</guid><description>Oxygen for chronic obstructive pulmonary disease if PaO2 ≤55 mmHg or SaO2 ≤89% (during rest, exercise, or sleep) to prevent cor pulmonale; only Rx proven to ↓ mortality (Annals 1980;93:391; Lancet 1981;i:681); no benefit in Pts with moderate hypoxemia (SaO2 89–93%) (NEJM 2016;375:1617) or nocturnal O2 alone (NEJM 2020;383:1129); unknown benefit of isolated exertional O2 (AJRCCM 2020;202:121).</description></item><item><title>oxygenation</title><link>https://htlin222.github.io/garden/oxygenation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/oxygenation/</guid><description>oxygenation 正常氧合（海平面）預測： 氧分壓 (Pa o 2 ) 為 75–100 mm Hg，21% FiO2（室內空氣），PaO2 為 ~ 660 mm Hg，100% FiO2 從輕度（異常 A-a 梯度）到重度（分流），氧合受損： Pao2 &amp;lt; 200 mm Hg on Fio2 of 100% = “分流生理學” 如果沒有“分流生理學”，Fio2 &amp;gt; 40%（~ &amp;gt; 6 L/min 通過鼻插管 (NC)）應該給出 Pao2 &amp;gt; 60 mm Hg，儘管病理會導致 A-a 梯度異常增加 6L的nc大概就要換來PaO2 60+ 表現出分流生理學的患者發生低氧性呼吸衰竭的風險很高，需要尋找根本原因，以及密切觀察和積極支持（例如胸部成像，100% Fi0 2 ） Hypoxemic respiratory failure is practically defined as a Pa o 2 &amp;lt; 60 mm Hg 重要定義(數字要記一下60) An acute drop in Pa o 2 &amp;lt; 60 mm Hg (but &amp;gt; 54 mm Hg), ie, “mild hypoxemia,” may cause a range of symptoms: Increased left ventricular end-diastolic pressure (LVEDP) (a.</description></item><item><title>Oxygenation of COPDAE</title><link>https://htlin222.github.io/garden/Oxygenation-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Oxygenation-of-COPDAE/</guid><description>Oxygenation of COPDAE ↑ FiO2 to achieve PaO2 ≥55–60 or SaO2 88–92% Watch for CO2 retention (due to ↑ V/Q mismatch, loss of hypoxemic resp drive, Haldane effect), but must maintain acceptable SaO2!</description></item><item><title>PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/PA-catheter-and-tailored-therapy/</guid><description>[[index]]
Rationale [[Rationale PA catheter and tailored therapy]]
Indication [[Indications PA catheter and tailored therapy]] (NEJM 2013;369:e35; Circ 2017;136:e268)
Efficacy [[Efficacy concerns PA catheter and tailored therapy]] (NEJM 2006;354:2213; JAMA 2005;294:1664)</description></item><item><title>Pacemaker Code</title><link>https://htlin222.github.io/garden/Pacemaker-Code/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pacemaker-Code/</guid><description>Pacemaker Code</description></item><item><title>Pacemaker Complications</title><link>https://htlin222.github.io/garden/Pacemaker-Complications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pacemaker-Complications/</guid><description>Pacemaker Complications Perforation Effusion/tamp/pain Typically acute, consider if HoTN
Failure to pace Bradycardia ↓ Battery, lead fx/dislodgment, ↑ pacing threshold due to tissue rxn/injury; oversense → inapprop.</description></item><item><title>Packed red blood cells</title><link>https://htlin222.github.io/garden/Packed-red-blood-cells/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Packed-red-blood-cells/</guid><description>Packed red blood cells For acute blood loss or to ↑ O2-carrying capacity if end organ ischemia. 1 U PRBC → ↑ Hb by ~1 g/dL.</description></item><item><title>packed red blood cells-resuscitation-initial management-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/packed-red-blood-cells-resuscitation-initial-management-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/packed-red-blood-cells-resuscitation-initial-management-gastrointestinal-bleeding/</guid><description>packed red blood cells-resuscitation-initial management-gastrointestinal bleeding resuscitate with packed red blood cells (RBCs) if hemoglobin (Hg) &amp;lt;7 g/dL, patient is hemodynamically unstable, or both</description></item><item><title>Pain</title><link>https://htlin222.github.io/garden/Pain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pain/</guid><description>Pain [[Pain: Pathophysiology and Management]] [[Chest Discomfort]] [[Abdominal Pain]] [[headache]] [[Back and Neck Pain]]</description></item><item><title>pain and palliative care</title><link>https://htlin222.github.io/garden/pain-and-palliative-care/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pain-and-palliative-care/</guid><description>pain and palliative care ✨重點: 疼痛可根據推斷的病理生理學、時間進程、部位或病因進行分類。 正確的疼痛分類可能有助於正確治療疼痛問題。 慢性非癌症相關疼痛與急性疼痛顯著不同，因為慢性非癌症相關疼痛沒有有用的生物學目的。 Topics: [[Classification of Pain]] [[paresthesia and dysesthesia]] [[deafferentation pain]] [[myofascial pain syndrome]]</description></item><item><title>palliative care</title><link>https://htlin222.github.io/garden/palliative-care/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/palliative-care/</guid><description>[[index]]</description></item><item><title>Pancoast’s syndrome</title><link>https://htlin222.github.io/garden/Pancoasts-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pancoasts-syndrome/</guid><description>Pancoast’s syndrome apical tumor → brachial plexus involvement (C8, T1, T2) → [[Horner’s syndrome]], shoulder pain, rib destruction, atrophy of hand muscles</description></item><item><title>pancreatic tumors</title><link>https://htlin222.github.io/garden/pancreatic-tumors/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pancreatic-tumors/</guid><description>pancreatic tumors</description></item><item><title>pancreatitis</title><link>https://htlin222.github.io/garden/pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pancreatitis/</guid><description>pancreatitis [[acute pancreatitis]] [[chronic pancreatitis]] [[autoimmune pancreatitis]]</description></item><item><title>pancytopenia</title><link>https://htlin222.github.io/garden/pancytopenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pancytopenia/</guid><description>pancytopenia [[Etiologies-pancytopenia]] Clinical manifestations Anemia → fatigue; neutropenia → recurrent infections; thrombocytopenia → mucosal bleeding &amp;amp; easy bruisability</description></item><item><title>Papillary thyroid cancer</title><link>https://htlin222.github.io/garden/Papillary-thyroid-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Papillary-thyroid-cancer/</guid><description>Papillary thyroid cancer Most common form (85% of differentiated thyroid cancers); peak incidence 30 to 50 y Risk factors: childhood radiation exposure, FHx in 1° relative, familial syndrome Low-risk, mort.</description></item><item><title>Paralytic ileus of the colon &amp; small bowel</title><link>https://htlin222.github.io/garden/Paralytic-ileus-of-the-colon-small-bowel/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Paralytic-ileus-of-the-colon-small-bowel/</guid><description>Paralytic ileus of the colon &amp;amp; small bowel (Dis Colon Rectum 2021;64:1046)
Definition: loss of intestinal peristalsis in absence of mechanical obstruction</description></item><item><title>Paraneoplastic syndromes</title><link>https://htlin222.github.io/garden/Paraneoplastic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Paraneoplastic-syndromes/</guid><description>Paraneoplastic syndromes 內分泌、肌肉、神經、血液
Endo SIADH (SCLC); ACTH (SCLC) → Cushing’s; PTH-rP (SCC) → hyperCa
Skeletal digital clubbing (NSCLC), [[hypertrophic pulm osteoarthropathy]] (adenocarcinoma) = symmetric polyarthritis and proliferative periostitis of long bones Neuro (SCLC) [[Eaton-Lambert]] peripheral neuropathy (anti-Hu, anti-PCA-2, anti-CRMP5), cerebellar degeneration (anti-Hu, anti-Yo, anti-Ri, anti-Tr), encephalomyelitis (anti-Hu, anti-Ma1/2, anti-CRMP5) Hematologic hypercoagulable state (adenocarcinoma) DIC</description></item><item><title>parapneumonic effusions</title><link>https://htlin222.github.io/garden/parapneumonic-effusions/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/parapneumonic-effusions/</guid><description>parapneumonic effusions parapneumonic積液是在與肺炎相鄰的胸膜空間中形成的胸腔積液。 當微生物感染胸膜空間時，可能會導致複雜的parapneumonic積液或膿胸。 在沒有相鄰的肺炎的情況下，膿胸也可以發展。</description></item><item><title>Parathyroid MIBI Scan</title><link>https://htlin222.github.io/garden/Parathyroid-MIBI-Scan/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Parathyroid-MIBI-Scan/</guid><description>Parathyroid MIBI Scan https://www.insideradiology.com.au/parathyroid-mibi-scan-hp/
甲狀旁腺 MIBI 掃描用於核醫學
甲狀旁腺掃描使用放射性同位素鎝 99m sestamibi（或 MIBI），將其註入體內並被過度活躍的甲狀旁腺線粒體吸收。 對伽馬相機拍攝的圖像進行掃描，發現一個過度活躍的腺體。 在某些情況下，在 MIBI 之前給予另一種放射性物質（高锝酸鈉），以便僅識別甲狀腺。 這允許評估甲狀旁腺相對於甲狀腺的位置。 進行甲狀旁腺 MIBI 掃描的先決條件是什麼？</description></item><item><title>paresthesia and dysesthesia</title><link>https://htlin222.github.io/garden/paresthesia-and-dysesthesia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/paresthesia-and-dysesthesia/</guid><description>paresthesia and dysesthesia ✨重點: paresthesia 感覺麻木被簡單地描述為一種無痛的感覺改變（例如，麻木）。 dysesthesia 感覺遲鈍是一種疼痛的感覺改變（例如，疼痛的麻木）。</description></item><item><title>Paroxysmal nocturnal hemoglobinuria</title><link>https://htlin222.github.io/garden/Paroxysmal-nocturnal-hemoglobinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Paroxysmal-nocturnal-hemoglobinuria/</guid><description>Paroxysmal nocturnal hemoglobinuria (PNH) (Blood 2009;113:6522)
Acquired clonal stem cell disorder = inactivating somatic mutation of PIG-A gene → deficiency of GPI-anchor for CD55 &amp;amp; CD59 (inhib of complement) → complement-mediated RBC lysis, plt aggregation, &amp;amp; hypercoagulability</description></item><item><title>pathogen</title><link>https://htlin222.github.io/garden/pathogen/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pathogen/</guid><description>pathogen [[Acinetobacter sp]] [[CAPT-resistant GNB]] [[HACEK]]</description></item><item><title>Pathogenesis epidemiology-clostridioides difficile infection</title><link>https://htlin222.github.io/garden/Pathogenesis-epidemiology-clostridioides-difficile-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathogenesis-epidemiology-clostridioides-difficile-infection/</guid><description>Pathogenesis epidemiology-clostridioides difficile infection Ingestion of C. diff spores → colonization when colonic flora Δ’d by abx or chemo → release of toxin A/B → colonic mucosal necrosis &amp;amp; inflammation → pseudomembranes</description></item><item><title>Pathogenesis etiology-chronic pancreatitis</title><link>https://htlin222.github.io/garden/Pathogenesis-etiology-chronic-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathogenesis-etiology-chronic-pancreatitis/</guid><description>Pathogenesis etiology-chronic pancreatitis (Gastro 2013;144:1292; JAMA 2019;322:2422)
Often recurrent acute attacks → inflam infiltrate → fibrosis → loss of exocrine &amp;amp; endocrine tissue.</description></item><item><title>pathogenesis of disseminated intravascular coagulation DIC</title><link>https://htlin222.github.io/garden/pathogenesis-of-disseminated-intravascular-coagulation-DIC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pathogenesis-of-disseminated-intravascular-coagulation-DIC/</guid><description>pathogenesis of disseminated intravascular coagulation (DIC) massive activation of coagulation that overwhelms control mechanisms
Thrombosis in microvasculature → ischemia + microangiopathic hemolytic anemia</description></item><item><title>pathogenesis of vasculitides</title><link>https://htlin222.github.io/garden/pathogenesis-of-vasculitides/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pathogenesis-of-vasculitides/</guid><description>pathogenesis of vasculitides is not well understood, but potential pathophysiologic processes leading to vascular damage include immune complex deposition, antineutrophil cytoplasmic antibodies (ANCAs) (humoral mechanism), and T-lymphocyte response with granuloma formation (cell-mediated mechanism).</description></item><item><title>Pathogenesis-acute pancreatitis</title><link>https://htlin222.github.io/garden/Pathogenesis-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathogenesis-acute-pancreatitis/</guid><description>Pathogenesis-acute pancreatitis Pancreatic duct and acinar injury via direct or indirect toxicity → impaired secretion and premature activation of digestive enzymes → autodigestion and acute inflammation</description></item><item><title>Pathogenesis-cholecystitis</title><link>https://htlin222.github.io/garden/Pathogenesis-cholecystitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathogenesis-cholecystitis/</guid><description>Pathogenesis-cholecystitis Acute cholecystitis: stone impaction in cystic duct → inflammation behind obstruction → GB swelling ± secondary infection (50%) of biliary fluid</description></item><item><title>Pathogenesis-chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Pathogenesis-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathogenesis-chronic-obstructive-pulmonary-disease/</guid><description>Pathogenesis-chronic obstructive pulmonary disease Lancet 2017;389:1931
Cigarette smoke (centrilobular emphysema, affects 15–20% of smokers) Recurrent airway infections [[α1-antitrypsin deficiency]] Low FEV1 in early adulthood associated with COPD (NEJM 2015;373:111)</description></item><item><title>Pathologic-Q-waves</title><link>https://htlin222.github.io/garden/Pathologic-Q-waves/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathologic-Q-waves/</guid><description>Pathologic-Q-waves Q wave, Q
Definition: ≥30 msec (≥20 msec V2–V3) or &amp;gt;25% height of R wave in that QRS complex</description></item><item><title>Pathology pathogenesis esophageal cancer</title><link>https://htlin222.github.io/garden/Pathology-pathogenesis-esophageal-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathology-pathogenesis-esophageal-cancer/</guid><description>Pathology pathogenesis esophageal cancer Squamous cell carcinoma Squamous cell carcinomas (SCCs) are usually located in the proximal or mid third of the esophagus.</description></item><item><title>Pathophysiology risk factors -aortic aneurysms</title><link>https://htlin222.github.io/garden/Pathophysiology-risk-factors-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-risk-factors-aortic-aneurysms/</guid><description>Pathophysiology risk factors -aortic aneurysms (JACC 2020:76:201 &amp;amp; 2021;78:201)
Medial degen and/or ↑ wall stress; wall stress ∝ [(∆P × r) / (wall thickness)] (Laplace’s law) TAA: medial degeneration (muscle apoptosis, elastin fiber weakening); a/w CTD, aortitis AAA: long-standing HTN + athero/inflammation → medial weakening Clinical risk factors: HTN, athero, smoking, age, ♂, presence of other aortic dilation CTD (Marfan, Ehlers-Danlos type IV, Loeys-Dietz); congenital (bicuspid AoV, Turner’s) aortitis (Takayasu’s GCA, spondyloarthritis, IgG4); infection (eg, syphilis); FQ; trauma</description></item><item><title>Pathophysiology and microbiology of fever and neutropenia</title><link>https://htlin222.github.io/garden/Pathophysiology-and-microbiology-of-fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-and-microbiology-of-fever-and-neutropenia/</guid><description>Pathophysiology and microbiology of fever and neutropenia Predisposing factors: catheters, skin breakdown, GI mucositis, obstruction (lymphatics, biliary tract, GI, urinary tract), immune defect associated with malignancy Often thought due to seeding of bloodstream by GI flora, eg, GNRs (esp.</description></item><item><title>pathophysiology gastroesophageal reflux disease</title><link>https://htlin222.github.io/garden/pathophysiology-gastroesophageal-reflux-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pathophysiology-gastroesophageal-reflux-disease/</guid><description>pathophysiology gastroesophageal reflux disease (JAMA 2020;324:2536)
↑ acid exposure in esophagus, caused by ↑ transient LES relaxations. Worsened by ↑ intraabd pressure (eg, obesity, pregnancy), ↓ esophagogastric motility, hiatal hernia.</description></item><item><title>Pathophysiology of Cryoglobulinemic vasculitis</title><link>https://htlin222.github.io/garden/Pathophysiology-of-Cryoglobulinemic-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-of-Cryoglobulinemic-vasculitis/</guid><description>Pathophysiology of Cryoglobulinemic vasculitis Type I: cryo precipitation in microcirculation → hyperviscosity &amp;amp; vascular occlusion Types II/III: defective/insufficient immune complex (IC) clearance → IC-mediated inflammation of blood vessels w/ complement activation → vasculitis</description></item><item><title>Pathophysiology of diverticulitis</title><link>https://htlin222.github.io/garden/Pathophysiology-of-diverticulitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-of-diverticulitis/</guid><description>Pathophysiology of diverticulitis (NEJM 2007;357:2057; Gastro 2015;149:1944)
Retention of undigested food and bacteria in diverticulum → fecalith formation → obstruction → compromise of diverticulum’s blood supply, infection, microperforation Uncomplicated (75%): microperforation → localized infection, LLQ pain, fever, ↑ WBC Complicated (25%): macroperf → abscess, peritonitis, fistula (65% w/ bladder), obstrxn Clinical manifestations LLQ abdominal pain, fever, nausea, vomiting, constipation or diarrhea PEx ranges from LLQ tenderness ± palpable mass to peritoneal signs &amp;amp; septic shock Ddx includes IBD, infectious colitis, PID, tubal pregnancy, cystitis, colorectal cancer</description></item><item><title>Pathophysiology of hypertrophic cardiomyopathy</title><link>https://htlin222.github.io/garden/Pathophysiology-of-hypertrophic-cardiomyopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-of-hypertrophic-cardiomyopathy/</guid><description>Pathophysiology of hypertrophic cardiomyopathy LV outflow tract obstruction (LVOTO) in ≥70%: narrowed tract 2° hypertrophied septum + systolic anterior motion (SAM) of ant.</description></item><item><title>Pathophysiology-Acetaminophen hepatotoxicity</title><link>https://htlin222.github.io/garden/Pathophysiology-Acetaminophen-hepatotoxicity/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-Acetaminophen-hepatotoxicity/</guid><description>Pathophysiology-Acetaminophen hepatotoxicity 90% of acetaminophen (N-acetyl-p-aminophenol, APAP) metab into nontoxic metab, but ~5% metab by CYP2E1 into NAPQI, a hepatotoxic metab detoxified by glutathione conjugation; APAP overdose (&amp;gt;10 g) depletes glutathione stores → injury</description></item><item><title>Pathophysiology-ascites</title><link>https://htlin222.github.io/garden/Pathophysiology-ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-ascites/</guid><description>Pathophysiology-ascites (Hepatology 2021;74:1014)
Portal HTN → ↑ NO &amp;amp; prostaglandins → splanchnic vasodilatation→ ↓ effective arterial volume → ↑ RAAS &amp;amp; ADH → renal Na &amp;amp; H2O retention → volume overload and ascites</description></item><item><title>Pathophysiology-constrictive pericarditis</title><link>https://htlin222.github.io/garden/Pathophysiology-constrictive-pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-constrictive-pericarditis/</guid><description>Pathophysiology-constrictive pericarditis Adhesion of visceral and parietal pericardial layers → rigid pericardium that limits diastolic filling of ventricles → ↑ systemic venous pressures Venous return is limited only after early rapid filling phase; ∴ rapid ↓ in RA pressure with atrial relaxation and opening of tricuspid valve and prominent x and y descents Kussmaul sign: JVP does not decrease with inspiration (↑ venous return with inspiration, but negative intrathoracic pressure not transmitted to heart because of rigid pericardium)</description></item><item><title>Pathophysiology-diabetic ketoacidosis</title><link>https://htlin222.github.io/garden/Pathophysiology-diabetic-ketoacidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-diabetic-ketoacidosis/</guid><description>Pathophysiology-diabetic ketoacidosis (NEJM 2015;372:546)
Occurs in T1D (and in ketosis-prone T2D); ↑ glucagon and ↓ insulin Hyperglycemia due to: ↑ gluconeogenesis, ↑ glycogenolysis, ↓ glucose uptake into cells Ketosis due to: insulin deficiency → mobilization and oxidation of fatty acids, ↑ substrate for ketogenesis, ↑ ketogenic state of the liver, ↓ ketone clearance</description></item><item><title>Pathophysiology-gastroesophageal reflux disease</title><link>https://htlin222.github.io/garden/Pathophysiology-gastroesophageal-reflux-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-gastroesophageal-reflux-disease/</guid><description>Pathophysiology-gastroesophageal reflux disease Gastroesophageal reflux disease (GERD) is the second most common gastrointestinal diagnosis in the ambulatory setting and affects 18%–28% of people living in the North America.</description></item><item><title>Pathophysiology-Heparin-Induced Thrombocytopenias</title><link>https://htlin222.github.io/garden/Pathophysiology-Heparin-Induced-Thrombocytopenias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-Heparin-Induced-Thrombocytopenias/</guid><description>Pathophysiology-Heparin-Induced Thrombocytopenias Ab binds heparin-PF4 → immune complex binds to plt → plt activation, further PF4 release → plt aggregates removed from circulation → thrombocytopenia; procoagulants released by plts and tissue factor released by endothelial cells damaged by HIT Abs → prothrombotic state</description></item><item><title>Pathophysiology-hypernatremia</title><link>https://htlin222.github.io/garden/Pathophysiology-hypernatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-hypernatremia/</guid><description>Pathophysiology-hypernatremia (Crit Care 2013;17:206; NEJM 2015;372:55)
Deficit of water relative to sodium; by definition, all hypernatremic Pts are hypertonic</description></item><item><title>Pathophysiology-hyponatremia</title><link>https://htlin222.github.io/garden/Pathophysiology-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-hyponatremia/</guid><description>Pathophysiology-hyponatremia (JASN 2008;19:1076; NEJM 2015;372:1349)
Pathophysiology (JASN 2008;19:1076; NEJM 2015;372:1349)
Excess H2O relative to Na, usually due to ↑ ADH ↑ ADH may be appropriate (eg, hypovolemia or hypervolemia with ↓ EAV) ↑ ADH may be inappropriate (SIADH) Rarely, ↓ ADH (appropriately suppressed), but kidneys unable to maintain nl [Na]serum at steady state, solute intake = solute excretion; urine output = solute excretion/Uosm nl dietary solute load ~750 mOsm/d, min Uosm = 50 mOsm/L, ∴ UOP can be up to ~15 L ↑ H2O intake (1° polydipsia): ingestion of massive quantities (usually &amp;gt;15 L/d) of free H2O overwhelms diluting ability of kidney → H2O retention ↓ solute intake (“tea &amp;amp; toast” &amp;amp; beer potomania): ↓↓ daily solute load → insufficient solute to excrete H2O intake (eg, if only 250 mOsm/d, minimum Uosm = 50 mOsm/L → excrete in ~5 L; if H2O ingestion exceeds this amount → H2O retention)</description></item><item><title>Pathophysiology-metabolic-alkalosis</title><link>https://htlin222.github.io/garden/Pathophysiology-metabolic-alkalosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-metabolic-alkalosis/</guid><description>Pathophysiology-metabolic-alkalosis (CJASN 2020;15:1848)
Saline-responsive etiologies require
initiating event and maintenance phase Initiating event: net HCO3− reabsorption (due to loss of volume, Cl-, and/or K+) or loss of H+ Loss of H+ (± Cl-) from GI tract, kidneys, or transcellular shift in hypokalemia Contraction alkalosis: loss of HCO3&amp;ndash;poor fluid → extracellular fluid “contracts” around fixed amount of HCO3- → ↑ HCO3- concentration 流失掉酸液 Exogenous alkali: iatrogenic HCO3- (with renal impairment), [[milk-alkali syndrome]] Posthypercapnia: resp.</description></item><item><title>Pathophysiology-pericardial tamponade</title><link>https://htlin222.github.io/garden/Pathophysiology-pericardial-tamponade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-pericardial-tamponade/</guid><description>Pathophysiology-pericardial tamponade ↑ intrapericardial pressure, compression of heart chambers, ↓ venous return → ↓ CO Diastolic pressures ↑ &amp;amp; equalize in all cardiac chambers → minimal flow of blood from RA to RV when TV opens → blunted y descent ↑ ventricular interdependence → pulsus paradoxus (pathologic exaggeration of nl physio) Inspiration → ↓ intrapericardial &amp;amp; RA pressures → ↑ venous return → ↑ RV size → septal shift to left.</description></item><item><title>Pathophysiology-pleural effusion</title><link>https://htlin222.github.io/garden/Pathophysiology-pleural-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pathophysiology-pleural-effusion/</guid><description>Pathophysiology-pleural effusion Systemic factors (eg, ↑ PCWP, ↓ oncotic pressure) → transudative effusion pcwp 肺毛細血管契壓 Local factors (ie, Δ pleural surface permeability) → exudative effusion</description></item><item><title>Patient isolation-tuberculosis</title><link>https://htlin222.github.io/garden/Patient-isolation-tuberculosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Patient-isolation-tuberculosis/</guid><description>Patient isolation-tuberculosis Decision based on likelihood of active disease. Consider when cough, dyspnea, hemoptysis, ≥1 risk factor (HIV ⊕, foreign born, substance use disorder, homeless, recent incarceration, prior TB or exposure).</description></item><item><title>Patterns of LFTs</title><link>https://htlin222.github.io/garden/Patterns-of-LFTs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Patterns-of-LFTs/</guid><description>Patterns of LFTs LFTs異常的四大類DDx hepatocellular 上升的ALT, aspartate aminotransferase，其他的不一定 Cholestatic Infiltrative Nonhepatic hepatocellular 想四個DDx Viral hepatitis, non-alcoholic fatty liver disease 一般來說會是ALT&amp;gt;AST Alchololic hepatitis AST&amp;gt;2*ALT Ischemic injury 四項都高，因此shock liver的診斷還是把四項都抽一抽 Wilson Disease Aφ : Tbili &amp;lt; 4 (if fulminat) Cholestatic Infiltrative 反而是Aφ, Bilirubin高 Nonhepatic Skeletal muscle injury Bone Disease Hemolysis</description></item><item><title>PD peritonitis</title><link>https://htlin222.github.io/garden/PD-peritonitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/PD-peritonitis/</guid><description>PD peritonitis : abd pain &amp;amp; cloudy drainage (WBC &amp;gt;100 &amp;amp; &amp;gt;50% PMNs). 60–70% GPC, 15–20% GNR. Rx: abx IV or in PD, catheter removal for certain org (yeast, Pseudomonas).</description></item><item><title>PD-1 PD-L1 pathway</title><link>https://htlin222.github.io/garden/PD-1-PD-L1-pathway/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/PD-1-PD-L1-pathway/</guid><description>PD-1 PD-L1 pathway Programmed Cell Death Protein 1 (PD-1) original: PD-1/PD-L1 pathway: current researches in cancer
PD-1/PD-L1 pathway controls the induction and maintenance of immune tolerance within the tumor microenvironment.</description></item><item><title>PD-L1</title><link>https://htlin222.github.io/garden/PD-L1/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/PD-L1/</guid><description>免疫治療|一文讀懂PD-L1檢測之抗體選擇 [[PD-1 PD-L1 pathway]]: current researches in cancer [[atezolizumab]]
TPS：腫瘤細胞陽性比例分數（Tumor Proportion Score)，計算公式如下：
PD-L1判讀標準（TPS）：
PD-L1強表達（TPS≥50%）；PD-L1表達（1%≤TPS≤49%）；PD-L1未表達（TPS＜1%）
CPS：陽性聯合分數（Combined Positive Score）。除了腫瘤細胞表達PD-L1之外，淋巴細胞、巨噬細胞等免疫細 胞也會有PD-L1表達。計算公式如下：
PD-L1判讀標準（CPS）：</description></item><item><title>Pel-Ebstein fever</title><link>https://htlin222.github.io/garden/Pel-Ebstein-fever/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pel-Ebstein-fever/</guid><description>Pel-Ebstein fever ✨重點: 這是 16% 的霍奇金病病例的發燒。 它的特點是發作持續數小時或數天，然後是數天甚至數週的無發熱期。 因此，這是典型的回歸熱。 它於 19 世紀由荷蘭人 Pieter Pel 和德國人 Wilhelm Ebstein 首次描述。 後者可能因為他的課外興趣而被更好地記住，從藝術和文學到歷史。</description></item><item><title>Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer</title><link>https://htlin222.github.io/garden/Pembrolizumab-plus-Chemotherapy-in-Metastatic-NonSmall-Cell-Lung-Cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pembrolizumab-plus-Chemotherapy-in-Metastatic-NonSmall-Cell-Lung-Cancer/</guid><description>Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.</description></item><item><title>Penetrating injury</title><link>https://htlin222.github.io/garden/Penetrating-injury/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Penetrating-injury/</guid><description>Penetrating injury Pseudomonas Can be a/w deep tissue abscess Directed based on suscept.</description></item><item><title>peptic ulcer disease</title><link>https://htlin222.github.io/garden/peptic-ulcer-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/peptic-ulcer-disease/</guid><description>peptic ulcer disease [[definition and etiologies of peptic ulcer disease]]
(20–60%; duodenal&amp;gt;gastric)
(Am J Gastro 2021;116:899)
See “PUD”
Treatment: PPI: 40 mg PO or IV BID</description></item><item><title>pericardial disease</title><link>https://htlin222.github.io/garden/pericardial-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pericardial-disease/</guid><description>pericardial disease Anatomy
2-layered (parietal &amp;amp; visceral) tissue sac surrounding heart &amp;amp; proximal great vessels Disease states
Inflammation (w/ or w/o fluid accumulation) → pericarditis</description></item><item><title>pericardial tamponade</title><link>https://htlin222.github.io/garden/pericardial-tamponade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pericardial-tamponade/</guid><description>pericardial tamponade [[Etiology-pericardial tamponade]] [[Pathophysiology-pericardial tamponade]] [[Clinical manifestations-pericardial tamponade]] [[Physical exam-pericardial tamponade]] [[Diagnostic studies-pericardial tamponade]] [[Treatment-pericardial tamponade]]</description></item><item><title>pericarditis and pericardial effusion</title><link>https://htlin222.github.io/garden/pericarditis-and-pericardial-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pericarditis-and-pericardial-effusion/</guid><description>pericarditis and pericardial effusion [[Etiologies of Acute Pericarditis]] [[Clinical manifestations-pericarditis and pericardial effusion]] [[Physical exam-pericarditis and pericardial effusion]] [[Diagnostic studies-pericarditis and pericardial effusion]] [[Workup for effusion]] [[Treatment of pericarditis]]</description></item><item><title>peripheral artery disease</title><link>https://htlin222.github.io/garden/peripheral-artery-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/peripheral-artery-disease/</guid><description>peripheral artery disease [[Clinical features-peripheral artery disease]] [[Diagnosis-peripheral artery disease]] [[Treatment-peripheral artery disease]] [[Acute limb ischemia (ALI)-peripheral artery disease]]</description></item><item><title>Periprocedural “Bridging” of Anticoagulation in Pts with Mechanical Valve s</title><link>https://htlin222.github.io/garden/Periprocedural-Bridging-of-Anticoagulation-in-Pts-with-Mechanical-Valves/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Periprocedural-Bridging-of-Anticoagulation-in-Pts-with-Mechanical-Valves/</guid><description>Periprocedural “Bridging” of Anticoagulation in Pts with Mechanical Valve(s) AVR w/o risk factors d/c warfarin 2–4 d before surg; restart 12–24 h after surg</description></item><item><title>Peritoneal dialysis PD</title><link>https://htlin222.github.io/garden/Peritoneal-dialysis-PD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Peritoneal-dialysis-PD/</guid><description>Peritoneal dialysis (PD) (JAMA 2017;317:1864)
Fluid removed via convection using oncotic pressure (eg, dextrose). ↑ concentrations and dwell times removes more fluid (less as glc equilibrates).</description></item><item><title>Peritoneal dialysis-associated-Bacterial peritonitis</title><link>https://htlin222.github.io/garden/Peritoneal-dialysis-associated-Bacterial-peritonitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Peritoneal-dialysis-associated-Bacterial-peritonitis/</guid><description>Peritoneal dialysis-associated-Bacterial peritonitis cloudy fluid, abd pain, fever, nausea. Dx can be made with &amp;gt;50 PMNs. Culture most often GPC (50%) or GNR (15%).</description></item><item><title>Pharmacologic options-Treatment-hypertension</title><link>https://htlin222.github.io/garden/Pharmacologic-options-Treatment-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pharmacologic-options-Treatment-hypertension/</guid><description>Pharmacologic options-Treatment-hypertension Pre-HTN: ARB prevents onset of HTN, no ↓ in clinical events (NEJM 2006;354:1685) HTN: choice of therapy controversial, concomitant disease and stage may help guide Rx; ?</description></item><item><title>Pharmacologic-stress-test</title><link>https://htlin222.github.io/garden/Pharmacologic-stress-test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pharmacologic-stress-test/</guid><description>Pharmacologic-stress-test Use if unable to exercise, low exercise tolerance, or recent MI. Se &amp;amp; Sp ≈ exercise.
Preferred if LBBB, WPW or V-paced, because higher prob of false ⊕ imaging with exercise</description></item><item><title>Phases of Chronic HBV Infection</title><link>https://htlin222.github.io/garden/Phases-of-Chronic-HBV-Infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Phases-of-Chronic-HBV-Infection/</guid><description>Phases of Chronic HBV Infection</description></item><item><title>pheochromocytoma and paraganglioma</title><link>https://htlin222.github.io/garden/pheochromocytoma-and-paraganglioma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pheochromocytoma-and-paraganglioma/</guid><description>pheochromocytoma and paraganglioma [[Clinical manifestations-pheochromocytoma and paraganglioma]] [[Diagnostic studies-pheochromocytoma and paraganglioma]] Treatment
α-blockade first (usually phenoxybenzamine) ± β-blockade (often propranolol) → surgery Preoperative volume expansion is critical due to possible hypotension after tumor excision</description></item><item><title>phosphate disorders</title><link>https://htlin222.github.io/garden/phosphate-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/phosphate-disorders/</guid><description>phosphate disorders [[Hypophosphatemia - Approach to the Patient]]</description></item><item><title>phosphate replacement therapies</title><link>https://htlin222.github.io/garden/phosphate-replacement-therapies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/phosphate-replacement-therapies/</guid><description>phosphate replacement therapies In adults with symptomatic mild hypophosphatemia (2-2.5 mg/dL [0.65-0.81 mmol/L]) treat with increased dietary phosphate or oral phosphate supplements 1,000-2,000 mg/day.</description></item><item><title>Physical exam heart failure</title><link>https://htlin222.github.io/garden/Physical-exam-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-heart-failure/</guid><description>Physical exam heart failure (“2-minute” hemodynamic profile; JAMA 1996;275:630 &amp;amp; 2002;287:628)
Physical exam (“2-minute” hemodynamic profile; JAMA 1996;275:630 &amp;amp; 2002;287:628)</description></item><item><title>Physical exam of hypertrophic cardiomyopathy</title><link>https://htlin222.github.io/garden/Physical-exam-of-hypertrophic-cardiomyopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-of-hypertrophic-cardiomyopathy/</guid><description>Physical exam of hypertrophic cardiomyopathy Sustained PMI, S2 paradoxically split if severe outflow obstruction, ⊕ S4 (occ. palpable)</description></item><item><title>Physical Exam Secret</title><link>https://htlin222.github.io/garden/Physical-Exam-Secret/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-Exam-Secret/</guid><description>Physical Exam Secret Postural dizziness (severe enough to stop the test) or an increase in heart rate of at least 30 beats/minute has sensitivity of 97% and specificity of 96% for blood loss &amp;gt;630 mL.</description></item><item><title>Physical exam-acute bacterial meningitis</title><link>https://htlin222.github.io/garden/Physical-exam-acute-bacterial-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-acute-bacterial-meningitis/</guid><description>Physical exam-acute bacterial meningitis Brudzinski and Kernig signs of meningeal irritation appear unreliable for diagnosis or ruling out of meningitis.</description></item><item><title>Physical exam-bacterial endocarditis</title><link>https://htlin222.github.io/garden/Physical-exam-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-bacterial-endocarditis/</guid><description>Physical exam-bacterial endocarditis Cardiac murmur (85%), s/s of new HF (pulmonary edema, JVP elevation, edema) Skin/ocular changes (uncommon but highly specific) Janeway lesions (painless hemorrhagic macules on palms/ soles due to septic emboli) Osler’s nodes (painful nodules on pads of digits due to immune complex deposition) Splinter hemorrhages in fingernails or toenails Roth spots (retinal hemorrhages) MSK: point tenderness along spine, red/hot joints Neurologic deficits c/f embolic stroke; vertebral tenderness c/f osteo or epidural abscess Devices: evaluate CVCs, PM/ICD pocket, and sites of other hardware/ prosthetics</description></item><item><title>Physical exam-cirrhosis</title><link>https://htlin222.github.io/garden/Physical-exam-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-cirrhosis/</guid><description>Physical exam-cirrhosis Liver: initially enlarged, palpable (L lobe predom), firm; eventually shrunken, nodular
Signs of liver failure: jaundice (bili &amp;gt;2.</description></item><item><title>Physical exam-constrictive pericarditis</title><link>https://htlin222.github.io/garden/Physical-exam-constrictive-pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-constrictive-pericarditis/</guid><description>Physical exam-constrictive pericarditis ↑ JVP with prominent y descent, ⊕ Kussmaul sign [Ddx: tricuspid stenosis, acute cor pulmonale, RV dysfxn (CMP, RV MI), SVC syndrome] Hepatosplenomegaly, ascites, peripheral edema.</description></item><item><title>physical exam-initial management-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/physical-exam-initial-management-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/physical-exam-initial-management-gastrointestinal-bleeding/</guid><description>physical exam-initial management-gastrointestinal bleeding localizable abdominal tenderness, 可局部化的腹部壓痛 peritoneal signs masses, LAN, prior surgery, signs of liver disease (hepatosplenomegaly, ascites, jaundice, telangiectasias), 肝臟疾病的跡象（肝脾腫大、腹水、黃疸、毛細血管擴張）， rectal exam: masses, hemorrhoids, anal fissures, stool appearance, color 直腸檢查：腫塊、痔瘡、肛裂、大便外觀、顏色</description></item><item><title>Physical exam-mitral-stenosis</title><link>https://htlin222.github.io/garden/Physical-exam-mitral-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-mitral-stenosis/</guid><description>Physical exam-mitral-stenosis Low-pitched mid-diastolic rumble at apex w/ presystolic accentuation (if not in AF); best heard in L lat decubitus position during expiration, ↑ w/ exercise; severity proportional to duration (not intensity) of murmur; loud S 1 Opening snap (high-pitched early diastolic sound at apex) from fused leaflet tips; MVA proportional to S2–OS interval (tighter valve → ↑ LA pressure → shorter interval) Loud S1 (unless MV calcified and immobile)</description></item><item><title>Physical exam-pericardial tamponade</title><link>https://htlin222.github.io/garden/Physical-exam-pericardial-tamponade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-pericardial-tamponade/</guid><description>Physical exam-pericardial tamponade Beck’s triad (present in minority of cases): distant heart sounds (28%), ↑ JVP (76%) w/ blunted y descent, hypotension (26%); ± pericardial friction rub (30%) Reflex tachycardia (77%), cool extremities Pulsus paradoxus (Se 82%, Sp 70%) = ↓ SBP ≥10 mmHg during inspiration ⊕ LR 3.</description></item><item><title>Physical exam-pericarditis and pericardial effusion</title><link>https://htlin222.github.io/garden/Physical-exam-pericarditis-and-pericardial-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-pericarditis-and-pericardial-effusion/</guid><description>Physical exam-pericarditis and pericardial effusion Pericarditis: multiphasic friction rub best heard at LLSB w/ diaphragm of stethoscope. Notoriously variable and evanescent leathery sound w/ up to 3 components: atrial contraction, ventricular contraction, ventricular relaxation (NEJM 2012;367:e20).</description></item><item><title>Physical Examination</title><link>https://htlin222.github.io/garden/Physical-examination/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-examination/</guid><description>Physical Examination Wheezing and prolonged expiratory phase
Presence of nasal polyps, rhinitis, rash → allergic component</description></item><item><title>physical findings may help identify the cause of a fever</title><link>https://htlin222.github.io/garden/physical-findings-may-help-identify-the-cause-of-a-fever/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/physical-findings-may-help-identify-the-cause-of-a-fever/</guid><description>physical findings may help identify the cause of a fever ✨重點: 無汗症支持中暑或乾擾出汗的藥物。
肌肉強直提示神經阻滯劑惡性綜合徵或惡性高熱。
黃疸可見於細菌感染，與肝膽系統直接受累無關（如膽管炎或肝炎，見問題 14）。</description></item><item><title>Physical-exam-aortic-regurgitation</title><link>https://htlin222.github.io/garden/Physical-exam-aortic-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-aortic-regurgitation/</guid><description>Physical-exam-aortic-regurgitation Early diastolic decrescendo murmur at LSB (RSB if dilated Ao root); ↑ w/ sitting forward, expir, handgrip; severity of AR ∝ duration of murmur (except in acute and severe late); Austin Flint murmur: mid-to-late diastolic rumble at apex (AR jet interfering w/ mitral inflow) Wide pulse pressure due to ↑ stroke volume, hyper-dynamic pulse; pulse pressure narrows in late AR with ↓ LV fxn; bisferiens (twice-beating) arterial pulse PMI diffuse and laterally displaced; soft S1 (early closure of MV); ± S3 (≠ ↓ EF but rather just volume overload in AR)</description></item><item><title>Physical-exam-aortic-stenosis</title><link>https://htlin222.github.io/garden/Physical-exam-aortic-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-aortic-stenosis/</guid><description>Physical-exam-aortic-stenosis Midsystolic crescendo-decrescendo murmur at RUSB, harsh, high-pitched, radiates to carotids, apex (holosystolic = Gallavardin effect), ↑ w/ passive leg raise, ↓ w/ standing &amp;amp; Valsalva.</description></item><item><title>Physical-exam-mitral-regurgitation</title><link>https://htlin222.github.io/garden/Physical-exam-mitral-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Physical-exam-mitral-regurgitation/</guid><description>Physical-exam-mitral-regurgitation Early diastolic decrescendo murmur at LSB (RSB if dilated Ao root); ↑ w/ sitting forward, expir, handgrip; severity of AR ∝ duration of murmur (except in acute and severe late); Austin Flint murmur: mid-to-late diastolic rumble at apex (AR jet interfering w/ mitral inflow) Wide pulse pressure due to ↑ stroke volume, hyper-dynamic pulse; pulse pressure narrows in late AR with ↓ LV fxn; bisferiens (twice-beating) arterial pulse PMI diffuse and laterally displaced; soft S1 (early closure of MV); ± S3 (≠ ↓ EF but rather just volume overload in AR) Classic Eponymous Signs in Chronic AR Corrigan’s pulse “water hammer” pulse (ie, rapid rise/fall or distention/collapse) Hill’s sign (popliteal SBP – brachial SBP) &amp;gt;60 mmHg Duroziez’s sign to-and-fro murmur heard over femoral artery w/ light compression Pistol shot sounds pistol shot sound heard over femoral artery Traube’s sound double sound heard over femoral artery when compressed distally de Musset’s sign head-bobbing with each heartbeat (low Se) Müller’s sign systolic pulsations of the uvula Quincke’s pulses subungual capillary pulsations (low Sp)</description></item><item><title>physiology of pulmary</title><link>https://htlin222.github.io/garden/physiology-of-pulmary/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/physiology-of-pulmary/</guid><description>physiology of pulmary 潮氣2.5L~3L 最大(Total lung capacity)兩倍=5L~6L 最小(Residual Vol)一半=1.25~1.5L Vital capacity = 最大-最小 reserve 潮氣 - 最小 最大 - 潮氣</description></item><item><title>PIK3CA</title><link>https://htlin222.github.io/garden/PIK3CA/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/PIK3CA/</guid><description>PIK3CA PI3K inhib Alpelisib + fulvestrant ↑ PFS in met HR⊕ (NEJM 2019;380:1929)</description></item><item><title>Pituitary apoplexy</title><link>https://htlin222.github.io/garden/Pituitary-apoplexy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pituitary-apoplexy/</guid><description>Pituitary apoplexy Rapid expansion of pituitary tumor (typically adenoma) due to hemorrhage or infarction Sx include excruciating headache, diplopia, hypopituitarism Rx: immediate high-dose glucocorticoids; prompt surgical decompression if severe neurologic impairment or Δ MS; conservative management if mild</description></item><item><title>pituitary disorders</title><link>https://htlin222.github.io/garden/pituitary-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pituitary-disorders/</guid><description>pituitary disorders [[hypopituitary syndromes]] [[hyperpituitary syndromes]]</description></item><item><title>Pituitary tumors</title><link>https://htlin222.github.io/garden/Pituitary-tumors/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pituitary-tumors/</guid><description>Pituitary tumors Pathophysiology: adenoma → excess of trophic hormone (if tumor fxnal, but 30–40% not) and potentially deficiencies in other trophic hormones due to compression; cosecretion of PRL and growth hormone in 10% of prolactinomas Clinical manifestations: specific syndromes due to oversecretion of hormones (see below) ± non-specific mass effect: headache, visual Δs, diplopia, cranial neuropathies Workup: MRI brain pituitary protocol, hormone levels, ± visual field testing if &amp;lt;10 mm, no mass effect, no hormone overproduction, can f/up in 12 mos</description></item><item><title>Placement PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/Placement-PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Placement-PA-catheter-and-tailored-therapy/</guid><description>Placement PA catheter and tailored therapy Insertion site: R IJ or L subclavian veins preferred for “anatomic” flotation into PA</description></item><item><title>platelet disorders</title><link>https://htlin222.github.io/garden/platelet-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/platelet-disorders/</guid><description>platelet disorders thrombocytopenia [[Thrombocytopenia and Risk of Bleeding]] [[Etiologies-of thrombocytopenia]] [[Diagnostic evaluation of thrombocytopenia]] [[Approach to thrombocytopenia]] [[Primary immune thrombocytopenic purpura (ITP) ]] [[Secondary immune thrombocytopenic purpura (2° ITP)]] [[Heparin-Induced Thrombocytopenias]] [[Thrombotic microangiopathies]] [[Disseminated intravascular coagulation (DIC)]] disorders of platelet function [[Mechanisms and Etiologies of Platelet Function Abnormalities]] Platelet aggregation tests: measure aggregation in response to agonists (eg, ADP) [[von Willebrand’s disease (vWD)]] [[Uremic bleeding]]</description></item><item><title>Platelets-transfusion</title><link>https://htlin222.github.io/garden/Platelets-transfusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Platelets-transfusion/</guid><description>Platelets-transfusion For plts &amp;lt;10k (NEJM 2010;362:600) due to chemo/abx. If &amp;lt;20k or if &amp;lt;50k w/ active bleeding. Variable pre-procedure.100k for neurosurgery.</description></item><item><title>pleocytosis</title><link>https://htlin222.github.io/garden/pleocytosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pleocytosis/</guid><description>pleocytosis 在血中叫leukocytosis 在CSF 中叫做pleocytosis 兩者都在是在細胞增多的意思
In medicine, pleocytosis (or pleiocytosis) is an increased cell count (from Greek pleion, &amp;ldquo;more&amp;rdquo;) particularly an increase in white blood cell count, in a bodily fluid, such as cerebrospinal fluid.</description></item><item><title>pleural effusion</title><link>https://htlin222.github.io/garden/pleural-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pleural-effusion/</guid><description>pleural effusion [[Pathophysiology-pleural effusion]]
[[Transudates]]
[[Exudates]]
[[Diagnostic studies-pleural effusion]]
[[Characteristics of Pleural Fluid]]</description></item><item><title>Pneumocystis jiroveci PCP pneumonia</title><link>https://htlin222.github.io/garden/Pneumocystis-jiroveci-PCP-pneumonia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pneumocystis-jiroveci-PCP-pneumonia/</guid><description>Pneumocystis jiroveci (PCP) pneumonia fever, night sweats, dyspnea on exertion, dry (“doorstop”) cough CXR w/ interstitial pattern, ↓ PaO2, ↑ A-a ∇, ↑ LDH, ⊕ PCP sputum stain, ⊕ β-glucan Rx if PaO2 &amp;gt;70: TMP-SMX 15–20 mg of TMP/kg divided tid, avg dose = DS 2 tabs PO tid Rx if PaO2 &amp;lt;70 or A-a gradient &amp;gt;35: prednisone before abx (40 mg PO bid; ↓ after 5 d) HIV ⊕ smokers much more likely to die from lung cancer than OI (JAMA 2017;177:1613)</description></item><item><title>pneumonia</title><link>https://htlin222.github.io/garden/pneumonia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pneumonia/</guid><description>pneumonia [[Definitions-and-clinical-manifestations]] [[Microbiology-of-Pneumonia]] [[Diagnostic studies-pneumonia]] (AJRCC 2019;200:e45) [[Triage-pneumonia]] [[Treatment-pneumonia]] (NEJM 2019;380:651; AJRCC 2019;200:e45) [[Prevention-pneumonia]] [[viral respiratory infections]] [[coronavirus (covid-19)]] / sars-cov-2 infection</description></item><item><title>POCUS</title><link>https://htlin222.github.io/garden/POCUS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/POCUS/</guid><description>[[index]] [[icu]]</description></item><item><title>Polyarteritis nodosa</title><link>https://htlin222.github.io/garden/Polyarteritis-nodosa/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Polyarteritis-nodosa/</guid><description>Polyarteritis nodosa Usually middle-aged males. Hepatitis B seropositivity in 30% of patients. Fever, weight loss, malaise, headache. GI: abdominal pain, melena.</description></item><item><title>Polycystic kidney disease</title><link>https://htlin222.github.io/garden/Polycystic-kidney-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Polycystic-kidney-disease/</guid><description>Polycystic kidney disease (NEJM 2008;359:1477; 2017;377:1988)
Mostly AD PKD1/PKD2 mutations → renal cysts. PKD1 (85%) younger-onset ESRD.
Rx: hydration, low-salt diet; tolvaptan reduces GFR decline.</description></item><item><title>Polymorphic ventricular tachycardia PMVT</title><link>https://htlin222.github.io/garden/Polymorphic-ventricular-tachycardia-PMVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Polymorphic-ventricular-tachycardia-PMVT/</guid><description>Polymorphic ventricular tachycardia (PMVT) QRS morphology changes from beat to beat Etiologies: ischemia; CMP; catecholaminergic torsades de pointes (TdP = “twisting of the points,” PMVT + ↑ QT): ↑ QT acquired (meds, lytes, stroke, see “ECG”) w/ risk ↑ w/ ↓ HR, freq PVCs (pause dependent) or congenital (K/Na channelopathies) w/ resting Tw abnl &amp;amp; TdP triggered by sympathetic stimulation (eg, exercise, emotion, sudden loud noises) (Lancet 2008;372:750) Brugada syndrome (Na channelopathy; JACC 2018;72:1046): ♂ &amp;gt; ♀; pseudo-RBBB w/ STE in V1–V3 (provoked w/ class IA or IC) on resting ECG</description></item><item><title>Polymyalgia rheumatica</title><link>https://htlin222.github.io/garden/Polymyalgia-rheumatica/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Polymyalgia-rheumatica/</guid><description>Polymyalgia rheumatica (JAMA 2016;315:2442; Lancet 2017;390:1700)
Prev 7/1000 of age ≥50. In 50% of GCA Pts; 15% of PMR Pts develop GCA.</description></item><item><title>Polyp or Tumor</title><link>https://htlin222.github.io/garden/Polyp-or-Tumor/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Polyp-or-Tumor/</guid><description>Polyp or Tumor Typically slow ooze, p/w fatigue, weight loss, iron deficiency, anemia</description></item><item><title>polyps</title><link>https://htlin222.github.io/garden/polyps/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/polyps/</guid><description>polyps Pathophysiology &amp;amp; epidemiology (NEJM 2016;374:1065) Accumulation of mutations in colonic epithelial cell DNA affecting oncogenes &amp;amp; tumor suppressor genes → tumor initiation (formation of adenoma; APC loss of fxn) → tumor progression (adenoma → carcinoma; K-ras gain of fxn, DCC, p53 loss of fxn) Risk factors: ↑ age, FHx (sporadic in 1° relatives, Lynch, FAP), IBD, ↑ dietary fat, central adiposity, ↑ EtOH, ↓ fiber, ↑ red meat, smoking, DM Protective factors: ↑ physical activity, ASA/NSAIDs, Ca2+ intake, HRT, ↓ BMI; possibly ↑ fiber, vitamin D, fish oil, statins, selenium Neoplastic polyps: adenomas (tubular, villous, tubulovillous dysplasia), sessile serrated adenomas/polyps (concern for interval CRC), carcinomas Non-neoplastic polyps: hyperplastic, juvenile, Peutz-Jeghers (can undergo malignant transformation), inflammatory [[CRC screening]]</description></item><item><title>polyuria</title><link>https://htlin222.github.io/garden/polyuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/polyuria/</guid><description>polyuria Definition and pathophysiology Polyuria defined as &amp;gt;3 L UOP per day Due to an osmotic or a water diuresis; almost always due to osmotic diuresis in inpatients Workup Perform a timed urine collection (6 h sufficient) and measure Uosm 24-h osmole excretion rate = 24-h UOP (actual or estimate) × Uosm 1000 mOsm/d → osmotic diuresis; &amp;lt;800 mOsm/d → water diuresis</description></item><item><title>Poor-R-wave-progression</title><link>https://htlin222.github.io/garden/Poor-R-wave-progression/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Poor-R-wave-progression/</guid><description>Poor-R-wave-progression Definition: loss of anterior forces w/o frank Q waves (V1–V3); R wave in V3 ≤3 mm
Etiologies: old anteroseptal MI (w/ R wave V3 ≤1.</description></item><item><title>Portal HTN gastropathy</title><link>https://htlin222.github.io/garden/Portal-HTN-gastropathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Portal-HTN-gastropathy/</guid><description>Portal HTN gastropathy ↑ portal venous pressure → ectatic vessels, hyperemia in gastric antrum. Rx: reduce portal HTN (octreotide), βB, TIPS.</description></item><item><title>Portal vein thrombosis PVT</title><link>https://htlin222.github.io/garden/Portal-vein-thrombosis-PVT-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Portal-vein-thrombosis-PVT-/</guid><description>Portal vein thrombosis (PVT) (Clin Liver Dis 2017;10:152; Gastro 2019;156:1582)
Definition: thrombosis of portal vein often w/ extension into mesenteric vein/splenic vein Etiologies: commonly due to cirrhosis or hypercoaguable state (cancer, infection, OCP, collagen vascular diseases, Behçet’s, IBD, surgery, trauma, OCPs, preg) [[Clinical manifestations-Portal vein thrombosis (PVT)]] [[Dx-Portal vein thrombosis (PVT)]] [[Treatment-Portal vein thrombosis (PVT)]]</description></item><item><title>Portopulmonary hypertension POPH</title><link>https://htlin222.github.io/garden/Portopulmonary-hypertension-POPH/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Portopulmonary-hypertension-POPH/</guid><description>Portopulmonary hypertension (POPH) (Expert Rev Gastro Hepatol 2015;9:983)
Pulm HTN in Pt w/ portal HTN w/o other cause. ESLD→ ↑ endothelin→ pulm vasoconst.</description></item><item><title>positioning-airway-management</title><link>https://htlin222.github.io/garden/positioning-airway-management/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/positioning-airway-management/</guid><description>positioning-airway-management ✨重點: 提供者站在床頭，患者的頭部應盡可能靠近床頭。 正確的定位可以創建從患者口腔到喉部的直接視線。 這是通過使用枕頭/毯子使頸椎彎曲大約 30° 以及伸展寰枕關節（經典的“嗅探姿勢”）來實現的。 定位肥胖患者可能特別具有挑戰性。 這可以通過形成一個坡道來實現，抬高上背部和肩部以適應足夠的頸椎屈曲。 Confirming horizontal alignment of the external auditory meatus with the sternal notch can be a useful guide.</description></item><item><title>positive and negative predictive values of tests</title><link>https://htlin222.github.io/garden/positive-and-negative-predictive-values-of-tests/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/positive-and-negative-predictive-values-of-tests/</guid><description>positive and negative predictive values of tests ✨重點: 敏感性：患有正在接受檢測的疾病並且檢測結果呈陽性的患者的百分比 特異性：未患病且檢測結果為陰性的患者百分比 陽性預測值：檢測結果呈陽性並患有正在檢測的疾病的患者百分比 陰性預測值：檢測結果為陰性但未患病的患者百分比</description></item><item><title>Post-exacerb care of COPDAE</title><link>https://htlin222.github.io/garden/Post-exacerb-care-of-COPDAE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Post-exacerb-care-of-COPDAE/</guid><description>Post-exacerb care of COPDAE Follow up within 1 mo; smoking cessation if current smoker; vaccinations (influenza, pneumococcal), referral to pulm rehab (AJRCCM 2007;176:532)</description></item><item><title>Post-renal acute kidney injury etiology</title><link>https://htlin222.github.io/garden/Post-renal-acute-kidney-injury-etiology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Post-renal-acute-kidney-injury-etiology/</guid><description>Post-renal acute kidney injury etiology Bladder neck: BPH, prostate cancer, neurogenic bladder, anticholinergic meds Ureteral (bilateral or unilateral in single kidney): malig, LAN, retroperitoneal fibrosis, nephrolithiasis UA, Sediment, Indices Bland ± non-dysmorphic RBCs, WBC, crystals</description></item><item><title>Post-sphincter-otomy bleeding</title><link>https://htlin222.github.io/garden/Post-sphincter-otomy-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Post-sphincter-otomy-bleeding/</guid><description>Post-sphincter-otomy bleeding Occurs in ~2% of ERCP w/ sphincterotomy; ↑ risk w/ more complic. procedure. Bleeding into duodenum. Rx w/ endo hemostasis.</description></item><item><title>potassium homeostasis</title><link>https://htlin222.github.io/garden/potassium-homeostasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/potassium-homeostasis/</guid><description>potassium homeostasis [[Overview-potassium homeostasis]] [[hypokalemia]] [[hyperkalemia]]</description></item><item><title>POUNDing Mnemonic</title><link>https://htlin222.github.io/garden/POUNDing-Mnemonic/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/POUNDing-Mnemonic/</guid><description>POUNDing Mnemonic Pulsatile hOurs (duration of 4-72 hours) Unilateral Nauseating Disabling</description></item><item><title>Prasugrel</title><link>https://htlin222.github.io/garden/Prasugrel/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prasugrel/</guid><description>Prasugrel 60 mg × 1 at PCI → 10 mg qd (consider 5 mg/d if &amp;lt;60 kg) Wait 7 d prior to surgery Contraindicated if h/o TIA/CVA; caution if &amp;gt;75 y More rapid and potent plt inhib c/w clopi 19% ↓ CVD/MI/stroke in ACS w/ planned PCI vs.</description></item><item><title>Precipitants of acute heart failure</title><link>https://htlin222.github.io/garden/Precipitants-of-acute-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Precipitants-of-acute-heart-failure/</guid><description>Precipitants of acute heart failure Dietary indiscretion or medical nonadherence (~40% of cases) Myocardial ischemia or infarction (~10–15% of cases); myocarditis Renal failure (acute, progression of CKD, or insufficient dialysis) → ↑ preload Hypertensive crisis (incl.</description></item><item><title>Precipitants of Migraine</title><link>https://htlin222.github.io/garden/Precipitants-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Precipitants-of-Migraine/</guid><description>Precipitants of Migraine stress foods (cheese, chocolate, MSG) fatigue EtOH menses exercise</description></item><item><title>Precipitants-diabetic ketoacidosis</title><link>https://htlin222.github.io/garden/Precipitants-diabetic-ketoacidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Precipitants-diabetic-ketoacidosis/</guid><description>Precipitants-diabetic ketoacidosis (the I’s)
Insulin defic. (ie, failure to take enough insulin); 炎 Infection (pneumonia, UTI) or Inflammation (pancreatitis, cholecystitis) 缺血 Ischemia or Infarction (myocardial, cerebral, gut); 外物 Iatrogenesis (glucocorticoids; SGLT2 inhibitors—can be w/o marked hyperglycemia; Diabetes Care 2016;39:532) Intoxication (alcohol, drugs)</description></item><item><title>Precipitants-hypertensive crises</title><link>https://htlin222.github.io/garden/Precipitants-hypertensive-crises/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Precipitants-hypertensive-crises/</guid><description>Precipitants-hypertensive crises Progression of essential HTN ± medical noncompliance (espec clonidine) or ∆ in diet Progression of renovascular disease; acute glomerulonephritis; scleroderma; preeclampsia Endocrine: pheochromocytoma, Cushing’s Sympathomimetics: cocaine, amphetamines, MAO inhibitors + foods rich in tyramine</description></item><item><title>predictors of difficult mask ventilation</title><link>https://htlin222.github.io/garden/predictors-of-difficult-mask-ventilation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/predictors-of-difficult-mask-ventilation/</guid><description>predictors of difficult mask ventilation 無牙頜年齡 55 歲或以上 男性患者 面部毛髮 肥胖 阻塞性睡眠呼吸暫停</description></item><item><title>premedication of airway-management</title><link>https://htlin222.github.io/garden/premedication-of-airway-management/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/premedication-of-airway-management/</guid><description>premedication of airway-management A: Atopine 1mg C: Cardiac monitor L: [[Lidocaine]] 1.0~1.5mg/kg 2% 50kg 75mg 胖一點的100mg S: Sedation: * dormicum 0.</description></item><item><title>Preoperative evaluation</title><link>https://htlin222.github.io/garden/Preoperative-evaluation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Preoperative-evaluation/</guid><description>Preoperative evaluation (Circ 2014;130:e278, NEJM 2015;373:2258, JAMA 2020;324:279)
(Modified with permission Circulation. 2014;130:2215-2245 © 2014 American Heart Association, Inc.)</description></item><item><title>preoxygenation</title><link>https://htlin222.github.io/garden/preoxygenation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/preoxygenation/</guid><description>preoxygenation 除最緊急的情況外，應在所有情況下提供充分的預氧合。
目的是用氧氣代替肺部的氮氣。
當患者出現呼吸暫停時，這會增加去飽和前的時間長度（“呼吸暫停時間”），從而在通氣和插管變得困難的情況下提供安全邊際。
可以使用面罩、連續或雙水平氣道正壓或高流量鼻導管 (HFNC) 進行預氧合，以至少 10 L/min 的流量提供 100% 氧氣。</description></item><item><title>Prerenal acute kidney injury etiology</title><link>https://htlin222.github.io/garden/Prerenal-acute-kidney-injury-etiology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prerenal-acute-kidney-injury-etiology/</guid><description>Prerenal acute kidney injury etiology ↓ Effective arterial volume (NEJM 2007;357:797) Hypovolemia, ↓ CO (CHF), ↓ oncotic pressure (cirrhosis, nephrotic), vasodilation (sepsis) Δ local renal perfusion: NSAIDs, ACEI/ARB, contrast, calcineurin inhib, HRS, hyperCa Large vessel: RAS (bilateral + ACEI), VTE, dissection, abd compart.</description></item><item><title>Presentation of Thyroid storm</title><link>https://htlin222.github.io/garden/Presentation-of-Thyroid-storm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Presentation-of-Thyroid-storm/</guid><description>Presentation of Thyroid storm delirium, fever, tachycardia, systolic HTN w/ wide pulse pressure and ↓ MAP, GI symptoms; 20–30% mortality</description></item><item><title>Pressors inotropes-sepsis and shock</title><link>https://htlin222.github.io/garden/Pressors-inotropes-sepsis-and-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pressors-inotropes-sepsis-and-shock/</guid><description>Pressors inotropes-sepsis and shock MAP target 65 mmHg as good as 80–85 and ↓ AF (NEJM 2014;370:1583; JAMA 2020;323:938)</description></item><item><title>Prevention of chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Prevention-of-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prevention-of-chronic-obstructive-pulmonary-disease/</guid><description>Prevention of chronic obstructive pulmonary disease Flu/Pneumovax; smoking cessation → 50% ↓ in lung function decline (AJRCCM 2002;166:675) and ↓ long-term mortality (Annals 2005;142:223)</description></item><item><title>Prevention-Contrast-induced acute kidney injury</title><link>https://htlin222.github.io/garden/Prevention-Contrast-induced-acute-kidney-injury/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prevention-Contrast-induced-acute-kidney-injury/</guid><description>Prevention-Contrast-induced acute kidney injury consider if eGFR &amp;lt;60 (espec. w/ proteinuria) DM MI HoTN (CJASN 2013;8:1618) Prevention Isotonic IV fluids: may be helpful if high risk (Lancet 2017;389:1312) Outpatients: 3 mL/kg/h × 1 h prior, 1–1.</description></item><item><title>Prevention-pneumonia</title><link>https://htlin222.github.io/garden/Prevention-pneumonia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prevention-pneumonia/</guid><description>Prevention-pneumonia All persons &amp;gt;65 or age 19–64 w/ CHF, lung disease, cirrhosis, DM, EtOH, smoker, immunosupp. (eg, ESRD, organ transplant, HIV, leukemia, lymphoma, asplenia) PCV20 vaccine or PCV15 + PPSV23 1 yr later</description></item><item><title>Preventive treatment of Migraine</title><link>https://htlin222.github.io/garden/Preventive-treatment-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Preventive-treatment-of-Migraine/</guid><description>Preventive treatment of Migraine Recommended for patients adversely affected on ≥2 days per month despite optimized acute therapy First-line medication Beta blockers (propranolol, metoprolol, atenolol, bisoprolol) [[Topiramate]] Candesartan Second-line medication Flunarizine Amitriptyline Sodium valproate Third-line medication CGRP monoclonal antibodies</description></item><item><title>Primary biliary cholangitis PBC</title><link>https://htlin222.github.io/garden/Primary-biliary-cholangitis-PBC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-biliary-cholangitis-PBC/</guid><description>Primary biliary cholangitis (PBC) (Hep 2019;69:394; Nat Rev 2020;17:93; Lancet 2020;396:1915)
Autoimmune destruction of intrahepatic bile ducts
Epi: ♀ 40–60 y; a/w Sjögren’s (50%), Raynaud’s, scleroderma, celiac &amp;amp; thyroid disease; may be triggered by infxns or toxins; a/w X monosomy, variants in IL12α &amp;amp; IL12R genes</description></item><item><title>Primary central nervous system vasculitis</title><link>https://htlin222.github.io/garden/Primary-central-nervous-system-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-central-nervous-system-vasculitis/</guid><description>Primary central nervous system vasculitis 原發性中樞神經系統血管炎是一種罕見的且知識淵博的血管炎，僅限於大腦和脊髓。 認識到這種疾病是一種獨特的病態實體，其歷史可以追溯到1950年代中期， 當時Cravioto和Feigin1描述了與神經系統相關的幾例非感染性肉芽腫性血管炎。
CNS，3、4或更具體地，CNS的非感染或特發性顆粒狀血管炎和中樞神經系統的鉅細胞動脈炎，7個CNS的7個孤立血管炎，8個CNS的原發性血管炎，9和CNS的原發性血管炎，9和CNS炎。CNS.</description></item><item><title>Primary glomerular diseases grouped by pathology</title><link>https://htlin222.github.io/garden/Primary-glomerular-diseases-grouped-by-pathology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-glomerular-diseases-grouped-by-pathology/</guid><description>Primary glomerular diseases (grouped by pathology) [[Focal segmental glomerulosclerosis]] [[Membranous nephropathy]] [[Minimal change disease]] [[Membranoproliferative GN]] Fibrillary-immunotactoid glomerulopathy (1%; JASN 2008;19:34) [[Mesangial proliferative GN]]</description></item><item><title>Primary headache syndromes</title><link>https://htlin222.github.io/garden/Primary-headache-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-headache-syndromes/</guid><description>Primary headache syndromes [[Tension-type headache]] [[Cluster headache]] [[Migraine]]</description></item><item><title>Primary Hyperaldosteronism</title><link>https://htlin222.github.io/garden/Primary-Hyperaldosteronism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-Hyperaldosteronism/</guid><description>Primary Hyperaldosteronism (adrenal disorders, renin-independent increase in aldosterone; JCEM 2015;100:1)
[[adrenal hyperplasia]] (60–70%), adenoma ([[Conn’s syndrome]], 30–40%), [[adrenocortical cancer]], [[glucocorticoid-remediable aldosteronism]] (GRA; ACTH-dep.</description></item><item><title>Primary hyperparathyroidism</title><link>https://htlin222.github.io/garden/Primary-hyperparathyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-hyperparathyroidism/</guid><description>Primary hyperparathyroidism The serum level of parathyroid hormone, calcium, phosphorus, and 25-hydroxyvitamin D should be measured. Patients with secondary hyperparathyroidism usually have low-normal calcium and elevated parathyroid hormone.</description></item><item><title>Primary immune thrombocytopenic purpura ITP</title><link>https://htlin222.github.io/garden/Primary-immune-thrombocytopenic-purpura-ITP-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-immune-thrombocytopenic-purpura-ITP-/</guid><description>Primary immune thrombocytopenic purpura (ITP) (Blood 2010;115:168)
Isolated thrombocytopenia due to immune plt destruction (auto-Ab to plts) &amp;amp; ↓ production (auto-Ab to megakaryocytes) without precipitant</description></item><item><title>Primary sclerosing cholangitis PSC</title><link>https://htlin222.github.io/garden/Primary-sclerosing-cholangitis-PSC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Primary-sclerosing-cholangitis-PSC/</guid><description>Primary sclerosing cholangitis (PSC) (NEJM 2016;375:1161; Clin Liver Dis 2020;15:125)
Diffuse inflammation of intrahepatic and extrahepatic bile ducts leading to fibrosis &amp;amp; stricturing of biliary system.</description></item><item><title>Principles of Imaging in Vasculitides</title><link>https://htlin222.github.io/garden/Principles-of-Imaging-in-Vasculitides/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Principles-of-Imaging-in-Vasculitides/</guid><description>Principles of Imaging in Vasculitides for large- and certain medium-vessel vasculitides, various imaging techniques can be useful magnetic resonance angiography (MRA) or computed tomography angiography (CTA) allow for the assessment of extensive vascular territories vessels not readily accessible for tissue biopsy ultrasound, particularly color-coded duplex sonography, is often used as first-line imaging in patients with suspected giant cell arteritis (GCA) small-vessel vasculitides difficult to directly visualize with imaging indirect signs can be detected; this may play a role in evaluating disease activity and extent of involvement Reference - Curr Rheumatol Rep 2020 Jun 19;22(8):34</description></item><item><title>Principles of treatment-asthma</title><link>https://htlin222.github.io/garden/Principles-of-treatment-asthma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Principles-of-treatment-asthma/</guid><description>Principles of treatment-asthma Education and avoidance of environmental triggers (Lancet 2015;386:1075); yearly flu shot
Use quick-relief rescue medication as needed for all Pts</description></item><item><title>Principles-solitary pulmonary nodule</title><link>https://htlin222.github.io/garden/Principles-solitary-pulmonary-nodule/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Principles-solitary-pulmonary-nodule/</guid><description>Principles-solitary pulmonary nodule Definition: single, well-defined, &amp;lt;3 cm, surrounded by nl lung, no LAN or pleural effusion
Often “incidentalomas,” esp with ↑ CT use, but may still be early, curable malignancy</description></item><item><title>Prinzmetal's variant angina</title><link>https://htlin222.github.io/garden/Prinzmetal-s-variant-angina/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prinzmetal-s-variant-angina/</guid><description>Prinzmetal&amp;rsquo;s variant angina Coronary spasm → transient STE usually w/o MI (but MI, AVB, VT can occur) Pts usually young, smokers ± other vasospastic disorders (eg, migraines, Raynaud’s) Angiography: nonobstructive CAD (spasm can be provoked during cath but rarely done) [[Treatment of Prinzmetals variant angina]] Cocaine-induced vasospasm: CCB, nitrates, ASA; ?</description></item><item><title>Procainamide</title><link>https://htlin222.github.io/garden/Procainamide/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Procainamide/</guid><description>Procainamide 10-15 mg/kg IV n/a decrease BP: 1 QT:± AVN blocker %
Backlink: [[Antiarrhythmic Drugs (AAD) for AF]]</description></item><item><title>Procedures-Endocarditis Prophylaxis</title><link>https://htlin222.github.io/garden/Procedures-Endocarditis-Prophylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Procedures-Endocarditis-Prophylaxis/</guid><description>Procedures-Endocarditis Prophylaxis Dental: manipulation of gingival tissue or periapical region of teeth or perf oral mucosa (eg, extraction, periodontal, implant, root canal, cleaning)</description></item><item><title>Prognosis-acute liver failure</title><link>https://htlin222.github.io/garden/Prognosis-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prognosis-acute-liver-failure/</guid><description>Prognosis-acute liver failure (Ann Intern Med 2016;164:724; World J Gastro 2016;22:1523)
Non-acetaminophen ALF mortality ~70%, acetaminophen-induced ALF mortality ~25–30%</description></item><item><title>Prognosis-acute pancreatitis</title><link>https://htlin222.github.io/garden/Prognosis-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prognosis-acute-pancreatitis/</guid><description>Prognosis-acute pancreatitis (NEJM 2016;375:1972)
Ranson’s, APACHE II: predict severity at 48 h using multiple physiolog. criteria; poor PPV</description></item><item><title>Prognosis-Alcohol-associated hepatitis</title><link>https://htlin222.github.io/garden/Prognosis-Alcohol-associated-hepatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prognosis-Alcohol-associated-hepatitis/</guid><description>Prognosis-Alcohol-associated hepatitis scoring systems include Maddrey’s discriminant fxn (MDF), Lille model, MELD
MDF (4.6 × [PT – control] + Tb) ≥32 w/ 30–50% 1-mo mortality if unRx’d (Gastro 1996;110:1847)</description></item><item><title>Prognosis-cirrhosis</title><link>https://htlin222.github.io/garden/Prognosis-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prognosis-cirrhosis/</guid><description>Prognosis-cirrhosis ( www.mdcalc.com/child-pugh-score-cirrhosis-mortality)
Modified Child-Turcotte-Pugh (CPS) score based on ascites, enceph., &amp;amp; labs (bili, alb &amp;amp; INR; see Appendix).</description></item><item><title>Prognosis-pulmonary hypertension</title><link>https://htlin222.github.io/garden/Prognosis-pulmonary-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prognosis-pulmonary-hypertension/</guid><description>Prognosis-pulmonary hypertension Median survival after dx ~2.8 y; PAH (all etiologies): 2-y 66%, 5-y 48% (Chest 2004;126:78–S)
Poor prognostic factors: clinical evidence of RV failure, rapidly progressive sx, WHO (modified NYHA) class IV, 6MWT &amp;lt;300 m, peak VO2 &amp;lt;10.</description></item><item><title>Prognosis-syncope</title><link>https://htlin222.github.io/garden/Prognosis-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prognosis-syncope/</guid><description>Prognosis-syncope (Ann Emerg Med 1997;29:459; NEJM 2002;347:878)
22% overall recurrence rate if idiopathic, else 3% recurrence Cardiac syncope has poor prognosis (20–40% 1-y SCD rate); vasovagal good prognosis Unexplained syncope w/ 1.</description></item><item><title>Prognosis-ulcerative colitis</title><link>https://htlin222.github.io/garden/Prognosis-ulcerative-colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prognosis-ulcerative-colitis/</guid><description>Prognosis-ulcerative colitis 50% in remission at any given time. Intermittent exacerbations in 90%; continual active disease in ~18%. Prox progression in 25% at 10 y.</description></item><item><title>Prolonged-QT-interval</title><link>https://htlin222.github.io/garden/Prolonged-QT-interval/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prolonged-QT-interval/</guid><description>Prolonged-QT-interval Prolonged QT interval (NEJM 2008;358:169; www.torsades.org) Measure QT using threshold method (start of QRS to end of Tw at isoelectric line) or tangent (QRS to where tangent of Tw downslope intersects baseline) when long tail.</description></item><item><title>Propafenone</title><link>https://htlin222.github.io/garden/Propafenone/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Propafenone/</guid><description>Propafenone 600 mg PO x 150-300mg tid n/a [[Flecainide]] %
Backlink: [[Antiarrhythmic Drugs (AAD) for AF]]</description></item><item><title>Properties and Antidotes for Anticoagulants Fibrinolytics</title><link>https://htlin222.github.io/garden/Properties-and-Antidotes-for-Anticoagulants-Fibrinolytics/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Properties-and-Antidotes-for-Anticoagulants-Fibrinolytics/</guid><description>Properties and Antidotes for Anticoagulants Fibrinolytics [[Direct Oral Anticoagulants (DOACs) for NVAF]]
UFH 60–90′, RES ↑ PTT Protamine IV 1 mg/100 U UFH (max 50 mg).</description></item><item><title>Prophylaxis-HIV AIDS</title><link>https://htlin222.github.io/garden/Prophylaxis-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Prophylaxis-HIV-AIDS/</guid><description>Prophylaxis-HIV AIDS (NEJM 2015;373:2237; Lancet 2016;387:53; J Infect Dis 2018;218:16; CDC 2021)
Pre-exposure (PrEP): TDF/FTC daily, ↓ transmission &amp;gt;90% if adherent.</description></item><item><title>prostate cancer</title><link>https://htlin222.github.io/garden/prostate-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/prostate-cancer/</guid><description>prostate cancer Epidemiology and risk factors (NEJM 2003;349:366) Most common cancer in U.S. men; 2nd most common cause of cancer death in men Lifetime risk of prostate cancer dx ~16%; lifetime risk of dying of prostate cancer ~3% ↑ risk with ↑ age (rare if &amp;lt;45 y), in African Americans, ⊕ FHx, BRCA mutations Clinical manifestations Most prostate cancers (78%) are asymptomatic and localized at diagnosis Metastatic dis.</description></item><item><title>prosthetic-heart-valves</title><link>https://htlin222.github.io/garden/prosthetic-heart-valves/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/prosthetic-heart-valves/</guid><description>prosthetic-heart-valves [[Mechanical-prosthetic-heart-valves]] [[Bioprosthetic]]
Physical exam Crisp sounds ± soft murmur during forward flow (normal to have small ∇) [[Anticoagulation antiplatelet therapy-prosthetic-heart-valves]] [[Correction of overanticoagulation]] (Circ 2021;143:e72) Endocarditis prophylaxis: for all prosthetic valves [[bacterial endocarditis]] [[Complications-prosthetic-heart-valves]]</description></item><item><title>protease inhibitors - PI-Antiretrovirals ARVs</title><link>https://htlin222.github.io/garden/protease-inhibitors-PI-Antiretrovirals-ARVs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/protease-inhibitors-PI-Antiretrovirals-ARVs/</guid><description>protease inhibitors - PI-Antiretrovirals (ARVs) atazanavir (ATV; Reyataz) darunavir (DRV; Prezista) lopinavir (LPV; Kaletra) PIs given w/boosters ritonavir or cobicistat for ↑ PK Class: GI intol; hepatotoxicity; inhibit CYP450 (many DDIs, eg statins, steroids, DOACs); ↑ glc; hyperlipid (less w/ ATV); MI (NEJM 2007;356:1723) ATV: crystalluria → nephrolithiasis DRV: rash (10%); possible sulfa cross-reactivity</description></item><item><title>Protein of cerebrospinal fluid</title><link>https://htlin222.github.io/garden/Protein-of-cerebrospinal-fluid/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Protein-of-cerebrospinal-fluid/</guid><description>Protein of cerebrospinal fluid 是大分子，會被BBB擋住，正常約 15–40 mg/dL 上升原因包括感染、腫瘤、腦炎等 ↑↑ (可能&amp;gt;200)：bacteria ↑：viral、fungus、TB、parasite、malignancy、viral/autoimmune encephalitis 等 另外 SAH、traumatic tapping 也可能使 protein 稍微上升</description></item><item><title>Protein of Urine Dipstick</title><link>https://htlin222.github.io/garden/Protein-of-Urine-Dipstick/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Protein-of-Urine-Dipstick/</guid><description>Protein of Urine Dipstick Detects albuminuria (&amp;gt;300 mg/d); False ⊖: dilute urine
1+ ≈30 mg/dL, 2+ ≈100 mg/dL, 3+ ≈300 mg/dL, 4+ &amp;gt;2 g/dL;</description></item><item><title>proteinuria</title><link>https://htlin222.github.io/garden/proteinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/proteinuria/</guid><description>proteinuria [[Etiologies of Proteinuria]]
[[Urine dipstick]] 1+ ≈30 mg/dL, 2+ ≈100 mg/dL, 3+ ≈300 mg/dL, 4+ &amp;gt;2 g/dL; interpretation depends on SG; eg, 3+ in very concentrated urine might not indicate heavy proteinuria</description></item><item><title>Pseudo-hypoparathyroidism</title><link>https://htlin222.github.io/garden/Pseudo-hypoparathyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pseudo-hypoparathyroidism/</guid><description>Pseudo-hypoparathyroidism (Endo Metab Clin North Am 2018;47:865)
1a, 1b, &amp;amp; 1c: PTH end-organ resistance (∴ ↑ serum PTH) 1a &amp;amp; 1c: + skeletal abnormalities, short stature &amp;amp; developmental delay 1b: w/o extra features Pseudopseudohypoparathyroidism = 1a mutation inherited from father, no hormonal abnormalities</description></item><item><title>Pseudoinfarct</title><link>https://htlin222.github.io/garden/Pseudoinfarct/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pseudoinfarct/</guid><description>Pseudoinfarct In left ventricular hypertrophy, there is often a QS deflection or poor R wave progression in the right precordial leads that suggests anterior myocardial infarction.</description></item><item><title>pulmonary</title><link>https://htlin222.github.io/garden/pulmonary/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pulmonary/</guid><description>pulmonary [[dyspnea]] [[pulmonary function tests]] [[asthma]] [[anaphylaxis]] [[chronic obstructive pulmonary disease]] [[solitary pulmonary nodule]] [[hemoptysis]] [[bronchiectasis]] [[cystic fibrosis]] [[interstitial lung disease]] [[pleural effusion]] [[venous thromboembolism]] [[pulmonary hypertension]] [[respiratory failure]] [[mechanical ventilation]] [[acute respiratory distress syndrome]] [[sepsis and shock]] [[toxicology]] [[lung transplant]]</description></item><item><title>pulmonary critical care</title><link>https://htlin222.github.io/garden/pulmonary-critical-care/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pulmonary-critical-care/</guid><description>pulmonary critical care 20 Respiratory Monitoring 21 Mechanical Ventilatory Support 22 Non‐Invasive Positive Pressure Ventilation 23 Acute Respiratory Distress Syndrome 24 Bronchospasm and Chronic Obstructive Pulmonary Disease 25 [[Weaning from Mechanical Ventilation]]</description></item><item><title>pulmonary function tests</title><link>https://htlin222.github.io/garden/pulmonary-function-tests/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pulmonary-function-tests/</guid><description>pulmonary function tests [[physiology of pulmary]]
Spirometry: evaluate for obstructive disease 肺活量測定：評估阻塞性疾病 Flow-volume loops: diagnose and/or localize obstruction：診斷和/或定位阻塞</description></item><item><title>pulmonary hypertension</title><link>https://htlin222.github.io/garden/pulmonary-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pulmonary-hypertension/</guid><description>pulmonary hypertension PHT defined as PA mean pressure ≥20 mmHg at rest (ERJ 2019;53:1801913) PA mean = CO × PVR + PA wedge pressure.</description></item><item><title>Pulmonary infiltrates with eosinophilia PIE</title><link>https://htlin222.github.io/garden/Pulmonary-infiltrates-with-eosinophilia-PIE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pulmonary-infiltrates-with-eosinophilia-PIE/</guid><description>Pulmonary infiltrates with eosinophilia (PIE) eos on BAL é peripheral blood
Allergic bronchopulmonary aspergillosis (ABPA)
EGPA</description></item><item><title>Pulmonary-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Pulmonary-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pulmonary-complications-of-HIV-AIDS/</guid><description>Pulmonary-complications of HIV AIDS Radiographic Pattern Common Causes
Normal Early PCP
Diffuse interstitial infiltrates PCP, TB, viral, or disseminated fungal</description></item><item><title>Pulmonary-Renal Syndromes</title><link>https://htlin222.github.io/garden/Pulmonary-Renal-Syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pulmonary-Renal-Syndromes/</guid><description>Pulmonary-Renal Syndromes differential diagnosis: hemorrhagic pulmonary edema associated with renal failure from superimposed CHF or pulmonary emboli.
Most Pulmonary-Renal Syndromes are associated with: antineutrophilic cytoplasmic Ab (anca) 講出來可以帥一波的診斷: Micorsopic polyangiitis Granulomatosis with polyangiitis Churg-Strauss systemic lupus erythematosus Goodpastur&amp;rsquo;s syndrome Behcet&amp;rsquo;s disease Rheumatoid vasculitis</description></item><item><title>Pulseless Arrest</title><link>https://htlin222.github.io/garden/Pulseless-Arrest/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pulseless-Arrest/</guid><description>Pulseless Arrest 頸60 股70 手80 足90
CPR Compressions
Push hard (2-2.4 inches) &amp;amp; fast (100-120/min) Minimize interruptions; rotate compressor q2min Airway: open airway (eg, head tilt-chin lift) Breathing: 10 breaths/min; 2 breaths q 30 compressions Bag-mask acceptable; supplemental O2</description></item><item><title>pulsus paradoxus</title><link>https://htlin222.github.io/garden/pulsus-paradoxus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pulsus-paradoxus/</guid><description>pulsus paradoxus 正常情況下，吸氣時血壓會稍微降低， 而呼氣時血壓會稍微上升，下降的正常範圍是&amp;lt;10 mmHg 如果下降的幅度&amp;gt;10mmHg則稱為pulsus paradoxus 理學檢查上的發現：聽診器可聽到心跳但在radial artery摸不到pulse。</description></item><item><title>Pure red cell aplasia</title><link>https://htlin222.github.io/garden/Pure-red-cell-aplasia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Pure-red-cell-aplasia/</guid><description>Pure red cell aplasia Destructive antibodies or lymphocytes → ineffective erythropoiesis
Associated with thymoma, CLL, parvovirus infection, autoimmunity, drugs</description></item><item><title>purpura</title><link>https://htlin222.github.io/garden/purpura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/purpura/</guid><description>purpura (nonblanching purple/red lesions due to extravasation of RBCs into dermis)
Nonpalpable (macular; ≤3 mm in diameter = petechiae; &amp;gt;3 mm = ecchymoses) platelet disorder: thrombocytopenia, defect in platelet fxn</description></item><item><title>pyenv</title><link>https://htlin222.github.io/garden/pyenv/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pyenv/</guid><description>/Users/htlin/.pyenv/versions/neovim2/bin/python
/Users/htlin/.pyenv/versions/neovim3/bin/python</description></item><item><title>Quartz Philosophy</title><link>https://htlin222.github.io/garden/notes/philosophy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/philosophy/</guid><description>“[One] who works with the door open gets all kinds of interruptions, but [they] also occasionally gets clues as to what the world is and what might be important.</description></item><item><title>radiation oncology</title><link>https://htlin222.github.io/garden/radiation-oncology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/radiation-oncology/</guid><description>radiation oncology Basic Radiation Biology and Physics External Beam Radiation Therapy Stereotactic Radiotherapy Brachytherapy Total Body Irradiation and TSEB Radiation Oncology Emergencies</description></item><item><title>radiology</title><link>https://htlin222.github.io/garden/radiology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/radiology/</guid><description>radiology [[chest radiograph]]</description></item><item><title>Rank the Differential Diagnosis</title><link>https://htlin222.github.io/garden/Rank-the-Differential-Diagnosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rank-the-Differential-Diagnosis/</guid><description>Rank the Differential Diagnosis</description></item><item><title>Rapid correction of Treatment-of-hyponatremia</title><link>https://htlin222.github.io/garden/Rapid-correction-of-Treatment-of-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rapid-correction-of-Treatment-of-hyponatremia/</guid><description>Rapid correction of Treatment-of-hyponatremia can lead to CPM/ODS (esp if chronic or Na &amp;lt;120 mEq/L). Should be emergently reversed w/ dDAVP ± D5W; partial neuro recovery possible (CJASN 2014;9:229).</description></item><item><title>rapid progressive glomerulonephritis RPGN</title><link>https://htlin222.github.io/garden/rapid-progressive-glomerulonephritis-RPGN/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/rapid-progressive-glomerulonephritis-RPGN/</guid><description>rapid progressive glomerulonephritis (RPGN) 切片下典型會出現廣泛的新月形成(crescent formation)。
新月形成(Crescent formation)
為應對腎絲球微血管壁嚴重傷害的非特異性反應，在多種嚴重的腎絲球發炎疾病都可能出現 腎絲球微血管壁受損後，血漿中的物質會進入Bowman’s space，進而導致fibrin形成。此外，發炎細胞和細胞激素的進入，也抑制了fibrin分解的過程 RPGN的種類 (1) Anti-GBM抗體
如Goodpasture’s disease，典型有腎臟和肺部的侵犯 (2) 免疫複合體介導
在腎絲球中能看到免疫複合體的沉積，不同疾病的沉積分子有差異，如IgA nephropathy、PSGN、lupus nephritis、冷凝球蛋白血症等 (3) Pauci-immune</description></item><item><title>RASi ACEI ARB</title><link>https://htlin222.github.io/garden/RASi-ACEI-ARB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/RASi-ACEI-ARB/</guid><description>RASi ACEI ARB Choose one of ARNI (ARB + neprilysin inhib), ACEI or ARB
36-hr washout when transitioning ACEI to ARNI</description></item><item><title>Rate Control-atrial fibrillation</title><link>https://htlin222.github.io/garden/Rate-Control-atrial-fibrillation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rate-Control-atrial-fibrillation/</guid><description>Rate Control-atrial fibrillation (if sx， goal HR ≤80; if asx &amp;amp; EF &amp;gt;40%. goal HR ≤110； Circ 2014:130e199)
Agent Acute (IV) Maint.</description></item><item><title>Rate of correction of hypernatremia</title><link>https://htlin222.github.io/garden/Rate-of-correction-of-hypernatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rate-of-correction-of-hypernatremia/</guid><description>Rate of correction of hypernatremia depends on acuity of onset and risk:
chronic (&amp;gt;48 hr): ~12 mEq/d appears safe w/o risk of cerebral edema (CJASN 2019;14:656)</description></item><item><title>Rationale PA catheter and tailored therapy</title><link>https://htlin222.github.io/garden/Rationale-PA-catheter-and-tailored-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rationale-PA-catheter-and-tailored-therapy/</guid><description>Rationale PA catheter and tailored therapy Cardiac output (CO) = SV × HR; optimize SV (and thereby CO) by manipulating preload/ LVEDV (w/ IVF, diuretics), contractility (w/ inotropes), &amp;amp; afterload (w/ vasodilators)</description></item><item><title>Raynaud phenomenon</title><link>https://htlin222.github.io/garden/Raynaud-phenomenon/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Raynaud-phenomenon/</guid><description>Raynaud phenomenon a problem that causes decreased blood flow to the fingers. In some cases, it also causes less blood flow to the ears, toes, nipples, knees, or nose.</description></item><item><title>RB-ILD resp bronchiolitis-assoc ILD</title><link>https://htlin222.github.io/garden/RB-ILD-resp-bronchiolitis-assoc-ILD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/RB-ILD-resp-bronchiolitis-assoc-ILD/</guid><description>RB-ILD resp bronchiolitis-assoc ILD Bronchial thickening, centrilobular nodules, patchy ground-glass opacities; upper lobe predom. Mφ in alveoli.</description></item><item><title>Recognizing and managing comorbidities of Migraine</title><link>https://htlin222.github.io/garden/Recognizing-and-managing-comorbidities-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Recognizing-and-managing-comorbidities-of-Migraine/</guid><description>Recognizing and managing comorbidities of Migraine Identify comorbid conditions Select drugs and adjust their use according to comorbidities present Alleviate comborbidities if possible to improve outcome</description></item><item><title>Recommended Chronic Therapy by HF Stage</title><link>https://htlin222.github.io/garden/Recommended-Chronic-Therapy-by-HF-Stage/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Recommended-Chronic-Therapy-by-HF-Stage/</guid><description>Recommended Chronic Therapy by HF Stage (JACC 2021;77:772)
Utility of BNP-guided Rx (inPt and outPt) remains debated (Eur Heart J 2014;35:16) Implantable PA pressure sensor in sx Pts: ~19–37% ↓ risk of hosp (Lancet 2016;387:453 &amp;amp; 2021;398:991) Stage (not NYHA Class) Therapy A At risk for HF (eg, HTN); but asx &amp;amp; w/o struct.</description></item><item><title>Recommended First-Line Oral Direct-Acting Antiviral DAA Regimens</title><link>https://htlin222.github.io/garden/Recommended-First-Line-Oral-Direct-Acting-Antiviral-DAA-Regimens/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Recommended-First-Line-Oral-Direct-Acting-Antiviral-DAA-Regimens/</guid><description>Recommended First-Line Oral Direct-Acting Antiviral (DAA) Regimens Sofosbuvir &amp;amp; velpatasvir Genotypes 1–6, 12 weeks Rx Glecaprevir &amp;amp; pibrentasvir Gentotypes 1–6; 8 weeks Rx Simplified treatment: adults w/ HCV w/o cirrhosis or w/ compensated cirrhosis &amp;amp; no prior HCV treatment; cannot have HIV, HBsAg ⊕, pregnancy, HCC, ESRD, or liver transplant; if decompensated or previously treated, refer to GI for assistance.</description></item><item><title>Recurrent infection-clostridioides difficile infection</title><link>https://htlin222.github.io/garden/Recurrent-infection-clostridioides-difficile-infection/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Recurrent-infection-clostridioides-difficile-infection/</guid><description>Recurrent infection-clostridioides difficile infection (15–30% risk after d/c of abx, most w/in 2 wk of stopping abx)
1st recurrence: fidaxomicin 200 mg PO bid × 10 d or vanco 125 mg PO q6h × 10–14 d.</description></item><item><title>Refractory ascites</title><link>https://htlin222.github.io/garden/Refractory-ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Refractory-ascites/</guid><description>Refractory ascites seen in 5–10% of Pts; 2-y survival 25%
Defined as diuretic-resistant if on 2-g Na diet w/ minimal weight loss on max diuretics, or diuretic-induced complications (AKI, Na &amp;lt;125, ↑ K, encephalopathy) Conflicting evid.</description></item><item><title>Regimens-Endocarditis Prophylaxis</title><link>https://htlin222.github.io/garden/Regimens-Endocarditis-Prophylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Regimens-Endocarditis-Prophylaxis/</guid><description>Regimens-Endocarditis Prophylaxis Oral: amoxicillin 2 g 30–60 min before Unable to take PO: amp 2 g IM/IV or cefazolin or CTX 1 g IM/IV PCN-allergic: cephalexin or azithro or claritho or doxy</description></item><item><title>Region or Exposure Common Etiologies -fever in a returned traveler</title><link>https://htlin222.github.io/garden/Region-or-Exposure-Common-Etiologies-fever-in-a-returned-traveler/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Region-or-Exposure-Common-Etiologies-fever-in-a-returned-traveler/</guid><description>Region or Exposure Common Etiologies -fever in a returned traveler Sub-Saharan Africa Malaria &amp;raquo; dengue and other arboviruses, rickettsial disease, enteric fever</description></item><item><title>Rejection-Kidney transplantation</title><link>https://htlin222.github.io/garden/Rejection-Kidney-transplantation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rejection-Kidney-transplantation/</guid><description>Rejection-Kidney transplantation : Ab (ABMR) or T-cell mediated (TCMR), a/w poor graft survival; BANFF criteria (Am J Transplant 2018;18:293). Rx options: ↑ immunosupp.</description></item><item><title>Reliever medications-asthma</title><link>https://htlin222.github.io/garden/Reliever-medications-asthma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Reliever-medications-asthma/</guid><description>Reliever medications-asthma (used prn to quickly relieve sx)
Low-dose inhaled corticosteroids (ICS) + long-acting inh β2-agonists (LABA): budesonide-formoterol (NEJM 2019;380:2020)</description></item><item><title>Renal H2O loss Uosm &lt;700–800</title><link>https://htlin222.github.io/garden/Renal-H2O-loss-Uosm-700800/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Renal-H2O-loss-Uosm-700800/</guid><description>Renal H2O loss (Uosm &amp;lt;700–800) Diuresis: osmotic (glucose, mannitol, urea), loop diuretics
Diabetes insipidus (Nature Reviews Nephrology 2015;11:576)</description></item><item><title>Renal losses of Hypovolemic-hypotonic-hyponatremia</title><link>https://htlin222.github.io/garden/Renal-losses-of-Hypovolemic-hypotonic-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Renal-losses-of-Hypovolemic-hypotonic-hyponatremia/</guid><description>Renal losses of Hypovolemic-hypotonic-hyponatremia (UNa &amp;gt;20 mEq/L, FENa &amp;gt;1%): diuretics (esp. thiazides, because loop diuretics ↓ tonicity of medullary interstitium, Δ for H2O absorption, &amp;amp; ∴ urine concentrating ability), salt-wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency</description></item><item><title>Renal potassium losses</title><link>https://htlin222.github.io/garden/Renal-potassium-losses/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Renal-potassium-losses/</guid><description>Renal potassium losses Hypotensive or normotensive acidosis: DKA, RTA [distal RTAs (type I) &amp;gt;proximal RTAs (type II)]
alkalosis: diuretics (thiazide &amp;gt;loop), vomiting/NGT drainage (via 2° hyperaldosteronism)</description></item><item><title>renal replacement and dialysis</title><link>https://htlin222.github.io/garden/renal-replacement-and-dialysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/renal-replacement-and-dialysis/</guid><description>renal replacement and dialysis [[General-renal replacement and dialysis]] [[Modalities-renal replacement and dialysis]] [[Hemodialysis (HD)]] [[Vascular Access-renal replacement and dialysis]] [[Continuous veno-venous hemofiltration (CVVH)]] [[Peritoneal dialysis (PD)]] [[Kidney transplantation]]</description></item><item><title>Renal tubular acidoses</title><link>https://htlin222.github.io/garden/Renal-tubular-acidoses/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Renal-tubular-acidoses/</guid><description>Renal tubular acidoses (RTAs) (Adv Ther 2021;38:949)
(Adv Ther 2021;38:949)
Proximal (Type II): ↓ proximal reabsorption of HCO3 1° (Fanconi’s syndrome) = ↓ proximal reabsorption of HCO3, PO4, glc, amino acids Acquired: paraprotein (MM, amyloidosis), metals (Pb, Cd, Hg, Cu), ↓ vit D, PNH, renal Tx Meds: acetazolamide, aminoglycosides, ifosfamide, cisplatin, topiramate, tenofovir Distal (Type I): defective distal H+ secretion 1°, autoimmune (Sjögren’s, RA, SLE), hypercalciuria, meds (ampho, Li, ifosfamide); normally a/w ↓ K; if with ↑ K → sickle cell, obstruction, renal transplant Hypoaldo (Type IV): hypoaldo → ↑ K → ↓ NH3 synthesis → ↓ urine acid-carrying capacity ↓ renin: diabetic nephropathy, NSAIDs, chronic interstitial nephritis, calcineurin inh, HIV ↓ aldo production: 1° AI, ACEI/ARBs, heparin, severe illness, inherited (↓ 21-hydroxylase) ↓ response to aldosterone Meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors Tubulointerstitial disease: sickle cell, SLE, amyloid, DM</description></item><item><title>renal-cell-carcinoma</title><link>https://htlin222.github.io/garden/renal-cell-carcinoma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/renal-cell-carcinoma/</guid><description>renal-cell-carcinoma [[systematic-Treatment]]</description></item><item><title>Renal-complications of HIV AIDS</title><link>https://htlin222.github.io/garden/Renal-complications-of-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Renal-complications-of-HIV-AIDS/</guid><description>Renal-complications of HIV AIDS HIV-assoc. nephropathy (collapsing FSGS); nephrotoxic drugs (eg, TDF → prox tub dysfxn)</description></item><item><title>Renal-limited vasculitis</title><link>https://htlin222.github.io/garden/Renal-limited-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Renal-limited-vasculitis/</guid><description>Renal-limited vasculitis Small vessel pauci-immune vasculitis causing RPGN w/o other organ involvement Dx studies: 80% ⊕ ANCA (MPO &amp;gt;PR3); biopsy with pauci-immune GN ± granulomas Treatment identical to that for GPA/MPA</description></item><item><title>renal-Secondary Causes of Hypertension</title><link>https://htlin222.github.io/garden/renal-Secondary-Causes-of-Hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/renal-Secondary-Causes-of-Hypertension/</guid><description>renal-Secondary Causes of Hypertension Renal parenchymal (2–3%) h/o DM, polycystic kidney disease, glomerulonephritis CrCl, albuminuria See “Kidney Disease”
Renovascular (1–2%) Athero (90%) FMD (10%, young women) PAN, scleroderma ARF induced by ACEI/ARB Recurrent flash pulm edema Renal bruit; hypokalemia (NEJM 2009;361:1972) MRA (&amp;gt;90% Se &amp;amp; Sp, less for FMD), CTA, duplex U/S, angio, plasma renin (low Sp)</description></item><item><title>Replace free H2O deficit</title><link>https://htlin222.github.io/garden/Replace-free-H2O-deficit/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Replace-free-H2O-deficit/</guid><description>Replace free H2O deficit (also replace concurrent volume deficit if appropriate):
eg, 1 L D5W given to 70-kg man w/ [Na] = 160 mEq/L will ↓ [Na]serum by 3.</description></item><item><title>Replacement fluid of continuous veno-venous hemofiltration</title><link>https://htlin222.github.io/garden/Replacement-fluid-of-continuous-veno-venous-hemofiltration/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Replacement-fluid-of-continuous-veno-venous-hemofiltration/</guid><description>Replacement fluid of continuous veno-venous hemofiltration Choice of replacement fluid buffer:
HCO3 (+ heparin to prevent clotting, although can be run heparin-free)</description></item><item><title>Residual syndrome</title><link>https://htlin222.github.io/garden/Residual-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Residual-syndrome/</guid><description>Residual syndrome Inadequate removal of uremic toxins through conventional dialysis may result in a phenomenon known as residual syndrome. Patients with this syndrome may experience subtle signs of malnutrition, mild lethargy, infection, and serositis</description></item><item><title>Resistant HTN</title><link>https://htlin222.github.io/garden/Resistant-HTN/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Resistant-HTN/</guid><description>Resistant HTN (BP &amp;gt;goal on ≥3 drugs incl diuretic; HTN 2018;72:e53)
Exclude: 2° causes (see table) and pseudoresistance: inaccurate measure (cuff size), diet noncomp (↑ Na), poor Rx compliance/dosing, white coat HTN (✓ ABPM) Ensure effective diuresis (chlorthalidone or indapamide &amp;gt;HCTZ; loop &amp;gt;thiazide if eGFR &amp;lt;30) Can add aldosterone antagonist (Lancet 2015;386:2059), β-blocker (particularly vasodilators such as carvedilol, labetalol, or nebivolol), α-blocker, or direct vasodilator Consider renal denervation therapy (Lancet 2018;391:2346; 2021;397:2476)</description></item><item><title>respiratory failure</title><link>https://htlin222.github.io/garden/respiratory-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/respiratory-failure/</guid><description>respiratory failure A-a gradient = PAO2 – PaO2: normal (on room air) = “4 + age/4” or “2.5 + (0.</description></item><item><title>respiratory-acidosis</title><link>https://htlin222.github.io/garden/respiratory-acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/respiratory-acidosis/</guid><description>respiratory-acidosis (NEJM 1989;321:1223; Crit Care 2010;14:220)
[[Etiologies of High elevated PaCO2]]
Etiologies (also see “Hypercapnia”; PaCO2 = VCO2/VE(1-VD/VT); VE = RR x VT)</description></item><item><title>respiratory-alkalosis</title><link>https://htlin222.github.io/garden/respiratory-alkalosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/respiratory-alkalosis/</guid><description>respiratory-alkalosis Etiologies (NEJM 2002;347:43; Crit Care 2010;14:220)
Hypoxia → hyperventilation: pneumonia, CHF, PE, restrictive lung disease, anemia Primary hyperventilation CNS stimulation, pain, anxiety, trauma, stroke, CNS infection, pontine tumors drugs: salicylates toxicity (early), β-agonists, progesterone, methylxanthines, nicotine pregnancy, sepsis, hepatic failure, hyperthyroidism, fever Pseudorespiratory alkalosis: ↓ perfusion w/ preserved ventilation (eg, CPR, severe HoTN) → ↓ delivery of CO2 to lungs for excretion; low PaCO2 but ↑ tissue CO2</description></item><item><title>restrictive infiltrative</title><link>https://htlin222.github.io/garden/restrictive-infiltrative/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/restrictive-infiltrative/</guid><description>restrictive infiltrative Definition (JACC 2018;71:1130 &amp;amp; 1149) Restrictive CMP: ↓ ventricular filling with ↓ compliance in nonhypertrophied, nondilated ventricles; nl/↓ diastolic volumes, nl or near-nl EF; must r/o pericardial disease</description></item><item><title>RESTRICTIVE---INFILTRATIVE</title><link>https://htlin222.github.io/garden/RESTRICTIVE---INFILTRATIVE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/RESTRICTIVE---INFILTRATIVE/</guid><description>RESTRICTIVE&amp;mdash;INFILTRATIVE</description></item><item><title>resuscitation-initial management-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/resuscitation-initial-management-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/resuscitation-initial-management-gastrointestinal-bleeding/</guid><description>resuscitation-initial management-gastrointestinal bleeding placement of 2 large-bore (18-gauge or larger) intravenous lines. 放置 2 條大口徑（18 號或更大）靜脈導管。
Volume replacement: NS or LR to achieve normal VS, UOP, &amp;amp; mental status.</description></item><item><title>Revascularization</title><link>https://htlin222.github.io/garden/Revascularization/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Revascularization/</guid><description>Revascularization OMT should be initial focus if stable &amp;amp; w/o evidence of critical anatomy &amp;amp; w/ normal EF Goal of revasc should be to ↓ risk of CV morbidity &amp;amp; mortality or to relieve refractory sx Older studies: survival benefit w/ revascularization (CABG) vs.</description></item><item><title>Rhabdomyolysis</title><link>https://htlin222.github.io/garden/Rhabdomyolysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rhabdomyolysis/</guid><description>Rhabdomyolysis (NEJM 2009;361:62)
Pathophys: myoglobin-induced oxidant injury, vasoconstriction, myoglobin precipitation &amp;amp; pre-renal (extravasation). Can lead to ↓ Ca, ↑ K, and ↑ PO4.</description></item><item><title>rheumatology</title><link>https://htlin222.github.io/garden/rheumatology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/rheumatology/</guid><description>rheumatology [[allergy immunology]]
[[approach to rheumatic disease]]
[[rheumatoid arthritis]]
[[adult-onset Still’s disease ]]&amp;amp; relapsing polychondritis</description></item><item><title>Rhythm control</title><link>https://htlin222.github.io/garden/Rhythm-control/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rhythm-control/</guid><description>Rhythm control (Lancet 2016;388:829)
Consider if sx w/ rate control (eg, HF), difficult to control rate, or tachycardia-mediated CMP If minimally sx or asx, previously no clear benefit vs.</description></item><item><title>Right-ventricular-hypertrophy</title><link>https://htlin222.github.io/garden/Right-ventricular-hypertrophy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Right-ventricular-hypertrophy/</guid><description>Right-ventricular-hypertrophy Etiologies: cor pulmonale, congenital (tetralogy of Fallot, TGA, PS, ASD, VSD), MS, TR
Criteria [all insensitive, but specific (except in COPD); all w/ poor PPV in general population]</description></item><item><title>risk factor of delirium</title><link>https://htlin222.github.io/garden/risk-factor-of-delirium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/risk-factor-of-delirium/</guid><description>risk factor of delirium older aged &amp;gt;65 baseline cognitive dysfunction preexisting hearing and visual impairment, as well as indices for poor overall health, including baseline immobility, malnutrition, and underlying medical or neurologic illness.</description></item><item><title>Risk Factors and Screening</title><link>https://htlin222.github.io/garden/Risk-Factors-and-Screening/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-Factors-and-Screening/</guid><description>Risk Factors and Screening High risk: &amp;gt;10 lifetime sexual partners, prior STI, MSM, sex workers Screening recommendations: differ based on sexual practices and risk.</description></item><item><title>Risk factors for bloodstream infections</title><link>https://htlin222.github.io/garden/Risk-factors-for-bloodstream-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-factors-for-bloodstream-infections/</guid><description>Risk factors for bloodstream infections (JAMA 2012;308:502; CID;2020;71)
Syndromes with high likelihood of bacteremia: Sepsis Endovascular infxns: endocarditis, infection of pacemaker, vascular graft or IV catheter Vertebral osteomyelitis, epidural abscess, septic arthritis Risk factors: indwelling lines, IVDU, immunosupp.</description></item><item><title>Risk factors-acute aortic syndromes</title><link>https://htlin222.github.io/garden/Risk-factors-acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-factors-acute-aortic-syndromes/</guid><description>Risk factors-acute aortic syndromes (Lancet 2015;385:800)
Classic (in older Pts): HTN (h/o HTN in &amp;gt;70% of dissections); age (60s–70s), sex (~65% ♂); smoking; ↑ lipids.</description></item><item><title>Risk Factors-bacterial endocarditis</title><link>https://htlin222.github.io/garden/Risk-Factors-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-Factors-bacterial-endocarditis/</guid><description>Risk Factors-bacterial endocarditis Abnormal valve (JAMA 1997;277:1794; JACC 2018;72:2443) High risk: prior endocarditis, prosthetic valve or ring, some congenital heart disease (unrepaired cyanotic; shunt/conduit; prosthesis in past 6 mos), transplant heart, valvulopathy, VAD Medium risk: previous rheumatic fever, non-rheumatic valve disease (including MVP w/ MR or thickened leaflet), HCM, bicuspid AoV Risk of bacteremia: IVDU, indwelling venous catheters, hemodialysis, prosthetic material in heart (eg, pacemaker, ICD, graft), poor dentition</description></item><item><title>Risk factors-venous thromboembolism</title><link>https://htlin222.github.io/garden/Risk-factors-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-factors-venous-thromboembolism/</guid><description>Risk factors-venous thromboembolism [[Virchow’s triad]] for thrombogenesis.
Malignancy (12% of “idiopathic” DVT/PE; Circ 2013;128:2614)
[[Venous Thromboembolism and Cancer]] History of thrombosis</description></item><item><title>Risk stratification for Pts with PE</title><link>https://htlin222.github.io/garden/Risk-stratification-for-Pts-with-PE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-stratification-for-Pts-with-PE/</guid><description>Risk stratification for Pts with PE clinical: [[simplified PE severity index]]
[[Hestia Criteria for Outpatient Pulmonary Embolism Treatment]] [[Pulmonary Embolism Severity Index PESI]] imaging:</description></item><item><title>Risk stratification of fever and neutropenia</title><link>https://htlin222.github.io/garden/Risk-stratification-of-fever-and-neutropenia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-stratification-of-fever-and-neutropenia/</guid><description>Risk stratification of fever and neutropenia History: outPt, ECOG 0–1, age &amp;lt;60 y, solid tumor, no sx, no major comorbidities, no h/o fungal infection, MASCC Risk Index ≥21 (Support Care Cancer 2013;21:1487) Exam: temp &amp;lt;39 °C, no tachypnea, no HoTN, no Δ MS, no dehydration Labs: ANC &amp;gt;100 cells/µL, anticipated duration of neutropenia ≤100 cells/µL &amp;lt;7 d</description></item><item><title>Risk-Stratification-andreatment-of-Localized-Prostate</title><link>https://htlin222.github.io/garden/Risk-Stratification-andreatment-of-Localized-Prostate/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Risk-Stratification-andreatment-of-Localized-Prostate/</guid><description>Risk-Stratification-andreatment-of-Localized-Prostate IMAGE: Risk Stratification and Treatment of Localized Prostate Cancer</description></item><item><title>Roflumilast</title><link>https://htlin222.github.io/garden/Roflumilast/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Roflumilast/</guid><description>Roflumilast (PDE-4 inhib) + bronchodil: ↑ FEV1, ↓ exacerb in Pts with severe COPD, chronic bronchitis, and a hx of exacerbations (Lancet 2015;385:857)</description></item><item><title>Role of Circulating Tumor DNA in Guiding Adjuvant Therapy in Colon Cancer</title><link>https://htlin222.github.io/garden/Role-of-Circulating-Tumor-DNA-in-Guiding-Adjuvant-Therapy-in-Colon-Cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Role-of-Circulating-Tumor-DNA-in-Guiding-Adjuvant-Therapy-in-Colon-Cancer/</guid><description>Role of Circulating Tumor DNA in Guiding Adjuvant Therapy in Colon Cancer Adjuvant chemotherapy after resection of stage III colon cancer appears to improve outcomes, but many patients are treated to benefit a few.</description></item><item><title>Role of hematopoietic growth factors</title><link>https://htlin222.github.io/garden/Role-of-hematopoietic-growth-factors/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Role-of-hematopoietic-growth-factors/</guid><description>Role of hematopoietic growth factors Granulocyte (G-CSF) and granulocyte-macrophage (GM-CSF) colony-stimulating factors can be used (but not in AML) as 1° Ppx when expected FN incidence &amp;gt;20% or as 2° Ppx after FN has occurred in a prior cycle (to maintain dose-intensity for curable tumors) CSFs ↓ rate of FN but have not been shown to affect mortality (Cochrane 2014 CD003039)</description></item><item><title>Rule out mimickers of ILD</title><link>https://htlin222.github.io/garden/Rule-out-mimickers-of-ILD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rule-out-mimickers-of-ILD/</guid><description>Rule out mimickers of ILD Congestive heart failure (✓ BNP, trial of diuresis); infection: viral, atypical bacterial; malignancy: lymphangitic carcinomatosis, bronchoalveolar, leukemia, lymphoma</description></item><item><title>Rx-Primary biliary cholangitis PBC</title><link>https://htlin222.github.io/garden/Rx-Primary-biliary-cholangitis-PBC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Rx-Primary-biliary-cholangitis-PBC/</guid><description>Rx-Primary biliary cholangitis (PBC) Obeticholic acid (FXR agonist): monoRx if cannot tolerate UDCA (but not in decompen cirrhosis) or if no Δ w/ UDCA after 1 y; found to ↓ Aφ, ↑ pruritus (NEJM 2016;375:631) ursodeoxycholic acid (UDCA) (13–15 mg/kg bid), monitor for 3–6 mos → ~25% complete response, ↑ survival &amp;amp; ↓ histologic change &amp;amp; ↓ complications (varices).</description></item><item><title>Salicylates-toxicology</title><link>https://htlin222.github.io/garden/Salicylates-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Salicylates-toxicology/</guid><description>Salicylates-toxicology Tinnitus, hyperventilation, abd. pain, vomiting, ΔMS, mixed ↑ AG &amp;amp; nl OG metabolic acidosis + respiratory alkalosis
IVF resuscitation</description></item><item><title>Salt H2O or raw oysters fish</title><link>https://htlin222.github.io/garden/Salt-H2O-or-raw-oysters-fish/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Salt-H2O-or-raw-oysters-fish/</guid><description>Salt H2O or raw oysters fish V. vulnificus Hemorrhagic bullae &amp;amp; sepsis (esp. in cirrhotics) Doxy + Ceftaz/CTX Mycobacterium marinum Indolent, nodules on extremities/ superficial lymphadenitis Macrolide + rifampin/ ethambutol</description></item><item><title>Sarcoidosis</title><link>https://htlin222.github.io/garden/Sarcoidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sarcoidosis/</guid><description>Sarcoidosis (AJRCCM 2020;201:e26; JAMA 2022;327:856)
Prevalence: African Americans, northern Europeans, and females; onset in 3rd-5th decade
Pathophysiology: depression of cellular immune system peripherally, activation centrally</description></item><item><title>Schistosoma haematobium</title><link>https://htlin222.github.io/garden/Schistosoma-haematobium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Schistosoma-haematobium/</guid><description>Schistosoma haematobium 埃及血吸蟲，一種扁形動物，寄生蟲，是寄生於人類引起血吸蟲病的一種血吸蟲</description></item><item><title>SCLC staging and treatment</title><link>https://htlin222.github.io/garden/SCLC-staging-and-treatment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/SCLC-staging-and-treatment/</guid><description>SCLC staging and treatment SCLC usually disseminated at presentation; poor overall survival Can be very responsive to chemotherapy, but rapidly develop resistance Diagnosis: all have Rb &amp;amp; p53 mutations (Nature 2015;524:47); 90% w/ neuroendo markers Treatment: primarily chemo (platinum + etoposide); adding anti-[[PD-L1]] Ab [[atezolizumab]] ↑ survival (NEJM 2018;379:2220), as does concurrent thoracic RT in limited-stage disease Prophylactic cranial irradiation (PCI) controversial.</description></item><item><title>Scleroderma renal crisis</title><link>https://htlin222.github.io/garden/Scleroderma-renal-crisis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Scleroderma-renal-crisis/</guid><description>Scleroderma renal crisis (Nature Neph 2016;12:678)
5–20% diffuse cutaneous SSc w/ narrowing glomerular vessels. Sx: renal failure, severe HTN, encephalopathy.</description></item><item><title>Screening and Diagnosis-HIV AIDS</title><link>https://htlin222.github.io/garden/Screening-and-Diagnosis-HIV-AIDS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Screening-and-Diagnosis-HIV-AIDS/</guid><description>Screening and Diagnosis-HIV AIDS (JAMA 2018;320:379)
Screen all 13–64 yo at least once, every preg, if new STI dx; screen high risk annually HIV Ab/p24Ag (ELISA assay): ⊕ 1–12 wk after acute infxn; &amp;gt;99% Se; 1° screening test If ⊕, Ab differentiation assay confirms and differentiates HIV-1 vs.</description></item><item><title>Screening for latent TB</title><link>https://htlin222.github.io/garden/Screening-for-latent-TB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Screening-for-latent-TB/</guid><description>Screening for latent TB Whom to screen: high likelihood of exposure and/or high risk of progression to active disease including HIV ⊕ and prior to immunosuppression (pre-transplant or anti-TNF) Relies on host immune system, so limited Se in immunosuppressed individuals Nb, testing for host exposure &amp;amp; immune response to TB, not whether TB active (vide infra) Screening tests IFN-γ release assays (IGRA): preferred test; Ag-stimulated IFN-γ release from Pt’s T-cells.</description></item><item><title>Screening of breast cancer</title><link>https://htlin222.github.io/garden/Screening-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Screening-of-breast-cancer/</guid><description>Screening of breast cancer (JAMA 2015;314:1599; Annals 2019;170:547)
Mammography: ~20–30% ↓ in breast cancer mortality, smaller abs. benefit in women &amp;lt;50 y (JAMA 2018;319:1814); digital breast tomosynthesis (3-D) ↑ specificity (JAMA Oncol 2019;5:635); suspicious findings: clustered microcalcifications, spiculated, enlarging ACS: annual mammo starting at 45 (consider biennial after 54), cont.</description></item><item><title>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</title><link>https://htlin222.github.io/garden/Screening-Test-Abnormalities-in-Inherited-and-Acquired-Coagulopathies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Screening-Test-Abnormalities-in-Inherited-and-Acquired-Coagulopathies/</guid><description>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</description></item><item><title>Screening-aortic aneurysms</title><link>https://htlin222.github.io/garden/Screening-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Screening-aortic-aneurysms/</guid><description>Screening-aortic aneurysms (JAMA 2015;313:1156)
TAA: if bicuspid AoV or 1° relative w/: (a) TAA or bicuspid AoV, (b) CTD as above AAA: ✓ for pulsatile abd mass; U/S ♂ &amp;gt;60 y w/ FHx of AAA &amp;amp; ♂ 65–75 y w/ prior tobacco</description></item><item><title>Search</title><link>https://htlin222.github.io/garden/notes/search/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/search/</guid><description>Quartz supports two modes of searching through content.
Full-text Full-text search is the default in Quartz. It produces results that exactly match the search query.</description></item><item><title>Second-line or maintainence therapy for idiopathic thrombocytopenic purpura</title><link>https://htlin222.github.io/garden/Second-line-or-maintainence-therapy-for-idiopathic-thrombocytopenic-purpura/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Second-line-or-maintainence-therapy-for-idiopathic-thrombocytopenic-purpura/</guid><description>Second-line or maintainence therapy for idiopathic thrombocytopenic purpura Romiplostim, el/avatrombopag TPO-R agonists → ↑ plt prod
Rituximab (anti-CD20) ± dex anti–B-cell Ab</description></item><item><title>secondary bacterial peritonitis</title><link>https://htlin222.github.io/garden/secondary-bacterial-peritonitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/secondary-bacterial-peritonitis/</guid><description>secondary bacterial peritonitis 2/2 intra-abd abscess, perf. Runyon’s criteria: AFTP &amp;gt;1 g/dL, glc &amp;lt;50 mg/dL, LDH &amp;gt;ULN for serum. Cx polymicrobial.</description></item><item><title>Secondary causes of headaches</title><link>https://htlin222.github.io/garden/Secondary-causes-of-headaches/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Secondary-causes-of-headaches/</guid><description>Secondary causes of headaches Traumatic: post-concussion, SAH, SDH, postcraniotomy ↑ ICP: mass (tumor, abscess, vascular malformations, ICH), hydrocephalus, idiopathic intracranial hypertension (pseudotumor cerebri), altitude-associated cerebral edema ↓ ICP: post-LP headache, CSF leak/dural tear, overshunting Vascular: stroke (esp.</description></item><item><title>Secondary Causes of Hypertension</title><link>https://htlin222.github.io/garden/Secondary-Causes-of-Hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Secondary-Causes-of-Hypertension/</guid><description>Secondary Causes of Hypertension [[renal-Secondary Causes of Hypertension]] [[endocrine-Secondary Causes of Hypertension]] [[other-Secondary Causes of Hypertension]]</description></item><item><title>Secondary causes of iron overload</title><link>https://htlin222.github.io/garden/Secondary-causes-of-iron-overload/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Secondary-causes-of-iron-overload/</guid><description>Secondary causes of iron overload iron-loading anemias (eg, thalassemia major, sideroblastic anemia, aplastic anemia), parenteral iron overload (RBC transfusions, long-term HD), chronic liver disease (due to EtOH, HBV, HCV, NASH, etc.</description></item><item><title>Secondary Hyperaldosteronism</title><link>https://htlin222.github.io/garden/Secondary-Hyperaldosteronism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Secondary-Hyperaldosteronism/</guid><description>Secondary Hyperaldosteronism (extra-adrenal disorders, ↑ aldosterone is renin-dependent) 2° hyperaldosteronism (eg, renovascular dis., [[renin-secreting tumor]])
Primary reninism: renin-secreting tumor (very rare) Secondary reninism: renovascular disease: RAS, malignant hypertension; edematous states w/ ↓ effective arterial volume: CHF, cirrhosis, nephrotic syndrome; hypovolemia, diuretics, T2D, Bartter’s (defective Na/K/2Cl transporter ≈ receiving loop diuretic), Gitelman’s (defective renal Na/Cl transporter ≈ receiving thiazide diuretic)</description></item><item><title>Secondary hyperPTH</title><link>https://htlin222.github.io/garden/Secondary-hyperPTH/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Secondary-hyperPTH/</guid><description>Secondary hyperPTH ↑ PO4, ↑ FGF-23, ↓ calcitriol, &amp;amp; ↓ Ca → ↑ PTH → renal osteodystrophy
Stage 3 4 5 Target parathyroid hormone (pg/mL) 35-70 70-110 150-600 [[chronic kidney disease (CKD)]]</description></item><item><title>Secondary immune thrombocytopenic purpura 2° ITP</title><link>https://htlin222.github.io/garden/Secondary-immune-thrombocytopenic-purpura-2-ITP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Secondary-immune-thrombocytopenic-purpura-2-ITP/</guid><description>Secondary immune thrombocytopenic purpura (2° ITP) Diagnosis: viral serologies (HIV, HCV, HBV, EBV), H. pylori Ab, ANA, pregnancy test, APLA, TSH, parvovirus, &amp;amp; CMV PCR.</description></item><item><title>Secretory diarrhea</title><link>https://htlin222.github.io/garden/Secretory-diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Secretory-diarrhea/</guid><description>Secretory diarrhea (watery; nl osmotic gap, no Δ diarrhea w/ fasting, nocturnal, cramps)
Caused by secretion of anions or K+ into lumen or inhib of Na absorption → ↑ H2O in stool.</description></item><item><title>Sedation-and-Analgesia</title><link>https://htlin222.github.io/garden/Sedation-and-Analgesia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sedation-and-Analgesia/</guid><description>Sedation-and-Analgesia [[Context sensitive half time]]</description></item><item><title>seizures</title><link>https://htlin222.github.io/garden/seizures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/seizures/</guid><description/></item><item><title>Select clinical manifestations-fever in a returned traveler</title><link>https://htlin222.github.io/garden/Select-clinical-manifestations-fever-in-a-returned-traveler/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Select-clinical-manifestations-fever-in-a-returned-traveler/</guid><description>Select clinical manifestations-fever in a returned traveler Ebola: fever in traveler from area with active transmission of Ebola w/in 21 d Malaria: nonspecific sx including diarrhea, headache, myalgias, cough, Δ MS Dengue: nonspecific sx including headache, severe myalgias, rash/petechiae Chikungunya: nonspecific sx including joint pain, moderate myalgias Typhoid (Lancet 2015;385:1136): diarrhea/constipation, abd pain, ± rash, relative bradycardia Rickettsial disease: headache, myalgias, lymphadenopathy, ± rash/eschar Zika: rash, arthralgia, headache, conjunctivitis; often less severe than dengue, Chikungunya</description></item><item><title>selexipag</title><link>https://htlin222.github.io/garden/selexipag/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/selexipag/</guid><description>selexipag k</description></item><item><title>sensible and insensible fluid losses</title><link>https://htlin222.github.io/garden/sensible-and-insensible-fluid-losses/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/sensible-and-insensible-fluid-losses/</guid><description>sensible and insensible fluid losses Insensible losses (nonmeasurable) Lungs: 200 mL Skin: 600 mL Sweat: Variable Sensible losses (measurable) Fecal: 200 mL Urine: 800 to 1500 mL These losses account for 2000 to 2500 mL/day, giving a 24-hour fluid requirement of 30 to 35 mL/kg to maintain normal fluid balance.</description></item><item><title>sepsis and shock</title><link>https://htlin222.github.io/garden/sepsis-and-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/sepsis-and-shock/</guid><description>sepsis and shock [[Definitions-sepsis and shock]] [[Shock]]
MANAGEMENT [[Fluids-sepsis and shock]] [[Pressors inotropes-sepsis and shock]] [[Targets-sepsis and shock]] [[Antibiotics-sepsis and shock]] [[Steroids-sepsis and shock]] [[Early Goal-Directed Therapy (EGDT)]]</description></item><item><title>Sequential management of bacterial meningitis</title><link>https://htlin222.github.io/garden/Sequential-management-of-bacterial-meningitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sequential-management-of-bacterial-meningitis/</guid><description>Sequential management of bacterial meningitis Blood cx, initiate empiric antibiotics, consider corticosteroids (vide infra) CT head if indicated (see below) LP ASAP (if not contraindicated); yield of CSF cx unlikely to be changed if obtained w/in ~4 h of initiation of abx Diagnostic studies (NEJM 2017;388:3036) Blood cultures ×2 before abx WBC count: &amp;gt;10,000 in &amp;gt;90% of bacterial meningitis in healthy hosts Head CT to r/o mass effect before LP if ≥1 high-risk feature: immunosupp.</description></item><item><title>Serologic and virologic tests</title><link>https://htlin222.github.io/garden/Serologic-and-virologic-tests/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Serologic-and-virologic-tests/</guid><description>Serologic and virologic tests Precore mutant: HBeAg not made, but anti-HBe can develop due to x-reactivity w/ HBcAg; a/w ↑ HBV DNA HBsAg: appears before sx; used to screen blood donors; persists &amp;gt;6 mo = chronic HBV</description></item><item><title>Serum parathyroid hormone PTH concentrations in hypercalcemia and hypocalcemia</title><link>https://htlin222.github.io/garden/Serum-parathyroid-hormone-PTH-concentrations-in-hypercalcemia-and-hypocalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Serum-parathyroid-hormone-PTH-concentrations-in-hypercalcemia-and-hypocalcemia/</guid><description>Serum parathyroid hormone (PTH) concentrations in hypercalcemia and hypocalcemia ⭐Serum parathyroid hormone (PTH) concentrations in hypercalcemia and hypocalcemia ⭐ iPTH 濃度根據不同疾病狀態下的血清總鈣濃度。 正常範圍顯示在白框中。 S 形曲線（綠色星形）源自對 38 名正常受試者進行的檸檬酸鈣輸注方案。 血清 PTH 和鈣值在甲狀旁腺功能減退症（藍色空心框）中較低，在原發性甲狀旁腺功能亢進症（藍色方塊）中較高。 非PTH引起的惡性腫瘤高鈣血症患者血清鈣濃度高，血清PTH適當低（紅色圓圈）。</description></item><item><title>Serum-ascites albumin gradient SAAG</title><link>https://htlin222.github.io/garden/Serum-ascites-albumin-gradient-SAAG/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Serum-ascites-albumin-gradient-SAAG/</guid><description>Serum-ascites albumin gradient (SAAG) serum alb (g/dL) – ascites alb (g/dL)
SAAG ≥1.1 diagnoses portal HTN with ~97% accuracy (Ann Intern Med 1992;117:215)</description></item><item><title>Severity of Asthma Exacerbation</title><link>https://htlin222.github.io/garden/Severity-of-Asthma-Exacerbation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Severity-of-Asthma-Exacerbation/</guid><description>Severity of Asthma Exacerbation Mild-Moderate Talks in phrases RR &amp;gt;20, HR 100-120, Room air Sa02 90-95%
50% predicted or best 02, SABA 4-10 puffs q20min, prednisone</description></item><item><title>Severity-acute pancreatitis</title><link>https://htlin222.github.io/garden/Severity-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Severity-acute-pancreatitis/</guid><description>Severity-acute pancreatitis (Gut 2013;62:102; Gastro 2018;154:1096)
Severity defined by presence of organ failure (AKI, resp failure, GIB, shock) &amp;amp; local or systemic complic.</description></item><item><title>sexually transmitted infections</title><link>https://htlin222.github.io/garden/sexually-transmitted-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/sexually-transmitted-infections/</guid><description>sexually transmitted infections [[Risk Factors and Screening]] (MMWR 2021;70:1) [[Genital Lesions]] (MMWR 2021; 70:1) [[Genital Discharge]] [[Diagnosis-sexually transmitted infections]] [[Treatment-sexually transmitted infections]]</description></item><item><title>SGLT2i</title><link>https://htlin222.github.io/garden/SGLT2i/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/SGLT2i/</guid><description>SGLT2i ~25% ↓ death or HF hospitalization in NYHA II–IV (DAPA-HF, NEJM 2019; 381:1995, EMPEROR-Reduced; NEJM 2020;383:1413).</description></item><item><title>SGLT2i in chronic kidney disease</title><link>https://htlin222.github.io/garden/SGLT2i-in-chronic-kidney-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/SGLT2i-in-chronic-kidney-disease/</guid><description>SGLT2i in chronic kidney disease in proteinuric CKD (min eGFR 25-30) w/ or w/o DM, transient ↓ in eGFR (&amp;lt;5) but then 30-40% ↓ risk of CKD progression &amp;amp; ↓ mortality (NEJM 2019;380:2295 &amp;amp; 2020;383:1436)</description></item><item><title>Shock</title><link>https://htlin222.github.io/garden/Shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Shock/</guid><description>Shock 被定義為由於氧氣遞送或萃取失調而導致末端損傷導致組織缺氧的狀態。臨床表現包括： 注意，不是血壓低就是shock不是血壓低就是shock
SHOCK的公式： #anki SHOCK 就是指DO2不太行產生end organ damamges
DO2 = (HR × SV) × CaO2 所以shock的部分，包含兩個層面：血壓跟血氧 CaO2 = (Hb × 1.</description></item><item><title>Short-Term Central Venous Catheter-Related Bloodstream Infxns</title><link>https://htlin222.github.io/garden/Short-Term-Central-Venous-Catheter-Related-Bloodstream-Infxns/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Short-Term-Central-Venous-Catheter-Related-Bloodstream-Infxns/</guid><description>Short-Term Central Venous Catheter-Related Bloodstream Infxns S. aureus Risk of endocarditis in bacteremia: ~25% (JACC 1997;30:1072). ID consult a/w ↓ mortality (ClD 2015;60:1451).</description></item><item><title>Showcase</title><link>https://htlin222.github.io/garden/notes/showcase/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/showcase/</guid><description>Want to see what Quartz can do? Here are some cool community gardens :)
Quartz Documentation (this site!) Jacky Zhao&amp;rsquo;s Garden Scaling Synthesis - A hypertext research notebook AWAGMI Intern Notes Shihyu&amp;rsquo;s PKM Chloe&amp;rsquo;s Garden SlRvb&amp;rsquo;s Site Course notes for Information Technology Advanced Theory Brandon Boswell&amp;rsquo;s Garden Siyang&amp;rsquo;s Courtyard Data Dictionary 🧠 sspaeti.</description></item><item><title>SIADH</title><link>https://htlin222.github.io/garden/SIADH/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/SIADH/</guid><description>SIADH (euvolemia or mild hypervolemia, typically inapprop Uosm &amp;gt;100, UNa &amp;gt;20 mEq/L ) Malignancy: lung (SCLC), brain, GI, GU, lymphoma, leukemia, thymoma, mesothelioma Pulmonary: pneumonia, TB, aspergillosis, asthma, COPD, PTX, mechanical ventilation Intracranial: trauma, stroke, SAH, seizure, infxn, hydrocephalus, Guillain-Barré Drugs: antipsychotics, antidepress.</description></item><item><title>Sickle cell anemia</title><link>https://htlin222.github.io/garden/Sickle-cell-anemia-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sickle-cell-anemia-/</guid><description>Sickle cell anemia (NEJM 2017;376:1561 &amp;amp; Lancet 2017;390:311)
Recessive β-globin mutation → structurally abnl hemoglobin (HbS). ~8% African Americans heterozygotes (“sickle trait”; usually w/o sx); ~1/400 homozygotes (sickle cell disease).</description></item><item><title>Sideroblastic anemia</title><link>https://htlin222.github.io/garden/Sideroblastic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sideroblastic-anemia/</guid><description>Sideroblastic anemia Defective heme biosynthesis within RBC precursors
Etiologies: hereditary/X-linked (ALAS2 mutations), idiopathic, MDS-RARS, reversible (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia)</description></item><item><title>Signs and Symptoms of Uremia -chronic kidney disease CKD</title><link>https://htlin222.github.io/garden/Signs-and-Symptoms-of-Uremia-chronic-kidney-disease-CKD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Signs-and-Symptoms-of-Uremia-chronic-kidney-disease-CKD/</guid><description>Signs and Symptoms of Uremia -chronic kidney disease (CKD) (NEJM 2018;379:669)
General Nausea, anorexia, malaise, uremic fetor, metallic taste, hypothermia</description></item><item><title>Simplified Wells Pretest Probability Scoring of DVT</title><link>https://htlin222.github.io/garden/Simplified-Wells-Pretest-Probability-Scoring-of-DVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Simplified-Wells-Pretest-Probability-Scoring-of-DVT/</guid><description>Simplified Wells Pretest Probability Scoring of DVT (JAMA 2006;295:199)
+1 point each for: active cancer (Rx ongoing or w/in 6 mo or palliative) paralysis, paresis, or recent immobilization of lower extremities recently bedridden for ≥3 d or major surgery w/in 12 wk localized tenderness along distribution of deep venous system entire leg swelling calf ≥3 cm larger than asx calf (at 10 cm below tibial tuberosity) pitting edema confined to sx leg collateral superficial veins (nonvaricose) previous DVT –2 points if alternative dx at least as likely as DVT Pretest Probability Assessment (useful if outPt, less so if inPt; JAMA IM 2015;175:1112) Low probability (5%) Score ≤0</description></item><item><title>Sinus bradycardia</title><link>https://htlin222.github.io/garden/Sinus-bradycardia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sinus-bradycardia/</guid><description>Sinus bradycardia (SB, &amp;lt;50–60 bpm) (NEJM 2000;342:703, Circ 2019;140:e382)
Etiologies: meds (incl βB, CCB, amio, Li, dig), ↑ vagal tone (incl.</description></item><item><title>Sinusoidal obstruction syndrome SOS</title><link>https://htlin222.github.io/garden/Sinusoidal-obstruction-syndrome-SOS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sinusoidal-obstruction-syndrome-SOS/</guid><description>Sinusoidal obstruction syndrome (SOS) (Bone Marrow Transplant 2020:55:485)
Occlusion of hepatic venules &amp;amp; sinusoids (formerly veno-occlusive disease) 2/2 toxic insult</description></item><item><title>skin and soft tissue infections</title><link>https://htlin222.github.io/garden/skin-and-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/skin-and-soft-tissue-infections/</guid><description>skin and soft tissue infections [[Definitions-skin and soft tissue infections]] Risk Factors
Trauma, edema, preceding skin inflammation or infection, obesity, DM, other immunosupp.</description></item><item><title>Small intestinal bacterial overgrowth</title><link>https://htlin222.github.io/garden/Small-intestinal-bacterial-overgrowth/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Small-intestinal-bacterial-overgrowth/</guid><description>Small intestinal bacterial overgrowth colonic bacteria in SI → steatorrhea, B12/Fe defic, protein-losing enteropathy. A/w dysmotility (DM neuropathy, scleroderma), Δ’d anatomy (Crohn’s, surgery, fistulae), immune deficiency, celiac, CF.</description></item><item><title>sodium and water homeostasis</title><link>https://htlin222.github.io/garden/sodium-and-water-homeostasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/sodium-and-water-homeostasis/</guid><description>sodium and water homeostasis [[overview-sodium and water homeostasis]] [[hyponatremia]] [[hypernatremia]] [[polyuria]]</description></item><item><title>solitary pulmonary nodule</title><link>https://htlin222.github.io/garden/solitary-pulmonary-nodule/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/solitary-pulmonary-nodule/</guid><description>solitary pulmonary nodule [[Principles-solitary pulmonary nodule]] [[Etiologies-solitary pulmonary nodule]] [[Initial evaluation-solitary pulmonary nodule]] [[Diagnostic studies of solitary pulmonary nodule]] [[Management-solitary pulmonary nodule]]</description></item><item><title>sorafenib</title><link>https://htlin222.github.io/garden/sorafenib/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/sorafenib/</guid><description>sorafenib inhib RAS and B-Raf
腫瘤生長鏈 RAS-&amp;gt;B-RAF-MEK-MAPK-Nuclear Transcription-Tumor cell prolifertaion</description></item><item><title>Sotalol</title><link>https://htlin222.github.io/garden/Sotalol/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sotalol/</guid><description>Sotalol n/a 80-160 mg bid check for HR, 1 QT; renal adj %
Backlink: [[Antiarrhythmic Drugs (AAD) for AF]]</description></item><item><title>Specialized Diagnostic Tests in Thyroid Disorders</title><link>https://htlin222.github.io/garden/Specialized-Diagnostic-Tests-in-Thyroid-Disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Specialized-Diagnostic-Tests-in-Thyroid-Disorders/</guid><description>Specialized Diagnostic Tests in Thyroid Disorders Total T4 Total serum concentrations (∴ influenced by TBG). Checked if concern that TSH and free T4 are not accurate.</description></item><item><title>Specific gravity of Urine Dipstick</title><link>https://htlin222.github.io/garden/Specific-gravity-of-Urine-Dipstick/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Specific-gravity-of-Urine-Dipstick/</guid><description>Specific gravity of Urine Dipstick 正常值：300-1000 mOsm/kg H2O
Estimate Uosm: each 0.001 above 1 ≈ 30 osm (SG 1.</description></item><item><title>Splenic vein thrombosis</title><link>https://htlin222.github.io/garden/Splenic-vein-thrombosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Splenic-vein-thrombosis/</guid><description>Splenic vein thrombosis Can occur 2/2 local inflam. (eg, panc.). Can p/w isol. gastric varices. Splenectomy curative.</description></item><item><title>Spontaneous bacterial peritonitis</title><link>https://htlin222.github.io/garden/Spontaneous-bacterial-peritonitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Spontaneous-bacterial-peritonitis/</guid><description>Spontaneous bacterial peritonitis (SBP; see “Ascites”; Hepatology 2021;74:1014)
High mortality rate; risk factors include ascitic TP &amp;lt;1 g/dL, hx of SBP, current GIB</description></item><item><title>Spontaneous bacterial peritonitis SBP</title><link>https://htlin222.github.io/garden/Spontaneous-bacterial-peritonitis-SBP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Spontaneous-bacterial-peritonitis-SBP/</guid><description>Spontaneous bacterial peritonitis (SBP) gut bacterial translocation to ascites. In cirrhosis, ↓ ascites opsonins (esp. if ↓AFTP) ↑ risk of infxn.</description></item><item><title>Spot urine</title><link>https://htlin222.github.io/garden/Spot-urine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Spot-urine/</guid><description>Spot urine protein (mg/dL)/creatinine (mg/dL) ≈ g/d of proteinuria (NEJM 1983;309:1543) unlike urine dipstick, will accurately measure myeloma light chains</description></item><item><title>ST-depression</title><link>https://htlin222.github.io/garden/ST-depression/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ST-depression/</guid><description>ST-depression Myocardial ischemia (± Tw abnl)
Acute true posterior MI: posterior STE appearing as anterior STD (± ↑ R wave) in V1–V3 ✓ posterior ECG leads; manage as a STEMI with rapid reperfusion (see “ACS”)</description></item><item><title>ST-elevation</title><link>https://htlin222.github.io/garden/ST-elevation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ST-elevation/</guid><description>ST-elevation Acute MI: upward convexity STE (ie, a “frown”) ± TWI (or prior MI w/ persistent STE)
Coronary spasm: Prinzmetal’s angina; transient STE in a coronary distribution</description></item><item><title>stable ischemic heart disease</title><link>https://htlin222.github.io/garden/stable-ischemic-heart-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/stable-ischemic-heart-disease/</guid><description>stable ischemic heart disease Definition SIHD refers to asx and stably sx Pts as well as low-risk new-onset chest pain felt to be due to IHD, and excludes Pts w/ rapidly progressive sx or rest sx (ie, ACS)</description></item><item><title>Stages of CKD</title><link>https://htlin222.github.io/garden/Stages-of-CKD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Stages-of-CKD/</guid><description>Stages of CKD (Kid Int 2013;3[Suppl]:5)
GFR Stage GFR mL/min/1.73 m2 : Goals
1 (nl or ↑ GFR) &amp;gt;90 Dx/Rx of underlying condition &amp;amp; comorbidities, slow progression; cardiovascular risk reduction</description></item><item><title>Staging and prognosis-chronic obstructive pulmonary disease</title><link>https://htlin222.github.io/garden/Staging-and-prognosis-chronic-obstructive-pulmonary-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Staging-and-prognosis-chronic-obstructive-pulmonary-disease/</guid><description>Staging and prognosis-chronic obstructive pulmonary disease Assess breathlessness, cough, sputum, exercise capacity &amp;amp; energy (tools such as CAT and mMRC may be used as part of assessment) Ratio of diam PA/aorta &amp;gt;1 associated with ~3× ↑ risk of exacerbations (NEJM 2012;367:913) FEV1 stages: I = ≥80%; II = 50–79% (~11% 3-y mort.</description></item><item><title>Staging of breast cancer</title><link>https://htlin222.github.io/garden/Staging-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Staging-of-breast-cancer/</guid><description>Staging of breast cancer Anatomic: tumor size, chest wall invasion, axillary LN mets (strongest prognostic factor) Histopathologic: type (little prognostic relevance) &amp;amp; grade; lymphatic/vascular invasion In situ carcinoma: no invasion of surrounding stroma Ductal (DCIS): ↑ risk of invasive cancer in ipsilateral breast (~30%/10 y) Lobular (LCIS): benign entity; marker of ↑ risk of inv.</description></item><item><title>Staging of lung cancer</title><link>https://htlin222.github.io/garden/Staging-of-lung-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Staging-of-lung-cancer/</guid><description>Staging of lung cancer based on tumor size and extent of invasion (T), regional LN involvement [N: N0 (none), N1 (ipsilat.</description></item><item><title>Standard workup-hypertension</title><link>https://htlin222.github.io/garden/Standard-workup-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Standard-workup-hypertension/</guid><description>Standard workup-hypertension Goals: (1) identify CV risk factors; (2) consider 2° causes; (3) assess for target-organ damage History: CAD, HF, TIA/CVA, PAD, DM, renal insufficiency, sleep apnea, preeclampsia; ⊕ FHx for HTN; diet, Na intake, smoking, alcohol, prescription and OTC meds, OCP Physical exam: ✓ BP in both arms; funduscopic exam, BMI, cardiac (LVH, murmurs), vascular (bruits, radial-femoral delay), abdominal (masses or bruits), neuro exam Testing: K, BUN, Cr, Ca, glc, Hct, U/A, lipids, TSH, urinary albumin:creatinine (if ↑ Cr, DM, peripheral edema), ?</description></item><item><title>STEMI</title><link>https://htlin222.github.io/garden/STEMI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/STEMI/</guid><description>STEMI Requisite STE (at J point) ≥2 contiguous leads w/ ≥1 mm (except for V2–V3: ≥2 mm in ♂ and ≥1.</description></item><item><title>Stepwise Evaluation of a Patient with Delirium</title><link>https://htlin222.github.io/garden/Stepwise-Evaluation-of-a-Patient-with-Delirium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Stepwise-Evaluation-of-a-Patient-with-Delirium/</guid><description>Stepwise Evaluation of a Patient with Delirium from Harrison&amp;rsquo;s Principles of Internal Medicine, 21e
Initial Evaluation History with special attention to medications (including over-the-counter and herbals) General physical examination and neurologic examination Complete blood count Electrolyte panel including calcium, magnesium, phosphorus Liver function tests, including albumin Renal function tests First-Tier Further Evaluation Guided by Initial Evaluation Systemic infection screen - Urinalysis and culture - Chest radiograph - Blood cultures Electrocardiogram Arterial blood gas Serum and/or urine toxicology screen (perform earlier in young persons) Brain imaging with MRI with diffusion and gadolinium (preferred) or CT Suspected CNS infection or other inflammatory disorder: [[lumbar puncture after brain imaging]] Suspected seizure-related etiology: electroencephalogram (EEG) (if high suspicion, should be performed immediately)</description></item><item><title>Steroids-sepsis and shock</title><link>https://htlin222.github.io/garden/Steroids-sepsis-and-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Steroids-sepsis-and-shock/</guid><description>Steroids-sepsis and shock Steroids (Crit Care Med 2018;46:1411)
Hydrocortisone 50 mg IV q6 + fludrocortisone 50 µg via NGT daily in septic shock ↓ duration of shock and may ↓ mortality (NEJM 2018; 378:797 &amp;amp; 809)</description></item><item><title>Stress testing</title><link>https://htlin222.github.io/garden/Stress-testing/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Stress-testing/</guid><description>Stress testing Indications: evaluate possible CAD sx or ∆ in clinical status in Pt w/ known CAD, risk stratify after chest pain, evaluate exercise tolerance, localize ischemia (imaging required)</description></item><item><title>stroke</title><link>https://htlin222.github.io/garden/stroke/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/stroke/</guid><description>stroke 急性中風分為兩種： 缺血性（約 85% 的病例） 出血性（約 15% 的病例）</description></item><item><title>Structural dysphagia</title><link>https://htlin222.github.io/garden/Structural-dysphagia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Structural-dysphagia/</guid><description>Structural dysphagia (solids &amp;gt;liquids; JAMA 2015;313:18; Gastro 2018;155:1022)
Oropharyngeal Zenker’s divertic. (pharyngeal pouch): in elderly, a/w aspir., dx w/ video fluoro, Rx endo/surg Malignancy; proximal strictures/rings/webs; infection; radiation injury; goiter; osteophytes Esophageal Rings (intermittent dysphagia, concentric obstructing tissue, Schatzki ring): near GE jxn, a/w food impaction, linked to GERD; Rx w/ PPI, dilation Webs: thin, partially occlusive structure, proximal, a/w Fe defic.</description></item><item><title>Subclinical hypothyroidism</title><link>https://htlin222.github.io/garden/Subclinical-hypothyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Subclinical-hypothyroidism/</guid><description>Subclinical hypothyroidism Mild ↑ TSH and normal free T4 with only subtle or no sx If TSH &amp;lt;7 or ⊖ anti-TPO Ab, ~½ resolve after 2 y (JCEM 2012;97:1962) if ↑ titers of antithyroid Abs, progression to overt hypothyroidism is ~4%/y No clear benefit to Rx (NEJM 2017;376:2534).</description></item><item><title>summary of etiology of upper gastrointestinal bleed</title><link>https://htlin222.github.io/garden/summary-of-etiology-of-upper-gastrointestinal-bleed/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/summary-of-etiology-of-upper-gastrointestinal-bleed/</guid><description>summary of etiology of upper gastrointestinal bleed 消化性潰瘍病（PUD） PUD (20–60%; duodenal&amp;gt;gastric)
上消化道出血的最常見原因（30%–65% 的病例） 通常與幽門螺桿菌感染或使用NSAIDs有關
胃炎、食管炎、十二指腸炎 與胃食管反流病 (GERD)、藥丸性食管炎、阿司匹林/非甾體抗炎藥 (NSAID) 使用、酒精使用、感染有關
靜脈曲張（詳見肝硬化） 馬洛里-韋斯撕裂 胃食管交界處黏膜撕裂導致出血，通常伴有嘔吐或乾嘔</description></item><item><title>supraventricular tachycardias SVTS</title><link>https://htlin222.github.io/garden/supraventricular-tachycardias-SVTS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/supraventricular-tachycardias-SVTS/</guid><description>supraventricular tachycardias (SVTS) Arise above the ventricles, ∴ narrow QRS unless aberrant conduction or pre-excitation. [[Common Etiologies of SVT]] [[Diagnosis of SVT Type]] [[Treatment of SVT]]</description></item><item><title>surgery and radiation for local control of breast cancer</title><link>https://htlin222.github.io/garden/surgery-and-radiation-for-local-control-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/surgery-and-radiation-for-local-control-of-breast-cancer/</guid><description>surgery and radiation for local control of breast cancer Intervention Indication Breast conserving Stage I–II, lumpectomy + sentinel lymph node biopsy* + RT Modified radical mastectomy Large tumor relative to breast, multicentric dis.</description></item><item><title>Surgery of inflammatory bowel disease</title><link>https://htlin222.github.io/garden/Surgery-of-inflammatory-bowel-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Surgery-of-inflammatory-bowel-disease/</guid><description>Surgery of inflammatory bowel disease UC: colectomy if sx refractory to or intolerable side effects from meds, CRC, perforation, toxic megacolon, uncontrolled hemorrhage.</description></item><item><title>surgical critical care</title><link>https://htlin222.github.io/garden/surgical-critical-care/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/surgical-critical-care/</guid><description>surgical critical care 33 Gastrointestinal Bleeding 34 Acute Abdomen and Abdominal Sepsis 35 Abdominal Compartment Syndrome 36 Acute Mesenteric Ischemia 37 Surgical Trauma 38 Burns 39 Acute Hepatic Failure 40 Abdominal Organ Transplantation 41 Obstetric Emergencies</description></item><item><title>surgical issues</title><link>https://htlin222.github.io/garden/surgical-issues/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/surgical-issues/</guid><description>surgical issues [[orthopaedic]]</description></item><item><title>SVC syndrome</title><link>https://htlin222.github.io/garden/SVC-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/SVC-syndrome/</guid><description>SVC syndrome (NEJM 2007;356:1862): central tumor → SVC compression → face/arm swelling (&amp;gt;80%), neck/chest vein distention (~60%), SOB/cough (~50%), HA (~10%); Rx = steroids, diuretics, RT ± chemo, SVC stent if severe sx, anticoag if clot</description></item><item><title>Sx of Hemochromatosis</title><link>https://htlin222.github.io/garden/Sx-of-Hemochromatosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Sx-of-Hemochromatosis/</guid><description>Sx of Hemochromatosis fatigue &amp;amp; arthralgias, loss of libido in ♂. In advanced disease (rare): bronze skin (melanin + iron), hypogonadism (esp.</description></item><item><title>symptom to diagnosis of dyspnea</title><link>https://htlin222.github.io/garden/symptom-to-diagnosis-of-dyspnea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/symptom-to-diagnosis-of-dyspnea/</guid><description>symptom to diagnosis of dyspnea Four most common Heart failure Pneumonia Obstructive lung disease (chronic obstructive pulmonary disease/asthma) Pulmonary embolism Immediate threat to life (ACT ASAP) (大概就是5T) Arrhythmia Coronary syndrome, Acute Tamponade Airway obstruction Stenosis, Aortic Anaphylaxis Pneumothorax [[Differential Diagnosis of Dyspnea]]</description></item><item><title>Symptoms-ascites</title><link>https://htlin222.github.io/garden/Symptoms-ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Symptoms-ascites/</guid><description>Symptoms-ascites ↑ abd girth, wt gain, new abd hernia, abd pain, dyspnea, nausea, early satiety</description></item><item><title>syncope</title><link>https://htlin222.github.io/garden/syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/syncope/</guid><description>syncope [[Definition-syncope]] [[Etiologies-syncope]] [[Workup-syncope]] [[Other diagnostic studies-syncope]] [[Approach to syncope-syncope]] [[High-risk features-syncope]] [[Treatment-syncope]] [[Prognosis-syncope]]</description></item><item><title>Synthesis and Metabolism of Vitamin D</title><link>https://htlin222.github.io/garden/Synthesis-and-Metabolism-of-Vitamin-D/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Synthesis-and-Metabolism-of-Vitamin-D/</guid><description>Synthesis and Metabolism of Vitamin D 維生素 D 最初是在皮膚中通過維生素 D3 到維生素 D3 的非酶轉化產生的。 維生素 D 的膳食攝入量通常相對有限，因為除某些魚類外，很少有食物含有大量；補充劑是常用的。 維生素 D 要么儲存在脂肪組織中，要么通過 25-羥化酶在肝臟中轉化為 25-羥基維生素 D3 (25[OH]D3)，這種形式以最高濃度循環並反映陽光和飲食暴露。 它在腎臟中轉化為活性代謝物 25-二羥基維生素 D (25[OH]2D) 或骨化三醇，儘管其他組織具有 1α-羥化酶酶活性。 骨化三醇的合成通過增加甲狀旁腺激素 (PTH) 的水平來增強 (+)，甲狀旁腺素 (PTH) 會隨著血清鈣水平的降低而升高。 血清磷酸鹽水平降低也可以增加（+）骨化三醇的產生。 它的合成被成纖維細胞生長因子 23 (FGF-23) 的產生抑制 (-)，該因子由骨基質中的骨細胞分泌。 骨化三醇抑制 1α-羥化酶 (CYP27B1) 的活性並刺激 24-羥化酶 (CYP24R1) 的活性，該酶可促進 25(OH)2D 的產生，這是一種非生物活性的維生素 D 產品。 在 CYP2R CYP27B 和 CYP24R 中，CYP 表示細胞色素 P。 KEY: 陽光在皮膚生成D3 肝加25、腎加1</description></item><item><title>systematic-Treatment</title><link>https://htlin222.github.io/garden/systematic-Treatment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/systematic-Treatment/</guid><description>systematic-Treatment The poor risk model used in the global ARCC trial to direct treatment with temsirolimus included at least 3 of the following 6 predictors of short survival:</description></item><item><title>Systemic diseases with secondary glomerular involvement</title><link>https://htlin222.github.io/garden/Systemic-diseases-with-secondary-glomerular-involvement/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Systemic-diseases-with-secondary-glomerular-involvement/</guid><description>Systemic diseases with secondary glomerular involvement [[diabetes mellitus]] (CJASN 2017;12:2032): nodular glomerulosclerosis (Kimmelstiel-Wilson lesion); glomerular hyperfiltration → microalbuminuria → dipstick ⊕ → nephrotic range (10–15 y).</description></item><item><title>systemic therapy of breast cancer</title><link>https://htlin222.github.io/garden/systemic-therapy-of-breast-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/systemic-therapy-of-breast-cancer/</guid><description>systemic therapy of breast cancer [[ER PR]] [[PIK3CA]] [[HER2]] treatment Stage I–III (above) Chemo
Neoadjuvant: to conserve breast &amp;amp; evaluate Rx efficacy, equivalent OS as adjuvant (JCO 2008;26:778) Adjuvant: use anthracycline ± taxane.</description></item><item><title>Systemic thrombolysis</title><link>https://htlin222.github.io/garden/Systemic-thrombolysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Systemic-thrombolysis/</guid><description>Systemic thrombolysis (EHJ 2020;41:543; Chest 2021;160:e545)
Typically TPA 100 mg over 2h or wt-adjusted TNK bolus; risk of ICH ~2-5%, ↑ w/ age</description></item><item><title>T-wave-inversion</title><link>https://htlin222.github.io/garden/T-wave-inversion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/T-wave-inversion/</guid><description>T-wave-inversion Ischemia or infarct; Wellens’ sign (deep, symm precordial TWI) → critical prox LAD lesion
Myopericarditis; CMP (Takotsubo, ARVC, apical HCM); MVP; PE (espec if TWI V1–V4)</description></item><item><title>Tachycardia-bradycardia “tachy-brady” syndrome</title><link>https://htlin222.github.io/garden/Tachycardia-bradycardia-tachy-brady-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tachycardia-bradycardia-tachy-brady-syndrome/</guid><description>Tachycardia-bradycardia (“tachy-brady”) syndrome (“tachy-brady”) syndrome
Features may include: periods of unprovoked SB, SA arrest, paroxysms of SB and atrial tachyarrhythmias, chronotropic incompetence w/ ETT Treatment: meds alone usually fail (adeq.</description></item><item><title>Tailored therapy in cardiogenic shock</title><link>https://htlin222.github.io/garden/Tailored-therapy-in-cardiogenic-shock-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tailored-therapy-in-cardiogenic-shock-/</guid><description>Tailored therapy in cardiogenic shock Goals: optimize both MAP and CO while ↓ risk of pulmonary edema MAP = CO × SVR; CO = HR × SV (which depends on preload, afterload, and contractility)</description></item><item><title>TaitaNo5</title><link>https://htlin222.github.io/garden/TaitaNo5/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/TaitaNo5/</guid><description>TaitaNo5 鈉離子 36mEq/L 氯離子 17 mEq/L 鉀離子 18 mEq/L 鎂離子 3 mEq/L phosphate 12 mM/L acetate 28 mEq/L 10% [[glucose water osmolarity]] 滲透壓為 669 mOsm/L -&amp;gt; 都是糖水貢獻的 Acetate 28mEq/L 適用於低磷血症病人之 phosphorus 補充(非糖尿病人） 持續性下 痢、肝炎、酒精中毒 營養不良患者之高熱能及電解質補充 外科、婦產科手術 前後營養及電解質之補充(尤其是骨折病人)。 中心靜脈營養注射之基礎液。</description></item><item><title>Takayasu’s arteritis</title><link>https://htlin222.github.io/garden/Takayasus-arteritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Takayasus-arteritis/</guid><description>Takayasu’s arteritis TL;DR
Usually Asian females &amp;lt; 40 years old.
&amp;ldquo;Pulseless disease&amp;rdquo; (weak upper extremity pulses), fever, night sweats, arthritis, myalgias, skin nodules, ocular disturbances.</description></item><item><title>Targets-sepsis and shock</title><link>https://htlin222.github.io/garden/Targets-sepsis-and-shock/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Targets-sepsis-and-shock/</guid><description>Targets-sepsis and shock Lactate clearance (≥20%/2 h) as effective as ScvO2 to guide resusc. (JAMA 2010;303:739)
Targeting capillary refill time ≤3 sec (check q30min) as good if not better than lactate clearance (JAMA 2019;321:654)</description></item><item><title>TAVI</title><link>https://htlin222.github.io/garden/TAVI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/TAVI/</guid><description>TAVI TAVI (transcatheter AoV implantation) (JAMA 2021;325:2480; Circ 2021;143:e72)
Valves: balloon-expandable or self-expanding. Most commonly deployed retrograde via perc. transfemoral access (best outcomes) Peri- &amp;amp; postprocedural complic.</description></item><item><title>Temporary pacing wires</title><link>https://htlin222.github.io/garden/Temporary-pacing-wires/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Temporary-pacing-wires/</guid><description>Temporary pacing wires Consider w/ bradycardia with hemodyn instability or unstable escape rhythm when perm pacer not readily available. Risks: infxn, RV perf, VT, PTX, CHB if existing LBBB.</description></item><item><title>tension pneumocephalus</title><link>https://htlin222.github.io/garden/tension-pneumocephalus/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/tension-pneumocephalus/</guid><description>tension pneumocephalus Tension pneumocephalus is a neurosurgical emergency that occurs when subdural air causes a mass-effect over the underlying brain parenchyma, often from a ball-valve mechanism causing one-way entry of air into the subdural space 1.</description></item><item><title>Tension-type headache</title><link>https://htlin222.github.io/garden/Tension-type-headache/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tension-type-headache/</guid><description>Tension-type headache bilateral, pressure-like pain of mild–mod intensity, not throbbing or aggravated by physical activity. A/w photophobia or phonophobia, not N/V.</description></item><item><title>terms used to describe patients with delirium</title><link>https://htlin222.github.io/garden/terms-used-to-describe-patients-with-delirium/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/terms-used-to-describe-patients-with-delirium/</guid><description>terms used to describe patients with delirium encephalopathy acute brain failure acute confusional state postoperative intensive care unit (ICU) psychosis</description></item><item><title>test</title><link>https://htlin222.github.io/garden/test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/test/</guid><description>test</description></item><item><title>test a link</title><link>https://htlin222.github.io/garden/test-a-link/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/test-a-link/</guid><description>test a link wow</description></item><item><title>test pandoc</title><link>https://htlin222.github.io/garden/demo/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/demo/</guid><description>test pandoc [@alavi2021american] Output [@2022evolution]</description></item><item><title>Test results noninvasive evaluation of CAD</title><link>https://htlin222.github.io/garden/noninvasive-evaluation-of-CAD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/noninvasive-evaluation-of-CAD/</guid><description>[[Stress testing]] (J Nucl Cardiol 2016;23:606; EHJ 2020;41:407) [[Exercise-tolerance-test]] (w/ ECG alone) [[Pharmacologic-stress-test]] (nb, requires imaging because ECG not interpretable) [[Imaging-for-stress-test]] [[Test-results-noninvasive evaluation of CAD]] High-risk test results (PPV ~50% for LM or 3VD, ∴ consider coronary angio) ECG: ST ↓ ≥2 mm or ≥1 mm in stage 1 or in ≥5 leads or ≥5 min in recovery; ST ↑; VT Physiologic: ↓ or fail to ↑ BP, &amp;lt;4 METS, angina during exercise, Duke score ≤–11; ↓ EF Radionuclide: ≥1 lg or ≥2 mod.</description></item><item><title>Test-results-noninvasive evaluation of CAD</title><link>https://htlin222.github.io/garden/Test-results-noninvasive-evaluation-of-CAD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Test-results-noninvasive-evaluation-of-CAD/</guid><description>Test-results-noninvasive evaluation of CAD HR (must achieve ≥85% of max pred HR [220-age] for exer. test to be dx), BP response, peak double product (HR × BP; nl &amp;gt;20k), HR recovery (HRpeak – HR1 min later; nl &amp;gt;12)</description></item><item><title>test1</title><link>https://htlin222.github.io/garden/test1/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/test1/</guid><description>test1 blbalblalballkja::short</description></item><item><title>test2</title><link>https://htlin222.github.io/garden/test2/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/test2/</guid><description>idea about how to treat cancer
There is no one-size-fits-all answer to this question, as the best way to treat cancer depends on the specific type and stage of cancer.</description></item><item><title>test202207</title><link>https://htlin222.github.io/garden/test202207/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/test202207/</guid><description>Test</description></item><item><title>testing</title><link>https://htlin222.github.io/garden/testing/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/testing/</guid><description> q1 answer q2 answer lsit list*</description></item><item><title>testing 1</title><link>https://htlin222.github.io/garden/testing-1/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/testing-1/</guid><description>testing</description></item><item><title>Tests of hepatic function</title><link>https://htlin222.github.io/garden/Tests-of-hepatic-function/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tests-of-hepatic-function/</guid><description>Tests of hepatic function Albumin: marker for liver protein synthesis, can help differentiate acute vs. chronic liver failure, may be normal in acute hepatocellular injury (t1/2 ~15–18 d)</description></item><item><title>Tests of hepatocellular injury or cholestasis</title><link>https://htlin222.github.io/garden/Tests-of-hepatocellular-injury-or-cholestasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tests-of-hepatocellular-injury-or-cholestasis/</guid><description>Tests of hepatocellular injury or cholestasis (J Clin Transl Hepatol 2017;5:394)
Aminotransferases (AST, ALT): intracellular enzymes released 2° necrosis/inflammation ALT more specific for liver than is AST (heart, skeletal muscle, kidney, brain, RBC/WBC)</description></item><item><title>Thalassemias</title><link>https://htlin222.github.io/garden/Thalassemias/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thalassemias/</guid><description>Thalassemias (Lancet 2018;391:155)
↓ synthesis of α- or β-globin chains of Hb → ≠ subunits → destruction of RBCs and erythroid precursors; ∴ anemia from hemolysis and ineffective erythropoiesis</description></item><item><title>The Confusion Assessment Method</title><link>https://htlin222.github.io/garden/The-Confusion-Assessment-Method/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/The-Confusion-Assessment-Method/</guid><description>The Confusion Assessment Method (CAM) Diagnostic Algorithm
The diagnosis of delirium requires the presence of
features 1 and 2 and either feature 3 or 4.</description></item><item><title>The Effect of Advances in Lung-Cancer Treatment on Population Mortality</title><link>https://htlin222.github.io/garden/The-Effect-of-Advances-in-Lung-Cancer-Treatment-on-Population-Mortality/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/The-Effect-of-Advances-in-Lung-Cancer-Treatment-on-Population-Mortality/</guid><description>The Effect of Advances in Lung-Cancer Treatment on Population Mortality NSCLC的正常性比該亞型的發生率更快，並且這種降低與隨著時間的流逝的生存率顯著提高，這與靶向治療的批准時間相對應。 在男性中，從2013年到2016年，NSCLC的發病率死亡率每年下降6.3％，而從2008年到2016年，發病率每年降低3.1％。 相應的肺癌特異性生存率從2001年診斷為NSCLC的男性的26％提高到2001年的26％。 在2014年被診斷出的人中，有35％的人在所有種族和種族中都發現了這種生存的改善。 在NSCLC女性中發現了類似的模式。 相比之下，SCLC的死亡率幾乎由於發病率下降而下降，生存率沒有提高。 該結果與我們檢查的時間範圍中SCLC的治療進展有限相關。</description></item><item><title>Therapeutic apheresis</title><link>https://htlin222.github.io/garden/Therapeutic-apheresis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Therapeutic-apheresis/</guid><description>Therapeutic apheresis Removes plasma large molec wt subst. (eg, cryoglobulinemia, Goodpasture’s, Guillain-Barré, hyperviscosity syndrome), or cells (eg, leukemia w/ hyperleukocytosis, sx thrombocytosis) from plasma.</description></item><item><title>thereis</title><link>https://htlin222.github.io/garden/thereis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/thereis/</guid><description>thereis 來自: [[emergency medicine]]</description></item><item><title>Thiazide diuretics</title><link>https://htlin222.github.io/garden/Thiazide-diuretics-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thiazide-diuretics-/</guid><description>Thiazide diuretics (JASN 2017;28:3414)
Drugs: hydrochlorothiazide (HCTZ), chlorothiazide (Diuril), metolazone (Zaroxolyn)
Mech: inhib Na-Cl cotransporter in the distal convoluted tubule (DCT); 5% Na reabsorp</description></item><item><title>this is a book</title><link>https://htlin222.github.io/garden/this-is-a-book/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/this-is-a-book/</guid><description/></item><item><title>This is the title of a note</title><link>https://htlin222.github.io/garden/This-is-the-title-of-a-note/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/This-is-the-title-of-a-note/</guid><description>Welcome to Notational Velocity!
This is the body of a note. Your notes can be as long or as short as you want, and you can embolden, italicize, or strike them.</description></item><item><title>Thoracentesis</title><link>https://htlin222.github.io/garden/Thoracentesis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thoracentesis/</guid><description>Thoracentesis (ideally U/S guided) (NEJM 2006;355:e16) [[indications of thoracentesis]]
[[Diagnostic studies of thoracentesis]]
Complications: PTX (5–10%), hemothorax (~1%), re-expansion pulm edema (if &amp;gt;1.</description></item><item><title>three-component friction rub</title><link>https://htlin222.github.io/garden/three-component-friction-rub/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/three-component-friction-rub/</guid><description>three-component friction rub ✨ 學習重點 🦎 (1) 一種發生在收縮期的任何地方，儘管最常見於收縮中期（因此對應於心室收縮）； (2) 兩個發生在舒張早期和晚期（因此分別對應於早期心室充盈和心房收縮）。</description></item><item><title>thromboangiitis obliterans</title><link>https://htlin222.github.io/garden/thromboangiitis-obliterans/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/thromboangiitis-obliterans/</guid><description>thromboangiitis obliterans Buerger disease Heavy tobacco smoking history, males &amp;lt; 40 years old. Intermittent claudication. May lead to gangrene, autoamputation of digits, superficial nodular phlebitis.</description></item><item><title>Thrombocytopenia and Risk of Bleeding</title><link>https://htlin222.github.io/garden/Thrombocytopenia-and-Risk-of-Bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thrombocytopenia-and-Risk-of-Bleeding/</guid><description>Thrombocytopenia and Risk of Bleeding 50,000–100,000 Risk with major trauma; can proceed with general surgery
&amp;lt;50,000 Risk with minor trauma or surgery</description></item><item><title>Thromboprophylaxis</title><link>https://htlin222.github.io/garden/Thromboprophylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thromboprophylaxis/</guid><description>Thromboprophylaxis Blood Adv 2018;2:3198
Low-risk med; same-day surg &amp;amp; &amp;lt;40 y Early, aggressive ambulation ± mechanical
Moderate-risk (hosp., ≥1 risk factor) or high-risk medical (hosp.</description></item><item><title>Thrombotic microangiopathies</title><link>https://htlin222.github.io/garden/Thrombotic-microangiopathies/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thrombotic-microangiopathies/</guid><description>Thrombotic microangiopathies (TMA; NEJM 2014;371:654; Lancet 2017;390:681)
Endothelial injury → plt aggreg. &amp;amp; microvasc. thrombosis → ↓ plt &amp;amp; RBC hemolysis (MAHA)</description></item><item><title>Thrombotic thrombocytopenic purpura TTP</title><link>https://htlin222.github.io/garden/Thrombotic-thrombocytopenic-purpura-TTP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thrombotic-thrombocytopenic-purpura-TTP/</guid><description>Thrombotic thrombocytopenic purpura (TTP) Pathophys: ↓↓ ADAMTS13 protease activity (hereditary [Upshaw Schulman Syn.] or autoAb) → vWF multimers persist on endothelial surface → plt adhesion/aggregation → thrombosis</description></item><item><title>thyroid cancer</title><link>https://htlin222.github.io/garden/thyroid-cancer/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/thyroid-cancer/</guid><description>thyroid cancer [[Thyroid nodules]] (JAMA 2018;319:914) [[Papillary thyroid cancer]] [[Follicular thyroid cancer]] [[Anaplastic thyroid cancer]] (Endo Metab Clin NA 2019;48:269) [[Medullary thyroid cancer]] (Endo Metab Clin NA 2019;48:285)</description></item><item><title>thyroid disorders</title><link>https://htlin222.github.io/garden/thyroid-disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/thyroid-disorders/</guid><description>thyroid disorders [[Common Diagnostic Tests in Thyroid Disorders]]
[[Specialized Diagnostic Tests in Thyroid Disorders]]
[[hypothyroidism]]</description></item><item><title>Thyroid nodules</title><link>https://htlin222.github.io/garden/Thyroid-nodules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thyroid-nodules/</guid><description>Thyroid nodules Prevalence 5–10% (50–60% if screen with U/S), ♀ &amp;gt; ♂, ~7–15% malignant Screening U/S recommended if FHx of MEN2 or medullary thyroid cancer, personal h/o neck XRT, palpable nodules or multinodular goiter Features a/w ↑ risk of malig: age &amp;lt;30 y, h/o neck XRT, family history of thyroid cancer U/S features a/w benign dx: cystic nodules, “spongiform” sonographic pattern Worrisome findings: hypoechoic, solid, irregular borders, microCa2+, height&amp;gt;width, &amp;gt;20 mm Indications for FNA: &amp;gt;10-mm nodule w/ suspicious features</description></item><item><title>Thyroid storm</title><link>https://htlin222.github.io/garden/Thyroid-storm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thyroid-storm/</guid><description>Thyroid storm [[Presentation of Thyroid storm]]: Diagnosis: no universally accepted criteria. Biochemical hyperthyroidism + severe sx, consider additional dx that may explain/contribute to sx.</description></item><item><title>Thyroiditis</title><link>https://htlin222.github.io/garden/Thyroiditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Thyroiditis/</guid><description>Thyroiditis Acute: bacterial infection (very rare in U.S. except postsurgical), typically Staph/Strep spp. Subacute: transient thyrotoxicosis → transient hypothyroidism → normal thyroid fxn</description></item><item><title>Ticagrelor</title><link>https://htlin222.github.io/garden/Ticagrelor/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ticagrelor/</guid><description>Ticagrelor 180 mg × 1 → 90 mg bid Reversible, but wait 3–5 d prior to surg. Antidote being developed (NEJM 2019;380:1825).</description></item><item><title>tick-borne diseases</title><link>https://htlin222.github.io/garden/tick-borne-diseases/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/tick-borne-diseases/</guid><description>tick-borne diseases</description></item><item><title>timeV</title><link>https://htlin222.github.io/garden/timeV/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/timeV/</guid><description>#![[Title 2 test]] #![[title 2 test test]]</description></item><item><title>TIMI Risk Score</title><link>https://htlin222.github.io/garden/TIMI-Risk-Score/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/TIMI-Risk-Score/</guid><description>TIMI Risk Score TIMI Score
Calculation of Risk Score Historical Age ≥65 y ≥3 Risk factors for CAD Known CAD (stenosis ≥50%) ASA use in past 7 d Presentation Severe angina (≥2 episodes w/in 24 h) ST deviation ≥0.</description></item><item><title>title</title><link>https://htlin222.github.io/garden/Untitled-2/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Untitled-2/</guid><description>title question abcde answer abcde</description></item><item><title>Title 2 test</title><link>https://htlin222.github.io/garden/Title-2-test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Title-2-test/</guid><description>Title 2 test some content</description></item><item><title>title 2 test test</title><link>https://htlin222.github.io/garden/title-2-test-test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/title-2-test-test/</guid><description>title 2 test test another conten #🌲</description></item><item><title>title1</title><link>https://htlin222.github.io/garden/duty/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/duty/</guid><description>title1 title2</description></item><item><title>Topiramate</title><link>https://htlin222.github.io/garden/Topiramate/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Topiramate/</guid><description>Topiramate 作用 用於成人及兩歲以上兒童局部癲癇或併有 [[Lennox Gastaut Syndrome]] 症候群之癲癇及原發性全身性強直陣攣癲癇的輔助治療，用於Partial Onset Seizure病患之單一藥物治療、預防偏頭痛。
注意事項 不可擅自停藥，突然停藥可能會導致反彈性癲癇之發作。 中、重度腎功能不全的病人需要降低劑量。肝功能不全的病人應小心使用。 易罹患腎結石的病人服用此藥可能會增加腎結石形成的危險性，建議給與足量的水份以降低此危險性。</description></item><item><title>toxicology</title><link>https://htlin222.github.io/garden/toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/toxicology/</guid><description>toxicology [[Acetaminophen-toxicology]] [[Salicylates-toxicology]] [[Opioids-toxicology]] [[Benzodiazepines-toxicology]] [[Calcium channel blockers-toxicology]] [[Beta blockers-toxicology]] [[Digoxin-toxicology]] [[Tricyclic antidepressants-toxicology]] [[Lithium-toxicology]] [[Ethylene glycol-toxicology]] [[Methanol-toxicology]] [[Isopropanol-toxicology]] [[Carbon monoxide-toxicology]] [[Organopho- sphate-toxicology]] [[Cyanide-toxicology]]</description></item><item><title>Transcellular shifts</title><link>https://htlin222.github.io/garden/Transcellular-shifts/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transcellular-shifts/</guid><description>Transcellular shifts Alkalemia, insulin, catecholamines, β2-agonists, hypothermia, hypokalemic/thyrotoxic periodic paralysis, acute ↑ hematopoiesis (megaloblastic anemia Rx w/ B12, AML crisis), chloroquine; overdose: Ba/Cs, antipsychotics (risperidone, quetiapine), theophylline</description></item><item><title>Transcellular shifts-hyperkalemia</title><link>https://htlin222.github.io/garden/Transcellular-shifts-hyperkalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transcellular-shifts-hyperkalemia/</guid><description>Transcellular shifts-hyperkalemia (BMJ 2009;339:1019)
Acidemia, ↓ insulin (DM), cell lysis (tumor, rhabdo, ischemic bowel, hemolysis, transfusions, resorbing hematomas, hyperthermia, rewarming), hyperkalemic periodic paralysis, ↑ osmolality.</description></item><item><title>Transfusion Complications</title><link>https://htlin222.github.io/garden/Transfusion-Complications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transfusion-Complications/</guid><description>Transfusion Complications Noninfectious Risk (per unit) Infectious Risk (per unit) Febrile 1:100 CMV Common Allergic 1:100 Hepatitis B 1:220,000 Delayed hemolytic 1:50–75,000 Hepatitis C 1:1,600,000 Acute hemolytic 1:200,000 HIV 1:1,800,000 Febr.</description></item><item><title>Transfusion reactions</title><link>https://htlin222.github.io/garden/Transfusion-reactions/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transfusion-reactions/</guid><description>Transfusion reactions Reason why blood products (unless massive txfusion) run 1 at a time. For all rxns (except minor allergic): stop txfusion; send remaining blood product + fresh blood draw to blood bank.</description></item><item><title>transfusion therapy</title><link>https://htlin222.github.io/garden/transfusion-therapy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/transfusion-therapy/</guid><description>transfusion therapy [[Blood Products and Indications ]] [[Transfusion Complications]] [[Transfusion reactions]]</description></item><item><title>Transfusion-associated circulatory overload</title><link>https://htlin222.github.io/garden/Transfusion-associated-circulatory-overload/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transfusion-associated-circulatory-overload/</guid><description>Transfusion-associated circulatory overload : ↑ volume → pulm. edema, ↑ BP. Rx: slow transfusion rate, diuretics, O2, ± nitrates, ± positive pressure ventilation.</description></item><item><title>transfusion-related acute lung injury</title><link>https://htlin222.github.io/garden/transfusion-related-acute-lung-injury/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/transfusion-related-acute-lung-injury/</guid><description>transfusion-related acute lung injury : non-cardiogenic pulm. edema due to donor allo-Abs (from multiparous ♀ plasma) binding recipient WBCs, which then aggregate in pulmonary vasculature and release mediators causing ↑ capillary permeability.</description></item><item><title>Transjugular intrahepatic portosystemic shunt TIPS</title><link>https://htlin222.github.io/garden/Transjugular-intrahepatic-portosystemic-shunt-TIPS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transjugular-intrahepatic-portosystemic-shunt-TIPS/</guid><description>Transjugular intrahepatic portosystemic shunt (TIPS) (Gastro 2017;152:157) ↓ ascites in 75%; ↑ CrCl, ↑ enceph, survival benefit over LVP remains controversial Contraindic: grade II enceph, CHF or pulm HTN, active infxn or biliary obstruction Complications: bleeding, fistula; stent thrombosis (1-y patency w/ coated stents ~80%); infxn (“endotipsitis”); new or ↑ enceph in 20–30% (Am J Gastro 2016;111:523), hemolysis Consider for liver transplant if above fail</description></item><item><title>transthoracic echo vs transesophageal echo in-Diagnosis-bacterial endocarditis</title><link>https://htlin222.github.io/garden/transthoracic-echo-vs-transesophageal-echo-in-Diagnosis-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/transthoracic-echo-vs-transesophageal-echo-in-Diagnosis-bacterial-endocarditis/</guid><description>transthoracic echo vs transesophageal echo in-Diagnosis-bacterial endocarditis NVE PVE Abscess Transthoracic (TTE) 39–58% 33% 18–63% Transesophageal (TEE) &amp;gt;90% 86% 76–100% (Mayo Clin Proc 2014;89:799; Circ 2015;132:1435; Eur Radiol 2015; 25:2125; J Am Soc Echo 2016;29:315)</description></item><item><title>Transudate vs exudate</title><link>https://htlin222.github.io/garden/Transudate-vs-exudate/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transudate-vs-exudate/</guid><description>Transudate vs exudate (JAMA 2014;311:2422)
Light’s criteria 基本上都是跟分子都是pleural，分母都是血 蛋大於五成、LDH大於六成或2/3
protein/serum protein ratio greater than 0.5 lactate dehydrogenase (LDH)/serum LDH ratio greater than 0.</description></item><item><title>Transudates</title><link>https://htlin222.github.io/garden/Transudates/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Transudates/</guid><description>Transudates Congestive heart failure (40%): 80% bilateral, ± cardiomegaly on CXR occasionally exudative (especially after aggressive diuresis or if chronic) Constrictive pericarditis (knock on exam, calcification or thickening on imaging) Cirrhosis (“hepatic hydrothorax”): diaphragmatic pores allow passage of ascitic fluid often right-sided (²∕³) &amp;amp; massive (even witho marked ascites) Nephrotic syndrome: usually small, bilateral, asymptomatic (r/o PE b/c hypercoag) Other: PE (usually exudate), malignancy (lymphatic obstruction), myxedema, CAPD</description></item><item><title>Treatment acute diarrhea</title><link>https://htlin222.github.io/garden/Treatment-acute-diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-acute-diarrhea/</guid><description>Treatment acute diarrhea (Am J Gastro 2016;111:602; Clin Infect Dis 2017;65:e45)
If no WS, nl PO intake → supportive: hydrate, loperamide, bismuth subsalicylate (Ø antichol)</description></item><item><title>Treatment and prognosis-Aplastic anemia</title><link>https://htlin222.github.io/garden/Treatment-and-prognosis-Aplastic-anemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-and-prognosis-Aplastic-anemia/</guid><description>Treatment and prognosis-Aplastic anemia Immunosuppression (CsA/tacrolimus, ATG): 70–80% respond, with 80–90% 5-y survival in responders (96% vs. 76% w/ horse vs.</description></item><item><title>Treatment for acute HBV</title><link>https://htlin222.github.io/garden/Treatment-for-acute-HBV/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-for-acute-HBV/</guid><description>Treatment for acute HBV [[When to treat chronic HBV with anti-virals]]
[[Entecavir or tenofovir]]
[[hepatitis B virus Rx duration]]</description></item><item><title>Treatment gastroesophageal reflux disease</title><link>https://htlin222.github.io/garden/Treatment-gastroesophageal-reflux-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-gastroesophageal-reflux-disease-/</guid><description>Treatment gastroesophageal reflux disease (World J Gastrointest Endosc 2018;10:175; Am J Gastro 2022;117:27)
Lifestyle: avoid precipitants, lose weight, no eating 2 hrs before bed, exercise, Ø tobacco</description></item><item><title>treatment gastroesophageal reflux disease</title><link>https://htlin222.github.io/garden/Treatment-gastroesophageal-reflux-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-gastroesophageal-reflux-disease/</guid><description>treatment gastroesophageal reflux disease (World J Gastrointest Endosc 2018;10:175; Am J Gastro 2022;117:27)
Lifestyle: avoid precipitants, lose weight, no eating 2 hrs before bed, exercise, Ø tobacco Medical: start low-dose PPI, uptitrate up to 40 mg bid; H2 blockers for intermittent sx Refractory (max dose ≥8 wks): confirm w/ pH testing on or off PPI, consider hernia repair If acidic or sx correlate w/ reflux episodes: surgical fundoplication (emerging Rx: LES sphincter augmentation w/ radiofrequency, implantable magnetic or electrical devices) If nl pH or no sx correlation = “fxnal dyspepsia” (Gastro 2020;158:2286); Rx w/ TCA, SSRI</description></item><item><title>Treatment of active tuberculosis</title><link>https://htlin222.github.io/garden/Treatment-of-active-tuberculosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-active-tuberculosis/</guid><description>Treatment of active tuberculosis (NEJM 2015;373:2149; Lancet 2016;387:1211)
Prior to treatment, consult ID, check LFTs, Cr, HIV &amp;amp; hepatitis A/B/C screen, DM screen, pregnancy screen, vision testing for acuity and color, EtOH use history Treatment requires several drugs to prevent resistance (see below) Suspect MDR TB if prior TB Rx (esp.</description></item><item><title>Treatment of acute advanced heart failure</title><link>https://htlin222.github.io/garden/Treatment-of-acute-advanced-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-acute-advanced-heart-failure/</guid><description>Treatment of acute advanced heart failure (Circ 2013;128:e240)
Consider PAC if not resp to Rx, unsure re: vol status, HoTN, hypoperfusion, need inotropes</description></item><item><title>treatment of acute decompensating heart failure</title><link>https://htlin222.github.io/garden/treatment-of-acute-decompensating-heart-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/treatment-of-acute-decompensating-heart-failure/</guid><description>treatment of acute decompensating heart failure (NEJM 2017;377:1964)
Assess congestion &amp;amp; adequacy of perfusion
For congestion: “LMNOP” Lasix IV; 1–2.</description></item><item><title>Treatment of Alchololic-associated hepatitis</title><link>https://htlin222.github.io/garden/Treatment-of-Alchololic-associated-hepatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Alchololic-associated-hepatitis/</guid><description>Treatment of Alchololic-associated hepatitis consider if MDF ≥32, MELD &amp;gt;18, or presence of encephalopathy
Glucocorticoids (eg, methylprednisolone 32 mg/d or prednisolone 40 mg/d × 4 wk → 4–6 wk taper) may ↓ 1-mo but not 6-mo mortality, a/w ↑ infection (NEJM 2015;372:1619, CD001511)</description></item><item><title>Treatment of Antiphospholipid syndrome</title><link>https://htlin222.github.io/garden/Treatment-of-Antiphospholipid-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Antiphospholipid-syndrome/</guid><description>Treatment of Antiphospholipid syndrome UFH/LMWH → warfarin (lifelong for most Pts)
Rivaroxaban inferior to warfarin in triple positive (⊕ ACL, LA, &amp;amp; β2-GP) (Blood 2018;132:1365)</description></item><item><title>Treatment of asymptomatic 1° HPT</title><link>https://htlin222.github.io/garden/Treatment-of-asymptomatic-1-HPT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-asymptomatic-1-HPT/</guid><description>Treatment of asymptomatic 1° HPT Surgery if: age &amp;lt;50 y; serum Ca &amp;gt;1 mg/dL &amp;gt;ULN; CrCl &amp;lt;60 mL/min, DEXA T score &amp;lt;–2.</description></item><item><title>Treatment of Behçet’s syndrome</title><link>https://htlin222.github.io/garden/Treatment-of-Beh%C3%A7ets-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Beh%C3%A7ets-syndrome/</guid><description>Treatment of Behçet’s syndrome Mucocutaneous: Mild: topical steroids, colchicine (esp. for erythema nodosum), dapsone, apremilast (PDE-4 inhib) for oral ulcers and ?</description></item><item><title>Treatment of Chronic HF with Reduced EF</title><link>https://htlin222.github.io/garden/Treatment-of-Chronic-HF-with-Reduced-EF/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Chronic-HF-with-Reduced-EF/</guid><description>Treatment of Chronic HF with Reduced EF (Circ 2017;136:e137; JACC 2021;77:772)
Diuretics | Loop ± thiazides diuretics (sx relief; no mortality benefit) [[RASi ACEI ARB]] [[β-blocker]] [[Aldosterone-antagonists]] [[SGLT2i]] [[Hydralazine&amp;mdash;nitrates]] [[Ivabradine]] (If blocker w/o ⊖ ino) [[Digoxin]] [[Vericiguat]] [[Cardiac-resynch-therapy]] (CRT, qv) [[ICD]] (see “Cardiac Rhythm Mgmt Devices”) [[Iron-supplementation]] [[Anticoagulation-Treatment of Chronic HF with Reduced EF]] Heart rhythm If AF &amp;amp; NYHA II–IV w/ EF &amp;lt;35%, catheter ablation ↓ D/HF hosp vs.</description></item><item><title>Treatment of Constipation</title><link>https://htlin222.github.io/garden/Treatment-of-Constipation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Constipation/</guid><description>Treatment of Constipation 1st line ↑ fluid, fiber, exercise; emollient laxative (docusate) to soften stool.
2nd line: Bulk laxatives (psyllium, methylcellulose) to ↑ colonic residue, ↑ peristalsis.</description></item><item><title>Treatment of Cryoglobulinemic vasculitis</title><link>https://htlin222.github.io/garden/Treatment-of-Cryoglobulinemic-vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Cryoglobulinemic-vasculitis/</guid><description>Treatment of Cryoglobulinemic vasculitis (Blood 2017;129:289; J Inflamm Res 2017;10:49): Rx underlying disorder. Heme malig → chemoradiation; HCV → antivirals; CTD → DMARD/steroids ± RTX.</description></item><item><title>Treatment of Cushing’s syndrome</title><link>https://htlin222.github.io/garden/Treatment-of-Cushings-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Cushings-syndrome/</guid><description>Treatment of Cushing’s syndrome (JCEM 2015;100:2807. J Intern Med 2019;286:526)
Surgical: * resection of pituitary adenoma, adrenal tumor or ectopic ACTH-secreting tumor, or bilateral surgical adrenalectomy if unable to control source of ACTH Medical: [[ketoconazole]] [[metyrapone]] [[osilodrostat]] [[cabergoline]] [[pasireotide]] mitotane to ↓ cortisol, and/or mifepristone to block cortisol action at glucocorticoid receptor frequently used as bridge to surgery or when surgery contraindicated Radiation: can do pituitary XRT, but not effective immediately (takes 6 mo to 2 y) Glucocorticoid replacement therapy × 6–36 mo after TSS (lifelong glucocorticoid + mineralocorticoid replacement if medical or surgical adrenalectomy)</description></item><item><title>Treatment of DKA</title><link>https://htlin222.github.io/garden/Treatment-of-DKA/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-DKA/</guid><description>Treatment of DKA (BMJ 2019;365:1114)
R/o possible precipitants Infection, intra-abdominal process, MI, etc. (see above) Aggressive hydration 1L NS then ~250 cc/hr, tailor to dehydration &amp;amp; CV status Insulin 0.</description></item><item><title>Treatment of Granulomatosis with polyangiitis</title><link>https://htlin222.github.io/garden/Treatment-of-Granulomatosis-with-polyangiitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Granulomatosis-with-polyangiitis/</guid><description>Treatment of Granulomatosis with polyangiitis assess severity w/ BVAS/GPA score (Arth Rheum Dis 2009;68:1827) same as [[Microscopic polyangiitis.md]]
Mild disease (no end-organ dysfxn; BVAS 0–3): MTX + steroids (Arth Rheum 2012;64:3472)</description></item><item><title>Treatment of Heart failure with preserved EF</title><link>https://htlin222.github.io/garden/Treatment-of-Heart-failure-with-preserved-EF/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Heart-failure-with-preserved-EF/</guid><description>Treatment of Heart failure with preserved EF diuresis, Rx HTN, tachycardia, and ischemia
SGLT2i ↓ CV death or HF hosp (NEJM 2021;385:1451; DELIVER)</description></item><item><title>Treatment of Hemochromatosis</title><link>https://htlin222.github.io/garden/Treatment-of-Hemochromatosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Hemochromatosis/</guid><description>Treatment of Hemochromatosis phlebotomy (250 mL = 1 unit, ~250 mg of Fe) qwk until Fe sat &amp;lt;50% &amp;amp; ferritin 50–100 µg/L, then q3–4mo; PPI ↓ intestinal Fe absorption &amp;amp; may ↓ need for phlebotomy; avoid vit C &amp;amp; uncooked seafood; deferoxamine if phleb.</description></item><item><title>Treatment of HIT</title><link>https://htlin222.github.io/garden/Treatment-of-HIT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-HIT/</guid><description>Treatment of HIT (NEJM 2015;373:252; Blood Adv 2018;2:3360)
Discontinue heparin (incl. flushes, LMWH Ppx, heparin lines). Avoid plts (anecdotal link w/ thrombosis); if given warfarin, give vit K to reverse, prevent warfarin skin necrosis.</description></item><item><title>Treatment of Hyperkalemia-hyperkalemia</title><link>https://htlin222.github.io/garden/Treatment-of-Hyperkalemia-hyperkalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Hyperkalemia-hyperkalemia/</guid><description>Treatment of Hyperkalemia-hyperkalemia [[Ca gluconate Ca chloride]] 1–2 amps IV onset &amp;lt;3 min with Transient effect (30–60 min) Stabilizes cell membrane CaCl contains more calcium and is typically reserved for codes (↑ risk of tissue necrosis) or via central line</description></item><item><title>Treatment of hypertrophic cardiomyopathy</title><link>https://htlin222.github.io/garden/Treatment-of-hypertrophic-cardiomyopathy/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-hypertrophic-cardiomyopathy/</guid><description>Treatment of hypertrophic cardiomyopathy (Circ 2020;142:e558; Lancet 2021;398:2102; JACC 2022;79:390)
Heart failure ⊖ inotropes/chronotropes: β-blockers (JACC 2021;78:2505), CCB (verapamil), disopyramide</description></item><item><title>Treatment of Hypervolemic hyponatremia</title><link>https://htlin222.github.io/garden/Treatment-of-Hypervolemic-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Hypervolemic-hyponatremia/</guid><description>Treatment of Hypervolemic hyponatremia free water restrict (1st line), diurese w/ loop diuretics (avoid thiazides) &amp;amp; ↑ EAV (vasodilators to ↑ CO in CHF, colloid infusion in cirrhosis)</description></item><item><title>Treatment of Hypovolemic hyponatremia</title><link>https://htlin222.github.io/garden/Treatment-of-Hypovolemic-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Hypovolemic-hyponatremia/</guid><description>Treatment of Hypovolemic hyponatremia volume repletion with isotonic 0.9% saline at a slow rate. Once volume replete → stimulus for ADH removed (w/ very short ADH t½) → kidneys excrete free H2O → serum Na will correct rapidly (D5W ± dDAVP if overcorrection)</description></item><item><title>Treatment of latent TB</title><link>https://htlin222.github.io/garden/Treatment-of-latent-TB/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-latent-TB/</guid><description>Treatment of latent TB If screening test ⊕ and no risk factors, confirm prior to treatment; if ⊕ w/ risk factors, proceed to treatment (CID 2017;64:11).</description></item><item><title>Treatment of LDL-C</title><link>https://htlin222.github.io/garden/Treatment-of-LDL-C/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-LDL-C/</guid><description>Treatment of LDL-C Statins: every 1 mmol (39 mg/dL) ↓ LDL-C → 22% ↓ major vascular events (CV death, MI, stroke, revasc) in individuals w/ &amp;amp; w/o CAD (Lancet 2010;376:1670) Ezetimibe: ↓ major vascular events incl MI &amp;amp; stroke when added to statin post-ACS, w/ magnitude of benefit consistent w/ LDL-statin relationship (IMPROVE-IT, NEJM 2015;372:2387) PCSK9 inhibitors: ~60% ↓ LDL-C on top of statin, as monoRx, and in FH (EHJ 2014;35:2249); ↓ CV outcomes (NEJM 2017;376:1713 &amp;amp; 2018;379:2097) In homozygous FH: apheresis; evinacumab (ANGPTL3 inhib) ↓ LDL-C by ~50% (NEJM 2020;383:711)</description></item><item><title>Treatment of Migraine</title><link>https://htlin222.github.io/garden/Treatment-of-Migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Migraine/</guid><description>Treatment of Migraine Abortive Rx: 5-HT1 agonists (triptans) effective if given early in migraine attack; Abortive: The goal of abortive treatment is to stop a migraine once it starts.</description></item><item><title>Treatment of other lipid fractions</title><link>https://htlin222.github.io/garden/Treatment-of-other-lipid-fractions/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-other-lipid-fractions/</guid><description>Treatment of other lipid fractions HDL-C: low levels a/w ↑ risk of MI, but no clinical benefit shown by raising Triglycerides: reasonable to treat levels &amp;gt;500 mg/dL w/ fibrates or Ω-3 FA to ↓ risk of pancreatitis.</description></item><item><title>Treatment of overt hypothyroidism</title><link>https://htlin222.github.io/garden/Treatment-of-overt-hypothyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-overt-hypothyroidism/</guid><description>Treatment of overt hypothyroidism Levothyroxine (1.5–1.7 µg/kg/d), re ✓ TSH q5–6wk, titrate q8-12 wks if TSH not in range Lower starting dose (0.</description></item><item><title>treatment of peptic ulcer disease</title><link>https://htlin222.github.io/garden/treatment-of-peptic-ulcer-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/treatment-of-peptic-ulcer-disease/</guid><description>treatment of peptic ulcer disease (Lancet 2016;388:2355; Gastro 2016;151:51; Gut 2017;66:6; AJG 2017;112:212)
If H. pylori ⊕ → eradicate (“test and treat”); if ⊖ → gastric acid suppression w/ PPI 1st line: Quad.</description></item><item><title>Treatment of pericarditis</title><link>https://htlin222.github.io/garden/Treatment-of-pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-pericarditis/</guid><description>Treatment of pericarditis High-dose NSAID (eg, ibuprofen 600–800 mg tid) or ASA (eg, 650–1000 mg tid) × 7–14 d then taper over wks; ASA preferred over NSAID in acute MI; consider PPI to ↓ risk of GIB Add colchicine 0.</description></item><item><title>Treatment of Primary ITP in Adults</title><link>https://htlin222.github.io/garden/Treatment-of-Primary-ITP-in-Adults/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Primary-ITP-in-Adults/</guid><description>Treatment of Primary ITP in Adults [[First-line or upfront therapy for idiopathic thrombocytopenic purpura]] [[Second-line or maintainence therapy for idiopathic thrombocytopenic purpura]] [[Chronic or refractory for idiopathic thrombocytopenic purpura]] [[Bleeding Treatment for idiopathic thrombocytopenic purpura]]</description></item><item><title>Treatment of Prinzmetals variant angina</title><link>https://htlin222.github.io/garden/Treatment-of-Prinzmetals-variant-angina/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Prinzmetals-variant-angina/</guid><description>Treatment of Prinzmetals variant angina high-dose CCB &amp;amp; standing nitrates (+SL prn), ? α-blockers/statins; d/c smoking; avoid high-dose ASA (can inhibit prostacyclin and worsen spasm), nonselect βB, triptans</description></item><item><title>Treatment of SIADH</title><link>https://htlin222.github.io/garden/Treatment-of-SIADH/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-SIADH/</guid><description>Treatment of SIADH (NEJM 2007;356:2064; AJKD 2020;76:203): fluid restrict + treat underlying cause
hypertonic saline (± loop diuretic; AJKD 2020;76:203) if sx or Na fails to ↑ w/ fluid restriction Intermittent bolus of 3% saline (~2 mL/kg q6h) vs.</description></item><item><title>Treatment of SVT</title><link>https://htlin222.github.io/garden/Treatment-of-SVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-SVT/</guid><description>Treatment of SVT Rhythm Acute Treatment Long-term Treatment
Unstable Acute: Cardioversion per ACLS n/a
ST Acute: Treat underlying stressor(s) Long-term: n/a</description></item><item><title>Treatment of Thyroid storm</title><link>https://htlin222.github.io/garden/Treatment-of-Thyroid-storm/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-Thyroid-storm/</guid><description>Treatment of Thyroid storm β-blocker, PTU or methimazole, iopanoic acid or iodide (for [[Wolff-Chaikoff effect]]) &amp;gt;1 h after PTU, ± steroids (↓ T4 → T3)</description></item><item><title>Treatment of UTIs</title><link>https://htlin222.github.io/garden/Treatment-of-UTIs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-UTIs/</guid><description>Treatment of UTIs Scenario Empiric Treatment Guidelines (narrow based on UCx)
Asymptomatic bacteruria Do not treat. Exceptions: pregnant women, renal transplant, prophylaxis prior to invasive urologic procedures (CID 2019;68:1611).</description></item><item><title>Treatment peptic ulcer disease</title><link>https://htlin222.github.io/garden/Treatment-peptic-ulcer-disease-/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-peptic-ulcer-disease-/</guid><description>Treatment peptic ulcer disease (Lancet 2016;388:2355; Gastro 2016;151:51; Gut 2017;66:6; AJG 2017;112:212)
If H. pylori ⊕ → eradicate (“test and treat”); if ⊖ → gastric acid suppression w/ PPI 1st line: Quad.</description></item><item><title>Treatment prevention-herpes zoster</title><link>https://htlin222.github.io/garden/Treatment-prevention-herpes-zoster/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-prevention-herpes-zoster/</guid><description>Treatment prevention-herpes zoster Uncomplicated: acyclovir, valacyclovir, or famciclovir x 7 d; initiate w/in 72 h of onset for greatest benefit; consider after 72 h if new lesions present; minimal benefit after crusting Superimposed bacterial cellulitis is common; if suspected, treat with appropriate antibiotics Disseminated/immunosupp.</description></item><item><title>Treatment-accessory pathways wolff-parkinson-white</title><link>https://htlin222.github.io/garden/Treatment-accessory-pathways-wolff-parkinson-white/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-accessory-pathways-wolff-parkinson-white/</guid><description>Treatment-accessory pathways (wolff-parkinson-white) (Heart Rhythm 2012;9:1006, Circ 2014;130:e199 &amp;amp; 2016;133:e506)
AVRT (orthodromic): vagal, βB, CCB; care w/ adenosine (can precip AF); have defib ready AF/AFL w/ conduction down accessory pathway: need to Rx arrhythmia and ↑ pathway refractoriness.</description></item><item><title>Treatment-Acetaminophen hepatotoxicity</title><link>https://htlin222.github.io/garden/Treatment-Acetaminophen-hepatotoxicity/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Acetaminophen-hepatotoxicity/</guid><description>Treatment-Acetaminophen hepatotoxicity NG lavage, activated charcoal if w/in 4 h. Consider early transfer to transplant ctr
N-acetylcysteine: administer up to 72 h after ingestion, if time of ingestion unknown or chronic ingestion &amp;gt;4g/d; low threshold to start NAC w/ low or undetectable APAP levels</description></item><item><title>Treatment-acute aortic syndromes</title><link>https://htlin222.github.io/garden/Treatment-acute-aortic-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-acute-aortic-syndromes/</guid><description>Treatment-acute aortic syndromes (Circ 2010;121:1544; EHJ 2018;39:739; JACC 2019;74:1494 &amp;amp; 2020;76:1703)
↓ dP/dt targeting HR &amp;lt;60 &amp;amp; central BP &amp;lt;120 (or lowest that preserves perfusion; r/o pseudohypotension, eg, arm BP ↓ due to subclavian dissection; use highest BP reading) First IV βB (eg, esmolol, labetalol) to blunt reflex ↑ HR &amp;amp; inotropy in response to vasodilators; verapamil/diltiazem if βB contraindic; then ↓ SBP w/ IV vasodilators (eg, nitroprusside) If HoTN: urgent surgical consult, IVF to achieve euvolemia, pressors to keep MAP 60-65 mmHg; r/o complication (eg, tamponade, contained rupture, severe AI) Proximal: surgery considered in all acute and in chronic if c/b progression, AI or aneurysm Distal: med Rx unless complication (see below) or favorable TEVAR anatomy w/ high-risk imaging features (JACC 2019;74:1494); pre-emptive TEVAR may ↓ late complic.</description></item><item><title>Treatment-acute mesenteric ischemia</title><link>https://htlin222.github.io/garden/Treatment-acute-mesenteric-ischemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-acute-mesenteric-ischemia/</guid><description>Treatment-acute mesenteric ischemia IVF, NPO, optimize hemodynamics (minimize pressors), broad-spectrum abx, anticoagulation w/ heparin ± tPA (for occlusive disease), IV papaverine (vasodilator; for non-occlusive mesenteric ischemia)</description></item><item><title>Treatment-acute pancreatitis</title><link>https://htlin222.github.io/garden/Treatment-acute-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-acute-pancreatitis/</guid><description>Treatment-acute pancreatitis Fluid resusc.: aggressive in 1st 24 hrs, even if mild. 20 mL/kg IVB → 3 mL/kg/hr. Goal ↓ BUN &amp;amp; Hct over 12–24 h.</description></item><item><title>Treatment-acute respiratory distress syndrome</title><link>https://htlin222.github.io/garden/Treatment-acute-respiratory-distress-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-acute-respiratory-distress-syndrome/</guid><description>Treatment-acute respiratory distress syndrome [[methylprednisolone]]</description></item><item><title>Treatment-adrenal insufficiency</title><link>https://htlin222.github.io/garden/Treatment-adrenal-insufficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-adrenal-insufficiency/</guid><description>Treatment-adrenal insufficiency Acute insufficiency: volume resusc. w/ normal saline + hydrocortisone IV (see below) Chronic insufficiency: (1) prednisone ~4–5 mg PO qam or hydrocortisone 15–25 mg PO qd (2/3 a.</description></item><item><title>Treatment-anaphylaxis</title><link>https://htlin222.github.io/garden/Treatment-anaphylaxis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-anaphylaxis/</guid><description>Treatment-anaphylaxis Epi: 0.5 mg IM (0.5 mL of 1 mg/mL solution) q5–15min as needed. For those who do not respond, IV infusion starting at 0.</description></item><item><title>Treatment-Anemia of chronic inflammation</title><link>https://htlin222.github.io/garden/Treatment-Anemia-of-chronic-inflammation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Anemia-of-chronic-inflammation/</guid><description>Treatment-Anemia of chronic inflammation treat underlying disease ± iron and/or erythropoiesis-stimulating agent (ESA; eg, Epo). Iron if ferritin &amp;lt;100 or Fe/TIBC &amp;lt;20%.</description></item><item><title>Treatment-aortic aneurysms</title><link>https://htlin222.github.io/garden/Treatment-aortic-aneurysms/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-aortic-aneurysms/</guid><description>Treatment-aortic aneurysms (Circ 2010;121:e266 &amp;amp; 2016;133:680; JACC 2020;76:201; NEJM 2021;385:1690)
Goal is to prevent rupture (50% mortality prior to hospital) by modifying risk factors Risk factor modification: smoking cessation; statins to achieve LDL-C &amp;lt;70 mg/dL BP control (goal SBP 100–120): βB (↓ dP/dt) ↓ aneurysm growth; ACEI a/w ↓ rupture risk (Lancet 2006;368:659); ARB may ↓ rate of aortic root growth in Marfan (NEJM 2008;358:2787) Mod CV exercise OK, no burst activity requiring Valsalva maneuvers (eg, heavy lifting) Indications for intervention (individualized based on FHx, body size, sex, anatomy) TAA: sxs; ascending Ao ≥5.</description></item><item><title>Treatment-aortic-regurgitation</title><link>https://htlin222.github.io/garden/Treatment-aortic-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-aortic-regurgitation/</guid><description>Treatment-aortic-regurgitation Acute decompensation (consider endocarditis as possible acute precipitant): surgery usually urgently needed for acute severe AR, which is poorly tolerated by LV IV afterload reduction (nitroprusside) and inotropic support (dobutamine) ± chronotropic support (↑ HR → ↓ diastole → ↓ time for regurgitation) pure vasoconstrictors and IABP contraindicated In chronic AR, management decisions based on LV size and fxn (and before sx occur); low diastolic BP and high resting HR associated with mortality (JACC 2020;75:29) Surgery (AVR, replacement or repair if possible): Severe and sx (if equivocal, consider stress test) Asx and either EF ≤55%, LV dilation [LVESD &amp;gt;50 mm or LVESDi (indexed to BSA) ≥ 25 mm/m2 (JACC 2019;73:1741)], or undergoing cardiac surg Transcatheter AoV implantation (TAVI) being explored (JACC 2013;61:1577 &amp;amp; 2017;70:2752) Medical therapy: vasodilators (nifedipine, ACEI/ARB, hydralazine) if severe AR w/ sx or LV dysfxn &amp;amp; not operative candidate or to improve hemodynamics before AVR.</description></item><item><title>Treatment-ascites</title><link>https://htlin222.github.io/garden/Treatment-ascites/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-ascites/</guid><description>Treatment-ascites ↓ Na intake (1–2 g/d); restrict intake of free water if Na &amp;lt;125
Diuretics: goal diurese ~1 L/d.</description></item><item><title>Treatment-bacterial endocarditis</title><link>https://htlin222.github.io/garden/Treatment-bacterial-endocarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-bacterial-endocarditis/</guid><description>Treatment-bacterial endocarditis Empiric NVE or PVE &amp;gt;12 mos post-op: vanc + CTX PVE &amp;lt;12 mos post op: vanc + CTX ± gentamicin (if OK renal fxn)</description></item><item><title>Treatment-bronchiectasis</title><link>https://htlin222.github.io/garden/Treatment-bronchiectasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-bronchiectasis/</guid><description>Treatment-bronchiectasis Acute exacerbations: antibiotics directed against prior pathogens; if no prior Cx data → FQ
Chronic mgmt: treat underlying condition, chest PT, inhaled hypertonic saline, bronchodil.</description></item><item><title>Treatment-Candida species</title><link>https://htlin222.github.io/garden/Treatment-Candida-species/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Candida-species/</guid><description>Treatment-Candida species Mucocutaneous Clotrimazole, nystatin, fluconazole, itraconazole Candiduria (if pyuria or sx of infxn) Fluconazole or intravesical ampho if severe infxn, immunosupp.</description></item><item><title>Treatment-cholangitis</title><link>https://htlin222.github.io/garden/Treatment-cholangitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-cholangitis/</guid><description>Treatment-cholangitis Antibiotics (broad spectrum) to cover common bile pathogens (see above) ampicillin + gentamicin (or levofloxacin) ± MNZ (if severe); carbapenems; pip/tazo ~80% respond to conservative Rx and abx → biliary drainage on elective basis ~20% require urgent biliary decompression via ERCP (papillotomy, stone extraction, and/or stent insertion).</description></item><item><title>Treatment-cholecystitis</title><link>https://htlin222.github.io/garden/Treatment-cholecystitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-cholecystitis/</guid><description>Treatment-cholecystitis (Ann Surg 2013;258:385; NEJM 2015;373:357)
NPO, IV fluids, nasogastric tube if intractable vomiting, analgesia
Antibiotics (E.</description></item><item><title>Treatment-cholelithiasis</title><link>https://htlin222.github.io/garden/Treatment-cholelithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-cholelithiasis/</guid><description>Treatment-cholelithiasis (Am Fam Physician 2014;89:795; J Hepatol 2016;65:146)
Cholecystectomy (CCY), usually laparoscopic, if symptomatic (earlier is better)
CCY in asx Pts if: GB calcification (↑ risk of cancer), GB polyps &amp;gt;10 mm, stones &amp;gt;3 cm; Pts undergoing bariatric surgery, cardiac Tx candidates, hemolytic anemia (sickle cell)</description></item><item><title>Treatment-chronic pancreatitis</title><link>https://htlin222.github.io/garden/Treatment-chronic-pancreatitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-chronic-pancreatitis/</guid><description>Treatment-chronic pancreatitis (JAMA 2019;322:2422; Lancet 2020;396:499)
Pancreatic enzyme replacement (may ↓ pain by reducing CCK). Rx routine vitamin D &amp;amp; Ca.</description></item><item><title>Treatment-cystic fibrosis</title><link>https://htlin222.github.io/garden/Treatment-cystic-fibrosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-cystic-fibrosis/</guid><description>Treatment-cystic fibrosis Lancet 2021;397:2195)
Acute exacerbations: may be assoc w/ persistent drop in FEV1 (AJRCCM 2010;182:627); continue aggressive airway clearance, target abx based on sputum cx (incl double coverage for PsA); common pathogens include PsA, S.</description></item><item><title>Treatment-diabetic foot infections</title><link>https://htlin222.github.io/garden/Treatment-diabetic-foot-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-diabetic-foot-infections/</guid><description>Treatment-diabetic foot infections (CID 2012;54:e132)
Mild infxn: oral abx. Target GPCs (diclox, cephalexin, or amox/clav); use TMP-SMX or doxy for MRSA.</description></item><item><title>Treatment-diverticulitis</title><link>https://htlin222.github.io/garden/Treatment-diverticulitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-diverticulitis/</guid><description>Treatment-diverticulitis (JAMA 2017;318:291; NEJM 2018;379:1635; Gastro 2021;160:906)
Mild: outPt Rx indicated if Pt has few comorbidities and can tolerate POs PO abx: (MNZ + FQ) or amox/clav for 7 d; liquid diet until clinical improvement No abx is noninferior to abx in uncomplicated diverti (Clin Gastroenterol Hepatol 2021;19:503)</description></item><item><title>Treatment-epidural abscess</title><link>https://htlin222.github.io/garden/Treatment-epidural-abscess/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-epidural-abscess/</guid><description>Treatment-epidural abscess Antibiotics (typically MRSA and gram-negative coverage initially then narrowed based on culture data) ± surgery (decompressive laminectomy and debridement) for failure to improve on medical Rx.</description></item><item><title>Treatment-fever of unknown origin</title><link>https://htlin222.github.io/garden/Treatment-fever-of-unknown-origin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-fever-of-unknown-origin/</guid><description>Treatment-fever of unknown origin Empiric abx not indicated (unless Pt neutropenic or critically ill) Empiric glucocorticoids not indicated unless strong suspicion for specific rheumatologic dx Stop unnecessary meds (only 20% with a med cause have eos or rash) Up to 30% of cases remain undiagnosed, most spontaneously defervesce (wks to mos)</description></item><item><title>Treatment-glomerulonephritis</title><link>https://htlin222.github.io/garden/Treatment-glomerulonephritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-glomerulonephritis/</guid><description>Treatment-glomerulonephritis (AJKD 2020;75:124 &amp;amp; 2020;76:265)
If acute GN/RPGN suspected, give 500–1000 mg methylpred. IV qd × 3d ASAP while awaiting bx results.</description></item><item><title>Treatment-hemoptysis</title><link>https://htlin222.github.io/garden/Treatment-hemoptysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hemoptysis/</guid><description>Treatment-hemoptysis Death is from asphyxiation窒息 not exsanguination; maintain gas exchange, reverse coagulopathy and Rx underlying condition; cough suppressant may ↑ risk of asphyxiation Inhaled tranexamic acid promising (Chest 2018;154:1379) nebulized TA (500 mg tid) Massive hemoptysis: put bleeding side dependent; selectively intubate nl lung if needed Angiography: Dx &amp;amp; Rx (vascular occlusion balloons or selective embol of bronchial art) Rigid bronch: allows more options (electrocautery, laser) than flexible bronch Surgical resection</description></item><item><title>Treatment-Hepatorenal syndrome HRS</title><link>https://htlin222.github.io/garden/Treatment-Hepatorenal-syndrome-HRS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Hepatorenal-syndrome-HRS/</guid><description>Treatment-Hepatorenal syndrome (HRS) if critically ill → vasopressor (eg, norepinephrine or vasopressin) + albumin (1 g/kg, max 100 g, bolus daily) to ↑ MAP 10 mmHg.</description></item><item><title>Treatment-hyperaldosteronism</title><link>https://htlin222.github.io/garden/Treatment-hyperaldosteronism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hyperaldosteronism/</guid><description>Treatment-hyperaldosteronism (SCNA 2014;94:643)
Adenoma → adrenalectomy vs. medical Rx w/ spironolactone or eplerenone Hyperplasia → spironolactone or eplerenone; GRA → glucocorticoids ± spironolactone Carcinoma → adrenalectomy</description></item><item><title>Treatment-hypernatremia</title><link>https://htlin222.github.io/garden/Treatment-hypernatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hypernatremia/</guid><description>Treatment-hypernatremia Restore access to H2O or supply daily requirement of H2O (≥1 L/d)
[[Replace free H2O deficit]]</description></item><item><title>Treatment-hyperosmolar hyperglycemic state</title><link>https://htlin222.github.io/garden/Treatment-hyperosmolar-hyperglycemic-state/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hyperosmolar-hyperglycemic-state/</guid><description>Treatment-hyperosmolar hyperglycemic state Rule-out possible precipitants; ~15% mortality due to precipitating factors Aggressive hydration: initially NS, then ½ NS, average fluid loss up to 8–10 L Insulin (eg, 10 U IV followed by 0.</description></item><item><title>Treatment-hypertension</title><link>https://htlin222.github.io/garden/Treatment-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hypertension/</guid><description>Treatment-hypertension Every ↓ 5 mmHg → ~10% ↓ ischemic heart disease, stroke, and HF (Lancet 2021;397:1625) Lifestyle modifications (each may ↓ SBP ~5 mmHg) weight loss: goal BMI 18.</description></item><item><title>Treatment-hypertensive crises</title><link>https://htlin222.github.io/garden/Treatment-hypertensive-crises/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hypertensive-crises/</guid><description>Treatment-hypertensive crises (Circ 2018;138:e426)
AoD, eclampsia/severe preeclampsia, pheo: target SBP &amp;lt;140 (&amp;lt;120 for AoD) in 1 hour Emerg w/o above: ↓ BP by ~25% in 1 h; to 160/100–110 over next 2–6 h, then nl over 1–2 d Acute ischemic stroke (w/in 72 hr from sx onset): &amp;lt;185/110 before lysis initiated, o/w target &amp;lt;220/120 (same SBP goal for ICH) Watch UOP, Cr, mental status: may indicate a lower BP is not tolerated [[IV Drugs for Hypertensive Crises]] HTN urgency: goal to return to normal BP over hrs to days.</description></item><item><title>Treatment-hyperthyroidism</title><link>https://htlin222.github.io/garden/Treatment-hyperthyroidism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hyperthyroidism/</guid><description>Treatment-hyperthyroidism β-blockers: control tachycardia (propranolol also ↓ T4 → T3 conversion) Graves’ disease: either antithyroid drugs or radioactive iodine (NEJM 2016;375:1552) methimazole: 60% chance of recurrence after 1 y; side effects include pruritus, rash, arthralgia, fever, N/V and agranulocytosis in 0.</description></item><item><title>Treatment-hypocalcemia</title><link>https://htlin222.github.io/garden/Treatment-hypocalcemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hypocalcemia/</guid><description>Treatment-hypocalcemia also treat concomitant vitamin D deficiency; Endocrine 2020;69:485
也要治療維生素 D 缺乏症
Severely symptomatic: Ca gluconate (1–2 g IV over 20 min) + oral Ca + calcitriol (but takes hrs to work) ± Mg (50–100 mEq/d); 10% CaCl2 in codes or via CVL</description></item><item><title>Treatment-hypokalemia</title><link>https://htlin222.github.io/garden/Treatment-hypokalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hypokalemia/</guid><description>Treatment-hypokalemia (JAMA 2000;160:2429)
If true potassium deficit: potassium repletion (↓ 1 mEq/L ≈ 200 mEq total body loss) Dosage: 40 mEq PO q4h, 10 mEq/h (IV), 20 mEq/h (central line), 40 mEq in 1 L IVF</description></item><item><title>Treatment-hypopituitary syndromes</title><link>https://htlin222.github.io/garden/Treatment-hypopituitary-syndromes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-hypopituitary-syndromes/</guid><description>Treatment-hypopituitary syndromes Replace deficient target gland hormones Most important deficiencies to recognize and treat in inpatients are adrenal insufficiency and hypothyroidism; if both present, treat with glucocorticoids first, then replace thyroid hormone so as not to precipitate adrenal crisis</description></item><item><title>Treatment-mitral-regurgitation</title><link>https://htlin222.github.io/garden/Treatment-mitral-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-mitral-regurgitation/</guid><description>Treatment-mitral-regurgitation Treatment (Lancet 2016;387:1312; Circ 2021;143:e72)
Acute decompensation (consider endocarditis as possible acute precipitant): surgery usually urgently needed for acute severe AR, which is poorly tolerated by LV IV afterload reduction (nitroprusside) and inotropic support (dobutamine) ± chronotropic support (↑ HR → ↓ diastole → ↓ time for regurgitation) pure vasoconstrictors and IABP contraindicated In chronic AR, management decisions based on LV size and fxn (and before sx occur); low diastolic BP and high resting HR associated with mortality (JACC 2020;75:29) Surgery (AVR, replacement or repair if possible): Severe and sx (if equivocal, consider stress test) Asx and either EF ≤55%, LV dilation [LVESD &amp;gt;50 mm or LVESDi (indexed to BSA) ≥ 25 mm/m2 (JACC 2019;73:1741)], or undergoing cardiac surg Transcatheter AoV implantation (TAVI) being explored (JACC 2013;61:1577 &amp;amp; 2017;70:2752) Medical therapy: vasodilators (nifedipine, ACEI/ARB, hydralazine) if severe AR w/ sx or LV dysfxn &amp;amp; not operative candidate or to improve hemodynamics before AVR.</description></item><item><title>Treatment-mitral-stenosis</title><link>https://htlin222.github.io/garden/Treatment-mitral-stenosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-mitral-stenosis/</guid><description>Treatment-mitral-stenosis Medical: Na restriction, cautious diuresis, βB, AF control, sx-limited physical stress Antibiotic Ppx recommended if h/o RHD w/ valvular disease for 10 y or until age 40 Anticoag w/ warfarin (not DOAC) if: AF; prior embolism; LA clot Mechanical intervention indicated if sx severe MS; reasonable if asx severe MS but PASP &amp;gt;50 mmHg and morphology favorable for PMBC; consider PMBC if non-severe MS but exertional sx and hemodyn signif w/ exercise, or if asx severe MS and new-onset AF Percutaneous mitral balloon commissurotomy (PMBC): preferred Rx if RHD; ≈ MVR if valvuloplasty score &amp;lt;8, Ø if mod-severe MR or LA clot Surgical (MV repair if possible, o/w replacement) if PMBC contraindicated Calcific MS: surgical MVR if severe &amp;amp; highly sx; use of transcatheter aortic prosthesis experimental and w/ high rate of complications (Circ CVI 2020;13:e008425) Pregnancy: if NYHA class III/IV → PMBC, o/w medical Rx w/ low-dose diuretic &amp;amp; βB</description></item><item><title>Treatment-nephrotic syndrome</title><link>https://htlin222.github.io/garden/Treatment-nephrotic-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-nephrotic-syndrome/</guid><description>Treatment-nephrotic syndrome (NEJM 2013;368:10)
General: protein suppl.; diuretics for edema; treat hyperlipidemia, Na restriction (&amp;lt;2 g/d)
ACEI or ARB: ↓ proteinuria → slow nonimmunologic progression of renal disease</description></item><item><title>Treatment-Nonalcoholic fatty liver disease NAFLD</title><link>https://htlin222.github.io/garden/Treatment-Nonalcoholic-fatty-liver-disease-NAFLD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Nonalcoholic-fatty-liver-disease-NAFLD/</guid><description>Treatment-Nonalcoholic fatty liver disease (NAFLD) wt loss (≥10%), exercise, DM control, liraglutide (Lancet 2016;387:679), statins (Metabolism 2017;71:17), vit E in Pts w/o DM (Hepatol 2018;67:328), bariatric surgery (World J Hepatol 2019;11:138).</description></item><item><title>Treatment-of-hyponatremia</title><link>https://htlin222.github.io/garden/Treatment-of-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-of-hyponatremia/</guid><description>Treatment-of-hyponatremia NEJM 2015;372:55; JASN 2017;28:1340; CJASN 2018;13:641 &amp;amp; 984)
[[Approach to treatment-of-hyponatremia]]: Frequent lab draws and IVF rate adjustments are cornerstones of treatment [[Rapid correction of Treatment-of-hyponatremia]]: [[Effect of IV fluids-treatment-of-hyponatremia]] [[Effect of 1 L infusion in 70-kg male]] 分類： [[Treatment of Hypovolemic hyponatremia]] [[Treatment of SIADH]] [[Treatment of Hypervolemic hyponatremia]]</description></item><item><title>Treatment-osteomyelitis</title><link>https://htlin222.github.io/garden/Treatment-osteomyelitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-osteomyelitis/</guid><description>Treatment-osteomyelitis Antibiotics: based on cx data. If clinically stable, consider holding antibiotics until bone bx obtained. Duration depends on Rx strategy/goals of Rx management (eg, 6 wks for vertebral osteo; Lancet 2015;385:875).</description></item><item><title>Treatment-Paroxysmal nocturnal hemoglobinuria</title><link>https://htlin222.github.io/garden/Treatment-Paroxysmal-nocturnal-hemoglobinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Paroxysmal-nocturnal-hemoglobinuria/</guid><description>Treatment-Paroxysmal nocturnal hemoglobinuria supportive care (iron, folate, transfusions); consider anticoagulation.
Allogeneic HSCT for hypoplasia or severe thrombosis.
Pegcetacoplan (binds C3, prevents complement cascade activation) superior to eculizumab (Ab inactivates terminal complement C5s) in ↓ hemolysis &amp;amp; stabilizing Hb levels (NEJM 2021;384:1028).</description></item><item><title>Treatment-pericardial tamponade</title><link>https://htlin222.github.io/garden/Treatment-pericardial-tamponade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-pericardial-tamponade/</guid><description>Treatment-pericardial tamponade Volume (but be careful b/c overfilling can worsen tamponade) and ⊕ inotropes (avoid βB) Avoid vasoconstrictors b/c will ↓ stroke volume &amp;amp; potentially ↓ HR Avoid positive pressure ventilation b/c it can further impair cardiac filling (Circ 2006;113:1622) Pericardiocentesis (except if due to aortic/myocardial rupture, for which emergent surgery is treatment of choice; if too unstable, consider small pericardiocentesis to prevent PEA) Surgical drainage considered if fluid rapidly reaccumulates, loculated, or hemorrhagic</description></item><item><title>Treatment-pleural effusion</title><link>https://htlin222.github.io/garden/Treatment-pleural-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-pleural-effusion/</guid><description>Treatment-pleural effusion Symptomatic effusion: therapeutic thoracentesis, treat underlying disease process
Parapneumonic effusion (Chest 2000;118:1158)
uncomplicated → antibiotics for pneumonia</description></item><item><title>Treatment-pneumonia</title><link>https://htlin222.github.io/garden/Treatment-pneumonia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-pneumonia/</guid><description>Treatment-pneumonia CAP (outPt) Amoxicillin, azithro, or doxy (avoid latter two if &amp;gt;25% resistance locally)
CAP (ward) [3rd-gen ceph + azithro] or levoflox; omadacycline ≈ FQ (NEJM 2019;380:517)</description></item><item><title>Treatment-polyuria</title><link>https://htlin222.github.io/garden/Treatment-polyuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-polyuria/</guid><description>Treatment-polyuria 1° polydipsia: treat psychiatric illness, check meds, restrict access to free H2O Osmotic diuresis: address underlying cause, replace free H 2O deficit (see “Hypernatremia” for formula to calculate) and ongoing losses Treatment of Diabetes insipidus Central DI: desmopressin (dDAVP, 1st line), low Na/protein diet + HCTZ, chlorpropamide Nephrogenic DI: treat underlying cause if possible; Na restriction + HCTZ (mild volume depletion → ↓ delivery of filtrate for free H2O absorption), consider amiloride for Li- induced DI (Kid Int 2009;76:44), indomethacin (NEJM 1991;324:850) or trial desmopression Pregnancy-induced DI: due to vasopressinase from placenta, ∴ Rx w/ dDAVP</description></item><item><title>Treatment-Portal vein thrombosis PVT</title><link>https://htlin222.github.io/garden/Treatment-Portal-vein-thrombosis-PVT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Portal-vein-thrombosis-PVT/</guid><description>Treatment-Portal vein thrombosis (PVT) Treatment: Acute: If noncirrhotic, LMWH → warfarin or DOAC × 6 mo, or indefinitely if irreversible cause.</description></item><item><title>Treatment-Primary sclerosing cholangitis PSC</title><link>https://htlin222.github.io/garden/Treatment-Primary-sclerosing-cholangitis-PSC/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Primary-sclerosing-cholangitis-PSC/</guid><description>Treatment-Primary sclerosing cholangitis (PSC) supportive care, fat-soluble vitamins; no meds have improved survival
UDCA may ↓ Aϕ &amp;amp; improve Sx, but unclear if beneficial</description></item><item><title>Treatment-pulmonary hypertension</title><link>https://htlin222.github.io/garden/Treatment-pulmonary-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-pulmonary-hypertension/</guid><description>Treatment-pulmonary hypertension Principles: 1) prevent &amp;amp; reverse vasoactive substance imbalance and vascular remodeling 2) prevent RV failure: ↓ wall stress (↓ PVR, PAP, RV diam); ensure adeq systemic DBP Supportive Oxygen: maintain SaO2 &amp;gt;90–92% (reduces vasoconstriction) Diuretics: ↓ RV wall stress and relieve RHF sx; gentle b/c RV is preload dependent Anticoag: not routinely used; ↓ VTE risk of RHF; ?</description></item><item><title>Treatment-Pure red cell aplasia</title><link>https://htlin222.github.io/garden/Treatment-Pure-red-cell-aplasia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Pure-red-cell-aplasia/</guid><description>Treatment-Pure red cell aplasia : thymectomy if thymus enlarged; IVIg if parvovirus and immunosuppressed (Clin Infect Dis 2013;56:968); immunosuppression/chemoRx if CLL or idiopathic; supportive care w/ PRBC transfusions; ?</description></item><item><title>Treatment-sexually transmitted infections</title><link>https://htlin222.github.io/garden/Treatment-sexually-transmitted-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-sexually-transmitted-infections/</guid><description>Treatment-sexually transmitted infections (MMWR 2021;70:1; JAMA 2022;327:161)
Syphilis 1°/2°/early latent: PCN G benzathine 2.4 mil U IM × 1 3°/late latent: PCN G 2.</description></item><item><title>Treatment-skin and soft tissue infections</title><link>https://htlin222.github.io/garden/Treatment-skin-and-soft-tissue-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-skin-and-soft-tissue-infections/</guid><description>Treatment-skin and soft tissue infections (CID 2014;60:169)
Urgent surgical exploration with debridement of necrotic tissue and ID consultation Empiric antibiotics: [pip/tazo or ceftriaxone + metronidazole or carbapenem] + [vanco or linezolid].</description></item><item><title>Treatment-syncope</title><link>https://htlin222.github.io/garden/Treatment-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-syncope/</guid><description>Treatment-syncope (JACC 2017;70:620 &amp;amp; 2019;74:2410; EHJ 2018;39:1883)
Arrhythmia, cardiac mechanical or neurologic syncope: treat underlying disorder, ? ICD if Brugada pattern, sarcoid, ARVC, early repol + syncope Vasovagal: avoidance of triggers; physical counterpressure; consider ↑ Na &amp;amp; fluid intake, fludrocortisone or midodrine (JACC 2016;68:1; Ann Intern Med 2021;174:1349); SSRI; ?</description></item><item><title>Treatment-Vitamin B12 deficiency</title><link>https://htlin222.github.io/garden/Treatment-Vitamin-B12-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Vitamin-B12-deficiency/</guid><description>Treatment-Vitamin B12 deficiency 1 mg B12 IM qd × 7 d → q wk × 4–8 wk → q month for life</description></item><item><title>Treatment-Wilson disease</title><link>https://htlin222.github.io/garden/Treatment-Wilson-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Treatment-Wilson-disease/</guid><description>Treatment-Wilson disease chelation w/ D-penicillamine (supplement B6 as D-pen inactivates); alternative is trientine (↓ toxicity w/ ≈ efficacy, but $$), ammonium or bis-choline tetrathiomolybdate (investigational) may ↓ neurologic deterioration compared to trientine.</description></item><item><title>Triage-pneumonia</title><link>https://htlin222.github.io/garden/Triage-pneumonia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Triage-pneumonia/</guid><description>Triage-pneumonia qSOFA predicts poor outcomes, prolonged ICU stay, and in-hospital mortality if &amp;gt;2 of 3: RR&amp;gt;22, AMS, SBP&amp;lt;100 (JAMA 2016; 315:801)</description></item><item><title>tricuspid-regurgitation</title><link>https://htlin222.github.io/garden/tricuspid-regurgitation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/tricuspid-regurgitation/</guid><description>tricuspid-regurgitation TRICUSPID REGURGITATION (Circ 2014;129:2440; Lancet 2016;388:2431)
Fxnl etiol (90%): RV dilation, PHT (may be 2° to L-sided dis.), large L → R shunts 1° etiol: myxomatous, IE, pacemaker leads, RHD, CTD, XRT, Ebstein’s, carcinoid, tumors Holosystolic murmur, 3rd/4th ICS, ↑ w/ insp (Carvallo’s sign); S3; prominent cv wave in JVP Consider repair/replacement in severe TR (eg, ERO ≥0.</description></item><item><title>Tricyclic antidepressants-toxicology</title><link>https://htlin222.github.io/garden/Tricyclic-antidepressants-toxicology/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tricyclic-antidepressants-toxicology/</guid><description>Tricyclic antidepressants-toxicology Hypotension, seizures, arrhythmia, ↑ QRS, ↑ QT
IVF resuscitation, IV sodium bicarbonate, vasopressors</description></item><item><title>Troponin</title><link>https://htlin222.github.io/garden/Troponin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Troponin/</guid><description>Troponin 99th %ile w/ rise and/or fall in approp. setting is dx of AMI (Circ 2018;138:e618)
[[Fourth Universal Definition of Myocardial Infarction (2018)]]</description></item><item><title>Troubleshooting and FAQ</title><link>https://htlin222.github.io/garden/notes/troubleshooting/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/troubleshooting/</guid><description>Still having trouble? Here are a list of common questions and problems people encounter when installing Quartz.
While you&amp;rsquo;re here, join our Discord :)</description></item><item><title>Tuberculin skin test</title><link>https://htlin222.github.io/garden/Tuberculin-skin-test/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tuberculin-skin-test/</guid><description>Tuberculin skin test (TST/ PPD): inject purified protein intradermally, examine for wheal 48–72 hrs later. Interpret based on max diameter of induration, not erythema.</description></item><item><title>tuberculosis</title><link>https://htlin222.github.io/garden/tuberculosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/tuberculosis/</guid><description>tuberculosis [[Definitions-tuberculosis]] [[Epidemiology-tuberculosis]] [[Screening for latent TB]] [[Clinical manifestations-Screening for latent TB]] [[Diagnostics for active TB]] [[Extrapulmonary TB]] [[Treatment of latent TB]] [[Patient isolation-tuberculosis]] [[Treatment of active tuberculosis]] [[Antituberculous Medications]] [[Antituberculous Treatment Regimens]]</description></item><item><title>Tubulointerstitial proteinuria</title><link>https://htlin222.github.io/garden/Tubulointerstitial-proteinuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Tubulointerstitial-proteinuria/</guid><description>Tubulointerstitial proteinuria (usually &amp;lt;1–2 g/d) ↓ reabsorption of freely filtered proteins → lose globulins
Etiologies ATN; AIN [[Fanconi’s syndrome]]</description></item><item><title>tutorial</title><link>https://htlin222.github.io/garden/tutorial/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/tutorial/</guid><description> CS 61A：编程入门（用的 Python，之前用的是 Scheme） CS 61B：算法与数据结构（用的 Java） CS 61C：计算机体系结构（用的 C）</description></item><item><title>type</title><link>https://htlin222.github.io/garden/type/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/type/</guid><description>type</description></item><item><title>type 1 MI</title><link>https://htlin222.github.io/garden/type-1-MI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/type-1-MI/</guid><description>type 1 MI includes detection of a rise and/or fall of cTn with at least one value above the 99th percentile and with at least one of the following: Symptoms of acute myocardial ischemia; New ischemic electrocardiographic (ECG) changes; Development of pathological Q waves; Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology; Identification of a coronary thrombus by angiography including intracoronary imaging or by autopsy.</description></item><item><title>type 2 MI</title><link>https://htlin222.github.io/garden/type-2-MI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/type-2-MI/</guid><description>type 2 MI includes detection of a rise and/or fall of cTn with at least one value above the 99th percentile and evidence of an imbalance between myocardial oxygen supply and demand unrelated to coronary thrombosis, requiring at least one of the following: Symptoms of acute myocardial ischemia; New ischemic ECG changes; Development of pathological Q waves; Imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality in a pattern consistent with an ischemic etiology.</description></item><item><title>type 3 myocardial infarction</title><link>https://htlin222.github.io/garden/type-3-myocardial-infarction/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/type-3-myocardial-infarction/</guid><description>type 3 myocardial infarction Cardiac death in patients with symptoms suggestive myocardialischaemia and presumed new ischaemic EcG changes before cTn values become available or abnormal meets criteria for type 3 MI</description></item><item><title>type my note</title><link>https://htlin222.github.io/garden/type-my-note/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/type-my-note/</guid><description>content</description></item><item><title>Type of Idiopathic interstitial pneumonias IIPs</title><link>https://htlin222.github.io/garden/Type-of-Idiopathic-interstitial-pneumonias-IIPs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Type-of-Idiopathic-interstitial-pneumonias-IIPs/</guid><description>Type of Idiopathic interstitial pneumonias (IIPs) [[IPF idiopathic pulm fibrosis]] [[NSIP nonspecific IP]] [[COP cryptogenic organizing PNA]] [[AIP acute IP (Hamman-Rich syndrome)]] [[DIP desquamative IP]] [[RB-ILD resp bronchiolitis-assoc ILD]]</description></item><item><title>Types of Cryoglobulinemia</title><link>https://htlin222.github.io/garden/Types-of-Cryoglobulinemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Types-of-Cryoglobulinemia/</guid><description>Types of Cryoglobulinemia</description></item><item><title>Types of gallstones-cholelithiasis</title><link>https://htlin222.github.io/garden/Types-of-gallstones-cholelithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Types-of-gallstones-cholelithiasis/</guid><description>Types of gallstones-cholelithiasis (J Hepatol 2016;65:146)
Cholesterol (90%): 2 subtypes mixed: contain &amp;gt;50% cholesterol; typically smaller, multiple stones</description></item><item><title>Types of stones and risk factors</title><link>https://htlin222.github.io/garden/Types-of-stones-and-risk-factors/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Types-of-stones-and-risk-factors/</guid><description>Types of stones and risk factors (Nat Rev Dis Prim 2016;2:16008)
Calcium (Ca oxalate &amp;gt;Ca phosphate): 70–90% of kidney stones (NEJM 2010;363:954)</description></item><item><title>Typical Characteristics and Diagnostic Studies of Chest Pain</title><link>https://htlin222.github.io/garden/Typical-Characteristics-and-Diagnostic-Studies-of-Chest-Pain/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Typical-Characteristics-and-Diagnostic-Studies-of-Chest-Pain/</guid><description>Typical Characteristics and Diagnostic Studies of Chest Pain Cardiovascular Causes Pulmonary Causes GI Causes Musculoskeletal and Miscellaneous Causes</description></item><item><title>typical electrocardiogram in a patient with acute pericarditis</title><link>https://htlin222.github.io/garden/typical-electrocardiogram-in-a-patient-with-acute-pericarditis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/typical-electrocardiogram-in-a-patient-with-acute-pericarditis/</guid><description>typical electrocardiogram in a patient with acute pericarditis 在所描繪的心電圖中，有一個 ST 段矢量指向前方、下方和左側，這導致除 AVR 和 V1 之外的所有導聯 ST 段抬高。 還有 PR 段壓低，這在導聯 II 中最為明顯。</description></item><item><title>UIP usual interstitial PNA IP</title><link>https://htlin222.github.io/garden/UIP-usual-interstitial-PNA-IP/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/UIP-usual-interstitial-PNA-IP/</guid><description>UIP usual interstitial PNA (IP) UIP imaging pattern: reticular opacities, honeycombing, traction bronchiectasis; peripheral, subpleural, &amp;amp; basal
Sx &amp;gt;12 mo</description></item><item><title>ulcerative colitis</title><link>https://htlin222.github.io/garden/ulcerative-colitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/ulcerative-colitis/</guid><description>ulcerative colitis (Lancet 2018;389:1756; Am J Gastro 2019:114:384)
[[Clinical manifestations-ulcerative colitis]] [[Diagnosis-ulcerative colitis]] [[Complications-ulcerative colitis]] [[Prognosis-ulcerative colitis]]</description></item><item><title>Untitled</title><link>https://htlin222.github.io/garden/Untitled/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Untitled/</guid><description>[[quick note]]
my new note</description></item><item><title>Untitled 1</title><link>https://htlin222.github.io/garden/Untitled-1/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Untitled-1/</guid><description/></item><item><title>Updating</title><link>https://htlin222.github.io/garden/notes/updating/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/notes/updating/</guid><description>Haven&amp;rsquo;t updated Quartz in a while and want all the cool new optimizations? On Unix/Mac systems you can run the following command for a one-line update!</description></item><item><title>Uremia</title><link>https://htlin222.github.io/garden/Uremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Uremia/</guid><description>Uremia hemodialysis indication: pericarditis, encephalopathy, bleeding
[[Residual syndrome]]
Classical signs of uremia are: progressive weakness and easy fatigue, loss of appetite due to nausea and vomiting, muscle atrophy, tremors, abnormal mental function, frequent shallow respiration, and metabolic acidosis.</description></item><item><title>Uremic bleeding</title><link>https://htlin222.github.io/garden/Uremic-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Uremic-bleeding/</guid><description>Uremic bleeding Uremia → platelet dysfunction including ↓ aggregation, impaired adhesiveness
Treatment: dDAVP, cryoprecipitate, correct anemia (improves plt aggregation and adhesion by increasing plt interactions with endothelium), consider holding anti-plt agents</description></item><item><title>urgent symptomatic interventions of leptomeningeal disease</title><link>https://htlin222.github.io/garden/urgent-symptomatic-interventions-of-leptomeningeal-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/urgent-symptomatic-interventions-of-leptomeningeal-disease/</guid><description>urgent symptomatic interventions of leptomeningeal disease Radiation to symptomatic sites
Hydrocephalus and increased intracranial pressure Glucocorticoids 8 to 16 mg Lumbar puncture</description></item><item><title>urinalysis</title><link>https://htlin222.github.io/garden/urinalysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/urinalysis/</guid><description>urinalysis [[Urine Dipstick]] [[Urine Sediment]] (microscopic examination)
[[proteinuria]] [[hematuria]] [[Etiologies of Hematuria]] [[Workup-of-hematuria]]
Backlink： [[Clinical manifestations-nephrolithiasis]] [[Diagnostic studies-urinary tract infections]] [[Diagnostic workup-hemoptysis]] [[Evaluation of vasculitis]] [[nephrology]] [[# The Profession of Medicine PA RT 1 ]] [[Stepwise Evaluation of a Patient with Delirium]] [[Workup-acute kidney injury (AKI)]]</description></item><item><title>urinary tract infections</title><link>https://htlin222.github.io/garden/urinary-tract-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/urinary-tract-infections/</guid><description>urinary tract infections [[Definitions-urinary tract infections]] [[Microbiology-urinary tract infections]] [[Clinical manifestations-urinary tract infections]] [[Diagnostic studies-urinary tract infections]] [[Treatment of UTIs]]</description></item><item><title>Urine Dipstick</title><link>https://htlin222.github.io/garden/Urine-Dipstick/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Urine-Dipstick/</guid><description>Urine Dipstick [[Specific gravity of Urine Dipstick]] [[pH of Urine Dipstick]] Range: 4.5–8.5; useful in evaluation of stones, RTAs, infection (urease UTI) [[Protein of Urine Dipstick]] Blood [[Workup-of-hematuria]] ⊕ from RBCs, free Hgb, or free myoglobin (eg, rhabdo) False ⊕: semen, dilute urine (→ osmotic cell lysis), ↑ pH, vaginal blood False ⊖: vit C WBC Suggests inflammation (UTI, interstitial nephritis, GN) Ketones Detects acetoacetate (ie, ketoacidosis) but not β-hydroxybutyrate Leuk est Lysed PMNs.</description></item><item><title>Urine Sediment</title><link>https://htlin222.github.io/garden/Urine-Sediment/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Urine-Sediment/</guid><description>Urine Sediment (Am J Kidney Dis 2008;51:1052)
Method Centrifuge fresh sample (prox. port if Foley) × 3–5 min at 1500–3000 rpm pour off supernatant in one motion resuspend pellet by agitating base of tube pour suspension onto slide w/ coverslip view under “high dry” power phase contrast for RBC morphology Urine Sediment Cells RBCs: assess amount &amp;amp; morphology (many dysmorphic → glomerular) WBCs: PMNs (UTI) vs.</description></item><item><title>urothelial carcinoma</title><link>https://htlin222.github.io/garden/urothelial-carcinoma/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/urothelial-carcinoma/</guid><description>topic: [[ddMVAC]]]</description></item><item><title>Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients</title><link>https://htlin222.github.io/garden/Use-of-13-%CE%B2-D-glucan-in-invasive-fungal-diseases-in-hematology-patients/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Use-of-13-%CE%B2-D-glucan-in-invasive-fungal-diseases-in-hematology-patients/</guid><description>Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients ✨重點: 入侵性真菌疾病（IFD）仍然是血液學患者發病和死亡率的主要原因。 在診斷驅動的方法中，使用血清（1）-β-D-Glucan（BDG）測試代表了IFD早期診斷和治療的有效工具。 涵蓋的區域：系統地檢索了有關BDG在血液學患者中使用的可用文獻。 然後，進行了審查和討論，以確定與該主題的臨床敘事介紹有關的關鍵問題。 專家評論： 使用BDG在有侵入性曲霉病風險的血液學患者中使用是使用半乳糖量使用的。 但是，由於BDG並非針對IA特定，因此它提供了診斷其他IFD的優勢， 例如念珠菌病和肺炎細胞症。 與其他隊列相比，BDG的局限性包括血液學患者的高成本和較低的敏感性。 在現實生活中，假陽性結果的風險可能低於理論上， 因為無葡聚醣設備可用，現代透析膜和血液產品通常不會釋放BDG。 因此，在經驗豐富的手和選定的臨床情況下，BDG是一種有用的診斷工具， 尤其是由於失誤時間短，結果和多功能性在診斷不同的IFD方面。</description></item><item><title>vagal maneuvers</title><link>https://htlin222.github.io/garden/vagal-maneuvers/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/vagal-maneuvers/</guid><description>vagal maneuvers 10s
頸動脈竇按摩: 將患者置於仰臥位，頸部伸展並旋轉到提供者打算按摩的頸動脈竇的另一側。頸動脈竇位於下頜角下方、胸鎖乳突肌前方和甲狀軟骨上層的動脈衝動處。提供者使用食指和中指的指尖在後內側方向施加壓力 5 到 10 秒。如果不成功，該過程可在 1 分鐘後重複。如果仍然不成功，臨床醫生可能會嘗試在另一側進行操作。 CSM 的輔助包括將患者置於特倫德倫伯臥位、抬腿、伴隨 VM 或同時對患者的上腹部施加壓力。對 CSM 的可能反應包括患者心率減慢、心律失常終止或無反應。</description></item><item><title>valve-replacement</title><link>https://htlin222.github.io/garden/valve-replacement/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/valve-replacement/</guid><description>valve-replacement (Circ 2021;143:e72)
Based on symptoms: once they develop → AVR needed Indicated in: sx severe (stage D1; D2; D3 if AS felt to be cause of sx); asx severe + EF &amp;lt;50% (stage C2); or severe (stage C1) and undergoing other cardiac surgery Reasonable if: asx severe (C1) but either sx or ↓ BP w/ exercise (can carefully exercise asx AS to uncover sx; do not exercise sx AS), very severe, ↑ BNP, rapid progression Growing data to support AVR in asx severe AS (NEJM 2020;382:111; Circ 2021;143:e72) Type of valve: mechanical reasonable if Pt &amp;lt;50 yrs, bioprosthetic if &amp;gt;65 yrs or cannot tolerate long-term anticoagulation; individualize if 50–65 yrs Transcatheter AoV implantation (TAVI, see below) attractive alternative to surgery Medical (if not AVR candidate or to temporize): careful diuresis prn, control HTN, maintain SR; digoxin if ↓ EF &amp;amp; HF or if AF; avoid venodilators (nitrates) &amp;amp; ⊖ inotropes (βB/CCB) if severe AS; avoid vigorous physical exertion once AS mod–severe ?</description></item><item><title>valvular heart disease</title><link>https://htlin222.github.io/garden/valvular-heart-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/valvular-heart-disease/</guid><description>valvular heart disease [[aortic-stenosis]] (AS) [[aortic-regurgitation]] (AR) [[mitral-regurgitation]] (MR) [[mitral-valve-prolapse]] (MVP) [[mitral-stenosis]] (MS) [[tricuspid-regurgitation]] (Circ 2014;129:2440; Lancet 2016;388:2431) [[prosthetic-heart-valves]]</description></item><item><title>Variable and Possible Etiology-fever and rash</title><link>https://htlin222.github.io/garden/Variable-and-Possible-Etiology-fever-and-rash/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Variable-and-Possible-Etiology-fever-and-rash/</guid><description>Variable and Possible Etiology-fever and rash Summer/fall &amp;gt; other seasons Enterovirus Winter Parvovirus, Meningococcemia Spring/summer Lyme, RMSF, Ehrlichiosis, Anaplasmosis Year-round Adenovirus, Mycoplasma Cat and dog exposure Bartonella, Pasteurella, Toxoplasma, Capnocytophaga Tick exposure Lyme, RMSF, Ehrlichiosis, Anaplasmosis Adult &amp;lt;30 y Mononucleosis (EBV or CMV) Inadequate immunization Measles, Rubella, VZV, influenza Sexually active HIV, syphilis, disseminated gonococcal infection, HSV</description></item><item><title>Vascular Access-renal replacement and dialysis</title><link>https://htlin222.github.io/garden/Vascular-Access-renal-replacement-and-dialysis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vascular-Access-renal-replacement-and-dialysis/</guid><description>Vascular Access-renal replacement and dialysis AV fistula Pros
Highest patency Lowest risk of bacteremia Lowest mortality (JASN 2013;24:465) Cons Long maturation time (2–6 mo) Primary nonfunction (20%) AVgraft Easier to create than AVF Maturation time (2–3 wk) Cons: Poor 1° patency, often requiring thrombectomy or angioplasty Catheter Immediate use Use as bridge to AVF/AVG Cons: Highest risk of bacteremia ↓ blood flow → ↓ HD efficiency</description></item><item><title>Vascular Beds Affected by Inherited and Acquired Hypercoagulable States</title><link>https://htlin222.github.io/garden/Vascular-Beds-Affected-by-Inherited-and-Acquired-Hypercoagulable-States/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vascular-Beds-Affected-by-Inherited-and-Acquired-Hypercoagulable-States/</guid><description>Vascular Beds Affected by Inherited and Acquired Hypercoagulable States Inher. Venous Factor V Leiden Prothrombin mutation ↓ protein C, S or AT III Venous and Arterial Hyperhomocysteinemia (inherited or acquired) Dysfibrinogenemia Acquired Venous Stasis: immobilization, surgery, CHF Malignancy Hormonal: OCPs, HRT, tamoxifen, pregnancy Nephrotic syndrome## Venous Venous and Arterial Platelet defects: myeloproliferative disorders, HIT, PNH (although venous &amp;gt;arterial) Hyperviscosity: polycythemia vera, Waldenström’s -macroglobulinemia, sickle cell, acute leukemia Vessel wall defects: vasculitis, trauma, foreign bodies Others: antiphospholipid syndrome, IBD</description></item><item><title>Vascular lower gastrointestinal bleed</title><link>https://htlin222.github.io/garden/Vascular-lower-gastrointestinal-bleed/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vascular-lower-gastrointestinal-bleed/</guid><description>Vascular lower gastrointestinal bleed Angioectasia &amp;amp; AVMs. Hereditary hemorrhagic telangiectasia (Weber-Osler-Rendu): diffuse AVMs throughout GI mucosa (also involve lips, oral mucosa, fingertips).</description></item><item><title>Vascular-gastrointestinal bleeding</title><link>https://htlin222.github.io/garden/Vascular-gastrointestinal-bleeding/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vascular-gastrointestinal-bleeding/</guid><description>Vascular-gastrointestinal bleeding Angioectasia AVMs, HHT (see below) AVMs congenital. Angioectasia (ectatic submucosal vessels) a/w ↑ age, CKD, cirrhosis, CTD, severe CV dis.</description></item><item><title>vasculitis</title><link>https://htlin222.github.io/garden/vasculitis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/vasculitis/</guid><description>vasculitis [[Background of vasculitis]] [[Evaluation of vasculitis]] [[Distinguihing Characteristics of Vascuiti Subtypes]] LARGE-VESSEL VASCULITIS [[Takayasu’s arteritis]] [[Giant cell arteritis]] (GCA) MEDIUM-VESSEL VASCULITIS [[Kawasaki disease]] (KD) [[Polyarteritis nodosa]] (PAN) [[thromboangiitis obliterans]] Buerger disease SMALL VESSEL VASCULITIS [[ANCA positive Vasculitis]] (AAV) [[immune complex (IC)–associated small-vessel vasculitis]] VARIABLE-VESSEL VASCULITIS [[Behçet’s syndrome]] [[Cogan&amp;rsquo;s syndrome]] Single-organ vasculitis [[Cutaneous leukocytoclastic angiitis]] [[Cutaneous arteritis]] [[Primary central nervous system vasculitis]] Isolated aortitis Others Vasculitis associated with systemic disease Lupus vasculitis Rheumatoid vasculitis Sarcoid vasculitis Others Vasculitis associated with probable etiology Hepatitis C virus-associated cryoglobulinemic vasculitis Hepatitis B virus-associated vasculitis Syphilis-associated aortitis Drug-associated immune complex vasculitis Drug-associated ANCA-associated vasculitis Cancer-associated vasculitis Others</description></item><item><title>Vasoactive Agents as Treatment-pulmonary hypertension</title><link>https://htlin222.github.io/garden/Vasoactive-Agents-as-Treatment-pulmonary-hypertension/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vasoactive-Agents-as-Treatment-pulmonary-hypertension/</guid><description>Vasoactive Agents as Treatment-pulmonary hypertension PDE-5 inhibitor sildenafil, tadalafil, [[vardenafil]] ↑ cGMP → vasodilatation, ↓ smooth muscle proliferation, ↓ sx, ↑ 6MWT, no data on clinical outcomes.</description></item><item><title>venous thromboembolism</title><link>https://htlin222.github.io/garden/venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/venous-thromboembolism/</guid><description>venous thromboembolism [[Definitions-venous thromboembolism]] [[Risk factors-venous thromboembolism]] [[Thromboprophylaxis]] clinical manifestations [[deep vein thrombosis]] [[pulmonary embolism]] treatment [[Whom to treat-venous thromboembolism]] [[Initial anticoagulation options for-venous thromboembolism]] [[Systemic thrombolysis]] [[Mechanical intervention-venous thromboembolism]] [[Duration of full-intensity anticoagulation-venous thromboembolism]] [[Long-term anticoagulation options-venous thromboembolism]] [[Extended DOAC strategies-venous thromboembolism]] [[Complications &amp;amp; prognosis-venous thromboembolism]] Ref: Acute Pulmonary Embolism: A Review | Emergency Medicine | JAMA | JAMA Network</description></item><item><title>Ventilator Modes and Principles</title><link>https://htlin222.github.io/garden/Ventilator-Modes-and-Principles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Ventilator-Modes-and-Principles/</guid><description>Ventilator Modes and Principles REF: Volume Control Ventilation – Basic Principles of Mechanical Ventilation
[[how the human body breathes]]
Backlink： [[mechanical ventilation]]</description></item><item><title>Vericiguat</title><link>https://htlin222.github.io/garden/Vericiguat/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vericiguat/</guid><description>Vericiguat 10% ↓ CV mort or HF hosp in NYHA II–IV (NEJM 2020;382:1883)</description></item><item><title>viral respiratory infections</title><link>https://htlin222.github.io/garden/viral-respiratory-infections/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/viral-respiratory-infections/</guid><description>viral respiratory infections Microbiology epidemiology-viral respiratory infections ( http://www.cdc.gov/flu/weekly)
Typical pathogens: Short, mild = rhinovirus, other non-SARS-CoV-2 coronavirus. Longer, more severe or complicated = influenza, parainfluenza, RSV, adenovirus, metapneumovirus, COVID-19 (vide infra).</description></item><item><title>Vitamin B12 deficiency</title><link>https://htlin222.github.io/garden/Vitamin-B12-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vitamin-B12-deficiency/</guid><description>Vitamin B12 deficiency (NEJM 2013;368:149)
B12 present only in foods of animal origin; total body stores sufficient for 2–3 y</description></item><item><title>vitamin D replacement</title><link>https://htlin222.github.io/garden/vitamin-D-replacement/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/vitamin-D-replacement/</guid><description>vitamin D replacement uptodate: - 維生素 D 及其代謝物因其與鈣穩態和骨代謝的相互關係而具有重要的臨床作用。 - 雖然由於嚴重的維生素 D 缺乏症（兒童）和骨軟化症（兒童和成人）現在並不常見（除了在陽光照射異常低、強化食品中缺乏維生素 D 和吸收不良綜合徵的人群）、亞臨床維生素 D 缺乏症、由低血清 25-羥基維生素 D (25[OH]D) 測量，是很常見的。 - 許多亞臨床維生素 D 缺乏症患者存在相對低鈣血症和高血清甲狀旁腺激素 (PTH) 濃度，這可能導致骨質疏鬆症的發展，並增加老年人骨折和跌倒的風險。 - 這種繼發性甲狀旁腺功能亢進可以通過服用維生素 D 補充劑來減輕 [58-60]。 ⭐ 學習重點 ⭐ 維生素 D 及其代謝物的多種製劑可用於治療維生素 D 缺乏症。 盡可能使用維生素 D，而不是其代謝物，因為成本較低。 兩種常用形式的維生素 D 補充劑是膽鈣化醇（維生素 D3）和麥角鈣化醇（維生素 D2）。 在一項七項隨機試驗的薈萃分析中，評估補充膽鈣化醇與麥角鈣化醇後血清 25(OH)D 濃度，膽鈣化醇比麥角鈣化醇更有效地增加血清 25(OH)D（血清 25[OH]D 的平均差異為 6 ng/毫升 [15.</description></item><item><title>Vitamin K deficiency</title><link>https://htlin222.github.io/garden/Vitamin-K-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Vitamin-K-deficiency/</guid><description>Vitamin K deficiency Etiologies: malnutrition, ↓ absorption (antibiotic suppression of vitamin K-producing intestinal flora or malabsorption), liver disease (↓ stores), warfarin</description></item><item><title>volume status</title><link>https://htlin222.github.io/garden/volume-status/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/volume-status/</guid><description>volume status (JVP, skin turgor, dry axilla, mucous membranes, edema, ascites), effusions, vital signs, orthostatics, BUN/Cr, FEUricAcid, UNa</description></item><item><title>von Willebrand’s disease vWD</title><link>https://htlin222.github.io/garden/von-Willebrands-disease-vWD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/von-Willebrands-disease-vWD/</guid><description>von Willebrand’s disease (vWD) (NEJM 2016;375:2067)
von Willebrand’s factor (vWF) function = platelet glue &amp;amp; plasma carrier of factor VIII</description></item><item><title>Washington Manual Thyroid Disorders</title><link>https://htlin222.github.io/garden/Washington-Manual-Thyroid-Disorders/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Washington-Manual-Thyroid-Disorders/</guid><description>Washington Manual Thyroid Disorders Hyperthyroidism4,5 GENERAL PRINCIPLES
Graves’ disease causes most cases of hyperthyroidism, especially in young patients. This autoimmune disorder may also cause proptosis (exophthalmos) and pretibial myxedema, neither of which is found in other causes of hyperthyroidism.</description></item><item><title>WBC of cerebrospinal fluid</title><link>https://htlin222.github.io/garden/WBC-of-cerebrospinal-fluid/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/WBC-of-cerebrospinal-fluid/</guid><description>WBC of cerebrospinal fluid 正常 CSF WBC &amp;lt; 5 若 traumatic tapping，每 500–1500 個 RBC 要減去 1 WBC 若 neutrophil 為主上升，可能原因包括：bacteria 若 lymphocyte 為主上升，可能原因包括： virus、fungus、TB、malignancy、viral/autoimmune encephalitis [[Lymphocytic pleocytosis]] 若 eosinophils 為主上升、可能原因包括：parasite、某些特殊感染或血液疾病等</description></item><item><title>weakness and neuromuscular dysfunction</title><link>https://htlin222.github.io/garden/weakness-and-neuromuscular-dysfunction/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/weakness-and-neuromuscular-dysfunction/</guid><description/></item><item><title>Weaning from Mechanical Ventilation</title><link>https://htlin222.github.io/garden/Weaning-from-Mechanical-Ventilation/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Weaning-from-Mechanical-Ventilation/</guid><description>Weaning from Mechanical Ventilation 肺損傷穩定或消退 充分的氣體交換，呼氣末正壓 (PEEP) 和吸入氧分數 (FiO 2 ) 要求低（例如，PEEP &amp;lt; 5–8 cm H2O，FiO 2 &amp;lt; 0.4–0.5） 血流動力學穩定性（例如，不需要升壓或斷奶，並且沒有嚴重的心律失常） 能夠啟動吸氣努力的患者 ✨ 學習重點 🦎 上述標準應作為斷奶篩查每天進行評估。對於通過每日斷奶篩查的患者，首先進行初步的簡短試驗或準備情況評估，在此期間對患者進行 1 至 5 分鐘的密切觀察，同時接受最少或不接受支持（持續氣道正壓通氣 [CPAP] ≤ 5 cm H 2 O)，評估他們進行正式自主呼吸試驗 (SBT) 的能力。 如果患者在準備情況評估期間表現良好，則進行大約 30 分鐘的 SBT。 在此期間，密切監測患者呼吸功能不全、血流動力學惡化、氣體交換問題或患者不適的跡象。 如果出現問題，將立即重新啟動全面的呼吸機支持。 成功完成 SBT 可高度預測成功停用呼吸機。</description></item><item><title>What are the most commonly encountered fever patterns</title><link>https://htlin222.github.io/garden/What-are-the-most-commonly-encountered-fever-patterns/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/What-are-the-most-commonly-encountered-fever-patterns/</guid><description>What are the most commonly encountered fever patterns Sustained or continued (little variability from day to day): this used to be the pattern of lobar pneumonia , steady until abruptly resolving by either crisis or death.</description></item><item><title>When to suspect migraine</title><link>https://htlin222.github.io/garden/When-to-suspect-migraine/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/When-to-suspect-migraine/</guid><description>When to suspect migraine Recurrent headache of moderate to severe intensity Visual aura Family history of migraine Onset of symptoms at or around puberty In the third edition of the International Classification of Headache Disorders (ICHD-3), migraine is classified into three main types:</description></item><item><title>When to treat chronic HBV with anti-virals</title><link>https://htlin222.github.io/garden/When-to-treat-chronic-HBV-with-anti-virals/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/When-to-treat-chronic-HBV-with-anti-virals/</guid><description>When to treat chronic HBV with anti-virals (1) immune active phase; (2) HBeAg ⊖ chronic hepatitis B; (3) cirrhosis w/ HBV DNA ≥2K; (4) decomp.</description></item><item><title>Whipple’s disease</title><link>https://htlin222.github.io/garden/Whipples-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Whipples-disease/</guid><description>Whipple’s disease infxn w/ T. whipplei (Lancet 2016;16:13)
Other s/s: fever, LAN, edema, arthritis, CNS Δs, gray-brown skin pigmentation, AI &amp;amp; MS, oculomasticatory myorhythmia (eye oscillations + mastication muscle contract).</description></item><item><title>Whom to treat-venous thromboembolism</title><link>https://htlin222.github.io/garden/Whom-to-treat-venous-thromboembolism/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Whom-to-treat-venous-thromboembolism/</guid><description>Whom to treat-venous thromboembolism (JAMA 2020;324:1765; Chest 2021;160:e545)
Superficial venous thrombosis:
elevate extremity, warm compresses, compression stockings, NSAIDs for sx.</description></item><item><title>wide complex</title><link>https://htlin222.github.io/garden/wide-complex/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/wide-complex/</guid><description>wide complex regular VT or unknown WCT try adenosine
if no response then: [[amiodarone]] or procainamide or sotalol or lidocaine (if VT) &amp;amp; prepare for synch cardioversion</description></item><item><title>wide-complex tachycardias WCTS</title><link>https://htlin222.github.io/garden/wide-complex-tachycardias-WCTS/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/wide-complex-tachycardias-WCTS/</guid><description>wide-complex tachycardias (WCTS) [[Etiologies-wide-complex tachycardias (WCTS)]] [[Monomorphic ventricular tachycardia (MMVT)]] [[Polymorphic ventricular tachycardia (PMVT)]] [[Diagnostic clues that favor VT]] [[Long-term management-wide-complex tachycardias (WCTS)]]</description></item><item><title>Wilson disease</title><link>https://htlin222.github.io/garden/Wilson-disease/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Wilson-disease/</guid><description>Wilson disease (World J Hepatol 2015;7:2859)
Recessive disorder of copper transport (mutation in ATP7B) → copper overload
Epidemiology: 1 in ~30,000 w/ age of presentation generally ranging from 3 to 55 y</description></item><item><title>Wolff-Chaikoff effect</title><link>https://htlin222.github.io/garden/Wolff-Chaikoff-effect/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Wolff-Chaikoff-effect/</guid><description>Wolff-Chaikoff effect Excess iodide transiently inhibits thyroid iodide organification (step 2) In individuals with a normal thyroid, the gland escapes from this inhibitory effect In individuals with underlying autoimmune thyroid disease (Hashimoto&amp;rsquo;s thyroiditis or Graves&amp;rsquo; disease), the suppressive effect may persist</description></item><item><title>woman health</title><link>https://htlin222.github.io/garden/woman-health/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/woman-health/</guid><description>woman health Contraception Vaginitis/Sexually Transmitted Infections (STIs)/Pelvic Inflammatory Disease (PID) Polycystic Ovary Syndrome (PCOS) Menstrual and Bleeding Disorders Menopause Preconception Care and Pregnancy Infertility Miscarriage and Abortion</description></item><item><title>Won’t Breathe as Etiologies of High elevated PaCO2</title><link>https://htlin222.github.io/garden/Wont-Breathe-as-Etiologies-of-High-elevated-PaCO2/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Wont-Breathe-as-Etiologies-of-High-elevated-PaCO2/</guid><description>Won’t Breathe as Etiologies of High elevated PaCO2 decreae RR Respiratory Drive Voluntary hypervent. NI Pimax &amp;amp; A-a grad Metabolic alkalosis 1° neurologic: brain- stem stroke, tumor, 1° alveolar hypovent 2° neurologic: sedatives, CNS infxn, hypothyroidism</description></item><item><title>Workup for effusion</title><link>https://htlin222.github.io/garden/Workup-for-effusion/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-for-effusion/</guid><description>Workup for effusion r/o infxn: usually apparent from Hx &amp;amp; CXR; ? value of ✓ acute and convalescent serologies</description></item><item><title>Workup for idiopathic VTE</title><link>https://htlin222.github.io/garden/Workup-for-idiopathic-VTE/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-for-idiopathic-VTE/</guid><description>Workup for idiopathic VTE (NEJM 2015;373:697)
Thrombophilia workup ✓ if ⊕ FH; may be helpful but consider timing as thrombus, heparin and warfarin Δ results Useful for relatives, if dx APLAS (given requires warfarin), or if not planning lifelong anticoagulation for Pt.</description></item><item><title>Workup for non-AG metabolic acidosis</title><link>https://htlin222.github.io/garden/Workup-for-non-AG-metabolic-acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-for-non-AG-metabolic-acidosis/</guid><description>Workup for non-AG metabolic acidosis Evaluate history for causes (see above)
✓ urine anion gap (UAG) = (UNa + UK) – UCl UAG = unmeasured anions – unmeasured cations; NH4+ is primary unmeasured cation (represented by UCl).</description></item><item><title>Workup of acute hypoxemia</title><link>https://htlin222.github.io/garden/Workup-of-acute-hypoxemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-of-acute-hypoxemia/</guid><description>Workup of acute hypoxemia Cyanosis: when &amp;gt;5 g/dL of deoxygenated Hb in vessels of skin/mucous membranes. Central: ↓ SaO2 (pulm disease, shunt); abnl Hb [metHb, sulfHb, COHb (not true cyanosis)] Peripheral: ↓ blood flow → ↑ O2 extraction (eg, ↓ CO, cold, arterial or venous obstruction)</description></item><item><title>Workup of chronic diarrhea</title><link>https://htlin222.github.io/garden/Workup-of-chronic-diarrhea/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-of-chronic-diarrhea/</guid><description>Workup of chronic diarrhea positive: FOB WBC calprotectin lactoferrin Inflammatory: stool culture, colonoscopy
positive: fecal fat Malabsorption: * Based on hx: ✔ tissue transglut.</description></item><item><title>Workup-acid-base disturbances</title><link>https://htlin222.github.io/garden/Workup-acid-base-disturbances/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-acid-base-disturbances/</guid><description>Workup-acid-base disturbances Traditional or physiologic approach (Brønsted-Lowry definition of acids &amp;amp; bases) Determine primary disorder: ✓ pH, PaCO2, HCO3 Determine if degree of compensation is appropriate [[Compensation-for-Acid-Base-Disorders]] Alternative approaches Base excess/deficit (NEJM 2018;378:1419) Strong ion difference or “Stewart Method” (NEJM 2014;371:1821)</description></item><item><title>Workup-acute kidney injury AKI</title><link>https://htlin222.github.io/garden/Workup-acute-kidney-injury-AKI/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-acute-kidney-injury-AKI/</guid><description>Workup-acute kidney injury (AKI) H&amp;amp;P: meds, contrast, or other nephrotoxins; ↓ PO intake, HoTN, infxn/sepsis; trauma, myalgias; BPH/retention. Search for insult 24–48 hr prior ↑ Cr.</description></item><item><title>Workup-acute liver failure</title><link>https://htlin222.github.io/garden/Workup-acute-liver-failure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-acute-liver-failure/</guid><description>Workup-acute liver failure (Clin Liver Dis 2017;21:769)
CBC, PT/PTT, LFTs, lytes, BUN/Cr, NH3, pH, arterial lactate, acetaminophen level, HIV, amylase/lipase, viral serologies (qv) in all Pts, with additional labs as below if suspected</description></item><item><title>Workup-cirrhosis</title><link>https://htlin222.github.io/garden/Workup-cirrhosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-cirrhosis/</guid><description>Workup-cirrhosis (Am J Gastro 2017;112:18; Lancet 2021;398:1359)
Abd U/S w/ Doppler: liver size &amp;amp; echotexture, r/o HCC, ascites, ✓ patency of vasculature</description></item><item><title>Workup-fever in a returned traveler</title><link>https://htlin222.github.io/garden/Workup-fever-in-a-returned-traveler/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-fever-in-a-returned-traveler/</guid><description>Workup-fever in a returned traveler Routine testing: CBC w/ diff, BMP, LFTs, BCx, UA, rapid malaria test Fever in a traveler from a malaria zone is malaria until proven otherwise; consider a medical emergency → hospitalization &amp;amp; empiric Rx.</description></item><item><title>Workup-fever of unknown origin</title><link>https://htlin222.github.io/garden/Workup-fever-of-unknown-origin/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-fever-of-unknown-origin/</guid><description>Workup-fever of unknown origin Initial: CBC w/ diff, CMP, ESR, CRP, 3 sets BCx (off abx), U/A, UCx, CXR Additional workup based on sx: ANA, RF, cryoglobulin, LDH, CK/aldolase, SPEP, TFTs, PPD or IGRA, HIV Ag/Ab ± PCR, RPR, EBV serologies, CMV PCR, HBV/HCV serologies Consider imaging: chest &amp;amp; abd CT, tagged WBC scan, FDG-PET, TTE, LE duplex US Tissue dx: consider bx of LN (excisional preferred), liver (especially if ↑ Aϕ), TA (for GCA), BM, kidney (RPGN)</description></item><item><title>Workup-for-AG-metabolic-acidosis</title><link>https://htlin222.github.io/garden/Workup-for-AG-metabolic-acidosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-for-AG-metabolic-acidosis/</guid><description>Workup-for-AG-metabolic-acidosis (AJKD 2021;78:A16)
✓ for ketonuria (dipstick acetoacetate) or plasma β-hydroxybutyrate (βOHB) nb, urine acetoacetate often not present in early ketoacidosis due to shunting to βOHB; ∴ acetoacetate may later turn ⊕ but does not signify worsening disease If ⊖ ketones, ✓ renal function, lactate, toxin screen, and osmolal gap If obtunded or ↑↑ AG, check osmolal gap (OG) = measured osmoles – calculated osmoles Calculated osmoles = (2 × Na) + (glucose/18) + (BUN/2.</description></item><item><title>Workup-glomerulonephritis</title><link>https://htlin222.github.io/garden/Workup-glomerulonephritis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-glomerulonephritis/</guid><description>Workup-glomerulonephritis (JAMA 2017;318:1276)
Acute GN/RPGN ± lung hemorrhage is an emergency → requires early Dx and Rx
UA + sediment (dysmorphic RBCs) ✓ ANCA, anti-GBM, C3/C4, SPEP, serum FLC</description></item><item><title>Workup-hyperkalemia</title><link>https://htlin222.github.io/garden/Workup-hyperkalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-hyperkalemia/</guid><description>Workup-hyperkalemia (Crit Care Med 2008;36:3246)
Rule out pseudohyperkalemia (IVF w/ K, tourniquet, hemolysis, ↑ plt or WBC), rule out transcellular shift</description></item><item><title>Workup-hypernatremia</title><link>https://htlin222.github.io/garden/Workup-hypernatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-hypernatremia/</guid><description>Workup-hypernatremia ✓ Uosm, UNa, volume status (vital signs, orthostatics, JVP, skin turgor, BUN, Cr)</description></item><item><title>Workup-hypokalemia</title><link>https://htlin222.github.io/garden/Workup-hypokalemia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-hypokalemia/</guid><description>Workup-hypokalemia (JAMA 2021;12:1216)
Identify transcellular shifts &amp;amp; treat. TTKG validity questioned (Curr Op Nephro 2011;20:547).
✓ UK:Cr: &amp;gt;13 mEq/g → renal loss; &amp;lt;13 mEq/g → extrarenal loss (AJKD 2019;74:682)</description></item><item><title>workup-hyponatremia</title><link>https://htlin222.github.io/garden/workup-hyponatremia/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/workup-hyponatremia/</guid><description>workup-hyponatremia (JASN 2012;23:1140 &amp;amp; 2017;28:1340; Crit Care 2013;17:206; NEJM 2015;372:55)
Workup History: acute vs. chronic (&amp;gt;48 h); sx severity; risk for neuro complications (alcoholism, malnourished, cirrhosis, older women on thiazides, hypoxia, hypoK) [[Measure plasma osmolality]] For hypotonic hyponatremia, ✓ [[volume status]] [[Measure Uosm]] If euvolemic and ↑ Uosm, evaluate for glucocorticoid insufficiency and hypothyroidism If available, consider FEUricAcid as &amp;gt;12% suggests SIADH (J Clinc Endo 2008;93:2991) Backlink： [[sodium and water homeostasis]]</description></item><item><title>Workup-nephrolithiasis</title><link>https://htlin222.github.io/garden/Workup-nephrolithiasis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-nephrolithiasis/</guid><description>Workup-nephrolithiasis Non-contrast CT 97% Se, 96% Sp (ureteral dilation w/o stone suggests recent passage); U/S (Se 57%, Sp 98%) may serve as initial test in stable patient (NEJM 2014;371:1100)</description></item><item><title>Workup-nephrotic syndrome</title><link>https://htlin222.github.io/garden/Workup-nephrotic-syndrome/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-nephrotic-syndrome/</guid><description>Workup-nephrotic syndrome (BMJ 2008;336:1185)
U/A + sediment: usually benign; ± oval fat bodies (“Maltese crosses”; NEJM 2007;357:806)
Measure proteinuria: 24-h urine or spot urine protein/Cr ratio (not accurate in AKI), renal bx</description></item><item><title>Workup-of-hematuria</title><link>https://htlin222.github.io/garden/Workup-of-hematuria/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-of-hematuria/</guid><description>Workup-of-hematuria (NEJM 2021;385:153)
Urine dipstick: ⊕ if ≥3 RBCs; ⊕ dipstick and ⊖ sediment → myo- or hemoglobinuria</description></item><item><title>Workup-syncope</title><link>https://htlin222.github.io/garden/Workup-syncope/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Workup-syncope/</guid><description>Workup-syncope (etiology cannot be determined in ~40% of cases) (JAMA 2019;321:2448)
H&amp;amp;P incl. orthostatic VS have highest yield and most cost effective R/o life-threatening dx including: cardiac syncope, severe blood loss, PE, SAH History (from Pt and witnesses if available) activity and posture before the incident precipitating factors: exertion (AS, HCMP, PHT), positional ∆ (orthostatic HoTN), stressors such as sight of blood, pain, emotional distress, fatigue, prolonged standing, warm environment, N/V, cough/deglutition/micturition/defecation (neurocardiogenic), head turning or shaving (carotid sinus hypersens.</description></item><item><title>wowoowow</title><link>https://htlin222.github.io/garden/wowoowow/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/wowoowow/</guid><description>wowoowow Thromboembolism is a book of writing is therefore is a book of Backlink： [[這裡主要就是一些實驗的內容]]</description></item><item><title>YPM0hbw1azf qwq2fpw</title><link>https://htlin222.github.io/garden/YPM0hbw1azf-qwq2fpw/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/YPM0hbw1azf-qwq2fpw/</guid><description/></item><item><title>zettle</title><link>https://htlin222.github.io/garden/zettle/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/zettle/</guid><description>zettle</description></item><item><title>Zygomycetes</title><link>https://htlin222.github.io/garden/Zygomycetes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/Zygomycetes/</guid><description>Zygomycetes Epidemiology: diabetes (espec. those w/ prior DKA), heme malignancy, neutropenia, transplant, chronic steroids, iron overload, trauma, h/o voriconazole Rx or Ppx Clinical: rhinocerebral = severe periorbital/facial pain, swelling, vision changes, sinusitis, opthalmoplegia, nasal ulcerations/ necrosis, HA.</description></item><item><title>α1-antitrypsin deficiency</title><link>https://htlin222.github.io/garden/%CE%B11-antitrypsin-deficiency/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%CE%B11-antitrypsin-deficiency/</guid><description>α1-antitrypsin deficiency early-onset panacinar emphysema or signif basilar disease,
1–3% of COPD cases. Suspect if age &amp;lt;45,
lower lungs affected,</description></item><item><title>α1-antitrypsin deficiency α1-AT</title><link>https://htlin222.github.io/garden/%CE%B11-antitrypsin-deficiency-%CE%B11-AT/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%CE%B11-antitrypsin-deficiency-%CE%B11-AT/</guid><description>α1-antitrypsin deficiency (α1-AT) (J Hepatol 2016;65:413; NEJM 2020;382:1443)
Abnl α1-AT → polymerization in liver (cirrhosis) &amp;amp; uninhibited protease activity in lung (emphysema).</description></item><item><title>β-blocker</title><link>https://htlin222.github.io/garden/%CE%B2-blocker/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%CE%B2-blocker/</guid><description>β-blocker (data for carvedilol, metoprolol, bisoprolol)
Add in concert w/ RASi
35% ↓ mort. &amp;amp; 40% ↓ rehosp. in NYHA II–IV (JAMA 2002;287:883)</description></item><item><title>→ periph blood plt count ~10,000 plt for every 1 plt seen at hpf 100×</title><link>https://htlin222.github.io/garden/pocket-medicine-fullText/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/pocket-medicine-fullText/</guid><description>ELECTROCARDIOGRAPHY
Approach (a systematic approach is vital)
Rate (? tachy or brady), rhythm (? P waves, regularity, P &amp;amp; QRS relationship)</description></item><item><title>其他科</title><link>https://htlin222.github.io/garden/%E5%85%B6%E4%BB%96%E7%A7%91/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%E5%85%B6%E4%BB%96%E7%A7%91/</guid><description>其他科</description></item><item><title>寶益兒多種維他命</title><link>https://htlin222.github.io/garden/%E5%AF%B6%E7%9B%8A%E5%85%92%E5%A4%9A%E7%A8%AE%E7%B6%AD%E4%BB%96%E5%91%BD/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%E5%AF%B6%E7%9B%8A%E5%85%92%E5%A4%9A%E7%A8%AE%E7%B6%AD%E4%BB%96%E5%91%BD/</guid><description>寶益兒多種維他命 寶益兒小兒滴劑，每日1cc為寶寶的健康加分！ 全新的綜合配方（含維他命D3 400IU)一次到位提供寶寶需要的各種營養素。
食用方式(用法用量) : 3 歲以下每日1cc，4-12 歲每日1.5cc， 13 歲以上每日2cc，老年人每日2-3cc。 請用吸管按壓吸取至刻度1為1cc。可直接餵食於口內或添加於開水、牛奶、果汁中飲用。</description></item><item><title>常見主訴的apporach</title><link>https://htlin222.github.io/garden/symptom-to-diagnosis/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/symptom-to-diagnosis/</guid><description>常見主訴的apporach 這是一個很好的思考練區
[[diagnostic process]] [[screening and health maintenance]] [[abdominal pain]] [[acid-base abnormalities]] [[aids hiv infection]] [[anemia]] [[back pain]] [[bleeding disorders]] [[chest pain]] [[cough, fever, and respiratory infections]] [[delirium and dementia]] [[diabetes]] [[diarrhea, acute]] [[dizziness]] [[dyspnea]] [[dysuria]] [[edema]] [[fatigue]] [[gi bleeding]] [[headache]] [[hematuria]] [[hypercalcemia]] [[hypertension]] [[hyponatremia and hypernatremia]] [[hypotension]] [[jaundice and abnormal liver enzymes]] [[joint pain]] [[acute kidney injury]] [[rash]] [[sore throat]] [[syncope]] [[unintentional weight loss]] [[wheezing and stridor]]</description></item><item><title>貼片</title><link>https://htlin222.github.io/garden/%E8%B2%BC%E7%89%87/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://htlin222.github.io/garden/%E8%B2%BC%E7%89%87/</guid><description>貼片 開機就轉到電擊模式 紅心(其實是腳)</description></item></channel></rss>